"companyid","keydevid","transcriptid","headline","mostimportantdateutc","keydeveventtypename","companyname","speakertypename","componenttextpreview","word_count","componenttext"
154924,323237239,933971,"Agilent Technologies Inc., Q1 2016 Earnings Call, Feb 16, 2016",2016-02-16,"Earnings Calls","Agilent Technologies, Inc.","Operator","Good day, ladies and gentlemen, and welcome to the First Quarter 2016 Agilent Technologies Inc. Earnings Conference Call. [Operator Instructions] As a reminder, today's program is being recorded. I would now like to introduce your host for today's program",48,"Good day, ladies and gentlemen, and welcome to the First Quarter 2016 Agilent Technologies Inc. Earnings Conference Call. [Operator Instructions] As a reminder, today's program is being recorded. I would now like to introduce your host for today's program, Alicia Rodriguez, Vice President, Investor Relations. Please go ahead."
154924,323237239,933971,"Agilent Technologies Inc., Q1 2016 Earnings Call, Feb 16, 2016",2016-02-16,"Earnings Calls","Agilent Technologies, Inc.","Executives","Thank you, Jonathan, and welcome, everyone, to Agilent First Quarter Conference Call for fiscal Year 2016. With me are Mike McMullen, Agilent's President and CEO; and Didier Hirsch, Agilent's Senior Vice President and CFO. Joining in the Q&A after Didier'",327,"Thank you, Jonathan, and welcome, everyone, to Agilent First Quarter Conference Call for fiscal Year 2016. With me are Mike McMullen, Agilent's President and CEO; and Didier Hirsch, Agilent's Senior Vice President and CFO. Joining in the Q&A after Didier's comments will be Patrick Kaltenbach, President of Agilent's Life Sciences and Applied Markets Group; Jacob Thaysen, President of Agilent's Diagnostics and Genomics Group; and Mark Doak, President of the Agilent CrossLab Group.
You can find the press release and information to supplement today's discussion on our website at www.investor.agilent.com. While there, please click on the link for financial results under the Financial Information tab. You'll find an investor presentation along with revenue breakouts and currency impacts, business segment results and historical financials for Agilent's operations. We will also post a copy of the prepared remarks following this call.
Today's comments by Mike and Didier will refer to non-GAAP financial measures. You will find the most directly comparable GAAP financial metrics and reconciliations on our website. Unless otherwise noted, all references to increases or decreases in financial metrics are year-over-year. As a reminder, we are no longer reporting or commenting on orders or book-to-bill. and our guidance is based on exchange rates as of the last day of the recorded quarter.
And please note that we will refer to core revenue growth, which excludes the impact of currency, the NMR business and acquisitions and divestitures within the past 12 months. Reconciliations between reported and core growth in dollars and percentages can be found in the financial results section on the IR website.
We will also make forward-looking statements about the financial performance of the company. These statements are subject to risks and uncertainties and are only valid as of today. The company assumes no obligation to update them. Please look at the company's recent SEC filings for a more complete picture of our risks and other factors. 
And now I'd like to turn the call over to Mike."
154924,323237239,933971,"Agilent Technologies Inc., Q1 2016 Earnings Call, Feb 16, 2016",2016-02-16,"Earnings Calls","Agilent Technologies, Inc.","Executives","Thanks, Lisa, and hello, everyone. Thank you for joining us on today's call. I'm pleased to report that our team delivered a very strong start to our fiscal 2016, both revenue and earnings are above the high end of our guidance. I would now highlight 3 ke",1234,"Thanks, Lisa, and hello, everyone. Thank you for joining us on today's call. I'm pleased to report that our team delivered a very strong start to our fiscal 2016, both revenue and earnings are above the high end of our guidance. I would now highlight 3 key results. 
First, revenue was up over 6% on a core basis. Second, we delivered an operating margin increase of 200 basis points from a year ago to 20.2% adjusted for Keysight billings. Finally, adjusted EPS of $0.46 was up 12% over last year.
Our Q1 results are driven by continued strength in the pharma, clinical and diagnostics markets with the return to growth in academia and government. Market demand remained strong for our liquid chromatography, CrossLab services and consumables, and diagnostics and genomics offering. Geographically, all regions grew on a core basis with strong growth in China. Let me highlight the Q1 results by our 3 business group.
The life science applied markets group delivered core revenue growth of 2%. We see continued strong global Pharma demand, growth return in academia and government markets, and China government investments in environmental and food markets. All of this offset continued weaknesses for new equipment purchases in the chemical and engineering market space. LSAG's operating margin for the quarter was 21.7%, up 210 basis points from 1 year ago. As a reminder, in November, we closed the acquisition of Seahorse Bioscience. Integration activities are in full swing with the team excited to be part of Agilent.
LSAG continued to strengthen its portfolio in Q1. We released 2 new refracted index detectors to 12 60 and 12 90 Infinity II RID. These detectors help expand the capabilities of modern new HPL state chromatography to make difficult measurements in certain chemical, biopharma and food application.
Agilent's innovation strength was recognized in the January edition of Analytical Science Magazine. We are honored with an innovation of work for our unique LC II needle technology. This is a breakthrough in the way samples are injected into Agilent's LC products. The unique design enables fast injection cycles, scalable injection volumes and ultralow carryover.
Next is the Agilent CrossLab Group. We continue to see consistently strong revenue results. Our core revenue growth was 10% in Q1. Strong pharma and chemical and energy market demand drove growth in our services and consumables offering.
Our operating margin was 22.1% for the quarter. This is up 140 basis points from 1 year ago. We continued bringing new chemistry to our market. For example, we released AdvanceBio SEC family of products. These innovative new products are designed for ad curate and precise site exclusion chromatography targeted at biopharma application. Early adopting customers are reporting significant economic and performance benefits over any current technologies offered by our competitors.
Finally, they Diagnostics and Genomics Group continued to demonstrate momentum. In Q1, the DGG delivered 12% core revenue growth with strength across all its businesses. The pathology business continued a steady trajectory to market growth rate. We see strong growth for Dako alumnus reagents and growing revenue PD-L1 diagnostics. The companion diagnostics business also continued to demonstrate momentum.
Double-digit growth in nucleic acids and genomics reflected strong demand from pharma and clinical markets in favorable compare. DGG's operating margin for the quarter was 9.6%, that's up 910 basis points from 1 year ago. I want to remind you that last year, this business broke even Q1 fiscal 2015.
Last year, our Dako complementary diagnostic for Bristol-Myers Squibb up to was approved by the FDA for non-squamous, non-small cell lung cancer. In January of this year, the FDA-approved to expand the use of this PD-L1 diagnostics to include patients with melanoma. Positive PD-L1 status in melanoma has been clearly able to treat the effectiveness of Bristol-Myers Squibb's drug treatment. Agilent's is the first company to provide FDA-approved test for lung cancer and melanoma for PD-L1 markets.
Now I'll take a brief look at Agilent's revenues by end market performance on a core basis. We saw strength in all our life sciences and diagnostics market, continued robust demand drove pharma revenue up 19%. Growth was fueled by technology refresh deals, new product uptake in aftermarket demand for services and consumables. Our clinical and diagnostics revenue was up 7%, and we experienced a return to growth in academia and government of 4%. This growth was sequentially driven by the authorization of larger research budgets in the U.S.
Line and market performance was generally soft except for environmental, which was up 9% driven by strength in China. Food declined 1%. Our food market strength in China was offset by soft demand developed countries. Chemical and energy declined 2% driven by the well-publicized macroeconomic concerns.
Let me provide an update on our operating margin proven initiatives. This quarter marks the fourth consecutive quarter of year-over-year operating margin improvement. This is how we are driving the sustained performance. We are building a new company portfolio. We have exited unattractive businesses and are acquiring new ones to enable our growth strategy. Our multiyear Agilent program is simplifying our company, making it more nubile and lowering our costs. Finally, while we improve our execution capabilities, transforming our culture to work as one team across the entire company. We called of this One Agilent.
As we enter the second year of the new Agilent, here is what you expect as we move forward. We are building the new business, one that delivers above market growth. We will continue to target operating margin expansion. Finally, we are driving a balanced capital allocation policy that includes increased levels of the cash flow being returned to shareholders.
Going forward, we will continue to make composition to ensure our long-term competitiveness. For example, we have just froze our U.S. defined benefits retirement plan. This change is effective in the second half of fiscal 2016. I've also spoke with many of you about our multiple ERP systems and oversized IT environment. We continue to streamline our IT systems and infrastructure to reduce costs and increase effectiveness. While work remains, we are pleased with the start of the second year of the new Agilent and our progress in transforming the company. Let me share my view on the current market outlook.
The principle of new Agilent is be realistic and to closely monitor market conditions that could affect our business. Global macroeconomic concerns are pressuring some end markets in emerging economies. The good news is that we'll see solid market conditions to other end markets and geography. I remain confident in our ability to achieve our full year core growth and operating margin goals. I am also confident that we will make course correction as market conditions dictate.
We are strengthening our portfolio, building on our prior year introductions. We have an exciting pipeline of compelling offering sets to launch this year. In tandem of these new offerings, we have created and you go-to-market capability. We have a focused, energized sales force, and we are overhauling our e-commerce environment to make it easier for customers to do business with us.
And most importantly, across the company, we have the organizational capability to execute and deliver. The Agilent team is aligned and highly energized, driven to in the marketplace. 
Thank you for being on the call today. I will now turn it over to Didier, who will provide additional insights on our financial results and our updated guidance. Didier?"
154924,323237239,933971,"Agilent Technologies Inc., Q1 2016 Earnings Call, Feb 16, 2016",2016-02-16,"Earnings Calls","Agilent Technologies, Inc.","Executives","Yes. Thank you, Mike, and hello, everyone. To summarize Q1 results, they are both the high end of our revenue and EPS guidance even as currency impacted revenue by $7 million and OP by $2 million.The EPS beats was the result of the higher revenues, as w",284,"Yes. Thank you, Mike, and hello, everyone. To summarize Q1 results, they are both the high end of our revenue and EPS guidance even as currency impacted revenue by $7 million and OP by $2 million.
The EPS beats was the result of the higher revenues, as well as favorable earnings. Our adjusted operating margin of 20.2% and operating cash flow of $106 million was strong. We bought back $200 million or 4.9 million shares in Q1. I'll turn out now to the guidance for fiscal year 2016. We are confirming the coral run rate growth guidance of 4.0% to 4.5% we provided in November. However, the strengthening of the U.S. dollar in our November guidance is expected to have a negative impact of about $50 million on reported revenues, $13 million on operating profit and 3.3 cents on EPS.
As a result, we now expect fiscal year '16 revenues of $4.1 billion to $4.12 billion, and EPS of $1.81 to $1.87. To note, in the last 2 weeks, we've seen the U.S. dollar weaken. If the weakening continues, we will reflect the positive impact in our May guidance.
Turning to our share buyback program. We remain committed to our plan of repurchasing another $280 million of shares before fiscal year-end. Finally, moving to the guidance for our second quarter. We're expecting Q2 revenues of $965 million and to $985 million, reflecting typical second quarter seasonality versus Q1.
The mid-point corresponds to a core revenue growth 4.0%. The sequential reduction revenues will translate into a sequential reduction in EPS. We expect Q2 EPS to branch between 39 -- excuse me, $0.37 to $0.39. 
With that, I'll turn it over to Alicia for the Q&A."
154924,323237239,933971,"Agilent Technologies Inc., Q1 2016 Earnings Call, Feb 16, 2016",2016-02-16,"Earnings Calls","Agilent Technologies, Inc.","Executives","Thank you, Didier. And Jonathan, will you please give the instructions for the Q&A?",14,"Thank you, Didier. And Jonathan, will you please give the instructions for the Q&A?"
154924,323237239,933971,"Agilent Technologies Inc., Q1 2016 Earnings Call, Feb 16, 2016",2016-02-16,"Earnings Calls","Agilent Technologies, Inc.","Operator","[Operator Instructions] Our first question comes from the line of Doug Schenkel from Cowin company.",15,"[Operator Instructions] Our first question comes from the line of Doug Schenkel from Cowin company."
154924,323237239,933971,"Agilent Technologies Inc., Q1 2016 Earnings Call, Feb 16, 2016",2016-02-16,"Earnings Calls","Agilent Technologies, Inc.","Analysts","This is Ryan Blicker filling in for Doug. Starting with operating margin guidance, it seems as though you reduced for your guidance by about 10 basis points. But it seems like, though, most of that was FX. Can you confirm that, that was all due to FX or a",57,"This is Ryan Blicker filling in for Doug. Starting with operating margin guidance, it seems as though you reduced for your guidance by about 10 basis points. But it seems like, though, most of that was FX. Can you confirm that, that was all due to FX or are there other changes we should be thinking about?"
154924,323237239,933971,"Agilent Technologies Inc., Q1 2016 Earnings Call, Feb 16, 2016",2016-02-16,"Earnings Calls","Agilent Technologies, Inc.","Executives","No, it was entirely due to FX, absolutely. As I have mentioned, the FX impact was $13 million. That is precisely the amount of the reduction in operating profit reflected in our guidance. And we have maintained the guidance at 20.2%, which was the average",57,"No, it was entirely due to FX, absolutely. As I have mentioned, the FX impact was $13 million. That is precisely the amount of the reduction in operating profit reflected in our guidance. And we have maintained the guidance at 20.2%, which was the average of 20% to 25% that we had guided to in November notion."
154924,323237239,933971,"Agilent Technologies Inc., Q1 2016 Earnings Call, Feb 16, 2016",2016-02-16,"Earnings Calls","Agilent Technologies, Inc.","Analysts","And looking at the pharma end market. Obviously, another very strong performing the quarter. Can you give us more detail on what drove the strength? And where there any one-time than it was like our budget flush or pull forward of revenue? And I guess, la",62,"And looking at the pharma end market. Obviously, another very strong performing the quarter. Can you give us more detail on what drove the strength? And where there any one-time than it was like our budget flush or pull forward of revenue? And I guess, lastly, do still expect growth in this end market to approximate high single-digits for the full year?"
154924,323237239,933971,"Agilent Technologies Inc., Q1 2016 Earnings Call, Feb 16, 2016",2016-02-16,"Earnings Calls","Agilent Technologies, Inc.","Executives","Brian, this is Mike. Let me make a few commence on the pharma strength we saw on the first quarter. Clearly, no one-time events. And we saw great pacing throughout the quarter. This would highlight a few points here. One, we're seeing a strong growth in l",150,"Brian, this is Mike. Let me make a few commence on the pharma strength we saw on the first quarter. Clearly, no one-time events. And we saw great pacing throughout the quarter. This would highlight a few points here. One, we're seeing a strong growth in liquid chromatography, both in terms of the uptake in our new audits, but also technology refresh of that is underway within this segment. Also, customers responding quite positively to our biopharma solutions. And then across the board between biopharma, pharma seen strong demand for enterprise-wide services consumables. 19% growth for the first quarter. We don't expect that level of double-digit growth continue all through the year, but we're quite confident in our projections of high single-digit we're calling for 8% overall growth for the year in pharma. So we see no signs that this market won't remind robust for the rest of this year."
154924,323237239,933971,"Agilent Technologies Inc., Q1 2016 Earnings Call, Feb 16, 2016",2016-02-16,"Earnings Calls","Agilent Technologies, Inc.","Operator","Our next question comes from the line of Paul Knight from Janney Montgomery.",13,"Our next question comes from the line of Paul Knight from Janney Montgomery."
154924,323237239,933971,"Agilent Technologies Inc., Q1 2016 Earnings Call, Feb 16, 2016",2016-02-16,"Earnings Calls","Agilent Technologies, Inc.","Analysts","Regarding the guidance of EPS. I know when you guided last time, the euro had already fallen relative to the dollars. So are you measuring the euro on today's exchange rate, last week's exchange rate? I mean, could you flesh out our bit for...",44,"Regarding the guidance of EPS. I know when you guided last time, the euro had already fallen relative to the dollars. So are you measuring the euro on today's exchange rate, last week's exchange rate? I mean, could you flesh out our bit for..."
154924,323237239,933971,"Agilent Technologies Inc., Q1 2016 Earnings Call, Feb 16, 2016",2016-02-16,"Earnings Calls","Agilent Technologies, Inc.","Executives","Great question, Paul, it's the same question I asked him. I'm going to pass it back to Didier.",18,"Great question, Paul, it's the same question I asked him. I'm going to pass it back to Didier."
154924,323237239,933971,"Agilent Technologies Inc., Q1 2016 Earnings Call, Feb 16, 2016",2016-02-16,"Earnings Calls","Agilent Technologies, Inc.","Executives","Yes, Paul, so the guidance is always based on the exchange rate on the last day of the quarter we report. So the new guidance is based on the exchange rate as of October -- also of January 30, 2016. And it was between November -- October 30, which was in",126,"Yes, Paul, so the guidance is always based on the exchange rate on the last day of the quarter we report. So the new guidance is based on the exchange rate as of October -- also of January 30, 2016. And it was between November -- October 30, which was in November guidance, and then January 30, which is the present guidance. The dollar strengthened, but we are seeing it weakening since November 30 a little bit, vis-a-vis the euro and certainly, vis-Ã -vis the yen. So if that continues, it will be reflected in our May guidance. Again, there was no change at all to our November guidance except for those that result directly from the change in exchange rates between October 30 and January 30."
154924,323237239,933971,"Agilent Technologies Inc., Q1 2016 Earnings Call, Feb 16, 2016",2016-02-16,"Earnings Calls","Agilent Technologies, Inc.","Executives","Yes, Paul, back in December side. Again, I mean, the fundamentals assumptions that we made that underlie our prior quarter guidance remain intact with the exception being FX.",28,"Yes, Paul, back in December side. Again, I mean, the fundamentals assumptions that we made that underlie our prior quarter guidance remain intact with the exception being FX."
154924,323237239,933971,"Agilent Technologies Inc., Q1 2016 Earnings Call, Feb 16, 2016",2016-02-16,"Earnings Calls","Agilent Technologies, Inc.","Analysts","And then, lastly, Mike, what stands out on technology is the PD-L1 approval and also, the large molecule technology in CrossLab. Do you sit there with those 2 products on your menu thinking there's a bias toward more organic? Or where are you at with thos",50,"And then, lastly, Mike, what stands out on technology is the PD-L1 approval and also, the large molecule technology in CrossLab. Do you sit there with those 2 products on your menu thinking there's a bias toward more organic? Or where are you at with those 2 that you mentioned?"
154924,323237239,933971,"Agilent Technologies Inc., Q1 2016 Earnings Call, Feb 16, 2016",2016-02-16,"Earnings Calls","Agilent Technologies, Inc.","Executives","Paul, just to make sure I understand the question. Relative to -- thanks for the comments and observation. Just want to make sure I understand the cushion. This will be relative to our expectation of a continued growth with those 2 new -- with those 2...",46,"Paul, just to make sure I understand the question. Relative to -- thanks for the comments and observation. Just want to make sure I understand the cushion. This will be relative to our expectation of a continued growth with those 2 new -- with those 2..."
154924,323237239,933971,"Agilent Technologies Inc., Q1 2016 Earnings Call, Feb 16, 2016",2016-02-16,"Earnings Calls","Agilent Technologies, Inc.","Analysts","Yes, are they enough to move the needle higher than what you would have thought 90 days ago on last guidance?",21,"Yes, are they enough to move the needle higher than what you would have thought 90 days ago on last guidance?"
154924,323237239,933971,"Agilent Technologies Inc., Q1 2016 Earnings Call, Feb 16, 2016",2016-02-16,"Earnings Calls","Agilent Technologies, Inc.","Executives","Well, let me make a comment on the CrossLab services and consumables, and then I'll pass it over to Jacob on the PD-L1. When we put together our guidance for the year, we were expecting a strong growth in our CrossLab and services and consumables business",151,"Well, let me make a comment on the CrossLab services and consumables, and then I'll pass it over to Jacob on the PD-L1. When we put together our guidance for the year, we were expecting a strong growth in our CrossLab and services and consumables business. So that's part of the reason why we had a lot of confidence coming this year and still have the confidence in this year about making our organic core revenue growth targets. Because as you've seen, even in the chemical energy space, which down in terms of new instrument purchases, they continue to buy and we see strong growth of service and consumables. So what I leave you is we expect continued strength in that space, but we were assuming that to be the case when we guided the company earlier this year. And then, Jacob, why don't you share your thoughts on the PD-L1?"
154924,323237239,933971,"Agilent Technologies Inc., Q1 2016 Earnings Call, Feb 16, 2016",2016-02-16,"Earnings Calls","Agilent Technologies, Inc.","Executives","Yes, Thanks, Paul. And you're right, you got indication approval also for the melanoma for the Aviva drug, and that's a great next step in the opportunities with PD-L1. I will not say that it would change a single on an Agilent level, but it definitely is",103,"Yes, Thanks, Paul. And you're right, you got indication approval also for the melanoma for the Aviva drug, and that's a great next step in the opportunities with PD-L1. I will not say that it would change a single on an Agilent level, but it definitely is a part of our growth story in DDG. But I will remind also that this drug or this companion diagnostic has also been out now for a few months, and we're still in the early days of seeing the uptake of it. So I see good progress, but not something that really moves the needle here."
154924,323237239,933971,"Agilent Technologies Inc., Q1 2016 Earnings Call, Feb 16, 2016",2016-02-16,"Earnings Calls","Agilent Technologies, Inc.","Operator","Our next question comes from the line of then Dan Arias from Citigroup.",13,"Our next question comes from the line of then Dan Arias from Citigroup."
154924,323237239,933971,"Agilent Technologies Inc., Q1 2016 Earnings Call, Feb 16, 2016",2016-02-16,"Earnings Calls","Agilent Technologies, Inc.","Analysts","Mike, last quarter, you mentioned that industrial weakness you are seeing had a spill over in the environmental business. I'm just wondering whether that's reversing a bit this quarter. So I guess, is it fair to say that maybe growth in environmental this",70,"Mike, last quarter, you mentioned that industrial weakness you are seeing had a spill over in the environmental business. I'm just wondering whether that's reversing a bit this quarter. So I guess, is it fair to say that maybe growth in environmental this year could be a couple of points higher than the cyclical segments? I guess, how would you just compare expectations from environmental versus industrial for this year?"
154924,323237239,933971,"Agilent Technologies Inc., Q1 2016 Earnings Call, Feb 16, 2016",2016-02-16,"Earnings Calls","Agilent Technologies, Inc.","Executives","Yes, Dan, thanks for the careful of our mentioned. What was actually the [indiscernible] was a pleasant surprise in the first quarter. We knew that China was going to be strong, and we've been talking about that China, in our view of investments, since Ch",184,"Yes, Dan, thanks for the careful of our mentioned. What was actually the [indiscernible] was a pleasant surprise in the first quarter. We knew that China was going to be strong, and we've been talking about that China, in our view of investments, since Chinese investments making in place in section of our mental market and include safety. But I will say that we are happy to see the growth in other segments because yes, the chemical space has been under pressure. But what we're still seeing is the fracking still going on. So the production, while prices of oil are down, the production demand is stable. And in fact, you look at the oil production, them in gasoline, the U.S. for example, perhaps going up. So we're seeing -- we're continuing to do environmental testing. So that's been a nice reaffirmation, if you will, of our outlook for the Ridge call for a low single-digit growth in the environmental. We thought that China will carry the whole load for us, but I think we got a little help from the U.S. as well."
154924,323237239,933971,"Agilent Technologies Inc., Q1 2016 Earnings Call, Feb 16, 2016",2016-02-16,"Earnings Calls","Agilent Technologies, Inc.","Analysts","Okay. And then maybe just staying in their break region. Any change in the way that you're thinking about Brazil and Russia and how might debt end up of this year?",31,"Okay. And then maybe just staying in their break region. Any change in the way that you're thinking about Brazil and Russia and how might debt end up of this year?"
154924,323237239,933971,"Agilent Technologies Inc., Q1 2016 Earnings Call, Feb 16, 2016",2016-02-16,"Earnings Calls","Agilent Technologies, Inc.","Executives","Unfortunately, no. I think we're still looking for very challenged conditions in those countries. I know there's been some recent news today about Russia. And perhaps, working with some of the other oil-producing countries to change some aspects and produ",66,"Unfortunately, no. I think we're still looking for very challenged conditions in those countries. I know there's been some recent news today about Russia. And perhaps, working with some of the other oil-producing countries to change some aspects and production. May be there has some dynamics in terms of their economy. But right now, we're assuming continuation of the current challenged conditions for Brazil and Russia."
154924,323237239,933971,"Agilent Technologies Inc., Q1 2016 Earnings Call, Feb 16, 2016",2016-02-16,"Earnings Calls","Agilent Technologies, Inc.","Operator","Our next question comes from the line of Isaac Ro from Goldman Sachs.",13,"Our next question comes from the line of Isaac Ro from Goldman Sachs."
154924,323237239,933971,"Agilent Technologies Inc., Q1 2016 Earnings Call, Feb 16, 2016",2016-02-16,"Earnings Calls","Agilent Technologies, Inc.","Analysts","Mike, first question was on gross margin. It's pretty big year-over-year improvement in there. What it was wondering if you could maybe -- the breakdown the key drivers of gross margin performance. The situation might have been one-time benefits and these",54,"Mike, first question was on gross margin. It's pretty big year-over-year improvement in there. What it was wondering if you could maybe -- the breakdown the key drivers of gross margin performance. The situation might have been one-time benefits and these there are some items that are going to continue as the year progresses."
154924,323237239,933971,"Agilent Technologies Inc., Q1 2016 Earnings Call, Feb 16, 2016",2016-02-16,"Earnings Calls","Agilent Technologies, Inc.","Executives","Yes let me make a few high level comments here then Didier, you can jump in and augment my comments. But I think, one, there were some one-time improvements, and I think we highlighted those in typically as it related to DDG, where we had some revenue tha",174,"Yes let me make a few high level comments here then Didier, you can jump in and augment my comments. But I think, one, there were some one-time improvements, and I think we highlighted those in typically as it related to DDG, where we had some revenue that it was really trapped last year the first quarter juju production issues. But the lion share of the improvement is resulting from our continued sustained efforts that I highlighted in my a call. Both the portal efforts in terms of the businesses were no longer in. The businesses of that requires to our change in our gross margin profile. We're taking real cost out of our system through the Agile Agilent program. So the worst some time event as it relates to the revenue for the DGG, but the bulk of our margin improvement is from the underlying core efforts we've had over the last several quarters to fundamentally change in the operating model of the company. Didier, anything else that you would add to that?"
154924,323237239,933971,"Agilent Technologies Inc., Q1 2016 Earnings Call, Feb 16, 2016",2016-02-16,"Earnings Calls","Agilent Technologies, Inc.","Executives","Just to point out also contributed. Number one, you will recall that last year, we were spending heavily on remediation points that drives the FDA warning letters. So that is -- now, we are spending a significant amount to maintain our strong position now",138,"Just to point out also contributed. Number one, you will recall that last year, we were spending heavily on remediation points that drives the FDA warning letters. So that is -- now, we are spending a significant amount to maintain our strong position now. But certainly, not in the same magnitude of what we have spent for 2 years in a row. And then the second point is there was a favorable mix. We talked about how strong the some of our businesses is an pharma does generate higher gross margin then the rest of the businesses. So favorable mix and I've noted the form of being just one of them, but a significant one. And then in the FDA -- the reduction that the FDA spend also in addition to all the point that Mike has made."
154924,323237239,933971,"Agilent Technologies Inc., Q1 2016 Earnings Call, Feb 16, 2016",2016-02-16,"Earnings Calls","Agilent Technologies, Inc.","Analysts","Okay, that's helpful. And then just a follow-up on CrossLab. You mentioned the driver there looking like it was just healthy demand in the end market. But I don't think that businesses this is really having as a cynical growth rate in that double-digit ra",92,"Okay, that's helpful. And then just a follow-up on CrossLab. You mentioned the driver there looking like it was just healthy demand in the end market. But I don't think that businesses this is really having as a cynical growth rate in that double-digit range. So much of those almond of market share that, that was helpful. It's just not market where we have a ton of quarter-to-quarter visibility. Some just wondering if you can put some color on the market share was helpful. How you would characterize rates it's coming from."
154924,323237239,933971,"Agilent Technologies Inc., Q1 2016 Earnings Call, Feb 16, 2016",2016-02-16,"Earnings Calls","Agilent Technologies, Inc.","Executives","Great, great question. I'll make a few comments and Mark why don't you jump in your thoughts here. As we looked at the overall growth rate for CrossLab, you should assume that we're right in the wage where we had talked about at the a ID. And we think the",113,"Great, great question. I'll make a few comments and Mark why don't you jump in your thoughts here. As we looked at the overall growth rate for CrossLab, you should assume that we're right in the wage where we had talked about at the a ID. And we think there is both market growth. But as you pointed out, market share gain opportunities for us where -- we've really have changed our view of what the addressable market is for our business. And there's no longer the Agilent installed base, but it's the entire lab. And Mark, why don't you talk about some of the things we're doing terms of capturing market share."
154924,323237239,933971,"Agilent Technologies Inc., Q1 2016 Earnings Call, Feb 16, 2016",2016-02-16,"Earnings Calls","Agilent Technologies, Inc.","Executives","Thanks, Mike. And I think you've hit on the primary piece, which is we continue to see the primary drivers in pharma and also China has been very strong for us. When you pull it all back to when capital spending is constrained, we continue to see customer",102,"Thanks, Mike. And I think you've hit on the primary piece, which is we continue to see the primary drivers in pharma and also China has been very strong for us. When you pull it all back to when capital spending is constrained, we continue to see customers improve the productivity of their assets through services and the chemistries we talked about earlier. But I think what's -- what we thought it was a year ago even is really the strength of our multi-vendor and enterprise portfolio. And that does allow you to take share, if you will, from the broader market."
154924,323237239,933971,"Agilent Technologies Inc., Q1 2016 Earnings Call, Feb 16, 2016",2016-02-16,"Earnings Calls","Agilent Technologies, Inc.","Operator","Our next question comes from the line of Ross Muken from Evercore ISI.",13,"Our next question comes from the line of Ross Muken from Evercore ISI."
154924,323237239,933971,"Agilent Technologies Inc., Q1 2016 Earnings Call, Feb 16, 2016",2016-02-16,"Earnings Calls","Agilent Technologies, Inc.","Analysts","So I'm just trying to double check on the guidance that. Because I think a few of us are a little bit confuse. So we heat the quarter right by around, I don't know, call it $0.03. We lost 3.3/10 on FX roughly, and the range came down forward. So I'm just",116,"So I'm just trying to double check on the guidance that. Because I think a few of us are a little bit confuse. So we heat the quarter right by around, I don't know, call it $0.03. We lost 3.3/10 on FX roughly, and the range came down forward. So I'm just trying to get a sense for -- again, it seems like FX was the key delta. But just the simple math was suggested to me a little less downward pressure on the full year range. And again, I realize there's probably a few moving parts. Some just trying to make sure I understand how are doing versus of the plan for the year."
154924,323237239,933971,"Agilent Technologies Inc., Q1 2016 Earnings Call, Feb 16, 2016",2016-02-16,"Earnings Calls","Agilent Technologies, Inc.","Executives","Sure, Ross, Didier will be happy to clarify.",8,"Sure, Ross, Didier will be happy to clarify."
154924,323237239,933971,"Agilent Technologies Inc., Q1 2016 Earnings Call, Feb 16, 2016",2016-02-16,"Earnings Calls","Agilent Technologies, Inc.","Executives","Yes. No, so the -- as I mentioned earlier, we have reduced our top line revenue from -- at mid-point Form 160 to Form 110, which is a $50 million reduction. We've reduced our operating profit from $830 million to $817 million, $13 million, and that's enti",206,"Yes. No, so the -- as I mentioned earlier, we have reduced our top line revenue from -- at mid-point Form 160 to Form 110, which is a $50 million reduction. We've reduced our operating profit from $830 million to $817 million, $13 million, and that's entirely due to the impact of the strengthening of the dollar and related to the $50 million. And then I mentioned 3.3. But with rounding, we are going from a mid-point of 184 to the new mid-point -- to the -- sorry, we're going from the mid-point of 188 to the mid-point of 184. That's a $0.04 and that's a 3.3, which is rounded because of going from want to the other. You can understand that. So basically, what we felt is even though we are starting the year very strongly, we felt that with the overall macroeconomic condition, it would not be wise, at this point in time, to change the guidance we have provided for revenue guidance of 4% to 4.5%. We have the same confidence us we've had in the month of November when we provided that guidance that we're in good shape to get it and perhaps did it. And certainly, didn't want to change it."
154924,323237239,933971,"Agilent Technologies Inc., Q1 2016 Earnings Call, Feb 16, 2016",2016-02-16,"Earnings Calls","Agilent Technologies, Inc.","Analysts","Yes, I guess, what I'm trying to get it is sort of the comments last quarter suggested sort of the conservatism, right? You obviously can't control what happens with the dollar. So that's understandable. I'm just trying to get a sense for how much conserv",87,"Yes, I guess, what I'm trying to get it is sort of the comments last quarter suggested sort of the conservatism, right? You obviously can't control what happens with the dollar. So that's understandable. I'm just trying to get a sense for how much conservatism there is now and the forecasting, whether or not we have risk to that core growth rate given again that the range came down. But you reiterated the top line. I'm just making sure that we're sort of not over extrapolating here."
154924,323237239,933971,"Agilent Technologies Inc., Q1 2016 Earnings Call, Feb 16, 2016",2016-02-16,"Earnings Calls","Agilent Technologies, Inc.","Executives","Sure, Russ. This is Mike. I really appreciate the opportunity to comment on this. So if you'll at the conservatism meter on our guidance, is at the same level as it was last quarter. So the only real fundamental change in terms of outlook is the review in",51,"Sure, Russ. This is Mike. I really appreciate the opportunity to comment on this. So if you'll at the conservatism meter on our guidance, is at the same level as it was last quarter. So the only real fundamental change in terms of outlook is the review in FX. That's it."
154924,323237239,933971,"Agilent Technologies Inc., Q1 2016 Earnings Call, Feb 16, 2016",2016-02-16,"Earnings Calls","Agilent Technologies, Inc.","Executives","And we saw no reason to change our core revenue growth to offset a part of the FX because FX can go up and down and it's too volatile nowadays to immediately, unless we see some long-term structural changes as we have last year and we reacted accordingly.",69,"And we saw no reason to change our core revenue growth to offset a part of the FX because FX can go up and down and it's too volatile nowadays to immediately, unless we see some long-term structural changes as we have last year and we reacted accordingly. We were not going to react why what we believe temporary changes in FX by actions on our structural spend."
154924,323237239,933971,"Agilent Technologies Inc., Q1 2016 Earnings Call, Feb 16, 2016",2016-02-16,"Earnings Calls","Agilent Technologies, Inc.","Analysts","Okay. So sorry, I'm going to less for a minute. Because I'm trying to make sure my end inbox line up on getting everyone. Sort of the answer Dana. So all right, we -- to be clear, we have the FX shift, I'd love to also understand what were the key currenc",156,"Okay. So sorry, I'm going to less for a minute. Because I'm trying to make sure my end inbox line up on getting everyone. Sort of the answer Dana. So all right, we -- to be clear, we have the FX shift, I'd love to also understand what were the key currencies because most of us can see the dollars actually again, we'll see if it sustain, weakened a bit. And so it seems like its outside of the euro and the end that might have cost some of the headwinds. So I'd love to hear. Just a little bit of color and maybe it's in the lawn or some of the other emerging market currencies. Just to be clear also on the checking point. So we didn't really baked in that deep from this quarter. So that sort of where the conservatism comes and? And then, I'm done, I promise. I'll see in the floor."
154924,323237239,933971,"Agilent Technologies Inc., Q1 2016 Earnings Call, Feb 16, 2016",2016-02-16,"Earnings Calls","Agilent Technologies, Inc.","Executives","Yes, I mean, in terms of the currencies, we have a detailed model that takes into account obviously all the currencies. The dollar versus the euro or the dollar versus the yen, had a major impact also, thing, dollar versus British pound. And again, the --",116,"Yes, I mean, in terms of the currencies, we have a detailed model that takes into account obviously all the currencies. The dollar versus the euro or the dollar versus the yen, had a major impact also, thing, dollar versus British pound. And again, the -- today's guidance is based on the October -- January 30 exchange rates, So the euro, $1.84 and the yen, and vis-a-vis this of the valiant -- the U.S. dollar is JPY 121.4. And we are seeing that to today's rate, if we had provided the guidance base and just say we're able to instantly reflect the currencies as of the date of the guidance, we'll have a very different guidance."
154924,323237239,933971,"Agilent Technologies Inc., Q1 2016 Earnings Call, Feb 16, 2016",2016-02-16,"Earnings Calls","Agilent Technologies, Inc.","Executives","I think your second statement is probably a fair one.",10,"I think your second statement is probably a fair one."
154924,323237239,933971,"Agilent Technologies Inc., Q1 2016 Earnings Call, Feb 16, 2016",2016-02-16,"Earnings Calls","Agilent Technologies, Inc.","Operator","Our next question comes from the line of Jeff Elliott from Robert W. Baird.",14,"Our next question comes from the line of Jeff Elliott from Robert W. Baird."
154924,323237239,933971,"Agilent Technologies Inc., Q1 2016 Earnings Call, Feb 16, 2016",2016-02-16,"Earnings Calls","Agilent Technologies, Inc.","Analysts","So question from Mike on chemical energy. You're down 2% this quarter. The last couple of quarters, you were down 9% or 10%. I guess, can you give us a sense for what's happening on the E&P side? You talked about civility on the fighting side. But with DC",72,"So question from Mike on chemical energy. You're down 2% this quarter. The last couple of quarters, you were down 9% or 10%. I guess, can you give us a sense for what's happening on the E&P side? You talked about civility on the fighting side. But with DC on the E&P side, it seems like that's what kind of a lot, I guess, the improvement relative to last couple of quarters?"
154924,323237239,933971,"Agilent Technologies Inc., Q1 2016 Earnings Call, Feb 16, 2016",2016-02-16,"Earnings Calls","Agilent Technologies, Inc.","Executives","Actually it's probably worth may be doing a bit of birch on the last few quarters because in fact, we've seen relative flat performance over the last several quarters. And while instruments were down, the percentage you were talking about high single-digi",268,"Actually it's probably worth may be doing a bit of birch on the last few quarters because in fact, we've seen relative flat performance over the last several quarters. And while instruments were down, the percentage you were talking about high single-digits, we've seen a continued ability to offset through services consumables. So what I would say is that the chemicals energy market is sort of plan out the way we had expected for the year. So we wish we had a different story here. But the oil prices is low, as you know, but the product demand still remains pretty strong for our customers product. So the refiners aren't running. The chemical plants are running and then really trying to sell to them and you come in these of the productivity message. But at the same point in time, recognize that if I use the equipment longer is an opportunity for us on the service and the consumables side. One thing I would ask you to reflect on is that Q1 '15, as you dig in some of the numbers, Q1 '15 really was our best quarter for the whole year. I think we grew 3% in the first quarter of last year on a core basis. We ended up growing, I think, 1% for the new lean year. So that just shows you we're declining through the year. And so I wouldn't over interpret the numbers. We think it's right and kind of the range where we had thought. And pressure, I don't know if you had any other comments you would add to that?"
154924,323237239,933971,"Agilent Technologies Inc., Q1 2016 Earnings Call, Feb 16, 2016",2016-02-16,"Earnings Calls","Agilent Technologies, Inc.","Executives","Well, no, not really. I think, as you said, it's playing out as we expected. It is continued pressure along the exploration side and the production side. But for the refinery side, demand really drives. We're also business we try to incentivize our custom",90,"Well, no, not really. I think, as you said, it's playing out as we expected. It is continued pressure along the exploration side and the production side. But for the refinery side, demand really drives. We're also business we try to incentivize our customers and give them opportunity to upgrade, to increase their productivity and efficiency. And on the chemical side, I would say that the level have not get fully materialize. So we stay with focus for the year -- for the whole segment to be just as flat."
154924,323237239,933971,"Agilent Technologies Inc., Q1 2016 Earnings Call, Feb 16, 2016",2016-02-16,"Earnings Calls","Agilent Technologies, Inc.","Executives","And Jeff, this is Mike. I think we shared this number the in the past. But we look at this business is about 15% or so in EMP, as you described, exploration and production, which will be about 3% to 4% of our total revenues. About 35% of that segment is i",75,"And Jeff, this is Mike. I think we shared this number the in the past. But we look at this business is about 15% or so in EMP, as you described, exploration and production, which will be about 3% to 4% of our total revenues. About 35% of that segment is in refining and the other 50% is in chemicals. So that's how we -- so it sort of remained stable at a subdued level."
154924,323237239,933971,"Agilent Technologies Inc., Q1 2016 Earnings Call, Feb 16, 2016",2016-02-16,"Earnings Calls","Agilent Technologies, Inc.","Operator","Our next version comes from the line of Steve Beuchaw from Morgan Stanley.",13,"Our next version comes from the line of Steve Beuchaw from Morgan Stanley."
154924,323237239,933971,"Agilent Technologies Inc., Q1 2016 Earnings Call, Feb 16, 2016",2016-02-16,"Earnings Calls","Agilent Technologies, Inc.","Analysts","Just follow up just a bit on the pharmaceutical space. It was really helpful to hear just how confident you guys are in the outlook for the year going 8% in pharma. I wonder if you could maybe add a little bit to the conversation of -- and talk about what",112,"Just follow up just a bit on the pharmaceutical space. It was really helpful to hear just how confident you guys are in the outlook for the year going 8% in pharma. I wonder if you could maybe add a little bit to the conversation of -- and talk about what you're hearing, deter or Patrick, your conversations with pharma customers as they talk about their budgets for this year. I apologize for coming back to the topic. But there's a lot of interest out there in the sustainability of growth in the space. So any color you can offer -- how we are customer certainly, think it will be really helpful."
154924,323237239,933971,"Agilent Technologies Inc., Q1 2016 Earnings Call, Feb 16, 2016",2016-02-16,"Earnings Calls","Agilent Technologies, Inc.","Executives","Yes, absolutely. So Patrick, why don't you take that one question and I will have one closing comment.",18,"Yes, absolutely. So Patrick, why don't you take that one question and I will have one closing comment."
154924,323237239,933971,"Agilent Technologies Inc., Q1 2016 Earnings Call, Feb 16, 2016",2016-02-16,"Earnings Calls","Agilent Technologies, Inc.","Executives","Yes. So what we're hearing from our customers is that they -- actually, they're holding their budgets and we don't see any significant reduction there. And this comes, by the way, across the board from small and medium-size from large enterprises. So it's",89,"Yes. So what we're hearing from our customers is that they -- actually, they're holding their budgets and we don't see any significant reduction there. And this comes, by the way, across the board from small and medium-size from large enterprises. So it's really, for us, it's a good mature between different size of company's and also between the different markets talking about small molecule versus biopharmaceuticals. The growth really comes from both side, and this is why we're confident to maintain. You'll see this high digit-growth for pharma."
154924,323237239,933971,"Agilent Technologies Inc., Q1 2016 Earnings Call, Feb 16, 2016",2016-02-16,"Earnings Calls","Agilent Technologies, Inc.","Executives","And the other thing that we've done -- so we've given a broad based demand across segments and then we also continue to do our own math in terms of what's out there in terms of the installed base of our products. So we have pretty idea -- these of the tec",65,"And the other thing that we've done -- so we've given a broad based demand across segments and then we also continue to do our own math in terms of what's out there in terms of the installed base of our products. So we have pretty idea -- these of the technology refresh site how much more demand we can expect in this segment."
154924,323237239,933971,"Agilent Technologies Inc., Q1 2016 Earnings Call, Feb 16, 2016",2016-02-16,"Earnings Calls","Agilent Technologies, Inc.","Analysts","That's extremely helpful. One corollary, one follow-up there. I wonder if you can give us a sense for -- to what the 6 that you're having with your pharma, the success you're having in CrossLab are interrelated? Are those 2 perhaps a little bit more or ov",68,"That's extremely helpful. One corollary, one follow-up there. I wonder if you can give us a sense for -- to what the 6 that you're having with your pharma, the success you're having in CrossLab are interrelated? Are those 2 perhaps a little bit more or overlapping than CrossLab been some of the other customer verticals? And it's more extent and is one depends on the other?"
154924,323237239,933971,"Agilent Technologies Inc., Q1 2016 Earnings Call, Feb 16, 2016",2016-02-16,"Earnings Calls","Agilent Technologies, Inc.","Executives","Great question. I'm happy to elaborate and they are highly connected. So when we talk about pharma market demand, it's both driving year, given purchases, which was the focus on Patrick's comments, but also there is a demand for enterprise wide services c",192,"Great question. I'm happy to elaborate and they are highly connected. So when we talk about pharma market demand, it's both driving year, given purchases, which was the focus on Patrick's comments, but also there is a demand for enterprise wide services consumables. But not -- on the CrossLab side, none of the day investing in ongoing chemistries and services to maintain their operations and support their application needs. What we're also seeing is a change of the model. So what they're doing is they are taking activities that historically have been done inside the company. And our creating, if you will, a new set of services for vendors of our space to handle things such as asset management. And that's created sort of a new set of services whether it will it is being created right now in pharma. We haven't seen that new set of services demand develop yet on the chemical energy side. But we're hopeful that it will down the road. But there's a couple of dynamics going on in the pharma space, which were driving both the new instruments purchases and the consumables and services for CrossLab."
154924,323237239,933971,"Agilent Technologies Inc., Q1 2016 Earnings Call, Feb 16, 2016",2016-02-16,"Earnings Calls","Agilent Technologies, Inc.","Operator","Our next question comes from the line of Tim Evans from Wells Fargo.",13,"Our next question comes from the line of Tim Evans from Wells Fargo."
154924,323237239,933971,"Agilent Technologies Inc., Q1 2016 Earnings Call, Feb 16, 2016",2016-02-16,"Earnings Calls","Agilent Technologies, Inc.","Analysts","Wondered if you could give us a update on market tuck-in acquisitions. What you're thinking about the stays in terms of where you might like to put some holes? And also, are you seeing more opportunities now that some valuations have come in?",44,"Wondered if you could give us a update on market tuck-in acquisitions. What you're thinking about the stays in terms of where you might like to put some holes? And also, are you seeing more opportunities now that some valuations have come in?"
154924,323237239,933971,"Agilent Technologies Inc., Q1 2016 Earnings Call, Feb 16, 2016",2016-02-16,"Earnings Calls","Agilent Technologies, Inc.","Executives","Yes. Thanks, I appreciate the opportunity to provide a perspective on here. So although we remain focused on our organic growth opportunities, we've got a lot of very exciting plans and new products coming out and working on the go-to-market capabilities.",225,"Yes. Thanks, I appreciate the opportunity to provide a perspective on here. So although we remain focused on our organic growth opportunities, we've got a lot of very exciting plans and new products coming out and working on the go-to-market capabilities. As I mentioned in my call, comments, we're really continuing to look for acquisitions and augment our current portfolio and add to our company capabilities. That's why I think you saw the Seahorse deal when you have capabilities and life science research, Cartagenia in the area of next-gen sequencing to build out our workflow there. We're still like to find ways to build our workflow in next-gen sequencing. And so our status strategies really adding capabilities, expand our portfolio, building on our full close with a particular emphasis on life science research next gen sequencing workflows in the overall consumable services please. There are priorities. Well, that being said, most people still have the memories of their 52-week highs. So we'll see how this plays out. And what I will tell you is we will continue to be very disciplined in terms of how we think about the M&A and does it provide an attractive return to our shareholders? And can we do something to make their business better? If you can't make the business better, it's not something that we'd be interested in."
154924,323237239,933971,"Agilent Technologies Inc., Q1 2016 Earnings Call, Feb 16, 2016",2016-02-16,"Earnings Calls","Agilent Technologies, Inc.","Operator","Our next question comes from the line of Brendan V from Jefferies.",12,"Our next question comes from the line of Brendan V from Jefferies."
154924,323237239,933971,"Agilent Technologies Inc., Q1 2016 Earnings Call, Feb 16, 2016",2016-02-16,"Earnings Calls","Agilent Technologies, Inc.","Analysts","Mike, you pointed to strengthen in China in the period. Just curious if you could elaborate on the actual growth rate in the first quarter and if there's been any deviation from sort of the mid-to high single-digit target for the year?",42,"Mike, you pointed to strengthen in China in the period. Just curious if you could elaborate on the actual growth rate in the first quarter and if there's been any deviation from sort of the mid-to high single-digit target for the year?"
154924,323237239,933971,"Agilent Technologies Inc., Q1 2016 Earnings Call, Feb 16, 2016",2016-02-16,"Earnings Calls","Agilent Technologies, Inc.","Executives","Yes. Now, thanks. Appreciate the opportunity to talk about China, one of my favorite topics. So we saw very good demand in China. High single-digit growth and our let business. And as I mentioned to you, in the past, the markets here are really being driv",224,"Yes. Now, thanks. Appreciate the opportunity to talk about China, one of my favorite topics. So we saw very good demand in China. High single-digit growth and our let business. And as I mentioned to you, in the past, the markets here are really being driven by strong investments in government and policy driven initiatives our product concerns whether the environment, drug and food safety. So all of our market with the exception of chemical energy really saw quite strong growth. And we're underpenetrated in DDG business compared to the rest of the company. We've talked about that in the past. And we -- we're under penetrated in growing market for cancer diagnostics, for example. And recently, we had office that I thought really quite amazing. There was a report by the Cancer Hospital of the Chinese medical science that said that every minute, an average of 6 people in the country were diagnosed with cancer. And 5 of those 6 would eventually die of the disease. But unfortunately, this would be a growing demand for cancer diagnostic as well. I'm going to wrap this all up by saying we remain quite comfortable with the mid- to high single-digit growth expectation we laid out for China. It was strong for us in the first quarter and we expect that to continue through the year."
154924,323237239,933971,"Agilent Technologies Inc., Q1 2016 Earnings Call, Feb 16, 2016",2016-02-16,"Earnings Calls","Agilent Technologies, Inc.","Analysts","And for then, one more for Didier. Could you split out the contribution from Seahorse relative to the headwind from EMR in the first quarter in terms of just dollars?",30,"And for then, one more for Didier. Could you split out the contribution from Seahorse relative to the headwind from EMR in the first quarter in terms of just dollars?"
154924,323237239,933971,"Agilent Technologies Inc., Q1 2016 Earnings Call, Feb 16, 2016",2016-02-16,"Earnings Calls","Agilent Technologies, Inc.","Executives","No, we don't provide guidance or informations regarding the acquisitions. We -- we have stated, and we are exactly in line that we expect Seahorse revenue to grow double digits in 2016 versus 2015. And we expect Seahorse operating margin to be also in the",53,"No, we don't provide guidance or informations regarding the acquisitions. We -- we have stated, and we are exactly in line that we expect Seahorse revenue to grow double digits in 2016 versus 2015. And we expect Seahorse operating margin to be also in the double digit. So no change to our expectations."
154924,323237239,933971,"Agilent Technologies Inc., Q1 2016 Earnings Call, Feb 16, 2016",2016-02-16,"Earnings Calls","Agilent Technologies, Inc.","Executives","And Patrick, maybe you can just add a few comments on how it's going so far.",16,"And Patrick, maybe you can just add a few comments on how it's going so far."
154924,323237239,933971,"Agilent Technologies Inc., Q1 2016 Earnings Call, Feb 16, 2016",2016-02-16,"Earnings Calls","Agilent Technologies, Inc.","Executives","All, the integration of Seahorse is going very well. It's giving us extended reach into the research model. This was the whole play. Plus, of course, used the opportunity use our strength in China to sell these products into the pharma space in areas like",92,"All, the integration of Seahorse is going very well. It's giving us extended reach into the research model. This was the whole play. Plus, of course, used the opportunity use our strength in China to sell these products into the pharma space in areas like disease discovery, as well as this is -- this business will drive the growth in fiscal year '16. As Didier said, we expect double-digit growth. We have to see full string, and we are looking forward to a very strong Q2, Q3, Q4 for this product line."
154924,323237239,933971,"Agilent Technologies Inc., Q1 2016 Earnings Call, Feb 16, 2016",2016-02-16,"Earnings Calls","Agilent Technologies, Inc.","Operator","Our next question comes from the line of Tycho Peterson from JPMorgan.",12,"Our next question comes from the line of Tycho Peterson from JPMorgan."
154924,323237239,933971,"Agilent Technologies Inc., Q1 2016 Earnings Call, Feb 16, 2016",2016-02-16,"Earnings Calls","Agilent Technologies, Inc.","Analysts","Maybe just first on capital deployment. You did $200 million in buybacks in the quarter. You got it for $480 million for the year. I mean, it sounds like you're all front-end loaded. I mean, how do we think about the reauthorization once you get to the tr",56,"Maybe just first on capital deployment. You did $200 million in buybacks in the quarter. You got it for $480 million for the year. I mean, it sounds like you're all front-end loaded. I mean, how do we think about the reauthorization once you get to the tranche given your socks covered into some precious model?"
154924,323237239,933971,"Agilent Technologies Inc., Q1 2016 Earnings Call, Feb 16, 2016",2016-02-16,"Earnings Calls","Agilent Technologies, Inc.","Executives","Well yes, we basically decided to buy back in Q1 what we had not been able to do in Q4 of the preceding year. And then we have 5 or 10 B 51. And we sort of a formula, for your model, you should issue that we are buying about 1/3 of the remaining $280 mill",60,"Well yes, we basically decided to buy back in Q1 what we had not been able to do in Q4 of the preceding year. And then we have 5 or 10 B 51. And we sort of a formula, for your model, you should issue that we are buying about 1/3 of the remaining $280 million on a per quarter."
154924,323237239,933971,"Agilent Technologies Inc., Q1 2016 Earnings Call, Feb 16, 2016",2016-02-16,"Earnings Calls","Agilent Technologies, Inc.","Analysts","And then just to clarify the margins because I've got a few questions. I mean, the $30 million hit at the FX hit, but I get people had a hard time understanding why you're not seen faster-than-expected realization of COGS from SG&A cost that you saw some",63,"And then just to clarify the margins because I've got a few questions. I mean, the $30 million hit at the FX hit, but I get people had a hard time understanding why you're not seen faster-than-expected realization of COGS from SG&A cost that you saw some of that in this quarter. What doesn't that carry through for the next 3 quarters?"
154924,323237239,933971,"Agilent Technologies Inc., Q1 2016 Earnings Call, Feb 16, 2016",2016-02-16,"Earnings Calls","Agilent Technologies, Inc.","Executives","Well, when I say it's not going to carry through. Merce Singh, we see no real reason in a percent to change the guidance on an operating margin, 20.2% that we have provided, 20% to 25%, that we had provided previously. So -- and again, with the same level",82,"Well, when I say it's not going to carry through. Merce Singh, we see no real reason in a percent to change the guidance on an operating margin, 20.2% that we have provided, 20% to 25%, that we had provided previously. So -- and again, with the same level of conservatism, as we had in November. So that's basically -- that was a premise for us maintaining both the core revenue growth and the operating margin that we have provided in November."
154924,323237239,933971,"Agilent Technologies Inc., Q1 2016 Earnings Call, Feb 16, 2016",2016-02-16,"Earnings Calls","Agilent Technologies, Inc.","Executives","And Didier, I just add to that. In my call comments, I tried to highlight a few things on a longer-term nature to show you that we're not out of the gas in this time in terms of ability to continue to move our operating margin. We have other larger hittin",96,"And Didier, I just add to that. In my call comments, I tried to highlight a few things on a longer-term nature to show you that we're not out of the gas in this time in terms of ability to continue to move our operating margin. We have other larger hitting programs that are coming on -- coming in the 2016, and will carry on into '17 as well. So this is not a one-time quarter where we just got a favorable mix. This will fundamental improvements underway and the operating margin capabilities of the company."
154924,323237239,933971,"Agilent Technologies Inc., Q1 2016 Earnings Call, Feb 16, 2016",2016-02-16,"Earnings Calls","Agilent Technologies, Inc.","Analysts","And then speaking out of running out of gas talk about if I is adding up this being used that at least 2 of the country's largest refiner's art cutting up both bustling. What gives you conviction that you're business there holds up?",44,"And then speaking out of running out of gas talk about if I is adding up this being used that at least 2 of the country's largest refiner's art cutting up both bustling. What gives you conviction that you're business there holds up?"
154924,323237239,933971,"Agilent Technologies Inc., Q1 2016 Earnings Call, Feb 16, 2016",2016-02-16,"Earnings Calls","Agilent Technologies, Inc.","Executives","I'm not sure exactly what you're referring to. But relative to our view is that gasoline will continue to be needed to do on the economy. And there's meet demand there. And what we try to share, and as long as production is running, and that there is dema",95,"I'm not sure exactly what you're referring to. But relative to our view is that gasoline will continue to be needed to do on the economy. And there's meet demand there. And what we try to share, and as long as production is running, and that there is demand, the refineries will meet that -- we've seen no significant changes in the underlying demand for gas. And in fact, Patrick, I think you will show me some statistics to the other day about what's going on in the eye area refineries in the U.S.."
154924,323237239,933971,"Agilent Technologies Inc., Q1 2016 Earnings Call, Feb 16, 2016",2016-02-16,"Earnings Calls","Agilent Technologies, Inc.","Executives","Yes, I mean, what we see, as Mike said, is the continued demand for, not only in the U.S, but also in the emerging economies like China. So the refineries are basically running at capacity right now. There will be no new builds. But we see that they repla",130,"Yes, I mean, what we see, as Mike said, is the continued demand for, not only in the U.S, but also in the emerging economies like China. So the refineries are basically running at capacity right now. There will be no new builds. But we see that they replaced the existing equipment and they also are going to service contracts. They look for opportunities to drive more efficiencies, which gives us an opportunity to upgrade the installed base with automation, features and other things to make sure that the customers can save money with the equipment as well. So the low prices is still driven by the fact that there is over capacity on the production side. But the refinery, volume has not gone down significantly over the last quarters."
154924,323237239,933971,"Agilent Technologies Inc., Q1 2016 Earnings Call, Feb 16, 2016",2016-02-16,"Earnings Calls","Agilent Technologies, Inc.","Analysts","Okay. And then just lastly, can you talk about myriad in the quarter anything notable in generated over the next's comps and January trends versus November and December?",28,"Okay. And then just lastly, can you talk about myriad in the quarter anything notable in generated over the next's comps and January trends versus November and December?"
154924,323237239,933971,"Agilent Technologies Inc., Q1 2016 Earnings Call, Feb 16, 2016",2016-02-16,"Earnings Calls","Agilent Technologies, Inc.","Executives","Yes. I just pointed to 2 things. One is in terms to our normal seasonality of the quarter. Q1 '16 was like prior quarters. We always see a nice strong December as we close off year-end with our customers. And it's followed our typical seasonality pattern",111,"Yes. I just pointed to 2 things. One is in terms to our normal seasonality of the quarter. Q1 '16 was like prior quarters. We always see a nice strong December as we close off year-end with our customers. And it's followed our typical seasonality pattern to November, December and January. I think probably, the only thing of note would be in the DDG side. We had, I think, 1 less day -- working day, I think this year. So this affect the genomic business in terms of how much revenue can get in that quarter. But we, it was sort of businesses usual, if you will, for the first quarter."
154924,323237239,933971,"Agilent Technologies Inc., Q1 2016 Earnings Call, Feb 16, 2016",2016-02-16,"Earnings Calls","Agilent Technologies, Inc.","Operator","Our next question come from the line of Jack Meehan from Barclays.",12,"Our next question come from the line of Jack Meehan from Barclays."
154924,323237239,933971,"Agilent Technologies Inc., Q1 2016 Earnings Call, Feb 16, 2016",2016-02-16,"Earnings Calls","Agilent Technologies, Inc.","Analysts","I wanted to follow up on Tycho's last question just around the academic end market. I'm curious you mentioned in the presentation are on some of the modestly larger research budgets being released in the U.S. Curious on your view on NIH and really timing",56,"I wanted to follow up on Tycho's last question just around the academic end market. I'm curious you mentioned in the presentation are on some of the modestly larger research budgets being released in the U.S. Curious on your view on NIH and really timing related there between the timing of the Congressional crew approvals."
154924,323237239,933971,"Agilent Technologies Inc., Q1 2016 Earnings Call, Feb 16, 2016",2016-02-16,"Earnings Calls","Agilent Technologies, Inc.","Executives","I can take this question, yes. As we have seen moderate growth again academia and government, which was a positive surprise, which is more batches available now the U.S, 2 batches slowly released that drove some of the growth for us in Q1 and looking at t",88,"I can take this question, yes. As we have seen moderate growth again academia and government, which was a positive surprise, which is more batches available now the U.S, 2 batches slowly released that drove some of the growth for us in Q1 and looking at the final moving forward. We actually see a good final there as well. So we stay with forecast of low single-digit growth of getting the government. At the moment mainly driven by the U.S, which is where we see the strongest demand."
154924,323237239,933971,"Agilent Technologies Inc., Q1 2016 Earnings Call, Feb 16, 2016",2016-02-16,"Earnings Calls","Agilent Technologies, Inc.","Analysts","Got it. And are your expectations for this level of growth to stay at the same rate through the end of the fiscal year? Or are you assuming the budget cuts leased a little bit faster than here?",38,"Got it. And are your expectations for this level of growth to stay at the same rate through the end of the fiscal year? Or are you assuming the budget cuts leased a little bit faster than here?"
154924,323237239,933971,"Agilent Technologies Inc., Q1 2016 Earnings Call, Feb 16, 2016",2016-02-16,"Earnings Calls","Agilent Technologies, Inc.","Executives","If the budgets will be release faster that will be probably upside for us we're now -- our current view is low single-digits for academia and government for the year.",31,"If the budgets will be release faster that will be probably upside for us we're now -- our current view is low single-digits for academia and government for the year."
154924,323237239,933971,"Agilent Technologies Inc., Q1 2016 Earnings Call, Feb 16, 2016",2016-02-16,"Earnings Calls","Agilent Technologies, Inc.","Analysts","Got it. And then just one other question on the margins and DDG. Definitely appreciate the year-over-year improvement. I'm just wondering what your thoughts were, which through the end of the year just given how the relative margins compared to the end of",44,"Got it. And then just one other question on the margins and DDG. Definitely appreciate the year-over-year improvement. I'm just wondering what your thoughts were, which through the end of the year just given how the relative margins compared to the end of 2015."
154924,323237239,933971,"Agilent Technologies Inc., Q1 2016 Earnings Call, Feb 16, 2016",2016-02-16,"Earnings Calls","Agilent Technologies, Inc.","Executives","Great. I know Jacob has got a lot of thought to that potential question. So I'll pass it over to Jacob to buy some color there.",26,"Great. I know Jacob has got a lot of thought to that potential question. So I'll pass it over to Jacob to buy some color there."
154924,323237239,933971,"Agilent Technologies Inc., Q1 2016 Earnings Call, Feb 16, 2016",2016-02-16,"Earnings Calls","Agilent Technologies, Inc.","Executives","Yes, first of all, we're pleased to see the improvement versus the Q1 last year. But you're also right that versus Q4, that we saw a bit of a decrease, and that was actually where we most expected. We sit in that DGG business for a prefix cost space. So w",105,"Yes, first of all, we're pleased to see the improvement versus the Q1 last year. But you're also right that versus Q4, that we saw a bit of a decrease, and that was actually where we most expected. We sit in that DGG business for a prefix cost space. So when you have a Q1 with a lower base than in Q4, you will see that our margins has also impacted accordingly. So we all we see us often Q1 and weaker Q1 of the gross margin also on our operating margin. So this is kind of by the book and as we as expected."
154924,323237239,933971,"Agilent Technologies Inc., Q1 2016 Earnings Call, Feb 16, 2016",2016-02-16,"Earnings Calls","Agilent Technologies, Inc.","Executives","Yes, I would just add that there's no change in France and Jack certainly committed to reaching 20% operating margin in 2017.",22,"Yes, I would just add that there's no change in France and Jack certainly committed to reaching 20% operating margin in 2017."
154924,323237239,933971,"Agilent Technologies Inc., Q1 2016 Earnings Call, Feb 16, 2016",2016-02-16,"Earnings Calls","Agilent Technologies, Inc.","Operator","Our next question comes from line of Derik De Bruin from Bank of America.",14,"Our next question comes from line of Derik De Bruin from Bank of America."
154924,323237239,933971,"Agilent Technologies Inc., Q1 2016 Earnings Call, Feb 16, 2016",2016-02-16,"Earnings Calls","Agilent Technologies, Inc.","Analysts","So I'm just curious. You're guiding to a 22% operating margin for 2017. So that's implying -- assuming the 20.2% mid-point, 130 to 180 basis points of margin expansion next year. I'm just curious if you can't -- if you couldn't find 10 additional basis po",71,"So I'm just curious. You're guiding to a 22% operating margin for 2017. So that's implying -- assuming the 20.2% mid-point, 130 to 180 basis points of margin expansion next year. I'm just curious if you can't -- if you couldn't find 10 additional basis points of margin expansion in 2016 to sort of offset the impact, what confidence are you able to that 130, 180 basis points next year?"
154924,323237239,933971,"Agilent Technologies Inc., Q1 2016 Earnings Call, Feb 16, 2016",2016-02-16,"Earnings Calls","Agilent Technologies, Inc.","Executives","I just reiterate, great question is one, again, by the way, one of the things you heard me in my comments we continue to make sure we're realistic and we think our business not on some hope and a prayer, but we actually have solid plans behind our long-te",205,"I just reiterate, great question is one, again, by the way, one of the things you heard me in my comments we continue to make sure we're realistic and we think our business not on some hope and a prayer, but we actually have solid plans behind our long-term operating goals. And I think we have a lot of comments for 2 reasons. One is we have a plan that can get us there with not all the top line. It's probably in the range of 4% ago. We can get the margin goals. We've laid out a plan that's got 50% that's coming from the cost side. And we have multiyear programs are going to take significant cost out of our structures. So I highlighted a few of them in my call performing changes in terms of our benefit structure. Changes in terms of our IP costs, ORT systems. These are major company-wide initiatives that right now we're underway. You won't start to see them going to the P&L until like late '16 going to '17. So these are kind of things that gives us confidence to say, ""Okay, there's a path that gets us to where we want to get to in '17."""
154924,323237239,933971,"Agilent Technologies Inc., Q1 2016 Earnings Call, Feb 16, 2016",2016-02-16,"Earnings Calls","Agilent Technologies, Inc.","Analysts","Okay, great. It was to late '16, early '17 that I think that was the key that I was sort of looking for that. Second question is given some of the turmoil going on in Europe, have you seen any sort of changes in the academic government spending? Is there",75,"Okay, great. It was to late '16, early '17 that I think that was the key that I was sort of looking for that. Second question is given some of the turmoil going on in Europe, have you seen any sort of changes in the academic government spending? Is there like a government are grapple with sort of the refugee crisis? Is there anything going on? Is there anything change to spending patterns in Europe."
154924,323237239,933971,"Agilent Technologies Inc., Q1 2016 Earnings Call, Feb 16, 2016",2016-02-16,"Earnings Calls","Agilent Technologies, Inc.","Executives","Bacher, I'm know you're shaking your head right now.",9,"Bacher, I'm know you're shaking your head right now."
154924,323237239,933971,"Agilent Technologies Inc., Q1 2016 Earnings Call, Feb 16, 2016",2016-02-16,"Earnings Calls","Agilent Technologies, Inc.","Executives","Yes, I'm shaking my head because we have not seen any significant changes over the last several quarters.",18,"Yes, I'm shaking my head because we have not seen any significant changes over the last several quarters."
154924,323237239,933971,"Agilent Technologies Inc., Q1 2016 Earnings Call, Feb 16, 2016",2016-02-16,"Earnings Calls","Agilent Technologies, Inc.","Operator","Our next question comes from line of Dan Leonard from Leerink partners.",12,"Our next question comes from line of Dan Leonard from Leerink partners."
154924,323237239,933971,"Agilent Technologies Inc., Q1 2016 Earnings Call, Feb 16, 2016",2016-02-16,"Earnings Calls","Agilent Technologies, Inc.","Analysts","All my questions have been answered.",6,"All my questions have been answered."
154924,323237239,933971,"Agilent Technologies Inc., Q1 2016 Earnings Call, Feb 16, 2016",2016-02-16,"Earnings Calls","Agilent Technologies, Inc.","Operator","Our next question comes from the line of Dane Leone from BTIG.",12,"Our next question comes from the line of Dane Leone from BTIG."
154924,323237239,933971,"Agilent Technologies Inc., Q1 2016 Earnings Call, Feb 16, 2016",2016-02-16,"Earnings Calls","Agilent Technologies, Inc.","Analysts","So on the gross margin line, can you just give a little bit more color in terms of the product mix? As I look at the different groups, really the margin leverage seems to come through the website and flats market grew. You guys almost reported a 59% gross",80,"So on the gross margin line, can you just give a little bit more color in terms of the product mix? As I look at the different groups, really the margin leverage seems to come through the website and flats market grew. You guys almost reported a 59% gross margin there. Comment on the next please and why the margin for that group specifically is expected to moderate when, I guess, historically, it's been pretty steady quarter-to-quarter through the year."
154924,323237239,933971,"Agilent Technologies Inc., Q1 2016 Earnings Call, Feb 16, 2016",2016-02-16,"Earnings Calls","Agilent Technologies, Inc.","Executives","I think there's 2 things I would point to and then Didier feel free to jump in as well. But first of all, remain by the change that we're making to our portfolio. So we've exited the NMR hardware business and we're starting to see some of those margin imp",105,"I think there's 2 things I would point to and then Didier feel free to jump in as well. But first of all, remain by the change that we're making to our portfolio. So we've exited the NMR hardware business and we're starting to see some of those margin improvements show up some of the P&L, where we have revenue in the NMR business in much higher revenues in FY '15. And then our farm businesses pull in the lot of liquid chromatography, which is one of our highest gross margin products. I think it's really does -- perhaps of those are the things."
154924,323237239,933971,"Agilent Technologies Inc., Q1 2016 Earnings Call, Feb 16, 2016",2016-02-16,"Earnings Calls","Agilent Technologies, Inc.","Executives","You stated it all out. Settling, our liquid -- I had mentioned earlier that the favorable mix, I mean, part from the farmer mix and within pharma, clearly liquid, the graph that has the higher-than-average operating margin and gross margin.",40,"You stated it all out. Settling, our liquid -- I had mentioned earlier that the favorable mix, I mean, part from the farmer mix and within pharma, clearly liquid, the graph that has the higher-than-average operating margin and gross margin."
154924,323237239,933971,"Agilent Technologies Inc., Q1 2016 Earnings Call, Feb 16, 2016",2016-02-16,"Earnings Calls","Agilent Technologies, Inc.","Analysts","So to clarify, you felt that there was either a catch-up ordering or a stalking in the quarter that those products specifically, that's not expected to continue for the rest of the year?",33,"So to clarify, you felt that there was either a catch-up ordering or a stalking in the quarter that those products specifically, that's not expected to continue for the rest of the year?"
154924,323237239,933971,"Agilent Technologies Inc., Q1 2016 Earnings Call, Feb 16, 2016",2016-02-16,"Earnings Calls","Agilent Technologies, Inc.","Executives","Well, almost think about the farm on -- I mean, we had 19% pharmaceutical growth in the first quarter. What we're seeing is we can't expect 19% to happen each of the next 3 quarters. What we do expect is good to strong demand. And right now, we're calling",72,"Well, almost think about the farm on -- I mean, we had 19% pharmaceutical growth in the first quarter. What we're seeing is we can't expect 19% to happen each of the next 3 quarters. What we do expect is good to strong demand. And right now, we're calling 8% for the entire. So that's what you're seeing in terms of reflected in our mix counter as it relates to gross margin."
154924,323237239,933971,"Agilent Technologies Inc., Q1 2016 Earnings Call, Feb 16, 2016",2016-02-16,"Earnings Calls","Agilent Technologies, Inc.","Analysts","Okay. And then on the FX rate. I'm still -- so if you just kind of use the DX live proxy, right? The last quarter, it was actually pretty elevated. But since then, the trend has actually come back into closer to where you guided the year. Are you expectin",78,"Okay. And then on the FX rate. I'm still -- so if you just kind of use the DX live proxy, right? The last quarter, it was actually pretty elevated. But since then, the trend has actually come back into closer to where you guided the year. Are you expecting -- is there some nuance within this on how certain currencies have moved? Or are you just kind of assuming worst-case that the dollar kind of broke year?"
154924,323237239,933971,"Agilent Technologies Inc., Q1 2016 Earnings Call, Feb 16, 2016",2016-02-16,"Earnings Calls","Agilent Technologies, Inc.","Executives","Well, it's just pure math. So are not making any projections all of about future levels of back. What Didier has done is he takes the currency spot rates on last 8 of the reported quarter, and that's how we guide the company. We said, okay, that's what we",70,"Well, it's just pure math. So are not making any projections all of about future levels of back. What Didier has done is he takes the currency spot rates on last 8 of the reported quarter, and that's how we guide the company. We said, okay, that's what we know this of that great stays the same for the rest of the. And then it's just pure math on there."
154924,323237239,933971,"Agilent Technologies Inc., Q1 2016 Earnings Call, Feb 16, 2016",2016-02-16,"Earnings Calls","Agilent Technologies, Inc.","Analysts","Okay. So it's extrapolating off of January 31, not what's happening...",11,"Okay. So it's extrapolating off of January 31, not what's happening..."
154924,323237239,933971,"Agilent Technologies Inc., Q1 2016 Earnings Call, Feb 16, 2016",2016-02-16,"Earnings Calls","Agilent Technologies, Inc.","Executives","Right. I made a comment during my script to that on my script that would we had used, for example, today at FX rates, the guidance would have been higher because the dollar between January 31 and today has weakened.",40,"Right. I made a comment during my script to that on my script that would we had used, for example, today at FX rates, the guidance would have been higher because the dollar between January 31 and today has weakened."
154924,323237239,933971,"Agilent Technologies Inc., Q1 2016 Earnings Call, Feb 16, 2016",2016-02-16,"Earnings Calls","Agilent Technologies, Inc.","Operator","And this does conclude the question-and-answer session of today's program. I'd like to hand the program back to Alicia Rodriguez for any further remarks.",25,"And this does conclude the question-and-answer session of today's program. I'd like to hand the program back to Alicia Rodriguez for any further remarks."
154924,323237239,933971,"Agilent Technologies Inc., Q1 2016 Earnings Call, Feb 16, 2016",2016-02-16,"Earnings Calls","Agilent Technologies, Inc.","Executives","All right. Thank you, everybody, for joining us on the call. And if you have any questions, please give us a question in IR. We'd like to wish you a good day, and I'm sure we'll be talking later. Thank you.",41,"All right. Thank you, everybody, for joining us on the call. And if you have any questions, please give us a question in IR. We'd like to wish you a good day, and I'm sure we'll be talking later. Thank you."
154924,323237239,933971,"Agilent Technologies Inc., Q1 2016 Earnings Call, Feb 16, 2016",2016-02-16,"Earnings Calls","Agilent Technologies, Inc.","Operator","Thank you, ladies and gentlemen, for your participation in today's conference. This does conclude the program. You may now disconnect. Good day.",22,"Thank you, ladies and gentlemen, for your participation in today's conference. This does conclude the program. You may now disconnect. Good day."
154924,323237239,934163,"Agilent Technologies Inc., Q1 2016 Earnings Call, Feb 16, 2016",2016-02-16,"Earnings Calls","Agilent Technologies, Inc.","Operator","Good day, ladies and gentlemen, and welcome to the First Quarter 2016 Agilent Technologies Inc. Earnings Conference Call. [Operator Instructions] As a reminder, today's program is being recorded. I would now like to introduce your host for today's program",48,"Good day, ladies and gentlemen, and welcome to the First Quarter 2016 Agilent Technologies Inc. Earnings Conference Call. [Operator Instructions] As a reminder, today's program is being recorded. I would now like to introduce your host for today's program, Alicia Rodriguez, Vice President, Investor Relations. Please go ahead."
154924,323237239,934163,"Agilent Technologies Inc., Q1 2016 Earnings Call, Feb 16, 2016",2016-02-16,"Earnings Calls","Agilent Technologies, Inc.","Executives","Thank you, Jonathan, and welcome, everyone, to Agilent's First Quarter Conference Call for Fiscal Year 2016. With me are Mike McMullen, Agilent's President and CEO; and Didier Hirsch, Agilent's Senior Vice President and CFO. Joining in the Q&A after Didie",328,"Thank you, Jonathan, and welcome, everyone, to Agilent's First Quarter Conference Call for Fiscal Year 2016. With me are Mike McMullen, Agilent's President and CEO; and Didier Hirsch, Agilent's Senior Vice President and CFO. Joining in the Q&A after Didier's comments will be Patrick Kaltenbach, President of Agilent's Life Sciences and Applied Markets Group; Jacob Thaysen, President of Agilent's Diagnostics and Genomics Group; and Mark Doak, President of the Agilent CrossLab Group.
You can find the press release and information to supplement today's discussion on our website at www.investor.agilent.com. While there, please click on the link for financial results under the Financial Information tab. You will find an investor presentation along with revenue breakouts and currency impacts, business segment results and historical financials for Agilent's operations. We will also post a copy of the prepared remarks following this call.
Today's comments by Mike and Didier will refer to non-GAAP financial measures. You will find the most directly comparable GAAP financial metrics and reconciliations on our website. Unless otherwise noted, all references to increases or decreases in financial metrics are year-over-year. As a reminder, we are no longer reporting or commenting on orders or book-to-bill. and our guidance is based on exchange rates as of the last day of the recorded quarter.
And please note that we will refer to core revenue growth, which excludes the impact of currency, the NMR business and acquisitions and divestitures within the past 12 months. Reconciliations between reported and core growth in dollars and percentages can be found in the financial results section on the IR website.
We will also make forward-looking statements about the financial performance of the company. These statements are subject to risks and uncertainties and are only valid as of today. The company assumes no obligation to update them. Please look at the company's recent SEC filings for a more complete picture of our risks and other factors. 
And now I'd like to turn the call over to Mike."
154924,323237239,934163,"Agilent Technologies Inc., Q1 2016 Earnings Call, Feb 16, 2016",2016-02-16,"Earnings Calls","Agilent Technologies, Inc.","Executives","Thanks, Lisa, and hello, everyone. Thank you for joining us on today's call. I'm pleased to report that our team delivered a very strong start to our fiscal 2016, both revenue and earnings are above the high end of our guidance. I would now highlight 3 ke",1234,"Thanks, Lisa, and hello, everyone. Thank you for joining us on today's call. I'm pleased to report that our team delivered a very strong start to our fiscal 2016, both revenue and earnings are above the high end of our guidance. I would now highlight 3 key results. 
First, revenue was up over 6% on a core basis. Second, we delivered an operating margin increase of 200 basis points from a year ago to 20.2% adjusted for Keysight billings. Finally, adjusted EPS of $0.46 was up 12% over last year.
Our Q1 results are driven by continued strength in the pharma, clinical and diagnostics markets with the return to growth in academia and government. Market demand remained strong for our liquid chromatography, CrossLab services and consumables, and diagnostics and genomics offering. Geographically, all regions grew on a core basis with strong growth in China. Let me highlight the Q1 results by our 3 business groups.
The Life Science and Applied Markets Group delivered core revenue growth of 2%. We see continued strong global pharma demand, growth return in academia and government markets, and China government investments in environmental and food markets. All of this offset continued weaknesses for new equipment purchases in the chemical and engineering market space. LSAG's operating margin for the quarter was 21.7%, up 210 basis points from a year ago. As a reminder, in November, we closed the acquisition of Seahorse Bioscience. Integration activities are in full swing with the team excited to be part of Agilent.
LSAG continued to strengthen its portfolio in Q1. We released 2 new refractive index detectors, the 1260 and 1290 Infinity II RID. These detectors help expand the capabilities of modern UHPLC chromatography to make difficult measurements in certain chemical, biopharma and food application.
Agilent's innovation strength was recognized in the January edition of Analytical Scientist magazine. We were honored with an Innovation Award for our unique LC dual needle technology. This is a breakthrough in the way samples are injected into Agilent's LC products. The unique design enables fast injection cycles, scalable injection volumes and ultralow carryover.
Next is the Agilent CrossLab Group. We continue to see consistently strong revenue results. Our core revenue growth was 10% in Q1. Strong pharma and chemical and energy market demand drove growth in our services and consumables offering.
Our operating margin was 22.1% for the quarter. This is up 140 basis points from a year ago. We continued bringing novel, new chemistries to market. For example, we released the AdvanceBio SEC family of products. These innovative new products are designed for accurate and precise size exclusion chromatography targeted at biopharma applications. Early adopting customers are reporting significant economic and performance benefits over any current technologies offered by our competitors.
Finally, they Diagnostics and Genomics Group continued to demonstrate momentum. In Q1, DGG delivered 12% core revenue growth with strength across all of its businesses. The pathology business continued a steady trajectory to market growth rate. We see strong growth for Dako Omnis reagents and growing revenue, PD-L1 diagnostics. The companion diagnostics business also continued to demonstrate momentum.
Double-digit growth in nucleic acids and genomics reflected strong demand from pharma and clinical markets in the favorable compare. DGG's operating margin for the quarter was 9.6%, that's up 910 basis points from a year ago. I want to remind you that last year, this business broke even in Q1 of fiscal 2015.
Last year, our Dako complementary diagnostic for Bristol-Myers Squibb's OPDIVO was approved by the FDA for non-squamous, non-small cell lung cancer. In January of this year, the FDA approved to expand the use of this PD-L1 diagnostics to include patients with melanoma. Positive PD-L1 status in melanoma has been correlated with the treatment effectiveness of Bristol-Myers Squibb's drug treatment. Agilent is the first company to provide FDA-approved test for lung cancer and melanoma for PD-L1 markers.
Now I'll take a brief look at Agilent's revenues by end market performance on a core basis. We saw strength in all our life sciences and diagnostics market. Continued robust demand drove pharma revenue up 19%. Growth was fueled by technology refresh deals, new product uptake and aftermarket demand for services and consumables. Our clinical and diagnostics revenue was up 7%, and we experienced a return to growth in academia and government of 4%. This growth was significantly driven by the authorization of larger research budgets in the U.S.
Applied end market performance was generally soft except for environmental, which was up 9%, driven by strength in China. Food declined 1%. Our food market strength in China was offset by soft demand in developed countries. Chemical and energy declined 2%, driven by the well-publicized macroeconomic concerns.
Let me provide an update on our operating margin-proven initiatives. This quarter marks the fourth consecutive quarter of year-over-year operating margin improvement. This is how we are driving the sustained performance. We are building a new company portfolio. We have exited unattractive businesses and are acquiring new ones to enable our growth strategy. Our multiyear Agile Agilent program is simplifying our company, making it more nimble and lowering our costs. Finally, while we are improving our execution capabilities, transforming our culture to work as one team across the entire company, we called this One Agilent.
As we enter the second year of the new Agilent, here is what you can expect as we move forward. We are building a new business, one that delivers above-market growth. We will continue to target operating margin expansion. Finally, we are driving a balanced capital allocation policy that includes increased levels of free cash flow being returned to shareholders.
Going forward, we will continue to make tough decisions to ensure our long-term competitiveness. For example, we have just frozen our U.S.-defined benefits retirement plan. This change is effective in the second half of fiscal 2016. I've also spoke with many of you about our multiple ERP systems and oversized IT environment. We continue to streamline our IT systems and infrastructure to reduce costs and increase effectiveness. While work remains, we are pleased with the start to the second year of the new Agilent and our progress in transforming the company. Let me share my view on the current market outlook.
The principle of new Agilent is be realistic and to closely monitor market conditions that could affect our business. Global macroeconomic concerns are pressuring some end markets in emerging economies. The good news is that we'll see solid market conditions to other end markets and geography. I remain confident in our ability to achieve our full year core growth and operating margin goals. I am also confident that we will make course correction as market conditions dictate.
We are strengthening our portfolio, building on our prior year introductions. We have an exciting pipeline of compelling new offerings set to launch this year. In tandem of these new offerings, we have created a new go-to-market capability. We have a focused, energized sales force, and we are overhauling our e-commerce environment to make it easier for customers to do business with us.
And most importantly, across the company, we have the organizational capability to execute and deliver. The Agilent team is aligned and highly energized, driven to win the marketplace. 
Thank you for being on the call today. I will now turn it over to Didier, who will provide additional insights on our financial results and our updated guidance. Didier?"
154924,323237239,934163,"Agilent Technologies Inc., Q1 2016 Earnings Call, Feb 16, 2016",2016-02-16,"Earnings Calls","Agilent Technologies, Inc.","Executives","Yes. Thank you, Mike, and hello, everyone. To summarize Q1 results, they are above the high end of our revenue and EPS guidance even as currency impacted revenue by $7 million and OP by $2 million.The EPS beat was the result of the higher revenues as we",283,"Yes. Thank you, Mike, and hello, everyone. To summarize Q1 results, they are above the high end of our revenue and EPS guidance even as currency impacted revenue by $7 million and OP by $2 million.
The EPS beat was the result of the higher revenues as well as favorable mix. Our adjusted operating margin of 20.2% and operating cash flow of $106 million were strong. We bought back $200 million or 4.9 million shares in Q1. 
I'll turn now to the guidance for fiscal year 2016. We are confirming the core revenue growth guidance of 4.0% to 4.5% we provided in November. However, the strengthening of the U.S. dollar in our November guidance is expected to have a negative impact of about $50 million on reported revenues, $13 million on operating profit and $0.033 on EPS.
As a result, we now expect fiscal year '16 revenues of $4.1 billion to $4.12 billion, and EPS of $1.81 to $1.87. To note, in the last 2 weeks, we've seen the U.S. dollar weaken. If the weakening continues, we will reflect the positive impact in our May guidance.
Turning to our share buyback program. We remain committed to our plan of repurchasing another $280 million of shares before fiscal year-end. 
Finally, moving to the guidance for our second quarter. We're expecting Q2 revenues of $965 million and to $985 million, reflecting typical second quarter seasonality versus Q1.
The mid-point corresponds to a core revenue growth of 4.0%. The sequential reduction in revenues will translate into a sequential reduction in EPS. We expect Q2 EPS to branch between 39 -- excuse me, $0.37 to $0.39. 
With that, I'll turn it over to Alicia for the Q&A."
154924,323237239,934163,"Agilent Technologies Inc., Q1 2016 Earnings Call, Feb 16, 2016",2016-02-16,"Earnings Calls","Agilent Technologies, Inc.","Executives","Thank you, Didier. And Jonathan, will you please give the instructions for the Q&A?",14,"Thank you, Didier. And Jonathan, will you please give the instructions for the Q&A?"
154924,323237239,934163,"Agilent Technologies Inc., Q1 2016 Earnings Call, Feb 16, 2016",2016-02-16,"Earnings Calls","Agilent Technologies, Inc.","Operator","[Operator Instructions] Our first question comes from the line of Doug Schenkel from Cowen and Company.",16,"[Operator Instructions] Our first question comes from the line of Doug Schenkel from Cowen and Company."
154924,323237239,934163,"Agilent Technologies Inc., Q1 2016 Earnings Call, Feb 16, 2016",2016-02-16,"Earnings Calls","Agilent Technologies, Inc.","Analysts","This is Ryan Blicker filling in for Doug. Starting with operating margin guidance, it seems as though you reduced full-year guidance by about 10 basis points. But it seems like, though, most of that was FX. Can you confirm that, that was all due to FX? Or",56,"This is Ryan Blicker filling in for Doug. Starting with operating margin guidance, it seems as though you reduced full-year guidance by about 10 basis points. But it seems like, though, most of that was FX. Can you confirm that, that was all due to FX? Or are there other changes we should be thinking about?"
154924,323237239,934163,"Agilent Technologies Inc., Q1 2016 Earnings Call, Feb 16, 2016",2016-02-16,"Earnings Calls","Agilent Technologies, Inc.","Executives","No, it was entirely due to FX, absolutely. As I had mentioned, the FX impact was $13 million. And that is precisely the amount of the reduction in operating profit reflected in our guidance. And we have maintained the guidance at 20.2%, which was the aver",59,"No, it was entirely due to FX, absolutely. As I had mentioned, the FX impact was $13 million. And that is precisely the amount of the reduction in operating profit reflected in our guidance. And we have maintained the guidance at 20.2%, which was the average of 20% to 25% that we had guided to in November notion [ph]."
154924,323237239,934163,"Agilent Technologies Inc., Q1 2016 Earnings Call, Feb 16, 2016",2016-02-16,"Earnings Calls","Agilent Technologies, Inc.","Analysts","Okay. And looking at the pharma end market. Obviously, another very strong performing the quarter. Can you give us more details on what drove the strength? And where there any one-time dynamics like a budget flush or pull forward of revenue? And I guess,",63,"Okay. And looking at the pharma end market. Obviously, another very strong performing the quarter. Can you give us more details on what drove the strength? And where there any one-time dynamics like a budget flush or pull forward of revenue? And I guess, lastly, do you still expect growth in this end market to approximate high single digits for the full year?"
154924,323237239,934163,"Agilent Technologies Inc., Q1 2016 Earnings Call, Feb 16, 2016",2016-02-16,"Earnings Calls","Agilent Technologies, Inc.","Executives","Sure, Brian, this is Mike. Let me make a few comments on the pharma strength we saw in the first quarter. Clearly, no one-time events. And we saw great pacing throughout the quarter. This would highlight a few points here. One, we're seeing a strong growt",157,"Sure, Brian, this is Mike. Let me make a few comments on the pharma strength we saw in the first quarter. Clearly, no one-time events. And we saw great pacing throughout the quarter. This would highlight a few points here. One, we're seeing a strong growth in liquid chromatography, both in terms of the uptake in our new products, but also technology refresh that is underway within this segment. Also, customers responding quite positively to our biopharma solutions. And then across the board between biopharma and pharma, we're seeing strong demand for enterprise-wide services and consumables. 19% growth for the first quarter. We don't expect that level of double-digit growth to continue all through the year, but we're quite confident in our projections of high single digit we're calling for 8% overall growth for the year in pharma. So we see no signs that this market won't remind robust for us for the rest of this year."
154924,323237239,934163,"Agilent Technologies Inc., Q1 2016 Earnings Call, Feb 16, 2016",2016-02-16,"Earnings Calls","Agilent Technologies, Inc.","Operator","Our next question comes from the line of Paul Knight from Janney Montgomery.",13,"Our next question comes from the line of Paul Knight from Janney Montgomery."
154924,323237239,934163,"Agilent Technologies Inc., Q1 2016 Earnings Call, Feb 16, 2016",2016-02-16,"Earnings Calls","Agilent Technologies, Inc.","Analysts","Regarding the guidance with EPS. I know when you guided last time, the euro had already fallen relative to the dollars. So are you measuring the euro on today's exchange rate, last week's exchange rate? I mean, could you flesh out a little bit more?",45,"Regarding the guidance with EPS. I know when you guided last time, the euro had already fallen relative to the dollars. So are you measuring the euro on today's exchange rate, last week's exchange rate? I mean, could you flesh out a little bit more?"
154924,323237239,934163,"Agilent Technologies Inc., Q1 2016 Earnings Call, Feb 16, 2016",2016-02-16,"Earnings Calls","Agilent Technologies, Inc.","Executives","Great question, Paul, it's the same question I asked Didier, and I'm going to pass it back to Didier.",19,"Great question, Paul, it's the same question I asked Didier, and I'm going to pass it back to Didier."
154924,323237239,934163,"Agilent Technologies Inc., Q1 2016 Earnings Call, Feb 16, 2016",2016-02-16,"Earnings Calls","Agilent Technologies, Inc.","Executives","Yes, Paul, so the guidance is always based on the exchange rate on the last day of the quarter we report. So the new guidance is based on the exchange rate as of October -- also of January 30, 2016. And it was between November -- October 30, which was in",126,"Yes, Paul, so the guidance is always based on the exchange rate on the last day of the quarter we report. So the new guidance is based on the exchange rate as of October -- also of January 30, 2016. And it was between November -- October 30, which was in November guidance, and then January 30, which is the present guidance. The dollar strengthened, but we are seeing it weakening since November 30 a little bit, vis-a-vis the euro and certainly, vis-Ã -vis the yen. So if that continues, it will be reflected in our May guidance. Again, there was no change at all to our November guidance except for those that result directly from the change in exchange rates between October 30 and January 30."
154924,323237239,934163,"Agilent Technologies Inc., Q1 2016 Earnings Call, Feb 16, 2016",2016-02-16,"Earnings Calls","Agilent Technologies, Inc.","Executives","Yes, Paul, if I could just emphasize that, again, I mean, the fundamentals assumptions we made that underlined our prior quarter guidance remain intact with the exception being FX.",29,"Yes, Paul, if I could just emphasize that, again, I mean, the fundamentals assumptions we made that underlined our prior quarter guidance remain intact with the exception being FX."
154924,323237239,934163,"Agilent Technologies Inc., Q1 2016 Earnings Call, Feb 16, 2016",2016-02-16,"Earnings Calls","Agilent Technologies, Inc.","Analysts","And then, lastly, Mike, what stands out on technology is the PD-L1 approval and also the large molecule technology in CrossLab. Do you sit there with those 2 products on your menu thinking there's a bias toward more organic? Or where you at with those 2 t",49,"And then, lastly, Mike, what stands out on technology is the PD-L1 approval and also the large molecule technology in CrossLab. Do you sit there with those 2 products on your menu thinking there's a bias toward more organic? Or where you at with those 2 that you mentioned?"
154924,323237239,934163,"Agilent Technologies Inc., Q1 2016 Earnings Call, Feb 16, 2016",2016-02-16,"Earnings Calls","Agilent Technologies, Inc.","Executives","Paul, just to make sure I understand the question. Relative to -- thanks for the comments and observation. Just make sure I understand the question. This will be relative to our expectation of a continued organic growth with those 2 new -- with those...",44,"Paul, just to make sure I understand the question. Relative to -- thanks for the comments and observation. Just make sure I understand the question. This will be relative to our expectation of a continued organic growth with those 2 new -- with those..."
154924,323237239,934163,"Agilent Technologies Inc., Q1 2016 Earnings Call, Feb 16, 2016",2016-02-16,"Earnings Calls","Agilent Technologies, Inc.","Analysts","Yes, are they enough to move the needle higher than what you would have thought 90 days ago on last guidance?",21,"Yes, are they enough to move the needle higher than what you would have thought 90 days ago on last guidance?"
154924,323237239,934163,"Agilent Technologies Inc., Q1 2016 Earnings Call, Feb 16, 2016",2016-02-16,"Earnings Calls","Agilent Technologies, Inc.","Executives","Well, let me make a comment on the CrossLab services and consumables, and then I'll pass it over to Jacob on the PD-L1. When we put together our guidance for the year, we were expecting a strong growth in our CrossLab and services and consumables business",154,"Well, let me make a comment on the CrossLab services and consumables, and then I'll pass it over to Jacob on the PD-L1. When we put together our guidance for the year, we were expecting a strong growth in our CrossLab and services and consumables business. So that's part of the reason why we had a lot of confidence coming this year and still have the confidence in this year about making our organic core revenue growth targets. Because as you've seen, even in a -- even in the chemical energy space, which down in terms of new instrument purchases, they continue to buy, and you see strong growth of service and consumables. So what I leave you is we expect continued strength in that space, but we were assuming that to be the case when we guided the company earlier this year. And, Jacob, why don't you share your thoughts on the PD-L1?"
154924,323237239,934163,"Agilent Technologies Inc., Q1 2016 Earnings Call, Feb 16, 2016",2016-02-16,"Earnings Calls","Agilent Technologies, Inc.","Executives","Yes, thanks, Paul. And you're right that we got the indication approval also for the melanoma for the OPDIVO drug, and that's a great next step in the opportunities with PD-L1. I will not say that it will change the needle on an Agilent level, but it defi",107,"Yes, thanks, Paul. And you're right that we got the indication approval also for the melanoma for the OPDIVO drug, and that's a great next step in the opportunities with PD-L1. I will not say that it will change the needle on an Agilent level, but it definitely is a part of our growth story in DDG. But I will remind also that this drug -- or this companion diagnostic has only been out now for a few months, and we are still in the early days of seeing the uptake of it. So I see good progress, but not something that really moves the needle here."
154924,323237239,934163,"Agilent Technologies Inc., Q1 2016 Earnings Call, Feb 16, 2016",2016-02-16,"Earnings Calls","Agilent Technologies, Inc.","Operator","Our next question comes from the line of Dan Arias from Citigroup.",12,"Our next question comes from the line of Dan Arias from Citigroup."
154924,323237239,934163,"Agilent Technologies Inc., Q1 2016 Earnings Call, Feb 16, 2016",2016-02-16,"Earnings Calls","Agilent Technologies, Inc.","Analysts","Mike, last quarter, you mentioned that industrial weakness you were seeing had a spilled over into the environmental business. I'm just wondering whether that's reversed a bit this quarter. So I guess, is it fair to say that maybe growth in environmental",70,"Mike, last quarter, you mentioned that industrial weakness you were seeing had a spilled over into the environmental business. I'm just wondering whether that's reversed a bit this quarter. So I guess, is it fair to say that maybe growth in environmental this year could be a couple of points higher than the cyclical segments? I guess, how would you just compare expectations from environmental versus industrial for this year?"
154924,323237239,934163,"Agilent Technologies Inc., Q1 2016 Earnings Call, Feb 16, 2016",2016-02-16,"Earnings Calls","Agilent Technologies, Inc.","Executives","Yes, Dan, thanks for the careful observation and -- it was actually the environmental business was a pleasant surprise in the first quarter. We knew that China was going to be strong, and we've been talking about China in our view of investments since Chi",192,"Yes, Dan, thanks for the careful observation and -- it was actually the environmental business was a pleasant surprise in the first quarter. We knew that China was going to be strong, and we've been talking about China in our view of investments since Chinese government is making in places such as the environmental market and food safety. So -- but I will say that we were happy to see the growth in other segments because yes, the chemical and energy space has been under pressure. But what we're still seeing is that fracking is still going on. So the production -- while prices of oil are down, the production demand is stable. And in fact, you look at the oil production, I mean gasoline production in the U.S., for example, is perhaps going up. So we're seeing a continued need to do environmental testings. So that's been a nice reaffirmation, if you will, of our outlook for the year which call for low single-digit growth in environmental. We thought that China would carry the whole load for us, but I think we got a little help from the U.S. as well."
154924,323237239,934163,"Agilent Technologies Inc., Q1 2016 Earnings Call, Feb 16, 2016",2016-02-16,"Earnings Calls","Agilent Technologies, Inc.","Analysts","Okay. And then maybe just staying in the BRIC region, any change in the way that you're thinking about Brazil and Russia, and how that might end up this year?",30,"Okay. And then maybe just staying in the BRIC region, any change in the way that you're thinking about Brazil and Russia, and how that might end up this year?"
154924,323237239,934163,"Agilent Technologies Inc., Q1 2016 Earnings Call, Feb 16, 2016",2016-02-16,"Earnings Calls","Agilent Technologies, Inc.","Executives","Unfortunately, no. I think we're still looking for very challenged conditions in those countries. I know there's been some recent news today about Russia, and perhaps working with some of the other oil-producing countries to change some aspects in product",65,"Unfortunately, no. I think we're still looking for very challenged conditions in those countries. I know there's been some recent news today about Russia, and perhaps working with some of the other oil-producing countries to change some aspects in production, maybe to have some dynamics in terms of their economy. But right now, we're assuming continuation of the current challenged conditions for Brazil and Russia."
154924,323237239,934163,"Agilent Technologies Inc., Q1 2016 Earnings Call, Feb 16, 2016",2016-02-16,"Earnings Calls","Agilent Technologies, Inc.","Operator","Our next question comes from the line of Isaac Ro from Goldman Sachs.",13,"Our next question comes from the line of Isaac Ro from Goldman Sachs."
154924,323237239,934163,"Agilent Technologies Inc., Q1 2016 Earnings Call, Feb 16, 2016",2016-02-16,"Earnings Calls","Agilent Technologies, Inc.","Analysts","Mike, first question was on gross margin. It's pretty big year-over-year improvement there. I was wondering if you could maybe -- the breakdown in the key drivers of gross margin performance, the situation might have been one-time benefits in these onto w",55,"Mike, first question was on gross margin. It's pretty big year-over-year improvement there. I was wondering if you could maybe -- the breakdown in the key drivers of gross margin performance, the situation might have been one-time benefits in these onto which there are some items that are going to continue as the year progresses."
154924,323237239,934163,"Agilent Technologies Inc., Q1 2016 Earnings Call, Feb 16, 2016",2016-02-16,"Earnings Calls","Agilent Technologies, Inc.","Executives","Yes, let me make a few level -- high-level comments here then, Didier, you can jump in and augment my comments. But I think, one, there were some one-time improvements, and I think we highlighted those in typically as it related to DDG, where we had some",178,"Yes, let me make a few level -- high-level comments here then, Didier, you can jump in and augment my comments. But I think, one, there were some one-time improvements, and I think we highlighted those in typically as it related to DDG, where we had some revenue that was really trapped last year in the first quarter due to production issues. But the lion's share of the improvement is resulting from our continued sustained efforts that I highlighted in my call, both the portfolio efforts in terms of the businesses we're no longer in, the businesses we acquired as to our change in our gross margin profile. We're taking real cost out of our system through the Agile Agilent program. So there were some one-time events as it relates to the revenue for DGG, but the bulk of our -- a bulk of our margin improvement is from the underlying core efforts we've had over the last several quarters to fundamentally change the operating model of the company. Didier, anything else that you would add to that?"
154924,323237239,934163,"Agilent Technologies Inc., Q1 2016 Earnings Call, Feb 16, 2016",2016-02-16,"Earnings Calls","Agilent Technologies, Inc.","Executives","Just to point that also contributed. Number one, you will recall that last year, we were spending heavily on remediation points that drives the FDA warning letters. So that is -- now we are spending a significant amounts to maintain our strong position no",134,"Just to point that also contributed. Number one, you will recall that last year, we were spending heavily on remediation points that drives the FDA warning letters. So that is -- now we are spending a significant amounts to maintain our strong position now, but certainly not in the same magnitude of what we have spent for 2 years in a row. And then the second point is there was a favorable mix. We talked about how strong the pharma businesses is, and pharma does generate higher gross margin than the rest of the businesses. So favorable mix. And I know that the pharma being just one of them, but a significant one. And then the FDA -- the reduction in FDA spend also in addition to all the points that Mike has made."
154924,323237239,934163,"Agilent Technologies Inc., Q1 2016 Earnings Call, Feb 16, 2016",2016-02-16,"Earnings Calls","Agilent Technologies, Inc.","Analysts","Okay, that's helpful. And then just a follow-up on CrossLab. You mentioned the driver there, looking like it was just healthy demand in the end market. But I don't think of that businesses as necessarily having as a sustainable growth rate in that double-",100,"Okay, that's helpful. And then just a follow-up on CrossLab. You mentioned the driver there, looking like it was just healthy demand in the end market. But I don't think of that businesses as necessarily having as a sustainable growth rate in that double-digit range. So I'm wondering if there was an element of market share that, that was helpful. It's just not a market where we have a ton of quarter-to-quarter visibility. So I was wondering if you could put some color around -- the accentuation market share was helpful and how you would characterize where it's coming from."
154924,323237239,934163,"Agilent Technologies Inc., Q1 2016 Earnings Call, Feb 16, 2016",2016-02-16,"Earnings Calls","Agilent Technologies, Inc.","Executives","Great, great question. I'll make a few comments. And Mark, why don't you jump in with your thoughts here. As we looked at the overall growth rate for CrossLab, you should assume that we're right in the range where we had talked about at the AID, and we th",114,"Great, great question. I'll make a few comments. And Mark, why don't you jump in with your thoughts here. As we looked at the overall growth rate for CrossLab, you should assume that we're right in the range where we had talked about at the AID, and we think there is both market growth. But as you've pointed out, market share gain opportunities for us where -- we've really have changed our view of what the addressable market is for our business. And there's no longer the Agilent install base, but it's the entire lab. And Mark, why don't you talk about some of the things we're doing in terms of capturing market share."
154924,323237239,934163,"Agilent Technologies Inc., Q1 2016 Earnings Call, Feb 16, 2016",2016-02-16,"Earnings Calls","Agilent Technologies, Inc.","Executives","Thanks, Mike. And I think you've hit on the primary piece, which is we continue to see the primary drivers in pharma and also China has been very strong for us. When you pull it all back to when capital spending is constrained, we continue to see customer",103,"Thanks, Mike. And I think you've hit on the primary piece, which is we continue to see the primary drivers in pharma and also China has been very strong for us. When you pull it all back to when capital spending is constrained, we continue to see customers improve the productivity of their assets through services and the chemistries we talked about earlier. But I think what's -- was more robust than it was a year ago even is really the strength of our multi-vendor and enterprise portfolio. And that does allow you to take share, if you will, from the broader market."
154924,323237239,934163,"Agilent Technologies Inc., Q1 2016 Earnings Call, Feb 16, 2016",2016-02-16,"Earnings Calls","Agilent Technologies, Inc.","Operator","Our next question comes from the line of Ross Muken from Evercore ISI.",13,"Our next question comes from the line of Ross Muken from Evercore ISI."
154924,323237239,934163,"Agilent Technologies Inc., Q1 2016 Earnings Call, Feb 16, 2016",2016-02-16,"Earnings Calls","Agilent Technologies, Inc.","Analysts","So I'm just trying to double check on the guidance math here because I think a few of us are a little bit confused. So we beat the quarter, right, by around, I don't know, call it $0.03. We lost $3.03 on FX, roughly, and the range came down forward. So I'",118,"So I'm just trying to double check on the guidance math here because I think a few of us are a little bit confused. So we beat the quarter, right, by around, I don't know, call it $0.03. We lost $3.03 on FX, roughly, and the range came down forward. So I'm just trying to get a sense for -- again, it seems like FX was the key delta. But just the simple math was suggested to me a little less downward pressure on the full year range. And again, I realize there's probably a few other moving parts. So I'm just trying to make sure I understand how we're doing versus the plan for the year."
154924,323237239,934163,"Agilent Technologies Inc., Q1 2016 Earnings Call, Feb 16, 2016",2016-02-16,"Earnings Calls","Agilent Technologies, Inc.","Executives","Sure, we're happy to -- Didier would be happy to clarify.",11,"Sure, we're happy to -- Didier would be happy to clarify."
154924,323237239,934163,"Agilent Technologies Inc., Q1 2016 Earnings Call, Feb 16, 2016",2016-02-16,"Earnings Calls","Agilent Technologies, Inc.","Executives","Yes. No, so the -- as I mentioned earlier, we have reduced our top line revenue from -- at midpoint from 4160 to 4110, which is a $50 million reduction. We've reduced our operating profit from $830 million to $817 million, that's $13 million, and that's e",209,"Yes. No, so the -- as I mentioned earlier, we have reduced our top line revenue from -- at midpoint from 4160 to 4110, which is a $50 million reduction. We've reduced our operating profit from $830 million to $817 million, that's $13 million, and that's entirely due to the impact of the strengthening of the dollar and related to the $50 million. And then I mentioned $0.033, but with rounding, we are going from a midpoint of $1.84 to the new midpoint of -- to the -- sorry, we're going from the midpoint of $1.88 to the mid-point of $1.84, and that's $0.04 and that's a $0.033, which is rounded because of the -- going from one to the other, you can understand that. So basically, what we felt is even though we are starting the year very strongly, we felt that with the overall macroeconomic condition, it would not be wise at this point in time to change the guidance we had provided for revenue guidance of 4% to 4.5%. We have the same confidence as we'd had in the month of November when we provided that guidance that we're in good shape to hit it and perhaps did it, but certainly, didn't want to change it."
154924,323237239,934163,"Agilent Technologies Inc., Q1 2016 Earnings Call, Feb 16, 2016",2016-02-16,"Earnings Calls","Agilent Technologies, Inc.","Analysts","Yes, I guess, what I'm trying to get at it is sort of the comments last quarter suggested sort of conservatism, right? You obviously can't control what happens with the dollar. So that's understandable. I'm just trying to get a sense for how much conserva",86,"Yes, I guess, what I'm trying to get at it is sort of the comments last quarter suggested sort of conservatism, right? You obviously can't control what happens with the dollar. So that's understandable. I'm just trying to get a sense for how much conservatism there is now in the forecasting, whether or not we have risk to that core growth rate, given again that the range came down. But you reiterated the top line. I'm just making sure that we're sort of not over-extrapolating here."
154924,323237239,934163,"Agilent Technologies Inc., Q1 2016 Earnings Call, Feb 16, 2016",2016-02-16,"Earnings Calls","Agilent Technologies, Inc.","Executives","Sure, Ross. This is Mike. I really appreciate the opportunity to comment on this. So if you'll -- that conservatism meter on our guidance, it's at the same level as it was last quarter. So the only real fundamental change in terms of our outlook is the vi",52,"Sure, Ross. This is Mike. I really appreciate the opportunity to comment on this. So if you'll -- that conservatism meter on our guidance, it's at the same level as it was last quarter. So the only real fundamental change in terms of our outlook is the view on FX. That's it."
154924,323237239,934163,"Agilent Technologies Inc., Q1 2016 Earnings Call, Feb 16, 2016",2016-02-16,"Earnings Calls","Agilent Technologies, Inc.","Executives","And we saw no reason to change our core revenue growth to offset a part of the FX because FX can go up and down and it's too volatile nowadays to immediately -- unless we see some long-term structural changes as we have last year and we reacted accordingl",71,"And we saw no reason to change our core revenue growth to offset a part of the FX because FX can go up and down and it's too volatile nowadays to immediately -- unless we see some long-term structural changes as we have last year and we reacted accordingly. We were not going to react by what we believe are temporary changes in FX by actions on our structural spend."
154924,323237239,934163,"Agilent Technologies Inc., Q1 2016 Earnings Call, Feb 16, 2016",2016-02-16,"Earnings Calls","Agilent Technologies, Inc.","Analysts","Okay. So sorry, I'm going to monopolize for a minute, just because I'm trying to make sure my inbox lines up. I'm getting everyone sort of the answers they need. So all right, so we -- to be clear, we have the FX hit, I'd love to also understand what were",158,"Okay. So sorry, I'm going to monopolize for a minute, just because I'm trying to make sure my inbox lines up. I'm getting everyone sort of the answers they need. So all right, so we -- to be clear, we have the FX hit, I'd love to also understand what were the key currencies because most of us can see that the dollars actually, again, we'll see if it sustains, weakened a bit. And so it seems like its outside of the euro and the yen that might have caused some of the headwinds. So I'd love to hear just a little bit of color on, maybe it's the won or some of the other emerging market currencies. And just to be clear also on the second point. So we didn't really baked in that deep from this quarter. Is that sort of where the conservatism comes in? And then, I'm done, I promise. I'll see the floor."
154924,323237239,934163,"Agilent Technologies Inc., Q1 2016 Earnings Call, Feb 16, 2016",2016-02-16,"Earnings Calls","Agilent Technologies, Inc.","Executives","Yes, I mean, in terms of the currencies, we have a detailed model that takes into account obviously all the currencies. The dollar versus the euro or the dollar versus the yen, had a major impact also, I think, dollar versus the British pound. And again,",125,"Yes, I mean, in terms of the currencies, we have a detailed model that takes into account obviously all the currencies. The dollar versus the euro or the dollar versus the yen, had a major impact also, I think, dollar versus the British pound. And again, the -- today, I mean today's guidance is based on the October -- January 30 exchange rates, so the euro to $1.84 and the yen, and vis-a-vis the yen -- the U.S. dollar is JPY 121.4. And we are seeing that at today's rate, if we had provided the guidance base on just say if we had -- we are able to instantly reflect the currencies as of the date of the guidance, we'll have a very different guidance."
154924,323237239,934163,"Agilent Technologies Inc., Q1 2016 Earnings Call, Feb 16, 2016",2016-02-16,"Earnings Calls","Agilent Technologies, Inc.","Executives","And I think your second statement is probably a fair one.",11,"And I think your second statement is probably a fair one."
154924,323237239,934163,"Agilent Technologies Inc., Q1 2016 Earnings Call, Feb 16, 2016",2016-02-16,"Earnings Calls","Agilent Technologies, Inc.","Operator","Our next question comes from the line of Jeff Elliott from Robert W. Baird.",14,"Our next question comes from the line of Jeff Elliott from Robert W. Baird."
154924,323237239,934163,"Agilent Technologies Inc., Q1 2016 Earnings Call, Feb 16, 2016",2016-02-16,"Earnings Calls","Agilent Technologies, Inc.","Analysts","So question on -- for Mike on chemical and energy. You're down 2% this quarter. The last couple of quarters, you're down 9% or 10%. I guess, can you give us a sense for what's happening on the E&P side? You talked about stability on the refining side. But",79,"So question on -- for Mike on chemical and energy. You're down 2% this quarter. The last couple of quarters, you're down 9% or 10%. I guess, can you give us a sense for what's happening on the E&P side? You talked about stability on the refining side. But what do you see on the E&P side? It seems like that's kind of what a lot of the -- I guess the improvement relative to last couple of quarters?"
154924,323237239,934163,"Agilent Technologies Inc., Q1 2016 Earnings Call, Feb 16, 2016",2016-02-16,"Earnings Calls","Agilent Technologies, Inc.","Executives","Yes, actually it's probably worth may be just doing a little bridge on the last few quarters because in fact, we've seen relative flat performance over the last, last several quarters. And while instruments were down, the percentage you were talking about",270,"Yes, actually it's probably worth may be just doing a little bridge on the last few quarters because in fact, we've seen relative flat performance over the last, last several quarters. And while instruments were down, the percentage you were talking about high single digits, we've seen a continued ability to offset through services and consumables. So what I would say is that the chemical/energy market is sort of playing out the way we had expected for the year. So we wish we had a different story here. But the price of -- oil price is low, as you know, but the product demand still remains pretty, pretty strong for our customers' products. So the refineries are running, the chemical plants are running and then we're really trying to sell to them new equipment based on a l productivity message. But at the same point in time, recognize that if I use the equipment longer, it's a good opportunity for us on the services and consumables side. One thing I would ask you to reflect on is that Q1 '15, as you dig in some of the numbers, Q1 '15 really was our best quarter for the whole year. I think we grew 3% in the first quarter of last year on a core basis. We ended up growing, I think, 1% for the whole year. So that shows we weren't declining through the year. And so I wouldn't over-interpret the numbers. We think it's right and kind of the range where we had thought. And Patrick, I don't know if you had any other comments you'd add to that?"
154924,323237239,934163,"Agilent Technologies Inc., Q1 2016 Earnings Call, Feb 16, 2016",2016-02-16,"Earnings Calls","Agilent Technologies, Inc.","Executives","Well, no, not really. I think, as you said, it's playing out as was expected. There's continued pressure along the exploration side and the production side. But for the refinery side, demand really drives. So also, we place some business for us. We try to",98,"Well, no, not really. I think, as you said, it's playing out as was expected. There's continued pressure along the exploration side and the production side. But for the refinery side, demand really drives. So also, we place some business for us. We try to incentivize our customers and give them opportunity to upgrade, to increase their productivity and efficiency. And on the chemical side, I would say that the lower feeds [ph] of price have not yet fully materialized. So we stay with focus for the year -- for the whole segment to be just a flat."
154924,323237239,934163,"Agilent Technologies Inc., Q1 2016 Earnings Call, Feb 16, 2016",2016-02-16,"Earnings Calls","Agilent Technologies, Inc.","Executives","And Jeff, this is Mike. I think we shared these numbers with you in the past, but the way we look at this -- the way we look at our business is about 15% or so in E&P, as you described, exploration and production, which will be about 3% to 4% of our total",87,"And Jeff, this is Mike. I think we shared these numbers with you in the past, but the way we look at this -- the way we look at our business is about 15% or so in E&P, as you described, exploration and production, which will be about 3% to 4% of our total revenues. About 35% of that segment is in refining and the other 50% is in chemicals. So that's how we -- so it sort of -- it remained stable at a subdued level."
154924,323237239,934163,"Agilent Technologies Inc., Q1 2016 Earnings Call, Feb 16, 2016",2016-02-16,"Earnings Calls","Agilent Technologies, Inc.","Operator","Our next question comes from the line of Steve Beuchaw from Morgan Stanley.",13,"Our next question comes from the line of Steve Beuchaw from Morgan Stanley."
154924,323237239,934163,"Agilent Technologies Inc., Q1 2016 Earnings Call, Feb 16, 2016",2016-02-16,"Earnings Calls","Agilent Technologies, Inc.","Analysts","I'd like to follow up just a bit on the pharmaceutical space. It was really helpful to hear just how confident you guys are in the outlook for the year growing 8% in pharma. I wonder if you could maybe add a little bit to the conversation now and talk abo",113,"I'd like to follow up just a bit on the pharmaceutical space. It was really helpful to hear just how confident you guys are in the outlook for the year growing 8% in pharma. I wonder if you could maybe add a little bit to the conversation now and talk about what you're hearing, Mike or Patrick, in your conversations with pharma customers as they talk about their budgets for this year. I apologize for coming back to the topic, but there's a lot of interest out there in the sustainability of growth in the space. So any color you could offer -- how your customers are thinking would be really helpful."
154924,323237239,934163,"Agilent Technologies Inc., Q1 2016 Earnings Call, Feb 16, 2016",2016-02-16,"Earnings Calls","Agilent Technologies, Inc.","Executives","Yes, absolutely. So Patrick, why don't you take that question and I will have one closing comment.",17,"Yes, absolutely. So Patrick, why don't you take that question and I will have one closing comment."
154924,323237239,934163,"Agilent Technologies Inc., Q1 2016 Earnings Call, Feb 16, 2016",2016-02-16,"Earnings Calls","Agilent Technologies, Inc.","Executives","Yes. So what we're hearing from our customers is that they -- actually, they are holding their budgets. We don't see any significant reduction there. And this comes, by the way, across the board from small and medium size and large enterprises. So it's re",95,"Yes. So what we're hearing from our customers is that they -- actually, they are holding their budgets. We don't see any significant reduction there. And this comes, by the way, across the board from small and medium size and large enterprises. So it's really, for us, it's a good mixture between different size companies and also between the different markets talking about small molecule versus biopharmaceuticals. The growth really comes from both side, and this is why we're so confident to be able to maintain, to see this high single digit growth for pharma."
154924,323237239,934163,"Agilent Technologies Inc., Q1 2016 Earnings Call, Feb 16, 2016",2016-02-16,"Earnings Calls","Agilent Technologies, Inc.","Executives","And the other thing that we've done -- so we're giving a broad-based demand across all segments of the market. Then we also continue to do our own math in terms of what's out there in terms of the install base of our products. So we have a pretty good ide",72,"And the other thing that we've done -- so we're giving a broad-based demand across all segments of the market. Then we also continue to do our own math in terms of what's out there in terms of the install base of our products. So we have a pretty good idea on the -- at least from the technology refresh side, how much more demand we can expect in this segment."
154924,323237239,934163,"Agilent Technologies Inc., Q1 2016 Earnings Call, Feb 16, 2016",2016-02-16,"Earnings Calls","Agilent Technologies, Inc.","Analysts","That's extremely helpful. One corollary, one follow-up there. I wonder if you could give us a sense for -- to what extent the success that you're having in pharma, the success you're having in CrossLab are interrelated? Are those to -- and perhaps a littl",69,"That's extremely helpful. One corollary, one follow-up there. I wonder if you could give us a sense for -- to what extent the success that you're having in pharma, the success you're having in CrossLab are interrelated? Are those to -- and perhaps a little bit more or overlapping than CrossLab against some of the other customer verticals? And to what extent is one dependent upon the other?"
154924,323237239,934163,"Agilent Technologies Inc., Q1 2016 Earnings Call, Feb 16, 2016",2016-02-16,"Earnings Calls","Agilent Technologies, Inc.","Executives","Yes. Great, great question. I'm happy to elaborate, and they are highly connected. So when we talk about pharma market demand, it's both driving new equipment purchases, which were the focus on Patrick's comments, but also there is a demand for enterprise",190,"Yes. Great, great question. I'm happy to elaborate, and they are highly connected. So when we talk about pharma market demand, it's both driving new equipment purchases, which were the focus on Patrick's comments, but also there is a demand for enterprise-wide services and consumables. But not -- on the CrossLab side, not only are they investing in ongoing chemistries and services to maintain their operations and support their application needs, what we're also seeing is a change of the model. So what they're doing is they are taking activities that historically have been done inside the company. And our creating, if you will, a new set of services for vendors in our space to handle things such as asset management. And that's created sort of a new set of services that are being created right now in pharma. We haven't seen that new set of services demand develop yet on the chemical/energy side. But we're hopeful that they will down the road. But there's a couple of dynamics going on in the pharma space, which are driving both the new instrument purchases and the consumables and services for CrossLab."
154924,323237239,934163,"Agilent Technologies Inc., Q1 2016 Earnings Call, Feb 16, 2016",2016-02-16,"Earnings Calls","Agilent Technologies, Inc.","Operator","Our next question comes from the line of Tim Evans from Wells Fargo.",13,"Our next question comes from the line of Tim Evans from Wells Fargo."
154924,323237239,934163,"Agilent Technologies Inc., Q1 2016 Earnings Call, Feb 16, 2016",2016-02-16,"Earnings Calls","Agilent Technologies, Inc.","Analysts","Wondered if you can give us a update on market tuck-in acquisitions. What you're thinking about these days in terms of where you might like to plug some holes? And also, are you seeing more opportunities now that some valuations have come in?",44,"Wondered if you can give us a update on market tuck-in acquisitions. What you're thinking about these days in terms of where you might like to plug some holes? And also, are you seeing more opportunities now that some valuations have come in?"
154924,323237239,934163,"Agilent Technologies Inc., Q1 2016 Earnings Call, Feb 16, 2016",2016-02-16,"Earnings Calls","Agilent Technologies, Inc.","Executives","Yes. Thanks, Tim, I appreciate the opportunity to provide a perspective on here. So although we remain focused on our organic growth opportunities, we got a lot of very exciting plans and new products coming out and working on the go-to-market capabilitie",232,"Yes. Thanks, Tim, I appreciate the opportunity to provide a perspective on here. So although we remain focused on our organic growth opportunities, we got a lot of very exciting plans and new products coming out and working on the go-to-market capabilities. As I mentioned in my call, comments, we're really continuing to look for acquisitions that augment our current portfolio and add to our company capabilities. So I think you saw us with the Seahorse deal where we added capabilities in life science research, Cartagenia in the area of next-gen sequencing. We -- to build out our workflow there, and we'd still like to find ways to build out our workflow in next-gen sequencing. And so our stated strategies are really adding capabilities, expand our portfolio, building on our work flow solutions, close with a particular emphasis on life sciences research, next-gen sequencing workflows in the overall consumables and services place. They're our priorities. Well, that being said, most people still have the memories of their 52-week highs. So we'll see how this plays out. And what I will tell you is we will continue to be very disciplined in terms of how we think about M&A, and does it provide an attractive return to our shareholders? And can we do something to make the business better? If we can't make the business better, it's not something we'd be interested in."
154924,323237239,934163,"Agilent Technologies Inc., Q1 2016 Earnings Call, Feb 16, 2016",2016-02-16,"Earnings Calls","Agilent Technologies, Inc.","Operator","Our next question comes from the line of Brandon Couillard from Jefferies.",12,"Our next question comes from the line of Brandon Couillard from Jefferies."
154924,323237239,934163,"Agilent Technologies Inc., Q1 2016 Earnings Call, Feb 16, 2016",2016-02-16,"Earnings Calls","Agilent Technologies, Inc.","Analysts","Mike, you pointed to strengthen in China in the period. Just curious if you could elaborate on the actual growth rate in the first quarter and if there's been any deviation from sort of the mid- to high single-digit target for the year?",43,"Mike, you pointed to strengthen in China in the period. Just curious if you could elaborate on the actual growth rate in the first quarter and if there's been any deviation from sort of the mid- to high single-digit target for the year?"
154924,323237239,934163,"Agilent Technologies Inc., Q1 2016 Earnings Call, Feb 16, 2016",2016-02-16,"Earnings Calls","Agilent Technologies, Inc.","Executives","Yes. Thanks. Appreciate the opportunity to talk about China, one of my favorite topics. So we saw a very good demand in China, high single-digit growth in our integral lab business. And as I mentioned to you, in the past, the markets here are really being",227,"Yes. Thanks. Appreciate the opportunity to talk about China, one of my favorite topics. So we saw a very good demand in China, high single-digit growth in our integral lab business. And as I mentioned to you, in the past, the markets here are really being driven by strong investments in government and policy-driven initiatives around quality-related concerns whether the environment, drug and food safety. So all the market except -- with the exception of chemical/energy, really saw quite strong growth. And we're underpenetrated in DDG business compared to the rest of the company. We've talked about that in the past. And we were under-penetrated in growing market for cancer diagnostics, for example. And I recently read -- saw some statistics that I thought were really quite amazing. There was a report by the Cancer Hospital of the Chinese Academy of Medical Sciences said that every minute, an average of 6 people in the country were diagnosed with cancer. And 5 of those 6 would eventually die of the disease. So unfortunately, there's going to be growing demand for cancer diagnostic as well. I'm going to wrap this all up by saying we remain quite comfortable with the mid- to high single-digit growth expectation we laid out for China. It was strong for us in the first quarter and we expect that to continue through the year."
154924,323237239,934163,"Agilent Technologies Inc., Q1 2016 Earnings Call, Feb 16, 2016",2016-02-16,"Earnings Calls","Agilent Technologies, Inc.","Analysts","But then, one more for Didier. Could you split out the contribution from Seahorse relative to the headwind from NMR in the first quarter in terms of just dollars?",29,"But then, one more for Didier. Could you split out the contribution from Seahorse relative to the headwind from NMR in the first quarter in terms of just dollars?"
154924,323237239,934163,"Agilent Technologies Inc., Q1 2016 Earnings Call, Feb 16, 2016",2016-02-16,"Earnings Calls","Agilent Technologies, Inc.","Executives","No, we don't provide guidance or information regarding the acquisitions. We have stated and we are exactly in line that we expect Seahorse revenue to grow double digits in 2016 versus 2015. And we expect Seahorse operating margin to be also in the double",51,"No, we don't provide guidance or information regarding the acquisitions. We have stated and we are exactly in line that we expect Seahorse revenue to grow double digits in 2016 versus 2015. And we expect Seahorse operating margin to be also in the double digit. So no change to our expectations."
154924,323237239,934163,"Agilent Technologies Inc., Q1 2016 Earnings Call, Feb 16, 2016",2016-02-16,"Earnings Calls","Agilent Technologies, Inc.","Executives","And Patrick, maybe you can just add a few color or comments on how it's going so far.",18,"And Patrick, maybe you can just add a few color or comments on how it's going so far."
154924,323237239,934163,"Agilent Technologies Inc., Q1 2016 Earnings Call, Feb 16, 2016",2016-02-16,"Earnings Calls","Agilent Technologies, Inc.","Executives","Well, the integration of Seahorse is going very well. It's giving us extended reach also into the research model, and this was the whole play. Plus, of course, used the opportunity, use our strength in pharma to sell these products into the pharma space i",91,"Well, the integration of Seahorse is going very well. It's giving us extended reach also into the research model, and this was the whole play. Plus, of course, used the opportunity, use our strength in pharma to sell these products into the pharma space in areas like disease discovery as well. And this business will drive the growth in fiscal year '16. As Didier said, we expect double-digit growth. We have to sail full steam, and we are looking forward to a very strong Q2, Q3, Q4 for this product line."
154924,323237239,934163,"Agilent Technologies Inc., Q1 2016 Earnings Call, Feb 16, 2016",2016-02-16,"Earnings Calls","Agilent Technologies, Inc.","Operator","Our next question comes from the line of Tycho Peterson from JPMorgan.",12,"Our next question comes from the line of Tycho Peterson from JPMorgan."
154924,323237239,934163,"Agilent Technologies Inc., Q1 2016 Earnings Call, Feb 16, 2016",2016-02-16,"Earnings Calls","Agilent Technologies, Inc.","Analysts","Maybe just first on capital deployment. You did $200 million in buybacks in the quarter. You got it for $480 million for the year. I mean, it sounds like you're all front-end loaded, and -- I mean, how do we think about reauthorization once you get to thi",57,"Maybe just first on capital deployment. You did $200 million in buybacks in the quarter. You got it for $480 million for the year. I mean, it sounds like you're all front-end loaded, and -- I mean, how do we think about reauthorization once you get to this tranche given your stocks covered under some precious model?"
154924,323237239,934163,"Agilent Technologies Inc., Q1 2016 Earnings Call, Feb 16, 2016",2016-02-16,"Earnings Calls","Agilent Technologies, Inc.","Executives","Yes, we decided to buy back in Q1 what we had not been able to do in Q4 of the preceding year. And then, we have 5 -- or 10b5-1. And we started forming our -- for your model, you should assume that we are buying about 1/3 of the remaining $280 million on",57,"Yes, we decided to buy back in Q1 what we had not been able to do in Q4 of the preceding year. And then, we have 5 -- or 10b5-1. And we started forming our -- for your model, you should assume that we are buying about 1/3 of the remaining $280 million on a per quarter."
154924,323237239,934163,"Agilent Technologies Inc., Q1 2016 Earnings Call, Feb 16, 2016",2016-02-16,"Earnings Calls","Agilent Technologies, Inc.","Analysts","And then just to clarify the margins because I've had a few questions. I mean, the $13 million hit is the FX hit, but I guess people are having a hard time understanding why you're not seeing faster-than-expected realization of the COGS and SG&A cuts that",64,"And then just to clarify the margins because I've had a few questions. I mean, the $13 million hit is the FX hit, but I guess people are having a hard time understanding why you're not seeing faster-than-expected realization of the COGS and SG&A cuts that you saw some of that this quarter. What doesn't that carry through for the next 3 quarters?"
154924,323237239,934163,"Agilent Technologies Inc., Q1 2016 Earnings Call, Feb 16, 2016",2016-02-16,"Earnings Calls","Agilent Technologies, Inc.","Executives","Well, when I say it's not going to carry through, what I was saying, we saw no reason in the present agreement to change the guidance on an operating margin basis, 20.2%, that we have provided -- 20% to 20.5% that we have provided previously. So -- and ag",87,"Well, when I say it's not going to carry through, what I was saying, we saw no reason in the present agreement to change the guidance on an operating margin basis, 20.2%, that we have provided -- 20% to 20.5% that we have provided previously. So -- and again, with the same level of conservatism, as we had in November. So that's basically the -- that was a premise for us maintaining both the core revenue growth and the operating margin that we have provided in November."
154924,323237239,934163,"Agilent Technologies Inc., Q1 2016 Earnings Call, Feb 16, 2016",2016-02-16,"Earnings Calls","Agilent Technologies, Inc.","Executives","And Didier, I'll just add that in my call comments, I tried to highlight a few things on a longer-term nature to show you that we're not out of gas on this tank in terms of our ability to continue to move our operating margin. We have other larger-hitting",98,"And Didier, I'll just add that in my call comments, I tried to highlight a few things on a longer-term nature to show you that we're not out of gas on this tank in terms of our ability to continue to move our operating margin. We have other larger-hitting programs that are coming on -- that are coming in late 2016 and will carry on in the '17 as well. So this is not a onetime quarter where we just got a favorable mix [indiscernible] there's real fundamental improvements underway in the operating margin capabilities of the company."
154924,323237239,934163,"Agilent Technologies Inc., Q1 2016 Earnings Call, Feb 16, 2016",2016-02-16,"Earnings Calls","Agilent Technologies, Inc.","Analysts","And then speaking of running out of gas, can you talk about refiners holding up? There's the news that -- no, at least 2 of the country's largest refiners are cutting out further gasoline. What gives you conviction that you're business there holds up?",44,"And then speaking of running out of gas, can you talk about refiners holding up? There's the news that -- no, at least 2 of the country's largest refiners are cutting out further gasoline. What gives you conviction that you're business there holds up?"
154924,323237239,934163,"Agilent Technologies Inc., Q1 2016 Earnings Call, Feb 16, 2016",2016-02-16,"Earnings Calls","Agilent Technologies, Inc.","Executives","I'm not sure exactly what you're referring to. But relative to our view is that gasoline will continue to be needed to -- on the economy. And there's going to be demand there. And what we try to share -- and as long as production is running and if there's",96,"I'm not sure exactly what you're referring to. But relative to our view is that gasoline will continue to be needed to -- on the economy. And there's going to be demand there. And what we try to share -- and as long as production is running and if there's demand, the refineries will meet that demand. We've seen no significant changes in the underlying demand for gas. And in fact, Patrick, I think you were showing me some statistics the other day about what's going on in the area of refineries in the U.S."
154924,323237239,934163,"Agilent Technologies Inc., Q1 2016 Earnings Call, Feb 16, 2016",2016-02-16,"Earnings Calls","Agilent Technologies, Inc.","Executives","Yes, I mean, what we see, as Mike said, is the continued demand for, not only in the U.S, but also in the emerging economies like China. So the refineries are basically running at capacity right now. There will be no new-builds. But we see that they repla",129,"Yes, I mean, what we see, as Mike said, is the continued demand for, not only in the U.S, but also in the emerging economies like China. So the refineries are basically running at capacity right now. There will be no new-builds. But we see that they replaced the existing equipment, and they also go into service contracts. But first, they look for opportunities to drive more efficiencies, which gives us an opportunity to upgrade the install base with automation, features and other things to make sure that the customers can save money with the equipment as well. So the oil prices is still driven by the fact that there is over-capacity on the production side. But the refinery volume has not gone down significantly over the last quarters."
154924,323237239,934163,"Agilent Technologies Inc., Q1 2016 Earnings Call, Feb 16, 2016",2016-02-16,"Earnings Calls","Agilent Technologies, Inc.","Analysts","Okay. And then just lastly, can you talk about linearity in the quarter, anything notable in January? You guys have an extra month versus a lot of your comps, so I was just wondering if there's anything worth calling out in January trends versus November",47,"Okay. And then just lastly, can you talk about linearity in the quarter, anything notable in January? You guys have an extra month versus a lot of your comps, so I was just wondering if there's anything worth calling out in January trends versus November or December?"
154924,323237239,934163,"Agilent Technologies Inc., Q1 2016 Earnings Call, Feb 16, 2016",2016-02-16,"Earnings Calls","Agilent Technologies, Inc.","Executives","Yes. I just pointed to 2 things. One is in terms to our normal seasonality of the quarter. Q1 '16 was like prior quarters. We always see a nice strong December as we close off year-end with our customers. And it's followed our typical seasonality pattern",113,"Yes. I just pointed to 2 things. One is in terms to our normal seasonality of the quarter. Q1 '16 was like prior quarters. We always see a nice strong December as we close off year-end with our customers. And it's followed our typical seasonality pattern to November, December and January. I think probably, the only thing of note would be in the DDG side. We had, I think, 1 less day -- working day, I think, this year. So that does affect the genomics business in terms of how much revenue we can get in that quarter. But really, it was sort of businesses usual, if you will, for the first quarter."
154924,323237239,934163,"Agilent Technologies Inc., Q1 2016 Earnings Call, Feb 16, 2016",2016-02-16,"Earnings Calls","Agilent Technologies, Inc.","Operator","Our next question comes from the line of Jack Meehan from Barclays.",12,"Our next question comes from the line of Jack Meehan from Barclays."
154924,323237239,934163,"Agilent Technologies Inc., Q1 2016 Earnings Call, Feb 16, 2016",2016-02-16,"Earnings Calls","Agilent Technologies, Inc.","Analysts","I wanted to follow up on Tycho's last question, just around the academic end market. I'm curious, you mentioned in the presentation are on some of the modestly larger research budgets being released in the U.S. Curious on your view on the NIH and just rea",61,"I wanted to follow up on Tycho's last question, just around the academic end market. I'm curious, you mentioned in the presentation are on some of the modestly larger research budgets being released in the U.S. Curious on your view on the NIH and just really timing related there because of the timing of the Congressional approvals at your end."
154924,323237239,934163,"Agilent Technologies Inc., Q1 2016 Earnings Call, Feb 16, 2016",2016-02-16,"Earnings Calls","Agilent Technologies, Inc.","Executives","Yes, I can take this question, yes. As we have seen moderate growth again in academia and government, which was a positive surprise, and as you've all have read, there are more budgets available now in the U.S. These budgets are slowly released that drove",99,"Yes, I can take this question, yes. As we have seen moderate growth again in academia and government, which was a positive surprise, and as you've all have read, there are more budgets available now in the U.S. These budgets are slowly released that drove some of the growth for us in Q1 and looking at the final, moving forward. We actually see a good final there as well. So we stay with forecast of low single-digit growth of academia and government, at the moment mainly driven by the U.S. But this is where we see the strongest demand."
154924,323237239,934163,"Agilent Technologies Inc., Q1 2016 Earnings Call, Feb 16, 2016",2016-02-16,"Earnings Calls","Agilent Technologies, Inc.","Analysts","Got it. And are your expectations for this level of growth to stay at the same rate through the end of the fiscal year? Or are you assuming the budgets got released a little bit faster from your end?",39,"Got it. And are your expectations for this level of growth to stay at the same rate through the end of the fiscal year? Or are you assuming the budgets got released a little bit faster from your end?"
154924,323237239,934163,"Agilent Technologies Inc., Q1 2016 Earnings Call, Feb 16, 2016",2016-02-16,"Earnings Calls","Agilent Technologies, Inc.","Executives","If the budgets will be released faster, I think it will be probably upside for us. We're now -- our current view is low single digits for academia and government for the year.",33,"If the budgets will be released faster, I think it will be probably upside for us. We're now -- our current view is low single digits for academia and government for the year."
154924,323237239,934163,"Agilent Technologies Inc., Q1 2016 Earnings Call, Feb 16, 2016",2016-02-16,"Earnings Calls","Agilent Technologies, Inc.","Analysts","Well, got it. And then just one other question on the margins and DDG. Definitely appreciate the year-over-year improvement. I was wondering what your thoughts were, bridging through the end of the year, just given how the relative margins compared to the",45,"Well, got it. And then just one other question on the margins and DDG. Definitely appreciate the year-over-year improvement. I was wondering what your thoughts were, bridging through the end of the year, just given how the relative margins compared to the end of 2015."
154924,323237239,934163,"Agilent Technologies Inc., Q1 2016 Earnings Call, Feb 16, 2016",2016-02-16,"Earnings Calls","Agilent Technologies, Inc.","Executives","Great. I know Jacob's given a lot of thought to that potential question, so I'll pass it over to you, Jacob, to provide some color there.",26,"Great. I know Jacob's given a lot of thought to that potential question, so I'll pass it over to you, Jacob, to provide some color there."
154924,323237239,934163,"Agilent Technologies Inc., Q1 2016 Earnings Call, Feb 16, 2016",2016-02-16,"Earnings Calls","Agilent Technologies, Inc.","Executives","Yes, thanks for that, Jack. And first of all, I want to say that we're very pleased to see the improvement versus the Q1 last year. But you're also right that versus Q4, that we saw a bit of a decrease, and that was actually where we most expected. We sit",122,"Yes, thanks for that, Jack. And first of all, I want to say that we're very pleased to see the improvement versus the Q1 last year. But you're also right that versus Q4, that we saw a bit of a decrease, and that was actually where we most expected. We sit in that DGG business for the -- pretty fixed cost space. So when you have a Q1 with a lower base than in Q4, you will see that our margins has also impacted accordingly. So you always see us coming up with a strong Q4 and a weaker Q1 under the gross margin and also on our operating margin. So this is kind of by the book and really as expected."
154924,323237239,934163,"Agilent Technologies Inc., Q1 2016 Earnings Call, Feb 16, 2016",2016-02-16,"Earnings Calls","Agilent Technologies, Inc.","Executives","Yes, I would just add that there's no change in plan, and Jacob is still certainly committed to reaching 20% operating margin in 2017.",24,"Yes, I would just add that there's no change in plan, and Jacob is still certainly committed to reaching 20% operating margin in 2017."
154924,323237239,934163,"Agilent Technologies Inc., Q1 2016 Earnings Call, Feb 16, 2016",2016-02-16,"Earnings Calls","Agilent Technologies, Inc.","Operator","Our next question comes from line of Derik De Bruin from Bank of America.",14,"Our next question comes from line of Derik De Bruin from Bank of America."
154924,323237239,934163,"Agilent Technologies Inc., Q1 2016 Earnings Call, Feb 16, 2016",2016-02-16,"Earnings Calls","Agilent Technologies, Inc.","Analysts","So I'm just curious. You're guiding to a 22% operating margin for 2017. So that's implying -- assuming the 20.2% midpoint, 130 to 180 basis points of margin expansion next year. I'm just curious if you can't -- if you couldn't find 10 additional basis poi",75,"So I'm just curious. You're guiding to a 22% operating margin for 2017. So that's implying -- assuming the 20.2% midpoint, 130 to 180 basis points of margin expansion next year. I'm just curious if you can't -- if you couldn't find 10 additional basis points of margin expansion in 2016 to sort of offset the impact, what gives you confidence you're going to be able to get 130, 180 basis points next year?"
154924,323237239,934163,"Agilent Technologies Inc., Q1 2016 Earnings Call, Feb 16, 2016",2016-02-16,"Earnings Calls","Agilent Technologies, Inc.","Executives","I just reiterate -- great question this one. Again, by the way, one of the things as you heard me say earlier in my comments, we continue to make sure we're realistic and we think about our business not on some hope and a prayer, but we actually have soli",215,"I just reiterate -- great question this one. Again, by the way, one of the things as you heard me say earlier in my comments, we continue to make sure we're realistic and we think about our business not on some hope and a prayer, but we actually have solid plans behind our long-term operating goals. And I think we have a lot of comments for 2 reasons: One is we have a plan that can get us there with -- not all on top line. It's probably in the range of 4% ago. We can get to the margin goals. We've laid out a plan that's got 60% of is coming from the cost side. And we have multiyear programs that are going to take significant cost out of our structures. So I highlighted a few of them in my call and changes in terms of our benefit structure, changes in terms of our IT costs, our IT systems. These are major company-wide initiatives that right now we're underway. You won't start to see them going to the P&L until like late '16 going to '17. So these are kind of things that gives us confidence to say, ""Okay, there's a path that gets us to where we want to get to in '17."""
154924,323237239,934163,"Agilent Technologies Inc., Q1 2016 Earnings Call, Feb 16, 2016",2016-02-16,"Earnings Calls","Agilent Technologies, Inc.","Analysts","Okay, great. It's the late '16, early '17 that I think that was the key that I was sort of looking for in that. Second question is given some of the turmoil going on in Europe, have you seen any sort of changes in the academic or government spending? And",80,"Okay, great. It's the late '16, early '17 that I think that was the key that I was sort of looking for in that. Second question is given some of the turmoil going on in Europe, have you seen any sort of changes in the academic or government spending? And sort of like the governments grapple with sort of like the refugee crisis and some of the things going on? Is there any noticeable change to spending patterns in Europe?"
154924,323237239,934163,"Agilent Technologies Inc., Q1 2016 Earnings Call, Feb 16, 2016",2016-02-16,"Earnings Calls","Agilent Technologies, Inc.","Executives","Patrick, you're shaking your head here right now.",8,"Patrick, you're shaking your head here right now."
154924,323237239,934163,"Agilent Technologies Inc., Q1 2016 Earnings Call, Feb 16, 2016",2016-02-16,"Earnings Calls","Agilent Technologies, Inc.","Executives","Yes, I'm shaking my head because we have not seen any significant change over the last several quarters.",18,"Yes, I'm shaking my head because we have not seen any significant change over the last several quarters."
154924,323237239,934163,"Agilent Technologies Inc., Q1 2016 Earnings Call, Feb 16, 2016",2016-02-16,"Earnings Calls","Agilent Technologies, Inc.","Operator","Our next question comes from the line of Dan Leonard from Leerink Partners.",13,"Our next question comes from the line of Dan Leonard from Leerink Partners."
154924,323237239,934163,"Agilent Technologies Inc., Q1 2016 Earnings Call, Feb 16, 2016",2016-02-16,"Earnings Calls","Agilent Technologies, Inc.","Analysts","All my questions have been answered.",6,"All my questions have been answered."
154924,323237239,934163,"Agilent Technologies Inc., Q1 2016 Earnings Call, Feb 16, 2016",2016-02-16,"Earnings Calls","Agilent Technologies, Inc.","Operator","Our next question comes from the line of Dane Leone from BTIG.",12,"Our next question comes from the line of Dane Leone from BTIG."
154924,323237239,934163,"Agilent Technologies Inc., Q1 2016 Earnings Call, Feb 16, 2016",2016-02-16,"Earnings Calls","Agilent Technologies, Inc.","Analysts","So on the gross margin line, can you just give a little bit more color in terms of the product mix? As I look at the different groups, really, the margin leverage seemed to come through the Life Sci and Applied Markets Group. You guys almost reported a 59",81,"So on the gross margin line, can you just give a little bit more color in terms of the product mix? As I look at the different groups, really, the margin leverage seemed to come through the Life Sci and Applied Markets Group. You guys almost reported a 59% gross margin there. Comment on the next, please, and why the margin for that group specifically is expected to moderate when, I guess, historically, it's been pretty steady quarter-to-quarter throughout the year."
154924,323237239,934163,"Agilent Technologies Inc., Q1 2016 Earnings Call, Feb 16, 2016",2016-02-16,"Earnings Calls","Agilent Technologies, Inc.","Executives","I think there's 2 things I would point to and then, Didier, feel free to jump in as well. But first of all, remember the change we're making to our portfolio. So we're -- we've exited the NMR hardware business and as we -- and we're starting to see some o",106,"I think there's 2 things I would point to and then, Didier, feel free to jump in as well. But first of all, remember the change we're making to our portfolio. So we're -- we've exited the NMR hardware business and as we -- and we're starting to see some of those margin improvements showing over the P&L, where we had revenue in the NMR business in much higher revenues in FY '15. And then our pharma business is pulling a lot of liquid chromatography, which is one of our highest gross margin products. I think it's really those -- perhaps those are the things."
154924,323237239,934163,"Agilent Technologies Inc., Q1 2016 Earnings Call, Feb 16, 2016",2016-02-16,"Earnings Calls","Agilent Technologies, Inc.","Executives","You've stated it all up. Certainly, our liquid -- I had mentioned earlier that the favorable mix get in part from the pharma mix. And within pharma, clearly, liquid chromatograph that has the higher-than-average operating margin and gross margin.",40,"You've stated it all up. Certainly, our liquid -- I had mentioned earlier that the favorable mix get in part from the pharma mix. And within pharma, clearly, liquid chromatograph that has the higher-than-average operating margin and gross margin."
154924,323237239,934163,"Agilent Technologies Inc., Q1 2016 Earnings Call, Feb 16, 2016",2016-02-16,"Earnings Calls","Agilent Technologies, Inc.","Analysts","So to clarify, you felt that there was either a catch-up ordering or of stocking in the quarter that -- on those products specifically, that's not expected to continue for the rest of the year?",35,"So to clarify, you felt that there was either a catch-up ordering or of stocking in the quarter that -- on those products specifically, that's not expected to continue for the rest of the year?"
154924,323237239,934163,"Agilent Technologies Inc., Q1 2016 Earnings Call, Feb 16, 2016",2016-02-16,"Earnings Calls","Agilent Technologies, Inc.","Executives","Well, you'd almost think about the pharma -- I mean, we had 19% pharmaceutical growth in the first quarter. What we're seeing is we can't expect 19% to happen each of the next 3 quarters. What we do expect is the continuous strong demand. And right now, w",73,"Well, you'd almost think about the pharma -- I mean, we had 19% pharmaceutical growth in the first quarter. What we're seeing is we can't expect 19% to happen each of the next 3 quarters. What we do expect is the continuous strong demand. And right now, we're calling 8% for the entire year. So that's what you're seeing in terms of reflected in our mix comp as it relates to gross margin."
154924,323237239,934163,"Agilent Technologies Inc., Q1 2016 Earnings Call, Feb 16, 2016",2016-02-16,"Earnings Calls","Agilent Technologies, Inc.","Analysts","Okay. And then on the FX rate. I'm still -- so if you just kind of use the DXY [ph] proxy, right, the last quarter was actually pretty elevated. But since then, the trend has actually come back and to closer to where you've guided the year. Are you expect",78,"Okay. And then on the FX rate. I'm still -- so if you just kind of use the DXY [ph] proxy, right, the last quarter was actually pretty elevated. But since then, the trend has actually come back and to closer to where you've guided the year. Are you expecting -- is there some nuance within this on how certain currencies have moved? Or are you just kind of assuming worst case that the dollar kind of [indiscernible]?"
154924,323237239,934163,"Agilent Technologies Inc., Q1 2016 Earnings Call, Feb 16, 2016",2016-02-16,"Earnings Calls","Agilent Technologies, Inc.","Executives","Actually, we're -- it's just pure math. So we're not making any projections all about the future levels of FX. What Didier has done is he takes the currency spot rates on the last days of the reported quarter, and that's how we guide the company. We said,",74,"Actually, we're -- it's just pure math. So we're not making any projections all about the future levels of FX. What Didier has done is he takes the currency spot rates on the last days of the reported quarter, and that's how we guide the company. We said, okay, that's what we know and assume that rate stays the same for the rest of the year. And then, it's just pure math from there."
154924,323237239,934163,"Agilent Technologies Inc., Q1 2016 Earnings Call, Feb 16, 2016",2016-02-16,"Earnings Calls","Agilent Technologies, Inc.","Executives","And helping methodology [ph] forever.",5,"And helping methodology [ph] forever."
154924,323237239,934163,"Agilent Technologies Inc., Q1 2016 Earnings Call, Feb 16, 2016",2016-02-16,"Earnings Calls","Agilent Technologies, Inc.","Analysts","Okay. So it's extrapolating off of January 31, not what's happening in February [indiscernible]. I got it.",17,"Okay. So it's extrapolating off of January 31, not what's happening in February [indiscernible]. I got it."
154924,323237239,934163,"Agilent Technologies Inc., Q1 2016 Earnings Call, Feb 16, 2016",2016-02-16,"Earnings Calls","Agilent Technologies, Inc.","Executives","That's correct. I made a comment during my script -- that on my script, that would we had used, for example, today's FX rates, the guidance would have been higher because the dollar between January 31 and today has weakened.",41,"That's correct. I made a comment during my script -- that on my script, that would we had used, for example, today's FX rates, the guidance would have been higher because the dollar between January 31 and today has weakened."
154924,323237239,934163,"Agilent Technologies Inc., Q1 2016 Earnings Call, Feb 16, 2016",2016-02-16,"Earnings Calls","Agilent Technologies, Inc.","Operator","And this does conclude the question-and-answer session of today's program. I'd like to hand the program back to Alicia Rodriguez for any further remarks.",25,"And this does conclude the question-and-answer session of today's program. I'd like to hand the program back to Alicia Rodriguez for any further remarks."
154924,323237239,934163,"Agilent Technologies Inc., Q1 2016 Earnings Call, Feb 16, 2016",2016-02-16,"Earnings Calls","Agilent Technologies, Inc.","Executives","All right. Thank you, everybody, for joining us on the call. And if you have any questions, please give us a call in IR. We'd like to wish you a good day and I'm sure we'll be talking later. Thank you.",41,"All right. Thank you, everybody, for joining us on the call. And if you have any questions, please give us a call in IR. We'd like to wish you a good day and I'm sure we'll be talking later. Thank you."
154924,323237239,934163,"Agilent Technologies Inc., Q1 2016 Earnings Call, Feb 16, 2016",2016-02-16,"Earnings Calls","Agilent Technologies, Inc.","Operator","Thank you, ladies and gentlemen, for your participation in today's conference. This does conclude the program. You may now disconnect. Good day.",22,"Thank you, ladies and gentlemen, for your participation in today's conference. This does conclude the program. You may now disconnect. Good day."
154924,323237239,934243,"Agilent Technologies Inc., Q1 2016 Earnings Call, Feb 16, 2016",2016-02-16,"Earnings Calls","Agilent Technologies, Inc.","Operator","Good day, ladies and gentlemen, and welcome to the First Quarter 2016 Agilent Technologies Inc. Earnings Conference Call. [Operator Instructions] As a reminder, today's program is being recorded. I would now like to introduce your host for today's program",48,"Good day, ladies and gentlemen, and welcome to the First Quarter 2016 Agilent Technologies Inc. Earnings Conference Call. [Operator Instructions] As a reminder, today's program is being recorded. I would now like to introduce your host for today's program, Alicia Rodriguez, Vice President, Investor Relations. Please go ahead."
154924,323237239,934243,"Agilent Technologies Inc., Q1 2016 Earnings Call, Feb 16, 2016",2016-02-16,"Earnings Calls","Agilent Technologies, Inc.","Executives","Thank you, Jonathan, and welcome, everyone, to Agilent's First Quarter Conference Call for Fiscal Year 2016. With me are Mike McMullen, Agilent's President and CEO; and Didier Hirsch, Agilent's Senior Vice President and CFO. Joining in the Q&A after Didie",328,"Thank you, Jonathan, and welcome, everyone, to Agilent's First Quarter Conference Call for Fiscal Year 2016. With me are Mike McMullen, Agilent's President and CEO; and Didier Hirsch, Agilent's Senior Vice President and CFO. Joining in the Q&A after Didier's comments will be Patrick Kaltenbach, President of Agilent's Life Sciences and Applied Markets Group; Jacob Thaysen, President of Agilent's Diagnostics and Genomics Group; and Mark Doak, President of the Agilent CrossLab Group.
You can find the press release and information to supplement today's discussion on our website at www.investor.agilent.com. While there, please click on the link for financial results under the Financial Information tab. You will find an investor presentation along with revenue breakouts and currency impacts, business segment results and historical financials for Agilent's operations. We will also post a copy of the prepared remarks following this call.
Today's comments by Mike and Didier will refer to non-GAAP financial measures. You will find the most directly comparable GAAP financial metrics and reconciliations on our website. Unless otherwise noted, all references to increases or decreases in financial metrics are year-over-year. As a reminder, we are no longer reporting or commenting on orders or book-to-bill and our guidance is based on exchange rates as of the last day of the reported quarter.
And please note that we will refer to core revenue growth, which excludes the impact of currency, the NMR business and acquisitions and divestitures within the past 12 months. Reconciliations between reported and core growth in dollars and percentages can be found in the financial results section on the IR website.
We will also make forward-looking statements about the financial performance of the company. These statements are subject to risks and uncertainties and are only valid as of today. The company assumes no obligation to update them. Please look at the company's recent SEC filings for a more complete picture of our risks and other factors. 
And now I'd like to turn the call over to Mike."
154924,323237239,934243,"Agilent Technologies Inc., Q1 2016 Earnings Call, Feb 16, 2016",2016-02-16,"Earnings Calls","Agilent Technologies, Inc.","Executives","Thanks, Lisa, and hello, everyone. Thank you for joining us on today's call. I'm pleased to report that our team delivered a very strong start to our fiscal 2016, both revenue and earnings are above the high end of our guidance. I would now highlight 3",1232,"Thanks, Lisa, and hello, everyone. Thank you for joining us on today's call. I'm pleased to report that our team delivered a very strong start to our fiscal 2016, both revenue and earnings are above the high end of our guidance. 
I would now highlight 3 key results. First, revenue was up over 6% on a core basis. Second, we delivered an operating margin increase of 200 basis points from a year ago to 20.2% adjusted for Keysight billings. Finally, adjusted EPS of $0.46 was up 12% over last year.
Our Q1 results are driven by continued strength in the pharma, clinical and diagnostics markets with the return to growth in academia and government. Market demand remained strong for our liquid chromatography, CrossLab services and consumables, and diagnostics and genomics offerings. Geographically, all regions grew on a core basis with strong growth in China. 
Let me highlight the Q1 results by our 3 business groups.
The Life Sciences and Applied Markets Group delivered a core revenue growth of 2%. We see continued strong global pharma demand, growth return in academia and government markets, and China government investments in environmental and food markets. All of this offset continued weaknesses for new equipment purchases in the chemical and engineering market space. LSAG's operating margin for the quarter was 21.7%, up 210 basis points from a year ago. As a reminder, in November, we closed the acquisition of Seahorse Bioscience. Integration activities are in full swing with the team excited to be part of Agilent.
LSAG continued to strengthen its portfolio in Q1. We released 2 new refractive index detectors, the 1260 and 1290 Infinity II RID. These detectors help expand the capabilities of modern UHPLC chromatography to make difficult measurements in certain chemical, biopharma and food applications.
Agilent's innovation strength was recognized in the January edition of Analytical Scientist magazine. We were honored with an Innovation Award for our unique LC dual-needle technology. This is a breakthrough in the way samples are injected into Agilent's LC products. The unique design enables fast injection cycles, scalable injection volumes and ultralow carryover.
Next is the Agilent CrossLab Group. We continue to see consistently strong revenue results. Our core revenue growth was 10% in Q1. Strong pharma and chemical and energy market demand drove growth in our services and consumables offering.
Our operating margin was 22.1% for the quarter. This is up 140 basis points from a year ago. We continued bringing novel, new chemistries to market. For example, we released the AdvanceBio SEC family of products. These innovative new products are designed for accurate and precise size exclusion chromatography targeted at biopharma applications. Early adopting customers are reporting significant economic and performance benefits over any current technologies offered by our competitors.
Finally, the Diagnostics and Genomics Group continued to demonstrate momentum. In Q1, DGG delivered 12% core revenue growth with strength across all of its businesses. The pathology business continued a steady trajectory to market growth rates. We see strong growth for Dako Omnis reagents and growing revenue, PD-L1 diagnostics. The companion diagnostics business also continued to demonstrate momentum.
Double-digit growth in nucleic acids and genomics reflected strong demand from pharma and clinical markets in the favorable compare. DGG's operating margin for the quarter was 9.6%, that's up 910 basis points from a year ago. I want to remind you that last year, this business broke even in Q1 of fiscal 2015.
Last year, our Dako complementary diagnostic for Bristol-Myers Squibb's OPDIVO was approved by the FDA for non-squamous, non-small cell lung cancer. In January of this year, the FDA approved expanded use of this PD-L1 diagnostic to include patients with melanoma. Positive PD-L1 status in melanoma has been correlated with the treatment effectiveness of Bristol-Myers Squibb's drug treatment. Agilent is the first company to provide FDA-approved tests for lung cancer and melanoma for PD-L1 markers.
Now I'll take a brief look at Agilent's revenues by end market performance on a core basis. We saw strength in all our life sciences and diagnostics markets. Continued robust demand drove pharma revenue up 19%. Growth was fueled by technology refresh deals, new product uptake and aftermarket demand for services and consumables. Our clinical and diagnostics revenue was up 7%, and we experienced a return to growth in academia and government of 4%. This growth was significantly driven by the authorization of larger research budgets in the U.S.
Applied end market performance was generally soft except for environmental, which was up 9%, driven by strength in China. Food declined 1%. Our food market strength in China was offset by soft demand in developed countries. Chemical and energy declined 2%, driven by the well-publicized macroeconomic concerns.
Let me provide an update on our operating margin-proven initiatives. This quarter marks the fourth consecutive quarter of year-over-year operating margin improvement. This is how we are driving the sustained performance. We are building a new company portfolio. We have exited unattractive businesses and are acquiring new ones to enable our growth strategy. Our multiyear Agile Agilent program is simplifying our company, making it more nimble and lowering our costs. Finally, while we are improving our execution capabilities, transforming our culture to work as one team across the entire company, we call this One Agilent.
As we enter the second year of the new Agilent, here is what you can expect as we move forward. We are building a new business, one that delivers above-market growth. We will continue to target operating margin expansion. Finally, we are driving a balanced capital allocation policy that includes increased levels of free cash flow being returned to shareholders.
Going forward, we will continue to make tough decisions to ensure our long-term competitiveness. For example, we have just frozen our U.S.-defined benefits retirement plan. This change is effective in the second half of fiscal 2016. I've also spoke with many of you about our multiple ERP systems and oversized IT environment. We continue to streamline our IT systems and infrastructure to reduce costs and increase effectiveness. While work remains, we are pleased with the start to the second year of the new Agilent and our progress in transforming the company. Let me share my view on the current market outlook.
The principle of new Agilent is be realistic and to closely monitor market conditions that could affect our business. Global macroeconomic concerns are pressuring some end markets in emerging economies. The good news is that we see solid market conditions in other end markets and geographies. I remain confident in our ability to achieve our full year core growth and operating margin goals. I am also confident that we will make course correction as market conditions dictate.
We are strengthening our portfolio, building on our prior year introductions. We have an exciting pipeline of compelling new offerings set to launch this year. In tandem of these new offerings, we have created a new go-to-market capability. We have a focused, energized sales force, and we are overhauling our e-commerce environment to make it easier for customers to do business with us.
And most importantly, across the company, we have the organizational capability to execute and deliver. The Agilent team is aligned and highly energized, driven to win the marketplace. 
Thank you for being on the call today. I will now turn it over to Didier, who will provide additional insights on our financial results and our updated guidance. Didier?"
154924,323237239,934243,"Agilent Technologies Inc., Q1 2016 Earnings Call, Feb 16, 2016",2016-02-16,"Earnings Calls","Agilent Technologies, Inc.","Executives","Yes. Thank you, Mike, and hello, everyone. To summarize Q1 results, they are above the high end of our revenue and EPS guidance even as currency impacted revenue by $7 million and OP by $2 million.The EPS beat was the result of the higher revenues as we",284,"Yes. Thank you, Mike, and hello, everyone. To summarize Q1 results, they are above the high end of our revenue and EPS guidance even as currency impacted revenue by $7 million and OP by $2 million.
The EPS beat was the result of the higher revenues as well as favorable mix. Our adjusted operating margin of 20.2% and operating cash flow of $106 million was strong. We bought back $200 million or 4.9 million shares in Q1. 
I'll turn now to the guidance for fiscal year 2016. We are confirming the core revenue growth guidance of 4.0% to 4.5% we provided in November. However, the strengthening of the U.S. dollar since our November guidance is expected to have a negative impact of about $50 million on reported revenues, $13 million on operating profit and $0.033 on EPS.
As a result, we now expect fiscal year '16 revenues of $4.1 billion to $4.12 billion, and EPS of $1.81 to $1.87. To note, in the last 2 weeks, we've seen the U.S. dollar weaken. If the weakening continues, we will reflect the positive impact in our May guidance.
Turning to our share buyback program. We remain committed to our plan of repurchasing another $280 million of shares before our fiscal year-end. 
Finally, moving to the guidance for our second quarter. We're expecting Q2 revenues of $965 million and to $985 million, reflecting typical second quarter seasonality versus Q1.
The mid-point corresponds to a core revenue growth of 4.0%. The sequential reduction in revenues will translate into a sequential reduction in EPS. We expect Q2 EPS to range between 39 -- excuse me, $0.37 to $0.39. 
With that, I'll turn it over to Alicia for the Q&A."
154924,323237239,934243,"Agilent Technologies Inc., Q1 2016 Earnings Call, Feb 16, 2016",2016-02-16,"Earnings Calls","Agilent Technologies, Inc.","Executives","Thank you, Didier. And Jonathan, will you please give the instructions for the Q&A?",14,"Thank you, Didier. And Jonathan, will you please give the instructions for the Q&A?"
154924,323237239,934243,"Agilent Technologies Inc., Q1 2016 Earnings Call, Feb 16, 2016",2016-02-16,"Earnings Calls","Agilent Technologies, Inc.","Operator","[Operator Instructions] Our first question comes from the line of Doug Schenkel from Cowen and Company.",16,"[Operator Instructions] Our first question comes from the line of Doug Schenkel from Cowen and Company."
154924,323237239,934243,"Agilent Technologies Inc., Q1 2016 Earnings Call, Feb 16, 2016",2016-02-16,"Earnings Calls","Agilent Technologies, Inc.","Analysts","This is Ryan Blicker filling in for Doug. Starting with operating margin guidance, it seems as though you reduced full-year guidance by about 10 basis points. But it seems like, as though, most of that was FX. Can you confirm that, that was all due to FX?",57,"This is Ryan Blicker filling in for Doug. Starting with operating margin guidance, it seems as though you reduced full-year guidance by about 10 basis points. But it seems like, as though, most of that was FX. Can you confirm that, that was all due to FX? Or are there other changes we should be thinking about?"
154924,323237239,934243,"Agilent Technologies Inc., Q1 2016 Earnings Call, Feb 16, 2016",2016-02-16,"Earnings Calls","Agilent Technologies, Inc.","Executives","No, it was entirely due to FX, absolutely. As I had mentioned, the FX impact was $13 million. And that is precisely the amount of the reduction in operating profit reflected in our guidance. And we have maintained the guidance at 20.2%, which was the aver",60,"No, it was entirely due to FX, absolutely. As I had mentioned, the FX impact was $13 million. And that is precisely the amount of the reduction in operating profit reflected in our guidance. And we have maintained the guidance at 20.2%, which was the average of 20% to 25% that we had guided to in November -- no change."
154924,323237239,934243,"Agilent Technologies Inc., Q1 2016 Earnings Call, Feb 16, 2016",2016-02-16,"Earnings Calls","Agilent Technologies, Inc.","Analysts","Okay. And looking at the pharma end market. Obviously, another very strong performance in the quarter. Can you give us more details on what drove the strength? And where there any one-time dynamics like a budget flush or pull forward of revenue? And I gue",64,"Okay. And looking at the pharma end market. Obviously, another very strong performance in the quarter. Can you give us more details on what drove the strength? And where there any one-time dynamics like a budget flush or pull forward of revenue? And I guess, lastly, do you still expect growth in this end market to approximate high single digits for the full year?"
154924,323237239,934243,"Agilent Technologies Inc., Q1 2016 Earnings Call, Feb 16, 2016",2016-02-16,"Earnings Calls","Agilent Technologies, Inc.","Executives","Sure, Brian, this is Mike. Let me make a few comments on the pharma strength we saw in the first quarter. Clearly, no one-time events. And we saw great pacing throughout the quarter. This would highlight a few points here. One, we're seeing a strong growt",158,"Sure, Brian, this is Mike. Let me make a few comments on the pharma strength we saw in the first quarter. Clearly, no one-time events. And we saw great pacing throughout the quarter. This would highlight a few points here. One, we're seeing a strong growth in liquid chromatography, both in terms of the uptake in our new products, but also the technology refresh that is underway within this segment. Also, customers responding quite positively to our biopharma solutions. And then across the board between biopharma and pharma, we're seeing strong demand for enterprise-wide services and consumables. 19% growth for the first quarter. We don't expect that level of double-digit growth to continue all through the year, but we're quite confident in our projections of high single digit. We're calling for 8% overall growth for the year in pharma. So we see no signs that this market won't remain robust for us for the rest of this year."
154924,323237239,934243,"Agilent Technologies Inc., Q1 2016 Earnings Call, Feb 16, 2016",2016-02-16,"Earnings Calls","Agilent Technologies, Inc.","Operator","Our next question comes from the line of Paul Knight from Janney Montgomery.",13,"Our next question comes from the line of Paul Knight from Janney Montgomery."
154924,323237239,934243,"Agilent Technologies Inc., Q1 2016 Earnings Call, Feb 16, 2016",2016-02-16,"Earnings Calls","Agilent Technologies, Inc.","Analysts","Regarding the guidance with EPS. I know when you guided last time, the euro had already fallen relative to the dollar. So are you measuring the euro on today's exchange rate, last week's exchange rate? I mean, could you flesh out a little bit more?",45,"Regarding the guidance with EPS. I know when you guided last time, the euro had already fallen relative to the dollar. So are you measuring the euro on today's exchange rate, last week's exchange rate? I mean, could you flesh out a little bit more?"
154924,323237239,934243,"Agilent Technologies Inc., Q1 2016 Earnings Call, Feb 16, 2016",2016-02-16,"Earnings Calls","Agilent Technologies, Inc.","Executives","Great question, Paul, it's the same question I asked Didier, and I'm going to pass it back to Didier.",19,"Great question, Paul, it's the same question I asked Didier, and I'm going to pass it back to Didier."
154924,323237239,934243,"Agilent Technologies Inc., Q1 2016 Earnings Call, Feb 16, 2016",2016-02-16,"Earnings Calls","Agilent Technologies, Inc.","Executives","Yes, Paul, so the guidance is always based on the exchange rate on the last day of the quarter we report. So the new guidance is based on the exchange rate as of October -- as of January 30, 2016. And it was between November -- October 30, which was in No",126,"Yes, Paul, so the guidance is always based on the exchange rate on the last day of the quarter we report. So the new guidance is based on the exchange rate as of October -- as of January 30, 2016. And it was between November -- October 30, which was in November guidance, and then January 30, which is the present guidance. The dollar strengthened, but we are seeing it weakening since November 30 a little bit, vis-a-vis the euro and certainly, vis-Ã -vis the yen. So if that continues, it will be reflected in our May guidance. Again, there was no change at all to our November guidance except for those that result directly from the change in exchange rates between October 30 and January 30."
154924,323237239,934243,"Agilent Technologies Inc., Q1 2016 Earnings Call, Feb 16, 2016",2016-02-16,"Earnings Calls","Agilent Technologies, Inc.","Executives","Yes, Paul, if I could just emphasize that, again, I mean, the fundamental assumptions we made that underlined our prior quarter guidance remain intact with the exception being FX.",29,"Yes, Paul, if I could just emphasize that, again, I mean, the fundamental assumptions we made that underlined our prior quarter guidance remain intact with the exception being FX."
154924,323237239,934243,"Agilent Technologies Inc., Q1 2016 Earnings Call, Feb 16, 2016",2016-02-16,"Earnings Calls","Agilent Technologies, Inc.","Analysts","And then, lastly, Mike, what stands out on technology is the PD-L1 approval and also the large molecule technology in CrossLab. Do you sit there with those 2 products on your menu thinking there's a bias toward more organic? Or where you at with those 2 t",49,"And then, lastly, Mike, what stands out on technology is the PD-L1 approval and also the large molecule technology in CrossLab. Do you sit there with those 2 products on your menu thinking there's a bias toward more organic? Or where you at with those 2 that you mentioned?"
154924,323237239,934243,"Agilent Technologies Inc., Q1 2016 Earnings Call, Feb 16, 2016",2016-02-16,"Earnings Calls","Agilent Technologies, Inc.","Executives","Paul, just to make sure I understand the question. Relative to -- thanks for the comments and observation. Just make sure I understand the question. This will be relative to our expectation of a continued organic growth with those 2 new -- with those...",44,"Paul, just to make sure I understand the question. Relative to -- thanks for the comments and observation. Just make sure I understand the question. This will be relative to our expectation of a continued organic growth with those 2 new -- with those..."
154924,323237239,934243,"Agilent Technologies Inc., Q1 2016 Earnings Call, Feb 16, 2016",2016-02-16,"Earnings Calls","Agilent Technologies, Inc.","Analysts","Yes, are they enough to move the needle higher than what you would have thought 90 days ago on last guidance?",21,"Yes, are they enough to move the needle higher than what you would have thought 90 days ago on last guidance?"
154924,323237239,934243,"Agilent Technologies Inc., Q1 2016 Earnings Call, Feb 16, 2016",2016-02-16,"Earnings Calls","Agilent Technologies, Inc.","Executives","Well, let me make a comment on the CrossLab services and consumables, and then I'll pass it over to Jacob on the PD-L1. When we put together our guidance for the year, we were expecting a strong growth in our CrossLab and services and consumables business",154,"Well, let me make a comment on the CrossLab services and consumables, and then I'll pass it over to Jacob on the PD-L1. When we put together our guidance for the year, we were expecting a strong growth in our CrossLab and services and consumables business. So that's part of the reason why we had a lot of confidence coming this year and still have the confidence in this year about making our organic core revenue growth targets. But as you've seen, even in a -- even in the chemical energy space, which down in terms of new instrument purchases, they continue to buy, and we see strong growth of service and consumables. So what I leave you is we expect continued strength in that space, but we were assuming that to be the case when we guided the company earlier this year. And, Jacob, why don't you share your thoughts on the PD-L1?"
154924,323237239,934243,"Agilent Technologies Inc., Q1 2016 Earnings Call, Feb 16, 2016",2016-02-16,"Earnings Calls","Agilent Technologies, Inc.","Executives","Yes, thanks, Paul. And you're right that we got the indication approval also for the melanoma for the OPDIVO drug, and that's a great next step in the opportunities with PD-L1. I will not say that it will change the needle on an Agilent level, but it defi",107,"Yes, thanks, Paul. And you're right that we got the indication approval also for the melanoma for the OPDIVO drug, and that's a great next step in the opportunities with PD-L1. I will not say that it will change the needle on an Agilent level, but it definitely is a part of our growth story in DDG. But I will remind also that this drug -- or this companion diagnostic has only been out now for a few months, and we are still in the early days of seeing the uptake of it. So I see good progress, but not something that really moves the needle here."
154924,323237239,934243,"Agilent Technologies Inc., Q1 2016 Earnings Call, Feb 16, 2016",2016-02-16,"Earnings Calls","Agilent Technologies, Inc.","Operator","Our next question comes from the line of Dan Arias from Citigroup.",12,"Our next question comes from the line of Dan Arias from Citigroup."
154924,323237239,934243,"Agilent Technologies Inc., Q1 2016 Earnings Call, Feb 16, 2016",2016-02-16,"Earnings Calls","Agilent Technologies, Inc.","Analysts","Mike, last quarter, you mentioned that industrial weakness you were seeing kind of spilled over into the environmental business. I'm just wondering whether that's reversed a bit this quarter. So I guess, is it fair to say that maybe growth in environmenta",70,"Mike, last quarter, you mentioned that industrial weakness you were seeing kind of spilled over into the environmental business. I'm just wondering whether that's reversed a bit this quarter. So I guess, is it fair to say that maybe growth in environmental this year could be a couple of points higher than the cyclical segments? I guess, how would you just compare expectations from environmental versus industrial for this year?"
154924,323237239,934243,"Agilent Technologies Inc., Q1 2016 Earnings Call, Feb 16, 2016",2016-02-16,"Earnings Calls","Agilent Technologies, Inc.","Executives","Yes, Dan, thanks for the careful observation and -- it was actually -- the environmental business was a pleasant surprise in the first quarter. We knew that China was going to be strong, and we've been talking about China and our view of the investments t",197,"Yes, Dan, thanks for the careful observation and -- it was actually -- the environmental business was a pleasant surprise in the first quarter. We knew that China was going to be strong, and we've been talking about China and our view of the investments that the Chinese government is making in places such as the environmental market and food safety. So -- but I will say that we were happy to see the growth in other segments because yes, the chemical energy space has been under pressure. But what we're still seeing is that fracking is still going on. So the production -- while prices of oil are down, the production demand is stable. And in fact, if you look at the oil production, I mean gasoline production in the U.S., for example, is perhaps going up. So we're seeing a continued need to do environmental testing. So that's been a nice reaffirmation, if you will, of our outlook for the year which called for low single-digit growth in environmental. We thought that China would carry the whole load for us, but I think we're going to get a little help from the U.S. as well."
154924,323237239,934243,"Agilent Technologies Inc., Q1 2016 Earnings Call, Feb 16, 2016",2016-02-16,"Earnings Calls","Agilent Technologies, Inc.","Analysts","Okay. And then maybe just staying in the BRIC region, any change in the way that you're thinking about Brazil and Russia, and how that might end up this year?",30,"Okay. And then maybe just staying in the BRIC region, any change in the way that you're thinking about Brazil and Russia, and how that might end up this year?"
154924,323237239,934243,"Agilent Technologies Inc., Q1 2016 Earnings Call, Feb 16, 2016",2016-02-16,"Earnings Calls","Agilent Technologies, Inc.","Executives","Unfortunately, no. I think we're still looking for very challenged conditions in those countries. I know there's been some recent news today about Russia, and perhaps working with some of the other oil-producing countries to change some aspects of product",65,"Unfortunately, no. I think we're still looking for very challenged conditions in those countries. I know there's been some recent news today about Russia, and perhaps working with some of the other oil-producing countries to change some aspects of production, maybe they'll have some dynamics in terms of their economy. But right now, we're assuming continuation of the current challenged conditions for Brazil and Russia."
154924,323237239,934243,"Agilent Technologies Inc., Q1 2016 Earnings Call, Feb 16, 2016",2016-02-16,"Earnings Calls","Agilent Technologies, Inc.","Operator","Our next question comes from the line of Isaac Ro from Goldman Sachs.",13,"Our next question comes from the line of Isaac Ro from Goldman Sachs."
154924,323237239,934243,"Agilent Technologies Inc., Q1 2016 Earnings Call, Feb 16, 2016",2016-02-16,"Earnings Calls","Agilent Technologies, Inc.","Analysts","Mike, first question was on gross margin. It's pretty big year-over-year improvement there. I was wondering if you could maybe breakdown the key drivers of gross margin performance, the accentuation [ph] there might have been one-time benefits in these an",55,"Mike, first question was on gross margin. It's pretty big year-over-year improvement there. I was wondering if you could maybe breakdown the key drivers of gross margin performance, the accentuation [ph] there might have been one-time benefits in these and towards [ph] there are some items that are going to continue as the year progresses."
154924,323237239,934243,"Agilent Technologies Inc., Q1 2016 Earnings Call, Feb 16, 2016",2016-02-16,"Earnings Calls","Agilent Technologies, Inc.","Executives","Yes, let me make a few level -- high-level comments here then, Didier, you can jump in and augment my comments. But I think, one, there were some one-time improvements, and I think we highlighted those in typically as it related to DDG, where we had some",178,"Yes, let me make a few level -- high-level comments here then, Didier, you can jump in and augment my comments. But I think, one, there were some one-time improvements, and I think we highlighted those in typically as it related to DDG, where we had some revenue that was really trapped last year in the first quarter due to production issues. But the lion's share of the improvement is resulting from our continued sustained efforts that I highlighted in my call, both the portfolio efforts in terms of the businesses we're no longer in, the businesses we acquired as to our change in our gross margin profile. We're taking real cost out of our system through the Agile Agilent program. So there were some one-time events as it relates to the revenue for DGG, but the bulk of our -- the bulk of our margin improvement is from the underlying core efforts we've had over the last several quarters to fundamentally change the operating model of the company. Didier, anything else that you would add to that?"
154924,323237239,934243,"Agilent Technologies Inc., Q1 2016 Earnings Call, Feb 16, 2016",2016-02-16,"Earnings Calls","Agilent Technologies, Inc.","Executives","Just to point out also contributed. Number one, you will recall that last year, we were spending heavily on remediation points to address the FDA warning letters. So that is -- now we are spending a significant amounts to maintain our strong position now,",134,"Just to point out also contributed. Number one, you will recall that last year, we were spending heavily on remediation points to address the FDA warning letters. So that is -- now we are spending a significant amounts to maintain our strong position now, but certainly not in the same magnitude of what we have spent for 2 years in a row. And then the second point is there was a favorable mix. We talked about how strong the pharma businesses is, and pharma does generate higher gross margin than the rest of the businesses. So favorable mix. And I know that the pharma being just one of them, but a significant one. And then the FDA -- the reduction in FDA spend also in addition to all the points that Mike has made."
154924,323237239,934243,"Agilent Technologies Inc., Q1 2016 Earnings Call, Feb 16, 2016",2016-02-16,"Earnings Calls","Agilent Technologies, Inc.","Analysts","Okay, that's helpful. And then just a follow-up on CrossLab. You mentioned the driver there, looking like it was just healthy demand in the end market. But I don't think of that business as necessarily having as a sustainable growth rate in that double-di",100,"Okay, that's helpful. And then just a follow-up on CrossLab. You mentioned the driver there, looking like it was just healthy demand in the end market. But I don't think of that business as necessarily having as a sustainable growth rate in that double-digit range. So I'm wondering if there was an element of market share that, that was helpful. It's just not a market where we have a ton of quarter-to-quarter visibility. So I was wondering if you could put some color around -- the accentuation market share was helpful and how you would characterize where it's coming from."
154924,323237239,934243,"Agilent Technologies Inc., Q1 2016 Earnings Call, Feb 16, 2016",2016-02-16,"Earnings Calls","Agilent Technologies, Inc.","Executives","Great, great question. I'll make a few comments. And Mark, why don't you jump in with your thoughts here. As we looked at the overall growth rate for CrossLab, you should assume that we're right in the range where we had talked about at the AID, and we th",114,"Great, great question. I'll make a few comments. And Mark, why don't you jump in with your thoughts here. As we looked at the overall growth rate for CrossLab, you should assume that we're right in the range where we had talked about at the AID, and we think there is both market growth. But as you've pointed out, market share gain opportunities for us where -- we really have changed our view of what the addressable market is for our business. And it's no longer the Agilent install base, but it's the entire lab. And Mark, why don't you talk about some of the things we're doing in terms of capturing market share."
154924,323237239,934243,"Agilent Technologies Inc., Q1 2016 Earnings Call, Feb 16, 2016",2016-02-16,"Earnings Calls","Agilent Technologies, Inc.","Executives","Thanks, Mike. And I think you've hit on the primary piece, which is we continue to see the primary drivers in pharma and also China has been very strong for us. When you pull it all back to when capital spending is constrained, we continue to see customer",101,"Thanks, Mike. And I think you've hit on the primary piece, which is we continue to see the primary drivers in pharma and also China has been very strong for us. When you pull it all back to when capital spending is constrained, we continue to see customers improve the productivity of their assets through services and the chemistries we talked about earlier. But I think what's more robust than it was a year ago even is really the strength of our multi-vendor and enterprise portfolio. And that does allow you to take share, if you will, from the broader market."
154924,323237239,934243,"Agilent Technologies Inc., Q1 2016 Earnings Call, Feb 16, 2016",2016-02-16,"Earnings Calls","Agilent Technologies, Inc.","Operator","Our next question comes from the line of Ross Muken from Evercore ISI.",13,"Our next question comes from the line of Ross Muken from Evercore ISI."
154924,323237239,934243,"Agilent Technologies Inc., Q1 2016 Earnings Call, Feb 16, 2016",2016-02-16,"Earnings Calls","Agilent Technologies, Inc.","Analysts","So I'm just trying to double check on the guidance math here because I think a few of us are a little bit confused. So we beat the quarter, right, by around, I don't know, call it $0.03. We lost $0.033 on FX, roughly, and the range came down $0.04. So I'm",119,"So I'm just trying to double check on the guidance math here because I think a few of us are a little bit confused. So we beat the quarter, right, by around, I don't know, call it $0.03. We lost $0.033 on FX, roughly, and the range came down $0.04. So I'm just trying to get a sense for -- again, it seems like FX was the key delta. But just the simple math would have suggested to me a little less downward pressure on the full year range. And again, I realize there's probably a few other moving parts. So I'm just trying to make sure I understand how we're doing versus the plan for the year."
154924,323237239,934243,"Agilent Technologies Inc., Q1 2016 Earnings Call, Feb 16, 2016",2016-02-16,"Earnings Calls","Agilent Technologies, Inc.","Executives","Sure, we're happy to -- Didier would be happy to clarify.",11,"Sure, we're happy to -- Didier would be happy to clarify."
154924,323237239,934243,"Agilent Technologies Inc., Q1 2016 Earnings Call, Feb 16, 2016",2016-02-16,"Earnings Calls","Agilent Technologies, Inc.","Executives","Yes. No, so the -- as I mentioned earlier, we have reduced our top line revenue from -- at midpoint from $4.160 billion to $4.110 billion, which is a $50 million reduction. We've reduced our operating profit from $830 million to $817 million, that's $13 m",211,"Yes. No, so the -- as I mentioned earlier, we have reduced our top line revenue from -- at midpoint from $4.160 billion to $4.110 billion, which is a $50 million reduction. We've reduced our operating profit from $830 million to $817 million, that's $13 million, and that's entirely due to the impact of the strengthening of the dollar and related to the $50 million. And then I mentioned $0.033, but with rounding, we are going from a midpoint of $1.84 to the new midpoint of -- to the -- sorry, we're going from the midpoint of $1.88 to the mid-point of $1.84, and that's $0.04 and that's the $0.033, which is rounded because of the -- going from one to the other, you can understand that. So basically, what we felt is even though we are starting the year very strongly, we felt that with the overall macroeconomic condition, it would not be wise at this point in time to change the guidance we had provided, core revenue guidance, of 4% to 4.5%. We have the same confidence as we'd had in the month of November when we provided that guidance that we're in good shape to hit it and perhaps did it, but certainly, didn't want to change it."
154924,323237239,934243,"Agilent Technologies Inc., Q1 2016 Earnings Call, Feb 16, 2016",2016-02-16,"Earnings Calls","Agilent Technologies, Inc.","Analysts","Yes, I guess, what I'm trying to get at it is sort of the comments last quarter suggested sort of conservatism, right? You obviously can't control what happens with the dollar. So that's understandable. I'm just trying to get a sense for how much conserva",86,"Yes, I guess, what I'm trying to get at it is sort of the comments last quarter suggested sort of conservatism, right? You obviously can't control what happens with the dollar. So that's understandable. I'm just trying to get a sense for how much conservatism there is now in the forecasting, whether or not we have risk to that core growth rate, given again that the range came down. But you reiterated the top line. I'm just making sure that we're sort of not over-extrapolating here."
154924,323237239,934243,"Agilent Technologies Inc., Q1 2016 Earnings Call, Feb 16, 2016",2016-02-16,"Earnings Calls","Agilent Technologies, Inc.","Executives","Sure, Ross. This is Mike. I really appreciate the opportunity to comment on this. So if you'll add that conservatism meter on our guidance, it's at the same level as it was last quarter. So the only real fundamental change in terms of our outlook is the v",52,"Sure, Ross. This is Mike. I really appreciate the opportunity to comment on this. So if you'll add that conservatism meter on our guidance, it's at the same level as it was last quarter. So the only real fundamental change in terms of our outlook is the view on FX. That's it."
154924,323237239,934243,"Agilent Technologies Inc., Q1 2016 Earnings Call, Feb 16, 2016",2016-02-16,"Earnings Calls","Agilent Technologies, Inc.","Executives","And we saw no reason to change our core revenue growth to offset a part of the FX because FX can go up and down and it's too volatile nowadays to immediately -- unless we see some long-term structural changes as we have last year and we reacted accordingl",71,"And we saw no reason to change our core revenue growth to offset a part of the FX because FX can go up and down and it's too volatile nowadays to immediately -- unless we see some long-term structural changes as we have last year and we reacted accordingly. We were not going to react by what we believe are temporary changes in FX by actions on our structural spend."
154924,323237239,934243,"Agilent Technologies Inc., Q1 2016 Earnings Call, Feb 16, 2016",2016-02-16,"Earnings Calls","Agilent Technologies, Inc.","Analysts","Okay. So sorry, I'm going to monopolize for a minute, just because I'm trying to make sure my inbox lines up. I'm getting everyone sort of the answers they need. So all right, so we -- to be clear, we have the FX hit, I'd love to also understand what were",158,"Okay. So sorry, I'm going to monopolize for a minute, just because I'm trying to make sure my inbox lines up. I'm getting everyone sort of the answers they need. So all right, so we -- to be clear, we have the FX hit, I'd love to also understand what were the key currencies because most of us can see that the dollar has actually, again, we'll see if it sustains, weakened a bit. And so it seems like it's outside the euro and the yen that might have caused some of the headwinds. So I'd love to hear just a little bit of color on, maybe it's the won or some of the other emerging market currencies. And just to be clear also on the second point. So we didn't really bake in the beat from this quarter. Is that sort of where the conservatism comes in? And then, I'm done, I promise. I'll cede the floor."
154924,323237239,934243,"Agilent Technologies Inc., Q1 2016 Earnings Call, Feb 16, 2016",2016-02-16,"Earnings Calls","Agilent Technologies, Inc.","Executives","Yes, I mean, in terms of the currencies, we have a detailed model that takes into account obviously all the currencies. The dollar versus the euro or the dollar versus the yen, had a major impact also, I think, dollar versus the British pound. And again,",125,"Yes, I mean, in terms of the currencies, we have a detailed model that takes into account obviously all the currencies. The dollar versus the euro or the dollar versus the yen, had a major impact also, I think, dollar versus the British pound. And again, the -- today, I mean today's guidance is based on the October -- January 30 exchange rates, so the euro to $1.84 and the yen, and vis-a-vis the yen -- the U.S. dollar is JPY 121.4. And we are seeing that at today's rate, if we had provided the guidance based on just say if we had -- we are able to instantly reflect the currencies as of the date of the guidance, we'd have a very different guidance."
154924,323237239,934243,"Agilent Technologies Inc., Q1 2016 Earnings Call, Feb 16, 2016",2016-02-16,"Earnings Calls","Agilent Technologies, Inc.","Executives","And I think your second statement is probably a fair one.",11,"And I think your second statement is probably a fair one."
154924,323237239,934243,"Agilent Technologies Inc., Q1 2016 Earnings Call, Feb 16, 2016",2016-02-16,"Earnings Calls","Agilent Technologies, Inc.","Operator","Our next question comes from the line of Jeff Elliott from Robert W. Baird.",14,"Our next question comes from the line of Jeff Elliott from Robert W. Baird."
154924,323237239,934243,"Agilent Technologies Inc., Q1 2016 Earnings Call, Feb 16, 2016",2016-02-16,"Earnings Calls","Agilent Technologies, Inc.","Analysts","So question on -- for Mike on chemical and energy. You're down 2% this quarter. The last couple of quarters, you're down 9% or 10%. I guess, can you give us a sense for what's happening on the E&P side? You talked about stability on the refining side. But",78,"So question on -- for Mike on chemical and energy. You're down 2% this quarter. The last couple of quarters, you're down 9% or 10%. I guess, can you give us a sense for what's happening on the E&P side? You talked about stability on the refining side. But what do you see on the E&P side? It seems like that's kind of what allowed the -- I guess the improvement relative to the last couple of quarters?"
154924,323237239,934243,"Agilent Technologies Inc., Q1 2016 Earnings Call, Feb 16, 2016",2016-02-16,"Earnings Calls","Agilent Technologies, Inc.","Executives","Yes, actually it's probably worth maybe just doing a little bridge on the last few quarters because in fact, we've seen relative flat performance over the last, last several quarters. And while instruments were down, the percentage you were talking about",270,"Yes, actually it's probably worth maybe just doing a little bridge on the last few quarters because in fact, we've seen relative flat performance over the last, last several quarters. And while instruments were down, the percentage you were talking about high single digits, we've seen a continued ability to offset through services and consumables. So what I would say is that the chemical/energy market is sort of playing out the way we had expected for the year. So we wish we had a different story here. But the price of -- oil price is low, as you know, but the product demand still remains pretty, pretty strong for our customers' products. So the refineries are running, the chemical plants are running and then we're really trying to sell to them new equipment based on a productivity message. But at the same point in time, recognize that if they use the equipment longer, it's a good opportunity for us on the services and consumables side. One thing I would ask you to reflect on is that Q1 '15, as you dig into some of the numbers, Q1 '15 really was our best quarter for the whole year. I think we grew 3% in the first quarter of last year on a core basis. We ended up growing, I think, 1% for the whole year. So that shows you we were in decline through the year. And so I wouldn't over-interpret the numbers. We think it's right in kind of the range where we had thought. And Patrick, I don't know if you had any other comments you'd add to that?"
154924,323237239,934243,"Agilent Technologies Inc., Q1 2016 Earnings Call, Feb 16, 2016",2016-02-16,"Earnings Calls","Agilent Technologies, Inc.","Executives","Well, no, not really. I think, as you said, it's playing out as was expected. There's continued pressure around the exploration side and the production side. But for the refinery side, demand really drives. Also, we placed some business for us. We tried t",97,"Well, no, not really. I think, as you said, it's playing out as was expected. There's continued pressure around the exploration side and the production side. But for the refinery side, demand really drives. Also, we placed some business for us. We tried to incentivize our customers and give them opportunity to upgrade, to increase their productivity and efficiency. And on the chemical side, I would say that the lower feed-sell [ph] price have not yet fully materialized. So we stay with focus for the year -- for the whole segment to be -- to stay flat."
154924,323237239,934243,"Agilent Technologies Inc., Q1 2016 Earnings Call, Feb 16, 2016",2016-02-16,"Earnings Calls","Agilent Technologies, Inc.","Executives","And Jeff, this is Mike. I think we shared these numbers with you in the past, but the way we looked at this -- we always look at our business, say about 15% or so is in E&P, as you described, exploration and production, which will be about 3% to 4% of our",87,"And Jeff, this is Mike. I think we shared these numbers with you in the past, but the way we looked at this -- we always look at our business, say about 15% or so is in E&P, as you described, exploration and production, which will be about 3% to 4% of our total revenues. About 35% of that segment is in refining and the other 50% is in chemicals. So that's how we -- so it sort of -- it remains stable at a subdued level."
154924,323237239,934243,"Agilent Technologies Inc., Q1 2016 Earnings Call, Feb 16, 2016",2016-02-16,"Earnings Calls","Agilent Technologies, Inc.","Operator","Our next question comes from the line of Steve Beuchaw from Morgan Stanley.",13,"Our next question comes from the line of Steve Beuchaw from Morgan Stanley."
154924,323237239,934243,"Agilent Technologies Inc., Q1 2016 Earnings Call, Feb 16, 2016",2016-02-16,"Earnings Calls","Agilent Technologies, Inc.","Analysts","I'd like to follow up just a bit on the pharmaceutical space. It was really helpful to hear just how confident you guys are in the outlook for the year growing 8% in pharma. I wonder if you could maybe add a little bit to the conversation though and talk",113,"I'd like to follow up just a bit on the pharmaceutical space. It was really helpful to hear just how confident you guys are in the outlook for the year growing 8% in pharma. I wonder if you could maybe add a little bit to the conversation though and talk about what you're hearing, Mike or Patrick, in your conversations with pharma customers as they talk about their budgets for this year. I apologize for coming back to the topic, but there's a lot of interest out there in the sustainability of growth in the space. So any color you could offer -- how your customers are thinking would be really helpful."
154924,323237239,934243,"Agilent Technologies Inc., Q1 2016 Earnings Call, Feb 16, 2016",2016-02-16,"Earnings Calls","Agilent Technologies, Inc.","Executives","Yes, absolutely. So Patrick, why don't you take that question and I will have one closing comment.",17,"Yes, absolutely. So Patrick, why don't you take that question and I will have one closing comment."
154924,323237239,934243,"Agilent Technologies Inc., Q1 2016 Earnings Call, Feb 16, 2016",2016-02-16,"Earnings Calls","Agilent Technologies, Inc.","Executives","Yes. So what we're hearing from our customers is that they -- actually, they are holding their budgets. We don't see any significant reduction there. And this comes, by the way, across the board from small and medium size and large enterprises. So it's re",95,"Yes. So what we're hearing from our customers is that they -- actually, they are holding their budgets. We don't see any significant reduction there. And this comes, by the way, across the board from small and medium size and large enterprises. So it's really, for us, it's a good mixture between different size companies and also between the different markets talking about small molecule versus biopharmaceuticals. The growth really comes from both sides, and this is why we're so confident to be able to maintain, to see this high single digit growth for pharma."
154924,323237239,934243,"Agilent Technologies Inc., Q1 2016 Earnings Call, Feb 16, 2016",2016-02-16,"Earnings Calls","Agilent Technologies, Inc.","Executives","And the other thing that we've done -- so we're given a broad-based demand across all segments of the market. Then we also continue to do our own math in terms of what's out there in terms of the install base of our products. So we have a pretty good idea",72,"And the other thing that we've done -- so we're given a broad-based demand across all segments of the market. Then we also continue to do our own math in terms of what's out there in terms of the install base of our products. So we have a pretty good idea on the -- at least from the technology refresh side, how much more demand we can expect in this segment."
154924,323237239,934243,"Agilent Technologies Inc., Q1 2016 Earnings Call, Feb 16, 2016",2016-02-16,"Earnings Calls","Agilent Technologies, Inc.","Analysts","That's extremely helpful. One corollary, one follow-up there. I wonder if you could give us a sense for -- to what extent the success that you're having in pharma, the success you're having in CrossLab are interrelated? Are those 2 perhaps a little bit mo",68,"That's extremely helpful. One corollary, one follow-up there. I wonder if you could give us a sense for -- to what extent the success that you're having in pharma, the success you're having in CrossLab are interrelated? Are those 2 perhaps a little bit more or overlapping than CrossLab is with some of the other customer verticals? And to what extent is one dependent upon the other?"
154924,323237239,934243,"Agilent Technologies Inc., Q1 2016 Earnings Call, Feb 16, 2016",2016-02-16,"Earnings Calls","Agilent Technologies, Inc.","Executives","Yes. Great, great question. I'm happy to elaborate, and they are highly connected. So when we talk about pharma market demand, it's both driving new equipment purchases, which were the focus on Patrick's comments, but also there is a demand for enterprise",190,"Yes. Great, great question. I'm happy to elaborate, and they are highly connected. So when we talk about pharma market demand, it's both driving new equipment purchases, which were the focus on Patrick's comments, but also there is a demand for enterprise-wide services and consumables. But not -- on the CrossLab side, not only are they investing in ongoing chemistries and services to maintain their operations and support their application needs, what we're also seeing is a change of the model. So what they're doing is they are taking activities that historically have been done inside the company and are creating, if you will, a new set of services for vendors in our space to handle things such as asset management. And that's created sort of a new set of services that are being created right now in pharma. We haven't seen that new set of services demand develop yet on the chemical/energy side. But we're hopeful that it will down the road. But there's a couple of dynamics going on in the pharma space, which are driving both the new instrument purchases and the consumables and services for CrossLab."
154924,323237239,934243,"Agilent Technologies Inc., Q1 2016 Earnings Call, Feb 16, 2016",2016-02-16,"Earnings Calls","Agilent Technologies, Inc.","Operator","Our next question comes from the line of Tim Evans from Wells Fargo.",13,"Our next question comes from the line of Tim Evans from Wells Fargo."
154924,323237239,934243,"Agilent Technologies Inc., Q1 2016 Earnings Call, Feb 16, 2016",2016-02-16,"Earnings Calls","Agilent Technologies, Inc.","Analysts","Wondered if you can give us a update on market for tuck-in acquisitions. What you're thinking about these days in terms of where you might like to plug some holes? And also, are you seeing more opportunities now that some valuations have come in?",45,"Wondered if you can give us a update on market for tuck-in acquisitions. What you're thinking about these days in terms of where you might like to plug some holes? And also, are you seeing more opportunities now that some valuations have come in?"
154924,323237239,934243,"Agilent Technologies Inc., Q1 2016 Earnings Call, Feb 16, 2016",2016-02-16,"Earnings Calls","Agilent Technologies, Inc.","Executives","Yes. Thanks, Tim, I appreciate the opportunity to provide a perspective on here. So although we remain focused on our organic growth opportunities, we got a lot of very exciting plans and new products coming out and working on the go-to-market capabilitie",231,"Yes. Thanks, Tim, I appreciate the opportunity to provide a perspective on here. So although we remain focused on our organic growth opportunities, we got a lot of very exciting plans and new products coming out and working on the go-to-market capabilities. As I mentioned in my call comments, we're really continuing to look for acquisitions that augment our current portfolio and add to our company capabilities. So I think you saw us with the Seahorse deal where we added capabilities in life science research, Cartagenia in the area of next-gen sequencing. We -- to build out our workflow there, and we'd still like to find ways to build out our workflow in next-gen sequencing. And so our stated strategies of really adding capabilities, expanding our portfolio, building on our work flow solutions, with a particular emphasis on life sciences research, next-gen sequencing workflows in the overall consumables and services place. They're our priorities. Well, that being said, most people still have the memories of their 52-week highs. So we'll see how this plays out. And what I will tell you is we will continue to be very disciplined in terms of how we think about M&A, and does it provide an attractive return to our shareholders? And can we do something to make the business better? If we can't make the business better, it's not something we'd be interested in."
154924,323237239,934243,"Agilent Technologies Inc., Q1 2016 Earnings Call, Feb 16, 2016",2016-02-16,"Earnings Calls","Agilent Technologies, Inc.","Operator","Our next question comes from the line of Brandon Couillard from Jefferies.",12,"Our next question comes from the line of Brandon Couillard from Jefferies."
154924,323237239,934243,"Agilent Technologies Inc., Q1 2016 Earnings Call, Feb 16, 2016",2016-02-16,"Earnings Calls","Agilent Technologies, Inc.","Analysts","Mike, you pointed to strength in China in the period. Just curious if you could elaborate on the actual growth rate in the first quarter and if there's been any deviation from sort of the mid- to high single-digit target for the year?",43,"Mike, you pointed to strength in China in the period. Just curious if you could elaborate on the actual growth rate in the first quarter and if there's been any deviation from sort of the mid- to high single-digit target for the year?"
154924,323237239,934243,"Agilent Technologies Inc., Q1 2016 Earnings Call, Feb 16, 2016",2016-02-16,"Earnings Calls","Agilent Technologies, Inc.","Executives","Yes. Thanks. Appreciate the opportunity to talk about China, one of my favorite topics. So we saw a very good demand in China, high single-digit growth in our integral lab business. And as I mentioned to you, in the past, the markets here are really being",229,"Yes. Thanks. Appreciate the opportunity to talk about China, one of my favorite topics. So we saw a very good demand in China, high single-digit growth in our integral lab business. And as I mentioned to you, in the past, the markets here are really being driven by strong investments in government and policy-driven initiatives around quality of life concerns whether the environment, drug and food safety. So all the market except -- with the exception of chemical/energy, really saw quite strong growth. And we're underpenetrated in DDG business compared to the rest of the company. We've talked about that in the past. And we were under-penetrated in growing market for cancer diagnostics, for example. And I recently read -- saw some statistics that I thought were really quite amazing. There was a report by the Cancer Hospital of the Chinese Academy of Medical Sciences said that every minute, an average of 6 people in the country were diagnosed with cancer. And 5 of those 6 would eventually die of the disease. So unfortunately, there's going to be growing demand for cancer diagnostics as well. I'm going to wrap this all up by saying we remain quite comfortable with the mid- to high single-digit growth expectation we laid out for China. It was strong for us in the first quarter and we expect that to continue through the year."
154924,323237239,934243,"Agilent Technologies Inc., Q1 2016 Earnings Call, Feb 16, 2016",2016-02-16,"Earnings Calls","Agilent Technologies, Inc.","Analysts","But then, one more for Didier. Could you split out the contribution from Seahorse relative to the headwind from the NMR in the first quarter in terms of just dollars?",30,"But then, one more for Didier. Could you split out the contribution from Seahorse relative to the headwind from the NMR in the first quarter in terms of just dollars?"
154924,323237239,934243,"Agilent Technologies Inc., Q1 2016 Earnings Call, Feb 16, 2016",2016-02-16,"Earnings Calls","Agilent Technologies, Inc.","Executives","No, we don't provide guidance or information regarding the acquisitions. We have stated and we are exactly in line that we expect Seahorse revenue to grow double digits in 2016 versus 2015. And we expect Seahorse operating margin to be also in the double",51,"No, we don't provide guidance or information regarding the acquisitions. We have stated and we are exactly in line that we expect Seahorse revenue to grow double digits in 2016 versus 2015. And we expect Seahorse operating margin to be also in the double digit. So no change to our expectations."
154924,323237239,934243,"Agilent Technologies Inc., Q1 2016 Earnings Call, Feb 16, 2016",2016-02-16,"Earnings Calls","Agilent Technologies, Inc.","Executives","And Patrick, maybe you can just add a few color comments on how it's going so far.",17,"And Patrick, maybe you can just add a few color comments on how it's going so far."
154924,323237239,934243,"Agilent Technologies Inc., Q1 2016 Earnings Call, Feb 16, 2016",2016-02-16,"Earnings Calls","Agilent Technologies, Inc.","Executives","Well, the integration of Seahorse is going very well. It's giving us extended reach also into the research market, and this was the whole play. Plus we, of course, used the opportunity, to use our strength in pharma to sell these products into the pharma",95,"Well, the integration of Seahorse is going very well. It's giving us extended reach also into the research market, and this was the whole play. Plus we, of course, used the opportunity, to use our strength in pharma to sell these products into the pharma space in areas like disease discovery as well. And this is what will drive the growth in fiscal year '16. As Didier said, we expect double-digit growth. We have to sail full steam [ph], and we are looking forward to a very strong Q2, Q3, Q4 for this product line."
154924,323237239,934243,"Agilent Technologies Inc., Q1 2016 Earnings Call, Feb 16, 2016",2016-02-16,"Earnings Calls","Agilent Technologies, Inc.","Operator","Our next question comes from the line of Tycho Peterson from JPMorgan.",12,"Our next question comes from the line of Tycho Peterson from JPMorgan."
154924,323237239,934243,"Agilent Technologies Inc., Q1 2016 Earnings Call, Feb 16, 2016",2016-02-16,"Earnings Calls","Agilent Technologies, Inc.","Analysts","Maybe just first on capital deployment. You did $200 million in buybacks in the quarter. You got it for $480 million for the year. I mean, it sounds like you'll front-end load it, and -- I mean, how do we think about a reauthorization once you get through",60,"Maybe just first on capital deployment. You did $200 million in buybacks in the quarter. You got it for $480 million for the year. I mean, it sounds like you'll front-end load it, and -- I mean, how do we think about a reauthorization once you get through this tranche given your stock is probably under some pressure now [ph]?"
154924,323237239,934243,"Agilent Technologies Inc., Q1 2016 Earnings Call, Feb 16, 2016",2016-02-16,"Earnings Calls","Agilent Technologies, Inc.","Executives","Yes, we basically decided to buy back in Q1 what we had not been able to do in Q4 of the preceding year. And then, we have 5 of 10b5-1. And we started forming our -- for your model, you should assume that we are buying about 1/3 of the remaining $280 mill",57,"Yes, we basically decided to buy back in Q1 what we had not been able to do in Q4 of the preceding year. And then, we have 5 of 10b5-1. And we started forming our -- for your model, you should assume that we are buying about 1/3 of the remaining $280 million on a per quarter."
154924,323237239,934243,"Agilent Technologies Inc., Q1 2016 Earnings Call, Feb 16, 2016",2016-02-16,"Earnings Calls","Agilent Technologies, Inc.","Analysts","And then just to clarify on the margins because I've had a few questions. I mean, the $13 million hit is the FX hit, but I guess people are having a hard time understanding why you're not seeing faster-than-expected realization of the COGS and SG&A cuts t",65,"And then just to clarify on the margins because I've had a few questions. I mean, the $13 million hit is the FX hit, but I guess people are having a hard time understanding why you're not seeing faster-than-expected realization of the COGS and SG&A cuts that you saw some of that this quarter. What doesn't that carry through for the next 3 quarters?"
154924,323237239,934243,"Agilent Technologies Inc., Q1 2016 Earnings Call, Feb 16, 2016",2016-02-16,"Earnings Calls","Agilent Technologies, Inc.","Executives","Well, we're not saying it's not going to carry through, we're saying, we saw no reason in the present agreement [ph] to change the guidance on an operating margin basis, 20.2%, that we have provided -- 20% to 20.5% that we have provided previously. So --",86,"Well, we're not saying it's not going to carry through, we're saying, we saw no reason in the present agreement [ph] to change the guidance on an operating margin basis, 20.2%, that we have provided -- 20% to 20.5% that we have provided previously. So -- and again, with the same level of conservatism, as we had in November. So that's basically the -- that was the premise for us maintaining both the core revenue growth and the operating margin that we have provided in November."
154924,323237239,934243,"Agilent Technologies Inc., Q1 2016 Earnings Call, Feb 16, 2016",2016-02-16,"Earnings Calls","Agilent Technologies, Inc.","Executives","And Didier, I'll just add that in my call comments, I tried to highlight a few things on a longer-term nature to show you that we're not out of gas in this tank in terms of our ability to continue to move our operating margin. We have other larger-hitting",97,"And Didier, I'll just add that in my call comments, I tried to highlight a few things on a longer-term nature to show you that we're not out of gas in this tank in terms of our ability to continue to move our operating margin. We have other larger-hitting programs that are coming on -- that are coming in late 2016 and will carry on into '17 as well. So this is not a onetime quarter where we just got a favorable mix, whatever, there's real fundamental improvements underway in the operating margin capabilities of the company."
154924,323237239,934243,"Agilent Technologies Inc., Q1 2016 Earnings Call, Feb 16, 2016",2016-02-16,"Earnings Calls","Agilent Technologies, Inc.","Analysts","And then speaking of running out of gas, you talked about refiners holding up. There's been news that at least 2 of the country's largest refiners are cutting out quota gasoline. What gives you conviction that your business there holds up?",41,"And then speaking of running out of gas, you talked about refiners holding up. There's been news that at least 2 of the country's largest refiners are cutting out quota gasoline. What gives you conviction that your business there holds up?"
154924,323237239,934243,"Agilent Technologies Inc., Q1 2016 Earnings Call, Feb 16, 2016",2016-02-16,"Earnings Calls","Agilent Technologies, Inc.","Executives","I'm not sure exactly what you're referring to, but relative to our view is that gasoline will continue to be needed to run the economy. And there's going to be demand there. And what we've tried to share -- and as long as production is running and if ther",95,"I'm not sure exactly what you're referring to, but relative to our view is that gasoline will continue to be needed to run the economy. And there's going to be demand there. And what we've tried to share -- and as long as production is running and if there's demand, the refineries will meet that demand. We've seen no significant changes in the underlying demand for gas. And in fact, Patrick, I think you were showing me some statistics the other day about what's going on in the area of refineries in the U.S."
154924,323237239,934243,"Agilent Technologies Inc., Q1 2016 Earnings Call, Feb 16, 2016",2016-02-16,"Earnings Calls","Agilent Technologies, Inc.","Executives","Yes, I mean, what we see, as Mike said, is the continued demand for, not only in the U.S, but also in the emerging economies like China. So the refineries are basically running at capacity right now. There will be no new-builds. But we see that they repla",129,"Yes, I mean, what we see, as Mike said, is the continued demand for, not only in the U.S, but also in the emerging economies like China. So the refineries are basically running at capacity right now. There will be no new-builds. But we see that they replaced the existing equipment, and they also go into service contracts. But first, they look for opportunities to drive more efficiencies, which gives us an opportunity to upgrade the install base with automation, features and other things to make sure that the customers can save money with the equipment as well. So the oil price is still driven by the fact that there is over-capacity on the production side. But the refinery volume has not gone down significantly over the last quarters."
154924,323237239,934243,"Agilent Technologies Inc., Q1 2016 Earnings Call, Feb 16, 2016",2016-02-16,"Earnings Calls","Agilent Technologies, Inc.","Analysts","Okay. And then just lastly, can you talk about linearity in the quarter, anything notable in January? You guys have an extra month versus a lot of your comps, so I was just wondering if there's anything worth calling out in January trends versus November",47,"Okay. And then just lastly, can you talk about linearity in the quarter, anything notable in January? You guys have an extra month versus a lot of your comps, so I was just wondering if there's anything worth calling out in January trends versus November and December?"
154924,323237239,934243,"Agilent Technologies Inc., Q1 2016 Earnings Call, Feb 16, 2016",2016-02-16,"Earnings Calls","Agilent Technologies, Inc.","Executives","Yes, no. I just point to 2 things. One is in terms to our normal seasonality through the quarter. Q1 '16 was like prior quarters. We always see a nice strong December as we close off year-end with our customers. And it followed our typical seasonality pat",114,"Yes, no. I just point to 2 things. One is in terms to our normal seasonality through the quarter. Q1 '16 was like prior quarters. We always see a nice strong December as we close off year-end with our customers. And it followed our typical seasonality patterns through November, December and January. I think probably, the only thing of note would be in the DDG side. We had, I think, 1 less day -- working day, I think, this year. So that does affect the genomics business in terms of how much revenue we can get in that quarter. But really, it was sort of businesses usual, if you will, through the first quarter."
154924,323237239,934243,"Agilent Technologies Inc., Q1 2016 Earnings Call, Feb 16, 2016",2016-02-16,"Earnings Calls","Agilent Technologies, Inc.","Operator","Our next question comes from the line of Jack Meehan from Barclays.",12,"Our next question comes from the line of Jack Meehan from Barclays."
154924,323237239,934243,"Agilent Technologies Inc., Q1 2016 Earnings Call, Feb 16, 2016",2016-02-16,"Earnings Calls","Agilent Technologies, Inc.","Analysts","I wanted to follow up on Tycho's last question, just around the academic end market. I'm curious, you mentioned in the presentation around some of the modestly larger research budgets being released in the U.S. Curious on your view on the NIH and just rea",60,"I wanted to follow up on Tycho's last question, just around the academic end market. I'm curious, you mentioned in the presentation around some of the modestly larger research budgets being released in the U.S. Curious on your view on the NIH and just really timing related there because of the timing of the Congressional approvals at your end."
154924,323237239,934243,"Agilent Technologies Inc., Q1 2016 Earnings Call, Feb 16, 2016",2016-02-16,"Earnings Calls","Agilent Technologies, Inc.","Executives","Yes, I can take this question, yes. As we have seen moderate growth again in academia and government, which was a positive surprise, and as you've all have read, there are more budgets available now in the U.S. These budgets are slowly released that drove",100,"Yes, I can take this question, yes. As we have seen moderate growth again in academia and government, which was a positive surprise, and as you've all have read, there are more budgets available now in the U.S. These budgets are slowly released that drove some of the growth for us in Q1 and looking at the funnel moving forward. We actually see a good funnel there as well. So we stay with the forecast of low single-digit growth of academia and government, at the moment mainly driven by the U.S. But this is where we see the strongest demand."
154924,323237239,934243,"Agilent Technologies Inc., Q1 2016 Earnings Call, Feb 16, 2016",2016-02-16,"Earnings Calls","Agilent Technologies, Inc.","Analysts","Got it. And are your expectations for this level of growth to stay at the same rate through the end of the fiscal year? Or are you assuming the budgets got released a little bit faster from here?",38,"Got it. And are your expectations for this level of growth to stay at the same rate through the end of the fiscal year? Or are you assuming the budgets got released a little bit faster from here?"
154924,323237239,934243,"Agilent Technologies Inc., Q1 2016 Earnings Call, Feb 16, 2016",2016-02-16,"Earnings Calls","Agilent Technologies, Inc.","Executives","If the budgets will be released faster, I think it will be probably upside for us. We're now -- our current view is low single digits for academia and government for the year.",33,"If the budgets will be released faster, I think it will be probably upside for us. We're now -- our current view is low single digits for academia and government for the year."
154924,323237239,934243,"Agilent Technologies Inc., Q1 2016 Earnings Call, Feb 16, 2016",2016-02-16,"Earnings Calls","Agilent Technologies, Inc.","Analysts","Well, got it. And then just one other question on the margins and DDG. Definitely appreciate the year-over-year improvement. I was wondering what your thoughts were, bridging through the end of the year, just given how the relative margins compared to the",45,"Well, got it. And then just one other question on the margins and DDG. Definitely appreciate the year-over-year improvement. I was wondering what your thoughts were, bridging through the end of the year, just given how the relative margins compared to the end of 2015."
154924,323237239,934243,"Agilent Technologies Inc., Q1 2016 Earnings Call, Feb 16, 2016",2016-02-16,"Earnings Calls","Agilent Technologies, Inc.","Executives","Great. I know Jacob's given a lot of thought to that potential question, so I'll pass it over to you, Jacob, to provide some color there.",26,"Great. I know Jacob's given a lot of thought to that potential question, so I'll pass it over to you, Jacob, to provide some color there."
154924,323237239,934243,"Agilent Technologies Inc., Q1 2016 Earnings Call, Feb 16, 2016",2016-02-16,"Earnings Calls","Agilent Technologies, Inc.","Executives","Yes, thanks for that, Jack. And first of all, I want to say that we're very pleased to see the improvement versus the Q1 last year. But you're also right that versus Q4, that we saw a bit of a decrease, and that was actually where we most expected. We sit",121,"Yes, thanks for that, Jack. And first of all, I want to say that we're very pleased to see the improvement versus the Q1 last year. But you're also right that versus Q4, that we saw a bit of a decrease, and that was actually where we most expected. We sit in the DGG business with a pretty fixed cost space. So when you have a Q1 with a lower base than in Q4, you will see that our margins has also impacted accordingly. So you always see us coming out with a strong Q4 and a weaker Q1 under the gross margin and also on our operating margin. So this is kind of by the book and really as expected."
154924,323237239,934243,"Agilent Technologies Inc., Q1 2016 Earnings Call, Feb 16, 2016",2016-02-16,"Earnings Calls","Agilent Technologies, Inc.","Executives","Yes, I would just add that there's no change in plan, and Jacob is still absolutely committed to reaching 20% operating margin in 2017. Absolutely.",25,"Yes, I would just add that there's no change in plan, and Jacob is still absolutely committed to reaching 20% operating margin in 2017. Absolutely."
154924,323237239,934243,"Agilent Technologies Inc., Q1 2016 Earnings Call, Feb 16, 2016",2016-02-16,"Earnings Calls","Agilent Technologies, Inc.","Operator","Our next question comes from line of Derik De Bruin from Bank of America.",14,"Our next question comes from line of Derik De Bruin from Bank of America."
154924,323237239,934243,"Agilent Technologies Inc., Q1 2016 Earnings Call, Feb 16, 2016",2016-02-16,"Earnings Calls","Agilent Technologies, Inc.","Analysts","So I'm just curious. You're guiding to a 22% operating margin for 2017. So that's implying -- assuming the 20.2% midpoint, 130 to 180 basis points of margin expansion next year. I'm just curious if you can't -- if you couldn't find 10 additional basis poi",75,"So I'm just curious. You're guiding to a 22% operating margin for 2017. So that's implying -- assuming the 20.2% midpoint, 130 to 180 basis points of margin expansion next year. I'm just curious if you can't -- if you couldn't find 10 additional basis points of margin expansion in 2016 to sort of offset the impact, what gives you confidence you're going to be able to get 130, 180 basis points next year?"
154924,323237239,934243,"Agilent Technologies Inc., Q1 2016 Earnings Call, Feb 16, 2016",2016-02-16,"Earnings Calls","Agilent Technologies, Inc.","Executives","I'd just reiterate -- great question this one. Again, by the way, one of the things as you heard me say earlier in my comments, we continue to make sure we're realistic and we think about our business not on some hope and a prayer, but we actually have so",219,"I'd just reiterate -- great question this one. Again, by the way, one of the things as you heard me say earlier in my comments, we continue to make sure we're realistic and we think about our business not on some hope and a prayer, but we actually have solid plans behind our long-term operating goals. And I think we have a lot of confidence for 2 reasons: One is we have a plan that can get us there with -- not all on top line. It's probably in the range of 4% ago [ph]. We can get to the margin goals. We've laid out a plan that's got 60% of it is coming from the cost side. And we have multiyear programs that are going to take significant cost out of our structures. So I highlighted a few of them in my call. I mean, changes in terms of our benefit structure, changes in terms of our IT costs, our IT systems. These are major company-wide initiatives that right now we're underway. You won't start to see them going to the P&L until like late '16 going into '17. So these are kind of things that give us confidence to say, ""Okay, there's a path that gets us to where we want to get to in '17."""
154924,323237239,934243,"Agilent Technologies Inc., Q1 2016 Earnings Call, Feb 16, 2016",2016-02-16,"Earnings Calls","Agilent Technologies, Inc.","Analysts","Okay, great. It's the late '16, early '17 that I think that was the key that I was sort of looking for in that. Second question is given some of the turmoil going on in Europe, have you seen any sort of changes in the academic or government spending? As s",81,"Okay, great. It's the late '16, early '17 that I think that was the key that I was sort of looking for in that. Second question is given some of the turmoil going on in Europe, have you seen any sort of changes in the academic or government spending? As sort of like the governments grapple with sort of like the refugee crisis and some of the other things going on? Is there any noticeable change to spending patterns in Europe?"
154924,323237239,934243,"Agilent Technologies Inc., Q1 2016 Earnings Call, Feb 16, 2016",2016-02-16,"Earnings Calls","Agilent Technologies, Inc.","Executives","Patrick, you're shaking your head here right now.",8,"Patrick, you're shaking your head here right now."
154924,323237239,934243,"Agilent Technologies Inc., Q1 2016 Earnings Call, Feb 16, 2016",2016-02-16,"Earnings Calls","Agilent Technologies, Inc.","Executives","Yes, I'm shaking my head because we have not seen any significant change over the last several quarters.",18,"Yes, I'm shaking my head because we have not seen any significant change over the last several quarters."
154924,323237239,934243,"Agilent Technologies Inc., Q1 2016 Earnings Call, Feb 16, 2016",2016-02-16,"Earnings Calls","Agilent Technologies, Inc.","Operator","Our next question comes from the line of Dan Leonard from Leerink Partners.",13,"Our next question comes from the line of Dan Leonard from Leerink Partners."
154924,323237239,934243,"Agilent Technologies Inc., Q1 2016 Earnings Call, Feb 16, 2016",2016-02-16,"Earnings Calls","Agilent Technologies, Inc.","Analysts","All my questions have been answered.",6,"All my questions have been answered."
154924,323237239,934243,"Agilent Technologies Inc., Q1 2016 Earnings Call, Feb 16, 2016",2016-02-16,"Earnings Calls","Agilent Technologies, Inc.","Operator","Our next question comes from the line of Dane Leone from BTIG.",12,"Our next question comes from the line of Dane Leone from BTIG."
154924,323237239,934243,"Agilent Technologies Inc., Q1 2016 Earnings Call, Feb 16, 2016",2016-02-16,"Earnings Calls","Agilent Technologies, Inc.","Analysts","So on the gross margin line, can you just give a little bit more color in terms of the product mix? As I look at the different groups, really, the margin leverage seemed to come through the Life Sci and Applied Markets Group. You guys almost reported a 59",81,"So on the gross margin line, can you just give a little bit more color in terms of the product mix? As I look at the different groups, really, the margin leverage seemed to come through the Life Sci and Applied Markets Group. You guys almost reported a 59% gross margin there. Comment on the mix, please, and why the margin for that group specifically is expected to moderate when, I guess, historically, it's been pretty steady quarter-to-quarter throughout the year."
154924,323237239,934243,"Agilent Technologies Inc., Q1 2016 Earnings Call, Feb 16, 2016",2016-02-16,"Earnings Calls","Agilent Technologies, Inc.","Executives","I think there's 2 things I would point to and then, Didier, feel free to jump in as well. But first of all, remember the change we're making to our portfolio. So we're -- we've exited the NMR hardware business and as we -- and we're starting to see some o",107,"I think there's 2 things I would point to and then, Didier, feel free to jump in as well. But first of all, remember the change we're making to our portfolio. So we're -- we've exited the NMR hardware business and as we -- and we're starting to see some of those margin improvements showing up in the P&L, where we had revenue in the NMR business in much higher revenues in FY '15. And then our pharma business is pulling a lot of liquid chromatography, which is one of our highest gross margin products. I think it's really those -- perhaps those are the things."
154924,323237239,934243,"Agilent Technologies Inc., Q1 2016 Earnings Call, Feb 16, 2016",2016-02-16,"Earnings Calls","Agilent Technologies, Inc.","Executives","You've stated it all absolutely there. Our liquid -- I had mentioned earlier that the favorable mix came in part from the pharma mix. And within pharma, clearly, liquid chromatograph that has the higher-than-average operating margin and gross margin.",40,"You've stated it all absolutely there. Our liquid -- I had mentioned earlier that the favorable mix came in part from the pharma mix. And within pharma, clearly, liquid chromatograph that has the higher-than-average operating margin and gross margin."
154924,323237239,934243,"Agilent Technologies Inc., Q1 2016 Earnings Call, Feb 16, 2016",2016-02-16,"Earnings Calls","Agilent Technologies, Inc.","Analysts","So to clarify, you felt that there was either a catch-up ordering or stocking in the quarter that -- on those products specifically, that's not expected to continue for the rest of the year?",34,"So to clarify, you felt that there was either a catch-up ordering or stocking in the quarter that -- on those products specifically, that's not expected to continue for the rest of the year?"
154924,323237239,934243,"Agilent Technologies Inc., Q1 2016 Earnings Call, Feb 16, 2016",2016-02-16,"Earnings Calls","Agilent Technologies, Inc.","Executives","Well, you almost think about the pharma -- I mean, we had 19% pharmaceutical growth in the first quarter. What we're saying is we can't expect 19% to happen each of the next 3 quarters. What we do expect is the continuous strong demand. And right now, we'",73,"Well, you almost think about the pharma -- I mean, we had 19% pharmaceutical growth in the first quarter. What we're saying is we can't expect 19% to happen each of the next 3 quarters. What we do expect is the continuous strong demand. And right now, we're calling 8% for the entire year. So that's what you're seeing in terms of reflected in our mix column as it relates to gross margin."
154924,323237239,934243,"Agilent Technologies Inc., Q1 2016 Earnings Call, Feb 16, 2016",2016-02-16,"Earnings Calls","Agilent Technologies, Inc.","Analysts","Okay. And then on the FX rate. I'm still -- so if you just kind of use the DXY proxy, right, the last quarter was actually pretty elevated. But since then, the trend has actually come back in to closer to where you guided the year. Are you expecting -- is",77,"Okay. And then on the FX rate. I'm still -- so if you just kind of use the DXY proxy, right, the last quarter was actually pretty elevated. But since then, the trend has actually come back in to closer to where you guided the year. Are you expecting -- is there some nuance within this on how certain currencies have moved? Or are you just kind of assuming worst case that the dollar kind of [indiscernible]?"
154924,323237239,934243,"Agilent Technologies Inc., Q1 2016 Earnings Call, Feb 16, 2016",2016-02-16,"Earnings Calls","Agilent Technologies, Inc.","Executives","Actually, we're -- it's just pure math. So we're not making any projections at all about the future levels of FX. What Didier has done is he takes the currency spot rates on the last day of the reported quarter, and that's how we guide the company. We say",76,"Actually, we're -- it's just pure math. So we're not making any projections at all about the future levels of FX. What Didier has done is he takes the currency spot rates on the last day of the reported quarter, and that's how we guide the company. We say, okay, that's what we know and we'll assume that rate stays the same for the rest of the year. And then, it's just pure math from there."
154924,323237239,934243,"Agilent Technologies Inc., Q1 2016 Earnings Call, Feb 16, 2016",2016-02-16,"Earnings Calls","Agilent Technologies, Inc.","Executives","And helping methodology [ph] forever.",5,"And helping methodology [ph] forever."
154924,323237239,934243,"Agilent Technologies Inc., Q1 2016 Earnings Call, Feb 16, 2016",2016-02-16,"Earnings Calls","Agilent Technologies, Inc.","Analysts","Okay. So it's extrapolation off of January 31, not what's happening in February. Okay, got it.",16,"Okay. So it's extrapolation off of January 31, not what's happening in February. Okay, got it."
154924,323237239,934243,"Agilent Technologies Inc., Q1 2016 Earnings Call, Feb 16, 2016",2016-02-16,"Earnings Calls","Agilent Technologies, Inc.","Executives","That's correct. I made a comment during my script -- that on my script, that would we had used, for example, today's exchange rates, the guidance would have been higher because the dollar between January 31 and today has weakened.",41,"That's correct. I made a comment during my script -- that on my script, that would we had used, for example, today's exchange rates, the guidance would have been higher because the dollar between January 31 and today has weakened."
154924,323237239,934243,"Agilent Technologies Inc., Q1 2016 Earnings Call, Feb 16, 2016",2016-02-16,"Earnings Calls","Agilent Technologies, Inc.","Operator","And this does conclude the question-and-answer session of today's program. I'd like to hand the program back to Alicia Rodriguez for any further remarks.",25,"And this does conclude the question-and-answer session of today's program. I'd like to hand the program back to Alicia Rodriguez for any further remarks."
154924,323237239,934243,"Agilent Technologies Inc., Q1 2016 Earnings Call, Feb 16, 2016",2016-02-16,"Earnings Calls","Agilent Technologies, Inc.","Executives","All right. Thank you, everybody, for joining us on the call. And if you have any questions, please give us a call in IR. We'd like to wish you a good day and I'm sure we'll be talking later. Thank you.",41,"All right. Thank you, everybody, for joining us on the call. And if you have any questions, please give us a call in IR. We'd like to wish you a good day and I'm sure we'll be talking later. Thank you."
154924,323237239,934243,"Agilent Technologies Inc., Q1 2016 Earnings Call, Feb 16, 2016",2016-02-16,"Earnings Calls","Agilent Technologies, Inc.","Operator","Thank you, ladies and gentlemen, for your participation in today's conference. This does conclude the program. You may now disconnect. Good day.",22,"Thank you, ladies and gentlemen, for your participation in today's conference. This does conclude the program. You may now disconnect. Good day."
154924,323237239,935096,"Agilent Technologies Inc., Q1 2016 Earnings Call, Feb 16, 2016",2016-02-16,"Earnings Calls","Agilent Technologies, Inc.","Operator","Good day, ladies and gentlemen, and welcome to the First Quarter 2016 Agilent Technologies Inc. Earnings Conference Call. [Operator Instructions] As a reminder, today's program is being recorded. I would now like to introduce your host for today's progr",48,"Good day, ladies and gentlemen, and welcome to the First Quarter 2016 Agilent Technologies Inc. Earnings Conference Call. [Operator Instructions] As a reminder, today's program is being recorded. 
I would now like to introduce your host for today's program, Alicia Rodriguez, Vice President, Investor Relations. Please go ahead."
154924,323237239,935096,"Agilent Technologies Inc., Q1 2016 Earnings Call, Feb 16, 2016",2016-02-16,"Earnings Calls","Agilent Technologies, Inc.","Executives","Thank you, Jonathan, and welcome everyone to Agilent's First Quarter Conference Call for Fiscal Year 2016. With me are Mike McMullen, Agilent's President and CEO; and Didier Hirsch, Agilent's Senior Vice President and CFO. Joining in the Q&A after Didier'",328,"Thank you, Jonathan, and welcome everyone to Agilent's First Quarter Conference Call for Fiscal Year 2016. With me are Mike McMullen, Agilent's President and CEO; and Didier Hirsch, Agilent's Senior Vice President and CFO. Joining in the Q&A after Didier's comments will be Patrick Kaltenbach, President of Agilent's Life Sciences and Applied Markets Group; Jacob Thaysen, President of Agilent's Diagnostics and Genomics Group; and Mark Doak, President of the Agilent CrossLab Group.
You can find the press release and information to supplement today's discussion on our website at www.investor.agilent.com. While there, please click on the link for financial results under the Financial Information tab. You will find an investor presentation along with revenue breakouts and currency impacts, business segment results and historical financials for Agilent's operations. We will also post a copy of the prepared remarks following this call.
Today's comments by Mike and Didier will refer to non-GAAP financial measures. You will find the most directly comparable GAAP financial metrics and reconciliations on our website. Unless otherwise noted, all references to increases or decreases in financial metrics are year-over-year. As a reminder, we are no longer reporting or commenting on orders or book-to-bill and our guidance is based on exchange rates as of the last day of the reported quarter.
And please note that we will refer to core revenue growth, which excludes the impact of currency, the NMR business and acquisitions and divestitures within the past 12 months. Reconciliations between reported and core growth in dollars and percentages can be found in the financial results section on the IR website.
We will also make forward-looking statements about the financial performance of the company. These statements are subject to risks and uncertainties and are only valid as of today. The company assumes no obligation to update them. Please look at the company's recent SEC filings for a more complete picture of our risks and other factors. 
And now I'd like to turn the call over to Mike."
154924,323237239,935096,"Agilent Technologies Inc., Q1 2016 Earnings Call, Feb 16, 2016",2016-02-16,"Earnings Calls","Agilent Technologies, Inc.","Executives","Thanks, Lisa, and hello, everyone. Thank you for joining us on today's call. I'm pleased to report that our team delivered a very strong start to our fiscal 2016, both revenue and earnings are above the high end of our guidance. I would now highlight 3",1232,"Thanks, Lisa, and hello, everyone. Thank you for joining us on today's call. I'm pleased to report that our team delivered a very strong start to our fiscal 2016, both revenue and earnings are above the high end of our guidance. 
I would now highlight 3 key results. First, revenue was up over 6% on a core basis. Second, we delivered an operating margin increase of 200 basis points from a year ago to 20.2% adjusted for Keysight billings. Finally, adjusted EPS of $0.46 was up 12% over last year.
Our Q1 results are driven by continued strength in the pharma, clinical and diagnostics markets with the return to growth in academia and government. Market demand remained strong for our liquid chromatography, CrossLab services and consumables, and diagnostics and genomics offerings. Geographically, all regions grew on a core basis with strong growth in China. 
Let me highlight the Q1 results by our 3 business groups.
The Life Sciences and Applied Markets Group delivered a core revenue growth of 2%. We see continued strong global pharma demand, growth return in academia and government markets, and China government investments in environmental and food markets. All of this offset continued weaknesses for new equipment purchases in the chemical and engineering market space. LSAG's operating margin for the quarter was 21.7%, up 210 basis points from a year ago. As a reminder, in November, we closed the acquisition of Seahorse Bioscience. Integration activities are in full swing with the team excited to be part of Agilent.
LSAG continued to strengthen its portfolio in Q1. We released 2 new refractive index detectors, the 1260 and 1290 Infinity II RID. These detectors help expand the capabilities of modern UHPLC chromatography to make difficult measurements in certain chemical, biopharma and food applications.
Agilent's innovation strength was recognized in the January edition of Analytical Scientist magazine. We were honored with an Innovation Award for our unique LC dual-needle technology. This is a breakthrough in the way samples are injected into Agilent's LC products. The unique design enables fast injection cycles, scalable injection volumes and ultralow carryover.
Next is the Agilent CrossLab Group. We continue to see consistently strong revenue results. Our core revenue growth was 10% in Q1. Strong pharma and chemical and energy market demand drove growth in our services and consumables offering.
Our operating margin was 22.1% for the quarter. This is up 140 basis points from a year ago. We continued bringing novel, new chemistries to market. For example, we released the AdvanceBio SEC family of products. These innovative new products are designed for accurate and precise size exclusion chromatography targeted at biopharma applications. Early adopting customers are reporting significant economic and performance benefits over any current technologies offered by our competitors.
Finally, the Diagnostics and Genomics Group continued to demonstrate momentum. In Q1, DGG delivered 12% core revenue growth with strength across all of its businesses. The pathology business continued a steady trajectory to market growth rates. We see strong growth for Dako Omnis reagents and growing revenue, PD-L1 diagnostics. The companion diagnostics business also continued to demonstrate momentum.
Double-digit growth in nucleic acids and genomics reflected strong demand from pharma and clinical markets in the favorable compare. DGG's operating margin for the quarter was 9.6%, that's up 910 basis points from a year ago. I want to remind you that last year, this business broke even in Q1 of fiscal 2015.
Last year, our Dako complementary diagnostic for Bristol-Myers Squibb's OPDIVO was approved by the FDA for non-squamous, non-small cell lung cancer. In January of this year, the FDA approved expanded use of this PD-L1 diagnostic to include patients with melanoma. Positive PD-L1 status in melanoma has been correlated with the treatment effectiveness of Bristol-Myers Squibb's drug treatment. Agilent is the first company to provide FDA-approved tests for lung cancer and melanoma for PD-L1 markers.
Now I'll take a brief look at Agilent's revenues by end market performance on a core basis. We saw strength in all our life sciences and diagnostics markets. Continued robust demand drove pharma revenue up 19%. Growth was fueled by technology refresh deals, new product uptake and aftermarket demand for services and consumables. Our clinical and diagnostics revenue was up 7%, and we experienced a return to growth in academia and government of 4%. This growth was significantly driven by the authorization of larger research budgets in the U.S.
Applied end market performance was generally soft except for environmental, which was up 9%, driven by strength in China. Food declined 1%. Our food market strength in China was offset by soft demand in developed countries. Chemical and energy declined 2%, driven by the well-publicized macroeconomic concerns.
Let me provide an update on our operating margin-proven initiatives. This quarter marks the fourth consecutive quarter of year-over-year operating margin improvement. This is how we are driving the sustained performance. We are building a new company portfolio. We have exited unattractive businesses and are acquiring new ones to enable our growth strategy. Our multiyear Agile Agilent program is simplifying our company, making it more nimble and lowering our costs. Finally, while we are improving our execution capabilities, transforming our culture to work as one team across the entire company, we call this One Agilent.
As we enter the second year of the new Agilent, here is what you can expect as we move forward. We are building a new business, one that delivers above-market growth. We will continue to target operating margin expansion. Finally, we are driving a balanced capital allocation policy that includes increased levels of free cash flow being returned to shareholders.
Going forward, we will continue to make tough decisions to ensure our long-term competitiveness. For example, we have just frozen our U.S.-defined benefits retirement plan. This change is effective in the second half of fiscal 2016. I've also spoke with many of you about our multiple ERP systems and oversized IT environment. We continue to streamline our IT systems and infrastructure to reduce costs and increase effectiveness. While work remains, we are pleased with the start to the second year of the new Agilent and our progress in transforming the company. Let me share my view on the current market outlook.
The principle of new Agilent is be realistic and to closely monitor market conditions that could affect our business. Global macroeconomic concerns are pressuring some end markets in emerging economies. The good news is that we see solid market conditions in other end markets and geographies. I remain confident in our ability to achieve our full year core growth and operating margin goals. I am also confident that we will make course correction as market conditions dictate.
We are strengthening our portfolio, building on our prior year introductions. We have an exciting pipeline of compelling new offerings set to launch this year. In tandem of these new offerings, we have created a new go-to-market capability. We have a focused, energized sales force, and we are overhauling our e-commerce environment to make it easier for customers to do business with us.
And most importantly, across the company, we have the organizational capability to execute and deliver. The Agilent team is aligned and highly energized, driven to win the marketplace. 
Thank you for being on the call today. I will now turn it over to Didier, who will provide additional insights on our financial results and our updated guidance. Didier?"
154924,323237239,935096,"Agilent Technologies Inc., Q1 2016 Earnings Call, Feb 16, 2016",2016-02-16,"Earnings Calls","Agilent Technologies, Inc.","Executives","Yes. Thank you, Mike, and hello, everyone. To summarize Q1 results, they are above the high end of our revenue and EPS guidance even as currency impacted revenue by $7 million and OP by $2 million.The EPS beat was the result of the higher revenues as we",284,"Yes. Thank you, Mike, and hello, everyone. To summarize Q1 results, they are above the high end of our revenue and EPS guidance even as currency impacted revenue by $7 million and OP by $2 million.
The EPS beat was the result of the higher revenues as well as favorable mix. Our adjusted operating margin of 20.2% and operating cash flow of $106 million was strong. We bought back $200 million or 4.9 million shares in Q1. 
I'll turn now to the guidance for fiscal year 2016. We are confirming the core revenue growth guidance of 4.0% to 4.5% we provided in November. However, the strengthening of the U.S. dollar since our November guidance is expected to have a negative impact of about $50 million on reported revenues, $13 million on operating profit and $0.033 on EPS.
As a result, we now expect fiscal year '16 revenues of $4.1 billion to $4.12 billion, and EPS of $1.81 to $1.87. To note, in the last 2 weeks, we've seen the U.S. dollar weaken. If the weakening continues, we will reflect the positive impact in our May guidance.
Turning to our share buyback program. We remain committed to our plan of repurchasing another $280 million of shares before our fiscal year-end. 
Finally, moving to the guidance for our second quarter. We're expecting Q2 revenues of $965 million and to $985 million, reflecting typical second quarter seasonality versus Q1.
The mid-point corresponds to a core revenue growth of 4.0%. The sequential reduction in revenues will translate into a sequential reduction in EPS. We expect Q2 EPS to range between 39 -- excuse me, $0.37 to $0.39. 
With that, I'll turn it over to Alicia for the Q&A."
154924,323237239,935096,"Agilent Technologies Inc., Q1 2016 Earnings Call, Feb 16, 2016",2016-02-16,"Earnings Calls","Agilent Technologies, Inc.","Executives","Thank you, Didier. And Jonathan, will you please give the instructions for the Q&A?",14,"Thank you, Didier. And Jonathan, will you please give the instructions for the Q&A?"
154924,323237239,935096,"Agilent Technologies Inc., Q1 2016 Earnings Call, Feb 16, 2016",2016-02-16,"Earnings Calls","Agilent Technologies, Inc.","Operator","[Operator Instructions] Our first question comes from the line of Doug Schenkel from Cowen and Company.",16,"[Operator Instructions] Our first question comes from the line of Doug Schenkel from Cowen and Company."
154924,323237239,935096,"Agilent Technologies Inc., Q1 2016 Earnings Call, Feb 16, 2016",2016-02-16,"Earnings Calls","Agilent Technologies, Inc.","Analysts","This is Ryan Blicker filling in for Doug. Starting with operating margin guidance, it seems as though you reduced full-year guidance by about 10 basis points. But it seems like, as though, most of that was FX. Can you confirm that, that was all due to FX?",57,"This is Ryan Blicker filling in for Doug. Starting with operating margin guidance, it seems as though you reduced full-year guidance by about 10 basis points. But it seems like, as though, most of that was FX. Can you confirm that, that was all due to FX? Or are there other changes we should be thinking about?"
154924,323237239,935096,"Agilent Technologies Inc., Q1 2016 Earnings Call, Feb 16, 2016",2016-02-16,"Earnings Calls","Agilent Technologies, Inc.","Executives","No, it was entirely due to FX, absolutely. As I had mentioned, the FX impact was $13 million. And that is precisely the amount of the reduction in operating profit reflected in our guidance. And we have maintained the guidance at 20.2%, which was the aver",60,"No, it was entirely due to FX, absolutely. As I had mentioned, the FX impact was $13 million. And that is precisely the amount of the reduction in operating profit reflected in our guidance. And we have maintained the guidance at 20.2%, which was the average of 20% to 25% that we had guided to in November -- no change."
154924,323237239,935096,"Agilent Technologies Inc., Q1 2016 Earnings Call, Feb 16, 2016",2016-02-16,"Earnings Calls","Agilent Technologies, Inc.","Analysts","Okay. And looking at the pharma end market. Obviously, another very strong performance in the quarter. Can you give us more details on what drove the strength? And where there any one-time dynamics like a budget flush or pull forward of revenue? And I gue",64,"Okay. And looking at the pharma end market. Obviously, another very strong performance in the quarter. Can you give us more details on what drove the strength? And where there any one-time dynamics like a budget flush or pull forward of revenue? And I guess, lastly, do you still expect growth in this end market to approximate high single digits for the full year?"
154924,323237239,935096,"Agilent Technologies Inc., Q1 2016 Earnings Call, Feb 16, 2016",2016-02-16,"Earnings Calls","Agilent Technologies, Inc.","Executives","Sure, Brian, this is Mike. Let me make a few comments on the pharma strength we saw in the first quarter. Clearly, no one-time events. And we saw great pacing throughout the quarter. This would highlight a few points here. One, we're seeing a strong growt",158,"Sure, Brian, this is Mike. Let me make a few comments on the pharma strength we saw in the first quarter. Clearly, no one-time events. And we saw great pacing throughout the quarter. This would highlight a few points here. One, we're seeing a strong growth in liquid chromatography, both in terms of the uptake in our new products, but also the technology refresh that is underway within this segment. Also, customers responding quite positively to our biopharma solutions. And then across the board between biopharma and pharma, we're seeing strong demand for enterprise-wide services and consumables. 19% growth for the first quarter. We don't expect that level of double-digit growth to continue all through the year, but we're quite confident in our projections of high single digit. We're calling for 8% overall growth for the year in pharma. So we see no signs that this market won't remain robust for us for the rest of this year."
154924,323237239,935096,"Agilent Technologies Inc., Q1 2016 Earnings Call, Feb 16, 2016",2016-02-16,"Earnings Calls","Agilent Technologies, Inc.","Operator","Our next question comes from the line of Paul Knight from Janney Montgomery.",13,"Our next question comes from the line of Paul Knight from Janney Montgomery."
154924,323237239,935096,"Agilent Technologies Inc., Q1 2016 Earnings Call, Feb 16, 2016",2016-02-16,"Earnings Calls","Agilent Technologies, Inc.","Analysts","Regarding the guidance with EPS. I know when you guided last time, the euro had already fallen relative to the dollar. So are you measuring the euro on today's exchange rate, last week's exchange rate? I mean, could you flesh out a little bit more?",45,"Regarding the guidance with EPS. I know when you guided last time, the euro had already fallen relative to the dollar. So are you measuring the euro on today's exchange rate, last week's exchange rate? I mean, could you flesh out a little bit more?"
154924,323237239,935096,"Agilent Technologies Inc., Q1 2016 Earnings Call, Feb 16, 2016",2016-02-16,"Earnings Calls","Agilent Technologies, Inc.","Executives","Great question, Paul, it's the same question I asked Didier, and I'm going to pass it back to Didier.",19,"Great question, Paul, it's the same question I asked Didier, and I'm going to pass it back to Didier."
154924,323237239,935096,"Agilent Technologies Inc., Q1 2016 Earnings Call, Feb 16, 2016",2016-02-16,"Earnings Calls","Agilent Technologies, Inc.","Executives","Yes, Paul, so the guidance is always based on the exchange rate on the last day of the quarter we report. So the new guidance is based on the exchange rate as of October -- as of January 30, 2016. And it was between November -- October 30, which was in No",126,"Yes, Paul, so the guidance is always based on the exchange rate on the last day of the quarter we report. So the new guidance is based on the exchange rate as of October -- as of January 30, 2016. And it was between November -- October 30, which was in November guidance, and then January 30, which is the present guidance. The dollar strengthened, but we are seeing it weakening since November 30 a little bit, vis-a-vis the euro and certainly, vis-Ã -vis the yen. So if that continues, it will be reflected in our May guidance. Again, there was no change at all to our November guidance except for those that result directly from the change in exchange rates between October 30 and January 30."
154924,323237239,935096,"Agilent Technologies Inc., Q1 2016 Earnings Call, Feb 16, 2016",2016-02-16,"Earnings Calls","Agilent Technologies, Inc.","Executives","Yes, Paul, if I could just emphasize that, again, I mean, the fundamental assumptions we made that underlined our prior quarter guidance remain intact with the exception being FX.",29,"Yes, Paul, if I could just emphasize that, again, I mean, the fundamental assumptions we made that underlined our prior quarter guidance remain intact with the exception being FX."
154924,323237239,935096,"Agilent Technologies Inc., Q1 2016 Earnings Call, Feb 16, 2016",2016-02-16,"Earnings Calls","Agilent Technologies, Inc.","Analysts","And then, lastly, Mike, what stands out on technology is the PD-L1 approval and also the large molecule technology in CrossLab. Do you sit there with those 2 products on your menu thinking there's a bias toward more organic? Or where you at with those 2 t",49,"And then, lastly, Mike, what stands out on technology is the PD-L1 approval and also the large molecule technology in CrossLab. Do you sit there with those 2 products on your menu thinking there's a bias toward more organic? Or where you at with those 2 that you mentioned?"
154924,323237239,935096,"Agilent Technologies Inc., Q1 2016 Earnings Call, Feb 16, 2016",2016-02-16,"Earnings Calls","Agilent Technologies, Inc.","Executives","Paul, just to make sure I understand the question. Relative to -- thanks for the comments and observation. Just make sure I understand the question. This will be relative to our expectation of a continued organic growth with those 2 new -- with those...",44,"Paul, just to make sure I understand the question. Relative to -- thanks for the comments and observation. Just make sure I understand the question. This will be relative to our expectation of a continued organic growth with those 2 new -- with those..."
154924,323237239,935096,"Agilent Technologies Inc., Q1 2016 Earnings Call, Feb 16, 2016",2016-02-16,"Earnings Calls","Agilent Technologies, Inc.","Analysts","Yes, are they enough to move the needle higher than what you would have thought 90 days ago on last guidance?",21,"Yes, are they enough to move the needle higher than what you would have thought 90 days ago on last guidance?"
154924,323237239,935096,"Agilent Technologies Inc., Q1 2016 Earnings Call, Feb 16, 2016",2016-02-16,"Earnings Calls","Agilent Technologies, Inc.","Executives","Well, let me make a comment on the CrossLab services and consumables, and then I'll pass it over to Jacob on the PD-L1. When we put together our guidance for the year, we were expecting a strong growth in our CrossLab and services and consumables business",154,"Well, let me make a comment on the CrossLab services and consumables, and then I'll pass it over to Jacob on the PD-L1. When we put together our guidance for the year, we were expecting a strong growth in our CrossLab and services and consumables business. So that's part of the reason why we had a lot of confidence coming this year and still have the confidence in this year about making our organic core revenue growth targets. But as you've seen, even in a -- even in the chemical energy space, which down in terms of new instrument purchases, they continue to buy, and we see strong growth of service and consumables. So what I leave you is we expect continued strength in that space, but we were assuming that to be the case when we guided the company earlier this year. And Jacob, why don't you share your thoughts on the PD-L1?"
154924,323237239,935096,"Agilent Technologies Inc., Q1 2016 Earnings Call, Feb 16, 2016",2016-02-16,"Earnings Calls","Agilent Technologies, Inc.","Executives","Yes, thanks, Paul. And you're right that we got the indication approval also for the melanoma for the OPDIVO drug, and that's a great next step in the opportunities with PD-L1. I will not say that it will change the needle on an Agilent level, but it defi",107,"Yes, thanks, Paul. And you're right that we got the indication approval also for the melanoma for the OPDIVO drug, and that's a great next step in the opportunities with PD-L1. I will not say that it will change the needle on an Agilent level, but it definitely is a part of our growth story in DDG. But I will remind also that this drug -- or this companion diagnostic has only been out now for a few months, and we are still in the early days of seeing the uptake of it. So I see good progress, but not something that really moves the needle here."
154924,323237239,935096,"Agilent Technologies Inc., Q1 2016 Earnings Call, Feb 16, 2016",2016-02-16,"Earnings Calls","Agilent Technologies, Inc.","Operator","Our next question comes from the line of Dan Arias from Citigroup.",12,"Our next question comes from the line of Dan Arias from Citigroup."
154924,323237239,935096,"Agilent Technologies Inc., Q1 2016 Earnings Call, Feb 16, 2016",2016-02-16,"Earnings Calls","Agilent Technologies, Inc.","Analysts","Mike, last quarter, you mentioned that industrial weakness you were seeing kind of spilled over into the environmental business. I'm just wondering whether that's reversed a bit this quarter. So I guess, is it fair to say that maybe growth in environmenta",70,"Mike, last quarter, you mentioned that industrial weakness you were seeing kind of spilled over into the environmental business. I'm just wondering whether that's reversed a bit this quarter. So I guess, is it fair to say that maybe growth in environmental this year could be a couple of points higher than the cyclical segments? I guess, how would you just compare expectations from environmental versus industrial for this year?"
154924,323237239,935096,"Agilent Technologies Inc., Q1 2016 Earnings Call, Feb 16, 2016",2016-02-16,"Earnings Calls","Agilent Technologies, Inc.","Executives","Yes, Dan, thanks for the careful observation and -- it was actually -- the environmental business was a pleasant surprise in the first quarter. We knew that China was going to be strong, and we've been talking about China and our view of the investments t",197,"Yes, Dan, thanks for the careful observation and -- it was actually -- the environmental business was a pleasant surprise in the first quarter. We knew that China was going to be strong, and we've been talking about China and our view of the investments that the Chinese government is making in places such as the environmental market and food safety. So -- but I will say that we were happy to see the growth in other segments because yes, the chemical energy space has been under pressure. But what we're still seeing is that fracking is still going on. So the production -- while prices of oil are down, the production demand is stable. And in fact, if you look at the oil production, I mean gasoline production in the U.S., for example, is perhaps going up. So we're seeing a continued need to do environmental testing. So that's been a nice reaffirmation, if you will, of our outlook for the year which called for low single-digit growth in environmental. We thought that China would carry the whole load for us, but I think we're going to get a little help from the U.S. as well."
154924,323237239,935096,"Agilent Technologies Inc., Q1 2016 Earnings Call, Feb 16, 2016",2016-02-16,"Earnings Calls","Agilent Technologies, Inc.","Analysts","Okay. And then maybe just staying in the BRIC region, any change in the way that you're thinking about Brazil and Russia, and how that might end up this year?",30,"Okay. And then maybe just staying in the BRIC region, any change in the way that you're thinking about Brazil and Russia, and how that might end up this year?"
154924,323237239,935096,"Agilent Technologies Inc., Q1 2016 Earnings Call, Feb 16, 2016",2016-02-16,"Earnings Calls","Agilent Technologies, Inc.","Executives","Unfortunately, no. I think we're still looking for very challenged conditions in those countries. I know there's been some recent news today about Russia, and perhaps working with some of the other oil-producing countries to change some aspects of product",65,"Unfortunately, no. I think we're still looking for very challenged conditions in those countries. I know there's been some recent news today about Russia, and perhaps working with some of the other oil-producing countries to change some aspects of production, maybe they'll have some dynamics in terms of their economy. But right now, we're assuming continuation of the current challenged conditions for Brazil and Russia."
154924,323237239,935096,"Agilent Technologies Inc., Q1 2016 Earnings Call, Feb 16, 2016",2016-02-16,"Earnings Calls","Agilent Technologies, Inc.","Operator","Our next question comes from the line of Isaac Ro from Goldman Sachs.",13,"Our next question comes from the line of Isaac Ro from Goldman Sachs."
154924,323237239,935096,"Agilent Technologies Inc., Q1 2016 Earnings Call, Feb 16, 2016",2016-02-16,"Earnings Calls","Agilent Technologies, Inc.","Analysts","Mike, first question was on gross margin. It's pretty big year-over-year improvement there. I was wondering if you could maybe breakdown the key drivers of gross margin performance, the accentuation [ph] there might have been one-time benefits in these an",55,"Mike, first question was on gross margin. It's pretty big year-over-year improvement there. I was wondering if you could maybe breakdown the key drivers of gross margin performance, the accentuation [ph] there might have been one-time benefits in these and towards [ph] there are some items that are going to continue as the year progresses."
154924,323237239,935096,"Agilent Technologies Inc., Q1 2016 Earnings Call, Feb 16, 2016",2016-02-16,"Earnings Calls","Agilent Technologies, Inc.","Executives","Yes, let me make a few level -- high-level comments here then, Didier, you can jump in and augment my comments. But I think, one, there were some one-time improvements, and I think we highlighted those in typically as it related to DDG, where we had some",178,"Yes, let me make a few level -- high-level comments here then, Didier, you can jump in and augment my comments. But I think, one, there were some one-time improvements, and I think we highlighted those in typically as it related to DDG, where we had some revenue that was really trapped last year in the first quarter due to production issues. But the lion's share of the improvement is resulting from our continued sustained efforts that I highlighted in my call, both the portfolio efforts in terms of the businesses we're no longer in, the businesses we acquired as to our change in our gross margin profile. We're taking real cost out of our system through the Agile Agilent program. So there were some one-time events as it relates to the revenue for DGG, but the bulk of our -- the bulk of our margin improvement is from the underlying core efforts we've had over the last several quarters to fundamentally change the operating model of the company. Didier, anything else that you would add to that?"
154924,323237239,935096,"Agilent Technologies Inc., Q1 2016 Earnings Call, Feb 16, 2016",2016-02-16,"Earnings Calls","Agilent Technologies, Inc.","Executives","Just to point out also contributed. Number one, you will recall that last year, we were spending heavily on remediation points to address the FDA warning letters. So that is -- now we are spending a significant amounts to maintain our strong position now,",134,"Just to point out also contributed. Number one, you will recall that last year, we were spending heavily on remediation points to address the FDA warning letters. So that is -- now we are spending a significant amounts to maintain our strong position now, but certainly not in the same magnitude of what we have spent for 2 years in a row. And then the second point is there was a favorable mix. We talked about how strong the pharma businesses is, and pharma does generate higher gross margin than the rest of the businesses. So favorable mix. And I know that the pharma being just one of them, but a significant one. And then the FDA -- the reduction in FDA spend also in addition to all the points that Mike has made."
154924,323237239,935096,"Agilent Technologies Inc., Q1 2016 Earnings Call, Feb 16, 2016",2016-02-16,"Earnings Calls","Agilent Technologies, Inc.","Analysts","Okay, that's helpful. And then just a follow-up on CrossLab. You mentioned the driver there, looking like it was just healthy demand in the end market. But I don't think of that business as necessarily having as a sustainable growth rate in that double-di",100,"Okay, that's helpful. And then just a follow-up on CrossLab. You mentioned the driver there, looking like it was just healthy demand in the end market. But I don't think of that business as necessarily having as a sustainable growth rate in that double-digit range. So I'm wondering if there was an element of market share that, that was helpful. It's just not a market where we have a ton of quarter-to-quarter visibility. So I was wondering if you could put some color around -- the accentuation market share was helpful and how you would characterize where it's coming from."
154924,323237239,935096,"Agilent Technologies Inc., Q1 2016 Earnings Call, Feb 16, 2016",2016-02-16,"Earnings Calls","Agilent Technologies, Inc.","Executives","Great, great question. I'll make a few comments. And Mark, why don't you jump in with your thoughts here. As we looked at the overall growth rate for CrossLab, you should assume that we're right in the range where we had talked about at the AID, and we th",114,"Great, great question. I'll make a few comments. And Mark, why don't you jump in with your thoughts here. As we looked at the overall growth rate for CrossLab, you should assume that we're right in the range where we had talked about at the AID, and we think there is both market growth. But as you've pointed out, market share gain opportunities for us where -- we really have changed our view of what the addressable market is for our business. And it's no longer the Agilent install base, but it's the entire lab. And Mark, why don't you talk about some of the things we're doing in terms of capturing market share."
154924,323237239,935096,"Agilent Technologies Inc., Q1 2016 Earnings Call, Feb 16, 2016",2016-02-16,"Earnings Calls","Agilent Technologies, Inc.","Executives","Thanks, Mike. And I think you've hit on the primary piece, which is we continue to see the primary drivers in pharma and also China has been very strong for us. When you pull it all back to when capital spending is constrained, we continue to see customer",101,"Thanks, Mike. And I think you've hit on the primary piece, which is we continue to see the primary drivers in pharma and also China has been very strong for us. When you pull it all back to when capital spending is constrained, we continue to see customers improve the productivity of their assets through services and the chemistries we talked about earlier. But I think what's more robust than it was a year ago even is really the strength of our multi-vendor and enterprise portfolio. And that does allow you to take share, if you will, from the broader market."
154924,323237239,935096,"Agilent Technologies Inc., Q1 2016 Earnings Call, Feb 16, 2016",2016-02-16,"Earnings Calls","Agilent Technologies, Inc.","Operator","Our next question comes from the line of Ross Muken from Evercore ISI.",13,"Our next question comes from the line of Ross Muken from Evercore ISI."
154924,323237239,935096,"Agilent Technologies Inc., Q1 2016 Earnings Call, Feb 16, 2016",2016-02-16,"Earnings Calls","Agilent Technologies, Inc.","Analysts","So I'm just trying to double check on the guidance math here because I think a few of us are a little bit confused. So we beat the quarter, right, by around, I don't know, call it $0.03. We lost $0.033 on FX, roughly, and the range came down $0.04. So I'm",119,"So I'm just trying to double check on the guidance math here because I think a few of us are a little bit confused. So we beat the quarter, right, by around, I don't know, call it $0.03. We lost $0.033 on FX, roughly, and the range came down $0.04. So I'm just trying to get a sense for -- again, it seems like FX was the key delta. But just the simple math would have suggested to me a little less downward pressure on the full year range. And again, I realize there's probably a few other moving parts. So I'm just trying to make sure I understand how we're doing versus the plan for the year."
154924,323237239,935096,"Agilent Technologies Inc., Q1 2016 Earnings Call, Feb 16, 2016",2016-02-16,"Earnings Calls","Agilent Technologies, Inc.","Executives","Sure, we're happy to -- Didier would be happy to clarify.",11,"Sure, we're happy to -- Didier would be happy to clarify."
154924,323237239,935096,"Agilent Technologies Inc., Q1 2016 Earnings Call, Feb 16, 2016",2016-02-16,"Earnings Calls","Agilent Technologies, Inc.","Executives","Yes. No, so the -- as I mentioned earlier, we have reduced our top line revenue from -- at midpoint from $4.160 billion to $4.110 billion, which is a $50 million reduction. We've reduced our operating profit from $830 million to $817 million, that's $13 m",211,"Yes. No, so the -- as I mentioned earlier, we have reduced our top line revenue from -- at midpoint from $4.160 billion to $4.110 billion, which is a $50 million reduction. We've reduced our operating profit from $830 million to $817 million, that's $13 million, and that's entirely due to the impact of the strengthening of the dollar and related to the $50 million. And then I mentioned $0.033, but with rounding, we are going from a midpoint of $1.84 to the new midpoint of -- to the -- sorry, we're going from the midpoint of $1.88 to the mid-point of $1.84, and that's $0.04 and that's the $0.033, which is rounded because of the -- going from one to the other, you can understand that. So basically, what we felt is even though we are starting the year very strongly, we felt that with the overall macroeconomic condition, it would not be wise at this point in time to change the guidance we had provided, core revenue guidance, of 4% to 4.5%. We have the same confidence as we'd had in the month of November when we provided that guidance that we're in good shape to hit it and perhaps did it, but certainly, didn't want to change it."
154924,323237239,935096,"Agilent Technologies Inc., Q1 2016 Earnings Call, Feb 16, 2016",2016-02-16,"Earnings Calls","Agilent Technologies, Inc.","Analysts","Yes, I guess, what I'm trying to get at it is sort of the comments last quarter suggested sort of conservatism, right? You obviously can't control what happens with the dollar. So that's understandable. I'm just trying to get a sense for how much conserva",86,"Yes, I guess, what I'm trying to get at it is sort of the comments last quarter suggested sort of conservatism, right? You obviously can't control what happens with the dollar. So that's understandable. I'm just trying to get a sense for how much conservatism there is now in the forecasting, whether or not we have risk to that core growth rate, given again that the range came down. But you reiterated the top line. I'm just making sure that we're sort of not over-extrapolating here."
154924,323237239,935096,"Agilent Technologies Inc., Q1 2016 Earnings Call, Feb 16, 2016",2016-02-16,"Earnings Calls","Agilent Technologies, Inc.","Executives","Sure, Ross. This is Mike. I really appreciate the opportunity to comment on this. So if you'll add that conservatism meter on our guidance, it's at the same level as it was last quarter. So the only real fundamental change in terms of our outlook is the v",52,"Sure, Ross. This is Mike. I really appreciate the opportunity to comment on this. So if you'll add that conservatism meter on our guidance, it's at the same level as it was last quarter. So the only real fundamental change in terms of our outlook is the view on FX. That's it."
154924,323237239,935096,"Agilent Technologies Inc., Q1 2016 Earnings Call, Feb 16, 2016",2016-02-16,"Earnings Calls","Agilent Technologies, Inc.","Executives","And we saw no reason to change our core revenue growth to offset a part of the FX because FX can go up and down and it's too volatile nowadays to immediately -- unless we see some long-term structural changes as we have last year and we reacted accordingl",71,"And we saw no reason to change our core revenue growth to offset a part of the FX because FX can go up and down and it's too volatile nowadays to immediately -- unless we see some long-term structural changes as we have last year and we reacted accordingly. We were not going to react by what we believe are temporary changes in FX by actions on our structural spend."
154924,323237239,935096,"Agilent Technologies Inc., Q1 2016 Earnings Call, Feb 16, 2016",2016-02-16,"Earnings Calls","Agilent Technologies, Inc.","Analysts","Okay. So sorry, I'm going to monopolize for a minute, just because I'm trying to make sure my inbox lines up. I'm getting everyone sort of the answers they need. So all right, so we -- to be clear, we have the FX hit, I'd love to also understand what were",158,"Okay. So sorry, I'm going to monopolize for a minute, just because I'm trying to make sure my inbox lines up. I'm getting everyone sort of the answers they need. So all right, so we -- to be clear, we have the FX hit, I'd love to also understand what were the key currencies because most of us can see that the dollar has actually, again, we'll see if it sustains, weakened a bit. And so it seems like it's outside the euro and the yen that might have caused some of the headwinds. So I'd love to hear just a little bit of color on, maybe it's the won or some of the other emerging market currencies. And just to be clear also on the second point. So we didn't really bake in the beat from this quarter. Is that sort of where the conservatism comes in? And then, I'm done, I promise. I'll cede the floor."
154924,323237239,935096,"Agilent Technologies Inc., Q1 2016 Earnings Call, Feb 16, 2016",2016-02-16,"Earnings Calls","Agilent Technologies, Inc.","Executives","Yes, I mean, in terms of the currencies, we have a detailed model that takes into account obviously all the currencies. The dollar versus the euro or the dollar versus the yen, had a major impact also, I think, dollar versus the British pound. And again,",125,"Yes, I mean, in terms of the currencies, we have a detailed model that takes into account obviously all the currencies. The dollar versus the euro or the dollar versus the yen, had a major impact also, I think, dollar versus the British pound. And again, the -- today, I mean today's guidance is based on the October -- January 30 exchange rates, so the euro to $1.84 and the yen, and vis-a-vis the yen -- the U.S. dollar is JPY 121.4. And we are seeing that at today's rate, if we had provided the guidance based on just say if we had -- we are able to instantly reflect the currencies as of the date of the guidance, we'd have a very different guidance."
154924,323237239,935096,"Agilent Technologies Inc., Q1 2016 Earnings Call, Feb 16, 2016",2016-02-16,"Earnings Calls","Agilent Technologies, Inc.","Executives","And I think your second statement is probably a fair one.",11,"And I think your second statement is probably a fair one."
154924,323237239,935096,"Agilent Technologies Inc., Q1 2016 Earnings Call, Feb 16, 2016",2016-02-16,"Earnings Calls","Agilent Technologies, Inc.","Operator","Our next question comes from the line of Jeff Elliott from Robert W. Baird.",14,"Our next question comes from the line of Jeff Elliott from Robert W. Baird."
154924,323237239,935096,"Agilent Technologies Inc., Q1 2016 Earnings Call, Feb 16, 2016",2016-02-16,"Earnings Calls","Agilent Technologies, Inc.","Analysts","So question on -- for Mike on chemical and energy. You're down 2% this quarter. The last couple of quarters, you're down 9% or 10%. I guess, can you give us a sense for what's happening on the E&P side? You talked about stability on the refining side. But",78,"So question on -- for Mike on chemical and energy. You're down 2% this quarter. The last couple of quarters, you're down 9% or 10%. I guess, can you give us a sense for what's happening on the E&P side? You talked about stability on the refining side. But what do you see on the E&P side? It seems like that's kind of what allowed the -- I guess the improvement relative to the last couple of quarters?"
154924,323237239,935096,"Agilent Technologies Inc., Q1 2016 Earnings Call, Feb 16, 2016",2016-02-16,"Earnings Calls","Agilent Technologies, Inc.","Executives","Yes, actually it's probably worth maybe just doing a little bridge on the last few quarters because in fact, we've seen relative flat performance over the last, last several quarters. And while instruments were down, the percentage you were talking about",270,"Yes, actually it's probably worth maybe just doing a little bridge on the last few quarters because in fact, we've seen relative flat performance over the last, last several quarters. And while instruments were down, the percentage you were talking about high single digits, we've seen a continued ability to offset through services and consumables. So what I would say is that the chemical/energy market is sort of playing out the way we had expected for the year. So we wish we had a different story here. But the price of -- oil price is low, as you know, but the product demand still remains pretty, pretty strong for our customers' products. So the refineries are running, the chemical plants are running and then we're really trying to sell to them new equipment based on a productivity message. But at the same point in time, recognize that if they use the equipment longer, it's a good opportunity for us on the services and consumables side. One thing I would ask you to reflect on is that Q1 '15, as you dig into some of the numbers, Q1 '15 really was our best quarter for the whole year. I think we grew 3% in the first quarter of last year on a core basis. We ended up growing, I think, 1% for the whole year. So that shows you we were in decline through the year. And so I wouldn't over-interpret the numbers. We think it's right in kind of the range where we had thought. And Patrick, I don't know if you had any other comments you'd add to that?"
154924,323237239,935096,"Agilent Technologies Inc., Q1 2016 Earnings Call, Feb 16, 2016",2016-02-16,"Earnings Calls","Agilent Technologies, Inc.","Executives","Well, no, not really. I think, as you said, it's playing out as was expected. There's continued pressure around the exploration side and the production side. But for the refinery side, demand really drives. Also, we placed some business for us. We tried t",97,"Well, no, not really. I think, as you said, it's playing out as was expected. There's continued pressure around the exploration side and the production side. But for the refinery side, demand really drives. Also, we placed some business for us. We tried to incentivize our customers and give them opportunity to upgrade, to increase their productivity and efficiency. And on the chemical side, I would say that the lower feed-sell [ph] price have not yet fully materialized. So we stay with focus for the year -- for the whole segment to be -- to stay flat."
154924,323237239,935096,"Agilent Technologies Inc., Q1 2016 Earnings Call, Feb 16, 2016",2016-02-16,"Earnings Calls","Agilent Technologies, Inc.","Executives","And Jeff, this is Mike. I think we shared these numbers with you in the past, but the way we looked at this -- we always look at our business, say about 15% or so is in E&P, as you described, exploration and production, which will be about 3% to 4% of our",87,"And Jeff, this is Mike. I think we shared these numbers with you in the past, but the way we looked at this -- we always look at our business, say about 15% or so is in E&P, as you described, exploration and production, which will be about 3% to 4% of our total revenues. About 35% of that segment is in refining and the other 50% is in chemicals. So that's how we -- so it sort of -- it remains stable at a subdued level."
154924,323237239,935096,"Agilent Technologies Inc., Q1 2016 Earnings Call, Feb 16, 2016",2016-02-16,"Earnings Calls","Agilent Technologies, Inc.","Operator","Our next question comes from the line of Steve Beuchaw from Morgan Stanley.",13,"Our next question comes from the line of Steve Beuchaw from Morgan Stanley."
154924,323237239,935096,"Agilent Technologies Inc., Q1 2016 Earnings Call, Feb 16, 2016",2016-02-16,"Earnings Calls","Agilent Technologies, Inc.","Analysts","I'd like to follow up just a bit on the pharmaceutical space. It was really helpful to hear just how confident you guys are in the outlook for the year growing 8% in pharma. I wonder if you could maybe add a little bit to the conversation though and talk",113,"I'd like to follow up just a bit on the pharmaceutical space. It was really helpful to hear just how confident you guys are in the outlook for the year growing 8% in pharma. I wonder if you could maybe add a little bit to the conversation though and talk about what you're hearing, Mike or Patrick, in your conversations with pharma customers as they talk about their budgets for this year. I apologize for coming back to the topic, but there's a lot of interest out there in the sustainability of growth in the space. So any color you could offer -- how your customers are thinking would be really helpful."
154924,323237239,935096,"Agilent Technologies Inc., Q1 2016 Earnings Call, Feb 16, 2016",2016-02-16,"Earnings Calls","Agilent Technologies, Inc.","Executives","Yes, absolutely. So Patrick, why don't you take that question and I will have one closing comment.",17,"Yes, absolutely. So Patrick, why don't you take that question and I will have one closing comment."
154924,323237239,935096,"Agilent Technologies Inc., Q1 2016 Earnings Call, Feb 16, 2016",2016-02-16,"Earnings Calls","Agilent Technologies, Inc.","Executives","Yes. So what we're hearing from our customers is that they -- actually, they are holding their budgets. We don't see any significant reduction there. And this comes, by the way, across the board from small and medium size and large enterprises. So it's re",95,"Yes. So what we're hearing from our customers is that they -- actually, they are holding their budgets. We don't see any significant reduction there. And this comes, by the way, across the board from small and medium size and large enterprises. So it's really, for us, it's a good mixture between different size companies and also between the different markets talking about small molecule versus biopharmaceuticals. The growth really comes from both sides, and this is why we're so confident to be able to maintain, to see this high single digit growth for pharma."
154924,323237239,935096,"Agilent Technologies Inc., Q1 2016 Earnings Call, Feb 16, 2016",2016-02-16,"Earnings Calls","Agilent Technologies, Inc.","Executives","And the other thing that we've done -- so we're given a broad-based demand across all segments of the market. Then we also continue to do our own math in terms of what's out there in terms of the install base of our products. So we have a pretty good idea",72,"And the other thing that we've done -- so we're given a broad-based demand across all segments of the market. Then we also continue to do our own math in terms of what's out there in terms of the install base of our products. So we have a pretty good idea on the -- at least from the technology refresh side, how much more demand we can expect in this segment."
154924,323237239,935096,"Agilent Technologies Inc., Q1 2016 Earnings Call, Feb 16, 2016",2016-02-16,"Earnings Calls","Agilent Technologies, Inc.","Analysts","That's extremely helpful. One corollary, one follow-up there. I wonder if you could give us a sense for -- to what extent the success that you're having in pharma, the success you're having in CrossLab are interrelated? Are those 2 perhaps a little bit mo",68,"That's extremely helpful. One corollary, one follow-up there. I wonder if you could give us a sense for -- to what extent the success that you're having in pharma, the success you're having in CrossLab are interrelated? Are those 2 perhaps a little bit more or overlapping than CrossLab is with some of the other customer verticals? And to what extent is one dependent upon the other?"
154924,323237239,935096,"Agilent Technologies Inc., Q1 2016 Earnings Call, Feb 16, 2016",2016-02-16,"Earnings Calls","Agilent Technologies, Inc.","Executives","Yes. Great, great question. I'm happy to elaborate, and they are highly connected. So when we talk about pharma market demand, it's both driving new equipment purchases, which were the focus on Patrick's comments, but also there is a demand for enterprise",190,"Yes. Great, great question. I'm happy to elaborate, and they are highly connected. So when we talk about pharma market demand, it's both driving new equipment purchases, which were the focus on Patrick's comments, but also there is a demand for enterprise-wide services and consumables. But not -- on the CrossLab side, not only are they investing in ongoing chemistries and services to maintain their operations and support their application needs, what we're also seeing is a change of the model. So what they're doing is they are taking activities that historically have been done inside the company and are creating, if you will, a new set of services for vendors in our space to handle things such as asset management. And that's created sort of a new set of services that are being created right now in pharma. We haven't seen that new set of services demand develop yet on the chemical/energy side. But we're hopeful that it will down the road. But there's a couple of dynamics going on in the pharma space, which are driving both the new instrument purchases and the consumables and services for CrossLab."
154924,323237239,935096,"Agilent Technologies Inc., Q1 2016 Earnings Call, Feb 16, 2016",2016-02-16,"Earnings Calls","Agilent Technologies, Inc.","Operator","Our next question comes from the line of Tim Evans from Wells Fargo.",13,"Our next question comes from the line of Tim Evans from Wells Fargo."
154924,323237239,935096,"Agilent Technologies Inc., Q1 2016 Earnings Call, Feb 16, 2016",2016-02-16,"Earnings Calls","Agilent Technologies, Inc.","Analysts","Wondered if you can give us a update on market for tuck-in acquisitions. What you're thinking about these days in terms of where you might like to plug some holes? And also, are you seeing more opportunities now that some valuations have come in?",45,"Wondered if you can give us a update on market for tuck-in acquisitions. What you're thinking about these days in terms of where you might like to plug some holes? And also, are you seeing more opportunities now that some valuations have come in?"
154924,323237239,935096,"Agilent Technologies Inc., Q1 2016 Earnings Call, Feb 16, 2016",2016-02-16,"Earnings Calls","Agilent Technologies, Inc.","Executives","Yes. Thanks, Tim, I appreciate the opportunity to provide a perspective on here. So although we remain focused on our organic growth opportunities, we got a lot of very exciting plans and new products coming out and working on the go-to-market capabilitie",231,"Yes. Thanks, Tim, I appreciate the opportunity to provide a perspective on here. So although we remain focused on our organic growth opportunities, we got a lot of very exciting plans and new products coming out and working on the go-to-market capabilities. As I mentioned in my call comments, we're really continuing to look for acquisitions that augment our current portfolio and add to our company capabilities. So I think you saw us with the Seahorse deal where we added capabilities in life science research, Cartagenia in the area of next-gen sequencing. We -- to build out our workflow there, and we'd still like to find ways to build out our workflow in next-gen sequencing. And so our stated strategies of really adding capabilities, expanding our portfolio, building on our work flow solutions, with a particular emphasis on life sciences research, next-gen sequencing workflows in the overall consumables and services place. They're our priorities. Well, that being said, most people still have the memories of their 52-week highs. So we'll see how this plays out. And what I will tell you is we will continue to be very disciplined in terms of how we think about M&A, and does it provide an attractive return to our shareholders? And can we do something to make the business better? If we can't make the business better, it's not something we'd be interested in."
154924,323237239,935096,"Agilent Technologies Inc., Q1 2016 Earnings Call, Feb 16, 2016",2016-02-16,"Earnings Calls","Agilent Technologies, Inc.","Operator","Our next question comes from the line of Brandon Couillard from Jefferies.",12,"Our next question comes from the line of Brandon Couillard from Jefferies."
154924,323237239,935096,"Agilent Technologies Inc., Q1 2016 Earnings Call, Feb 16, 2016",2016-02-16,"Earnings Calls","Agilent Technologies, Inc.","Analysts","Mike, you pointed to strength in China in the period. Just curious if you could elaborate on the actual growth rate in the first quarter and if there's been any deviation from sort of the mid- to high single-digit target for the year?",43,"Mike, you pointed to strength in China in the period. Just curious if you could elaborate on the actual growth rate in the first quarter and if there's been any deviation from sort of the mid- to high single-digit target for the year?"
154924,323237239,935096,"Agilent Technologies Inc., Q1 2016 Earnings Call, Feb 16, 2016",2016-02-16,"Earnings Calls","Agilent Technologies, Inc.","Executives","Yes. Thanks. Appreciate the opportunity to talk about China, one of my favorite topics. So we saw a very good demand in China, high single-digit growth in our integral lab business. And as I mentioned to you, in the past, the markets here are really being",229,"Yes. Thanks. Appreciate the opportunity to talk about China, one of my favorite topics. So we saw a very good demand in China, high single-digit growth in our integral lab business. And as I mentioned to you, in the past, the markets here are really being driven by strong investments in government and policy-driven initiatives around quality of life concerns whether the environment, drug and food safety. So all the market except -- with the exception of chemical/energy, really saw quite strong growth. And we're underpenetrated in DDG business compared to the rest of the company. We've talked about that in the past. And we were under-penetrated in growing market for cancer diagnostics, for example. And I recently read -- saw some statistics that I thought were really quite amazing. There was a report by the Cancer Hospital of the Chinese Academy of Medical Sciences said that every minute, an average of 6 people in the country were diagnosed with cancer. And 5 of those 6 would eventually die of the disease. So unfortunately, there's going to be growing demand for cancer diagnostics as well. I'm going to wrap this all up by saying we remain quite comfortable with the mid- to high single-digit growth expectation we laid out for China. It was strong for us in the first quarter and we expect that to continue through the year."
154924,323237239,935096,"Agilent Technologies Inc., Q1 2016 Earnings Call, Feb 16, 2016",2016-02-16,"Earnings Calls","Agilent Technologies, Inc.","Analysts","But then, one more for Didier. Could you split out the contribution from Seahorse relative to the headwind from the NMR in the first quarter in terms of just dollars?",30,"But then, one more for Didier. Could you split out the contribution from Seahorse relative to the headwind from the NMR in the first quarter in terms of just dollars?"
154924,323237239,935096,"Agilent Technologies Inc., Q1 2016 Earnings Call, Feb 16, 2016",2016-02-16,"Earnings Calls","Agilent Technologies, Inc.","Executives","No, we don't provide guidance or information regarding the acquisitions. We have stated and we are exactly in line that we expect Seahorse revenue to grow double digits in 2016 versus 2015. And we expect Seahorse operating margin to be also in the double",51,"No, we don't provide guidance or information regarding the acquisitions. We have stated and we are exactly in line that we expect Seahorse revenue to grow double digits in 2016 versus 2015. And we expect Seahorse operating margin to be also in the double digit. So no change to our expectations."
154924,323237239,935096,"Agilent Technologies Inc., Q1 2016 Earnings Call, Feb 16, 2016",2016-02-16,"Earnings Calls","Agilent Technologies, Inc.","Executives","And Patrick, maybe you can just add a few color comments on how it's going so far.",17,"And Patrick, maybe you can just add a few color comments on how it's going so far."
154924,323237239,935096,"Agilent Technologies Inc., Q1 2016 Earnings Call, Feb 16, 2016",2016-02-16,"Earnings Calls","Agilent Technologies, Inc.","Executives","Well, the integration of Seahorse is going very well. It's giving us extended reach also into the research market, and this was the whole play. Plus we, of course, used the opportunity, to use our strength in pharma to sell these products into the pharma",95,"Well, the integration of Seahorse is going very well. It's giving us extended reach also into the research market, and this was the whole play. Plus we, of course, used the opportunity, to use our strength in pharma to sell these products into the pharma space in areas like disease discovery as well. And this is what will drive the growth in fiscal year '16. As Didier said, we expect double-digit growth. We have to sail full steam [ph], and we are looking forward to a very strong Q2, Q3, Q4 for this product line."
154924,323237239,935096,"Agilent Technologies Inc., Q1 2016 Earnings Call, Feb 16, 2016",2016-02-16,"Earnings Calls","Agilent Technologies, Inc.","Operator","Our next question comes from the line of Tycho Peterson from JPMorgan.",12,"Our next question comes from the line of Tycho Peterson from JPMorgan."
154924,323237239,935096,"Agilent Technologies Inc., Q1 2016 Earnings Call, Feb 16, 2016",2016-02-16,"Earnings Calls","Agilent Technologies, Inc.","Analysts","Maybe just first on capital deployment. You did $200 million in buybacks in the quarter. You got it for $480 million for the year. I mean, it sounds like you'll front-end load it, and -- I mean, how do we think about a reauthorization once you get through",60,"Maybe just first on capital deployment. You did $200 million in buybacks in the quarter. You got it for $480 million for the year. I mean, it sounds like you'll front-end load it, and -- I mean, how do we think about a reauthorization once you get through this tranche given your stock is probably under some pressure now [ph]?"
154924,323237239,935096,"Agilent Technologies Inc., Q1 2016 Earnings Call, Feb 16, 2016",2016-02-16,"Earnings Calls","Agilent Technologies, Inc.","Executives","Yes, we basically decided to buy back in Q1 what we had not been able to do in Q4 of the preceding year. And then, we have 5 of 10b5-1. And we started forming our -- for your model, you should assume that we are buying about 1/3 of the remaining $280 mill",57,"Yes, we basically decided to buy back in Q1 what we had not been able to do in Q4 of the preceding year. And then, we have 5 of 10b5-1. And we started forming our -- for your model, you should assume that we are buying about 1/3 of the remaining $280 million on a per quarter."
154924,323237239,935096,"Agilent Technologies Inc., Q1 2016 Earnings Call, Feb 16, 2016",2016-02-16,"Earnings Calls","Agilent Technologies, Inc.","Analysts","And then just to clarify on the margins because I've had a few questions. I mean, the $13 million hit is the FX hit, but I guess people are having a hard time understanding why you're not seeing faster-than-expected realization of the COGS and SG&A cuts t",65,"And then just to clarify on the margins because I've had a few questions. I mean, the $13 million hit is the FX hit, but I guess people are having a hard time understanding why you're not seeing faster-than-expected realization of the COGS and SG&A cuts that you saw some of that this quarter. What doesn't that carry through for the next 3 quarters?"
154924,323237239,935096,"Agilent Technologies Inc., Q1 2016 Earnings Call, Feb 16, 2016",2016-02-16,"Earnings Calls","Agilent Technologies, Inc.","Executives","Well, we're not saying it's not going to carry through, we're saying, we saw no reason in the present agreement [ph] to change the guidance on an operating margin basis, 20.2%, that we have provided -- 20% to 20.5% that we have provided previously. So --",86,"Well, we're not saying it's not going to carry through, we're saying, we saw no reason in the present agreement [ph] to change the guidance on an operating margin basis, 20.2%, that we have provided -- 20% to 20.5% that we have provided previously. So -- and again, with the same level of conservatism, as we had in November. So that's basically the -- that was the premise for us maintaining both the core revenue growth and the operating margin that we have provided in November."
154924,323237239,935096,"Agilent Technologies Inc., Q1 2016 Earnings Call, Feb 16, 2016",2016-02-16,"Earnings Calls","Agilent Technologies, Inc.","Executives","And Didier, I'll just add that in my call comments, I tried to highlight a few things on a longer-term nature to show you that we're not out of gas in this tank in terms of our ability to continue to move our operating margin. We have other larger-hitting",97,"And Didier, I'll just add that in my call comments, I tried to highlight a few things on a longer-term nature to show you that we're not out of gas in this tank in terms of our ability to continue to move our operating margin. We have other larger-hitting programs that are coming on -- that are coming in late 2016 and will carry on into '17 as well. So this is not a onetime quarter where we just got a favorable mix, whatever, there's real fundamental improvements underway in the operating margin capabilities of the company."
154924,323237239,935096,"Agilent Technologies Inc., Q1 2016 Earnings Call, Feb 16, 2016",2016-02-16,"Earnings Calls","Agilent Technologies, Inc.","Analysts","And then speaking of running out of gas, you talked about refiners holding up. There's been news that at least 2 of the country's largest refiners are cutting out quota gasoline. What gives you conviction that your business there holds up?",41,"And then speaking of running out of gas, you talked about refiners holding up. There's been news that at least 2 of the country's largest refiners are cutting out quota gasoline. What gives you conviction that your business there holds up?"
154924,323237239,935096,"Agilent Technologies Inc., Q1 2016 Earnings Call, Feb 16, 2016",2016-02-16,"Earnings Calls","Agilent Technologies, Inc.","Executives","I'm not sure exactly what you're referring to, but relative to our view is that gasoline will continue to be needed to run the economy. And there's going to be demand there. And what we've tried to share -- and as long as production is running and if ther",95,"I'm not sure exactly what you're referring to, but relative to our view is that gasoline will continue to be needed to run the economy. And there's going to be demand there. And what we've tried to share -- and as long as production is running and if there's demand, the refineries will meet that demand. We've seen no significant changes in the underlying demand for gas. And in fact, Patrick, I think you were showing me some statistics the other day about what's going on in the area of refineries in the U.S."
154924,323237239,935096,"Agilent Technologies Inc., Q1 2016 Earnings Call, Feb 16, 2016",2016-02-16,"Earnings Calls","Agilent Technologies, Inc.","Executives","Yes, I mean, what we see, as Mike said, is the continued demand for, not only in the U.S, but also in the emerging economies like China. So the refineries are basically running at capacity right now. There will be no new-builds. But we see that they repla",129,"Yes, I mean, what we see, as Mike said, is the continued demand for, not only in the U.S, but also in the emerging economies like China. So the refineries are basically running at capacity right now. There will be no new-builds. But we see that they replaced the existing equipment, and they also go into service contracts. But first, they look for opportunities to drive more efficiencies, which gives us an opportunity to upgrade the install base with automation, features and other things to make sure that the customers can save money with the equipment as well. So the oil price is still driven by the fact that there is over-capacity on the production side. But the refinery volume has not gone down significantly over the last quarters."
154924,323237239,935096,"Agilent Technologies Inc., Q1 2016 Earnings Call, Feb 16, 2016",2016-02-16,"Earnings Calls","Agilent Technologies, Inc.","Analysts","Okay. And then just lastly, can you talk about linearity in the quarter, anything notable in January? You guys have an extra month versus a lot of your comps, so I was just wondering if there's anything worth calling out in January trends versus November",47,"Okay. And then just lastly, can you talk about linearity in the quarter, anything notable in January? You guys have an extra month versus a lot of your comps, so I was just wondering if there's anything worth calling out in January trends versus November and December."
154924,323237239,935096,"Agilent Technologies Inc., Q1 2016 Earnings Call, Feb 16, 2016",2016-02-16,"Earnings Calls","Agilent Technologies, Inc.","Executives","Yes, no. I just point to 2 things. One is in terms to our normal seasonality through the quarter. Q1 '16 was like prior quarters. We always see a nice strong December as we close off year-end with our customers. And it followed our typical seasonality pat",114,"Yes, no. I just point to 2 things. One is in terms to our normal seasonality through the quarter. Q1 '16 was like prior quarters. We always see a nice strong December as we close off year-end with our customers. And it followed our typical seasonality patterns through November, December and January. I think probably, the only thing of note would be in the DDG side. We had, I think, 1 less day -- working day, I think, this year. So that does affect the genomics business in terms of how much revenue we can get in that quarter. But really, it was sort of businesses usual, if you will, through the first quarter."
154924,323237239,935096,"Agilent Technologies Inc., Q1 2016 Earnings Call, Feb 16, 2016",2016-02-16,"Earnings Calls","Agilent Technologies, Inc.","Operator","Our next question comes from the line of Jack Meehan from Barclays.",12,"Our next question comes from the line of Jack Meehan from Barclays."
154924,323237239,935096,"Agilent Technologies Inc., Q1 2016 Earnings Call, Feb 16, 2016",2016-02-16,"Earnings Calls","Agilent Technologies, Inc.","Analysts","I wanted to follow up on Tycho's last question, just around the academic end market. I'm curious, you mentioned in the presentation around some of the modestly larger research budgets being released in the U.S. Curious on your view on the NIH and just rea",60,"I wanted to follow up on Tycho's last question, just around the academic end market. I'm curious, you mentioned in the presentation around some of the modestly larger research budgets being released in the U.S. Curious on your view on the NIH and just really timing related there because of the timing of the Congressional approvals at your end."
154924,323237239,935096,"Agilent Technologies Inc., Q1 2016 Earnings Call, Feb 16, 2016",2016-02-16,"Earnings Calls","Agilent Technologies, Inc.","Executives","Yes, I can take this question, yes. As we have seen moderate growth again in academia and government, which was a positive surprise, and as you've all have read, there are more budgets available now in the U.S. These budgets are slowly released that drove",100,"Yes, I can take this question, yes. As we have seen moderate growth again in academia and government, which was a positive surprise, and as you've all have read, there are more budgets available now in the U.S. These budgets are slowly released that drove some of the growth for us in Q1 and looking at the funnel moving forward. We actually see a good funnel there as well. So we stay with the forecast of low single-digit growth of academia and government, at the moment mainly driven by the U.S. But this is where we see the strongest demand."
154924,323237239,935096,"Agilent Technologies Inc., Q1 2016 Earnings Call, Feb 16, 2016",2016-02-16,"Earnings Calls","Agilent Technologies, Inc.","Analysts","Got it. And are your expectations for this level of growth to stay at the same rate through the end of the fiscal year? Or are you assuming the budgets got released a little bit faster from here?",38,"Got it. And are your expectations for this level of growth to stay at the same rate through the end of the fiscal year? Or are you assuming the budgets got released a little bit faster from here?"
154924,323237239,935096,"Agilent Technologies Inc., Q1 2016 Earnings Call, Feb 16, 2016",2016-02-16,"Earnings Calls","Agilent Technologies, Inc.","Executives","If the budgets will be released faster, I think it will be probably upside for us. We're now -- our current view is low single digits for academia and government for the year.",33,"If the budgets will be released faster, I think it will be probably upside for us. We're now -- our current view is low single digits for academia and government for the year."
154924,323237239,935096,"Agilent Technologies Inc., Q1 2016 Earnings Call, Feb 16, 2016",2016-02-16,"Earnings Calls","Agilent Technologies, Inc.","Analysts","Well, got it. And then just one other question on the margins and DDG. Definitely appreciate the year-over-year improvement. I was wondering what your thoughts were, bridging through the end of the year, just given how the relative margins compared to the",45,"Well, got it. And then just one other question on the margins and DDG. Definitely appreciate the year-over-year improvement. I was wondering what your thoughts were, bridging through the end of the year, just given how the relative margins compared to the end of 2015."
154924,323237239,935096,"Agilent Technologies Inc., Q1 2016 Earnings Call, Feb 16, 2016",2016-02-16,"Earnings Calls","Agilent Technologies, Inc.","Executives","Great. I know Jacob's given a lot of thought to that potential question, so I'll pass it over to you, Jacob, to provide some color there.",26,"Great. I know Jacob's given a lot of thought to that potential question, so I'll pass it over to you, Jacob, to provide some color there."
154924,323237239,935096,"Agilent Technologies Inc., Q1 2016 Earnings Call, Feb 16, 2016",2016-02-16,"Earnings Calls","Agilent Technologies, Inc.","Executives","Yes, thanks for that, Jack. And first of all, I want to say that we're very pleased to see the improvement versus the Q1 last year. But you're also right that versus Q4, that we saw a bit of a decrease, and that was actually where we most expected. We sit",121,"Yes, thanks for that, Jack. And first of all, I want to say that we're very pleased to see the improvement versus the Q1 last year. But you're also right that versus Q4, that we saw a bit of a decrease, and that was actually where we most expected. We sit in the DGG business with a pretty fixed cost space. So when you have a Q1 with a lower base than in Q4, you will see that our margins has also impacted accordingly. So you always see us coming out with a strong Q4 and a weaker Q1 under the gross margin and also on our operating margin. So this is kind of by the book and really as expected."
154924,323237239,935096,"Agilent Technologies Inc., Q1 2016 Earnings Call, Feb 16, 2016",2016-02-16,"Earnings Calls","Agilent Technologies, Inc.","Executives","Yes, I would just add that there's no change in plan, and Jacob is still absolutely committed to reaching 20% operating margin in 2017. Absolutely.",25,"Yes, I would just add that there's no change in plan, and Jacob is still absolutely committed to reaching 20% operating margin in 2017. Absolutely."
154924,323237239,935096,"Agilent Technologies Inc., Q1 2016 Earnings Call, Feb 16, 2016",2016-02-16,"Earnings Calls","Agilent Technologies, Inc.","Operator","Our next question comes from line of Derik De Bruin from Bank of America.",14,"Our next question comes from line of Derik De Bruin from Bank of America."
154924,323237239,935096,"Agilent Technologies Inc., Q1 2016 Earnings Call, Feb 16, 2016",2016-02-16,"Earnings Calls","Agilent Technologies, Inc.","Analysts","So I'm just curious. You're guiding to a 22% operating margin for 2017. So that's implying -- assuming the 20.2% midpoint, 130 to 180 basis points of margin expansion next year. I'm just curious if you can't -- if you couldn't find 10 additional basis poi",75,"So I'm just curious. You're guiding to a 22% operating margin for 2017. So that's implying -- assuming the 20.2% midpoint, 130 to 180 basis points of margin expansion next year. I'm just curious if you can't -- if you couldn't find 10 additional basis points of margin expansion in 2016 to sort of offset the impact, what gives you confidence you're going to be able to get 130, 180 basis points next year?"
154924,323237239,935096,"Agilent Technologies Inc., Q1 2016 Earnings Call, Feb 16, 2016",2016-02-16,"Earnings Calls","Agilent Technologies, Inc.","Executives","I'd just reiterate -- great question this one. Again, by the way, one of the things as you heard me say earlier in my comments, we continue to make sure we're realistic and we think about our business not on some hope and a prayer, but we actually have so",219,"I'd just reiterate -- great question this one. Again, by the way, one of the things as you heard me say earlier in my comments, we continue to make sure we're realistic and we think about our business not on some hope and a prayer, but we actually have solid plans behind our long-term operating goals. And I think we have a lot of confidence for 2 reasons: One is we have a plan that can get us there with -- not all on top line. It's probably in the range of 4% ago [ph]. We can get to the margin goals. We've laid out a plan that's got 60% of it is coming from the cost side. And we have multiyear programs that are going to take significant cost out of our structures. So I highlighted a few of them in my call. I mean, changes in terms of our benefit structure, changes in terms of our IT costs, our IT systems. These are major company-wide initiatives that right now we're underway. You won't start to see them going to the P&L until like late '16 going into '17. So these are kind of things that give us confidence to say, ""Okay, there's a path that gets us to where we want to get to in '17."""
154924,323237239,935096,"Agilent Technologies Inc., Q1 2016 Earnings Call, Feb 16, 2016",2016-02-16,"Earnings Calls","Agilent Technologies, Inc.","Analysts","Okay, great. It's the late '16, early '17 that I think that was the key that I was sort of looking for in that. Second question is given some of the turmoil going on in Europe, have you seen any sort of changes in the academic or government spending? As s",81,"Okay, great. It's the late '16, early '17 that I think that was the key that I was sort of looking for in that. Second question is given some of the turmoil going on in Europe, have you seen any sort of changes in the academic or government spending? As sort of like the governments grapple with sort of like the refugee crisis and some of the other things going on? Is there any noticeable change to spending patterns in Europe?"
154924,323237239,935096,"Agilent Technologies Inc., Q1 2016 Earnings Call, Feb 16, 2016",2016-02-16,"Earnings Calls","Agilent Technologies, Inc.","Executives","Patrick, you're shaking your head here right now.",8,"Patrick, you're shaking your head here right now."
154924,323237239,935096,"Agilent Technologies Inc., Q1 2016 Earnings Call, Feb 16, 2016",2016-02-16,"Earnings Calls","Agilent Technologies, Inc.","Executives","Yes, I'm shaking my head because we have not seen any significant change over the last several quarters.",18,"Yes, I'm shaking my head because we have not seen any significant change over the last several quarters."
154924,323237239,935096,"Agilent Technologies Inc., Q1 2016 Earnings Call, Feb 16, 2016",2016-02-16,"Earnings Calls","Agilent Technologies, Inc.","Operator","Our next question comes from the line of Dan Leonard from Leerink Partners.",13,"Our next question comes from the line of Dan Leonard from Leerink Partners."
154924,323237239,935096,"Agilent Technologies Inc., Q1 2016 Earnings Call, Feb 16, 2016",2016-02-16,"Earnings Calls","Agilent Technologies, Inc.","Analysts","All my questions have been answered.",6,"All my questions have been answered."
154924,323237239,935096,"Agilent Technologies Inc., Q1 2016 Earnings Call, Feb 16, 2016",2016-02-16,"Earnings Calls","Agilent Technologies, Inc.","Operator","Our next question comes from the line of Dane Leone from BTIG.",12,"Our next question comes from the line of Dane Leone from BTIG."
154924,323237239,935096,"Agilent Technologies Inc., Q1 2016 Earnings Call, Feb 16, 2016",2016-02-16,"Earnings Calls","Agilent Technologies, Inc.","Analysts","So on the gross margin line, can you just give a little bit more color in terms of the product mix? As I look at the different groups, really, the margin leverage seemed to come through the Life Sci and Applied Markets Group. You guys almost reported a 59",81,"So on the gross margin line, can you just give a little bit more color in terms of the product mix? As I look at the different groups, really, the margin leverage seemed to come through the Life Sci and Applied Markets Group. You guys almost reported a 59% gross margin there. Comment on the mix, please, and why the margin for that group specifically is expected to moderate when, I guess, historically, it's been pretty steady quarter-to-quarter throughout the year."
154924,323237239,935096,"Agilent Technologies Inc., Q1 2016 Earnings Call, Feb 16, 2016",2016-02-16,"Earnings Calls","Agilent Technologies, Inc.","Executives","I think there's 2 things I would point to and then, Didier, feel free to jump in as well. But first of all, remember the change we're making to our portfolio. So we're -- we've exited the NMR hardware business and as we -- and we're starting to see some o",107,"I think there's 2 things I would point to and then, Didier, feel free to jump in as well. But first of all, remember the change we're making to our portfolio. So we're -- we've exited the NMR hardware business and as we -- and we're starting to see some of those margin improvements showing up in the P&L, where we had revenue in the NMR business in much higher revenues in FY '15. And then our pharma business is pulling a lot of liquid chromatography, which is one of our highest gross margin products. I think it's really those -- perhaps those are the things."
154924,323237239,935096,"Agilent Technologies Inc., Q1 2016 Earnings Call, Feb 16, 2016",2016-02-16,"Earnings Calls","Agilent Technologies, Inc.","Executives","You've stated it all absolutely there. Our liquid -- I had mentioned earlier that the favorable mix came in part from the pharma mix. And within pharma, clearly, liquid chromatograph that has the higher-than-average operating margin and gross margin.",40,"You've stated it all absolutely there. Our liquid -- I had mentioned earlier that the favorable mix came in part from the pharma mix. And within pharma, clearly, liquid chromatograph that has the higher-than-average operating margin and gross margin."
154924,323237239,935096,"Agilent Technologies Inc., Q1 2016 Earnings Call, Feb 16, 2016",2016-02-16,"Earnings Calls","Agilent Technologies, Inc.","Analysts","So to clarify, you felt that there was either a catch-up ordering or stocking in the quarter that -- on those products specifically, that's not expected to continue for the rest of the year?",34,"So to clarify, you felt that there was either a catch-up ordering or stocking in the quarter that -- on those products specifically, that's not expected to continue for the rest of the year?"
154924,323237239,935096,"Agilent Technologies Inc., Q1 2016 Earnings Call, Feb 16, 2016",2016-02-16,"Earnings Calls","Agilent Technologies, Inc.","Executives","Well, you almost think about the pharma -- I mean, we had 19% pharmaceutical growth in the first quarter. What we're saying is we can't expect 19% to happen each of the next 3 quarters. What we do expect is the continuous strong demand. And right now, we'",73,"Well, you almost think about the pharma -- I mean, we had 19% pharmaceutical growth in the first quarter. What we're saying is we can't expect 19% to happen each of the next 3 quarters. What we do expect is the continuous strong demand. And right now, we're calling 8% for the entire year. So that's what you're seeing in terms of reflected in our mix column as it relates to gross margin."
154924,323237239,935096,"Agilent Technologies Inc., Q1 2016 Earnings Call, Feb 16, 2016",2016-02-16,"Earnings Calls","Agilent Technologies, Inc.","Analysts","Okay. And then on the FX rate. I'm still -- so if you just kind of use the DXY proxy, right, the last quarter was actually pretty elevated. But since then, the trend has actually come back in to closer to where you guided the year. Are you expecting -- is",77,"Okay. And then on the FX rate. I'm still -- so if you just kind of use the DXY proxy, right, the last quarter was actually pretty elevated. But since then, the trend has actually come back in to closer to where you guided the year. Are you expecting -- is there some nuance within this on how certain currencies have moved? Or are you just kind of assuming worst case that the dollar kind of [indiscernible]?"
154924,323237239,935096,"Agilent Technologies Inc., Q1 2016 Earnings Call, Feb 16, 2016",2016-02-16,"Earnings Calls","Agilent Technologies, Inc.","Executives","Actually, we're -- it's just pure math. So we're not making any projections at all about the future levels of FX. What Didier has done is he takes the currency spot rates on the last day of the reported quarter, and that's how we guide the company. We say",76,"Actually, we're -- it's just pure math. So we're not making any projections at all about the future levels of FX. What Didier has done is he takes the currency spot rates on the last day of the reported quarter, and that's how we guide the company. We say, okay, that's what we know and we'll assume that rate stays the same for the rest of the year. And then, it's just pure math from there."
154924,323237239,935096,"Agilent Technologies Inc., Q1 2016 Earnings Call, Feb 16, 2016",2016-02-16,"Earnings Calls","Agilent Technologies, Inc.","Executives","And helping methodology [ph] forever.",5,"And helping methodology [ph] forever."
154924,323237239,935096,"Agilent Technologies Inc., Q1 2016 Earnings Call, Feb 16, 2016",2016-02-16,"Earnings Calls","Agilent Technologies, Inc.","Analysts","Okay. So it's extrapolation off of January 31, not what's happening in February. Okay, got it.",16,"Okay. So it's extrapolation off of January 31, not what's happening in February. Okay, got it."
154924,323237239,935096,"Agilent Technologies Inc., Q1 2016 Earnings Call, Feb 16, 2016",2016-02-16,"Earnings Calls","Agilent Technologies, Inc.","Executives","That's correct. I made a comment during my script -- that on my script, that would we had used, for example, today's exchange rates, the guidance would have been higher because the dollar between January 31 and today has weakened.",41,"That's correct. I made a comment during my script -- that on my script, that would we had used, for example, today's exchange rates, the guidance would have been higher because the dollar between January 31 and today has weakened."
154924,323237239,935096,"Agilent Technologies Inc., Q1 2016 Earnings Call, Feb 16, 2016",2016-02-16,"Earnings Calls","Agilent Technologies, Inc.","Operator","And this does conclude the question-and-answer session of today's program. I'd like to hand the program back to Alicia Rodriguez for any further remarks.",25,"And this does conclude the question-and-answer session of today's program. I'd like to hand the program back to Alicia Rodriguez for any further remarks."
154924,323237239,935096,"Agilent Technologies Inc., Q1 2016 Earnings Call, Feb 16, 2016",2016-02-16,"Earnings Calls","Agilent Technologies, Inc.","Executives","All right. Thank you, everybody, for joining us on the call. And if you have any questions, please give us a call in IR. We'd like to wish you a good day and I'm sure we'll be talking later. Thank you.",41,"All right. Thank you, everybody, for joining us on the call. And if you have any questions, please give us a call in IR. We'd like to wish you a good day and I'm sure we'll be talking later. Thank you."
154924,323237239,935096,"Agilent Technologies Inc., Q1 2016 Earnings Call, Feb 16, 2016",2016-02-16,"Earnings Calls","Agilent Technologies, Inc.","Operator","Thank you, ladies and gentlemen, for your participation in today's conference. This does conclude the program. You may now disconnect. Good day.",22,"Thank you, ladies and gentlemen, for your participation in today's conference. This does conclude the program. You may now disconnect. Good day."
154924,333332053,986335,"Agilent Technologies, Inc., Q2 2016 Earnings Call, May 16, 2016",2016-05-16,"Earnings Calls","Agilent Technologies, Inc.","Operator","Good day, ladies and gentlemen, and welcome to the Q2 2016 Agilent Technologies Inc. Earnings Conference Call. [Operator Instructions] As a reminder, this call is being recorded. I would now like to turn the conference over to Alicia Rodriguez, Vice Presi",47,"Good day, ladies and gentlemen, and welcome to the Q2 2016 Agilent Technologies Inc. Earnings Conference Call. [Operator Instructions] As a reminder, this call is being recorded. I would now like to turn the conference over to Alicia Rodriguez, Vice President of Investor Relations. Please go ahead."
154924,333332053,986335,"Agilent Technologies, Inc., Q2 2016 Earnings Call, May 16, 2016",2016-05-16,"Earnings Calls","Agilent Technologies, Inc.","Executives","Thank you, Sabrina, and welcome, everyone, to Agilent's Second Quarter Conference Call for Fiscal Year 2016. With me are Mike McMullen, Agilent's Presidency and CEO; and Didier Hirsch, Agilent's Senior Vice President and CFO. Joining in the Q&A after Didi",328,"Thank you, Sabrina, and welcome, everyone, to Agilent's Second Quarter Conference Call for Fiscal Year 2016. With me are Mike McMullen, Agilent's Presidency and CEO; and Didier Hirsch, Agilent's Senior Vice President and CFO. Joining in the Q&A after Didier's comments will be Patrick Kaltenbach, President of Agilent's Life Sciences and Applied Markets Group; Jacob Thaysen, President of Agilent's Diagnostics and Genomics Group; and Mark Doak, President of the Agilent CrossLab Group.
You can find the press release and information to supplement today's discussion on our website at www.investor.agilent.com. While there, please click on the link for financial results under the Financial Information tab. You will find an investor presentation along with revenue breakouts and currency impacts, business segment results and historical financials for Agilent's operations. We will also post a copy of the prepared remarks following this call.
Today's comments by Mike and Didier will refer to non-GAAP financial measures. You will find the most directly comparable GAAP financial metrics and reconciliations on our website. And please note that we will refer to core revenue growth, which excludes the impact of currency, the NMR business and acquisitions and divestitures within the past 12 months. Unless otherwise noted, all references to increases or decreases in financial metrics are year-over-year. Guidance is based on exchange rates as of the last saved reported quarter.
We will also make forward-looking statements about the financial performance of the company. These statements are subject to risks and uncertainties and are only valid as of today. The company assumes no obligation to update them. Please look at the company's recent SEC filings for a more complete picture of our risks and other factors.
Before turning things over to Mike, I'd like to remind you that Agilent will host its Analyst and Investor Meeting in New York City on May 25. Details about the meeting and webcasts are available on the Agilent Investor Relations website. 
And now let me turn the call over to Mike."
154924,333332053,986335,"Agilent Technologies, Inc., Q2 2016 Earnings Call, May 16, 2016",2016-05-16,"Earnings Calls","Agilent Technologies, Inc.","Executives","Thanks, Alicia and hello, everyone. Thank you for joining us on today's call. The Agilent team delivered another strong water, both Q2 revenue and earnings were above the high end of our guidance. Let me highlight 3 key results. First, revenue growth wa",1570,"Thanks, Alicia and hello, everyone. Thank you for joining us on today's call. The Agilent team delivered another strong water, both Q2 revenue and earnings were above the high end of our guidance. Let me highlight 3 key results. 
First, revenue growth was up more than 8% on a core basis. Second, we delivered adjusted operating margin of 19.4%, an increase of 110 basis points from 1 year ago. Finally, EPS of $0.44 was up 16% over last year. 
Before moving on to a review of our Q2 results, I do want to address our year-over-year quarterly comparisons, which reflect unusual event from last year. Now the 8% core growth that we're announcing today, about 1.5 percentage points is due to shift of revenue last year from Q2 '15 into Q3 '15. 
In the second quarter a year ago, we experienced $50 million of shipment delays due to start-up challenges with our new U.S. logistics center. In addition, were process of the efforts over the past few quarters to convert incoming orders more quickly to revenue have paid off. We have reduced our order to revenue cycle times, particularly in China. Consequently, some shipments initially forecast for Q3 of this year were delivered Q2. 
Agilent's strong Q2 results were led by double-digit core growth in pharma and food markets. We also experienced continued strength in academia and government, environmental and diagnostic and clinical markets. All end markets grew except chemical and energy. Growth was broad based across most of our portfolio. 
Geographically, all regions grew except Japan, led by very strong growth in China. Let me highlight our Q2 results for our business group. The Life Sciences and Applied Markets Group delivered core revenue growth of 8%, led by strong demand in the pharma and food markets. About 3 percentage points of the 8% was thanks to a softer compare due to timing issue mentioned earlier from last year's U.S. logistics center startup. 
The combination of strong top line growth, expense management and gross margin improvements partially due to the NMR exit drove LSAG's operating margin to 19%, up 320 basis points from a year ago. LSAG continues to strengthen its portfolio. In Q2, Agilent introduced software. Disto software speeds up clinical research data analysis so scientists can more quickly understand the underlying causes of diseases such as cancer. This reflects trend since Agilent's leadership position in meta-belomics. Last week, we announced new Agilent 1216 Infinity II LC at the analytical tradeshow. This provides best-in-class lab efficiency and improves performance for the full backward compatibility. 
Next, the Agilent cost side group continues to deliver consistently strong revenue results. Core revenue growth in Q2 was 10%, led by strength in contract services, LC columns and lab supply. Expansion and penetration in Asia continued to be stronger contributors to our growth. Operating margin was flat versus a year go at 21.5%. 
CrossLab represents a strategic transformation of our services and consumables business. I'm pleased to report that Agilent's recognized with the 2016 Reviewers Choice Award for Customer Surveys. This award is from Select Science, an independent expert-led scientific review. This is the second year in a row that scientists in North America have judged Agilent's customer service to be the best in the laboratory products industry. 
Finally, the Diagnostics and Genomics Group delivered 5% core growth in Q2 against a difficult compare. The pathology business continues on its ready trajectory back to market growth rates, highlighted by strong demand for our new PD-L1 companion and complementary diagnostic test. Genomics showed strong market performance, led by our SureSelect target enrichment and our array CGH offerings. DDG's operating margin was flat versus a year ago at 15%. 
In Q2, Agilent announced an $80 million investment in Lasergen, an emerging biotechnology company with innovative next-gen sequencing technology. Our two companies will collaborate on building and and adjust workflow for clinical applications. 
In Q2, Agilent also announced the commercial availability has expanded to the EU for a new PD-L1 diagnostic test for nonsquamous, nonsmall cell lung cancer. This diagnostic was developed in collaboration mover so my script, the maker of OPDIVO. 
Now I'll provide an overview of Agilent score revenue by end market. Life scientist and diagnostics markets saw a continuation of our first quarter performance would strength across all end markets. Pharma grew 14%, fueled by technology refresh deals, new product uptake and sustained growth in the aftermarket. This is the fifth consecutive quarter of greater than mid- to high double-digit growth in pharma. 
Academia and government grew 7%, driven by strong demand in China and an uptick in the U.S. Clinical and Diagnostics also grew 7% with strength in genomics, led by target enrichment and array CGH. Applied end market performance was mixed. Flu was up 25% with strong sales in China and the Americas. China also drove 6% worldwide growth in environmental forensics. Chemical energy declined 3%, reflecting continued macroeconomic concerns and the effects of lower oil prices. Now I'll turn on update on our operating margin improvement initiatives. 
Q2 marks the fifth consecutive quarter of year-over-year operating margin improvement delivered by the new Agilent team. This is a result of our ability to outgrow the market while driving operational efficiency improvements. Our multiyear Agile Agilent program continues to simplify the company making us more nimble and lowering our costs. Our execution and company-wide streamlined of organizations, processes and systems continue to be on track to deliver incremental savings in 2017. 
For example, in Q3, we would take a major step forward in simplifying the company systems infrastructure there that all of our financial systems now on SAP. 
On the capital deployment front, we paid $37 million in dividends, repurchased $24 million of Agilent stock and invested $80 million to enable our NGS workflow strategy. Finally, our One Agilent initiative is driving a well receive cultural transformation to improve cross company collaboration and delivery of results. Last year's analyst and Investor Day, described the shareholder value equation for Agilent to be driven by a growing the market, expanding operating margins and a balanced capital allocation policy. I'd like to take a minute to position Q2 results in the context of our longer-term goals. 
After delivering our highest annual core revenue growth since 2011 of 6.4% of 2015, we now have 2 strong quarters to start 2016, including this quarter's 8% core revenue growth. Since the new Agilent leadership team is put in place, the team have delivered year-over-year operating margin improvements every quarter. We had completely offset initial $40 million of synergies from the company split. 
In fiscal 2015, we returned $400 million to shareholders and $370 million year-to-date in 2016 through cash dividends and share repurchase. From 2015 onto now, we've also invested our $400 million in new business via M&A and equity investments. Didier will share more specifics later, but we are raising our full year 2016 outlook for core growth, operating margin, EPS and cash flow. Let me now talk about our second half '16 forecast in light of what we have already achieved in 2016 and what we plan to deliver in 2017. 
When we look at today's overall market environment, while we face increase leads of compares, we expect strength in the farmers to continue in the second half 2016 and into 2017. China is also expected to remain strong in second half 2016 and 2017. Taking a closer look at the chemical and energy market, we have been experiencing a more prolonged and steeper slowdown as initially anticipated. We are now forecast in overall low single-digit market declines for the year versus our not so flat guidance assumptions. The oil exploration segment of this market has been down significantly for some time with a recent well reported spill over into the refining segment. There are initial indicators, however, of a bottoming with increased deal activity in the large chemical segment of the market. 
We have projected an improved chemical energy market environment in 2017. We are assuming we will continue to face headwinds in this market for the remainder of 2016. We are currently modeling 2017 with an above market core revenue growth of 4.5% in the mid-point. This, in line with our projected full year 2016 core growth rates, but higher than our expected core growth rate in the second half of 2016. There are 2 reasons for this increase. 
First, we expect to have a very strong your product introduction in the second half of FY '16, which will drive revenue growth in FY '17. Second, on the end market front, we expect chemical energy to have bottomed out by year-end accompanied by continuing solid conditions in all of our other end markets and in China. 
Overall, we remain on track with our 2017 goal to outgrow the market and improve our operating margins at 22%. Looking inside the company, I can share with you today that our One Agilent team is working well together and is driven to win in the marketplace. I look forward to seeing many of you at our analyst and Investor Day, where I'll share our progress versus our commitments, how we will sustain or improve performance and the longer-term outlook for the company. Thank you for being on the call today. I will now turn it over to Didier, who will provide additional insights on our financial results and guidance for the third quarter and full year 2016. Didier?"
154924,333332053,986335,"Agilent Technologies, Inc., Q2 2016 Earnings Call, May 16, 2016",2016-05-16,"Earnings Calls","Agilent Technologies, Inc.","Executives","Thank you, Mike, and hello, everyone. As Mike stated, we delivered a strong performance this quarter again, 8% core revenue growth, 110 basis points of operating margin expansion and $256 million in operating cash flow. After addressing for last year's $1",319,"Thank you, Mike, and hello, everyone. As Mike stated, we delivered a strong performance this quarter again, 8% core revenue growth, 110 basis points of operating margin expansion and $256 million in operating cash flow. After addressing for last year's $15 million slippage in revenue from Q2 to Q3 as we launch our new U.S. logistics center, our core revenue growth of 6.5% remained well above markets. 
During the quarter, we brought back $94 million of stocks and paid $37 million in dividends. Finally, on May 3, we successfully moved all finance applications from Oracle to SAP, which is our main ERP. This will result in significant simplifications of our finance and IT operations. I'll now turn to the guidance for our third quarter. 
We expect Q3 revenues of $1.03 billion to $1.05 billion and EPS of $0.45 to $0.47. At mid-point, revenue will grow 1.3% on a core basis or close to 3% adjusting for last year's $50 million impact from the U.S. logistics center. And turning to share repurchase, we expect to buy back $93 million this Q3. Now to the guidance of fiscal year 2016.
We are raising the mid-point of our revenue guidance by $60 million, including $50 million due to currency. As a result, we're increasing our core revenue growth guidance at mid-point from 4.25% to 4.50%. We're also raising the mid-point of our EPS guidance by $0.06, including $0.03 coming from currency and $0.03 from operational performance. 
And one important note, after further review, we and our auditors have concluded to account for the Lasergen investment using the cost method of accounting. This means that we'll not book our share of Lasergen losses as previously communicated. 
Finally, we are raising our operating cash flow guidance from $650 million to $740 million, and there's no chance to our CapEx guidance of $140 million. 
With that, I'll turn it over to Alicia for the Q&A."
154924,333332053,986335,"Agilent Technologies, Inc., Q2 2016 Earnings Call, May 16, 2016",2016-05-16,"Earnings Calls","Agilent Technologies, Inc.","Executives","Thank you, Didier. And Sabrina, will you please give the instructions for the Q&A?",14,"Thank you, Didier. And Sabrina, will you please give the instructions for the Q&A?"
154924,333332053,986335,"Agilent Technologies, Inc., Q2 2016 Earnings Call, May 16, 2016",2016-05-16,"Earnings Calls","Agilent Technologies, Inc.","Operator","[Operator Instructions] And our first question comes from the line of Dan Leonard of Leerink Partners.",16,"[Operator Instructions] And our first question comes from the line of Dan Leonard of Leerink Partners."
154924,333332053,986335,"Agilent Technologies, Inc., Q2 2016 Earnings Call, May 16, 2016",2016-05-16,"Earnings Calls","Agilent Technologies, Inc.","Analysts","Two questions. First off, can you elaborate on the business trends you're seeing Europe? And then secondly, on the pharma end market. Can you talk about what gives you confidence in the fiscal 2017 outlook that you had yet another strong year in pharma fo",61,"Two questions. First off, can you elaborate on the business trends you're seeing Europe? And then secondly, on the pharma end market. Can you talk about what gives you confidence in the fiscal 2017 outlook that you had yet another strong year in pharma following 2 years in of tough comps in capital markets, which have been more or less shot."
154924,333332053,986335,"Agilent Technologies, Inc., Q2 2016 Earnings Call, May 16, 2016",2016-05-16,"Earnings Calls","Agilent Technologies, Inc.","Executives","Thanks, Dan. I think I'm actually going to pass that over to Patrick, who is just back from a trip from Europe and maybe can provide some insight in what's going on Europe and also, if he can pick up the question in pharma as well.",46,"Thanks, Dan. I think I'm actually going to pass that over to Patrick, who is just back from a trip from Europe and maybe can provide some insight in what's going on Europe and also, if he can pick up the question in pharma as well."
154924,333332053,986335,"Agilent Technologies, Inc., Q2 2016 Earnings Call, May 16, 2016",2016-05-16,"Earnings Calls","Agilent Technologies, Inc.","Executives","Sure, I'm happy to do so. So let me start first to giving you some insights on Europe. We had seen actually some decent growth in central Europe. We have seen some weakness on what we call the case in Europe and that's mainly driven by the chemical and en",240,"Sure, I'm happy to do so. So let me start first to giving you some insights on Europe. We had seen actually some decent growth in central Europe. We have seen some weakness on what we call the case in Europe and that's mainly driven by the chemical and energy markets or the energy market on that side. In central Europe, there's steadily strength in Germany almost around that. We still see some issues on the academia and government side, as well on the flat. But pharma, for example, is also very strong Europe. For your pharma question, overall, we are confident that we will continue to see pretty high growth in pharma for the remainder of this year, which we target low double-digit growth for pharma. And looking into 2017, we think the pharma market will be -- continue to be strong for us, driven by 2 factors. We see a continued demand in the replacement business. And as you probably know, we just launched the conference. We launched our new 1216 for entrails as an example together with the consumables and servicing. And we think that will drive, continue to drive a lot of good replacement to focus for us in pharma. And then, results of continued demand in the biopharma space that are looking for new solutions helping with more complex and molecules in terms of analysis, and we have a very comprehensive operating space as well."
154924,333332053,986335,"Agilent Technologies, Inc., Q2 2016 Earnings Call, May 16, 2016",2016-05-16,"Earnings Calls","Agilent Technologies, Inc.","Operator","And our next question comes from the line of Jonathan Groberg of UBS.",13,"And our next question comes from the line of Jonathan Groberg of UBS."
154924,333332053,986335,"Agilent Technologies, Inc., Q2 2016 Earnings Call, May 16, 2016",2016-05-16,"Earnings Calls","Agilent Technologies, Inc.","Analysts","Can you maybe just elaborate a little bit on, I think you said core guidance, if I'm looking at your presentation, core revenue guidance in the third quarter us pretty precise at 1.3%. But then I think I just heard that you still expect pharma to grow low",68,"Can you maybe just elaborate a little bit on, I think you said core guidance, if I'm looking at your presentation, core revenue guidance in the third quarter us pretty precise at 1.3%. But then I think I just heard that you still expect pharma to grow low double-digits. Can you maybe just give a little kind of insight as to what you're seeing in the third quarter?"
154924,333332053,986335,"Agilent Technologies, Inc., Q2 2016 Earnings Call, May 16, 2016",2016-05-16,"Earnings Calls","Agilent Technologies, Inc.","Executives","Yes. What we looked at was with our growth rate that we've had over the first half of this year and as we look into Q3 and Q4. And what I point to is a couple of things, Jonathan. First of all, tough compares and this is inclusive of a few one-time moves",306,"Yes. What we looked at was with our growth rate that we've had over the first half of this year and as we look into Q3 and Q4. And what I point to is a couple of things, Jonathan. First of all, tough compares and this is inclusive of a few one-time moves between quarters, which actually were driven by improvements of raw operations. So as Didier mentioned, we had this $50 million shift in Q2 of last year into Q3, which when we had a start-up issue on the new logistics center. So you adjust for that, you catch up about 3% growth. The other thing we saw happen in Q2 was we're working really hard to improve the overall cycle time from the time a customer places order to actually install and we can recognize a revenue. In Q2, we actually exceeded our expectations and it got there a lot faster. Had thought and what that meant was we had significant amount of revenue, probably $20 million to $25 million that came from Q3 into Q2 or initially as forecasted into the second -- third quarter. All in all, you kind of take in account those things, you've got put more a consistent kind of a growth scenario between Q2 and Q3. 
I would tell you, though, the chemical energy is still looking for a bottom. And that's why we have -- that outlook for the year, which basically is down -- stay down for the rest of the year. There are some signs that it could be getting better. But we have -- we're not convinced yet. We've seen the bottom of that kind of energy. So I think the combination of those tough compares as well as our outlook and chemical energy is what's driving the overall guidance for the second half."
154924,333332053,986335,"Agilent Technologies, Inc., Q2 2016 Earnings Call, May 16, 2016",2016-05-16,"Earnings Calls","Agilent Technologies, Inc.","Analysts","Okay, that's helpful. And then, I guess, just one more. Are there any sometimes when we see shifts on the one platform like Oracle to SAP, is there anything at all any kind of wiggle room you left there in terms of hiccups in the quarter or may be...",49,"Okay, that's helpful. And then, I guess, just one more. Are there any sometimes when we see shifts on the one platform like Oracle to SAP, is there anything at all any kind of wiggle room you left there in terms of hiccups in the quarter or may be..."
154924,333332053,986335,"Agilent Technologies, Inc., Q2 2016 Earnings Call, May 16, 2016",2016-05-16,"Earnings Calls","Agilent Technologies, Inc.","Executives","Yes, what we try to, you're exactly right, Jonathan. So the wiggle room we left was we made sure we went live the first month of the quarter. And Didier is in a conference from here, smiling. And Didier, the want to add additional color and how it's going",51,"Yes, what we try to, you're exactly right, Jonathan. So the wiggle room we left was we made sure we went live the first month of the quarter. And Didier is in a conference from here, smiling. And Didier, the want to add additional color and how it's going so far?"
154924,333332053,986335,"Agilent Technologies, Inc., Q2 2016 Earnings Call, May 16, 2016",2016-05-16,"Earnings Calls","Agilent Technologies, Inc.","Executives","Yes, it's going very well, the migrations and the start-up of the operations. There were 0 disruption. Obviously, we expect to have to deal with some stabilization activities throughout the quarter. We'll do 2 close before we do the quarterly close. So ev",96,"Yes, it's going very well, the migrations and the start-up of the operations. There were 0 disruption. Obviously, we expect to have to deal with some stabilization activities throughout the quarter. We'll do 2 close before we do the quarterly close. So everything is -- we couldn't be happier about how well it went. And you're correct, it is a very complex endeavor, one that we are pretty used to. We've done a few of those in the past. But still, it remains a very complex endeavor and we are really happy how smoothly it went."
154924,333332053,986335,"Agilent Technologies, Inc., Q2 2016 Earnings Call, May 16, 2016",2016-05-16,"Earnings Calls","Agilent Technologies, Inc.","Executives","And Jonathan, as I pointed out in my script, this is one of the agile Agilent initiative, which we'll start to see pay off in our cost structure and as we move into '17.",34,"And Jonathan, as I pointed out in my script, this is one of the agile Agilent initiative, which we'll start to see pay off in our cost structure and as we move into '17."
154924,333332053,986335,"Agilent Technologies, Inc., Q2 2016 Earnings Call, May 16, 2016",2016-05-16,"Earnings Calls","Agilent Technologies, Inc.","Operator","And our next question comes from the line of Tycho Peterson of JPMorgan.",13,"And our next question comes from the line of Tycho Peterson of JPMorgan."
154924,333332053,986335,"Agilent Technologies, Inc., Q2 2016 Earnings Call, May 16, 2016",2016-05-16,"Earnings Calls","Agilent Technologies, Inc.","Analysts","Just following up on that last point on the asset be margins can you maybe, no market impact, can you maybe quantify how much that could play on margins for this year?",32,"Just following up on that last point on the asset be margins can you maybe, no market impact, can you maybe quantify how much that could play on margins for this year?"
154924,333332053,986335,"Agilent Technologies, Inc., Q2 2016 Earnings Call, May 16, 2016",2016-05-16,"Earnings Calls","Agilent Technologies, Inc.","Executives","For 2016, I think it'll be very limited, Tycho, because we'll be running some duplicate backup systems and then the other aspects of our a single. Actual don't come out until '17. So I'd really position that in -- I actually think about this more of a '17",68,"For 2016, I think it'll be very limited, Tycho, because we'll be running some duplicate backup systems and then the other aspects of our a single. Actual don't come out until '17. So I'd really position that in -- I actually think about this more of a '17 impact. But the proof point why we think we're going to be able to improve our margins again in '17."
154924,333332053,986335,"Agilent Technologies, Inc., Q2 2016 Earnings Call, May 16, 2016",2016-05-16,"Earnings Calls","Agilent Technologies, Inc.","Analysts","And then academic 7%, can you maybe just talk us the very seen an acceleration there what you saw this quarter?",22,"And then academic 7%, can you maybe just talk us the very seen an acceleration there what you saw this quarter?"
154924,333332053,986335,"Agilent Technologies, Inc., Q2 2016 Earnings Call, May 16, 2016",2016-05-16,"Earnings Calls","Agilent Technologies, Inc.","Executives","Yes, what we saw in the last quarter is really strong performance in China and some increased signs of life in the U.S. side of things. I think that's what we point to an uptick. Not a lot of significant moves on the European side. It's mainly a China try",74,"Yes, what we saw in the last quarter is really strong performance in China and some increased signs of life in the U.S. side of things. I think that's what we point to an uptick. Not a lot of significant moves on the European side. It's mainly a China trying to Jim sorry and I think that there will be upside to it will come from the U.S. That's how we're thinking about it."
154924,333332053,986335,"Agilent Technologies, Inc., Q2 2016 Earnings Call, May 16, 2016",2016-05-16,"Earnings Calls","Agilent Technologies, Inc.","Analysts","Okay. And then, lastly, just in terms of pharma. Obviously, that's been a nice driver. Can you maybe talk about where you think we are in the LCMS upgrade cycle looks and how much are growth going forward is going to be contingent on already budget expand",51,"Okay. And then, lastly, just in terms of pharma. Obviously, that's been a nice driver. Can you maybe talk about where you think we are in the LCMS upgrade cycle looks and how much are growth going forward is going to be contingent on already budget expanded versus the upgrade cycle?"
154924,333332053,986335,"Agilent Technologies, Inc., Q2 2016 Earnings Call, May 16, 2016",2016-05-16,"Earnings Calls","Agilent Technologies, Inc.","Executives","Yes, sure, Tycho, great question. I know, Patrick, I know you look at this pretty closely and what's the updated view on that?",23,"Yes, sure, Tycho, great question. I know, Patrick, I know you look at this pretty closely and what's the updated view on that?"
154924,333332053,986335,"Agilent Technologies, Inc., Q2 2016 Earnings Call, May 16, 2016",2016-05-16,"Earnings Calls","Agilent Technologies, Inc.","Executives","Yes, so I think you had 2 cycles you're looking at. The first cycle went through was general upgrade cycle from standard HPLC to HPLC, which is still ongoing but a considerable part of that probably has been done. But when you look at the installed base o",157,"Yes, so I think you had 2 cycles you're looking at. The first cycle went through was general upgrade cycle from standard HPLC to HPLC, which is still ongoing but a considerable part of that probably has been done. But when you look at the installed base of instrumentation, its these deals with oil this is where we are targeting with the new Infinity II series like now. There's still a lot of replacement pending out there. Just us we reminder, that probably about 150,000 systems out there based on the 1100, 1200 platform, which over time will be up for replacement. And we have positioned extremely with all the platforms because it is 100% bank compatible and also able, for example, emulate some of our competitors systems on our platform. If we [indiscernible] I said intelligence system emulation technology. And they had actually compelled very nicely different customers gives us a unique advantage in the market."
154924,333332053,986335,"Agilent Technologies, Inc., Q2 2016 Earnings Call, May 16, 2016",2016-05-16,"Earnings Calls","Agilent Technologies, Inc.","Executives","So I think we see both those having legs into '17.",11,"So I think we see both those having legs into '17."
154924,333332053,986335,"Agilent Technologies, Inc., Q2 2016 Earnings Call, May 16, 2016",2016-05-16,"Earnings Calls","Agilent Technologies, Inc.","Executives","Absolutely. I think this goes on into '17 combined again with the IPC coming out of biopharma.",17,"Absolutely. I think this goes on into '17 combined again with the IPC coming out of biopharma."
154924,333332053,986335,"Agilent Technologies, Inc., Q2 2016 Earnings Call, May 16, 2016",2016-05-16,"Earnings Calls","Agilent Technologies, Inc.","Operator","And our next question comes from the line of Jack Meehan of Barclays.",13,"And our next question comes from the line of Jack Meehan of Barclays."
154924,333332053,986335,"Agilent Technologies, Inc., Q2 2016 Earnings Call, May 16, 2016",2016-05-16,"Earnings Calls","Agilent Technologies, Inc.","Analysts","I just wanted to start the better at least relative to what I was looking for you had better margins in the else ask segment now 2 quarters in a row. Can you just talk about was the nodal changeable so there are so there anything with product mix of that'",67,"I just wanted to start the better at least relative to what I was looking for you had better margins in the else ask segment now 2 quarters in a row. Can you just talk about was the nodal changeable so there are so there anything with product mix of that's improving the improvement or do think this distend of new norm that we will look for."
154924,333332053,986335,"Agilent Technologies, Inc., Q2 2016 Earnings Call, May 16, 2016",2016-05-16,"Earnings Calls","Agilent Technologies, Inc.","Executives","I think -- let me make some initial comes and then Didier or Patrick maybe can build to it. So in terms of product mix, part of what you're seeing is the fact that we are winding down through our P&L the impact of the NMR business. And I think you can see",161,"I think -- let me make some initial comes and then Didier or Patrick maybe can build to it. So in terms of product mix, part of what you're seeing is the fact that we are winding down through our P&L the impact of the NMR business. And I think you can see the benefit of that exit decision on the P&L because it really hasn't been contributed into improved gross margins. Nothing of the whole story. The other stories obviously, the strong demand for the products and the volume benefits were getting as well as the focus on taking costs out of our material cost side of the business as well as we talked a lot about the logistics last year. We could also talk about logistics this year, which is doing a much better job in terms of overall logistics operations that's blowing through on the P&L as well. So Didier, I'm not sure if I missed anything else."
154924,333332053,986335,"Agilent Technologies, Inc., Q2 2016 Earnings Call, May 16, 2016",2016-05-16,"Earnings Calls","Agilent Technologies, Inc.","Executives","No, you covered it all.",5,"No, you covered it all."
154924,333332053,986335,"Agilent Technologies, Inc., Q2 2016 Earnings Call, May 16, 2016",2016-05-16,"Earnings Calls","Agilent Technologies, Inc.","Analysts","Great. And then just one more for the adoption of the companion diagnostics now a few quarters into the launch. Are you positioned? Can you maybe help us signs that what that business is today or just in the market where you think you hold in terms of mar",50,"Great. And then just one more for the adoption of the companion diagnostics now a few quarters into the launch. Are you positioned? Can you maybe help us signs that what that business is today or just in the market where you think you hold in terms of market share?"
154924,333332053,986335,"Agilent Technologies, Inc., Q2 2016 Earnings Call, May 16, 2016",2016-05-16,"Earnings Calls","Agilent Technologies, Inc.","Executives","Why don't you take that, Jacob?",7,"Why don't you take that, Jacob?"
154924,333332053,986335,"Agilent Technologies, Inc., Q2 2016 Earnings Call, May 16, 2016",2016-05-16,"Earnings Calls","Agilent Technologies, Inc.","Executives","Yes, thanks for the question. And we're definitely pleased with the pickup of the PD-L1, and this continues during the last, basically, it's now 3 quarters. The market is still very early. We still really only, and U.S, we have had of the press release is",163,"Yes, thanks for the question. And we're definitely pleased with the pickup of the PD-L1, and this continues during the last, basically, it's now 3 quarters. The market is still very early. We still really only, and U.S, we have had of the press release is here lately also that were entering your that we're just scratching the surface in Europe. And furthermore, it's still a second line -- it's still addressing the second line treatment. And if that also goes to the first-line treatment in the market will become significantly larger. At this point in time, it's still small revenue in the biggest scheme of things. But I do believe that the PD-L1 has an opportunity to be as big as of the HER 2 market. However, will also remind you that there are at least Barclays 4, probably 5 different potential box and the bank diagnostics out there had to share that market. So still early days, but a great opportunity."
154924,333332053,986335,"Agilent Technologies, Inc., Q2 2016 Earnings Call, May 16, 2016",2016-05-16,"Earnings Calls","Agilent Technologies, Inc.","Operator","And our next question comes from the line of Brandon Couillard of Jefferies.",13,"And our next question comes from the line of Brandon Couillard of Jefferies."
154924,333332053,986335,"Agilent Technologies, Inc., Q2 2016 Earnings Call, May 16, 2016",2016-05-16,"Earnings Calls","Agilent Technologies, Inc.","Analysts","Mike or Didier, can you give us the China growth rate percentage and if you can speak to demand in the food area outside of China and Asia, that will be helpful.",32,"Mike or Didier, can you give us the China growth rate percentage and if you can speak to demand in the food area outside of China and Asia, that will be helpful."
154924,333332053,986335,"Agilent Technologies, Inc., Q2 2016 Earnings Call, May 16, 2016",2016-05-16,"Earnings Calls","Agilent Technologies, Inc.","Executives","Yes. So in the China result for Q2, what we've been pointing to is strong double-digit growth. So it was a very, very strong quarter for us in China. I would remind you that part of the strong growth was not only the strength of the market, but those oper",138,"Yes. So in the China result for Q2, what we've been pointing to is strong double-digit growth. So it was a very, very strong quarter for us in China. I would remind you that part of the strong growth was not only the strength of the market, but those operational efficiency improvement I talked about where we really had shortened the improved cycle time from Borders to install that was really dramatic in China. So the overall basically quite strong for the year you should not expect those strong double-digit growth every quarter though for Q3 and Q4. But overall, China is complete story here. When you came into this year, we thought that the overall performance for Agilent in China might be high single-digits. we're now looking at low double-digit growth in China for the full year."
154924,333332053,986335,"Agilent Technologies, Inc., Q2 2016 Earnings Call, May 16, 2016",2016-05-16,"Earnings Calls","Agilent Technologies, Inc.","Analysts","Thanks, and then one more for Didier I know you bumped the operating cash flow guidance of about $90 million. How much of an impact does the -- others the tax refund benefit the if you can quantify that and just help us bridge the delta between prior vers",50,"Thanks, and then one more for Didier I know you bumped the operating cash flow guidance of about $90 million. How much of an impact does the -- others the tax refund benefit the if you can quantify that and just help us bridge the delta between prior versus new."
154924,333332053,986335,"Agilent Technologies, Inc., Q2 2016 Earnings Call, May 16, 2016",2016-05-16,"Earnings Calls","Agilent Technologies, Inc.","Executives","There was the overall tax outlays forecasted for the year where I think about $10 million less than what we had initially -- anticipated initial guidance $10 million or $15 million, and the rest is really operational performance improvements in our workin",52,"There was the overall tax outlays forecasted for the year where I think about $10 million less than what we had initially -- anticipated initial guidance $10 million or $15 million, and the rest is really operational performance improvements in our working capital management and FX and then just the operating profits."
154924,333332053,986335,"Agilent Technologies, Inc., Q2 2016 Earnings Call, May 16, 2016",2016-05-16,"Earnings Calls","Agilent Technologies, Inc.","Operator","And our next question comes from the line of Ross Muken of Evercore.",13,"And our next question comes from the line of Ross Muken of Evercore."
154924,333332053,986335,"Agilent Technologies, Inc., Q2 2016 Earnings Call, May 16, 2016",2016-05-16,"Earnings Calls","Agilent Technologies, Inc.","Analysts","So Mike, since taking over, it's only been a pretty had to journey and near messaging from the beginners been pretty consistent around growth and margins in returns. Obviously, last few quarters, you start to develop cadence last quarter results were good",128,"So Mike, since taking over, it's only been a pretty had to journey and near messaging from the beginners been pretty consistent around growth and margins in returns. Obviously, last few quarters, you start to develop cadence last quarter results were good will we had the challenges on FX. Do you feel like this is the first quarter where you feel like you got to deliver the full bag, where you're able to sort of drop through the top line outperformance, which is clearly better than market. You drove the margins. You're buying stock. The returns are up and cash flow's good. Then you were finally able to shows that the business model's working and that feed, I guess into your confidence also I would assume on '17?"
154924,333332053,986335,"Agilent Technologies, Inc., Q2 2016 Earnings Call, May 16, 2016",2016-05-16,"Earnings Calls","Agilent Technologies, Inc.","Executives","Yes, I couldn't said it better than myself. Thanks, Ross, for the question. I think that we've been working really hard for the last 4 or 5 quarters of the new leadership team. And as you look at everything came together this quarter. I mean, we've had ho",275,"Yes, I couldn't said it better than myself. Thanks, Ross, for the question. I think that we've been working really hard for the last 4 or 5 quarters of the new leadership team. And as you look at everything came together this quarter. I mean, we've had how strong growth. We've had improvement our operating margin as I pointed out in '15. But all of the factors really came together nicely in the second quarter. And I was particularly pleased on some of the more operational activities that have been working on side of the company that may not always be so apparent initially on the outside but you start to see the results the fact that were doing -- we've adjusted our logistics you oranges. I have to talk about on year-over-year compares with its fix and it's actually no contributed to improve results. Yes, that I talk about the Chardon cycle time for ways to the revenue and but in some revenues that we niche we have planned for the third quarter, but we made those oppression improvements. The cycle times are shorter and this is now the new normal. So I guess, that will be the closing comments, which were the new normal for the company. We have got a lot of confidence about 2017, perhaps steal a bit of my thunder for the Analyst Meeting Mexico but, I still hope everyone attends. But when you start having this proof points of quarter in and quarter out, I think it starts to show you that the team is delivering. And I think the results are now starting to be appreciated and believe."
154924,333332053,986335,"Agilent Technologies, Inc., Q2 2016 Earnings Call, May 16, 2016",2016-05-16,"Earnings Calls","Agilent Technologies, Inc.","Analysts","Great. And maybe quickly just on Seahorse. Can you just give us an update on how that business is performing relative to your expectations and how it's plugged in and where you're sort of seeing maybe the early fruits and some cross synergy with the exist",47,"Great. And maybe quickly just on Seahorse. Can you just give us an update on how that business is performing relative to your expectations and how it's plugged in and where you're sort of seeing maybe the early fruits and some cross synergy with the existing business?"
154924,333332053,986335,"Agilent Technologies, Inc., Q2 2016 Earnings Call, May 16, 2016",2016-05-16,"Earnings Calls","Agilent Technologies, Inc.","Executives","Yes, which is in fact, a very timely question, Ross. We just had our 180-day review this morning. And Patrick, why don't you go ahead and share a couple of highlights from that session.",34,"Yes, which is in fact, a very timely question, Ross. We just had our 180-day review this morning. And Patrick, why don't you go ahead and share a couple of highlights from that session."
154924,333332053,986335,"Agilent Technologies, Inc., Q2 2016 Earnings Call, May 16, 2016",2016-05-16,"Earnings Calls","Agilent Technologies, Inc.","Executives","Sure, absolutely. So - but I really would want to evaluate is how seamlessly of the Seahorse wins. So we are now 6 months in integration. And we would say we're targeting full integration by June, which means that we have implemented all of the systems, w",154,"Sure, absolutely. So - but I really would want to evaluate is how seamlessly of the Seahorse wins. So we are now 6 months in integration. And we would say we're targeting full integration by June, which means that we have implemented all of the systems, which is a very fast space. At the same time, we are seeing the positioning of Seahorse with an old portfolio really works out. We're seeing nice deals and combined sales of LC-MS and seahorse in years like disease research and disease recovery that's actually exactly where we thought its complementing our strength and metabolomics with the life cell metabolism, which Sievers brings to the table of this is a very nice torii that very well with our customers. We are -- again, we're are in the integration side. We are very pleased with where we stand and we are looking forward to some very successful second half."
154924,333332053,986335,"Agilent Technologies, Inc., Q2 2016 Earnings Call, May 16, 2016",2016-05-16,"Earnings Calls","Agilent Technologies, Inc.","Executives","Yes, Ross, I'll just add 2 things. The common thing this morning is this is the fastest I've seen us do an integration. These things usually plot along for many quarters and in some cases, for years. This one is moving along really, really fast. And we're",74,"Yes, Ross, I'll just add 2 things. The common thing this morning is this is the fastest I've seen us do an integration. These things usually plot along for many quarters and in some cases, for years. This one is moving along really, really fast. And we're getting some wins. In fact, we won an LC/MS deal because of Seahorse. So I mean, it's the complementary nature of the portfolios is starting to work."
154924,333332053,986335,"Agilent Technologies, Inc., Q2 2016 Earnings Call, May 16, 2016",2016-05-16,"Earnings Calls","Agilent Technologies, Inc.","Operator","And our next question comes from the line of Paul Knight of Jenna Montgomery Scott.",15,"And our next question comes from the line of Paul Knight of Jenna Montgomery Scott."
154924,333332053,986335,"Agilent Technologies, Inc., Q2 2016 Earnings Call, May 16, 2016",2016-05-16,"Earnings Calls","Agilent Technologies, Inc.","Analysts","The move you make to create CrossLab since to be gaining beginning traction. Can you give us on the CrossLab in terms of the who do you think is taking share from somebody at that kind of growth rate? Could you give us more color on CrossLab?",47,"The move you make to create CrossLab since to be gaining beginning traction. Can you give us on the CrossLab in terms of the who do you think is taking share from somebody at that kind of growth rate? Could you give us more color on CrossLab?"
154924,333332053,986335,"Agilent Technologies, Inc., Q2 2016 Earnings Call, May 16, 2016",2016-05-16,"Earnings Calls","Agilent Technologies, Inc.","Executives","Yes. So as you mentioned, that was a major strategic move where some of the company, we established Agilent CrossLab Group. We had this vision about how we could really attack and go after the enterprise-wide services and consumables opportunity. And as y",230,"Yes. So as you mentioned, that was a major strategic move where some of the company, we established Agilent CrossLab Group. We had this vision about how we could really attack and go after the enterprise-wide services and consumables opportunity. And as you see, Mark and the team Eberle delivering. And we know that the customers are responding to the value proposition that Agilent offers, both in terms of the power our service capabilities is viewed. And that's why he mentioned in my script about the external recognition we initially received. But they're also pushing the fact we're able to give them insights terms of actually helping them improve the business operations, and we're seeing a real strong demand for this in the pharma and growing interest in other parts of the market. So we know that we're growing faster than some of our competitors in this space. We also know that there's only few companies really tried to grow after this type of business. I believe this is where the market is already going to come and I think you want to be a player here. and I leave it to you guys to figure out who's the losing share. But as you see or as I can tell you is we're growing close to double digits in the space. So obviously, that's been an attractive move for us."
154924,333332053,986335,"Agilent Technologies, Inc., Q2 2016 Earnings Call, May 16, 2016",2016-05-16,"Earnings Calls","Agilent Technologies, Inc.","Operator","And our next question comes from the line of Tim Evans of Wells Fargo Securities.",15,"And our next question comes from the line of Tim Evans of Wells Fargo Securities."
154924,333332053,986335,"Agilent Technologies, Inc., Q2 2016 Earnings Call, May 16, 2016",2016-05-16,"Earnings Calls","Agilent Technologies, Inc.","Analysts","I just want to make sure it is in the various of the quarter relative to what you're expecting I believe you had called last quarter for 4% core growth and we saw 8% this quarter. I hear you that it sounds like about half of that maybe, maybe about 200 ba",105,"I just want to make sure it is in the various of the quarter relative to what you're expecting I believe you had called last quarter for 4% core growth and we saw 8% this quarter. I hear you that it sounds like about half of that maybe, maybe about 200 basis point, was from the better book backlog to revenue conversion in this quarter. And I know you also called out the compare relative to last year. But that compare should have already been known. So I just want to understand what's the other 200 basis points that really surprised in the quarter."
154924,333332053,986335,"Agilent Technologies, Inc., Q2 2016 Earnings Call, May 16, 2016",2016-05-16,"Earnings Calls","Agilent Technologies, Inc.","Executives","Sure, Tim, how about -- thanks for your comments. And I can give you a few dollar numbers of revenue impact the way we've been looking at it and you can do perhaps the math on the impact on the growth rates. But what we saw a lot of to our initial expecta",250,"Sure, Tim, how about -- thanks for your comments. And I can give you a few dollar numbers of revenue impact the way we've been looking at it and you can do perhaps the math on the impact on the growth rates. But what we saw a lot of to our initial expectations for the quarter were really, first of all, it starts with the market, right? so the overall market demand came in as we predicted. We saw good growth across entire portfolio led by pharma and food markets in China, sue heard early. But I'd ask you to look at 2 things. One is this higher conversion of orders revenue than forecast. So basically, what we've done is we reduced the cycle time and by our estimates, it happened a lot faster than we had thought. So I think it's good news from a standpoint of operational efficiency that it great some forecasting challenges but probably 20 million to 25 million came from Q3 into Q2. The other thing I think you should take a look at is the FX assumptions. So around $9 million or so DDA give some numbers. So FX added about another $9 million. So between the cycle time improvements, the FX assumptions and just the fact that market continues, were getting our fair share of markets where there growing. I think those comes to those 3 facts I think will help me bridge the difference between our guided growth and what actually occurred."
154924,333332053,986335,"Agilent Technologies, Inc., Q2 2016 Earnings Call, May 16, 2016",2016-05-16,"Earnings Calls","Agilent Technologies, Inc.","Analysts","Just similar question on the margin side, probably a little bit of the margin in the quarter was the drop through cycle, it looks like a probably did better than you're expecting an absolute dollar basis on the SG&A as well. Can you help me understand may",57,"Just similar question on the margin side, probably a little bit of the margin in the quarter was the drop through cycle, it looks like a probably did better than you're expecting an absolute dollar basis on the SG&A as well. Can you help me understand maybe what is going a little faster than the new anticipated?"
154924,333332053,986335,"Agilent Technologies, Inc., Q2 2016 Earnings Call, May 16, 2016",2016-05-16,"Earnings Calls","Agilent Technologies, Inc.","Executives","Yes, I think on the SG&A front, I mean, we've got a couple of our programs inside of the Agilent are little bit ahead of plan. And but if there's anything else...",32,"Yes, I think on the SG&A front, I mean, we've got a couple of our programs inside of the Agilent are little bit ahead of plan. And but if there's anything else..."
154924,333332053,986335,"Agilent Technologies, Inc., Q2 2016 Earnings Call, May 16, 2016",2016-05-16,"Earnings Calls","Agilent Technologies, Inc.","Executives","Most of the impact was volume driven [indiscernible] effects. But there was versus the initial guidance.",16,"Most of the impact was volume driven [indiscernible] effects. But there was versus the initial guidance."
154924,333332053,986335,"Agilent Technologies, Inc., Q2 2016 Earnings Call, May 16, 2016",2016-05-16,"Earnings Calls","Agilent Technologies, Inc.","Executives","I will tell you the field structure that we put in place last year was really stable down. I think delivering, helping us on the growth side and also, on the SG&A front as a more efficient go-to-market channel.",39,"I will tell you the field structure that we put in place last year was really stable down. I think delivering, helping us on the growth side and also, on the SG&A front as a more efficient go-to-market channel."
154924,333332053,986335,"Agilent Technologies, Inc., Q2 2016 Earnings Call, May 16, 2016",2016-05-16,"Earnings Calls","Agilent Technologies, Inc.","Operator","And our next question comes from the line of Isaac Ro of Goldman Sachs.",14,"And our next question comes from the line of Isaac Ro of Goldman Sachs."
154924,333332053,986335,"Agilent Technologies, Inc., Q2 2016 Earnings Call, May 16, 2016",2016-05-16,"Earnings Calls","Agilent Technologies, Inc.","Analysts","I had a question on margins as well. On the gross margin side, I was curious if we should expect maybe another wave of improvement now that you have ERP integration done and on our margin side, curious how satisfied you are with the sales force realignmen",61,"I had a question on margins as well. On the gross margin side, I was curious if we should expect maybe another wave of improvement now that you have ERP integration done and on our margin side, curious how satisfied you are with the sales force realignment and whether or not in there still more synergies do have there as well."
154924,333332053,986335,"Agilent Technologies, Inc., Q2 2016 Earnings Call, May 16, 2016",2016-05-16,"Earnings Calls","Agilent Technologies, Inc.","Executives","Yes, a couple of comments here then I'll plans it over to Didier in case like that a few things here. But in terms of the sales force integration and go-to-market -- we couldn't be happier. I mean, that was a major move we made last year, where we basical",341,"Yes, a couple of comments here then I'll plans it over to Didier in case like that a few things here. But in terms of the sales force integration and go-to-market -- we couldn't be happier. I mean, that was a major move we made last year, where we basically went from 5 sales force then the 2 sales force as 1 focused on the analytical laboratory marketplace and then the other 1 focused on the regulated diagnostic market-based. At the time, I remember sharing with you, hey, we're making a big change share and it could affect the top line and the short one. That didn't happen. In fact, I submit that as we go out into '16 and '17, we're now putting more resources of specialization in academia in biopharma. So I think you're going to see the changes paying off in terms of longer-term growth. So we're really happy with but the fact that we've got it all behind us and settle down and I think its starting to pay off on the initial benefits that we envision when we created that structure. 
Relative to gross margin ERP, just keep in mind that what we've been talking about is a -- the financial systems, which really go into the SG&A line. So it really won't affect the gross margin. That being said, we do think we can do more on gross margin as we move forward in '16 and '17. I'll talk a little bit about more about in detail next week in New York. But as you may know, our initial 400 basis points of improvement to when I came onboard, we said half would come through OpEx and other operational cost, and then others through growth. And the growth piece would be a lot will be driven by our ability to capture the gross margin improvements on increased volume. So we think we still have room to improve our material cost, and we think that we've got room to continue to bring down our logistics costs."
154924,333332053,986335,"Agilent Technologies, Inc., Q2 2016 Earnings Call, May 16, 2016",2016-05-16,"Earnings Calls","Agilent Technologies, Inc.","Analysts","That's very helpful. Maybe just a follow-up. Just to clarify 2 topics, 1 in biopharma and then the other 1 of the comments you made in China. Biopharma, could you just compare the growth rates you're seeing in the QAQC setting versus R&D? And then in Chin",79,"That's very helpful. Maybe just a follow-up. Just to clarify 2 topics, 1 in biopharma and then the other 1 of the comments you made in China. Biopharma, could you just compare the growth rates you're seeing in the QAQC setting versus R&D? And then in China, just years how much of your improved outlook there is based on the visibility you have with government-funded versus sort of end markets that are more on the private industry side."
154924,333332053,986335,"Agilent Technologies, Inc., Q2 2016 Earnings Call, May 16, 2016",2016-05-16,"Earnings Calls","Agilent Technologies, Inc.","Executives","I think that on the -- your question, we're not seeing it really significant expenses in growth rates across of the segments you described in pharma. I do think if you go out a couple of years down the road, I think we'd expect that growth rate biopharma",146,"I think that on the -- your question, we're not seeing it really significant expenses in growth rates across of the segments you described in pharma. I do think if you go out a couple of years down the road, I think we'd expect that growth rate biopharma should be higher than the small molecule. But it's not at all the case right now. As you heard any from Patrick, we expect that to continue through '17. We're getting more clarity about what's going on in China. I think there was a lot of concerns at one point in time on the private sector outside of the business but probably as you know, Isaac, the government drive this to a large extent a getting more clarity on what's happening in funding. So that's why we have increase confidence in our outlook for our business in China."
154924,333332053,986335,"Agilent Technologies, Inc., Q2 2016 Earnings Call, May 16, 2016",2016-05-16,"Earnings Calls","Agilent Technologies, Inc.","Operator","And our next question comes from the line of Derik De Bruin of Bank of America.",16,"And our next question comes from the line of Derik De Bruin of Bank of America."
154924,333332053,986335,"Agilent Technologies, Inc., Q2 2016 Earnings Call, May 16, 2016",2016-05-16,"Earnings Calls","Agilent Technologies, Inc.","Analysts","Just wanted to clarify. Did I hear you correctly that you said your initial flash for core growth guidance for fiscal '17 was 4.5% the mid-point?",26,"Just wanted to clarify. Did I hear you correctly that you said your initial flash for core growth guidance for fiscal '17 was 4.5% the mid-point?"
154924,333332053,986335,"Agilent Technologies, Inc., Q2 2016 Earnings Call, May 16, 2016",2016-05-16,"Earnings Calls","Agilent Technologies, Inc.","Executives","Yes, yes.",2,"Yes, yes."
154924,333332053,986335,"Agilent Technologies, Inc., Q2 2016 Earnings Call, May 16, 2016",2016-05-16,"Earnings Calls","Agilent Technologies, Inc.","Analysts","Okay. And so can you sort of like flank that in terms of what you're thinking for the chemical and energy market there? I mean, just sort of what you're expecting in terms of a rebound. And I'm just -- can you help us frame that comment a little bit more",60,"Okay. And so can you sort of like flank that in terms of what you're thinking for the chemical and energy market there? I mean, just sort of what you're expecting in terms of a rebound. And I'm just -- can you help us frame that comment a little bit more in terms of some of the puts and takes?"
154924,333332053,986335,"Agilent Technologies, Inc., Q2 2016 Earnings Call, May 16, 2016",2016-05-16,"Earnings Calls","Agilent Technologies, Inc.","Executives","Yes, sure I'd be happy to because sometimes, you use corporate language, it doesn't give you the insights unit. So let me try to clarify he. So what we said was in this year, we thought our performance will be flat for the entire year. While in fact, it's",334,"Yes, sure I'd be happy to because sometimes, you use corporate language, it doesn't give you the insights unit. So let me try to clarify he. So what we said was in this year, we thought our performance will be flat for the entire year. While in fact, it's going to be down. You probably think in the range of 2.5% for the year, for the entire year. And that is a change from our assumptions come into this year. And that was the assumption that we have made initial bonus, which makes our revenue results that much more -- really pleased results, given the fact that the chemical energy market is not developed the way that we initially thought. That being said, in '17, we actually think it will be improved, which means it won't be declining. And in fact, it will probably be flat or maybe low single-digits. And why do we believe that? If you look at how our business breaks down in that segment, we often talk about the oil side. But 50% of our business historically has been in the exploration, around 35% has been in the refining. The other half, which is by far the biggest individual segment, the chemical side.  They're benefiting by a lower feedstock costs. They've got pent op investment demands and we're starting to see increased deal activity. So it in fact, Patrick and I were talking about this morning it going of reminds me of a pro forma a few years ago basically it would have 2 years of shrinking performance in this marketplace, a lot of pent-up demand. So long story short, our growth assumption for next year assumes low single-digit chemical energy growth for the year. Again, we still believe we're surged for the bottom. So -- and it's still early in the year for 2016. But that's our basic assumption for '17, which is an improved environment, not dramatic, but improved from what we've seen over the last 24 months."
154924,333332053,986335,"Agilent Technologies, Inc., Q2 2016 Earnings Call, May 16, 2016",2016-05-16,"Earnings Calls","Agilent Technologies, Inc.","Analysts","Just as a critical follow-up on the chemical's comment. You're not worried that some of the activity between Dow and DuPont looks like there may be some Monsanto either the companies that are down to ground. Are you worried that, that could sort of stymie",69,"Just as a critical follow-up on the chemical's comment. You're not worried that some of the activity between Dow and DuPont looks like there may be some Monsanto either the companies that are down to ground. Are you worried that, that could sort of stymied investment if you're using the far methodology of sort of accommodation of this completes. Is there some potential headwind from the chemicals markets?"
154924,333332053,986335,"Agilent Technologies, Inc., Q2 2016 Earnings Call, May 16, 2016",2016-05-16,"Earnings Calls","Agilent Technologies, Inc.","Executives","No, Derik, that's a great question. We look at his pretty closely when the announcement was first made. And although Dow and DuPont are very important customers to us, that particular deal activity really is immaterial to the total company's performance.",112,"No, Derik, that's a great question. We look at his pretty closely when the announcement was first made. And although Dow and DuPont are very important customers to us, that particular deal activity really is immaterial to the total company's performance. And we didn't, as I see it, as a sign of a new acceleration of M&A and consolidations going on in the space. So of course, there will be some costs. You're seeing more of that. But we're not overly concerned about that. And I guess of the beauty of this business has been the broad-based nature of our customer base. So we're not overly dependent on any one single customer."
154924,333332053,986335,"Agilent Technologies, Inc., Q2 2016 Earnings Call, May 16, 2016",2016-05-16,"Earnings Calls","Agilent Technologies, Inc.","Operator","And our next question comes from the line of Dan Arias of Citigroup.",13,"And our next question comes from the line of Dan Arias of Citigroup."
154924,333332053,986335,"Agilent Technologies, Inc., Q2 2016 Earnings Call, May 16, 2016",2016-05-16,"Earnings Calls","Agilent Technologies, Inc.","Analysts","Mike, can you just talk on Japan and things that you saw during the quarter in terms of trends and maybe what you're looking for at this point on the year?",31,"Mike, can you just talk on Japan and things that you saw during the quarter in terms of trends and maybe what you're looking for at this point on the year?"
154924,333332053,986335,"Agilent Technologies, Inc., Q2 2016 Earnings Call, May 16, 2016",2016-05-16,"Earnings Calls","Agilent Technologies, Inc.","Executives","Yes. So that's a good question. And if you a little bit of my history, I spent 5 years in Japan. So I've always been a supporter of Japan in terms of long-term view of the market. And I'd ask you to take a long-term view of the market in Japan. And so tha",172,"Yes. So that's a good question. And if you a little bit of my history, I spent 5 years in Japan. So I've always been a supporter of Japan in terms of long-term view of the market. And I'd ask you to take a long-term view of the market in Japan. And so that was the only market that actually was down for us in the second quarter. And we are expecting continued subdue performance in Japan. So we're not expecting much in terms of improvement in the overall market environment in Japan. We do think that, that could be a market, which often will respond to new technologies, innovative new products. So we do hope -- we do hold out hope that we could take some share from some our new interests coming out in the second half this year of an overall market perspective, we're expecting the remain subdued in our internal forecast are not base based on any type of material improvement at all on our performance in Japan."
154924,333332053,986335,"Agilent Technologies, Inc., Q2 2016 Earnings Call, May 16, 2016",2016-05-16,"Earnings Calls","Agilent Technologies, Inc.","Analysts","And then you kind of tea some new product introductions in the back half that should be meaningful to growth. I'm sure you don't want to give away any secrets. But can you just sort of you're anticipating seeing the boost in 2017?",43,"And then you kind of tea some new product introductions in the back half that should be meaningful to growth. I'm sure you don't want to give away any secrets. But can you just sort of you're anticipating seeing the boost in 2017?"
154924,333332053,986335,"Agilent Technologies, Inc., Q2 2016 Earnings Call, May 16, 2016",2016-05-16,"Earnings Calls","Agilent Technologies, Inc.","Executives","Yes. So thanks for the caveat on your question. So what we can point to with great confidence and clarity is the recent introduction than we had an analytic. And then what I would say to you, you will see broad-based reductions across the entire portfolio",160,"Yes. So thanks for the caveat on your question. So what we can point to with great confidence and clarity is the recent introduction than we had an analytic. And then what I would say to you, you will see broad-based reductions across the entire portfolio. And core growth essential to our business plan. As you know, I came in last year. We spent a lot of time realizing R&D structure and also, reallocating where we put money. And I think you're going to start to CDx some of that starting to pay off as we go into the latter part of '16. So we did want to put a tees out there, but also to make sure you had confidence in terms of what's behind our view of improved Agilent performance in '17 off of the second half of this year. But I think you're going to expect to see us talk about active across all 3 business groups."
154924,333332053,986335,"Agilent Technologies, Inc., Q2 2016 Earnings Call, May 16, 2016",2016-05-16,"Earnings Calls","Agilent Technologies, Inc.","Operator","And our next question comes from the line of Doug Schenkel of Callanan Company.",14,"And our next question comes from the line of Doug Schenkel of Callanan Company."
154924,333332053,986335,"Agilent Technologies, Inc., Q2 2016 Earnings Call, May 16, 2016",2016-05-16,"Earnings Calls","Agilent Technologies, Inc.","Analysts","Mike, I want to go back to some of the comments you made on our efforts to tighten cycle times from ordered to revenue, which seem to be yielding benefit better than expected, particularly on China. Can you provide a bit more background on this effort and",116,"Mike, I want to go back to some of the comments you made on our efforts to tighten cycle times from ordered to revenue, which seem to be yielding benefit better than expected, particularly on China. Can you provide a bit more background on this effort and wireless most impactful in China? And then maybe talk about similar efforts underway in other geographies. And relatedly, you positioned these in answering some questions as if they were temporary. At least, it seems like your guidance does intrigue the sustainable improvements. Yet, everything else you said to just these are truly sustainable improvements. So I was just hoping you could help us understand that a little bit better."
154924,333332053,986335,"Agilent Technologies, Inc., Q2 2016 Earnings Call, May 16, 2016",2016-05-16,"Earnings Calls","Agilent Technologies, Inc.","Executives","Yes, sure, Doug. I appreciate the question. And maybe let me start with the last part of your question, which is the Takeaway here, we do believe there's a stable improvement. So in my mind, this is this is the new normal in terms of our ability to conver",434,"Yes, sure, Doug. I appreciate the question. And maybe let me start with the last part of your question, which is the Takeaway here, we do believe there's a stable improvement. So in my mind, this is this is the new normal in terms of our ability to convert quarters to revenue. And so I would characterize this as new normal how are they going to operate. So how do we get here and why do they look us. So significantly different in China. So first of all, starts with the looking at the entire process from an end-to-end customer perspective from the time of order placement until shipment into customer installation a curse blunt, as you know, when I restructure the company, was really trying to break out the silos and we had very silent oriented approach to this end-to-end process from a customer perspective. In the company, we looked at each slice of the process but nobody's looking at the collective process for end-to-end. You start doing that heavy start seeing where the issues are. The opportunities are. So we found ways to improve our order linearity. We've improved the quality of booked orders, and this usually gets to your question about China. Often, you're dealing with letters of credit issues and other trade issues that in the past have delayed our ability to actually book them as clean orders and turned them into revenue, we call this delivery box. We've been working making sure we had material availability. I think we hit one of our best one is ever in terms of having maternal ready for all our shouldn't so we improved our ability to get an order duly your fashion make sure those orders are clean and not have a lot of rework, and then we've improve our delivery performance. And then spent a lot of time improving our efforts between shipment insulation, which sometimes can go on for several weeks. So I think it all starts to this looking at the whole process from an end-to-end perspective and the result has been a significant improvement in cycle time and noticed and turned into revenue more quickly than in the past. I do think this represents our newly up operating. And again, as I mentioned in my remarks, it did great some -- it did have invitations of how we guide the company for the second and third quarter. But I think we're delighted to be able to actually have ongoing strong operational efficiency improvement in place so that we know how to predict revenue even better in the future."
154924,333332053,986335,"Agilent Technologies, Inc., Q2 2016 Earnings Call, May 16, 2016",2016-05-16,"Earnings Calls","Agilent Technologies, Inc.","Analysts","But just to be really clear, recognizing these are well-earned, sustainable improvements, it's not apparent that this is fully -- these improvements sustainably is fully perfected in guidance. If that's the case is just because you want to see this couple",49,"But just to be really clear, recognizing these are well-earned, sustainable improvements, it's not apparent that this is fully -- these improvements sustainably is fully perfected in guidance. If that's the case is just because you want to see this couple of quarters before you start taking it in."
154924,333332053,986335,"Agilent Technologies, Inc., Q2 2016 Earnings Call, May 16, 2016",2016-05-16,"Earnings Calls","Agilent Technologies, Inc.","Executives","I think the confusion might be that what we have stated is that this quarter in Q2, we got $20 million to $25 million of revenue that we had anticipated to be recognized in Q3 as we were bringing all those programs to fruition. We had earlier results, whi",120,"I think the confusion might be that what we have stated is that this quarter in Q2, we got $20 million to $25 million of revenue that we had anticipated to be recognized in Q3 as we were bringing all those programs to fruition. We had earlier results, which is great. From where we are now, the order to revenue cycle time is sustainable but we will not see further improvement that will bring Q4 revenue into Q3 or whatever it is. And so the 20 to 25, that's one-time. We've got to the level we wanted to be at. And from now on, it's just business as usual without any fundamental change in the order to revenue cycle time."
154924,333332053,986335,"Agilent Technologies, Inc., Q2 2016 Earnings Call, May 16, 2016",2016-05-16,"Earnings Calls","Agilent Technologies, Inc.","Analysts","And just one last one for you. On the change in Lasergen accounting, was there any dilution in the quarter? And based on the accounting change that we no longer expect this to be $0.02 to $0.03 dilutive deal for the year?",42,"And just one last one for you. On the change in Lasergen accounting, was there any dilution in the quarter? And based on the accounting change that we no longer expect this to be $0.02 to $0.03 dilutive deal for the year?"
154924,333332053,986335,"Agilent Technologies, Inc., Q2 2016 Earnings Call, May 16, 2016",2016-05-16,"Earnings Calls","Agilent Technologies, Inc.","Executives","Yes, correct. You're correct. So there was no dilution in Q2 and there will not be a dilution in -- for the rest of '16 or '17 until we exercise our call option. And then we will just fully consolidate if we do that, obviously, fully consolidate delays of",116,"Yes, correct. You're correct. So there was no dilution in Q2 and there will not be a dilution in -- for the rest of '16 or '17 until we exercise our call option. And then we will just fully consolidate if we do that, obviously, fully consolidate delays of Lasergen revenue. So that's a change. There was a lot of them in discussions with the auditors, the surprises a little bit by going to national to get specially to kind of challenge kind of the accounting that we had anticipated locally among the 2 teams, and then we agreed to the recommendation. And therefore, no dilution to EPS coming from Lasergen in the next 2 years."
154924,333332053,986335,"Agilent Technologies, Inc., Q2 2016 Earnings Call, May 16, 2016",2016-05-16,"Earnings Calls","Agilent Technologies, Inc.","Executives","Right. We are pleased to get this closed off before we finish the quarter.",14,"Right. We are pleased to get this closed off before we finish the quarter."
154924,333332053,986335,"Agilent Technologies, Inc., Q2 2016 Earnings Call, May 16, 2016",2016-05-16,"Earnings Calls","Agilent Technologies, Inc.","Operator","And our next question comes from the line of Miroslava Minkova of Stifel.",13,"And our next question comes from the line of Miroslava Minkova of Stifel."
154924,333332053,986335,"Agilent Technologies, Inc., Q2 2016 Earnings Call, May 16, 2016",2016-05-16,"Earnings Calls","Agilent Technologies, Inc.","Analysts","Maybe if I could focus on operating margins again for a second. Just help us remind us. There's a lot going out there in terms of the programs you have in place and improvements you have going on. Help us remind us the bridge between fiscal '16 and '17? W",57,"Maybe if I could focus on operating margins again for a second. Just help us remind us. There's a lot going out there in terms of the programs you have in place and improvements you have going on. Help us remind us the bridge between fiscal '16 and '17? What's get you to the 22% operating margin?"
154924,333332053,986335,"Agilent Technologies, Inc., Q2 2016 Earnings Call, May 16, 2016",2016-05-16,"Earnings Calls","Agilent Technologies, Inc.","Executives","Well, as a teaser, we're going to go through this in some detail.",13,"Well, as a teaser, we're going to go through this in some detail."
154924,333332053,986335,"Agilent Technologies, Inc., Q2 2016 Earnings Call, May 16, 2016",2016-05-16,"Earnings Calls","Agilent Technologies, Inc.","Executives","There's slide on the topic next week. But what I'll share with you conceptually is that we will be continuing and completing off the integration of the Dako acquisition. We have a serious of operational programs. We talked to about one of those already, w",97,"There's slide on the topic next week. But what I'll share with you conceptually is that we will be continuing and completing off the integration of the Dako acquisition. We have a serious of operational programs. We talked to about one of those already, which is the implications of the ERP, and the continued focus on the gross margin improvements specifically, material cost reductions and he just sticks savings. So I think the combination of those 3 factors plus with the overall quarter growth assumptions that we're currently model around 4.5 gets us to the 22."
154924,333332053,986335,"Agilent Technologies, Inc., Q2 2016 Earnings Call, May 16, 2016",2016-05-16,"Earnings Calls","Agilent Technologies, Inc.","Analysts","Okay, great. And the strength in the flood market, was this all China or are you seeing strength elsewhere as well?",21,"Okay, great. And the strength in the flood market, was this all China or are you seeing strength elsewhere as well?"
154924,333332053,986335,"Agilent Technologies, Inc., Q2 2016 Earnings Call, May 16, 2016",2016-05-16,"Earnings Calls","Agilent Technologies, Inc.","Executives","Actually, it was both in food, I mean, excuse me, both in China and in the United States. As you may recall, from our Q1 announcement, this business tended to be a little rumpy, whereas I think the performance in food market in China has been sustained. B",59,"Actually, it was both in food, I mean, excuse me, both in China and in the United States. As you may recall, from our Q1 announcement, this business tended to be a little rumpy, whereas I think the performance in food market in China has been sustained. But we saw nice rebound in the U.S. in the second quarter."
154924,333332053,986335,"Agilent Technologies, Inc., Q2 2016 Earnings Call, May 16, 2016",2016-05-16,"Earnings Calls","Agilent Technologies, Inc.","Analysts","Got you. Okay, maybe finally, can give us your view of the M&A pipeline we've seen you do a couple of deals just recently here. Now that you have sort of many of the operational initiatives for the new Agilent in place, should we expect you're more active",53,"Got you. Okay, maybe finally, can give us your view of the M&A pipeline we've seen you do a couple of deals just recently here. Now that you have sort of many of the operational initiatives for the new Agilent in place, should we expect you're more active with the talking's going forward?"
154924,333332053,986335,"Agilent Technologies, Inc., Q2 2016 Earnings Call, May 16, 2016",2016-05-16,"Earnings Calls","Agilent Technologies, Inc.","Executives","Again, this is a teaser number 2, which is were going to talk about this a little bit in more detail next week. But I do feel that the company's foundation is really firmly established. And as I mentioned earlier, I think we're getting a lot better in ter",138,"Again, this is a teaser number 2, which is were going to talk about this a little bit in more detail next week. But I do feel that the company's foundation is really firmly established. And as I mentioned earlier, I think we're getting a lot better in terms of our speed to be able to integrate. But what -- I think you're going to expect to is to remain disciplined and focused in terms of finding those opportunities that make sense for us. And it would ask you to think about us being complimentary M&A in nature. We're going to continue to look for those. So our balance sheet is a huge asset for the -- for our shareholders and one which are like to deploy relative to M&A, but it has to be the right target."
154924,333332053,986335,"Agilent Technologies, Inc., Q2 2016 Earnings Call, May 16, 2016",2016-05-16,"Earnings Calls","Agilent Technologies, Inc.","Operator","And our next question comes from the line of Steve, Beuchaw of Morgan Stanley.",14,"And our next question comes from the line of Steve, Beuchaw of Morgan Stanley."
154924,333332053,986335,"Agilent Technologies, Inc., Q2 2016 Earnings Call, May 16, 2016",2016-05-16,"Earnings Calls","Agilent Technologies, Inc.","Analysts","Just 2 clarifications on how you're thinking about the '16, '17 progression. The first is actually on the NIH. To what extent, if any, are you anticipating a pickup in the research channel from NIH funding when we start to see that get dispersed in the se",99,"Just 2 clarifications on how you're thinking about the '16, '17 progression. The first is actually on the NIH. To what extent, if any, are you anticipating a pickup in the research channel from NIH funding when we start to see that get dispersed in the second half of the year? And then second and just maybe even a longer-term question. But how do you think about the evolution of FSMA regulations in the flood space in the U.S. Is it too soon to start getting of the mentally optimistic about how they could contribute to the outlook?"
154924,333332053,986335,"Agilent Technologies, Inc., Q2 2016 Earnings Call, May 16, 2016",2016-05-16,"Earnings Calls","Agilent Technologies, Inc.","Executives","Yes, thanks. I'm glad to address both of your questions. So on NIH front, I think, when we talked about the uptick in sort of our improved confidence about spends in academe and government in the U.S. I think we do think that the NIH staff will start to f",212,"Yes, thanks. I'm glad to address both of your questions. So on NIH front, I think, when we talked about the uptick in sort of our improved confidence about spends in academe and government in the U.S. I think we do think that the NIH staff will start to flow through to our business. Relative to some in our space, we don't have it as higher percentage of our business time in age but it will be a positive for us. And I think, again, one more pattern page points to continued view on this market will be solid for us as we move into '17. I think I'd have to agree with the comment, which is, I think it's really is too soon to get overall excited about this from a U.S. spending. I've seen this before where a legislation just announced and there's a lot of fanfare about it. But we don't obviously, backed up by investments. Although we did -- we are seeing some -- it looks like some maybe more friendly government allocations to this agency unlike we've seen to the EPD. So we're not expecting anything dramatic to occur differently in the market because of this. But if it would, that would be good news for us."
154924,333332053,986335,"Agilent Technologies, Inc., Q2 2016 Earnings Call, May 16, 2016",2016-05-16,"Earnings Calls","Agilent Technologies, Inc.","Operator","And our next question comes from the line of Jeff Elliott of Robert W. Baird.",15,"And our next question comes from the line of Jeff Elliott of Robert W. Baird."
154924,333332053,986335,"Agilent Technologies, Inc., Q2 2016 Earnings Call, May 16, 2016",2016-05-16,"Earnings Calls","Agilent Technologies, Inc.","Analysts","Mike, on the margin, overall, a really good quarter. But then when you look at the margins in DGG in Cland, basically flat year-over-year. I think is at what you're expecting? And anything you can call out in the quarter. I know there's moving pieces in t",49,"Mike, on the margin, overall, a really good quarter. But then when you look at the margins in DGG in Cland, basically flat year-over-year. I think is at what you're expecting? And anything you can call out in the quarter. I know there's moving pieces in the top line."
154924,333332053,986335,"Agilent Technologies, Inc., Q2 2016 Earnings Call, May 16, 2016",2016-05-16,"Earnings Calls","Agilent Technologies, Inc.","Executives","Why did you take that one, Didier?",7,"Why did you take that one, Didier?"
154924,333332053,986335,"Agilent Technologies, Inc., Q2 2016 Earnings Call, May 16, 2016",2016-05-16,"Earnings Calls","Agilent Technologies, Inc.","Executives","No, it's a great question and the answer is yes. It's precisely what we had expected. One of the obviously, based from 1 quarter to the next, there could be some one-time add-ins that adds a little bit of volatility. For example, last year, both ACG and D",128,"No, it's a great question and the answer is yes. It's precisely what we had expected. One of the obviously, based from 1 quarter to the next, there could be some one-time add-ins that adds a little bit of volatility. For example, last year, both ACG and DGG had very favorable hedging gains, which have gone away for the whole company, the hedging gains last year in Q2 was over $7 million and this Q2 was about to 1.5. So -- and it was mostly ACG in DDG. And there are other one-time items that included regarding the allocation of our shared services among the different businesses, which explain. But both businesses are underway to contribute to the operating margin expansion and the 22% that we're committed to."
154924,333332053,986335,"Agilent Technologies, Inc., Q2 2016 Earnings Call, May 16, 2016",2016-05-16,"Earnings Calls","Agilent Technologies, Inc.","Executives","Hey, Didier, it also asked Mark to -- we've talked about this earlier this last week as well about the operational efficiency improvements that underline what looks to be flat margin so when you peel back the onion hedging there's actually some real opera",44,"Hey, Didier, it also asked Mark to -- we've talked about this earlier this last week as well about the operational efficiency improvements that underline what looks to be flat margin so when you peel back the onion hedging there's actually some real operations..."
154924,333332053,986335,"Agilent Technologies, Inc., Q2 2016 Earnings Call, May 16, 2016",2016-05-16,"Earnings Calls","Agilent Technologies, Inc.","Executives","Thanks, Mike and Didier, As Didier said, there are several things that were factors it's a lesser that didn't come into play this year. But we're working on a lot of things in terms of improvements. The mix is somewhat favorable in the context of what we'",99,"Thanks, Mike and Didier, As Didier said, there are several things that were factors it's a lesser that didn't come into play this year. But we're working on a lot of things in terms of improvements. The mix is somewhat favorable in the context of what we're selling. But overall, we look at our plans for the first half, we're up 70 basis points in the first half over last year. So our ability to actually -- due to margin improvements, when you pull back and look at the first half regardless of all those things, it's quite possible."
154924,333332053,986335,"Agilent Technologies, Inc., Q2 2016 Earnings Call, May 16, 2016",2016-05-16,"Earnings Calls","Agilent Technologies, Inc.","Executives","Yes, it is our fastest growing business, you've been picking up more of the corporate cost.",16,"Yes, it is our fastest growing business, you've been picking up more of the corporate cost."
154924,333332053,986335,"Agilent Technologies, Inc., Q2 2016 Earnings Call, May 16, 2016",2016-05-16,"Earnings Calls","Agilent Technologies, Inc.","Executives","Shared services.",2,"Shared services."
154924,333332053,986335,"Agilent Technologies, Inc., Q2 2016 Earnings Call, May 16, 2016",2016-05-16,"Earnings Calls","Agilent Technologies, Inc.","Executives","Yes, shared services.",3,"Yes, shared services."
154924,333332053,986335,"Agilent Technologies, Inc., Q2 2016 Earnings Call, May 16, 2016",2016-05-16,"Earnings Calls","Agilent Technologies, Inc.","Operator","And our final question comes from the line of the Dane Leone of BTIG.",14,"And our final question comes from the line of the Dane Leone of BTIG."
154924,333332053,986335,"Agilent Technologies, Inc., Q2 2016 Earnings Call, May 16, 2016",2016-05-16,"Earnings Calls","Agilent Technologies, Inc.","Analysts","I just had a quick clarification from earlier. So you're talking about the replacement cycle in biopharma and quoted, I think, 150,000 LC system based on the 1100, 1200 platform. Can you clarify if that's what you think the opportunity is ahead of you? Ou",62,"I just had a quick clarification from earlier. So you're talking about the replacement cycle in biopharma and quoted, I think, 150,000 LC system based on the 1100, 1200 platform. Can you clarify if that's what you think the opportunity is ahead of you? Our of that opportunity in progress? And if so, kind of what -- how far you into that?"
154924,333332053,986335,"Agilent Technologies, Inc., Q2 2016 Earnings Call, May 16, 2016",2016-05-16,"Earnings Calls","Agilent Technologies, Inc.","Executives","This is Patrick. Let me answer this question. So first and foremost, it's not biopharma. This is pharma and biopharma combined. And when I talk about 150,000 system sound, it's the installed base of LC systems in all markets. So it's not only from a bioph",122,"This is Patrick. Let me answer this question. So first and foremost, it's not biopharma. This is pharma and biopharma combined. And when I talk about 150,000 system sound, it's the installed base of LC systems in all markets. So it's not only from a biopharma. But we think that the biggest pushes actually right now, coming from pharma and biopharma and, and I would still say we are in the midst of the replacement cycle. We don't see that to be over -- in the next couple of quarters. So there's a healthy demand behind the negotiation across our customers on upcoming preplacement and how we place of the systems and how we plan it out for them so sound that."
154924,333332053,986335,"Agilent Technologies, Inc., Q2 2016 Earnings Call, May 16, 2016",2016-05-16,"Earnings Calls","Agilent Technologies, Inc.","Executives","And then, if I can add to one for the quest meant of Patrick's response. We are focused on today's call on 5-mile [ph] biopharma but keep in mind that the replacement cycles have been very, very subdued on the applied market site in liquid chromatography.",83,"And then, if I can add to one for the quest meant of Patrick's response. We are focused on today's call on 5-mile [ph] biopharma but keep in mind that the replacement cycles have been very, very subdued on the applied market site in liquid chromatography. So we have several tens of thousands and systems on the right side of the house a small plug-in, this is why we look out the '17 and '18. We think that our growth rates are sustainable."
154924,333332053,986335,"Agilent Technologies, Inc., Q2 2016 Earnings Call, May 16, 2016",2016-05-16,"Earnings Calls","Agilent Technologies, Inc.","Analysts","And I've could handicap using baseball analogy or something like that, like what inning you think at?",18,"And I've could handicap using baseball analogy or something like that, like what inning you think at?"
154924,333332053,986335,"Agilent Technologies, Inc., Q2 2016 Earnings Call, May 16, 2016",2016-05-16,"Earnings Calls","Agilent Technologies, Inc.","Executives","No, don't ask a German.",5,"No, don't ask a German."
154924,333332053,986335,"Agilent Technologies, Inc., Q2 2016 Earnings Call, May 16, 2016",2016-05-16,"Earnings Calls","Agilent Technologies, Inc.","Executives","I'd say, on the pharma aside, you're probably innings 5 or 6. I mean, [indiscernible] 2/3 late, yes, maybe 2/3.",21,"I'd say, on the pharma aside, you're probably innings 5 or 6. I mean, [indiscernible] 2/3 late, yes, maybe 2/3."
154924,333332053,986335,"Agilent Technologies, Inc., Q2 2016 Earnings Call, May 16, 2016",2016-05-16,"Earnings Calls","Agilent Technologies, Inc.","Executives","I think my point would be that I think the ballgame is just getting started. You made the first inning. We hope to be the first inning soon that cycle and the applied market side.",35,"I think my point would be that I think the ballgame is just getting started. You made the first inning. We hope to be the first inning soon that cycle and the applied market side."
154924,333332053,986335,"Agilent Technologies, Inc., Q2 2016 Earnings Call, May 16, 2016",2016-05-16,"Earnings Calls","Agilent Technologies, Inc.","Operator","And I'm showing no further questions at this time. It now like to attend a conference over to Alicia Rodriguez for closing remarks.",24,"And I'm showing no further questions at this time. It now like to attend a conference over to Alicia Rodriguez for closing remarks."
154924,333332053,986335,"Agilent Technologies, Inc., Q2 2016 Earnings Call, May 16, 2016",2016-05-16,"Earnings Calls","Agilent Technologies, Inc.","Executives","Thank you, everybody, and I'd like to thank you all for joining us today on the call. If you have any questions, of course, please give us a call in IR. I just would hope that we'll see you next week at our Analyst Day in New York City. Thanks again. Bye-",52,"Thank you, everybody, and I'd like to thank you all for joining us today on the call. If you have any questions, of course, please give us a call in IR. I just would hope that we'll see you next week at our Analyst Day in New York City. Thanks again. Bye-bye."
154924,333332053,986335,"Agilent Technologies, Inc., Q2 2016 Earnings Call, May 16, 2016",2016-05-16,"Earnings Calls","Agilent Technologies, Inc.","Operator","Ladies and gentlemen, thank you for participating in today's conference. This does conclude the program. You may all disconnect. Everyone, have a great day.",24,"Ladies and gentlemen, thank you for participating in today's conference. This does conclude the program. You may all disconnect. Everyone, have a great day."
154924,333332053,986479,"Agilent Technologies, Inc., Q2 2016 Earnings Call, May 16, 2016",2016-05-16,"Earnings Calls","Agilent Technologies, Inc.","Operator","Good day, ladies and gentlemen, and welcome to the Q2 2016 Agilent Technologies Inc. Earnings Conference Call. [Operator Instructions] As a reminder, this call is being recorded. I would now like to turn the conference over to Alicia Rodriguez, Vice Presi",47,"Good day, ladies and gentlemen, and welcome to the Q2 2016 Agilent Technologies Inc. Earnings Conference Call. [Operator Instructions] As a reminder, this call is being recorded. I would now like to turn the conference over to Alicia Rodriguez, Vice President of Investor Relations. Please go ahead."
154924,333332053,986479,"Agilent Technologies, Inc., Q2 2016 Earnings Call, May 16, 2016",2016-05-16,"Earnings Calls","Agilent Technologies, Inc.","Executives","Thank you, Sabrina, and welcome, everyone, to Agilent's Second Quarter Conference Call for Fiscal Year 2016. With me are Mike McMullen, Agilent's President and CEO; and Didier Hirsch, Agilent's Senior Vice President and CFO. Joining in the Q&A after Didie",330,"Thank you, Sabrina, and welcome, everyone, to Agilent's Second Quarter Conference Call for Fiscal Year 2016. With me are Mike McMullen, Agilent's President and CEO; and Didier Hirsch, Agilent's Senior Vice President and CFO. Joining in the Q&A after Didier's comments will be Patrick Kaltenbach, President of Agilent's Life Sciences and Applied Markets Group; Jacob Thaysen, President of Agilent's Diagnostics and Genomics Group; and Mark Doak, President of the Agilent CrossLab Group.
You can find the press release and information to supplement today's discussion on our website at www.investor.agilent.com. While there, please click on the link for financial results under the Financial Information tab. You will find an investor presentation along with revenue breakouts and currency impacts, business segment results and historical financials for Agilent's operations. We will also post a copy of the prepared remarks following this call.
Today's comments by Mike and Didier will refer to non-GAAP financial measures. You will find the most directly comparable GAAP financial metrics and reconciliations on our website. And please note that we will refer to core revenue growth, which excludes the impact of currency, the NMR business and acquisitions and divestitures within the past 12 months. Unless otherwise noted, all references to increases or decreases in financial metrics are year-over-year. Guidance is based on exchange rate as of the last day of the reported quarter.
We will also make forward-looking statements about the financial performance of the company. These statements are subject to risks and uncertainties and are only valid as of today. The company assumes no obligation to update them. Please look at the company's recent SEC filings for a more complete picture of our risks and other factors.
Before turning things over to Mike, I'd like to remind you that Agilent will host its Analyst and Investor Meeting in New York City on May 25. Details about the meeting and webcast are available on the Agilent Investor Relations website. 
And now let me turn the call over to Mike."
154924,333332053,986479,"Agilent Technologies, Inc., Q2 2016 Earnings Call, May 16, 2016",2016-05-16,"Earnings Calls","Agilent Technologies, Inc.","Executives","Thanks, Alicia and hello, everyone. Thank you for joining us on today's call. The Agilent team delivered another strong quarter. Both Q2 revenue and earnings were above the high end of our guidance. Let me highlight 3 key results. First, revenue growth",1569,"Thanks, Alicia and hello, everyone. Thank you for joining us on today's call. The Agilent team delivered another strong quarter. Both Q2 revenue and earnings were above the high end of our guidance. Let me highlight 3 key results. 
First, revenue growth was up more than 8% on a core basis. Second, we delivered adjusted operating margin of 19.4%, an increase of 110 basis points from a year ago. Finally, EPS of $0.44 was up 16% over last year. 
Before moving on to a review of our Q2 results, I do want to address our year-over-year quarterly comparisons, which reflect an unusual event from last year. Of the 8% core growth that we're announcing today, about 1.5 percentage points is due to a shift of revenue last year from Q2 '15 into Q3 '15. 
In the second quarter a year ago, we experienced $50 million of shipment delays due to start-up challenges with our new U.S. logistics center. In addition, our process-improvement efforts over the past few quarters to convert incoming orders more quickly to revenue have paid off. We have reduced our order to revenue cycle times, particularly in China. Consequently, some shipments initially forecast for Q3 of this year were delivered in Q2. 
Agilent's strong Q2 results were led by double-digit core growth in pharma and food markets. We also experienced continued strength in academia and government, environmental and diagnostic and clinical markets. All end markets grew except chemical and energy. Growth was broad based across most of our portfolio. 
Geographically, all regions grew except Japan, led by very strong growth in China. Let me highlight our Q2 results by business group. The Life Sciences and Applied Markets Group delivered core revenue growth of 8%, led by strong demand in the pharma and food markets. About 3 percentage points of the 8% increase was thanks to a softer compare due to the timing issues mentioned earlier from last year's U.S. logistics center startup. 
A combination of strong top line growth, expense management and gross margin improvements, partially due to the NMR exit, drove LSAG's operating margin to 19%, up 320 basis points from a year ago. LSAG continues to strengthen its portfolio. In Q2, Agilent introduced VistaFlux software. This new software speeds up clinical research data analysis, so scientists can more quickly understand the underlying causes of diseases such as cancer. VistaFlux strengthens Agilent's leadership position in metabolomics. Last week, we announced a new Agilent 1216 Infinity II LC at the analytical tradeshow. This instrument provides best-in-class lab efficiency and improves the performance of full backward compatibility. 
Next, the Agilent CrossLab Group continues to deliver consistently strong revenue results. Core revenue growth in Q2 was 10%, led by strength in contract services, LC columns and lab supplies. Expansion and penetration in Asia continued to be strong contributors to our growth. Operating margin was flat versus a year go at 21.5%. 
CrossLab represents a strategic transformation of our services and consumables business. I'm pleased to report that Agilent was recognized with the 2016 Reviewers' Choice Award for Customer Service. This award is from SelectScience, an independent expert-led scientific review. This is the second year in a row that scientists in North America have judged Agilent's customer service to be the best in the laboratory products industry. 
Finally, the Diagnostics and Genomics Group delivered 5% core growth in Q2 against a difficult compare. The pathology business continues on a steady trajectory back to market growth rates, highlighted by strong demand for our new PD-L1 companion and complementary diagnostic tests. Genomics showed strong market performance, led by our SureSelect target enrichment and array CGH offerings. DGG's operating margin was flat versus a year ago at 15%. 
In Q2, Agilent announced an $80 million investment in Lasergen, an emerging biotechnology company with innovative next-gen sequencing technology. Our two companies will collaborate on building an NGS workflow for clinical applications. 
In Q2, Agilent also announced the commercial availability has expanded to the EU for a new PD-L1 diagnostic test for nonsquamous, nonsmall cell lung cancer. This diagnostic was developed through a collaboration with Bristol-Myers Squibb, the maker of OPDIVO. 
Now I'll provide an overview of Agilent's core revenues by end market. Life Sciences and Diagnostics markets saw a continuation of our first quarter performance, with strength across all end markets. Pharma grew 14%, fueled by technology refresh deals, new product uptake and sustained growth in the aftermarket. This is the fifth consecutive quarter of greater than mid- to high double-digit growth in pharma. 
Academia and government grew 7%, driven by strong demand in China and an uptick in the U.S. Clinical and diagnostics also grew 7% with strength in genomics, led by target enrichment and array CGH. Applied end market performance was mixed. Food was up 25% with strong sales in China and the Americas. China also drove 6% worldwide growth in environmental and forensics. Chemical energy declined 3%, reflecting continued macroeconomic concerns and the effects of lower oil prices. Now I'll turn to an update on our operating margin improvement initiative. 
Q2 marks the fifth consecutive quarter of year-over-year operating margin improvement delivered by the new Agilent team. This is a result of our ability to outgrow the market, while driving operational efficiency improvements. Our multiyear Agile Agilent program continues to simplify the company making us more nimble and lowering our cost. Our execution of company-wide streamlining organizations, processes and systems continue to be on track to deliver incremental savings in 2017. 
For example, in Q3, we would take a major step forward in simplifying the company's systems infrastructure with all of our financial systems now on SAP. 
On the capital deployment front, we paid $37 million in dividends, repurchased $94 million of Agilent stock and invested $80 million to enable our NGS workflow strategy. Finally, our One Agilent initiative is driving a well-received cultural transformation to improve cross-company collaboration and delivering of results. At last year's Analyst and Investor Day, I described a shareholder value creation model for Agilent to be driven by outgrowing the market, expanding operating margins and a balanced capital allocation policy. I'd like to take a minute to position the Q2 results in the context of our longer-term goals. 
After delivering our highest annual core revenue growth since 2011 of 6.4% in 2015, we've now had 2 strong quarters to start 2016, including this quarter's 8% core revenue growth. Since the new Agilent team -- leadership team was put in place, the team has delivered year-over-year operating margin improvements every quarter. We have completely offset the initial $40 million into synergies from the company split. 
In fiscal 2015, we returned $400 million to shareholders and $370 million year-to-date in 2016 through cash dividends and share repurchase. From 2015 onto now, we've also invested our $400 million in new business via M&A and equity investments. Didier will share more specifics later, but we are raising our full year 2016 outlook for core growth, operating margin, EPS and cash flow. Let me now talk about our second half  '16 forecast in light of what we have already achieved in 2016 and what we plan to deliver in 2017. 
When we look at today's overall market environment, while we face increasingly tough compares, we expect strength in pharma to continue in the second half 2016 and into 2017. China is also expected to remain strong in second half 2016 and 2017. Taking a closer look at the chemical and energy market, we have been experiencing a more prolonged and steeper slowdown than initially anticipated. We are now forecasting overall low single-digit market declines for the year versus our initial flat guidance assumptions. The oil exploration segment of this market has been down significantly for some time, with a recent well-reported spillover into the refining segment. There are initial indications, however, of a bottoming with increased deal activity in the large chemical segment of the market. 
We have projected an improved chemical energy market environment in 2017. We are assuming we will continue to face headwinds in this market for the remainder of 2016. We are currently modeling 2017 with an above-market core revenue growth of 4.5% of the midpoint. This is in line with our projected full year 2016 core growth rates, but higher than our expected core growth rate in the second half of 2016. There are 2 reasons for this increase. 
First, we expect to have a very strong new product introductions in the second half of FY '16, which will drive revenue growth in FY '17. Second, on the end market front, we expect chemical energy to have bottomed out by year-end accompanied by continuing solid conditions in all of our other end markets and in China. 
Overall, we remain on track with our 2017 goal to outgrow the market and improve our operating margins at 22%. Looking inside the company, I can share with you today that the One Agilent team is working well together and is driven to win in the marketplace. I look forward to seeing many of you at our Analyst and Investor Day, where I'll share our progress versus our commitments, how we will sustain or improve performance and the longer-term outlook for the company. Thank you for being on the call today. I will now turn it over to Didier, who will provide additional insights on our financial results and guidance for the third quarter and full year 2016. Didier?"
154924,333332053,986479,"Agilent Technologies, Inc., Q2 2016 Earnings Call, May 16, 2016",2016-05-16,"Earnings Calls","Agilent Technologies, Inc.","Executives","Thank you, Mike, and hello, everyone. As Mike stated, we delivered a strong performance this quarter again, 8% core revenue growth, 110 basis points of operating margin expansion and $256 million in operating cash flow. After adjusting for last year's $15",319,"Thank you, Mike, and hello, everyone. As Mike stated, we delivered a strong performance this quarter again, 8% core revenue growth, 110 basis points of operating margin expansion and $256 million in operating cash flow. After adjusting for last year's $15 million slippage in revenue from Q2 to Q3 as we launch our new U.S. logistics center, our core revenue growth of 6.5% remained well above market.
During the quarter, we brought back $94 million of stock and paid $37 million in dividends. Finally, on May 3, we successfully moved all finance applications from Oracle to SAP, which is our main ERP. This will result in significant simplifications of our finance and IT operations. I'll now turn to the guidance for our third quarter. 
We expect Q3 revenues of $1.03 billion to $1.05 billion and EPS of $0.45 to $0.47. At midpoint, revenue will grow 1.3% on a core basis or close to 3% adjusting for last year's $50 million impact from the U.S. logistics center. And turning to share repurchase, we expect to buy back $93 million this Q3. Now to the guidance of fiscal year 2016.
We are raising the midpoint of our revenue guidance by $60 million, including $50 million due to currency. As a result, we're increasing our core revenue growth guidance at midpoint from 4.25% to 4.50%. We're also raising the midpoint of our EPS guidance by $0.06, including $0.03 coming from currency and $0.03 from operational performance. 
And one important note. After further review, we and our auditors have concluded to account for the Lasergen investment using the cost method of accounting. This means that we'll not book our share of Lasergen losses as previously communicated. 
Finally, we are raising our operating cash flow guidance from $650 million to $740 million, and there's no change to our CapEx guidance of $140 million. 
With that, I'll turn it over to Alicia for the Q&A."
154924,333332053,986479,"Agilent Technologies, Inc., Q2 2016 Earnings Call, May 16, 2016",2016-05-16,"Earnings Calls","Agilent Technologies, Inc.","Executives","Thank you, Didier. And Sabrina, will you please give the instructions for the Q&A?",14,"Thank you, Didier. And Sabrina, will you please give the instructions for the Q&A?"
154924,333332053,986479,"Agilent Technologies, Inc., Q2 2016 Earnings Call, May 16, 2016",2016-05-16,"Earnings Calls","Agilent Technologies, Inc.","Operator","[Operator Instructions] And our first question comes from the line of Dan Leonard of Leerink Partners.",16,"[Operator Instructions] And our first question comes from the line of Dan Leonard of Leerink Partners."
154924,333332053,986479,"Agilent Technologies, Inc., Q2 2016 Earnings Call, May 16, 2016",2016-05-16,"Earnings Calls","Agilent Technologies, Inc.","Analysts","Two questions. First off, can you elaborate on the business trends you're seeing in Europe? And then, secondly, on the pharma end market, can you talk about what gives you confidence in the fiscal 2017 outlook that you'd have yet another strong year in ph",62,"Two questions. First off, can you elaborate on the business trends you're seeing in Europe? And then, secondly, on the pharma end market, can you talk about what gives you confidence in the fiscal 2017 outlook that you'd have yet another strong year in pharma following 2 years then of tough comps in capital markets, which have been more or less shut?"
154924,333332053,986479,"Agilent Technologies, Inc., Q2 2016 Earnings Call, May 16, 2016",2016-05-16,"Earnings Calls","Agilent Technologies, Inc.","Executives","Thanks, Dan. I think I'm actually going to pass that over to Patrick, who is just back from a trip to Europe and maybe can provide some insight in what's going on Europe and then also, if he can pick up the question on pharma as well.",47,"Thanks, Dan. I think I'm actually going to pass that over to Patrick, who is just back from a trip to Europe and maybe can provide some insight in what's going on Europe and then also, if he can pick up the question on pharma as well."
154924,333332053,986479,"Agilent Technologies, Inc., Q2 2016 Earnings Call, May 16, 2016",2016-05-16,"Earnings Calls","Agilent Technologies, Inc.","Executives","Sure, I'm happy to do so. So let me start first to giving you some insights on Europe. We have seen actually some decent growth in Central Europe. We had seen some weakness on what we call the  [indiscernible] states and Eastern Europe and that's mainly d",246,"Sure, I'm happy to do so. So let me start first to giving you some insights on Europe. We have seen actually some decent growth in Central Europe. We had seen some weakness on what we call the  [indiscernible] states and Eastern Europe and that's mainly driven by the chemical and energy market or the energy market on that side. In Central Europe, there's generally strength in Germany and other states around it. We still see some issues on the academia and government side that is rather flat. But pharma, for example, is also very strong Europe. For your pharma question, overall, we are confident that we will continue to see pretty high growth in pharma for the remainder of this year. We target low double-digit growth for pharma. And looking into 2017, we think the pharma market will be -- continue to be strong for us, driven by 2 vectors. We see a continued demand in the replacement business. And as you probably know, we just launched at the [indiscernible] conference. We launched our new 1260 Infinity LC as an example, together with the lab consumables and servicing. And we think that will drive -- continue to drive a lot of good replacement for us in pharma. And then, we see also continued demand in the biopharma space that are looking for new solutions helping what is more complex molecules in terms of analysis, and we have a very comprehensive operating forensic space as well."
154924,333332053,986479,"Agilent Technologies, Inc., Q2 2016 Earnings Call, May 16, 2016",2016-05-16,"Earnings Calls","Agilent Technologies, Inc.","Operator","And our next question comes from the line of Jonathan Groberg of UBS.",13,"And our next question comes from the line of Jonathan Groberg of UBS."
154924,333332053,986479,"Agilent Technologies, Inc., Q2 2016 Earnings Call, May 16, 2016",2016-05-16,"Earnings Calls","Agilent Technologies, Inc.","Analysts","Can you maybe just elaborate a little bit on -- I think you said core guidance. If I'm looking at your presentation, core revenue growth guidance in the third quarter is pretty precise at 1.3%. But then I think I just heard that you still expect pharma to",71,"Can you maybe just elaborate a little bit on -- I think you said core guidance. If I'm looking at your presentation, core revenue growth guidance in the third quarter is pretty precise at 1.3%. But then I think I just heard that you still expect pharma to grow low double digits. Can you maybe just give a little kind of insight as to what you're seeing in the third quarter?"
154924,333332053,986479,"Agilent Technologies, Inc., Q2 2016 Earnings Call, May 16, 2016",2016-05-16,"Earnings Calls","Agilent Technologies, Inc.","Executives","Yes. What we looked at was with our growth rate that we've had over the first half of this year and as we looked into Q3 and Q4, and what I point to is a couple of things, Jonathan. First of all, tough compares and this is inclusive of a few onetime moves",313,"Yes. What we looked at was with our growth rate that we've had over the first half of this year and as we looked into Q3 and Q4, and what I point to is a couple of things, Jonathan. First of all, tough compares and this is inclusive of a few onetime moves between quarters, which actually were driven by improvements of raw operations. So as Didier mentioned, we had this $50 million shift in Q2 of last year into Q3, which when we had our start-up issues with our new logistics center. So if you adjust for that, it gets you at about 3% growth. The other thing we saw happen in Q2 was we've been working really hard to improve the overall cycle time from the time a customer places order to actually it's installed and we can recognize a revenue. In Q2, we actually exceeded our expectations and we got there a lot faster, we had thought, and what that meant was we had significant amount of revenue, probably $20 million to $25 million that came from Q3 into Q2 where initially we'd forecasted into the second -- third quarter. All in all, if you kind of take into account those things, you've got putting more of a consistent kind of a growth scenario between Q2 and Q3. 
I would tell you, though, the chemical energy is still looking for a bottom. And that's why we have that outlook for the year, which basically is down -- it's going to stay down for the rest of the year. There are some signs that it could be getting better. But we have -- we're not convinced yet we've seen the bottom in chemical energy. So I think the combination of those tough compares as well as our outlook and chemical energy is what's driving the overall guidance for the second half."
154924,333332053,986479,"Agilent Technologies, Inc., Q2 2016 Earnings Call, May 16, 2016",2016-05-16,"Earnings Calls","Agilent Technologies, Inc.","Analysts","Okay, that's helpful. And then, I guess, just one more. Are there any -- sometimes when we see shifts onto one platform like Oracle to SAP, is there anything at all any kind of wiggle room you left there in terms of hiccups in the quarter or maybe...",48,"Okay, that's helpful. And then, I guess, just one more. Are there any -- sometimes when we see shifts onto one platform like Oracle to SAP, is there anything at all any kind of wiggle room you left there in terms of hiccups in the quarter or maybe..."
154924,333332053,986479,"Agilent Technologies, Inc., Q2 2016 Earnings Call, May 16, 2016",2016-05-16,"Earnings Calls","Agilent Technologies, Inc.","Executives","Yes, what we try to do, you're exactly right, Jonathan. So the wiggle room we left was, we made sure we went live the first month of the quarter. And Didier is in the conference room here smiling. And Didier, I don't know if you want to add any additional",57,"Yes, what we try to do, you're exactly right, Jonathan. So the wiggle room we left was, we made sure we went live the first month of the quarter. And Didier is in the conference room here smiling. And Didier, I don't know if you want to add any additional color on how it's going so far?"
154924,333332053,986479,"Agilent Technologies, Inc., Q2 2016 Earnings Call, May 16, 2016",2016-05-16,"Earnings Calls","Agilent Technologies, Inc.","Executives","Yes, it's going very well, the migrations and the start-up of the operations. There were 0 disruption. Obviously, we expect to have to deal with some stabilization activities throughout the quarter. We'll do 2 close before we do the quarterly close. So ev",95,"Yes, it's going very well, the migrations and the start-up of the operations. There were 0 disruption. Obviously, we expect to have to deal with some stabilization activities throughout the quarter. We'll do 2 close before we do the quarterly close. So everything is -- we couldn't be happier about how it went. And you're correct. It is a very complex endeavor, one that we are pretty used to. We've done a few of those in the past. But still, it remains a very complex endeavor and we are really happy how smoothly it went."
154924,333332053,986479,"Agilent Technologies, Inc., Q2 2016 Earnings Call, May 16, 2016",2016-05-16,"Earnings Calls","Agilent Technologies, Inc.","Executives","And Jonathan, as I pointed out in my script, this is one of the Agile Agilent initiatives, which you'll start to see pay off in our cost structure, as we move into '17.",33,"And Jonathan, as I pointed out in my script, this is one of the Agile Agilent initiatives, which you'll start to see pay off in our cost structure, as we move into '17."
154924,333332053,986479,"Agilent Technologies, Inc., Q2 2016 Earnings Call, May 16, 2016",2016-05-16,"Earnings Calls","Agilent Technologies, Inc.","Operator","And our next question comes from the line of Tycho Peterson of JPMorgan.",13,"And our next question comes from the line of Tycho Peterson of JPMorgan."
154924,333332053,986479,"Agilent Technologies, Inc., Q2 2016 Earnings Call, May 16, 2016",2016-05-16,"Earnings Calls","Agilent Technologies, Inc.","Analysts","Just following up on that last point on the SAP margins, can you maybe -- or the market impact. Can you maybe quantify how much that could play on margins for this year?",33,"Just following up on that last point on the SAP margins, can you maybe -- or the market impact. Can you maybe quantify how much that could play on margins for this year?"
154924,333332053,986479,"Agilent Technologies, Inc., Q2 2016 Earnings Call, May 16, 2016",2016-05-16,"Earnings Calls","Agilent Technologies, Inc.","Executives","For 2016, I think it'll be very limited at best, Tycho, because we'll be running some duplicate backup systems and then the other aspects of our external [indiscernible] don't come out until '17. So I'd really position that in -- I actually think about th",70,"For 2016, I think it'll be very limited at best, Tycho, because we'll be running some duplicate backup systems and then the other aspects of our external [indiscernible] don't come out until '17. So I'd really position that in -- I actually think about this more of a '17 impact, but a proof point of why we think we're going to be able to improve our margins again in '17."
154924,333332053,986479,"Agilent Technologies, Inc., Q2 2016 Earnings Call, May 16, 2016",2016-05-16,"Earnings Calls","Agilent Technologies, Inc.","Analysts","And then academic 7%, can you maybe just talk as to whether you're seeing an acceleration there, in terms of what you saw this quarter?",26,"And then academic 7%, can you maybe just talk as to whether you're seeing an acceleration there, in terms of what you saw this quarter?"
154924,333332053,986479,"Agilent Technologies, Inc., Q2 2016 Earnings Call, May 16, 2016",2016-05-16,"Earnings Calls","Agilent Technologies, Inc.","Executives","Yes, what we saw in the last quarter is a really strong performance in China and some increased signs of life in the U.S. side of things. I think that's what we point to an uptick. Not a lot of significant moves on the European side. It's mainly a China-G",73,"Yes, what we saw in the last quarter is a really strong performance in China and some increased signs of life in the U.S. side of things. I think that's what we point to an uptick. Not a lot of significant moves on the European side. It's mainly a China-German story, and I think if there will be upside to it, it would come from the U.S. That's how we're thinking about it."
154924,333332053,986479,"Agilent Technologies, Inc., Q2 2016 Earnings Call, May 16, 2016",2016-05-16,"Earnings Calls","Agilent Technologies, Inc.","Analysts","Okay. And then, lastly, just in terms of pharma, obviously, that's been a nice driver. Can you maybe talk about where you think we are in the LCMS upgrade cycle? And how much your growth going forward is going to be contingent on already budget expanded v",50,"Okay. And then, lastly, just in terms of pharma, obviously, that's been a nice driver. Can you maybe talk about where you think we are in the LCMS upgrade cycle? And how much your growth going forward is going to be contingent on already budget expanded versus the upgrade cycle?"
154924,333332053,986479,"Agilent Technologies, Inc., Q2 2016 Earnings Call, May 16, 2016",2016-05-16,"Earnings Calls","Agilent Technologies, Inc.","Executives","Yes, sure, Tycho, great question. I know, Patrick, I know you look at this pretty closely and what's the updated view on that?",23,"Yes, sure, Tycho, great question. I know, Patrick, I know you look at this pretty closely and what's the updated view on that?"
154924,333332053,986479,"Agilent Technologies, Inc., Q2 2016 Earnings Call, May 16, 2016",2016-05-16,"Earnings Calls","Agilent Technologies, Inc.","Executives","Yes, so I think there are 2 cycles we're looking at. The first cycle we went through was general upgrade cycle from standard HPLC to UHPLC, which is still ongoing but a considerable part of that probably has been done. But when you look at the installed b",163,"Yes, so I think there are 2 cycles we're looking at. The first cycle we went through was general upgrade cycle from standard HPLC to UHPLC, which is still ongoing but a considerable part of that probably has been done. But when you look at the installed base of instrumentation, it still deals with core LC and this is where we are targeting with the Infinity II series right now. There's still a lot of replacement pending out there. Just as a reminder, we have probably about 150,000 systems out there based on the 1100, 1200 platform, which over time will be up for replacement. And we are positioned extremely well with our platforms because it's 100% backwards compatible and we're also able, for example, to emulate some of our competitor's systems on our platform of a technology we call ISET, intelligence system emulation technology. And that actually compares very nicely with our customers and gives us a unique advantage in the market."
154924,333332053,986479,"Agilent Technologies, Inc., Q2 2016 Earnings Call, May 16, 2016",2016-05-16,"Earnings Calls","Agilent Technologies, Inc.","Executives","So I think we see both of those having legs into -- through  '17.",14,"So I think we see both of those having legs into -- through  '17."
154924,333332053,986479,"Agilent Technologies, Inc., Q2 2016 Earnings Call, May 16, 2016",2016-05-16,"Earnings Calls","Agilent Technologies, Inc.","Executives","Absolutely. I think this goes on into '17, combined again with the [indiscernible] coming out of biopharma.",17,"Absolutely. I think this goes on into '17, combined again with the [indiscernible] coming out of biopharma."
154924,333332053,986479,"Agilent Technologies, Inc., Q2 2016 Earnings Call, May 16, 2016",2016-05-16,"Earnings Calls","Agilent Technologies, Inc.","Operator","And our next question comes from the line of Jack Meehan of Barclays.",13,"And our next question comes from the line of Jack Meehan of Barclays."
154924,333332053,986479,"Agilent Technologies, Inc., Q2 2016 Earnings Call, May 16, 2016",2016-05-16,"Earnings Calls","Agilent Technologies, Inc.","Analysts","I just wanted to start the better -- at least relative to what I was looking for. Looked like you had better gross margins in the LSAG segment now 2 quarters in a row. Can you just talk about what some of the notable changes there are? Is there anything w",69,"I just wanted to start the better -- at least relative to what I was looking for. Looked like you had better gross margins in the LSAG segment now 2 quarters in a row. Can you just talk about what some of the notable changes there are? Is there anything with product mix that's driven the improvement? Or do you think this is the new norm to look for?"
154924,333332053,986479,"Agilent Technologies, Inc., Q2 2016 Earnings Call, May 16, 2016",2016-05-16,"Earnings Calls","Agilent Technologies, Inc.","Executives","I think -- let me make some initial comments and then Didier or Patrick, maybe you can build to it. So in terms of product mix, part of what you're seeing is the fact that we are winding down through our P&L the impact of the NMR business. And I think you",165,"I think -- let me make some initial comments and then Didier or Patrick, maybe you can build to it. So in terms of product mix, part of what you're seeing is the fact that we are winding down through our P&L the impact of the NMR business. And I think you can see the benefit of that exit decision on the P&L because it really has been contributing to the improved gross margins. [indiscernible] up the whole story. The other story is, obviously, the strong demand for the products and the volume benefits we're getting as well as the focus on taking cost out of our material cost side of the business as well as we talked a lot about the logistics last year. We could also talk about logistics this year, which is, we're doing a much better job in terms of overall logistics operations that's blowing through on the P&L as well. So Didier, I'm not sure if I missed anything else."
154924,333332053,986479,"Agilent Technologies, Inc., Q2 2016 Earnings Call, May 16, 2016",2016-05-16,"Earnings Calls","Agilent Technologies, Inc.","Executives","No, you covered it all.",5,"No, you covered it all."
154924,333332053,986479,"Agilent Technologies, Inc., Q2 2016 Earnings Call, May 16, 2016",2016-05-16,"Earnings Calls","Agilent Technologies, Inc.","Analysts","Great. And then just one more for the adoption of the companion diagnostics now a few quarters into the launch. Are you in a position -- could you maybe just help us size what that business is today or just in the market what you think you hold in terms o",53,"Great. And then just one more for the adoption of the companion diagnostics now a few quarters into the launch. Are you in a position -- could you maybe just help us size what that business is today or just in the market what you think you hold in terms of market share?"
154924,333332053,986479,"Agilent Technologies, Inc., Q2 2016 Earnings Call, May 16, 2016",2016-05-16,"Earnings Calls","Agilent Technologies, Inc.","Executives","Why don't you take that, Jacob?",7,"Why don't you take that, Jacob?"
154924,333332053,986479,"Agilent Technologies, Inc., Q2 2016 Earnings Call, May 16, 2016",2016-05-16,"Earnings Calls","Agilent Technologies, Inc.","Executives","Yes, thanks for that question. And we are definitely pleased with the pickup of the PD-L1, and this continues during the last, basically, it's now 3 quarters. The market is still very early. We still really only, in U.S, we have had a few press releases h",160,"Yes, thanks for that question. And we are definitely pleased with the pickup of the PD-L1, and this continues during the last, basically, it's now 3 quarters. The market is still very early. We still really only, in U.S, we have had a few press releases here lately. Also that we're entering into Europe, but we're just scratching the surface in Europe. And furthermore, it's still a second line -- it's still addressing the second line treatment. And if that also goes to the first-line treatment, the market will become significantly larger. At this point in time, it's still small revenue in the biggest scheme of things. But I do believe that the PD-L1 has an opportunity to be as big as of the HER 2 market. However, we'll also remind you that of at least 4, probably 5 different potential box and companion diagnostics out there has to share that market. So still early days, but a great opportunity."
154924,333332053,986479,"Agilent Technologies, Inc., Q2 2016 Earnings Call, May 16, 2016",2016-05-16,"Earnings Calls","Agilent Technologies, Inc.","Operator","And our next question comes from the line of Brandon Couillard of Jefferies.",13,"And our next question comes from the line of Brandon Couillard of Jefferies."
154924,333332053,986479,"Agilent Technologies, Inc., Q2 2016 Earnings Call, May 16, 2016",2016-05-16,"Earnings Calls","Agilent Technologies, Inc.","Analysts","Mike, could you give us -- or Didier, could you give us the China growth rate -- the percentage change in the quarter? And if you could speak to demand in the food area outside of China and Asia, that will be helpful.",43,"Mike, could you give us -- or Didier, could you give us the China growth rate -- the percentage change in the quarter? And if you could speak to demand in the food area outside of China and Asia, that will be helpful."
154924,333332053,986479,"Agilent Technologies, Inc., Q2 2016 Earnings Call, May 16, 2016",2016-05-16,"Earnings Calls","Agilent Technologies, Inc.","Executives","Yes. So in the China result for Q2, what we've been pointing to is strong double-digit growth. So it was a very, very strong quarter for us in China. I would remind you that part of the strong growth was not only the strength in the market, but that those",145,"Yes. So in the China result for Q2, what we've been pointing to is strong double-digit growth. So it was a very, very strong quarter for us in China. I would remind you that part of the strong growth was not only the strength in the market, but that those operational efficiency improvement I talked about where we really had shortened the improved cycle time from orders to install that was really dramatic in China. So we overall were basically quite strong for the year. You should not expect those strong double-digit growth every quarter though for Q3 and Q4. But overall, China is -- just to complete the story here. When we came into this year, we thought that the overall performance for Agilent in China might be high single digits. We're now looking at low double-digit growth in China for the full year."
154924,333332053,986479,"Agilent Technologies, Inc., Q2 2016 Earnings Call, May 16, 2016",2016-05-16,"Earnings Calls","Agilent Technologies, Inc.","Analysts","And then one more for Didier. I noticed you bumped the operating cash flow guidance of about $90 million. How much of an impact does the -- I noticed a tax refund benefit. If you could quantify that and then just help us bridge the delta between prior ver",50,"And then one more for Didier. I noticed you bumped the operating cash flow guidance of about $90 million. How much of an impact does the -- I noticed a tax refund benefit. If you could quantify that and then just help us bridge the delta between prior versus new."
154924,333332053,986479,"Agilent Technologies, Inc., Q2 2016 Earnings Call, May 16, 2016",2016-05-16,"Earnings Calls","Agilent Technologies, Inc.","Executives","There was the overall tax outlays forecasted for this year were, I think, about $10 million less than what we had initially -- anticipated in our initial guidance $10 million or $15 million, and the rest is really operational performance improvements in o",54,"There was the overall tax outlays forecasted for this year were, I think, about $10 million less than what we had initially -- anticipated in our initial guidance $10 million or $15 million, and the rest is really operational performance improvements in our working capital management and FX and then just our operating profits."
154924,333332053,986479,"Agilent Technologies, Inc., Q2 2016 Earnings Call, May 16, 2016",2016-05-16,"Earnings Calls","Agilent Technologies, Inc.","Operator","And our next question comes from the line of Ross Muken of Evercore.",13,"And our next question comes from the line of Ross Muken of Evercore."
154924,333332053,986479,"Agilent Technologies, Inc., Q2 2016 Earnings Call, May 16, 2016",2016-05-16,"Earnings Calls","Agilent Technologies, Inc.","Analysts","So Mike, since taking over, it's obviously been a pretty hectic journey and your messaging from the beginning has been pretty consistent around growth in margins and returns. Obviously, last few quarters, you started to develop a cadence. Last quarter res",133,"So Mike, since taking over, it's obviously been a pretty hectic journey and your messaging from the beginning has been pretty consistent around growth in margins and returns. Obviously, last few quarters, you started to develop a cadence. Last quarter results were good when we had the challenges on FX. Do you feel like this is the first quarter where you feel like you got to deliver the full bag, where you're able to sort of drop through the top line outperformance, which is clearly better than market? You drove the margins. You're buying stock. The returns are up. The cash flow is good. That you're finally able to sort of show the market that the business model's working and that feeds, I guess, into your confidence also, I would assume on '17?"
154924,333332053,986479,"Agilent Technologies, Inc., Q2 2016 Earnings Call, May 16, 2016",2016-05-16,"Earnings Calls","Agilent Technologies, Inc.","Executives","Yes, I couldn't have said it better myself. Thanks, Ross, for the question. I think that we've been working really hard the last 4 or 5 quarters with the new leadership team. And as you look at -- everything came together this quarter. I mean, we've had s",278,"Yes, I couldn't have said it better myself. Thanks, Ross, for the question. I think that we've been working really hard the last 4 or 5 quarters with the new leadership team. And as you look at -- everything came together this quarter. I mean, we've had strong growth. We've had improvement in our operating margin, as I pointed out in '15. But all the vectors really came together nicely in the second quarter. And I was particularly pleased on some of the more operational activities that have been working on inside the company. And that may not always be so apparent initially on the outside world, but you start to see in the results. And the fact that we're doing -- we've adjusted our logistic challenges. We don't have to talk about on year-over-year compares, but it's fixed and actually now is contributing to improved results. Yes, we had a talk about the shortened cycle time for orders to revenue and bought in some revenues that we initially had planned for the third quarter, but we made those operation improvements. The cycle times are shorter, and this is now the new normal. So I guess, that will be the closing comments, which -- yes, we're the new normal for the company. We have got a lot of confidence about 2017, perhaps steal a little bit of my thunder for the Analyst Meeting next week, but I still hope everyone attends. But when you start having these proof points quarter in and quarter out, I think it starts to show you the team is delivering. And I think the results are now starting to be appreciated and believed."
154924,333332053,986479,"Agilent Technologies, Inc., Q2 2016 Earnings Call, May 16, 2016",2016-05-16,"Earnings Calls","Agilent Technologies, Inc.","Analysts","Great. And maybe quickly just on Seahorse. Can you just give us an update on how that business is performing relative to your expectations and how it's plugged in and where you're sort of seeing maybe the early fruits and some cross-synergy with the exist",46,"Great. And maybe quickly just on Seahorse. Can you just give us an update on how that business is performing relative to your expectations and how it's plugged in and where you're sort of seeing maybe the early fruits and some cross-synergy with the existing business?"
154924,333332053,986479,"Agilent Technologies, Inc., Q2 2016 Earnings Call, May 16, 2016",2016-05-16,"Earnings Calls","Agilent Technologies, Inc.","Executives","Yes, which is in fact, a very timely question, Ross. We just had our 180-day review this morning. And Patrick, why don't you go ahead and share a couple of highlights from that session?",34,"Yes, which is in fact, a very timely question, Ross. We just had our 180-day review this morning. And Patrick, why don't you go ahead and share a couple of highlights from that session?"
154924,333332053,986479,"Agilent Technologies, Inc., Q2 2016 Earnings Call, May 16, 2016",2016-05-16,"Earnings Calls","Agilent Technologies, Inc.","Executives","Sure, absolutely. So - what I really would like to highlight is how seamlessly we did the integration of Seahorse wins. So we are now 6 months in the integration. And we would say we're targeting full integration by June, which means that we have implemen",156,"Sure, absolutely. So - what I really would like to highlight is how seamlessly we did the integration of Seahorse wins. So we are now 6 months in the integration. And we would say we're targeting full integration by June, which means that we have implemented all of the systems, which is a very fast pace. At the same time, we are seeing the positioning of Seahorse within our portfolio really works out. We're seeing nice deals and combined sales of LC-MS and seahorse in areas like disease research and disease discovery. That's actually exactly where we thought its complementing our strength in metabolomics with the life cell metabolism, which Seahorse brings to the table. And this is a very nice story that resonates very well with our customers. We are -- again, on the integration side, we are very pleased with where we stand and we are looking forward to some very successful second half."
154924,333332053,986479,"Agilent Technologies, Inc., Q2 2016 Earnings Call, May 16, 2016",2016-05-16,"Earnings Calls","Agilent Technologies, Inc.","Executives","Yes, Ross, I'll just add 2 things. The common major theme this morning is this is the fastest I've seen us do an integration. These things usually plot along for many quarters and in some cases, for years. This one is moving along really, really fast. And",75,"Yes, Ross, I'll just add 2 things. The common major theme this morning is this is the fastest I've seen us do an integration. These things usually plot along for many quarters and in some cases, for years. This one is moving along really, really fast. And we're getting some wins. In fact, we won an LC/MS deal because of Seahorse. So I mean, it's the complementary nature of the portfolios is starting to work."
154924,333332053,986479,"Agilent Technologies, Inc., Q2 2016 Earnings Call, May 16, 2016",2016-05-16,"Earnings Calls","Agilent Technologies, Inc.","Operator","And our next question comes from the line of Paul Knight of Janney Montgomery Scott.",15,"And our next question comes from the line of Paul Knight of Janney Montgomery Scott."
154924,333332053,986479,"Agilent Technologies, Inc., Q2 2016 Earnings Call, May 16, 2016",2016-05-16,"Earnings Calls","Agilent Technologies, Inc.","Analysts","The move you made to create CrossLab seems to be gaining traction. Can you give us a little background on CrossLab in terms of, who do you think is taking share from somebody at that kind of growth rate? Could you give us more color on CrossLab?",47,"The move you made to create CrossLab seems to be gaining traction. Can you give us a little background on CrossLab in terms of, who do you think is taking share from somebody at that kind of growth rate? Could you give us more color on CrossLab?"
154924,333332053,986479,"Agilent Technologies, Inc., Q2 2016 Earnings Call, May 16, 2016",2016-05-16,"Earnings Calls","Agilent Technologies, Inc.","Executives","Yes. So as you mentioned, that was a major strategic move where when we set up the company, we established Agilent CrossLab Group. We had this vision about how we could really attack and go after the enterprise-wide services and consumables opportunity. A",234,"Yes. So as you mentioned, that was a major strategic move where when we set up the company, we established Agilent CrossLab Group. We had this vision about how we could really attack and go after the enterprise-wide services and consumables opportunity. And as you see, Mark and the team have really been delivering. And we know that the customers are responding to the value proposition that Agilent offers, both in terms of how our service capability is viewed. And that's why I mentioned in my script about the external recognition we recently received. But they also appreciate the fact we're able to give them insights in terms of actually helping them improve the business operations, and we're seeing a real strong demand for this in the pharma and growing interest in other parts of the applied market. So we know that we're growing faster than some of our competitors in this space. We also know that there's only a few companies really trying to go after this type of business. I believe this is where the market is already going to and I think you want to be a player here. And I leave it to you guys to figure out who's the losing share. But as you can see, all I can tell you is we're growing close to double digit in the space. So it's been an attractive move for us."
154924,333332053,986479,"Agilent Technologies, Inc., Q2 2016 Earnings Call, May 16, 2016",2016-05-16,"Earnings Calls","Agilent Technologies, Inc.","Operator","And our next question comes from the line of Tim Evans of Wells Fargo Securities.",15,"And our next question comes from the line of Tim Evans of Wells Fargo Securities."
154924,333332053,986479,"Agilent Technologies, Inc., Q2 2016 Earnings Call, May 16, 2016",2016-05-16,"Earnings Calls","Agilent Technologies, Inc.","Analysts","I'm just trying to understand the variance in the quarter relative to what you are expecting. I believe you had called last quarter for 4% core growth, and we saw 8% this quarter. I hear you that it sounds like about half of that variance, about 200 basis",102,"I'm just trying to understand the variance in the quarter relative to what you are expecting. I believe you had called last quarter for 4% core growth, and we saw 8% this quarter. I hear you that it sounds like about half of that variance, about 200 basis points, was from the better book backlog to revenue conversion in this quarter. And I know you also called out the compare relative to last year. But that compare should have already been known. So I just want to understand what's the other 200 basis points that really surprised you in the quarter?"
154924,333332053,986479,"Agilent Technologies, Inc., Q2 2016 Earnings Call, May 16, 2016",2016-05-16,"Earnings Calls","Agilent Technologies, Inc.","Executives","Sure, Tim, how about if I -- again, thanks for your comment. And I can give you a few dollar numbers of revenue impact the way we've been looking at it and you can do them -- perhaps the math on the impact on the growth rates. But what we saw relative to",257,"Sure, Tim, how about if I -- again, thanks for your comment. And I can give you a few dollar numbers of revenue impact the way we've been looking at it and you can do them -- perhaps the math on the impact on the growth rates. But what we saw relative to our initial expectations for the quarter were really, first of all, it starts with the market, right? So the overall market demand came in as we predicted. We saw good growth across entire portfolio led by pharma and food markets in China, as you heard early. But I'd ask you to look at 2 things. One is this higher conversion of orders to revenue than forecast. So basically, what we've done is we reduced the cycle time and by our estimates, it happened a lot faster than we had thought, which I think is good news from the standpoint of operational efficiency did create some forecasting challenges, but probably $20 million to $25 million came from Q3 into Q2. The other thing, I think, you should take a look at is the FX assumptions. So around $9 million or so, Didier, I think was the number. So FX added about another $9 million. So between the cycle time improvements, the FX assumptions and just the fact that the market continues, we're getting our fair share of markets where they're growing. I think those -- combination of those facts, I think, will help you bridge the difference between our guided growth and what actually occurred."
154924,333332053,986479,"Agilent Technologies, Inc., Q2 2016 Earnings Call, May 16, 2016",2016-05-16,"Earnings Calls","Agilent Technologies, Inc.","Analysts","Okay. Just a real quick similar question on the margin side. Obviously, a little bit of the margin in the quarter was the drop through, but it looks like you probably did better than you're expecting on an absolute dollar basis on the SG&A as well. Can yo",62,"Okay. Just a real quick similar question on the margin side. Obviously, a little bit of the margin in the quarter was the drop through, but it looks like you probably did better than you're expecting on an absolute dollar basis on the SG&A as well. Can you help me understand, maybe, what is going a little faster there than you anticipated?"
154924,333332053,986479,"Agilent Technologies, Inc., Q2 2016 Earnings Call, May 16, 2016",2016-05-16,"Earnings Calls","Agilent Technologies, Inc.","Executives","Yes, I think on the SG&A front, I mean, we've got a couple of our programs inside the Agile Agilent are little bit ahead of plan. And --but Didier, I don't know if there's anything else of...",37,"Yes, I think on the SG&A front, I mean, we've got a couple of our programs inside the Agile Agilent are little bit ahead of plan. And --but Didier, I don't know if there's anything else of..."
154924,333332053,986479,"Agilent Technologies, Inc., Q2 2016 Earnings Call, May 16, 2016",2016-05-16,"Earnings Calls","Agilent Technologies, Inc.","Executives","Most of the impact was volume driven and obviously, the FX, but there was -- versus the initial guidance.",19,"Most of the impact was volume driven and obviously, the FX, but there was -- versus the initial guidance."
154924,333332053,986479,"Agilent Technologies, Inc., Q2 2016 Earnings Call, May 16, 2016",2016-05-16,"Earnings Calls","Agilent Technologies, Inc.","Executives","I will tell you the field structure that we put in place last year, it's really stabled down. I think it's delivering, helping us on the growth side and also, on the SG&A front as a more efficient go-to-market channel.",40,"I will tell you the field structure that we put in place last year, it's really stabled down. I think it's delivering, helping us on the growth side and also, on the SG&A front as a more efficient go-to-market channel."
154924,333332053,986479,"Agilent Technologies, Inc., Q2 2016 Earnings Call, May 16, 2016",2016-05-16,"Earnings Calls","Agilent Technologies, Inc.","Operator","And our next question comes from the line of Isaac Ro of Goldman Sachs.",14,"And our next question comes from the line of Isaac Ro of Goldman Sachs."
154924,333332053,986479,"Agilent Technologies, Inc., Q2 2016 Earnings Call, May 16, 2016",2016-05-16,"Earnings Calls","Agilent Technologies, Inc.","Analysts","I had a question on margins as well. On the gross margin side, I was curious if we should expect maybe another wave of improvement now that you have the ERP integration done and on the margin side, curious how satisfied you are with the sales force realig",62,"I had a question on margins as well. On the gross margin side, I was curious if we should expect maybe another wave of improvement now that you have the ERP integration done and on the margin side, curious how satisfied you are with the sales force realignment and whether or not there's still more synergies to be had there as well."
154924,333332053,986479,"Agilent Technologies, Inc., Q2 2016 Earnings Call, May 16, 2016",2016-05-16,"Earnings Calls","Agilent Technologies, Inc.","Executives","Yes, a couple of comments here. Then I'll bounce it over to Didier in case he'd like to add a few things here. But in terms of the sales force integration and go-to-market -- we couldn't be happier. I mean, that was a major move we made last year, where w",347,"Yes, a couple of comments here. Then I'll bounce it over to Didier in case he'd like to add a few things here. But in terms of the sales force integration and go-to-market -- we couldn't be happier. I mean, that was a major move we made last year, where we basically went from 5 sales force to the 2 sales force, one focused on the analytical laboratory marketplace and then the other one focused on the regulated diagnostic marketplace. At the time, I remember sharing with you, ""Hey, we're making a big change here and it could affect the top line and the short one. That didn't happen. In fact, I submit that as we go out into '16 and '17, we're now putting more resources of specialization in academia, in biopharma. So I think you're going to see the changes paying off in terms of longer-term growth. So we're really happy with both the fact that we've got it all behind us, it's settled down and I think it's starting to pay off on the initial benefits that we envisioned when we created that structure. 
Relative to gross margin ERP, I just keep in mind that what we've been talking about is a -- the financial systems, which really go into the SG&A line. So it really won't affect the gross margin. That being said, we do think we can do more on gross margins as we move forward in '16 and '17. I'll talk a little bit about -- more about in detail next week when we're in New York. But as you may know, on our initial 400 basis points of improvement when I came onboard, we said half would come through OpEx and other operational costs, and then others through growth. And the growth piece would be -- a lot would be driven by our ability to capture the gross margin improvements on increased volume. So we think we still have room to improve our material cost, and we think that we've got room to continue to bring down our logistics costs."
154924,333332053,986479,"Agilent Technologies, Inc., Q2 2016 Earnings Call, May 16, 2016",2016-05-16,"Earnings Calls","Agilent Technologies, Inc.","Analysts","That's very helpful. Maybe just a follow-up. Just to clarify on 2 topics, one on biopharma and then the other one on the comments you made around China. On biopharma, could you just compare the growth rates you're seeing in the QAQC setting versus R&D? An",82,"That's very helpful. Maybe just a follow-up. Just to clarify on 2 topics, one on biopharma and then the other one on the comments you made around China. On biopharma, could you just compare the growth rates you're seeing in the QAQC setting versus R&D? And then in China, just curious, how much of your improved outlook there is based on the visibility you have with government funding versus sort of end markets that are more on the private industry side?"
154924,333332053,986479,"Agilent Technologies, Inc., Q2 2016 Earnings Call, May 16, 2016",2016-05-16,"Earnings Calls","Agilent Technologies, Inc.","Executives","I think that on the -- your question, we're not seeing any real significant differences in growth rates across the segments you described in pharma. I do think if you go out a couple of years down the road, I think we'd expect the growth rate in the bioph",152,"I think that on the -- your question, we're not seeing any real significant differences in growth rates across the segments you described in pharma. I do think if you go out a couple of years down the road, I think we'd expect the growth rate in the biopharma should be higher than the small molecule. But it's not at all the case right now. As you heard earlier from Patrick, we expect that to continue through '17. We're getting more clarity about what's going on in China. I think there was a lot of concerns at one point in time on the private sector, this side of the business, but obviously, as you know, Isaac, the government drives the market there to a large extent, and we're getting more clarity on what's happening in funding. So that's why we have this increased confidence in our outlook for our business in China."
154924,333332053,986479,"Agilent Technologies, Inc., Q2 2016 Earnings Call, May 16, 2016",2016-05-16,"Earnings Calls","Agilent Technologies, Inc.","Operator","And our next question comes from the line of Derik De Bruin of Bank of America.",16,"And our next question comes from the line of Derik De Bruin of Bank of America."
154924,333332053,986479,"Agilent Technologies, Inc., Q2 2016 Earnings Call, May 16, 2016",2016-05-16,"Earnings Calls","Agilent Technologies, Inc.","Analysts","Just wanted to clarify. Did I hear you correctly that you said your initial flash for core growth guidance for fiscal '17 was 4.5% the midpoint?",26,"Just wanted to clarify. Did I hear you correctly that you said your initial flash for core growth guidance for fiscal '17 was 4.5% the midpoint?"
154924,333332053,986479,"Agilent Technologies, Inc., Q2 2016 Earnings Call, May 16, 2016",2016-05-16,"Earnings Calls","Agilent Technologies, Inc.","Executives","Yes, yes.",2,"Yes, yes."
154924,333332053,986479,"Agilent Technologies, Inc., Q2 2016 Earnings Call, May 16, 2016",2016-05-16,"Earnings Calls","Agilent Technologies, Inc.","Analysts","Okay. And so can you sort of like flank that in terms of what you're thinking for the chemical and energy market there? I mean, just sort of what you're expecting in terms of a rebound. And I'm just -- could you help us frame that comment a little bit mor",60,"Okay. And so can you sort of like flank that in terms of what you're thinking for the chemical and energy market there? I mean, just sort of what you're expecting in terms of a rebound. And I'm just -- could you help us frame that comment a little bit more in terms of some of the puts and takes?"
154924,333332053,986479,"Agilent Technologies, Inc., Q2 2016 Earnings Call, May 16, 2016",2016-05-16,"Earnings Calls","Agilent Technologies, Inc.","Executives","Yes, sure I'd be happy to because sometimes, you can use corporate language, which doesn't really give you the insights you need. So let me try to clarify here. So what we said was in this year, we thought our performance will be flat for the entire year,",346,"Yes, sure I'd be happy to because sometimes, you can use corporate language, which doesn't really give you the insights you need. So let me try to clarify here. So what we said was in this year, we thought our performance will be flat for the entire year, while in fact, it's going to be down, we probably think in the range of 2.5% for the year, for the entire year. And that is a change from our assumptions coming into this year. And that was the assumption we made at the time of our initial guidance, which makes our revenue results even much more -- we're really pleased with the results, given the fact that the chemical energy market has not developed the way we initially had thought. That being said, in '17, we actually think it will be improved, which means it won't be declining. And in fact, it will probably be flat or maybe low single digits. And why do we believe that? If you look at how our business breaks down in that segment, we often talk about the oil side. But 50% of our business historically has been in the exploration and another 35% has been in the refining. The other half, which is by far the biggest individual segment, is the chemical side, and they're benefiting by lower feedstock costs. They've got pent-up investment demands, and we're starting to see increased deal activity. So in fact, Patrick and I were talking about this, this morning and it kind of reminds me of a pro forma a few years ago basically we're going to have 2 years of shrinking performance in this marketplace, a lot of pent-up demand. So long story short, our growth assumption for next year assumes low single-digit chemical energy growth for the year. Again, we still believe we're searching for the bottom. So -- and it's still early in the year 2016. But that's our basic assumption for '17, which is an improved environment, not dramatic, but improved from what we've seen over the last 24 months."
154924,333332053,986479,"Agilent Technologies, Inc., Q2 2016 Earnings Call, May 16, 2016",2016-05-16,"Earnings Calls","Agilent Technologies, Inc.","Analysts","And just as a quick follow-up on the chemical comment. You're not worried that some of the activity between Dow and DuPont and -- looks like there may be Monsanto and so these are the companies that are dancing around. Are you worried that, that could sor",73,"And just as a quick follow-up on the chemical comment. You're not worried that some of the activity between Dow and DuPont and -- looks like there may be Monsanto and so these are the companies that are dancing around. Are you worried that, that could sort of stymie investment if you're using the pharma analogy of sort of combinations of those companies? Is there some potential headwind from the chemicals market?"
154924,333332053,986479,"Agilent Technologies, Inc., Q2 2016 Earnings Call, May 16, 2016",2016-05-16,"Earnings Calls","Agilent Technologies, Inc.","Executives","No, Derik, that's a great question. We looked at this pretty closely when the announcement was first made. And although Dow and DuPont are very important customers to us, that particular deal activity really is immaterial to the total company's performanc",111,"No, Derik, that's a great question. We looked at this pretty closely when the announcement was first made. And although Dow and DuPont are very important customers to us, that particular deal activity really is immaterial to the total company's performance. And we didn't necessarily see it as a sign of an acceleration of M&A and consolidations going on in the space. So of course, there will be some pause if we'd see more of that, but we're not overly concerned about that. And I guess, the beauty of this business has been just the broad-based nature of our customer base. So we're not overly dependent on any one single customer."
154924,333332053,986479,"Agilent Technologies, Inc., Q2 2016 Earnings Call, May 16, 2016",2016-05-16,"Earnings Calls","Agilent Technologies, Inc.","Operator","And our next question comes from the line of Dan Arias of Citigroup.",13,"And our next question comes from the line of Dan Arias of Citigroup."
154924,333332053,986479,"Agilent Technologies, Inc., Q2 2016 Earnings Call, May 16, 2016",2016-05-16,"Earnings Calls","Agilent Technologies, Inc.","Analysts","Mike, can you just talk on Japan? Mike, can you just touch on Japan and things that you saw during the quarter in terms of trends and then maybe what you're looking for at this point on the year?",39,"Mike, can you just talk on Japan? Mike, can you just touch on Japan and things that you saw during the quarter in terms of trends and then maybe what you're looking for at this point on the year?"
154924,333332053,986479,"Agilent Technologies, Inc., Q2 2016 Earnings Call, May 16, 2016",2016-05-16,"Earnings Calls","Agilent Technologies, Inc.","Executives","Yes. So Dan, thanks for the question. And if you -- a little bit of my history. I spent 5 years in Japan. So I've always been a big supporter of Japan in terms of the long-term view of the market. And I'd ask you to take a long-term view of the market in",177,"Yes. So Dan, thanks for the question. And if you -- a little bit of my history. I spent 5 years in Japan. So I've always been a big supporter of Japan in terms of the long-term view of the market. And I'd ask you to take a long-term view of the market in Japan. So that was the only market that actually was down for us in the second quarter. And we are expecting continued subdued performance in Japan. So we're not expecting much in terms of improvement in the overall market environment in Japan. We do think that it could be a market, which often will respond to new technologies, innovative new products. So we do hope -- we do hold out hope that we could take some share from some of our new intros coming out in the second part of this year. But from an overall market perspective, we're expecting to remain subdued and our internal forecasts are not based on any type of material improvement at all on our performance in Japan."
154924,333332053,986479,"Agilent Technologies, Inc., Q2 2016 Earnings Call, May 16, 2016",2016-05-16,"Earnings Calls","Agilent Technologies, Inc.","Analysts","Okay. Thanks for that color. And then you kind of teased some new product introductions in the back half that should be meaningful to growth. I'm sure you don't want to give away any secrets, but can you just sort of help us with what part of the business",56,"Okay. Thanks for that color. And then you kind of teased some new product introductions in the back half that should be meaningful to growth. I'm sure you don't want to give away any secrets, but can you just sort of help us with what part of the business you're anticipating seeing the boost in 2017?"
154924,333332053,986479,"Agilent Technologies, Inc., Q2 2016 Earnings Call, May 16, 2016",2016-05-16,"Earnings Calls","Agilent Technologies, Inc.","Executives","Yes. So thanks for the caveat on your question. So what we can point to with great confidence and clarity is the recent introduction we made in analytic. And that what I would say to you, you will see broad-based introductions across the entire portfolio.",163,"Yes. So thanks for the caveat on your question. So what we can point to with great confidence and clarity is the recent introduction we made in analytic. And that what I would say to you, you will see broad-based introductions across the entire portfolio. And core growth is essential to our business plan. As you know, when I came in last year, we spent a lot of time reorganizing the R&D structure and also, reallocating where we put money. And I think you're going to start to see some of that starting to pay off, as we go into the latter part of '16. So we did want to put a teaser out there, but also just to make sure you had confidence in terms of what's behind our view of improved Agilent performance in '17 off of the second half of this year. But I think you're going to expect to see us talking about activities across all 3 business groups."
154924,333332053,986479,"Agilent Technologies, Inc., Q2 2016 Earnings Call, May 16, 2016",2016-05-16,"Earnings Calls","Agilent Technologies, Inc.","Operator","And our next question comes from the line of Doug Schenkel of Cowen and Company.",15,"And our next question comes from the line of Doug Schenkel of Cowen and Company."
154924,333332053,986479,"Agilent Technologies, Inc., Q2 2016 Earnings Call, May 16, 2016",2016-05-16,"Earnings Calls","Agilent Technologies, Inc.","Analysts","Mike, I want to go back to some of the comments you made on efforts to tighten cycle times from order to revenue, which seem to be yielding benefits greater than expected, particularly on China. Can you provide a bit more background on this effort and why",118,"Mike, I want to go back to some of the comments you made on efforts to tighten cycle times from order to revenue, which seem to be yielding benefits greater than expected, particularly on China. Can you provide a bit more background on this effort and why it was most impactful in China? And then maybe talk about similar efforts underway in other geographies. And relatedly, you positioned these in answering some questions as if they were temporary. At least, it seems like your guidance doesn't treat these as sustainable improvements. Yet, everything else you've said suggests that these are truly sustainable improvements. So I was just hoping you could help us understand that a little bit better."
154924,333332053,986479,"Agilent Technologies, Inc., Q2 2016 Earnings Call, May 16, 2016",2016-05-16,"Earnings Calls","Agilent Technologies, Inc.","Executives","Yes, sure, Doug. I really appreciate the question. And maybe let me start with the last part of your question, which is the takeaway here, we do believe that there's a stable improvement. So in my mind or the language I use, this is the new normal in term",441,"Yes, sure, Doug. I really appreciate the question. And maybe let me start with the last part of your question, which is the takeaway here, we do believe that there's a stable improvement. So in my mind or the language I use, this is the new normal in terms of our ability to convert orders to revenue. And so I would characterize this as new normal of how we're going to operate. So how did we get here and why do they look so significantly different in China? So first of all, it starts with looking at the entire process from an end-to-end customer perspective from the time of order placement till shipment until customer installation occurs and, as you know, when I restructured the company, I was really trying to break down the silos and we had a very silo'd [ph] oriented approach to this end-to-end process from a customer perspective. In the company, we looked at each slice of the process but nobody's looking at the collective process for end-to-end. You start doing that, then you start seeing where the issues are, the opportunities are. So we found ways to improve our order linearity. We've improved the quality of booked orders, and this really gets to your question about China. Often, you're dealing with letters of credit issues and other trade issues that in the past have delayed our ability to actually book them as clean orders and turned them into revenue. We call this delivery box. We've been working on making sure we had material availability. I think we hit one of our best quarters ever in terms of having material ready for all of our shipments. So we improved our ability to get orders in a linear fashion, make sure those orders are clean and not have lot of rework, and then we've improved our delivery performance. And then spent a lot of time improving our efforts between shipment installation, which sometimes can go on for several weeks. So I think it all starts with this looking at the whole process from an end-to-end perspective and the result has been a significant improvement in cycle time and orders turned into revenue more quickly than in the past. I do think this represents our new way of operating. And again, as I mentioned in my remarks, it did create some -- it did have implications of how we guide the company for the second and third quarter. But I think we're delighted to be able to actually have ongoing strong operational efficiency improvement in place so that we know how to predict revenue even better in the future."
154924,333332053,986479,"Agilent Technologies, Inc., Q2 2016 Earnings Call, May 16, 2016",2016-05-16,"Earnings Calls","Agilent Technologies, Inc.","Analysts","Okay. Mike, but just to be really clear, recognizing these are well-earned, sustainable improvements, it's not apparent that this is fully -- these improvements, the sustainably is fully reflected in guidance. If that's the case, is that just because you",57,"Okay. Mike, but just to be really clear, recognizing these are well-earned, sustainable improvements, it's not apparent that this is fully -- these improvements, the sustainably is fully reflected in guidance. If that's the case, is that just because you want to see this play out for a couple of quarters before you start baking it in?"
154924,333332053,986479,"Agilent Technologies, Inc., Q2 2016 Earnings Call, May 16, 2016",2016-05-16,"Earnings Calls","Agilent Technologies, Inc.","Executives","Yes. I think the confusion might be that what we have stated is that this quarter in Q2, we got $20 million to $25 million of revenue that we had anticipated to be recognized in Q3 as we were bringing all those programs to fruition. We had earlier results",120,"Yes. I think the confusion might be that what we have stated is that this quarter in Q2, we got $20 million to $25 million of revenue that we had anticipated to be recognized in Q3 as we were bringing all those programs to fruition. We had earlier results, which is great. From where we are now, the order to revenue cycle time is sustainable, but we will not see further improvement that will bring Q4 revenue into Q3 or whatever it is. So the 20 to 25, that's onetime. We've got to the level we wanted to be at. And from now on, it's just business as usual without any fundamental change in the order to revenue cycle time."
154924,333332053,986479,"Agilent Technologies, Inc., Q2 2016 Earnings Call, May 16, 2016",2016-05-16,"Earnings Calls","Agilent Technologies, Inc.","Analysts","All right. And just one last one for you. On the change in Lasergen accounting, was there any dilution in the quarter? And based on the accounting change, should we no longer expect this to be $0.02 to $0.03 dilutive deal for the year?",44,"All right. And just one last one for you. On the change in Lasergen accounting, was there any dilution in the quarter? And based on the accounting change, should we no longer expect this to be $0.02 to $0.03 dilutive deal for the year?"
154924,333332053,986479,"Agilent Technologies, Inc., Q2 2016 Earnings Call, May 16, 2016",2016-05-16,"Earnings Calls","Agilent Technologies, Inc.","Executives","Correct. You're correct. So there was no dilution in Q2, and there will not be any dilution in -- for the rest of '16 or '17 until we exercise our call option. And then we will just fully consolidate, if we do that, obviously, fully consolidate the Laserg",117,"Correct. You're correct. So there was no dilution in Q2, and there will not be any dilution in -- for the rest of '16 or '17 until we exercise our call option. And then we will just fully consolidate, if we do that, obviously, fully consolidate the Lasergen revenue. So that's a change that there was a lot of -- I mean, discussions with the auditors. They surprised us a little bit by going to national to get specially some kind of challenge kind of the accounting that we had anticipated locally among the 2 teams, and then we agreed to the recommendation. And therefore, no dilution to EPS coming from Lasergen in the next 2 years."
154924,333332053,986479,"Agilent Technologies, Inc., Q2 2016 Earnings Call, May 16, 2016",2016-05-16,"Earnings Calls","Agilent Technologies, Inc.","Executives","Right. And we were pleased we were able to get this closed off before we finished the quarter.",18,"Right. And we were pleased we were able to get this closed off before we finished the quarter."
154924,333332053,986479,"Agilent Technologies, Inc., Q2 2016 Earnings Call, May 16, 2016",2016-05-16,"Earnings Calls","Agilent Technologies, Inc.","Operator","And our next question comes from the line of Miroslava Minkova of Stifel.",13,"And our next question comes from the line of Miroslava Minkova of Stifel."
154924,333332053,986479,"Agilent Technologies, Inc., Q2 2016 Earnings Call, May 16, 2016",2016-05-16,"Earnings Calls","Agilent Technologies, Inc.","Analysts","Maybe if I could focus on operating margins, again, for a second. Just help us remind us. There's a lot going on there in terms of the programs you have in place and improvements you have going on. Help us remind us the bridge between fiscal '16 and '17?",57,"Maybe if I could focus on operating margins, again, for a second. Just help us remind us. There's a lot going on there in terms of the programs you have in place and improvements you have going on. Help us remind us the bridge between fiscal '16 and '17? What's gets you to the 22% operating margin?"
154924,333332053,986479,"Agilent Technologies, Inc., Q2 2016 Earnings Call, May 16, 2016",2016-05-16,"Earnings Calls","Agilent Technologies, Inc.","Executives","Well, as a teaser, we're going to go through this in some detail.",13,"Well, as a teaser, we're going to go through this in some detail."
154924,333332053,986479,"Agilent Technologies, Inc., Q2 2016 Earnings Call, May 16, 2016",2016-05-16,"Earnings Calls","Agilent Technologies, Inc.","Executives","There will be a slide on the topic next week.",10,"There will be a slide on the topic next week."
154924,333332053,986479,"Agilent Technologies, Inc., Q2 2016 Earnings Call, May 16, 2016",2016-05-16,"Earnings Calls","Agilent Technologies, Inc.","Executives","But what I can share with you conceptually is that we will be continuing and completing off the integration of the Dako acquisition. We have a series of operational programs. We talked about one of those already, which is the implications of the ERP, and",86,"But what I can share with you conceptually is that we will be continuing and completing off the integration of the Dako acquisition. We have a series of operational programs. We talked about one of those already, which is the implications of the ERP, and the continued focus on gross margin improvement specifically, material cost reductions and logistic savings. So I think the combination of those 3 factors plus with the overall quarter growth assumptions that we're currently modeling around 4.5 gets us to the 22%."
154924,333332053,986479,"Agilent Technologies, Inc., Q2 2016 Earnings Call, May 16, 2016",2016-05-16,"Earnings Calls","Agilent Technologies, Inc.","Analysts","Okay, great. And the strength in the food market, was this all China or are you seeing strength elsewhere as well?",21,"Okay, great. And the strength in the food market, was this all China or are you seeing strength elsewhere as well?"
154924,333332053,986479,"Agilent Technologies, Inc., Q2 2016 Earnings Call, May 16, 2016",2016-05-16,"Earnings Calls","Agilent Technologies, Inc.","Executives","Actually, it was both in food, I mean, excuse me, both -- food market, both in China and in the United States. As you may recall, from our Q1 announcement, this business tends to be a little lumpy, whereas I think the performance in food market in China h",64,"Actually, it was both in food, I mean, excuse me, both -- food market, both in China and in the United States. As you may recall, from our Q1 announcement, this business tends to be a little lumpy, whereas I think the performance in food market in China has been sustained. But we saw a nice rebound in the U.S. in the second quarter."
154924,333332053,986479,"Agilent Technologies, Inc., Q2 2016 Earnings Call, May 16, 2016",2016-05-16,"Earnings Calls","Agilent Technologies, Inc.","Analysts","Got you. Okay. And maybe finally, give us your view of the M&A pipeline. We've seen you do a couple of deals just recently here. Now that you have sort of many of the operational initiatives for the new Agilent in place, should we expect you're more activ",53,"Got you. Okay. And maybe finally, give us your view of the M&A pipeline. We've seen you do a couple of deals just recently here. Now that you have sort of many of the operational initiatives for the new Agilent in place, should we expect you're more active with the tuck-ins going forward?"
154924,333332053,986479,"Agilent Technologies, Inc., Q2 2016 Earnings Call, May 16, 2016",2016-05-16,"Earnings Calls","Agilent Technologies, Inc.","Executives","Again, this is a teaser #2, which is we're going to talk about this a little bit in more detail next week. But I do feel that the company's foundation is really firmly established. And as I mentioned earlier, I think we're getting a lot better in terms of",140,"Again, this is a teaser #2, which is we're going to talk about this a little bit in more detail next week. But I do feel that the company's foundation is really firmly established. And as I mentioned earlier, I think we're getting a lot better in terms of our speed to be able to integrate. But what -- I think you're going to expect us to do is to remain disciplined and focused in terms of finding those opportunities that make sense for us. And I would ask you to think about as being complimentary M&A in nature. We're going to continue to look for those. So our balance sheet is a huge asset for the -- for our shareholders in one which we would like to deploy relative to M&A, but it has to be the right target."
154924,333332053,986479,"Agilent Technologies, Inc., Q2 2016 Earnings Call, May 16, 2016",2016-05-16,"Earnings Calls","Agilent Technologies, Inc.","Operator","And our next question comes from the line of Steve Beuchaw of Morgan Stanley.",14,"And our next question comes from the line of Steve Beuchaw of Morgan Stanley."
154924,333332053,986479,"Agilent Technologies, Inc., Q2 2016 Earnings Call, May 16, 2016",2016-05-16,"Earnings Calls","Agilent Technologies, Inc.","Analysts","Just 2 clarifications on how you're thinking about the '16, '17 progression. The first is actually on the NIH. To what extent, if any, are you anticipating a pick-up in the research channel from NIH funding when we start to see that get dispersed in the s",98,"Just 2 clarifications on how you're thinking about the '16, '17 progression. The first is actually on the NIH. To what extent, if any, are you anticipating a pick-up in the research channel from NIH funding when we start to see that get dispersed in the second half of the year? And then second, and this may be even a longer-term question. But how do you think about the evolution of FSMA regulations in the food space in the U.S.? Is it too soon to start getting incrementally optimistic about how they could contribute to the outlook?"
154924,333332053,986479,"Agilent Technologies, Inc., Q2 2016 Earnings Call, May 16, 2016",2016-05-16,"Earnings Calls","Agilent Technologies, Inc.","Executives","Yes, thanks. I'm glad to address both of your questions. So on the NIH front, I think, when we talked about the uptick in sort of our improved confidence about spends in academia and government in the U.S., I think we do think that the NIH stuff will star",217,"Yes, thanks. I'm glad to address both of your questions. So on the NIH front, I think, when we talked about the uptick in sort of our improved confidence about spends in academia and government in the U.S., I think we do think that the NIH stuff will start to flow through to our business. Relative to some in our space, we don't have as high a percentage of our business tied to the NIH, but it will be a positive for us. And I think, again, one more fact pattern which points to continued view that this market will be solid for us as we move into '17. I think I'd have to agree with the comment, which is, I think it really is too soon to get overall excited about this from a U.S. spend. I've seen this before where the legislation is announced and there's a lot of fanfare about it. But we don't obviously are backed up by investments. Although we did -- we are seeing some -- it looks like some maybe more friendly government allocations to this agency unlike we've seen to the EPA. So we're not expecting anything dramatic to occur definitely in the market because of this. But if it would, that would be clearly good news for us."
154924,333332053,986479,"Agilent Technologies, Inc., Q2 2016 Earnings Call, May 16, 2016",2016-05-16,"Earnings Calls","Agilent Technologies, Inc.","Operator","And our next question comes from the line of Jeff Elliott of Robert W. Baird.",15,"And our next question comes from the line of Jeff Elliott of Robert W. Baird."
154924,333332053,986479,"Agilent Technologies, Inc., Q2 2016 Earnings Call, May 16, 2016",2016-05-16,"Earnings Calls","Agilent Technologies, Inc.","Analysts","Mike, on the margin, overall, a really good quarter. But then when you look at the margins in DGG and in CrossLab, you're basically flat year-over-year. I guess, is that what you're expecting? Anything kind of you could call out in the quarter? I know the",53,"Mike, on the margin, overall, a really good quarter. But then when you look at the margins in DGG and in CrossLab, you're basically flat year-over-year. I guess, is that what you're expecting? Anything kind of you could call out in the quarter? I know there's some moving pieces in the top line."
154924,333332053,986479,"Agilent Technologies, Inc., Q2 2016 Earnings Call, May 16, 2016",2016-05-16,"Earnings Calls","Agilent Technologies, Inc.","Executives","Why don't you take that one, Didier?",8,"Why don't you take that one, Didier?"
154924,333332053,986479,"Agilent Technologies, Inc., Q2 2016 Earnings Call, May 16, 2016",2016-05-16,"Earnings Calls","Agilent Technologies, Inc.","Executives","No, it's a great question and the answer is yes. It's precisely what we had expected. One of the, obviously, based from one quarter to the next, there could be some onetime add-ins that adds a little bit of volatility. For example, last year, both ACG and",134,"No, it's a great question and the answer is yes. It's precisely what we had expected. One of the, obviously, based from one quarter to the next, there could be some onetime add-ins that adds a little bit of volatility. For example, last year, both ACG and DGG had very favorable hedging gains, which have gone away. For the whole company, the hedging gains last year in Q2 was over $7 million and this Q2 was about $1.5 million, something like that. So -- and it was mostly in ACG and DGG. And there are other onetime items that including regarding the allocation of our shared services among the different businesses, which explain. But both businesses are on their way to contribute to the operating margin expansion and the 22% that we're committing to."
154924,333332053,986479,"Agilent Technologies, Inc., Q2 2016 Earnings Call, May 16, 2016",2016-05-16,"Earnings Calls","Agilent Technologies, Inc.","Executives","Didier, maybe I'll also ask Mark to -- we've talked about this earlier this last week as well about the operational efficiency improvements that underline what looks to be flat margin, but when we peel back the [indiscernible], the hedging gains and the o",52,"Didier, maybe I'll also ask Mark to -- we've talked about this earlier this last week as well about the operational efficiency improvements that underline what looks to be flat margin, but when we peel back the [indiscernible], the hedging gains and the other things, there's actually some real operations down there."
154924,333332053,986479,"Agilent Technologies, Inc., Q2 2016 Earnings Call, May 16, 2016",2016-05-16,"Earnings Calls","Agilent Technologies, Inc.","Executives","Thanks, Mike and Didier, As Didier said, there are several things that were factors in it last year that didn't come into play this year. But we're working on a lot of things in terms of improvements. The mix is somewhat favorable in the context of what w",100,"Thanks, Mike and Didier, As Didier said, there are several things that were factors in it last year that didn't come into play this year. But we're working on a lot of things in terms of improvements. The mix is somewhat favorable in the context of what we're selling. But overall, when we look at our plans for the first half, we're up 70 basis points in the first half over last year. So our ability to actually do to margin improvements, when you pull back and look at the first half regardless of all those things, it's quite positive."
154924,333332053,986479,"Agilent Technologies, Inc., Q2 2016 Earnings Call, May 16, 2016",2016-05-16,"Earnings Calls","Agilent Technologies, Inc.","Executives","And as our fastest growing business, he's been picking up more of the corporate costs.",15,"And as our fastest growing business, he's been picking up more of the corporate costs."
154924,333332053,986479,"Agilent Technologies, Inc., Q2 2016 Earnings Call, May 16, 2016",2016-05-16,"Earnings Calls","Agilent Technologies, Inc.","Executives","Shared services.",2,"Shared services."
154924,333332053,986479,"Agilent Technologies, Inc., Q2 2016 Earnings Call, May 16, 2016",2016-05-16,"Earnings Calls","Agilent Technologies, Inc.","Executives","Shared services.",2,"Shared services."
154924,333332053,986479,"Agilent Technologies, Inc., Q2 2016 Earnings Call, May 16, 2016",2016-05-16,"Earnings Calls","Agilent Technologies, Inc.","Executives","Yes, shared services.",3,"Yes, shared services."
154924,333332053,986479,"Agilent Technologies, Inc., Q2 2016 Earnings Call, May 16, 2016",2016-05-16,"Earnings Calls","Agilent Technologies, Inc.","Operator","And our final question comes from the line of the Dane Leone of BTIG.",14,"And our final question comes from the line of the Dane Leone of BTIG."
154924,333332053,986479,"Agilent Technologies, Inc., Q2 2016 Earnings Call, May 16, 2016",2016-05-16,"Earnings Calls","Agilent Technologies, Inc.","Analysts","I just had a quick clarification from earlier. So you're talking about the replacement cycle in biopharma and quoted, I think, 150,000 LC systems based on the 1100, 1200 platform. Did you -- can you clarify if that's what you think the opportunity is ahea",66,"I just had a quick clarification from earlier. So you're talking about the replacement cycle in biopharma and quoted, I think, 150,000 LC systems based on the 1100, 1200 platform. Did you -- can you clarify if that's what you think the opportunity is ahead of you? Or that's the opportunity in progress? And if so, kind of what -- how far are you into that?"
154924,333332053,986479,"Agilent Technologies, Inc., Q2 2016 Earnings Call, May 16, 2016",2016-05-16,"Earnings Calls","Agilent Technologies, Inc.","Executives","This is Patrick. Let me answer this question. So first and foremost, this is not biopharma at all. This is pharma and biopharma combined. And when I talk about 150,000 systems out there, it's the installed base of LC systems in all markets. So it's not on",131,"This is Patrick. Let me answer this question. So first and foremost, this is not biopharma at all. This is pharma and biopharma combined. And when I talk about 150,000 systems out there, it's the installed base of LC systems in all markets. So it's not only in pharma and biopharma. But we think the biggest push is actually right now, coming from pharma and biopharma, and I would still say we are in the midst of the replacement cycle. We don't see that to be over -- in the next couple of quarters. There's a healthy demand and we are in negotiations with a lot of our core customers on upcoming replacements and how we place these systems and how we plan it out for them so it works out."
154924,333332053,986479,"Agilent Technologies, Inc., Q2 2016 Earnings Call, May 16, 2016",2016-05-16,"Earnings Calls","Agilent Technologies, Inc.","Executives","And Dane, if I could add this one other comment to Patrick's response. We were focused a lot today -- in today's call on pharma and biopharma, but keep in mind that the replacement cycles have been very, very subdued on the implied market side in liquid c",89,"And Dane, if I could add this one other comment to Patrick's response. We were focused a lot today -- in today's call on pharma and biopharma, but keep in mind that the replacement cycles have been very, very subdued on the implied market side in liquid chromatography. So we have several -- we have tens of thousands of systems on that side of the house as well. And again, this is why when we look out into '17 and '18, we think that our growth rates are sustainable."
154924,333332053,986479,"Agilent Technologies, Inc., Q2 2016 Earnings Call, May 16, 2016",2016-05-16,"Earnings Calls","Agilent Technologies, Inc.","Analysts","Any way you could handicap using a baseball analogy or something like that, like what inning you think you're at?",20,"Any way you could handicap using a baseball analogy or something like that, like what inning you think you're at?"
154924,333332053,986479,"Agilent Technologies, Inc., Q2 2016 Earnings Call, May 16, 2016",2016-05-16,"Earnings Calls","Agilent Technologies, Inc.","Executives","No, don't ask a German about the baseball [indiscernible].",9,"No, don't ask a German about the baseball [indiscernible]."
154924,333332053,986479,"Agilent Technologies, Inc., Q2 2016 Earnings Call, May 16, 2016",2016-05-16,"Earnings Calls","Agilent Technologies, Inc.","Executives","I'd say, on the pharma side, you're probably innings 5 or 6. I mean, if there's a way through, maybe 2/3. I think -- and my point would be that I think the ballgame is just getting started. We may be in the first inning. We hope to be in the first inning",63,"I'd say, on the pharma side, you're probably innings 5 or 6. I mean, if there's a way through, maybe 2/3. I think -- and my point would be that I think the ballgame is just getting started. We may be in the first inning. We hope to be in the first inning soon of that cycle on the implied market side."
154924,333332053,986479,"Agilent Technologies, Inc., Q2 2016 Earnings Call, May 16, 2016",2016-05-16,"Earnings Calls","Agilent Technologies, Inc.","Operator","And I'm showing no further questions at this time. I'd now like to turn the conference back to Alicia Rodriguez for closing remarks.",24,"And I'm showing no further questions at this time. I'd now like to turn the conference back to Alicia Rodriguez for closing remarks."
154924,333332053,986479,"Agilent Technologies, Inc., Q2 2016 Earnings Call, May 16, 2016",2016-05-16,"Earnings Calls","Agilent Technologies, Inc.","Executives","Thank you, everybody, and I'd like to thank you all for joining us today on the call. If you have any questions, of course, please give us a call in IR. And just would hope that we'll see you next week at our Analyst Day in New York City. Thanks again. By",52,"Thank you, everybody, and I'd like to thank you all for joining us today on the call. If you have any questions, of course, please give us a call in IR. And just would hope that we'll see you next week at our Analyst Day in New York City. Thanks again. Bye-bye."
154924,333332053,986479,"Agilent Technologies, Inc., Q2 2016 Earnings Call, May 16, 2016",2016-05-16,"Earnings Calls","Agilent Technologies, Inc.","Operator","Ladies and gentlemen, thank you for participating in today's conference. This does conclude the program. You may all disconnect. Everyone, have a great day.",24,"Ladies and gentlemen, thank you for participating in today's conference. This does conclude the program. You may all disconnect. Everyone, have a great day."
154924,333332053,986521,"Agilent Technologies, Inc., Q2 2016 Earnings Call, May 16, 2016",2016-05-16,"Earnings Calls","Agilent Technologies, Inc.","Operator","Good day, ladies and gentlemen, and welcome to the Q2 2016 Agilent Technologies Inc. Earnings Conference Call. [Operator Instructions] As a reminder, this call is being recorded. I would now like to turn the conference over to Alicia Rodriguez, Vice Presi",47,"Good day, ladies and gentlemen, and welcome to the Q2 2016 Agilent Technologies Inc. Earnings Conference Call. [Operator Instructions] As a reminder, this call is being recorded. I would now like to turn the conference over to Alicia Rodriguez, Vice President of Investor Relations. Please go ahead."
154924,333332053,986521,"Agilent Technologies, Inc., Q2 2016 Earnings Call, May 16, 2016",2016-05-16,"Earnings Calls","Agilent Technologies, Inc.","Executives","Thank you, Sabrina, and welcome, everyone, to Agilent's Second Quarter Conference Call for Fiscal Year 2016. With me are Mike McMullen, Agilent's President and CEO; and Didier Hirsch, Agilent's Senior Vice President and CFO. Joining in the Q&A after Didie",330,"Thank you, Sabrina, and welcome, everyone, to Agilent's Second Quarter Conference Call for Fiscal Year 2016. With me are Mike McMullen, Agilent's President and CEO; and Didier Hirsch, Agilent's Senior Vice President and CFO. Joining in the Q&A after Didier's comments will be Patrick Kaltenbach, President of Agilent's Life Sciences and Applied Markets Group; Jacob Thaysen, President of Agilent's Diagnostics and Genomics Group; and Mark Doak, President of the Agilent CrossLab Group.
You can find the press release and information to supplement today's discussion on our website at www.investor.agilent.com. While there, please click on the link for financial results under the Financial Information tab. You will find an investor presentation along with revenue breakouts and currency impacts, business segment results and historical financials for Agilent's operations. We will also post a copy of the prepared remarks following this call.
Today's comments by Mike and Didier will refer to non-GAAP financial measures. You will find the most directly comparable GAAP financial metrics and reconciliations on our website. And please note that we will refer to core revenue growth, which excludes the impact of currency, the NMR business and acquisitions and divestitures within the past 12 months. Unless otherwise noted, all references to increases or decreases in financial metrics are year-over-year. Guidance is based on exchange rates as of the last day of the reported quarter.
We will also make forward-looking statements about the financial performance of the company. These statements are subject to risks and uncertainties and are only valid as of today. The company assumes no obligation to update them. Please look at the company's recent SEC filings for a more complete picture of our risks and other factors.
Before turning things over to Mike, I'd like to remind you that Agilent will host its Analyst and Investor Meeting in New York City on May 25. Details about the meeting and webcast are available on the Agilent Investor Relations website. 
And now let me turn the call over to Mike."
154924,333332053,986521,"Agilent Technologies, Inc., Q2 2016 Earnings Call, May 16, 2016",2016-05-16,"Earnings Calls","Agilent Technologies, Inc.","Executives","Thanks, Alicia and hello, everyone. Thank you for joining us on today's call. The Agilent team delivered another strong quarter. Both Q2 revenue and earnings were above the high end of our guidance. Let me highlight 3 key results. First, revenue growth",1570,"Thanks, Alicia and hello, everyone. Thank you for joining us on today's call. The Agilent team delivered another strong quarter. Both Q2 revenue and earnings were above the high end of our guidance. Let me highlight 3 key results. 
First, revenue growth was up more than 8% on a core basis. Second, we delivered adjusted operating margin of 19.4%, an increase of 110 basis points from a year ago. Finally, EPS of $0.44 was up 15% over last year. 
Before moving on to a review of our Q2 results, I do want to address our year-over-year quarterly comparisons, which reflect an unusual event from last year. Of the 8% core growth that we're announcing today, about 1.5 percentage points is due to a shift of revenue last year from Q2 '15 into Q3 '15. 
In the second quarter a year ago, we experienced $50 million of shipment delays due to start-up challenges with our new U.S. logistics center. In addition, our process-improvement efforts over the past few quarters to convert incoming orders more quickly to revenue have paid off. We have reduced our order to revenue cycle times, particularly in China. Consequently, some shipments initially forecast for Q3 of this year were delivered in Q2. 
Agilent's strong Q2 results were led by double-digit core growth in pharma and food markets. We also experienced continued strength in academia and government, environmental and diagnostic and clinical markets. All end markets grew except chemical and energy. Growth was broad based across most of our portfolio. 
Geographically, all regions grew except Japan, led by very strong growth in China. Let me highlight our Q2 results by business group. The Life Sciences and Applied Markets Group delivered core revenue growth of 8%, led by strong demand in the pharma and food markets. About 3 percentage points of the 8% increase was thanks to a softer compare due to the timing issues mentioned earlier from last year's U.S. logistics center startup. 
The combination of strong top line growth, expense management and gross margin improvements, partially due to the NMR exit, drove LSAG's operating margin to 19%, up 320 basis points from a year ago. LSAG continues to strengthen its portfolio. In Q2, Agilent introduced VistaFlux software. This new software speeds up clinical research data analysis, so scientists can more quickly understand the underlying causes of diseases such as cancer. VistaFlux strengthens Agilent's leadership position in metabolomics. Last week, we announced a new Agilent 1216 Infinity II LC at the analytical tradeshow. This instrument provides best-in-class lab efficiency and improves performance with full backward compatibility. 
Next, the Agilent CrossLab Group continues to deliver consistently strong revenue results. Core revenue growth in Q2 was 10%, led by strength in contract services, LC columns and lab supplies. Expansion and penetration in Asia continued to be strong contributors to our growth. Operating margin was flat versus a year ago at 21.5%. 
CrossLab represents a strategic transformation of our services and consumables business. I'm pleased to report that Agilent was recognized with the 2016 Reviewers' Choice Award for Customer Service. This award is from SelectScience, an independent expert-led scientific review. This is the second year in a row that scientists in North America have judged Agilent's customer service to be the best in the laboratory products industry. 
Finally, the Diagnostics and Genomics Group delivered 5% core growth in Q2 against a difficult compare. The pathology business continues on a steady trajectory back to market growth rates, highlighted by strong demand for our new PD-L1 companion and complementary diagnostic tests. Genomics showed strong market performance, led by our SureSelect target enrichment and array CGH offerings. DGG's operating margin was flat versus a year ago at 15%. 
In Q2, Agilent announced an $80 million investment in Lasergen, an emerging biotechnology company with innovative next-gen sequencing technology. Our two companies will collaborate on building an NGS workflow for clinical applications. 
In Q2, Agilent also announced that commercial availability has expanded to the EU for a new PD-L1 diagnostic test for nonsquamous, nonsmall cell lung cancer. This diagnostic was developed through a collaboration with Bristol-Myers Squibb, the maker of OPDIVO. 
Now I'll provide an overview of Agilent's core revenues by end market. Life Sciences and Diagnostics markets saw a continuation of our first quarter performance, with strength across all end markets. Pharma grew 14%, fueled by technology refresh deals, new product uptake and sustained growth in the aftermarket. This is the fifth consecutive quarter of greater than mid- to high double-digit growth in pharma. 
Academia and government grew 7%, driven by strong demand in China and an uptick in the U.S. Clinical and diagnostics also grew 7% with strength in genomics, led by target enrichment and array CGH. Applied end market performance was mixed. Food was up 25% with strong sales in China and the Americas. China also drove 6% worldwide growth in environmental and forensics. Chemical energy declined 3%, reflecting continued macroeconomic concerns and the effects of lower oil prices. Now I'll turn to an update on our operating margin improvement initiative. 
Q2 marks the fifth consecutive quarter of year-over-year operating margin improvement delivered by the new Agilent team. This is a result of our ability to outgrow the market, while driving operational efficiency improvements. Our multiyear Agile Agilent program continues to simplify the company making us more nimble and lowering our cost. Our execution of company-wide streamlining organizations, processes and systems continue to be on track to deliver incremental savings in 2017. 
For example, in Q3, we would take a major step forward in simplifying the company's systems infrastructure with all of our financial systems now on SAP. 
On the capital deployment front, we paid $37 million in dividends, repurchased $94 million of Agilent stock and invested $80 million to enable our NGS workflow strategy. Finally, our One Agilent initiative is driving a well-received cultural transformation to improve cross-company collaboration and delivery of results. At last year's Analyst and Investor Day, I described a shareholder value creation model for Agilent to be driven by outgrowing the market, expanding operating margins and a balanced capital allocation policy. I'd like to take a minute to position the Q2 results in the context of our longer-term goals. 
After delivering our highest annual core revenue growth since 2011 of 6.4% in 2015, we've now had 2 strong quarters to start 2016, including this quarter's 8% core revenue growth. Since the new Agilent team -- leadership team was put in place, the team has delivered year-over-year operating margin improvements every quarter. We have completely offset the initial $40 million into synergies from the company split. 
In fiscal 2015, we returned $400 million to shareholders and $370 million year-to-date in 2016 through cash dividends and share repurchase. From 2015 until now, we've also invested around $400 million in new business via M&A and equity investments. Didier will share more specifics later, but we are raising our full year 2016 outlook for core growth, operating margin, EPS and cash flow. Let me now talk about our second half '16 forecast in light of what we have already achieved in 2016 and what we plan to deliver in 2017. 
When we look at today's overall market environment, while we face increasingly tough compares, we expect strength in pharma to continue in the second half 2016 and into 2017. China is also expected to remain strong in the second half of 2016 and 2017. Taking a closer look at the chemical and energy market, we have been experiencing a more prolonged and steeper slowdown than initially anticipated. We are now forecasting overall low single-digit market declines for the year versus our initial flat guidance assumptions. The oil exploration segment of this market has been down significantly for some time, with a recent well-reported spillover into the refining segment. There are initial indications, however, of a bottoming, with increased deal activity in the large chemical segment of the market. 
We have projected an improved chemical energy market environment in 2017. We are assuming we will continue to face headwinds in this market for the remainder of 2016. We are currently modeling 2017 with an above-market core revenue growth of 4.5% at the midpoint. This is in line with our projected full year 2016 core growth rates, but higher than our expected core growth rate in the second half of 2016. There are 2 reasons for this increase. 
First, we expect to have a very strong new product introduction in the second half of FY '16, which will drive revenue growth in FY '17. Second, on the end market front, we expect chemical energy to have bottomed out by year-end, accompanied by continuing solid conditions in all of our other end markets and in China. 
Overall, we remain on track with our 2017 goal to outgrow the market and improve our operating margins of 22%. Looking inside the company, I can share with you today that the One Agilent team is working well together and is driven to win in the marketplace. I look forward to seeing many of you at our Analyst and Investor Day, where I'll share our progress versus our commitments, how we will sustain or improve performance and the longer-term outlook for the company. Thank you for being on the call today. I will now turn it over to Didier, who will provide additional insights on our financial results and guidance for the third quarter and full year 2016. Didier?"
154924,333332053,986521,"Agilent Technologies, Inc., Q2 2016 Earnings Call, May 16, 2016",2016-05-16,"Earnings Calls","Agilent Technologies, Inc.","Executives","Thank you, Mike, and hello, everyone. As Mike stated, we delivered a strong performance this quarter again, 8% core revenue growth, 110 basis points of operating margin expansion and $256 million in operating cash flow. After adjusting for last year's $15",319,"Thank you, Mike, and hello, everyone. As Mike stated, we delivered a strong performance this quarter again, 8% core revenue growth, 110 basis points of operating margin expansion and $256 million in operating cash flow. After adjusting for last year's $15 million slippage in revenue from Q2 to Q3 as we launch our new U.S. logistics center, our core revenue growth of 6.5% remained well above market.
During the quarter, we brought back $94 million of stock and paid $37 million in dividends. Finally, on May 3, we successfully moved all finance applications from Oracle to SAP, which is our main ERP. This will result in significant simplifications of our finance and IT operations. I'll now turn to the guidance for our third quarter. 
We expect Q3 revenues of $1.03 billion to $1.05 billion and EPS of $0.45 to $0.47. At midpoint, revenue will grow 1.3% on a core basis or close to 3% adjusting for last year's $50 million impact from the U.S. logistics center. And turning to share repurchase, we expect to buy back $93 million this Q3. Now to the guidance of fiscal year 2016.
We are raising the midpoint of our revenue guidance by $60 million, including $50 million due to currency. As a result, we're increasing our core revenue growth guidance at midpoint from 4.25% to 4.50%. We're also raising the midpoint of our EPS guidance by $0.06, including $0.03 coming from currency and $0.03 from operational performance. 
And one important note. After further review, we and our auditors have concluded to account for the Lasergen investment using the cost method of accounting. This means that we'll not book our share of Lasergen losses as previously communicated. 
Finally, we are raising our operating cash flow guidance from $650 million to $740 million, and there's no change to our CapEx guidance of $140 million. 
With that, I'll turn it over to Alicia for the Q&A."
154924,333332053,986521,"Agilent Technologies, Inc., Q2 2016 Earnings Call, May 16, 2016",2016-05-16,"Earnings Calls","Agilent Technologies, Inc.","Executives","Thank you, Didier. And Sabrina, will you please give the instructions for the Q&A?",14,"Thank you, Didier. And Sabrina, will you please give the instructions for the Q&A?"
154924,333332053,986521,"Agilent Technologies, Inc., Q2 2016 Earnings Call, May 16, 2016",2016-05-16,"Earnings Calls","Agilent Technologies, Inc.","Operator","[Operator Instructions] And our first question comes from the line of Dan Leonard of Leerink Partners.",16,"[Operator Instructions] And our first question comes from the line of Dan Leonard of Leerink Partners."
154924,333332053,986521,"Agilent Technologies, Inc., Q2 2016 Earnings Call, May 16, 2016",2016-05-16,"Earnings Calls","Agilent Technologies, Inc.","Analysts","Two questions. First off, can you elaborate on the business trends you're seeing in Europe? And then, secondly, on the pharma end market, can you talk about what gives you confidence in the fiscal 2017 outlook that you'd have yet another strong year in ph",62,"Two questions. First off, can you elaborate on the business trends you're seeing in Europe? And then, secondly, on the pharma end market, can you talk about what gives you confidence in the fiscal 2017 outlook that you'd have yet another strong year in pharma following 2 years then of tough comps in capital markets, which have been more or less shut?"
154924,333332053,986521,"Agilent Technologies, Inc., Q2 2016 Earnings Call, May 16, 2016",2016-05-16,"Earnings Calls","Agilent Technologies, Inc.","Executives","Thanks, Dan. I think I'm actually going to pass that over to Patrick, who is just back from a trip to Europe and maybe can provide some insight on what's going on Europe and then also, if he can pick up the question on pharma as well.",47,"Thanks, Dan. I think I'm actually going to pass that over to Patrick, who is just back from a trip to Europe and maybe can provide some insight on what's going on Europe and then also, if he can pick up the question on pharma as well."
154924,333332053,986521,"Agilent Technologies, Inc., Q2 2016 Earnings Call, May 16, 2016",2016-05-16,"Earnings Calls","Agilent Technologies, Inc.","Executives","Sure, I'm happy to do so. So let me start first to giving you some insights on Europe. We have seen actually some decent growth in Central Europe. We had seen some weakness on what we call the IDO, Eastern Europe and that's mainly driven by the chemical a",248,"Sure, I'm happy to do so. So let me start first to giving you some insights on Europe. We have seen actually some decent growth in Central Europe. We had seen some weakness on what we call the IDO, Eastern Europe and that's mainly driven by the chemical and energy market or the energy market on that side. In Central Europe, there's generally strength in Germany and other states around it. We still see some issues on the academia and government side that is rather flat. But pharma, for example, is also very strong in Europe. For your pharma question, overall, we are confident that we will continue to see pretty high growth in pharma for the remainder of this year. We target low double-digit growth for pharma. And looking into 2017, we think the pharma market will be -- continue to be strong for us, driven by 2 vectors. We see a continued demand in the replacement business. And as you probably know, we just launched -- at the analytical conference, we launched our new 1260 Infinity LC as an example, together with the Infinity lab consumables and servicing. And we think that will drive -- continue to drive a lot of good replacement for us in pharma. And then, we see also continued demand in the biopharma space that are looking for new solutions helping with these more complex molecules in terms of analysis, and we have a very comprehensive operating for that space as well."
154924,333332053,986521,"Agilent Technologies, Inc., Q2 2016 Earnings Call, May 16, 2016",2016-05-16,"Earnings Calls","Agilent Technologies, Inc.","Operator","And our next question comes from the line of Jonathan Groberg of UBS.",13,"And our next question comes from the line of Jonathan Groberg of UBS."
154924,333332053,986521,"Agilent Technologies, Inc., Q2 2016 Earnings Call, May 16, 2016",2016-05-16,"Earnings Calls","Agilent Technologies, Inc.","Analysts","Can you maybe just elaborate a little bit on -- I think you said core guidance. I'm looking at your presentation, core revenue growth guidance in the third quarter was pretty precise at 1.3%. But then I think I just heard that you still expect pharma to g",70,"Can you maybe just elaborate a little bit on -- I think you said core guidance. I'm looking at your presentation, core revenue growth guidance in the third quarter was pretty precise at 1.3%. But then I think I just heard that you still expect pharma to grow low double digits. Can you maybe just give a little kind of insight as to what you're seeing in the third quarter?"
154924,333332053,986521,"Agilent Technologies, Inc., Q2 2016 Earnings Call, May 16, 2016",2016-05-16,"Earnings Calls","Agilent Technologies, Inc.","Executives","Yes. What we looked at was with our growth rate that we've had over the first half of this year and as we looked into Q3 and Q4, and what I point to is a couple of things, Jonathan. First of all, tough compares and this is inclusive of a few onetime moves",316,"Yes. What we looked at was with our growth rate that we've had over the first half of this year and as we looked into Q3 and Q4, and what I point to is a couple of things, Jonathan. First of all, tough compares and this is inclusive of a few onetime moves between quarters, which actually were driven by improvements of overall operations. So as Didier mentioned, we had this $50 million shift in Q2 of last year into Q3, which when we had our start-up issues with our new logistics center. So if you adjust for that, it gets you to about 3% growth. The other thing we saw happen in Q2 was we've been working really hard to improve the overall cycle time from the time a customer places order to actually it's installed and we can recognize the revenue. In Q2, we actually exceeded our expectations and we got there a lot faster than we had thought, and what that meant was we had a significant amount of revenue, probably $20 million to $25 million that came from Q3 into Q2 where initially we'd forecasted into the second -- third quarter. All in all, if you kind of take into account those things, you've got pretty -- more of a consistent kind of a growth scenario between Q2 and Q3. 
I would tell you, though, the chemical energy is still looking for a bottom. And that's why we have that outlook for the year, which basically is down -- it's going to stay down for the rest of the year. There are some signs that it could be getting better. But we have -- we're not convinced yet we've seen the bottom in chemical energy. So I think the combination of those tough compares as well as our outlook on chemical energy is what's driving the overall guidance for the second half."
154924,333332053,986521,"Agilent Technologies, Inc., Q2 2016 Earnings Call, May 16, 2016",2016-05-16,"Earnings Calls","Agilent Technologies, Inc.","Analysts","Okay, that's helpful. And then, I guess, just one more. Are there any -- sometimes when we see shifts onto one platform like Oracle to SAP, is there anything at all -- any kind of wiggle room you left there in terms of hiccups in the quarter or maybe...",49,"Okay, that's helpful. And then, I guess, just one more. Are there any -- sometimes when we see shifts onto one platform like Oracle to SAP, is there anything at all -- any kind of wiggle room you left there in terms of hiccups in the quarter or maybe..."
154924,333332053,986521,"Agilent Technologies, Inc., Q2 2016 Earnings Call, May 16, 2016",2016-05-16,"Earnings Calls","Agilent Technologies, Inc.","Executives","Yes, what we try to do -- you're exactly right, Jonathan. So the wiggle room we left was, we made sure we went live the first month of the quarter. And Didier is in the conference room here smiling. And Didier, I don't know if you want to add any addition",58,"Yes, what we try to do -- you're exactly right, Jonathan. So the wiggle room we left was, we made sure we went live the first month of the quarter. And Didier is in the conference room here smiling. And Didier, I don't know if you want to add any additional color on how it's going so far?"
154924,333332053,986521,"Agilent Technologies, Inc., Q2 2016 Earnings Call, May 16, 2016",2016-05-16,"Earnings Calls","Agilent Technologies, Inc.","Executives","Yes, it's going very well, the migrations and the start-up of the operations. There were 0 disruption. Obviously, we expect to have to deal with some stabilization activities throughout the quarter. We'll do 2 close before we do the quarterly close. So ev",95,"Yes, it's going very well, the migrations and the start-up of the operations. There were 0 disruption. Obviously, we expect to have to deal with some stabilization activities throughout the quarter. We'll do 2 close before we do the quarterly close. So everything is -- we couldn't be happier about how it went. And you're correct. It is a very complex endeavor, one that we are pretty used to. We've done a few of those in the past. But still, it remains a very complex endeavor and we are really happy how smoothly it went."
154924,333332053,986521,"Agilent Technologies, Inc., Q2 2016 Earnings Call, May 16, 2016",2016-05-16,"Earnings Calls","Agilent Technologies, Inc.","Executives","And Jonathan, as I pointed out in my script, this is one of the Agile Agilent initiatives, which you'll start to see pay off in our cost structure, as we move into '17.",33,"And Jonathan, as I pointed out in my script, this is one of the Agile Agilent initiatives, which you'll start to see pay off in our cost structure, as we move into '17."
154924,333332053,986521,"Agilent Technologies, Inc., Q2 2016 Earnings Call, May 16, 2016",2016-05-16,"Earnings Calls","Agilent Technologies, Inc.","Operator","And our next question comes from the line of Tycho Peterson of JPMorgan.",13,"And our next question comes from the line of Tycho Peterson of JPMorgan."
154924,333332053,986521,"Agilent Technologies, Inc., Q2 2016 Earnings Call, May 16, 2016",2016-05-16,"Earnings Calls","Agilent Technologies, Inc.","Analysts","Just following up on that last point on the SAP margins, can you maybe -- or the market impact. Can you maybe quantify how much that could play on margins for this year?",33,"Just following up on that last point on the SAP margins, can you maybe -- or the market impact. Can you maybe quantify how much that could play on margins for this year?"
154924,333332053,986521,"Agilent Technologies, Inc., Q2 2016 Earnings Call, May 16, 2016",2016-05-16,"Earnings Calls","Agilent Technologies, Inc.","Executives","For 2016, I think it'll be very limited at best, Tycho, because we'll be running some duplicate backup systems and then the other aspects of our external spends really don't come out until '17. So I'd really position that in -- I actually think about this",71,"For 2016, I think it'll be very limited at best, Tycho, because we'll be running some duplicate backup systems and then the other aspects of our external spends really don't come out until '17. So I'd really position that in -- I actually think about this more of a '17 impact, but a proof point of why we think we're going to be able to improve our margins again in '17."
154924,333332053,986521,"Agilent Technologies, Inc., Q2 2016 Earnings Call, May 16, 2016",2016-05-16,"Earnings Calls","Agilent Technologies, Inc.","Analysts","And then academic 7%, can you maybe just talk as to whether you're seeing an acceleration there, in terms of what you saw this quarter?",26,"And then academic 7%, can you maybe just talk as to whether you're seeing an acceleration there, in terms of what you saw this quarter?"
154924,333332053,986521,"Agilent Technologies, Inc., Q2 2016 Earnings Call, May 16, 2016",2016-05-16,"Earnings Calls","Agilent Technologies, Inc.","Executives","Yes, what we saw in the last quarter is a really strong performance in China and some increased signs of life in the U.S. side of things. I think -- and that's where we pointed to an uptick. Not a lot of significant moves on the European side. It's mainly",75,"Yes, what we saw in the last quarter is a really strong performance in China and some increased signs of life in the U.S. side of things. I think -- and that's where we pointed to an uptick. Not a lot of significant moves on the European side. It's mainly a China-German story, and I think if there will be upside to it, it would come from the U.S. That's how we're thinking about it."
154924,333332053,986521,"Agilent Technologies, Inc., Q2 2016 Earnings Call, May 16, 2016",2016-05-16,"Earnings Calls","Agilent Technologies, Inc.","Analysts","Okay. And then, lastly, just in terms of pharma, obviously, that's been a nice driver. Can you maybe talk about where you think we are in the LCMS upgrade cycle? And how much your growth going forward is going to be contingent on already budget expanding",50,"Okay. And then, lastly, just in terms of pharma, obviously, that's been a nice driver. Can you maybe talk about where you think we are in the LCMS upgrade cycle? And how much your growth going forward is going to be contingent on already budget expanding versus the upgrade cycle?"
154924,333332053,986521,"Agilent Technologies, Inc., Q2 2016 Earnings Call, May 16, 2016",2016-05-16,"Earnings Calls","Agilent Technologies, Inc.","Executives","Yes, sure, Tycho, great question. I know, Patrick, I know you look at this pretty closely and what's the updated view on that?",23,"Yes, sure, Tycho, great question. I know, Patrick, I know you look at this pretty closely and what's the updated view on that?"
154924,333332053,986521,"Agilent Technologies, Inc., Q2 2016 Earnings Call, May 16, 2016",2016-05-16,"Earnings Calls","Agilent Technologies, Inc.","Executives","Yes, so I think there are 2 cycles we're looking at. The first cycle we went through was general upgrade cycle from standard HPLC to UHPLC, which is still ongoing but a considerable part of that probably has been done. But when you look at the installed b",163,"Yes, so I think there are 2 cycles we're looking at. The first cycle we went through was general upgrade cycle from standard HPLC to UHPLC, which is still ongoing but a considerable part of that probably has been done. But when you look at the installed base of instrumentation, it still deals with core LC and this is where we are targeting with the Infinity II series right now. There's still a lot of replacement pending out there. Just as a reminder, we have probably about 150,000 systems out there based on the 1100, 1200 platform, which over time will be up for replacement. And we are positioned extremely well with our platforms because it's 100% backwards compatible and we're also able, for example, to emulate some of our competitors' systems on our platform with a technology we call ISET, intelligence system emulation technology. And that actually compels very nicely with our customers and gives us a unique advantage in the market."
154924,333332053,986521,"Agilent Technologies, Inc., Q2 2016 Earnings Call, May 16, 2016",2016-05-16,"Earnings Calls","Agilent Technologies, Inc.","Executives","So I think we see both of those having legs into -- through  '17.",14,"So I think we see both of those having legs into -- through  '17."
154924,333332053,986521,"Agilent Technologies, Inc., Q2 2016 Earnings Call, May 16, 2016",2016-05-16,"Earnings Calls","Agilent Technologies, Inc.","Executives","Absolutely. I think this goes on into '17, combined again with the drive we see coming out of biopharma.",19,"Absolutely. I think this goes on into '17, combined again with the drive we see coming out of biopharma."
154924,333332053,986521,"Agilent Technologies, Inc., Q2 2016 Earnings Call, May 16, 2016",2016-05-16,"Earnings Calls","Agilent Technologies, Inc.","Operator","And our next question comes from the line of Jack Meehan of Barclays.",13,"And our next question comes from the line of Jack Meehan of Barclays."
154924,333332053,986521,"Agilent Technologies, Inc., Q2 2016 Earnings Call, May 16, 2016",2016-05-16,"Earnings Calls","Agilent Technologies, Inc.","Analysts","I just wanted to start, the growth was better -- at least relative to what I was looking for. Looked like you had better gross margins in the LSAG segment now 2 quarters in a row. Can you just talk about what some of the notable changes there are? Is ther",71,"I just wanted to start, the growth was better -- at least relative to what I was looking for. Looked like you had better gross margins in the LSAG segment now 2 quarters in a row. Can you just talk about what some of the notable changes there are? Is there anything with product mix that's driven the improvement? Or do you think this is the new norm to look for?"
154924,333332053,986521,"Agilent Technologies, Inc., Q2 2016 Earnings Call, May 16, 2016",2016-05-16,"Earnings Calls","Agilent Technologies, Inc.","Executives","I think -- let me make some initial comments and then Didier or Patrick, maybe you can build on it. So in terms of product mix, part of what you're seeing is the fact that we are winding down through our P&L the impact of the NMR business. And I think you",166,"I think -- let me make some initial comments and then Didier or Patrick, maybe you can build on it. So in terms of product mix, part of what you're seeing is the fact that we are winding down through our P&L the impact of the NMR business. And I think you can see the benefit of that exit decision on the P&L because it really has been contributing to the improved gross margins. And that's not the whole story. The other story is, obviously, the strong demand for the products and the volume benefits we're getting as well as the focus on taking cost out of our material cost side of the business as well as we talked a lot about the logistics last year. We could also talk about logistics this year, which is, we're doing a much better job in terms of overall logistics operations; that's blowing through on the P&L as well. So Didier, I'm not sure if I missed anything else."
154924,333332053,986521,"Agilent Technologies, Inc., Q2 2016 Earnings Call, May 16, 2016",2016-05-16,"Earnings Calls","Agilent Technologies, Inc.","Executives","No, you covered it all.",5,"No, you covered it all."
154924,333332053,986521,"Agilent Technologies, Inc., Q2 2016 Earnings Call, May 16, 2016",2016-05-16,"Earnings Calls","Agilent Technologies, Inc.","Analysts","Great. And then just one more for the adoption of the companion diagnostics now a few quarters into the launch. Are you in a position -- could you maybe just help us size what that business is today or just in the market what you think you hold in terms o",53,"Great. And then just one more for the adoption of the companion diagnostics now a few quarters into the launch. Are you in a position -- could you maybe just help us size what that business is today or just in the market what you think you hold in terms of market share?"
154924,333332053,986521,"Agilent Technologies, Inc., Q2 2016 Earnings Call, May 16, 2016",2016-05-16,"Earnings Calls","Agilent Technologies, Inc.","Executives","Why don't you take that, Jacob?",7,"Why don't you take that, Jacob?"
154924,333332053,986521,"Agilent Technologies, Inc., Q2 2016 Earnings Call, May 16, 2016",2016-05-16,"Earnings Calls","Agilent Technologies, Inc.","Executives","Yes, thanks for that question. And we are definitely pleased with the pickup of the PD-L1, and this continues during the last -- basically, it's now 3 quarters. The market is still very early. We still really only, in U.S, we have had a few press releases",160,"Yes, thanks for that question. And we are definitely pleased with the pickup of the PD-L1, and this continues during the last -- basically, it's now 3 quarters. The market is still very early. We still really only, in U.S, we have had a few press releases here lately. Also that we're entering into Europe, but we're just scratching the surface in Europe. And furthermore, it's still a second line -- it's still addressing the second line treatment. And if that also goes to the first-line treatment, the market will become significantly larger. At this point in time, it's still small revenue in the bigger scheme of things. But I do believe that the PD-L1 has an opportunity to be as big as the HER 2 market. However, we'll also remind you that of at least 4, probably 5 different potential drugs and companion diagnostics out there has to share that market. So still early days, but a great opportunity."
154924,333332053,986521,"Agilent Technologies, Inc., Q2 2016 Earnings Call, May 16, 2016",2016-05-16,"Earnings Calls","Agilent Technologies, Inc.","Operator","And our next question comes from the line of Brandon Couillard of Jefferies.",13,"And our next question comes from the line of Brandon Couillard of Jefferies."
154924,333332053,986521,"Agilent Technologies, Inc., Q2 2016 Earnings Call, May 16, 2016",2016-05-16,"Earnings Calls","Agilent Technologies, Inc.","Analysts","Mike, could you give us -- or Didier, could you give us the China growth rate -- the percentage change in the quarter? And if you could speak to demand in the food area outside of China and Asia, that will be helpful.",43,"Mike, could you give us -- or Didier, could you give us the China growth rate -- the percentage change in the quarter? And if you could speak to demand in the food area outside of China and Asia, that will be helpful."
154924,333332053,986521,"Agilent Technologies, Inc., Q2 2016 Earnings Call, May 16, 2016",2016-05-16,"Earnings Calls","Agilent Technologies, Inc.","Executives","Yes. So in the China result for Q2, what we've been pointing to is strong double-digit growth. So it was a very, very strong quarter for us in China. I would remind you that part of the strong growth was not only the strength in the market, but that those",146,"Yes. So in the China result for Q2, what we've been pointing to is strong double-digit growth. So it was a very, very strong quarter for us in China. I would remind you that part of the strong growth was not only the strength in the market, but that those operational efficiency improvements I talked about where we really had shortened the improved cycle time from orders to install that was really dramatic in China. So the overall business will be quite strong for the year. You should not expect a strong double-digit growth every quarter, though, for Q3 and Q4. But overall, China is -- just to complete the story here. When we came into this year, we thought that the overall performance for Agilent in China might be high single digits. We're now looking at low double-digit growth in China for the full year."
154924,333332053,986521,"Agilent Technologies, Inc., Q2 2016 Earnings Call, May 16, 2016",2016-05-16,"Earnings Calls","Agilent Technologies, Inc.","Analysts","And then one more for Didier. I noticed you bumped the operating cash flow guidance up about $90 million. How much of an impact does the -- I noticed a tax refund benefit. If you could quantify that and then just help us bridge the delta between prior ver",50,"And then one more for Didier. I noticed you bumped the operating cash flow guidance up about $90 million. How much of an impact does the -- I noticed a tax refund benefit. If you could quantify that and then just help us bridge the delta between prior versus new."
154924,333332053,986521,"Agilent Technologies, Inc., Q2 2016 Earnings Call, May 16, 2016",2016-05-16,"Earnings Calls","Agilent Technologies, Inc.","Executives","There was -- the overall tax outlays forecasted for this year were, I think, about $10 million less than what we had initially anticipated in our initial guidance, $10 million or $15 million, and the rest is really operational performance improvements in",54,"There was -- the overall tax outlays forecasted for this year were, I think, about $10 million less than what we had initially anticipated in our initial guidance, $10 million or $15 million, and the rest is really operational performance improvements in our working capital management and FX and then just our operating profits."
154924,333332053,986521,"Agilent Technologies, Inc., Q2 2016 Earnings Call, May 16, 2016",2016-05-16,"Earnings Calls","Agilent Technologies, Inc.","Operator","And our next question comes from the line of Ross Muken of Evercore.",13,"And our next question comes from the line of Ross Muken of Evercore."
154924,333332053,986521,"Agilent Technologies, Inc., Q2 2016 Earnings Call, May 16, 2016",2016-05-16,"Earnings Calls","Agilent Technologies, Inc.","Analysts","So Mike, since taking over, it's obviously been a pretty hectic journey and your messaging from the beginning has been pretty consistent around growth in margins and returns. Obviously, last few quarters, you started to develop a cadence. Last quarter res",136,"So Mike, since taking over, it's obviously been a pretty hectic journey and your messaging from the beginning has been pretty consistent around growth in margins and returns. Obviously, last few quarters, you started to develop a cadence. Last quarter results were good, but we had the challenges on FX. Do you feel like this is the first quarter where you feel like you got to deliver the full bag, where you were able to sort of drop through the top line outperformance, which is clearly better than market? You drove the margins. You're buying stock. The returns are up. The cash flow is good. That you were finally able to sort of show the market that the business model is working and that feeds, I guess, into your confidence also, I would assume on '17?"
154924,333332053,986521,"Agilent Technologies, Inc., Q2 2016 Earnings Call, May 16, 2016",2016-05-16,"Earnings Calls","Agilent Technologies, Inc.","Executives","Yes, I couldn't have said it better myself. Thanks, Ross, for the question. I think that we've been working really hard the last 4 or 5 quarters with the new leadership team. And as you look at -- everything came together this quarter. I mean, we've had s",282,"Yes, I couldn't have said it better myself. Thanks, Ross, for the question. I think that we've been working really hard the last 4 or 5 quarters with the new leadership team. And as you look at -- everything came together this quarter. I mean, we've had strong growth. We've had improvement in our operating margin, as I pointed out in '15. But all the vectors really came together nicely in the second quarter. And I was particularly pleased on some of the more operational activities that we've been working on inside the company. And that may not always be so apparent initially on the outside world, but you start to see it in the results. And the fact that we're doing -- we've adjusted our logistic challenges. Yeah, I have to talk about it in the year-over-year compares, but it's fixed and actually now is contributing to improved results. Yes, we had to talk about the shortened cycle time for orders to revenue and it brought in some revenues that we initially had planned for the third quarter, but we made those operational improvements. The cycle times are shorter, and this is now the new normal. So I guess, that will be the closing comments, which -- yes, we're the new normal for the company. We have got a lot of confidence about 2017, perhaps steal a little bit of my thunder for the Analyst Meeting next week, but I still hope everyone attends. But when you start having these proof points quarter in and quarter out, I think it starts to show you the team is delivering. And I think the results are now starting to be appreciated and believed."
154924,333332053,986521,"Agilent Technologies, Inc., Q2 2016 Earnings Call, May 16, 2016",2016-05-16,"Earnings Calls","Agilent Technologies, Inc.","Analysts","Great. And maybe quickly just on Seahorse. Can you just give us an update on how that business is performing relative to your expectations and how it's plugged in and where you're sort of seeing maybe the early fruits and some cross-synergy with the exist",46,"Great. And maybe quickly just on Seahorse. Can you just give us an update on how that business is performing relative to your expectations and how it's plugged in and where you're sort of seeing maybe the early fruits and some cross-synergy with the existing business?"
154924,333332053,986521,"Agilent Technologies, Inc., Q2 2016 Earnings Call, May 16, 2016",2016-05-16,"Earnings Calls","Agilent Technologies, Inc.","Executives","Yes, which is in fact, a very timely question, Ross. We just had our 180-day review this morning. And Patrick, why don't you go ahead and share a couple of highlights from that session?",34,"Yes, which is in fact, a very timely question, Ross. We just had our 180-day review this morning. And Patrick, why don't you go ahead and share a couple of highlights from that session?"
154924,333332053,986521,"Agilent Technologies, Inc., Q2 2016 Earnings Call, May 16, 2016",2016-05-16,"Earnings Calls","Agilent Technologies, Inc.","Executives","Sure, absolutely. So - what I really would like to highlight is how seamlessly we did -- the integration of Seahorse went. So we are now 6 months in the integration. And we would say we're targeting full integration by June, which means that we will have",158,"Sure, absolutely. So - what I really would like to highlight is how seamlessly we did -- the integration of Seahorse went. So we are now 6 months in the integration. And we would say we're targeting full integration by June, which means that we will have implemented all of the systems, which is a very fast pace. At the same time, we are seeing the positioning of Seahorse within our portfolio really works out. We're seeing nice deals and combined sales of LC-MS and Seahorse in areas like disease research and disease discovery. That's actually exactly where we thought its complementing our strength in metabolomics with the life cell metabolism which Seahorse brings to the table. And this is a very nice story that resonates very well with our customers. We are -- again, on the integration side, we are very pleased with where we stand and we are looking forward to some very successful second half."
154924,333332053,986521,"Agilent Technologies, Inc., Q2 2016 Earnings Call, May 16, 2016",2016-05-16,"Earnings Calls","Agilent Technologies, Inc.","Executives","Yes, Ross, I'll just add 2 things. The comment I made to the team this morning is this is the fastest I've seen us do an integration. These things usually plod along for many quarters and in some cases, for years. This one is moving along really, really f",78,"Yes, Ross, I'll just add 2 things. The comment I made to the team this morning is this is the fastest I've seen us do an integration. These things usually plod along for many quarters and in some cases, for years. This one is moving along really, really fast. And we're getting some wins. In fact, we won an LC/MS deal because of Seahorse. So I mean, it's the complementary nature of the portfolios is starting to work."
154924,333332053,986521,"Agilent Technologies, Inc., Q2 2016 Earnings Call, May 16, 2016",2016-05-16,"Earnings Calls","Agilent Technologies, Inc.","Operator","And our next question comes from the line of Paul Knight of Janney Montgomery Scott.",15,"And our next question comes from the line of Paul Knight of Janney Montgomery Scott."
154924,333332053,986521,"Agilent Technologies, Inc., Q2 2016 Earnings Call, May 16, 2016",2016-05-16,"Earnings Calls","Agilent Technologies, Inc.","Analysts","The move you made to create CrossLab seems to be gaining traction. Can you give us a little background on CrossLab in terms of, who do you think is -- is taking share from somebody at that kind of growth rate? Could you give us more color on CrossLab?",49,"The move you made to create CrossLab seems to be gaining traction. Can you give us a little background on CrossLab in terms of, who do you think is -- is taking share from somebody at that kind of growth rate? Could you give us more color on CrossLab?"
154924,333332053,986521,"Agilent Technologies, Inc., Q2 2016 Earnings Call, May 16, 2016",2016-05-16,"Earnings Calls","Agilent Technologies, Inc.","Executives","Yes. So as you mentioned, that was a major strategic move where when we set up the company, we established Agilent CrossLab Group. We had this vision about how we could really attack and go after the enterprise-wide services and consumables opportunity. A",236,"Yes. So as you mentioned, that was a major strategic move where when we set up the company, we established Agilent CrossLab Group. We had this vision about how we could really attack and go after the enterprise-wide services and consumables opportunity. And as you see, Mark and the team have really been delivering. And we know that the customers are responding to the value proposition that Agilent offers, both in terms of how our service capability is viewed -- and that's why I mentioned in my script about the external recognition we recently received -- but they also appreciate the fact we're able to give them insights in terms of actually helping them improve the business operations, and we're seeing a real strong demand for this in the pharma and growing interest in other parts of the applied market. So we know that we're growing faster than some of our competitors in this space. We also know that there's only a few companies really trying to go after this type of business. I believe this is where the market is already going to and I think you want to be a player here. And I leave it to you guys to figure out who's the losing share. But as you can see, all I can tell you is we're growing close to double digit in the space. So it's been an attractive move for us."
154924,333332053,986521,"Agilent Technologies, Inc., Q2 2016 Earnings Call, May 16, 2016",2016-05-16,"Earnings Calls","Agilent Technologies, Inc.","Operator","And our next question comes from the line of Tim Evans of Wells Fargo Securities.",15,"And our next question comes from the line of Tim Evans of Wells Fargo Securities."
154924,333332053,986521,"Agilent Technologies, Inc., Q2 2016 Earnings Call, May 16, 2016",2016-05-16,"Earnings Calls","Agilent Technologies, Inc.","Analysts","I'm just trying to understand the variance in the quarter relative to what you were expecting. I believe you had called last quarter for 4% core growth, and we saw 8% this quarter. I hear you that it sounds like about half of that variance, about 200 basi",102,"I'm just trying to understand the variance in the quarter relative to what you were expecting. I believe you had called last quarter for 4% core growth, and we saw 8% this quarter. I hear you that it sounds like about half of that variance, about 200 basis points, was from the better book backlog to revenue conversion in this quarter. And I know you also called out the compare relative to last year. But that compare should have already been known. So I just want to understand what's the other 200 basis points that really surprised you in the quarter?"
154924,333332053,986521,"Agilent Technologies, Inc., Q2 2016 Earnings Call, May 16, 2016",2016-05-16,"Earnings Calls","Agilent Technologies, Inc.","Executives","Sure, Tim, how about if I -- again, thanks for your comment. And I can give you a few dollar numbers of revenue impact the way we've been looking at it and you can do them -- perhaps the math on the impact on the growth rates. But what we saw relative to",259,"Sure, Tim, how about if I -- again, thanks for your comment. And I can give you a few dollar numbers of revenue impact the way we've been looking at it and you can do them -- perhaps the math on the impact on the growth rates. But what we saw relative to our initial expectations for the quarter were really -- first of all, it starts with the market, right? So the overall market demand came in as we predicted. We saw good growth across the entire portfolio led by pharma and food markets in China, as you heard early. But I'd ask you to look at 2 things. One is this higher conversion of orders to revenue than forecast. So basically, what we've done is we reduced the cycle time and by our estimates, it happened a lot faster than we had thought, which I think is good news from the standpoint of operational efficiency; did create some forecasting challenges, but probably $20 million to $25 million came from Q3 into Q2. The other thing, I think, you should take a look at is the FX assumptions. So around $9 million or so, Didier, I think was the number. So FX added about another $9 million. So between the cycle time improvements, the FX assumptions and just the fact that the market continues, we're getting our fair share of markets where they're growing. I think those -- combination of those facts, I think, will help you bridge the difference between our guided growth and what actually occurred."
154924,333332053,986521,"Agilent Technologies, Inc., Q2 2016 Earnings Call, May 16, 2016",2016-05-16,"Earnings Calls","Agilent Technologies, Inc.","Analysts","Okay. Just a real quick similar question on the margin side. Obviously, a little bit of the margin in the quarter was the drop through, but it looks like you probably did better than you were expecting on an absolute dollar basis on the SG&A as well. Can",63,"Okay. Just a real quick similar question on the margin side. Obviously, a little bit of the margin in the quarter was the drop through, but it looks like you probably did better than you were expecting on an absolute dollar basis on the SG&A as well. Can you help me understand, maybe, what is going a little faster there than you anticipated?"
154924,333332053,986521,"Agilent Technologies, Inc., Q2 2016 Earnings Call, May 16, 2016",2016-05-16,"Earnings Calls","Agilent Technologies, Inc.","Executives","Yes, I think on the SG&A front, I mean, we've got a couple of our programs inside the Agile Agilent are little bit ahead of plan. And -- but Didier, I don't know if there's anything else of...",38,"Yes, I think on the SG&A front, I mean, we've got a couple of our programs inside the Agile Agilent are little bit ahead of plan. And -- but Didier, I don't know if there's anything else of..."
154924,333332053,986521,"Agilent Technologies, Inc., Q2 2016 Earnings Call, May 16, 2016",2016-05-16,"Earnings Calls","Agilent Technologies, Inc.","Executives","Most of the impact was volume driven and obviously, the FX, but there was -- versus the initial guidance.",19,"Most of the impact was volume driven and obviously, the FX, but there was -- versus the initial guidance."
154924,333332053,986521,"Agilent Technologies, Inc., Q2 2016 Earnings Call, May 16, 2016",2016-05-16,"Earnings Calls","Agilent Technologies, Inc.","Executives","I will tell you the field structure that we put in place last year, it's really stabled down. I think it's delivering, helping us on the growth side and also, on the SG&A front as a more efficient go-to-market channel.",40,"I will tell you the field structure that we put in place last year, it's really stabled down. I think it's delivering, helping us on the growth side and also, on the SG&A front as a more efficient go-to-market channel."
154924,333332053,986521,"Agilent Technologies, Inc., Q2 2016 Earnings Call, May 16, 2016",2016-05-16,"Earnings Calls","Agilent Technologies, Inc.","Operator","And our next question comes from the line of Isaac Ro of Goldman Sachs.",14,"And our next question comes from the line of Isaac Ro of Goldman Sachs."
154924,333332053,986521,"Agilent Technologies, Inc., Q2 2016 Earnings Call, May 16, 2016",2016-05-16,"Earnings Calls","Agilent Technologies, Inc.","Analysts","I had a question on margins as well. On the gross margin side, I was curious if we should expect maybe another wave of improvement now that you have the ERP integration done and on the margin side, curious how satisfied you are with the sales force realig",62,"I had a question on margins as well. On the gross margin side, I was curious if we should expect maybe another wave of improvement now that you have the ERP integration done and on the margin side, curious how satisfied you are with the sales force realignment and whether or not there's still more synergies to be had there as well."
154924,333332053,986521,"Agilent Technologies, Inc., Q2 2016 Earnings Call, May 16, 2016",2016-05-16,"Earnings Calls","Agilent Technologies, Inc.","Executives","Yes, a couple of comments here. Then I'll bounce it over to Didier in case he'd like to add a few things here. But in terms of the sales force integration and go-to-market -- we couldn't be happier. I mean, that was a major move we made last year, where w",347,"Yes, a couple of comments here. Then I'll bounce it over to Didier in case he'd like to add a few things here. But in terms of the sales force integration and go-to-market -- we couldn't be happier. I mean, that was a major move we made last year, where we basically went from 5 sales forces to the 2 sales forces, one focused on the analytical laboratory marketplace and then the other one focused on the regulated diagnostic marketplace. At the time, I remember sharing with you, ""Hey, we're making a big change here and it could affect the top line and the short one. That didn't happen. In fact, I submit that as we go out into '16 and '17, we're now putting more resources of specialization in academia, in biopharma. So I think you're going to see the changes paying off in terms of our longer-term growth. So we're really happy with both the fact that we've got it all behind us, it's settled down and I think it's starting to pay off on the initial benefits that we envisioned when we created that structure. 
Relative to gross margin ERP, just keep in mind that what we've been talking about is a -- the financial systems, which really go into the SG&A line. So it really won't affect the gross margin. That being said, we do think we can do more on gross margins as we move forward in '16 and '17. I'll talk a little bit about -- more about in detail next week when we're in New York. But as you may know, on our initial 400 basis points of improvement, when I came onboard, we said half would come through OpEx and other operational costs, and then others through growth. And the growth piece would be -- a lot would be driven by our ability to capture the gross margin improvements on increased volume. So we think we still have room to improve our material cost, and we think that we've got room to continue to bring down our logistics costs."
154924,333332053,986521,"Agilent Technologies, Inc., Q2 2016 Earnings Call, May 16, 2016",2016-05-16,"Earnings Calls","Agilent Technologies, Inc.","Analysts","That's very helpful. Maybe just a follow-up. Just to clarify on 2 topics, one on biopharma and then the other one on the comments you made around China. On biopharma, could you just compare the growth rates you're seeing in the QAQC setting versus R&D? An",82,"That's very helpful. Maybe just a follow-up. Just to clarify on 2 topics, one on biopharma and then the other one on the comments you made around China. On biopharma, could you just compare the growth rates you're seeing in the QAQC setting versus R&D? And then in China, just curious, how much of your improved outlook there is based on the visibility you have with government funding versus sort of end markets that are more on the private industry side?"
154924,333332053,986521,"Agilent Technologies, Inc., Q2 2016 Earnings Call, May 16, 2016",2016-05-16,"Earnings Calls","Agilent Technologies, Inc.","Executives","I think that on the -- your question, we're not seeing any real significant differences in growth rates across the segments you described in pharma. I do think if you go out a couple of years down the road, I think we'd expect the growth rate in the bioph",152,"I think that on the -- your question, we're not seeing any real significant differences in growth rates across the segments you described in pharma. I do think if you go out a couple of years down the road, I think we'd expect the growth rate in the biopharma should be higher than the small molecule. But it's not at all the case right now. As you heard earlier from Patrick, we expect that to continue through '17. We're getting more clarity about what's going on in China. I think there was a lot of concerns at one point in time on the private sector, this side of the business, but obviously, as you know, Isaac, the government drives the market there to a large extent, and we're getting more clarity on what's happening in funding. So that's why we have this increased confidence in our outlook for our business in China."
154924,333332053,986521,"Agilent Technologies, Inc., Q2 2016 Earnings Call, May 16, 2016",2016-05-16,"Earnings Calls","Agilent Technologies, Inc.","Operator","And our next question comes from the line of Derik De Bruin of Bank of America.",16,"And our next question comes from the line of Derik De Bruin of Bank of America."
154924,333332053,986521,"Agilent Technologies, Inc., Q2 2016 Earnings Call, May 16, 2016",2016-05-16,"Earnings Calls","Agilent Technologies, Inc.","Analysts","Just wanted to clarify. Did I hear you correctly that you said your initial flash for core growth guidance for fiscal '17 was 4.5% midpoint?",25,"Just wanted to clarify. Did I hear you correctly that you said your initial flash for core growth guidance for fiscal '17 was 4.5% midpoint?"
154924,333332053,986521,"Agilent Technologies, Inc., Q2 2016 Earnings Call, May 16, 2016",2016-05-16,"Earnings Calls","Agilent Technologies, Inc.","Executives","Yes, yes.",2,"Yes, yes."
154924,333332053,986521,"Agilent Technologies, Inc., Q2 2016 Earnings Call, May 16, 2016",2016-05-16,"Earnings Calls","Agilent Technologies, Inc.","Analysts","Okay. And so can you sort of like flank that in terms of what you're thinking for the chemical and energy market there? I mean, just sort of what you're expecting in terms of a rebound. And I'm just -- could you help us frame that comment a little bit mor",60,"Okay. And so can you sort of like flank that in terms of what you're thinking for the chemical and energy market there? I mean, just sort of what you're expecting in terms of a rebound. And I'm just -- could you help us frame that comment a little bit more in terms of some of the puts and takes?"
154924,333332053,986521,"Agilent Technologies, Inc., Q2 2016 Earnings Call, May 16, 2016",2016-05-16,"Earnings Calls","Agilent Technologies, Inc.","Executives","Yes, sure I'd be happy to because sometimes, you can use colorful language, which doesn't really give you the insights you need. So let me try to clarify here. So what we said was in this year, we thought our performance would be flat for the entire year,",348,"Yes, sure I'd be happy to because sometimes, you can use colorful language, which doesn't really give you the insights you need. So let me try to clarify here. So what we said was in this year, we thought our performance would be flat for the entire year, while in fact, it's going to be down, we probably think in the range of 2.5% for the year, for the entire year. And that is a change from our assumptions coming into this year. And that was the assumption we made at the time of our initial guidance, which makes our revenue results even much more -- we're really pleased with the results, given the fact that the chemical energy market has not developed the way we initially had thought. That being said, in '17, we actually think it will be improved, which means it won't be declining. And in fact, it will probably be flat or maybe low single digits. And why do we believe that? If you look at how our business breaks down in that segment, we often talk about the oil side. But 50% of our business historically has been in the exploration and another 35% has been in the refining. The other half, which is by far the biggest individual segment, is the chemical side, and they're benefiting by lower feedstock costs. They've got pent-up investment demands, and we're starting to see increased deal activity. So in fact, Patrick and I were talking about this, this morning and it kind of reminds me of pharma a few years ago where basically we were going to have 2 years of shrinking performance in this marketplace, a lot of pent-up demand. So long story short, our growth assumption for next year assumes low single-digit chemical energy growth for the year. Again, we still believe we're searching for the bottom. So -- and it's still early in the year of 2016. But that's our basic assumption for '17, which is an improved environment -- not dramatic, but improved from what we've seen over the last 24 months."
154924,333332053,986521,"Agilent Technologies, Inc., Q2 2016 Earnings Call, May 16, 2016",2016-05-16,"Earnings Calls","Agilent Technologies, Inc.","Analysts","And just as a quick follow-up on the chemical comment. You're not worried that some of the activity between Dow and DuPont and -- looks like there may be Monsanto and so these are the companies that are dancing around. Are you worried that, that could sor",73,"And just as a quick follow-up on the chemical comment. You're not worried that some of the activity between Dow and DuPont and -- looks like there may be Monsanto and so these are the companies that are dancing around. Are you worried that, that could sort of stymie investment? If you're using the pharma analogy of sort of combinations of those companies? Is there some potential headwind from the chemicals market?"
154924,333332053,986521,"Agilent Technologies, Inc., Q2 2016 Earnings Call, May 16, 2016",2016-05-16,"Earnings Calls","Agilent Technologies, Inc.","Executives","No, Derik, that's a great question. We looked at this pretty closely when the announcement was first made. And although Dow and DuPont are very important customers to us, that particular deal activity really is immaterial to the total company's performanc",111,"No, Derik, that's a great question. We looked at this pretty closely when the announcement was first made. And although Dow and DuPont are very important customers to us, that particular deal activity really is immaterial to the total company's performance. And we didn't necessarily see it as a sign of an acceleration of M&A and consolidations going on in the space. So of course, there would be some pause if we'd seen more of that, but we're not overly concerned about that. And I guess, the beauty of this business has been just the broad-based nature of our customer base. So we're not overly dependent on any one single customer."
154924,333332053,986521,"Agilent Technologies, Inc., Q2 2016 Earnings Call, May 16, 2016",2016-05-16,"Earnings Calls","Agilent Technologies, Inc.","Operator","And our next question comes from the line of Dan Arias of Citigroup.",13,"And our next question comes from the line of Dan Arias of Citigroup."
154924,333332053,986521,"Agilent Technologies, Inc., Q2 2016 Earnings Call, May 16, 2016",2016-05-16,"Earnings Calls","Agilent Technologies, Inc.","Analysts","Hi Mike, can you just touch on Japan and things that you saw during the quarter in terms of trends and then maybe what you're looking for at this point on the year?",33,"Hi Mike, can you just touch on Japan and things that you saw during the quarter in terms of trends and then maybe what you're looking for at this point on the year?"
154924,333332053,986521,"Agilent Technologies, Inc., Q2 2016 Earnings Call, May 16, 2016",2016-05-16,"Earnings Calls","Agilent Technologies, Inc.","Executives","Yes. So Dan, thanks for the question. And if you know a little bit of my history, I spent 5 years in Japan. So I've always been a big supporter of Japan in terms of the long-term view of the market. And I'd ask you to take a long-term view of the market i",178,"Yes. So Dan, thanks for the question. And if you know a little bit of my history, I spent 5 years in Japan. So I've always been a big supporter of Japan in terms of the long-term view of the market. And I'd ask you to take a long-term view of the market in Japan. So that was the only market that actually was down for us in the second quarter. And we are expecting continued subdued performance in Japan. So we're not expecting much in terms of improvement in the overall market environment in Japan. We do think that it could be a market which often will respond to new technologies, innovative new products. So we do hope -- we do hold out hope that we could take some share from some of our new intros coming out in the second part of this year. But from an overall market perspective, we're expecting it to remain subdued and our internal forecasts are not based on any type of material improvement at all on our performance in Japan."
154924,333332053,986521,"Agilent Technologies, Inc., Q2 2016 Earnings Call, May 16, 2016",2016-05-16,"Earnings Calls","Agilent Technologies, Inc.","Analysts","Okay. Thanks for that color. And then you kind of teased some new product introductions in the back half that should be meaningful to growth. I'm sure you don't want to give away any secrets, but can you just sort of help us with what part of the business",56,"Okay. Thanks for that color. And then you kind of teased some new product introductions in the back half that should be meaningful to growth. I'm sure you don't want to give away any secrets, but can you just sort of help us with what part of the business you're anticipating seeing the boost in 2017?"
154924,333332053,986521,"Agilent Technologies, Inc., Q2 2016 Earnings Call, May 16, 2016",2016-05-16,"Earnings Calls","Agilent Technologies, Inc.","Executives","Yes. So thanks for the caveat on your question. So what we can point to with great confidence and clarity is the recent introduction we made in analytic. And that what I would say to you, you will see broad-based introductions across the entire portfolio.",163,"Yes. So thanks for the caveat on your question. So what we can point to with great confidence and clarity is the recent introduction we made in analytic. And that what I would say to you, you will see broad-based introductions across the entire portfolio. And core growth is essential to our business plan. As you know, when I came in last year, we spent a lot of time reorganizing the R&D structure and also, reallocating where we put money. And I think you're going to start to see some of that starting to pay off, as we go into the latter part of '16. So we did want to put a teaser out there, but also just to make sure you had confidence in terms of what's behind our view of improved Agilent performance in '17 off of the second half of this year. But I think you're going to expect to see us talking about activities across all 3 business groups."
154924,333332053,986521,"Agilent Technologies, Inc., Q2 2016 Earnings Call, May 16, 2016",2016-05-16,"Earnings Calls","Agilent Technologies, Inc.","Operator","And our next question comes from the line of Doug Schenkel of Cowen and Company.",15,"And our next question comes from the line of Doug Schenkel of Cowen and Company."
154924,333332053,986521,"Agilent Technologies, Inc., Q2 2016 Earnings Call, May 16, 2016",2016-05-16,"Earnings Calls","Agilent Technologies, Inc.","Analysts","Mike, I wanted to go back to some of the comments you made on efforts to tighten cycle times from order to revenue, which seem to be yielding benefits greater than expected, particularly on China. Can you provide a bit more background on this effort and w",118,"Mike, I wanted to go back to some of the comments you made on efforts to tighten cycle times from order to revenue, which seem to be yielding benefits greater than expected, particularly on China. Can you provide a bit more background on this effort and why it was most impactful in China? And then maybe talk about similar efforts underway in other geographies. And relatedly, you positioned these in answering some questions as if they were temporary. At least, it seems like your guidance doesn't treat these as sustainable improvements. Yet, everything else you've said suggests that these are truly sustainable improvements. So I was just hoping you could help us understand that a little bit better."
154924,333332053,986521,"Agilent Technologies, Inc., Q2 2016 Earnings Call, May 16, 2016",2016-05-16,"Earnings Calls","Agilent Technologies, Inc.","Executives","Yes, sure, Doug. I really appreciate the question. And maybe let me start with the last part of your question, which is the takeaway here, we do believe that there's a stable improvement. So in my mind or the language I use, this is the new normal in term",443,"Yes, sure, Doug. I really appreciate the question. And maybe let me start with the last part of your question, which is the takeaway here, we do believe that there's a stable improvement. So in my mind or the language I use, this is the new normal in terms of our ability to convert orders to revenue. And so I would characterize this as new normal of how we're going to operate. So how did we get here and why do they look so significantly different in China? So first of all, it starts with looking at the entire process from an end-to-end customer perspective from the time of order placement till shipment until customer installation occurs -- and, as you know, when I restructured the company, I was really trying to break down the silos and we had a very silo-oriented approach to this end-to-end process from a customer perspective. In the company, we looked at each slice of the process but nobody was looking at the collective process for end-to-end. You start doing that, and then you start seeing where the issues are, the opportunities are. So we found ways to improve our order linearity. We've improved the quality of booked orders, and this really gets to your question about China. Often, you're dealing with letters of credit issues and other trade issues that in the past have delayed our ability to actually book them as clean orders and turn them into revenue. We call this delivery box. We've been working on making sure we had material availability. I think we hit one of our best quarters ever in terms of having material ready for all of our shipments. So we improved our ability to get in orders in a linear fashion, make sure those orders are clean and not have lot of rework, and then we've improved our delivery performance. And then spent a lot of time improving our efforts between shipment installation, which sometimes can go on for several weeks. So I think it all starts with this looking at the whole process from an end-to-end perspective, and the result has been a significant improvement in cycle time and orders turned into revenue more quickly than in the past. I do think this represents our new way of operating. And again, as I mentioned in my remarks, it did create some -- it did have implications of how we guide the company for the second and third quarter. But I think we're delighted to be able to actually have ongoing strong operational efficiency improvement in place so that we know how to predict revenue even better in the future."
154924,333332053,986521,"Agilent Technologies, Inc., Q2 2016 Earnings Call, May 16, 2016",2016-05-16,"Earnings Calls","Agilent Technologies, Inc.","Analysts","Okay. Mike, but just to be really clear, recognizing these are well-earned, sustainable improvements, it's not apparent that this is fully -- these improvements, the sustainably is fully reflected in guidance. If that's the case, is that just because you",57,"Okay. Mike, but just to be really clear, recognizing these are well-earned, sustainable improvements, it's not apparent that this is fully -- these improvements, the sustainably is fully reflected in guidance. If that's the case, is that just because you want to see this play out for a couple of quarters before you start baking it in?"
154924,333332053,986521,"Agilent Technologies, Inc., Q2 2016 Earnings Call, May 16, 2016",2016-05-16,"Earnings Calls","Agilent Technologies, Inc.","Executives","Yes. I think the confusion might be that what we have stated is that this quarter in Q2, we got $20 million to $25 million of revenue that we had anticipated to be recognized in Q3 as we were bringing all those programs to fruition. We had earlier results",120,"Yes. I think the confusion might be that what we have stated is that this quarter in Q2, we got $20 million to $25 million of revenue that we had anticipated to be recognized in Q3 as we were bringing all those programs to fruition. We had earlier results, which is great. From where we are now, the order to revenue cycle time is sustainable, but we will not see further improvement that will bring Q4 revenue into Q3 or whatever it is. So the 20 to 25, that's onetime. We've got to the level we wanted to be at. And from now on, it's just business as usual without any fundamental change in the order to revenue cycle time."
154924,333332053,986521,"Agilent Technologies, Inc., Q2 2016 Earnings Call, May 16, 2016",2016-05-16,"Earnings Calls","Agilent Technologies, Inc.","Analysts","All right. And just one last one for you. On the change in Lasergen accounting, was there any dilution in the quarter? And based on the accounting change, should we no longer expect this to be $0.02 to $0.03 dilutive deal for the year?",44,"All right. And just one last one for you. On the change in Lasergen accounting, was there any dilution in the quarter? And based on the accounting change, should we no longer expect this to be $0.02 to $0.03 dilutive deal for the year?"
154924,333332053,986521,"Agilent Technologies, Inc., Q2 2016 Earnings Call, May 16, 2016",2016-05-16,"Earnings Calls","Agilent Technologies, Inc.","Executives","Correct. You're correct. So there was no dilution in Q2, and there will not be any dilution in -- for the rest of '16 or '17 until we exercise our call option. And then we will just fully consolidate -- if we do that, obviously -- fully consolidate the La",120,"Correct. You're correct. So there was no dilution in Q2, and there will not be any dilution in -- for the rest of '16 or '17 until we exercise our call option. And then we will just fully consolidate -- if we do that, obviously -- fully consolidate the Lasergen revenue. So that's a change that there was a lot of -- I mean, discussions with the auditors. They surprised us a little bit by going to national to get specially some kind of -- challenge kind of the accounting that we had anticipated locally among the 2 teams, and then we agreed to the recommendation. And therefore, no dilution to EPS coming from Lasergen in the next 2 years."
154924,333332053,986521,"Agilent Technologies, Inc., Q2 2016 Earnings Call, May 16, 2016",2016-05-16,"Earnings Calls","Agilent Technologies, Inc.","Executives","Right. And we were pleased we were able to get this closed off before we finished the quarter.",18,"Right. And we were pleased we were able to get this closed off before we finished the quarter."
154924,333332053,986521,"Agilent Technologies, Inc., Q2 2016 Earnings Call, May 16, 2016",2016-05-16,"Earnings Calls","Agilent Technologies, Inc.","Operator","And our next question comes from the line of Miroslava Minkova of Stifel.",13,"And our next question comes from the line of Miroslava Minkova of Stifel."
154924,333332053,986521,"Agilent Technologies, Inc., Q2 2016 Earnings Call, May 16, 2016",2016-05-16,"Earnings Calls","Agilent Technologies, Inc.","Analysts","Maybe if I could focus on operating margins, again, for a second. Just help us, remind us. There's a lot going on there in terms of the programs you have in place and improvements you have going on. Help us -- remind us the bridge between fiscal '16 and '",58,"Maybe if I could focus on operating margins, again, for a second. Just help us, remind us. There's a lot going on there in terms of the programs you have in place and improvements you have going on. Help us -- remind us the bridge between fiscal '16 and '17? What's gets you to the 22% operating margin?"
154924,333332053,986521,"Agilent Technologies, Inc., Q2 2016 Earnings Call, May 16, 2016",2016-05-16,"Earnings Calls","Agilent Technologies, Inc.","Executives","Well, as a teaser, we're going to go through this in some detail.",13,"Well, as a teaser, we're going to go through this in some detail."
154924,333332053,986521,"Agilent Technologies, Inc., Q2 2016 Earnings Call, May 16, 2016",2016-05-16,"Earnings Calls","Agilent Technologies, Inc.","Executives","There will be a slide on the topic next week.",10,"There will be a slide on the topic next week."
154924,333332053,986521,"Agilent Technologies, Inc., Q2 2016 Earnings Call, May 16, 2016",2016-05-16,"Earnings Calls","Agilent Technologies, Inc.","Executives","But what I can share with you conceptually is that we will be continuing and completing off the integration of the Dako acquisition. We have a series of operational programs. We talked about one of those already, which is the implications of the ERP, and",86,"But what I can share with you conceptually is that we will be continuing and completing off the integration of the Dako acquisition. We have a series of operational programs. We talked about one of those already, which is the implications of the ERP, and the continued focus on gross margin improvement, specifically material cost reductions and logistic savings. So I think the combination of those 3 factors plus with the overall quarter growth assumptions that we're currently modeling around 4.5 gets us to the 22%."
154924,333332053,986521,"Agilent Technologies, Inc., Q2 2016 Earnings Call, May 16, 2016",2016-05-16,"Earnings Calls","Agilent Technologies, Inc.","Analysts","Okay, great. And the strength in the food market, was this all China or are you seeing strength elsewhere as well?",21,"Okay, great. And the strength in the food market, was this all China or are you seeing strength elsewhere as well?"
154924,333332053,986521,"Agilent Technologies, Inc., Q2 2016 Earnings Call, May 16, 2016",2016-05-16,"Earnings Calls","Agilent Technologies, Inc.","Executives","Actually, it was both in food, I mean, excuse me, both -- food market, both in China and in the United States. As you may recall, from our Q1 announcement, this business tends to be a little lumpy, whereas I think the performance in the food market in Chi",65,"Actually, it was both in food, I mean, excuse me, both -- food market, both in China and in the United States. As you may recall, from our Q1 announcement, this business tends to be a little lumpy, whereas I think the performance in the food market in China has been sustained. But we saw a nice rebound in the U.S. in the second quarter."
154924,333332053,986521,"Agilent Technologies, Inc., Q2 2016 Earnings Call, May 16, 2016",2016-05-16,"Earnings Calls","Agilent Technologies, Inc.","Analysts","Got you. Okay. And maybe finally, give us your view of the M&A pipeline. We've seen you do a couple of deals just recently here. Now that you have sort of many of the operational initiatives for the new Agilent in place, should we expect you're more activ",53,"Got you. Okay. And maybe finally, give us your view of the M&A pipeline. We've seen you do a couple of deals just recently here. Now that you have sort of many of the operational initiatives for the new Agilent in place, should we expect you're more active with the tuck-ins going forward?"
154924,333332053,986521,"Agilent Technologies, Inc., Q2 2016 Earnings Call, May 16, 2016",2016-05-16,"Earnings Calls","Agilent Technologies, Inc.","Executives","Again, this is a teaser #2, which is we're going to talk about this a little bit in more detail next week. But I do feel that the company's foundation is really firmly established. And as I mentioned earlier, I think we're getting a lot better in terms of",140,"Again, this is a teaser #2, which is we're going to talk about this a little bit in more detail next week. But I do feel that the company's foundation is really firmly established. And as I mentioned earlier, I think we're getting a lot better in terms of our speed to be able to integrate. But what -- I think you're going to expect us to do is to remain disciplined and focused in terms of finding those opportunities that make sense for us. And I would ask you to think about as being complementary M&A in nature. We're going to continue to look for those. So our balance sheet is a huge asset for the -- for our shareholders and one which we would like to deploy relative to M&A, but it has to be the right target."
154924,333332053,986521,"Agilent Technologies, Inc., Q2 2016 Earnings Call, May 16, 2016",2016-05-16,"Earnings Calls","Agilent Technologies, Inc.","Operator","And our next question comes from the line of Steve Beuchaw of Morgan Stanley.",14,"And our next question comes from the line of Steve Beuchaw of Morgan Stanley."
154924,333332053,986521,"Agilent Technologies, Inc., Q2 2016 Earnings Call, May 16, 2016",2016-05-16,"Earnings Calls","Agilent Technologies, Inc.","Analysts","Just 2 clarifications on how you're thinking about the '16, '17 progression. The first is actually on the NIH. To what extent, if any, are you anticipating a pick-up in the research channel from NIH funding when we start to see that get dispersed in the s",98,"Just 2 clarifications on how you're thinking about the '16, '17 progression. The first is actually on the NIH. To what extent, if any, are you anticipating a pick-up in the research channel from NIH funding when we start to see that get dispersed in the second half of the year? And then second, and this may be even a longer-term question. But how do you think about the evolution of FSMA regulations in the food space in the U.S.? Is it too soon to start getting incrementally optimistic about how they could contribute to the outlook?"
154924,333332053,986521,"Agilent Technologies, Inc., Q2 2016 Earnings Call, May 16, 2016",2016-05-16,"Earnings Calls","Agilent Technologies, Inc.","Executives","Yes, thanks. I'm glad to address both of your questions. So on the NIH front, I think, when we talked about the uptick in sort of our improved confidence about spends in academia and government in the U.S., I think we do think that the NIH stuff will star",219,"Yes, thanks. I'm glad to address both of your questions. So on the NIH front, I think, when we talked about the uptick in sort of our improved confidence about spends in academia and government in the U.S., I think we do think that the NIH stuff will start to flow through to our business. Relative to some in our space, we don't have it as high a percentage of our business tied to the NIH, but it will be a positive for us. And I think, again, one more fact pattern which points to a continued view that this market will be solid for us as we move into '17. I think I'd have to agree with the comment, which is, I think it really is too soon to get overall excited about this from a U.S. spending. I've seen this before where the legislation is announced and there's a lot of fanfare about it. But they don't always get backed up by investments. Although we did -- we are seeing some -- it looks like some maybe more friendly government allocations to this agency unlike we've seen to the EPA. So we're not expecting anything dramatic to occur definitely in the market because of this. But if it would, that would be clearly good news for us."
154924,333332053,986521,"Agilent Technologies, Inc., Q2 2016 Earnings Call, May 16, 2016",2016-05-16,"Earnings Calls","Agilent Technologies, Inc.","Operator","And our next question comes from the line of Jeff Elliott of Robert W. Baird.",15,"And our next question comes from the line of Jeff Elliott of Robert W. Baird."
154924,333332053,986521,"Agilent Technologies, Inc., Q2 2016 Earnings Call, May 16, 2016",2016-05-16,"Earnings Calls","Agilent Technologies, Inc.","Analysts","Mike, on the margin, overall, a really good quarter. But then when you look at the margins in DGG and in CrossLab, you're basically flat year-over-year. I guess, is that what you're expecting? Anything kind of you could call out in the quarter? I know the",53,"Mike, on the margin, overall, a really good quarter. But then when you look at the margins in DGG and in CrossLab, you're basically flat year-over-year. I guess, is that what you're expecting? Anything kind of you could call out in the quarter? I know there's some moving pieces in the top line."
154924,333332053,986521,"Agilent Technologies, Inc., Q2 2016 Earnings Call, May 16, 2016",2016-05-16,"Earnings Calls","Agilent Technologies, Inc.","Executives","Why don't you take that one, Didier?",8,"Why don't you take that one, Didier?"
154924,333332053,986521,"Agilent Technologies, Inc., Q2 2016 Earnings Call, May 16, 2016",2016-05-16,"Earnings Calls","Agilent Technologies, Inc.","Executives","No, it's a great question and the answer is yes. It's precisely what we had expected. One of the, obviously, based from one quarter to the next, there could be some onetime add-ins that adds a little bit of volatility. For example, last year, both ACG and",136,"No, it's a great question and the answer is yes. It's precisely what we had expected. One of the, obviously, based from one quarter to the next, there could be some onetime add-ins that adds a little bit of volatility. For example, last year, both ACG and DGG had very favorable hedging gains, which have gone away. For the whole company, the hedging gains last year in Q2 was over $7 million and this Q2 was about $1.5 million, something like that. So -- and it was mostly in ACG and DGG. And there are other onetime items that -- including -- regarding the allocation of our shared services among the different businesses, which explain. But both businesses are on their way to contribute to the operating margin expansion and the 22% that we're committing to."
154924,333332053,986521,"Agilent Technologies, Inc., Q2 2016 Earnings Call, May 16, 2016",2016-05-16,"Earnings Calls","Agilent Technologies, Inc.","Executives","Didier, maybe I'll also ask Mark to -- we've talked about this earlier this last week as well about the operational efficiency improvements that underline what looks to be flat margins, but when you peel back the onion with the hedging gains and the other",54,"Didier, maybe I'll also ask Mark to -- we've talked about this earlier this last week as well about the operational efficiency improvements that underline what looks to be flat margins, but when you peel back the onion with the hedging gains and the other things, there's actually some real operations stuff down there."
154924,333332053,986521,"Agilent Technologies, Inc., Q2 2016 Earnings Call, May 16, 2016",2016-05-16,"Earnings Calls","Agilent Technologies, Inc.","Executives","Thanks, Mike and Didier, As Didier said, there are several things that were factors in this last year that didn't come into play this year. But we were working on a lot of things in terms of improvements. The mix is somewhat favorable in the context of wh",101,"Thanks, Mike and Didier, As Didier said, there are several things that were factors in this last year that didn't come into play this year. But we were working on a lot of things in terms of improvements. The mix is somewhat favorable in the context of what we're selling. But overall, when we look at our plans for the first half, we're up 70 basis points in the first half over last year. So our ability to actually do to margin improvements, when you pull back and look at the first half regardless of all those things, it's quite positive."
154924,333332053,986521,"Agilent Technologies, Inc., Q2 2016 Earnings Call, May 16, 2016",2016-05-16,"Earnings Calls","Agilent Technologies, Inc.","Executives","And as our fastest growing business, he's been picking up more of the corporate costs.",15,"And as our fastest growing business, he's been picking up more of the corporate costs."
154924,333332053,986521,"Agilent Technologies, Inc., Q2 2016 Earnings Call, May 16, 2016",2016-05-16,"Earnings Calls","Agilent Technologies, Inc.","Executives","Shared services.",2,"Shared services."
154924,333332053,986521,"Agilent Technologies, Inc., Q2 2016 Earnings Call, May 16, 2016",2016-05-16,"Earnings Calls","Agilent Technologies, Inc.","Executives","Shared services.",2,"Shared services."
154924,333332053,986521,"Agilent Technologies, Inc., Q2 2016 Earnings Call, May 16, 2016",2016-05-16,"Earnings Calls","Agilent Technologies, Inc.","Executives","Yes, shared services.",3,"Yes, shared services."
154924,333332053,986521,"Agilent Technologies, Inc., Q2 2016 Earnings Call, May 16, 2016",2016-05-16,"Earnings Calls","Agilent Technologies, Inc.","Operator","And our final question comes from the line of the Dane Leone of BTIG.",14,"And our final question comes from the line of the Dane Leone of BTIG."
154924,333332053,986521,"Agilent Technologies, Inc., Q2 2016 Earnings Call, May 16, 2016",2016-05-16,"Earnings Calls","Agilent Technologies, Inc.","Analysts","I just had a quick clarification from earlier. So you're talking about the replacement cycle in biopharma and quoted, I think, 150,000 LC systems based on the 1100, 1200 platform. Did you -- can you clarify if that's what you think the opportunity is ahea",67,"I just had a quick clarification from earlier. So you're talking about the replacement cycle in biopharma and quoted, I think, 150,000 LC systems based on the 1100, 1200 platform. Did you -- can you clarify if that's what you think the opportunity is ahead of you or if that's an opportunity in progress? And if so, kind of what -- how far are you into that?"
154924,333332053,986521,"Agilent Technologies, Inc., Q2 2016 Earnings Call, May 16, 2016",2016-05-16,"Earnings Calls","Agilent Technologies, Inc.","Executives","This is Patrick. Let me answer this question. So first and foremost, this is not biopharma at all. This is pharma and biopharma combined. And when I talk about 150,000 systems out there, it's the installed base of LC systems in all markets. So it's not on",132,"This is Patrick. Let me answer this question. So first and foremost, this is not biopharma at all. This is pharma and biopharma combined. And when I talk about 150,000 systems out there, it's the installed base of LC systems in all markets. So it's not only in pharma and biopharma. But we think the biggest push is actually right now, coming from pharma and biopharma, and I would still say we are in the midst of the replacement cycle. We don't see that to be over -- in the next couple of quarters. There's a healthy demand and we are in negotiation with a lot of our core customers on upcoming replacements and how we place these systems and how we plan it out for them so it works for them."
154924,333332053,986521,"Agilent Technologies, Inc., Q2 2016 Earnings Call, May 16, 2016",2016-05-16,"Earnings Calls","Agilent Technologies, Inc.","Executives","And Dane, if I could add this one other comment to Patrick's response. We've been focused a lot today -- in today's call on pharma and biopharma, but keep in mind that the replacement cycles have been very, very subdued on the implied market side in liqui",89,"And Dane, if I could add this one other comment to Patrick's response. We've been focused a lot today -- in today's call on pharma and biopharma, but keep in mind that the replacement cycles have been very, very subdued on the implied market side in liquid chromatography. So we have several -- we have tens of thousands of systems on that side of the house as well. And again, this is why when we look out into '17 and '18, we think that our growth rates are sustainable."
154924,333332053,986521,"Agilent Technologies, Inc., Q2 2016 Earnings Call, May 16, 2016",2016-05-16,"Earnings Calls","Agilent Technologies, Inc.","Analysts","Any way you could handicap using a baseball analogy or something like that, like what inning you think you're at?",20,"Any way you could handicap using a baseball analogy or something like that, like what inning you think you're at?"
154924,333332053,986521,"Agilent Technologies, Inc., Q2 2016 Earnings Call, May 16, 2016",2016-05-16,"Earnings Calls","Agilent Technologies, Inc.","Executives","No, don't ask a German about a baseball analogy.",9,"No, don't ask a German about a baseball analogy."
154924,333332053,986521,"Agilent Technologies, Inc., Q2 2016 Earnings Call, May 16, 2016",2016-05-16,"Earnings Calls","Agilent Technologies, Inc.","Executives","I'd say, on the pharma side, you're probably innings 5 or 6. I mean, if there's a way through, maybe 2/3. I think -- and my point would be that I think the ballgame is just getting started. We may be in the first inning. We hope to be in the first inning",63,"I'd say, on the pharma side, you're probably innings 5 or 6. I mean, if there's a way through, maybe 2/3. I think -- and my point would be that I think the ballgame is just getting started. We may be in the first inning. We hope to be in the first inning soon of that cycle on the implied market side."
154924,333332053,986521,"Agilent Technologies, Inc., Q2 2016 Earnings Call, May 16, 2016",2016-05-16,"Earnings Calls","Agilent Technologies, Inc.","Operator","And I'm showing no further questions at this time. I'd now like to turn the conference back to Alicia Rodriguez for closing remarks.",24,"And I'm showing no further questions at this time. I'd now like to turn the conference back to Alicia Rodriguez for closing remarks."
154924,333332053,986521,"Agilent Technologies, Inc., Q2 2016 Earnings Call, May 16, 2016",2016-05-16,"Earnings Calls","Agilent Technologies, Inc.","Executives","Thank you, everybody, and I'd like to thank you all for joining us today on the call. If you have any questions, of course, please give us a call in IR. And just would hope that we'll see you next week at our Analyst Day in New York City. Thanks again. By",52,"Thank you, everybody, and I'd like to thank you all for joining us today on the call. If you have any questions, of course, please give us a call in IR. And just would hope that we'll see you next week at our Analyst Day in New York City. Thanks again. Bye-bye."
154924,333332053,986521,"Agilent Technologies, Inc., Q2 2016 Earnings Call, May 16, 2016",2016-05-16,"Earnings Calls","Agilent Technologies, Inc.","Operator","Ladies and gentlemen, thank you for participating in today's conference. This does conclude the program. You may all disconnect. Everyone, have a great day.",24,"Ladies and gentlemen, thank you for participating in today's conference. This does conclude the program. You may all disconnect. Everyone, have a great day."
154924,333332053,986953,"Agilent Technologies, Inc., Q2 2016 Earnings Call, May 16, 2016",2016-05-16,"Earnings Calls","Agilent Technologies, Inc.","Operator","Good day, ladies and gentlemen, and welcome to the Q2 2016 Agilent Technologies Inc. Earnings Conference Call. [Operator Instructions] As a reminder, this call is being recorded. I would now like to turn the conference over to Alicia Rodriguez, Vice Presi",47,"Good day, ladies and gentlemen, and welcome to the Q2 2016 Agilent Technologies Inc. Earnings Conference Call. [Operator Instructions] As a reminder, this call is being recorded. I would now like to turn the conference over to Alicia Rodriguez, Vice President of Investor Relations. Please go ahead."
154924,333332053,986953,"Agilent Technologies, Inc., Q2 2016 Earnings Call, May 16, 2016",2016-05-16,"Earnings Calls","Agilent Technologies, Inc.","Executives","Thank you, Sabrina, and welcome, everyone, to Agilent's Second Quarter Conference Call for Fiscal Year 2016. With me are Mike McMullen, Agilent's President and CEO; and Didier Hirsch, Agilent's Senior Vice President and CFO. Joining in the Q&A after Didie",330,"Thank you, Sabrina, and welcome, everyone, to Agilent's Second Quarter Conference Call for Fiscal Year 2016. With me are Mike McMullen, Agilent's President and CEO; and Didier Hirsch, Agilent's Senior Vice President and CFO. Joining in the Q&A after Didier's comments will be Patrick Kaltenbach, President of Agilent's Life Sciences and Applied Markets Group; Jacob Thaysen, President of Agilent's Diagnostics and Genomics Group; and Mark Doak, President of the Agilent CrossLab Group.
You can find the press release and information to supplement today's discussion on our website at www.investor.agilent.com. While there, please click on the link for financial results under the Financial Information tab. You will find an investor presentation along with revenue breakouts and currency impacts, business segment results and historical financials for Agilent's operations. We will also post a copy of the prepared remarks following this call.
Today's comments by Mike and Didier will refer to non-GAAP financial measures. You will find the most directly comparable GAAP financial metrics and reconciliations on our website. And please note that we will refer to core revenue growth, which excludes the impact of currency, the NMR business and acquisitions and divestitures within the past 12 months. Unless otherwise noted, all references to increases or decreases in financial metrics are year-over-year. Guidance is based on exchange rates as of the last day of the reported quarter.
We will also make forward-looking statements about the financial performance of the company. These statements are subject to risks and uncertainties and are only valid as of today. The company assumes no obligation to update them. Please look at the company's recent SEC filings for a more complete picture of our risks and other factors.
Before turning things over to Mike, I'd like to remind you that Agilent will host its Analyst and Investor Meeting in New York City on May 25. Details about the meeting and webcast are available on the Agilent Investor Relations website. 
And now let me turn the call over to Mike."
154924,333332053,986953,"Agilent Technologies, Inc., Q2 2016 Earnings Call, May 16, 2016",2016-05-16,"Earnings Calls","Agilent Technologies, Inc.","Executives","Thanks, Alicia and hello, everyone. Thank you for joining us on today's call. The Agilent team delivered another strong quarter. Both Q2 revenue and earnings were above the high end of our guidance. Let me highlight 3 key results. First, revenue growth",1570,"Thanks, Alicia and hello, everyone. Thank you for joining us on today's call. The Agilent team delivered another strong quarter. Both Q2 revenue and earnings were above the high end of our guidance. Let me highlight 3 key results. 
First, revenue growth was up more than 8% on a core basis. Second, we delivered adjusted operating margin of 19.4%, an increase of 110 basis points from a year ago. Finally, EPS of $0.44 was up 16% over last year. 
Before moving on to a review of our Q2 results, I do want to address our year-over-year quarterly comparisons, which reflect an unusual event from last year. Of the 8% core growth that we're announcing today, about 1.5 percentage points is due to a shift of revenue last year from Q2 '15 into Q3 '15. 
In the second quarter a year ago, we experienced $50 million of shipment delays due to start-up challenges with our new U.S. logistics center. In addition, our process-improvement efforts over the past few quarters to convert incoming orders more quickly to revenue have paid off. We have reduced our order to revenue cycle times, particularly in China. Consequently, some shipments initially forecast for Q3 of this year were delivered in Q2. 
Agilent's strong Q2 results were led by double-digit core growth in pharma and food markets. We also experienced continued strength in academia and government, environmental and diagnostic and clinical markets. All end markets grew except chemical and energy. Growth was broad based across most of our portfolio. 
Geographically, all regions grew except Japan, led by very strong growth in China. Let me highlight our Q2 results by business group. The Life Sciences and Applied Markets Group delivered core revenue growth of 8%, led by strong demand in the pharma and food markets. About 3 percentage points of the 8% increase was thanks to a softer compare due to the timing issues mentioned earlier from last year's U.S. logistics center startup. 
The combination of strong top line growth, expense management and gross margin improvements, partially due to the NMR exit, drove LSAG's operating margin to 19%, up 320 basis points from a year ago. LSAG continues to strengthen its portfolio. In Q2, Agilent introduced VistaFlux software. This new software speeds up clinical research data analysis, so scientists can more quickly understand the underlying causes of diseases such as cancer. VistaFlux strengthens Agilent's leadership position in metabolomics. Last week, we announced a new Agilent 1216 Infinity II LC at the analytical tradeshow. This instrument provides best-in-class lab efficiency and improves performance with full backward compatibility. 
Next, the Agilent CrossLab Group continues to deliver consistently strong revenue results. Core revenue growth in Q2 was 10%, led by strength in contract services, LC columns and lab supplies. Expansion and penetration in Asia continued to be strong contributors to our growth. Operating margin was flat versus a year ago at 21.5%. 
CrossLab represents a strategic transformation of our services and consumables business. I'm pleased to report that Agilent was recognized with the 2016 Reviewers' Choice Award for Customer Service. This award is from SelectScience, an independent expert-led scientific review. This is the second year in a row that scientists in North America have judged Agilent's customer service to be the best in the laboratory products industry. 
Finally, the Diagnostics and Genomics Group delivered 5% core growth in Q2 against a difficult compare. The pathology business continues on a steady trajectory back to market growth rates, highlighted by strong demand for our new PD-L1 companion and complementary diagnostic tests. Genomics showed strong market performance, led by our SureSelect target enrichment and array CGH offerings. DGG's operating margin was flat versus a year ago at 15%. 
In Q2, Agilent announced an $80 million investment in Lasergen, an emerging biotechnology company with innovative next-gen sequencing technology. Our two companies will collaborate on building an NGS workflow for clinical applications. 
In Q2, Agilent also announced that commercial availability has expanded to the EU for a new PD-L1 diagnostic test for nonsquamous, nonsmall cell lung cancer. This diagnostic was developed through a collaboration with Bristol-Myers Squibb, the maker of OPDIVO. 
Now I'll provide an overview of Agilent's core revenues by end market. Life Sciences and Diagnostics markets saw a continuation of our first quarter performance, with strength across all end markets. Pharma grew 14%, fueled by technology refresh deals, new product uptake and sustained growth in the aftermarket. This is the fifth consecutive quarter of greater than mid- to high double-digit growth in pharma. 
Academia and government grew 7%, driven by strong demand in China and an uptick in the U.S. Clinical and diagnostics also grew 7% with strength in genomics, led by target enrichment and array CGH. Applied end market performance was mixed. Food was up 25% with strong sales in China and the Americas. China also drove 6% worldwide growth in environmental and forensics. Chemical energy declined 3%, reflecting continued macroeconomic concerns and the effects of lower oil prices. Now I'll turn to an update on our operating margin improvement initiative. 
Q2 marks the fifth consecutive quarter of year-over-year operating margin improvement delivered by the new Agilent team. This is a result of our ability to outgrow the market, while driving operational efficiency improvements. Our multiyear Agile Agilent program continues to simplify the company making us more nimble and lowering our cost. Our execution of company-wide streamlining organizations, processes and systems continue to be on track to deliver incremental savings in 2017. 
For example, in Q3, we would take a major step forward in simplifying the company's systems infrastructure with all of our financial systems now on SAP. 
On the capital deployment front, we paid $37 million in dividends, repurchased $94 million of Agilent stock and invested $80 million to enable our NGS workflow strategy. Finally, our One Agilent initiative is driving a well-received cultural transformation to improve cross-company collaboration and delivery of results. At last year's Analyst and Investor Day, I described a shareholder value creation model for Agilent to be driven by outgrowing the market, expanding operating margins and a balanced capital allocation policy. I'd like to take a minute to position the Q2 results in the context of our longer-term goals. 
After delivering our highest annual core revenue growth since 2011 of 6.4% in 2015, we've now had 2 strong quarters to start 2016, including this quarter's 8% core revenue growth. Since the new Agilent team -- leadership team was put in place, the team has delivered year-over-year operating margin improvements every quarter. We have completely offset the initial $40 million into synergies from the company split. 
In fiscal 2015, we returned $400 million to shareholders and $370 million year-to-date in 2016 through cash dividends and share repurchase. From 2015 until now, we've also invested around $400 million in new business via M&A and equity investments. Didier will share more specifics later, but we are raising our full year 2016 outlook for core growth, operating margin, EPS and cash flow. Let me now talk about our second half '16 forecast in light of what we have already achieved in 2016 and what we plan to deliver in 2017. 
When we look at today's overall market environment, while we face increasingly tough compares, we expect strength in pharma to continue in the second half 2016 and into 2017. China is also expected to remain strong in the second half of 2016 and 2017. Taking a closer look at the chemical and energy market, we have been experiencing a more prolonged and steeper slowdown than initially anticipated. We are now forecasting overall low single-digit market declines for the year versus our initial flat guidance assumptions. The oil exploration segment of this market has been down significantly for some time, with a recent well-reported spillover into the refining segment. There are initial indications, however, of a bottoming, with increased deal activity in the large chemical segment of the market. 
We have projected an improved chemical energy market environment in 2017. We are assuming we will continue to face headwinds in this market for the remainder of 2016. We are currently modeling 2017 with an above-market core revenue growth of 4.5% at the midpoint. This is in line with our projected full year 2016 core growth rates, but higher than our expected core growth rate in the second half of 2016. There are 2 reasons for this increase. 
First, we expect to have a very strong new product introduction in the second half of FY '16, which will drive revenue growth in FY '17. Second, on the end market front, we expect chemical energy to have bottomed out by year-end, accompanied by continuing solid conditions in all of our other end markets and in China. 
Overall, we remain on track with our 2017 goal to outgrow the market and improve our operating margins of 22%. Looking inside the company, I can share with you today that the One Agilent team is working well together and is driven to win in the marketplace. I look forward to seeing many of you at our Analyst and Investor Day, where I'll share our progress versus our commitments, how we will sustain or improve performance and the longer-term outlook for the company. Thank you for being on the call today. I will now turn it over to Didier, who will provide additional insights on our financial results and guidance for the third quarter and full year 2016. Didier?"
154924,333332053,986953,"Agilent Technologies, Inc., Q2 2016 Earnings Call, May 16, 2016",2016-05-16,"Earnings Calls","Agilent Technologies, Inc.","Executives","Thank you, Mike, and hello, everyone. As Mike stated, we delivered a strong performance this quarter again, 8% core revenue growth, 110 basis points of operating margin expansion and $256 million in operating cash flow. After adjusting for last year's $15",319,"Thank you, Mike, and hello, everyone. As Mike stated, we delivered a strong performance this quarter again, 8% core revenue growth, 110 basis points of operating margin expansion and $256 million in operating cash flow. After adjusting for last year's $15 million slippage in revenue from Q2 to Q3 as we launch our new U.S. logistics center, our core revenue growth of 6.5% remained well above market.
During the quarter, we brought back $94 million of stock and paid $37 million in dividends. Finally, on May 3, we successfully moved all finance applications from Oracle to SAP, which is our main ERP. This will result in significant simplifications of our finance and IT operations. I'll now turn to the guidance for our third quarter. 
We expect Q3 revenues of $1.03 billion to $1.05 billion and EPS of $0.45 to $0.47. At midpoint, revenue will grow 1.3% on a core basis or close to 3% adjusting for last year's $50 million impact from the U.S. logistics center. And turning to share repurchase, we expect to buy back $93 million this Q3. Now to the guidance of fiscal year 2016.
We are raising the midpoint of our revenue guidance by $60 million, including $50 million due to currency. As a result, we're increasing our core revenue growth guidance at midpoint from 4.25% to 4.50%. We're also raising the midpoint of our EPS guidance by $0.06, including $0.03 coming from currency and $0.03 from operational performance. 
And one important note. After further review, we and our auditors have concluded to account for the Lasergen investment using the cost method of accounting. This means that we'll not book our share of Lasergen losses as previously communicated. 
Finally, we are raising our operating cash flow guidance from $650 million to $740 million, and there's no change to our CapEx guidance of $140 million. 
With that, I'll turn it over to Alicia for the Q&A."
154924,333332053,986953,"Agilent Technologies, Inc., Q2 2016 Earnings Call, May 16, 2016",2016-05-16,"Earnings Calls","Agilent Technologies, Inc.","Executives","Thank you, Didier. And Sabrina, will you please give the instructions for the Q&A?",14,"Thank you, Didier. And Sabrina, will you please give the instructions for the Q&A?"
154924,333332053,986953,"Agilent Technologies, Inc., Q2 2016 Earnings Call, May 16, 2016",2016-05-16,"Earnings Calls","Agilent Technologies, Inc.","Operator","[Operator Instructions] And our first question comes from the line of Dan Leonard of Leerink Partners.",16,"[Operator Instructions] And our first question comes from the line of Dan Leonard of Leerink Partners."
154924,333332053,986953,"Agilent Technologies, Inc., Q2 2016 Earnings Call, May 16, 2016",2016-05-16,"Earnings Calls","Agilent Technologies, Inc.","Analysts","Two questions. First off, can you elaborate on the business trends you're seeing in Europe? And then, secondly, on the pharma end market, can you talk about what gives you confidence in the fiscal 2017 outlook that you'd have yet another strong year in ph",62,"Two questions. First off, can you elaborate on the business trends you're seeing in Europe? And then, secondly, on the pharma end market, can you talk about what gives you confidence in the fiscal 2017 outlook that you'd have yet another strong year in pharma following 2 years then of tough comps in capital markets, which have been more or less shut?"
154924,333332053,986953,"Agilent Technologies, Inc., Q2 2016 Earnings Call, May 16, 2016",2016-05-16,"Earnings Calls","Agilent Technologies, Inc.","Executives","Thanks, Dan. I think I'm actually going to pass that over to Patrick, who is just back from a trip to Europe and maybe can provide some insight on what's going on Europe and then also, if he can pick up the question on pharma as well.",47,"Thanks, Dan. I think I'm actually going to pass that over to Patrick, who is just back from a trip to Europe and maybe can provide some insight on what's going on Europe and then also, if he can pick up the question on pharma as well."
154924,333332053,986953,"Agilent Technologies, Inc., Q2 2016 Earnings Call, May 16, 2016",2016-05-16,"Earnings Calls","Agilent Technologies, Inc.","Executives","Sure, I'm happy to do so. So let me start first to giving you some insights on Europe. We have seen actually some decent growth in Central Europe. We had seen some weakness on what we call the IDO, Eastern Europe and that's mainly driven by the chemical a",248,"Sure, I'm happy to do so. So let me start first to giving you some insights on Europe. We have seen actually some decent growth in Central Europe. We had seen some weakness on what we call the IDO, Eastern Europe and that's mainly driven by the chemical and energy market or the energy market on that side. In Central Europe, there's generally strength in Germany and other states around it. We still see some issues on the academia and government side that is rather flat. But pharma, for example, is also very strong in Europe. For your pharma question, overall, we are confident that we will continue to see pretty high growth in pharma for the remainder of this year. We target low double-digit growth for pharma. And looking into 2017, we think the pharma market will be -- continue to be strong for us, driven by 2 vectors. We see a continued demand in the replacement business. And as you probably know, we just launched -- at the analytical conference, we launched our new 1260 Infinity LC as an example, together with the Infinity lab consumables and servicing. And we think that will drive -- continue to drive a lot of good replacement for us in pharma. And then, we see also continued demand in the biopharma space that are looking for new solutions helping with these more complex molecules in terms of analysis, and we have a very comprehensive operating for that space as well."
154924,333332053,986953,"Agilent Technologies, Inc., Q2 2016 Earnings Call, May 16, 2016",2016-05-16,"Earnings Calls","Agilent Technologies, Inc.","Operator","And our next question comes from the line of Jonathan Groberg of UBS.",13,"And our next question comes from the line of Jonathan Groberg of UBS."
154924,333332053,986953,"Agilent Technologies, Inc., Q2 2016 Earnings Call, May 16, 2016",2016-05-16,"Earnings Calls","Agilent Technologies, Inc.","Analysts","Can you maybe just elaborate a little bit on -- I think you said core guidance. I'm looking at your presentation, core revenue growth guidance in the third quarter was pretty precise at 1.3%. But then I think I just heard that you still expect pharma to g",70,"Can you maybe just elaborate a little bit on -- I think you said core guidance. I'm looking at your presentation, core revenue growth guidance in the third quarter was pretty precise at 1.3%. But then I think I just heard that you still expect pharma to grow low double digits. Can you maybe just give a little kind of insight as to what you're seeing in the third quarter?"
154924,333332053,986953,"Agilent Technologies, Inc., Q2 2016 Earnings Call, May 16, 2016",2016-05-16,"Earnings Calls","Agilent Technologies, Inc.","Executives","Yes. What we looked at was with our growth rate that we've had over the first half of this year and as we looked into Q3 and Q4, and what I point to is a couple of things, Jonathan. First of all, tough compares and this is inclusive of a few onetime moves",316,"Yes. What we looked at was with our growth rate that we've had over the first half of this year and as we looked into Q3 and Q4, and what I point to is a couple of things, Jonathan. First of all, tough compares and this is inclusive of a few onetime moves between quarters, which actually were driven by improvements of overall operations. So as Didier mentioned, we had this $50 million shift in Q2 of last year into Q3, which when we had our start-up issues with our new logistics center. So if you adjust for that, it gets you to about 3% growth. The other thing we saw happen in Q2 was we've been working really hard to improve the overall cycle time from the time a customer places order to actually it's installed and we can recognize the revenue. In Q2, we actually exceeded our expectations and we got there a lot faster than we had thought, and what that meant was we had a significant amount of revenue, probably $20 million to $25 million that came from Q3 into Q2 where initially we'd forecasted into the second -- third quarter. All in all, if you kind of take into account those things, you've got pretty -- more of a consistent kind of a growth scenario between Q2 and Q3. 
I would tell you, though, the chemical energy is still looking for a bottom. And that's why we have that outlook for the year, which basically is down -- it's going to stay down for the rest of the year. There are some signs that it could be getting better. But we have -- we're not convinced yet we've seen the bottom in chemical energy. So I think the combination of those tough compares as well as our outlook on chemical energy is what's driving the overall guidance for the second half."
154924,333332053,986953,"Agilent Technologies, Inc., Q2 2016 Earnings Call, May 16, 2016",2016-05-16,"Earnings Calls","Agilent Technologies, Inc.","Analysts","Okay, that's helpful. And then, I guess, just one more. Are there any -- sometimes when we see shifts onto one platform like Oracle to SAP, is there anything at all -- any kind of wiggle room you left there in terms of hiccups in the quarter or maybe...",49,"Okay, that's helpful. And then, I guess, just one more. Are there any -- sometimes when we see shifts onto one platform like Oracle to SAP, is there anything at all -- any kind of wiggle room you left there in terms of hiccups in the quarter or maybe..."
154924,333332053,986953,"Agilent Technologies, Inc., Q2 2016 Earnings Call, May 16, 2016",2016-05-16,"Earnings Calls","Agilent Technologies, Inc.","Executives","Yes, what we try to do -- you're exactly right, Jonathan. So the wiggle room we left was, we made sure we went live the first month of the quarter. And Didier is in the conference room here smiling. And Didier, I don't know if you want to add any addition",58,"Yes, what we try to do -- you're exactly right, Jonathan. So the wiggle room we left was, we made sure we went live the first month of the quarter. And Didier is in the conference room here smiling. And Didier, I don't know if you want to add any additional color on how it's going so far?"
154924,333332053,986953,"Agilent Technologies, Inc., Q2 2016 Earnings Call, May 16, 2016",2016-05-16,"Earnings Calls","Agilent Technologies, Inc.","Executives","Yes, it's going very well, the migrations and the start-up of the operations. There were 0 disruption. Obviously, we expect to have to deal with some stabilization activities throughout the quarter. We'll do 2 close before we do the quarterly close. So ev",95,"Yes, it's going very well, the migrations and the start-up of the operations. There were 0 disruption. Obviously, we expect to have to deal with some stabilization activities throughout the quarter. We'll do 2 close before we do the quarterly close. So everything is -- we couldn't be happier about how it went. And you're correct. It is a very complex endeavor, one that we are pretty used to. We've done a few of those in the past. But still, it remains a very complex endeavor and we are really happy how smoothly it went."
154924,333332053,986953,"Agilent Technologies, Inc., Q2 2016 Earnings Call, May 16, 2016",2016-05-16,"Earnings Calls","Agilent Technologies, Inc.","Executives","And Jonathan, as I pointed out in my script, this is one of the Agile Agilent initiatives, which you'll start to see pay off in our cost structure, as we move into '17.",33,"And Jonathan, as I pointed out in my script, this is one of the Agile Agilent initiatives, which you'll start to see pay off in our cost structure, as we move into '17."
154924,333332053,986953,"Agilent Technologies, Inc., Q2 2016 Earnings Call, May 16, 2016",2016-05-16,"Earnings Calls","Agilent Technologies, Inc.","Operator","And our next question comes from the line of Tycho Peterson of JPMorgan.",13,"And our next question comes from the line of Tycho Peterson of JPMorgan."
154924,333332053,986953,"Agilent Technologies, Inc., Q2 2016 Earnings Call, May 16, 2016",2016-05-16,"Earnings Calls","Agilent Technologies, Inc.","Analysts","Just following up on that last point on the SAP margins, can you maybe -- or the market impact. Can you maybe quantify how much that could play on margins for this year?",33,"Just following up on that last point on the SAP margins, can you maybe -- or the market impact. Can you maybe quantify how much that could play on margins for this year?"
154924,333332053,986953,"Agilent Technologies, Inc., Q2 2016 Earnings Call, May 16, 2016",2016-05-16,"Earnings Calls","Agilent Technologies, Inc.","Executives","For 2016, I think it'll be very limited at best, Tycho, because we'll be running some duplicate backup systems and then the other aspects of our external spends really don't come out until '17. So I'd really position that in -- I actually think about this",71,"For 2016, I think it'll be very limited at best, Tycho, because we'll be running some duplicate backup systems and then the other aspects of our external spends really don't come out until '17. So I'd really position that in -- I actually think about this more of a '17 impact, but a proof point of why we think we're going to be able to improve our margins again in '17."
154924,333332053,986953,"Agilent Technologies, Inc., Q2 2016 Earnings Call, May 16, 2016",2016-05-16,"Earnings Calls","Agilent Technologies, Inc.","Analysts","And then academic 7%, can you maybe just talk as to whether you're seeing an acceleration there, in terms of what you saw this quarter?",26,"And then academic 7%, can you maybe just talk as to whether you're seeing an acceleration there, in terms of what you saw this quarter?"
154924,333332053,986953,"Agilent Technologies, Inc., Q2 2016 Earnings Call, May 16, 2016",2016-05-16,"Earnings Calls","Agilent Technologies, Inc.","Executives","Yes, what we saw in the last quarter is a really strong performance in China and some increased signs of life in the U.S. side of things. I think -- and that's where we pointed to an uptick. Not a lot of significant moves on the European side. It's mainly",75,"Yes, what we saw in the last quarter is a really strong performance in China and some increased signs of life in the U.S. side of things. I think -- and that's where we pointed to an uptick. Not a lot of significant moves on the European side. It's mainly a China-German story, and I think if there will be upside to it, it would come from the U.S. That's how we're thinking about it."
154924,333332053,986953,"Agilent Technologies, Inc., Q2 2016 Earnings Call, May 16, 2016",2016-05-16,"Earnings Calls","Agilent Technologies, Inc.","Analysts","Okay. And then, lastly, just in terms of pharma, obviously, that's been a nice driver. Can you maybe talk about where you think we are in the LCMS upgrade cycle? And how much your growth going forward is going to be contingent on already budget expanding",50,"Okay. And then, lastly, just in terms of pharma, obviously, that's been a nice driver. Can you maybe talk about where you think we are in the LCMS upgrade cycle? And how much your growth going forward is going to be contingent on already budget expanding versus the upgrade cycle?"
154924,333332053,986953,"Agilent Technologies, Inc., Q2 2016 Earnings Call, May 16, 2016",2016-05-16,"Earnings Calls","Agilent Technologies, Inc.","Executives","Yes, sure, Tycho, great question. I know, Patrick, I know you look at this pretty closely and what's the updated view on that?",23,"Yes, sure, Tycho, great question. I know, Patrick, I know you look at this pretty closely and what's the updated view on that?"
154924,333332053,986953,"Agilent Technologies, Inc., Q2 2016 Earnings Call, May 16, 2016",2016-05-16,"Earnings Calls","Agilent Technologies, Inc.","Executives","Yes, so I think there are 2 cycles we're looking at. The first cycle we went through was general upgrade cycle from standard HPLC to UHPLC, which is still ongoing but a considerable part of that probably has been done. But when you look at the installed b",163,"Yes, so I think there are 2 cycles we're looking at. The first cycle we went through was general upgrade cycle from standard HPLC to UHPLC, which is still ongoing but a considerable part of that probably has been done. But when you look at the installed base of instrumentation, it still deals with core LC and this is where we are targeting with the Infinity II series right now. There's still a lot of replacement pending out there. Just as a reminder, we have probably about 150,000 systems out there based on the 1100, 1200 platform, which over time will be up for replacement. And we are positioned extremely well with our platforms because it's 100% backwards compatible and we're also able, for example, to emulate some of our competitors' systems on our platform with a technology we call ISET, intelligence system emulation technology. And that actually compels very nicely with our customers and gives us a unique advantage in the market."
154924,333332053,986953,"Agilent Technologies, Inc., Q2 2016 Earnings Call, May 16, 2016",2016-05-16,"Earnings Calls","Agilent Technologies, Inc.","Executives","So I think we see both of those having legs into -- through  '17.",14,"So I think we see both of those having legs into -- through  '17."
154924,333332053,986953,"Agilent Technologies, Inc., Q2 2016 Earnings Call, May 16, 2016",2016-05-16,"Earnings Calls","Agilent Technologies, Inc.","Executives","Absolutely. I think this goes on into '17, combined again with the drive we see coming out of biopharma.",19,"Absolutely. I think this goes on into '17, combined again with the drive we see coming out of biopharma."
154924,333332053,986953,"Agilent Technologies, Inc., Q2 2016 Earnings Call, May 16, 2016",2016-05-16,"Earnings Calls","Agilent Technologies, Inc.","Operator","And our next question comes from the line of Jack Meehan of Barclays.",13,"And our next question comes from the line of Jack Meehan of Barclays."
154924,333332053,986953,"Agilent Technologies, Inc., Q2 2016 Earnings Call, May 16, 2016",2016-05-16,"Earnings Calls","Agilent Technologies, Inc.","Analysts","I just wanted to start, the growth was better -- at least relative to what I was looking for. Looked like you had better gross margins in the LSAG segment now 2 quarters in a row. Can you just talk about what some of the notable changes there are? Is ther",71,"I just wanted to start, the growth was better -- at least relative to what I was looking for. Looked like you had better gross margins in the LSAG segment now 2 quarters in a row. Can you just talk about what some of the notable changes there are? Is there anything with product mix that's driven the improvement? Or do you think this is the new norm to look for?"
154924,333332053,986953,"Agilent Technologies, Inc., Q2 2016 Earnings Call, May 16, 2016",2016-05-16,"Earnings Calls","Agilent Technologies, Inc.","Executives","I think -- let me make some initial comments and then Didier or Patrick, maybe you can build on it. So in terms of product mix, part of what you're seeing is the fact that we are winding down through our P&L the impact of the NMR business. And I think you",166,"I think -- let me make some initial comments and then Didier or Patrick, maybe you can build on it. So in terms of product mix, part of what you're seeing is the fact that we are winding down through our P&L the impact of the NMR business. And I think you can see the benefit of that exit decision on the P&L because it really has been contributing to the improved gross margins. And that's not the whole story. The other story is, obviously, the strong demand for the products and the volume benefits we're getting as well as the focus on taking cost out of our material cost side of the business as well as we talked a lot about the logistics last year. We could also talk about logistics this year, which is, we're doing a much better job in terms of overall logistics operations; that's blowing through on the P&L as well. So Didier, I'm not sure if I missed anything else."
154924,333332053,986953,"Agilent Technologies, Inc., Q2 2016 Earnings Call, May 16, 2016",2016-05-16,"Earnings Calls","Agilent Technologies, Inc.","Executives","No, you covered it all.",5,"No, you covered it all."
154924,333332053,986953,"Agilent Technologies, Inc., Q2 2016 Earnings Call, May 16, 2016",2016-05-16,"Earnings Calls","Agilent Technologies, Inc.","Analysts","Great. And then just one more for the adoption of the companion diagnostics now a few quarters into the launch. Are you in a position -- could you maybe just help us size what that business is today or just in the market what you think you hold in terms o",53,"Great. And then just one more for the adoption of the companion diagnostics now a few quarters into the launch. Are you in a position -- could you maybe just help us size what that business is today or just in the market what you think you hold in terms of market share?"
154924,333332053,986953,"Agilent Technologies, Inc., Q2 2016 Earnings Call, May 16, 2016",2016-05-16,"Earnings Calls","Agilent Technologies, Inc.","Executives","Why don't you take that, Jacob?",7,"Why don't you take that, Jacob?"
154924,333332053,986953,"Agilent Technologies, Inc., Q2 2016 Earnings Call, May 16, 2016",2016-05-16,"Earnings Calls","Agilent Technologies, Inc.","Executives","Yes, thanks for that question. And we are definitely pleased with the pickup of the PD-L1, and this continues during the last -- basically, it's now 3 quarters. The market is still very early. We still really only, in U.S, we have had a few press releases",160,"Yes, thanks for that question. And we are definitely pleased with the pickup of the PD-L1, and this continues during the last -- basically, it's now 3 quarters. The market is still very early. We still really only, in U.S, we have had a few press releases here lately. Also that we're entering into Europe, but we're just scratching the surface in Europe. And furthermore, it's still a second line -- it's still addressing the second line treatment. And if that also goes to the first-line treatment, the market will become significantly larger. At this point in time, it's still small revenue in the bigger scheme of things. But I do believe that the PD-L1 has an opportunity to be as big as the HER 2 market. However, we'll also remind you that of at least 4, probably 5 different potential drugs and companion diagnostics out there has to share that market. So still early days, but a great opportunity."
154924,333332053,986953,"Agilent Technologies, Inc., Q2 2016 Earnings Call, May 16, 2016",2016-05-16,"Earnings Calls","Agilent Technologies, Inc.","Operator","And our next question comes from the line of Brandon Couillard of Jefferies.",13,"And our next question comes from the line of Brandon Couillard of Jefferies."
154924,333332053,986953,"Agilent Technologies, Inc., Q2 2016 Earnings Call, May 16, 2016",2016-05-16,"Earnings Calls","Agilent Technologies, Inc.","Analysts","Mike, could you give us -- or Didier, could you give us the China growth rate -- the percentage change in the quarter? And if you could speak to demand in the food area outside of China and Asia, that will be helpful.",43,"Mike, could you give us -- or Didier, could you give us the China growth rate -- the percentage change in the quarter? And if you could speak to demand in the food area outside of China and Asia, that will be helpful."
154924,333332053,986953,"Agilent Technologies, Inc., Q2 2016 Earnings Call, May 16, 2016",2016-05-16,"Earnings Calls","Agilent Technologies, Inc.","Executives","Yes. So in the China result for Q2, what we've been pointing to is strong double-digit growth. So it was a very, very strong quarter for us in China. I would remind you that part of the strong growth was not only the strength in the market, but that those",146,"Yes. So in the China result for Q2, what we've been pointing to is strong double-digit growth. So it was a very, very strong quarter for us in China. I would remind you that part of the strong growth was not only the strength in the market, but that those operational efficiency improvements I talked about where we really had shortened the improved cycle time from orders to install that was really dramatic in China. So the overall business will be quite strong for the year. You should not expect a strong double-digit growth every quarter, though, for Q3 and Q4. But overall, China is -- just to complete the story here. When we came into this year, we thought that the overall performance for Agilent in China might be high single digits. We're now looking at low double-digit growth in China for the full year."
154924,333332053,986953,"Agilent Technologies, Inc., Q2 2016 Earnings Call, May 16, 2016",2016-05-16,"Earnings Calls","Agilent Technologies, Inc.","Analysts","And then one more for Didier. I noticed you bumped the operating cash flow guidance up about $90 million. How much of an impact does the -- I noticed a tax refund benefit. If you could quantify that and then just help us bridge the delta between prior ver",50,"And then one more for Didier. I noticed you bumped the operating cash flow guidance up about $90 million. How much of an impact does the -- I noticed a tax refund benefit. If you could quantify that and then just help us bridge the delta between prior versus new."
154924,333332053,986953,"Agilent Technologies, Inc., Q2 2016 Earnings Call, May 16, 2016",2016-05-16,"Earnings Calls","Agilent Technologies, Inc.","Executives","There was -- the overall tax outlays forecasted for this year were, I think, about $10 million less than what we had initially anticipated in our initial guidance, $10 million or $15 million, and the rest is really operational performance improvements in",54,"There was -- the overall tax outlays forecasted for this year were, I think, about $10 million less than what we had initially anticipated in our initial guidance, $10 million or $15 million, and the rest is really operational performance improvements in our working capital management and FX and then just our operating profits."
154924,333332053,986953,"Agilent Technologies, Inc., Q2 2016 Earnings Call, May 16, 2016",2016-05-16,"Earnings Calls","Agilent Technologies, Inc.","Operator","And our next question comes from the line of Ross Muken of Evercore.",13,"And our next question comes from the line of Ross Muken of Evercore."
154924,333332053,986953,"Agilent Technologies, Inc., Q2 2016 Earnings Call, May 16, 2016",2016-05-16,"Earnings Calls","Agilent Technologies, Inc.","Analysts","So Mike, since taking over, it's obviously been a pretty hectic journey and your messaging from the beginning has been pretty consistent around growth in margins and returns. Obviously, last few quarters, you started to develop a cadence. Last quarter res",136,"So Mike, since taking over, it's obviously been a pretty hectic journey and your messaging from the beginning has been pretty consistent around growth in margins and returns. Obviously, last few quarters, you started to develop a cadence. Last quarter results were good, but we had the challenges on FX. Do you feel like this is the first quarter where you feel like you got to deliver the full bag, where you were able to sort of drop through the top line outperformance, which is clearly better than market? You drove the margins. You're buying stock. The returns are up. The cash flow is good. That you were finally able to sort of show the market that the business model is working and that feeds, I guess, into your confidence also, I would assume on '17?"
154924,333332053,986953,"Agilent Technologies, Inc., Q2 2016 Earnings Call, May 16, 2016",2016-05-16,"Earnings Calls","Agilent Technologies, Inc.","Executives","Yes, I couldn't have said it better myself. Thanks, Ross, for the question. I think that we've been working really hard the last 4 or 5 quarters with the new leadership team. And as you look at -- everything came together this quarter. I mean, we've had s",282,"Yes, I couldn't have said it better myself. Thanks, Ross, for the question. I think that we've been working really hard the last 4 or 5 quarters with the new leadership team. And as you look at -- everything came together this quarter. I mean, we've had strong growth. We've had improvement in our operating margin, as I pointed out in '15. But all the vectors really came together nicely in the second quarter. And I was particularly pleased on some of the more operational activities that we've been working on inside the company. And that may not always be so apparent initially on the outside world, but you start to see it in the results. And the fact that we're doing -- we've adjusted our logistic challenges. Yeah, I have to talk about it in the year-over-year compares, but it's fixed and actually now is contributing to improved results. Yes, we had to talk about the shortened cycle time for orders to revenue and it brought in some revenues that we initially had planned for the third quarter, but we made those operational improvements. The cycle times are shorter, and this is now the new normal. So I guess, that will be the closing comments, which -- yes, we're the new normal for the company. We have got a lot of confidence about 2017, perhaps steal a little bit of my thunder for the Analyst Meeting next week, but I still hope everyone attends. But when you start having these proof points quarter in and quarter out, I think it starts to show you the team is delivering. And I think the results are now starting to be appreciated and believed."
154924,333332053,986953,"Agilent Technologies, Inc., Q2 2016 Earnings Call, May 16, 2016",2016-05-16,"Earnings Calls","Agilent Technologies, Inc.","Analysts","Great. And maybe quickly just on Seahorse. Can you just give us an update on how that business is performing relative to your expectations and how it's plugged in and where you're sort of seeing maybe the early fruits and some cross-synergy with the exist",46,"Great. And maybe quickly just on Seahorse. Can you just give us an update on how that business is performing relative to your expectations and how it's plugged in and where you're sort of seeing maybe the early fruits and some cross-synergy with the existing business?"
154924,333332053,986953,"Agilent Technologies, Inc., Q2 2016 Earnings Call, May 16, 2016",2016-05-16,"Earnings Calls","Agilent Technologies, Inc.","Executives","Yes, which is in fact, a very timely question, Ross. We just had our 180-day review this morning. And Patrick, why don't you go ahead and share a couple of highlights from that session?",34,"Yes, which is in fact, a very timely question, Ross. We just had our 180-day review this morning. And Patrick, why don't you go ahead and share a couple of highlights from that session?"
154924,333332053,986953,"Agilent Technologies, Inc., Q2 2016 Earnings Call, May 16, 2016",2016-05-16,"Earnings Calls","Agilent Technologies, Inc.","Executives","Sure, absolutely. So - what I really would like to highlight is how seamlessly we did -- the integration of Seahorse went. So we are now 6 months in the integration. And we would say we're targeting full integration by June, which means that we will have",158,"Sure, absolutely. So - what I really would like to highlight is how seamlessly we did -- the integration of Seahorse went. So we are now 6 months in the integration. And we would say we're targeting full integration by June, which means that we will have implemented all of the systems, which is a very fast pace. At the same time, we are seeing the positioning of Seahorse within our portfolio really works out. We're seeing nice deals and combined sales of LC-MS and Seahorse in areas like disease research and disease discovery. That's actually exactly where we thought its complementing our strength in metabolomics with the life cell metabolism which Seahorse brings to the table. And this is a very nice story that resonates very well with our customers. We are -- again, on the integration side, we are very pleased with where we stand and we are looking forward to some very successful second half."
154924,333332053,986953,"Agilent Technologies, Inc., Q2 2016 Earnings Call, May 16, 2016",2016-05-16,"Earnings Calls","Agilent Technologies, Inc.","Executives","Yes, Ross, I'll just add 2 things. The comment I made to the team this morning is this is the fastest I've seen us do an integration. These things usually plod along for many quarters and in some cases, for years. This one is moving along really, really f",78,"Yes, Ross, I'll just add 2 things. The comment I made to the team this morning is this is the fastest I've seen us do an integration. These things usually plod along for many quarters and in some cases, for years. This one is moving along really, really fast. And we're getting some wins. In fact, we won an LC/MS deal because of Seahorse. So I mean, it's the complementary nature of the portfolios is starting to work."
154924,333332053,986953,"Agilent Technologies, Inc., Q2 2016 Earnings Call, May 16, 2016",2016-05-16,"Earnings Calls","Agilent Technologies, Inc.","Operator","And our next question comes from the line of Paul Knight of Janney Montgomery Scott.",15,"And our next question comes from the line of Paul Knight of Janney Montgomery Scott."
154924,333332053,986953,"Agilent Technologies, Inc., Q2 2016 Earnings Call, May 16, 2016",2016-05-16,"Earnings Calls","Agilent Technologies, Inc.","Analysts","The move you made to create CrossLab seems to be gaining traction. Can you give us a little background on CrossLab in terms of, who do you think is -- is taking share from somebody at that kind of growth rate? Could you give us more color on CrossLab?",49,"The move you made to create CrossLab seems to be gaining traction. Can you give us a little background on CrossLab in terms of, who do you think is -- is taking share from somebody at that kind of growth rate? Could you give us more color on CrossLab?"
154924,333332053,986953,"Agilent Technologies, Inc., Q2 2016 Earnings Call, May 16, 2016",2016-05-16,"Earnings Calls","Agilent Technologies, Inc.","Executives","Yes. So as you mentioned, that was a major strategic move where when we set up the company, we established Agilent CrossLab Group. We had this vision about how we could really attack and go after the enterprise-wide services and consumables opportunity. A",236,"Yes. So as you mentioned, that was a major strategic move where when we set up the company, we established Agilent CrossLab Group. We had this vision about how we could really attack and go after the enterprise-wide services and consumables opportunity. And as you see, Mark and the team have really been delivering. And we know that the customers are responding to the value proposition that Agilent offers, both in terms of how our service capability is viewed -- and that's why I mentioned in my script about the external recognition we recently received -- but they also appreciate the fact we're able to give them insights in terms of actually helping them improve the business operations, and we're seeing a real strong demand for this in the pharma and growing interest in other parts of the applied market. So we know that we're growing faster than some of our competitors in this space. We also know that there's only a few companies really trying to go after this type of business. I believe this is where the market is already going to and I think you want to be a player here. And I leave it to you guys to figure out who's the losing share. But as you can see, all I can tell you is we're growing close to double digit in the space. So it's been an attractive move for us."
154924,333332053,986953,"Agilent Technologies, Inc., Q2 2016 Earnings Call, May 16, 2016",2016-05-16,"Earnings Calls","Agilent Technologies, Inc.","Operator","And our next question comes from the line of Tim Evans of Wells Fargo Securities.",15,"And our next question comes from the line of Tim Evans of Wells Fargo Securities."
154924,333332053,986953,"Agilent Technologies, Inc., Q2 2016 Earnings Call, May 16, 2016",2016-05-16,"Earnings Calls","Agilent Technologies, Inc.","Analysts","I'm just trying to understand the variance in the quarter relative to what you were expecting. I believe you had called last quarter for 4% core growth, and we saw 8% this quarter. I hear you that it sounds like about half of that variance, about 200 basi",102,"I'm just trying to understand the variance in the quarter relative to what you were expecting. I believe you had called last quarter for 4% core growth, and we saw 8% this quarter. I hear you that it sounds like about half of that variance, about 200 basis points, was from the better book backlog to revenue conversion in this quarter. And I know you also called out the compare relative to last year. But that compare should have already been known. So I just want to understand what's the other 200 basis points that really surprised you in the quarter?"
154924,333332053,986953,"Agilent Technologies, Inc., Q2 2016 Earnings Call, May 16, 2016",2016-05-16,"Earnings Calls","Agilent Technologies, Inc.","Executives","Sure, Tim, how about if I -- again, thanks for your comment. And I can give you a few dollar numbers of revenue impact the way we've been looking at it and you can do them -- perhaps the math on the impact on the growth rates. But what we saw relative to",259,"Sure, Tim, how about if I -- again, thanks for your comment. And I can give you a few dollar numbers of revenue impact the way we've been looking at it and you can do them -- perhaps the math on the impact on the growth rates. But what we saw relative to our initial expectations for the quarter were really -- first of all, it starts with the market, right? So the overall market demand came in as we predicted. We saw good growth across the entire portfolio led by pharma and food markets in China, as you heard early. But I'd ask you to look at 2 things. One is this higher conversion of orders to revenue than forecast. So basically, what we've done is we reduced the cycle time and by our estimates, it happened a lot faster than we had thought, which I think is good news from the standpoint of operational efficiency; did create some forecasting challenges, but probably $20 million to $25 million came from Q3 into Q2. The other thing, I think, you should take a look at is the FX assumptions. So around $9 million or so, Didier, I think was the number. So FX added about another $9 million. So between the cycle time improvements, the FX assumptions and just the fact that the market continues, we're getting our fair share of markets where they're growing. I think those -- combination of those facts, I think, will help you bridge the difference between our guided growth and what actually occurred."
154924,333332053,986953,"Agilent Technologies, Inc., Q2 2016 Earnings Call, May 16, 2016",2016-05-16,"Earnings Calls","Agilent Technologies, Inc.","Analysts","Okay. Just a real quick similar question on the margin side. Obviously, a little bit of the margin in the quarter was the drop through, but it looks like you probably did better than you were expecting on an absolute dollar basis on the SG&A as well. Can",63,"Okay. Just a real quick similar question on the margin side. Obviously, a little bit of the margin in the quarter was the drop through, but it looks like you probably did better than you were expecting on an absolute dollar basis on the SG&A as well. Can you help me understand, maybe, what is going a little faster there than you anticipated?"
154924,333332053,986953,"Agilent Technologies, Inc., Q2 2016 Earnings Call, May 16, 2016",2016-05-16,"Earnings Calls","Agilent Technologies, Inc.","Executives","Yes, I think on the SG&A front, I mean, we've got a couple of our programs inside the Agile Agilent are little bit ahead of plan. And -- but Didier, I don't know if there's anything else of...",38,"Yes, I think on the SG&A front, I mean, we've got a couple of our programs inside the Agile Agilent are little bit ahead of plan. And -- but Didier, I don't know if there's anything else of..."
154924,333332053,986953,"Agilent Technologies, Inc., Q2 2016 Earnings Call, May 16, 2016",2016-05-16,"Earnings Calls","Agilent Technologies, Inc.","Executives","Most of the impact was volume driven and obviously, the FX, but there was -- versus the initial guidance.",19,"Most of the impact was volume driven and obviously, the FX, but there was -- versus the initial guidance."
154924,333332053,986953,"Agilent Technologies, Inc., Q2 2016 Earnings Call, May 16, 2016",2016-05-16,"Earnings Calls","Agilent Technologies, Inc.","Executives","I will tell you the field structure that we put in place last year, it's really stabled down. I think it's delivering, helping us on the growth side and also, on the SG&A front as a more efficient go-to-market channel.",40,"I will tell you the field structure that we put in place last year, it's really stabled down. I think it's delivering, helping us on the growth side and also, on the SG&A front as a more efficient go-to-market channel."
154924,333332053,986953,"Agilent Technologies, Inc., Q2 2016 Earnings Call, May 16, 2016",2016-05-16,"Earnings Calls","Agilent Technologies, Inc.","Operator","And our next question comes from the line of Isaac Ro of Goldman Sachs.",14,"And our next question comes from the line of Isaac Ro of Goldman Sachs."
154924,333332053,986953,"Agilent Technologies, Inc., Q2 2016 Earnings Call, May 16, 2016",2016-05-16,"Earnings Calls","Agilent Technologies, Inc.","Analysts","I had a question on margins as well. On the gross margin side, I was curious if we should expect maybe another wave of improvement now that you have the ERP integration done and on the margin side, curious how satisfied you are with the sales force realig",62,"I had a question on margins as well. On the gross margin side, I was curious if we should expect maybe another wave of improvement now that you have the ERP integration done and on the margin side, curious how satisfied you are with the sales force realignment and whether or not there's still more synergies to be had there as well."
154924,333332053,986953,"Agilent Technologies, Inc., Q2 2016 Earnings Call, May 16, 2016",2016-05-16,"Earnings Calls","Agilent Technologies, Inc.","Executives","Yes, a couple of comments here. Then I'll bounce it over to Didier in case he'd like to add a few things here. But in terms of the sales force integration and go-to-market -- we couldn't be happier. I mean, that was a major move we made last year, where w",347,"Yes, a couple of comments here. Then I'll bounce it over to Didier in case he'd like to add a few things here. But in terms of the sales force integration and go-to-market -- we couldn't be happier. I mean, that was a major move we made last year, where we basically went from 5 sales forces to the 2 sales forces, one focused on the analytical laboratory marketplace and then the other one focused on the regulated diagnostic marketplace. At the time, I remember sharing with you, ""Hey, we're making a big change here and it could affect the top line and the short one. That didn't happen. In fact, I submit that as we go out into '16 and '17, we're now putting more resources of specialization in academia, in biopharma. So I think you're going to see the changes paying off in terms of our longer-term growth. So we're really happy with both the fact that we've got it all behind us, it's settled down and I think it's starting to pay off on the initial benefits that we envisioned when we created that structure. 
Relative to gross margin ERP, just keep in mind that what we've been talking about is a -- the financial systems, which really go into the SG&A line. So it really won't affect the gross margin. That being said, we do think we can do more on gross margins as we move forward in '16 and '17. I'll talk a little bit about -- more about in detail next week when we're in New York. But as you may know, on our initial 400 basis points of improvement, when I came onboard, we said half would come through OpEx and other operational costs, and then others through growth. And the growth piece would be -- a lot would be driven by our ability to capture the gross margin improvements on increased volume. So we think we still have room to improve our material cost, and we think that we've got room to continue to bring down our logistics costs."
154924,333332053,986953,"Agilent Technologies, Inc., Q2 2016 Earnings Call, May 16, 2016",2016-05-16,"Earnings Calls","Agilent Technologies, Inc.","Analysts","That's very helpful. Maybe just a follow-up. Just to clarify on 2 topics, one on biopharma and then the other one on the comments you made around China. On biopharma, could you just compare the growth rates you're seeing in the QAQC setting versus R&D? An",82,"That's very helpful. Maybe just a follow-up. Just to clarify on 2 topics, one on biopharma and then the other one on the comments you made around China. On biopharma, could you just compare the growth rates you're seeing in the QAQC setting versus R&D? And then in China, just curious, how much of your improved outlook there is based on the visibility you have with government funding versus sort of end markets that are more on the private industry side?"
154924,333332053,986953,"Agilent Technologies, Inc., Q2 2016 Earnings Call, May 16, 2016",2016-05-16,"Earnings Calls","Agilent Technologies, Inc.","Executives","I think that on the -- your question, we're not seeing any real significant differences in growth rates across the segments you described in pharma. I do think if you go out a couple of years down the road, I think we'd expect the growth rate in the bioph",152,"I think that on the -- your question, we're not seeing any real significant differences in growth rates across the segments you described in pharma. I do think if you go out a couple of years down the road, I think we'd expect the growth rate in the biopharma should be higher than the small molecule. But it's not at all the case right now. As you heard earlier from Patrick, we expect that to continue through '17. We're getting more clarity about what's going on in China. I think there was a lot of concerns at one point in time on the private sector, this side of the business, but obviously, as you know, Isaac, the government drives the market there to a large extent, and we're getting more clarity on what's happening in funding. So that's why we have this increased confidence in our outlook for our business in China."
154924,333332053,986953,"Agilent Technologies, Inc., Q2 2016 Earnings Call, May 16, 2016",2016-05-16,"Earnings Calls","Agilent Technologies, Inc.","Operator","And our next question comes from the line of Derik De Bruin of Bank of America.",16,"And our next question comes from the line of Derik De Bruin of Bank of America."
154924,333332053,986953,"Agilent Technologies, Inc., Q2 2016 Earnings Call, May 16, 2016",2016-05-16,"Earnings Calls","Agilent Technologies, Inc.","Analysts","Just wanted to clarify. Did I hear you correctly that you said your initial flash for core growth guidance for fiscal '17 was 4.5% midpoint?",25,"Just wanted to clarify. Did I hear you correctly that you said your initial flash for core growth guidance for fiscal '17 was 4.5% midpoint?"
154924,333332053,986953,"Agilent Technologies, Inc., Q2 2016 Earnings Call, May 16, 2016",2016-05-16,"Earnings Calls","Agilent Technologies, Inc.","Executives","Yes, yes.",2,"Yes, yes."
154924,333332053,986953,"Agilent Technologies, Inc., Q2 2016 Earnings Call, May 16, 2016",2016-05-16,"Earnings Calls","Agilent Technologies, Inc.","Analysts","Okay. And so can you sort of like flank that in terms of what you're thinking for the chemical and energy market there? I mean, just sort of what you're expecting in terms of a rebound. And I'm just -- could you help us frame that comment a little bit mor",60,"Okay. And so can you sort of like flank that in terms of what you're thinking for the chemical and energy market there? I mean, just sort of what you're expecting in terms of a rebound. And I'm just -- could you help us frame that comment a little bit more in terms of some of the puts and takes?"
154924,333332053,986953,"Agilent Technologies, Inc., Q2 2016 Earnings Call, May 16, 2016",2016-05-16,"Earnings Calls","Agilent Technologies, Inc.","Executives","Yes, sure I'd be happy to because sometimes, you can use colorful language, which doesn't really give you the insights you need. So let me try to clarify here. So what we said was in this year, we thought our performance would be flat for the entire year,",348,"Yes, sure I'd be happy to because sometimes, you can use colorful language, which doesn't really give you the insights you need. So let me try to clarify here. So what we said was in this year, we thought our performance would be flat for the entire year, while in fact, it's going to be down, we probably think in the range of 2.5% for the year, for the entire year. And that is a change from our assumptions coming into this year. And that was the assumption we made at the time of our initial guidance, which makes our revenue results even much more -- we're really pleased with the results, given the fact that the chemical energy market has not developed the way we initially had thought. That being said, in '17, we actually think it will be improved, which means it won't be declining. And in fact, it will probably be flat or maybe low single digits. And why do we believe that? If you look at how our business breaks down in that segment, we often talk about the oil side. But 50% of our business historically has been in the exploration and another 35% has been in the refining. The other half, which is by far the biggest individual segment, is the chemical side, and they're benefiting by lower feedstock costs. They've got pent-up investment demands, and we're starting to see increased deal activity. So in fact, Patrick and I were talking about this, this morning and it kind of reminds me of pharma a few years ago where basically we were going to have 2 years of shrinking performance in this marketplace, a lot of pent-up demand. So long story short, our growth assumption for next year assumes low single-digit chemical energy growth for the year. Again, we still believe we're searching for the bottom. So -- and it's still early in the year of 2016. But that's our basic assumption for '17, which is an improved environment -- not dramatic, but improved from what we've seen over the last 24 months."
154924,333332053,986953,"Agilent Technologies, Inc., Q2 2016 Earnings Call, May 16, 2016",2016-05-16,"Earnings Calls","Agilent Technologies, Inc.","Analysts","And just as a quick follow-up on the chemical comment. You're not worried that some of the activity between Dow and DuPont and -- looks like there may be Monsanto and so these are the companies that are dancing around. Are you worried that, that could sor",73,"And just as a quick follow-up on the chemical comment. You're not worried that some of the activity between Dow and DuPont and -- looks like there may be Monsanto and so these are the companies that are dancing around. Are you worried that, that could sort of stymie investment? If you're using the pharma analogy of sort of combinations of those companies? Is there some potential headwind from the chemicals market?"
154924,333332053,986953,"Agilent Technologies, Inc., Q2 2016 Earnings Call, May 16, 2016",2016-05-16,"Earnings Calls","Agilent Technologies, Inc.","Executives","No, Derik, that's a great question. We looked at this pretty closely when the announcement was first made. And although Dow and DuPont are very important customers to us, that particular deal activity really is immaterial to the total company's performanc",111,"No, Derik, that's a great question. We looked at this pretty closely when the announcement was first made. And although Dow and DuPont are very important customers to us, that particular deal activity really is immaterial to the total company's performance. And we didn't necessarily see it as a sign of an acceleration of M&A and consolidations going on in the space. So of course, there would be some pause if we'd seen more of that, but we're not overly concerned about that. And I guess, the beauty of this business has been just the broad-based nature of our customer base. So we're not overly dependent on any one single customer."
154924,333332053,986953,"Agilent Technologies, Inc., Q2 2016 Earnings Call, May 16, 2016",2016-05-16,"Earnings Calls","Agilent Technologies, Inc.","Operator","And our next question comes from the line of Dan Arias of Citigroup.",13,"And our next question comes from the line of Dan Arias of Citigroup."
154924,333332053,986953,"Agilent Technologies, Inc., Q2 2016 Earnings Call, May 16, 2016",2016-05-16,"Earnings Calls","Agilent Technologies, Inc.","Analysts","Hi Mike, can you just touch on Japan and things that you saw during the quarter in terms of trends and then maybe what you're looking for at this point on the year?",33,"Hi Mike, can you just touch on Japan and things that you saw during the quarter in terms of trends and then maybe what you're looking for at this point on the year?"
154924,333332053,986953,"Agilent Technologies, Inc., Q2 2016 Earnings Call, May 16, 2016",2016-05-16,"Earnings Calls","Agilent Technologies, Inc.","Executives","Yes. So Dan, thanks for the question. And if you know a little bit of my history, I spent 5 years in Japan. So I've always been a big supporter of Japan in terms of the long-term view of the market. And I'd ask you to take a long-term view of the market i",178,"Yes. So Dan, thanks for the question. And if you know a little bit of my history, I spent 5 years in Japan. So I've always been a big supporter of Japan in terms of the long-term view of the market. And I'd ask you to take a long-term view of the market in Japan. So that was the only market that actually was down for us in the second quarter. And we are expecting continued subdued performance in Japan. So we're not expecting much in terms of improvement in the overall market environment in Japan. We do think that it could be a market which often will respond to new technologies, innovative new products. So we do hope -- we do hold out hope that we could take some share from some of our new intros coming out in the second part of this year. But from an overall market perspective, we're expecting it to remain subdued and our internal forecasts are not based on any type of material improvement at all on our performance in Japan."
154924,333332053,986953,"Agilent Technologies, Inc., Q2 2016 Earnings Call, May 16, 2016",2016-05-16,"Earnings Calls","Agilent Technologies, Inc.","Analysts","Okay. Thanks for that color. And then you kind of teased some new product introductions in the back half that should be meaningful to growth. I'm sure you don't want to give away any secrets, but can you just sort of help us with what part of the business",56,"Okay. Thanks for that color. And then you kind of teased some new product introductions in the back half that should be meaningful to growth. I'm sure you don't want to give away any secrets, but can you just sort of help us with what part of the business you're anticipating seeing the boost in 2017?"
154924,333332053,986953,"Agilent Technologies, Inc., Q2 2016 Earnings Call, May 16, 2016",2016-05-16,"Earnings Calls","Agilent Technologies, Inc.","Executives","Yes. So thanks for the caveat on your question. So what we can point to with great confidence and clarity is the recent introduction we made in analytic. And that what I would say to you, you will see broad-based introductions across the entire portfolio.",163,"Yes. So thanks for the caveat on your question. So what we can point to with great confidence and clarity is the recent introduction we made in analytic. And that what I would say to you, you will see broad-based introductions across the entire portfolio. And core growth is essential to our business plan. As you know, when I came in last year, we spent a lot of time reorganizing the R&D structure and also, reallocating where we put money. And I think you're going to start to see some of that starting to pay off, as we go into the latter part of '16. So we did want to put a teaser out there, but also just to make sure you had confidence in terms of what's behind our view of improved Agilent performance in '17 off of the second half of this year. But I think you're going to expect to see us talking about activities across all 3 business groups."
154924,333332053,986953,"Agilent Technologies, Inc., Q2 2016 Earnings Call, May 16, 2016",2016-05-16,"Earnings Calls","Agilent Technologies, Inc.","Operator","And our next question comes from the line of Doug Schenkel of Cowen and Company.",15,"And our next question comes from the line of Doug Schenkel of Cowen and Company."
154924,333332053,986953,"Agilent Technologies, Inc., Q2 2016 Earnings Call, May 16, 2016",2016-05-16,"Earnings Calls","Agilent Technologies, Inc.","Analysts","Mike, I wanted to go back to some of the comments you made on efforts to tighten cycle times from order to revenue, which seem to be yielding benefits greater than expected, particularly on China. Can you provide a bit more background on this effort and w",118,"Mike, I wanted to go back to some of the comments you made on efforts to tighten cycle times from order to revenue, which seem to be yielding benefits greater than expected, particularly on China. Can you provide a bit more background on this effort and why it was most impactful in China? And then maybe talk about similar efforts underway in other geographies. And relatedly, you positioned these in answering some questions as if they were temporary. At least, it seems like your guidance doesn't treat these as sustainable improvements. Yet, everything else you've said suggests that these are truly sustainable improvements. So I was just hoping you could help us understand that a little bit better."
154924,333332053,986953,"Agilent Technologies, Inc., Q2 2016 Earnings Call, May 16, 2016",2016-05-16,"Earnings Calls","Agilent Technologies, Inc.","Executives","Yes, sure, Doug. I really appreciate the question. And maybe let me start with the last part of your question, which is the takeaway here, we do believe that there's a stable improvement. So in my mind or the language I use, this is the new normal in term",443,"Yes, sure, Doug. I really appreciate the question. And maybe let me start with the last part of your question, which is the takeaway here, we do believe that there's a stable improvement. So in my mind or the language I use, this is the new normal in terms of our ability to convert orders to revenue. And so I would characterize this as new normal of how we're going to operate. So how did we get here and why do they look so significantly different in China? So first of all, it starts with looking at the entire process from an end-to-end customer perspective from the time of order placement till shipment until customer installation occurs -- and, as you know, when I restructured the company, I was really trying to break down the silos and we had a very silo-oriented approach to this end-to-end process from a customer perspective. In the company, we looked at each slice of the process but nobody was looking at the collective process for end-to-end. You start doing that, and then you start seeing where the issues are, the opportunities are. So we found ways to improve our order linearity. We've improved the quality of booked orders, and this really gets to your question about China. Often, you're dealing with letters of credit issues and other trade issues that in the past have delayed our ability to actually book them as clean orders and turn them into revenue. We call this delivery box. We've been working on making sure we had material availability. I think we hit one of our best quarters ever in terms of having material ready for all of our shipments. So we improved our ability to get in orders in a linear fashion, make sure those orders are clean and not have lot of rework, and then we've improved our delivery performance. And then spent a lot of time improving our efforts between shipment installation, which sometimes can go on for several weeks. So I think it all starts with this looking at the whole process from an end-to-end perspective, and the result has been a significant improvement in cycle time and orders turned into revenue more quickly than in the past. I do think this represents our new way of operating. And again, as I mentioned in my remarks, it did create some -- it did have implications of how we guide the company for the second and third quarter. But I think we're delighted to be able to actually have ongoing strong operational efficiency improvement in place so that we know how to predict revenue even better in the future."
154924,333332053,986953,"Agilent Technologies, Inc., Q2 2016 Earnings Call, May 16, 2016",2016-05-16,"Earnings Calls","Agilent Technologies, Inc.","Analysts","Okay. Mike, but just to be really clear, recognizing these are well-earned, sustainable improvements, it's not apparent that this is fully -- these improvements, the sustainably is fully reflected in guidance. If that's the case, is that just because you",57,"Okay. Mike, but just to be really clear, recognizing these are well-earned, sustainable improvements, it's not apparent that this is fully -- these improvements, the sustainably is fully reflected in guidance. If that's the case, is that just because you want to see this play out for a couple of quarters before you start baking it in?"
154924,333332053,986953,"Agilent Technologies, Inc., Q2 2016 Earnings Call, May 16, 2016",2016-05-16,"Earnings Calls","Agilent Technologies, Inc.","Executives","Yes. I think the confusion might be that what we have stated is that this quarter in Q2, we got $20 million to $25 million of revenue that we had anticipated to be recognized in Q3 as we were bringing all those programs to fruition. We had earlier results",120,"Yes. I think the confusion might be that what we have stated is that this quarter in Q2, we got $20 million to $25 million of revenue that we had anticipated to be recognized in Q3 as we were bringing all those programs to fruition. We had earlier results, which is great. From where we are now, the order to revenue cycle time is sustainable, but we will not see further improvement that will bring Q4 revenue into Q3 or whatever it is. So the 20 to 25, that's onetime. We've got to the level we wanted to be at. And from now on, it's just business as usual without any fundamental change in the order to revenue cycle time."
154924,333332053,986953,"Agilent Technologies, Inc., Q2 2016 Earnings Call, May 16, 2016",2016-05-16,"Earnings Calls","Agilent Technologies, Inc.","Analysts","All right. And just one last one for you. On the change in Lasergen accounting, was there any dilution in the quarter? And based on the accounting change, should we no longer expect this to be $0.02 to $0.03 dilutive deal for the year?",44,"All right. And just one last one for you. On the change in Lasergen accounting, was there any dilution in the quarter? And based on the accounting change, should we no longer expect this to be $0.02 to $0.03 dilutive deal for the year?"
154924,333332053,986953,"Agilent Technologies, Inc., Q2 2016 Earnings Call, May 16, 2016",2016-05-16,"Earnings Calls","Agilent Technologies, Inc.","Executives","Correct. You're correct. So there was no dilution in Q2, and there will not be any dilution in -- for the rest of '16 or '17 until we exercise our call option. And then we will just fully consolidate -- if we do that, obviously -- fully consolidate the La",120,"Correct. You're correct. So there was no dilution in Q2, and there will not be any dilution in -- for the rest of '16 or '17 until we exercise our call option. And then we will just fully consolidate -- if we do that, obviously -- fully consolidate the Lasergen revenue. So that's a change that there was a lot of -- I mean, discussions with the auditors. They surprised us a little bit by going to national to get specially some kind of -- challenge kind of the accounting that we had anticipated locally among the 2 teams, and then we agreed to the recommendation. And therefore, no dilution to EPS coming from Lasergen in the next 2 years."
154924,333332053,986953,"Agilent Technologies, Inc., Q2 2016 Earnings Call, May 16, 2016",2016-05-16,"Earnings Calls","Agilent Technologies, Inc.","Executives","Right. And we were pleased we were able to get this closed off before we finished the quarter.",18,"Right. And we were pleased we were able to get this closed off before we finished the quarter."
154924,333332053,986953,"Agilent Technologies, Inc., Q2 2016 Earnings Call, May 16, 2016",2016-05-16,"Earnings Calls","Agilent Technologies, Inc.","Operator","And our next question comes from the line of Miroslava Minkova of Stifel.",13,"And our next question comes from the line of Miroslava Minkova of Stifel."
154924,333332053,986953,"Agilent Technologies, Inc., Q2 2016 Earnings Call, May 16, 2016",2016-05-16,"Earnings Calls","Agilent Technologies, Inc.","Analysts","Maybe if I could focus on operating margins, again, for a second. Just help us, remind us. There's a lot going on there in terms of the programs you have in place and improvements you have going on. Help us -- remind us the bridge between fiscal '16 and '",58,"Maybe if I could focus on operating margins, again, for a second. Just help us, remind us. There's a lot going on there in terms of the programs you have in place and improvements you have going on. Help us -- remind us the bridge between fiscal '16 and '17? What's gets you to the 22% operating margin?"
154924,333332053,986953,"Agilent Technologies, Inc., Q2 2016 Earnings Call, May 16, 2016",2016-05-16,"Earnings Calls","Agilent Technologies, Inc.","Executives","Well, as a teaser, we're going to go through this in some detail.",13,"Well, as a teaser, we're going to go through this in some detail."
154924,333332053,986953,"Agilent Technologies, Inc., Q2 2016 Earnings Call, May 16, 2016",2016-05-16,"Earnings Calls","Agilent Technologies, Inc.","Executives","There will be a slide on the topic next week.",10,"There will be a slide on the topic next week."
154924,333332053,986953,"Agilent Technologies, Inc., Q2 2016 Earnings Call, May 16, 2016",2016-05-16,"Earnings Calls","Agilent Technologies, Inc.","Executives","But what I can share with you conceptually is that we will be continuing and completing off the integration of the Dako acquisition. We have a series of operational programs. We talked about one of those already, which is the implications of the ERP, and",86,"But what I can share with you conceptually is that we will be continuing and completing off the integration of the Dako acquisition. We have a series of operational programs. We talked about one of those already, which is the implications of the ERP, and the continued focus on gross margin improvement, specifically material cost reductions and logistic savings. So I think the combination of those 3 factors plus with the overall quarter growth assumptions that we're currently modeling around 4.5 gets us to the 22%."
154924,333332053,986953,"Agilent Technologies, Inc., Q2 2016 Earnings Call, May 16, 2016",2016-05-16,"Earnings Calls","Agilent Technologies, Inc.","Analysts","Okay, great. And the strength in the food market, was this all China or are you seeing strength elsewhere as well?",21,"Okay, great. And the strength in the food market, was this all China or are you seeing strength elsewhere as well?"
154924,333332053,986953,"Agilent Technologies, Inc., Q2 2016 Earnings Call, May 16, 2016",2016-05-16,"Earnings Calls","Agilent Technologies, Inc.","Executives","Actually, it was both in food, I mean, excuse me, both -- food market, both in China and in the United States. As you may recall, from our Q1 announcement, this business tends to be a little lumpy, whereas I think the performance in the food market in Chi",65,"Actually, it was both in food, I mean, excuse me, both -- food market, both in China and in the United States. As you may recall, from our Q1 announcement, this business tends to be a little lumpy, whereas I think the performance in the food market in China has been sustained. But we saw a nice rebound in the U.S. in the second quarter."
154924,333332053,986953,"Agilent Technologies, Inc., Q2 2016 Earnings Call, May 16, 2016",2016-05-16,"Earnings Calls","Agilent Technologies, Inc.","Analysts","Got you. Okay. And maybe finally, give us your view of the M&A pipeline. We've seen you do a couple of deals just recently here. Now that you have sort of many of the operational initiatives for the new Agilent in place, should we expect you're more activ",53,"Got you. Okay. And maybe finally, give us your view of the M&A pipeline. We've seen you do a couple of deals just recently here. Now that you have sort of many of the operational initiatives for the new Agilent in place, should we expect you're more active with the tuck-ins going forward?"
154924,333332053,986953,"Agilent Technologies, Inc., Q2 2016 Earnings Call, May 16, 2016",2016-05-16,"Earnings Calls","Agilent Technologies, Inc.","Executives","Again, this is a teaser #2, which is we're going to talk about this a little bit in more detail next week. But I do feel that the company's foundation is really firmly established. And as I mentioned earlier, I think we're getting a lot better in terms of",140,"Again, this is a teaser #2, which is we're going to talk about this a little bit in more detail next week. But I do feel that the company's foundation is really firmly established. And as I mentioned earlier, I think we're getting a lot better in terms of our speed to be able to integrate. But what -- I think you're going to expect us to do is to remain disciplined and focused in terms of finding those opportunities that make sense for us. And I would ask you to think about as being complementary M&A in nature. We're going to continue to look for those. So our balance sheet is a huge asset for the -- for our shareholders and one which we would like to deploy relative to M&A, but it has to be the right target."
154924,333332053,986953,"Agilent Technologies, Inc., Q2 2016 Earnings Call, May 16, 2016",2016-05-16,"Earnings Calls","Agilent Technologies, Inc.","Operator","And our next question comes from the line of Steve Beuchaw of Morgan Stanley.",14,"And our next question comes from the line of Steve Beuchaw of Morgan Stanley."
154924,333332053,986953,"Agilent Technologies, Inc., Q2 2016 Earnings Call, May 16, 2016",2016-05-16,"Earnings Calls","Agilent Technologies, Inc.","Analysts","Just 2 clarifications on how you're thinking about the '16, '17 progression. The first is actually on the NIH. To what extent, if any, are you anticipating a pick-up in the research channel from NIH funding when we start to see that get dispersed in the s",98,"Just 2 clarifications on how you're thinking about the '16, '17 progression. The first is actually on the NIH. To what extent, if any, are you anticipating a pick-up in the research channel from NIH funding when we start to see that get dispersed in the second half of the year? And then second, and this may be even a longer-term question. But how do you think about the evolution of FSMA regulations in the food space in the U.S.? Is it too soon to start getting incrementally optimistic about how they could contribute to the outlook?"
154924,333332053,986953,"Agilent Technologies, Inc., Q2 2016 Earnings Call, May 16, 2016",2016-05-16,"Earnings Calls","Agilent Technologies, Inc.","Executives","Yes, thanks. I'm glad to address both of your questions. So on the NIH front, I think, when we talked about the uptick in sort of our improved confidence about spends in academia and government in the U.S., I think we do think that the NIH stuff will star",219,"Yes, thanks. I'm glad to address both of your questions. So on the NIH front, I think, when we talked about the uptick in sort of our improved confidence about spends in academia and government in the U.S., I think we do think that the NIH stuff will start to flow through to our business. Relative to some in our space, we don't have it as high a percentage of our business tied to the NIH, but it will be a positive for us. And I think, again, one more fact pattern which points to a continued view that this market will be solid for us as we move into '17. I think I'd have to agree with the comment, which is, I think it really is too soon to get overall excited about this from a U.S. spending. I've seen this before where the legislation is announced and there's a lot of fanfare about it. But they don't always get backed up by investments. Although we did -- we are seeing some -- it looks like some maybe more friendly government allocations to this agency unlike we've seen to the EPA. So we're not expecting anything dramatic to occur definitely in the market because of this. But if it would, that would be clearly good news for us."
154924,333332053,986953,"Agilent Technologies, Inc., Q2 2016 Earnings Call, May 16, 2016",2016-05-16,"Earnings Calls","Agilent Technologies, Inc.","Operator","And our next question comes from the line of Jeff Elliott of Robert W. Baird.",15,"And our next question comes from the line of Jeff Elliott of Robert W. Baird."
154924,333332053,986953,"Agilent Technologies, Inc., Q2 2016 Earnings Call, May 16, 2016",2016-05-16,"Earnings Calls","Agilent Technologies, Inc.","Analysts","Mike, on the margin, overall, a really good quarter. But then when you look at the margins in DGG and in CrossLab, you're basically flat year-over-year. I guess, is that what you're expecting? Anything kind of you could call out in the quarter? I know the",53,"Mike, on the margin, overall, a really good quarter. But then when you look at the margins in DGG and in CrossLab, you're basically flat year-over-year. I guess, is that what you're expecting? Anything kind of you could call out in the quarter? I know there's some moving pieces in the top line."
154924,333332053,986953,"Agilent Technologies, Inc., Q2 2016 Earnings Call, May 16, 2016",2016-05-16,"Earnings Calls","Agilent Technologies, Inc.","Executives","Why don't you take that one, Didier?",8,"Why don't you take that one, Didier?"
154924,333332053,986953,"Agilent Technologies, Inc., Q2 2016 Earnings Call, May 16, 2016",2016-05-16,"Earnings Calls","Agilent Technologies, Inc.","Executives","No, it's a great question and the answer is yes. It's precisely what we had expected. One of the, obviously, based from one quarter to the next, there could be some onetime add-ins that adds a little bit of volatility. For example, last year, both ACG and",136,"No, it's a great question and the answer is yes. It's precisely what we had expected. One of the, obviously, based from one quarter to the next, there could be some onetime add-ins that adds a little bit of volatility. For example, last year, both ACG and DGG had very favorable hedging gains, which have gone away. For the whole company, the hedging gains last year in Q2 was over $7 million and this Q2 was about $1.5 million, something like that. So -- and it was mostly in ACG and DGG. And there are other onetime items that -- including -- regarding the allocation of our shared services among the different businesses, which explain. But both businesses are on their way to contribute to the operating margin expansion and the 22% that we're committing to."
154924,333332053,986953,"Agilent Technologies, Inc., Q2 2016 Earnings Call, May 16, 2016",2016-05-16,"Earnings Calls","Agilent Technologies, Inc.","Executives","Didier, maybe I'll also ask Mark to -- we've talked about this earlier this last week as well about the operational efficiency improvements that underline what looks to be flat margins, but when you peel back the onion with the hedging gains and the other",54,"Didier, maybe I'll also ask Mark to -- we've talked about this earlier this last week as well about the operational efficiency improvements that underline what looks to be flat margins, but when you peel back the onion with the hedging gains and the other things, there's actually some real operations stuff down there."
154924,333332053,986953,"Agilent Technologies, Inc., Q2 2016 Earnings Call, May 16, 2016",2016-05-16,"Earnings Calls","Agilent Technologies, Inc.","Executives","Thanks, Mike and Didier, As Didier said, there are several things that were factors in this last year that didn't come into play this year. But we were working on a lot of things in terms of improvements. The mix is somewhat favorable in the context of wh",101,"Thanks, Mike and Didier, As Didier said, there are several things that were factors in this last year that didn't come into play this year. But we were working on a lot of things in terms of improvements. The mix is somewhat favorable in the context of what we're selling. But overall, when we look at our plans for the first half, we're up 70 basis points in the first half over last year. So our ability to actually do to margin improvements, when you pull back and look at the first half regardless of all those things, it's quite positive."
154924,333332053,986953,"Agilent Technologies, Inc., Q2 2016 Earnings Call, May 16, 2016",2016-05-16,"Earnings Calls","Agilent Technologies, Inc.","Executives","And as our fastest growing business, he's been picking up more of the corporate costs.",15,"And as our fastest growing business, he's been picking up more of the corporate costs."
154924,333332053,986953,"Agilent Technologies, Inc., Q2 2016 Earnings Call, May 16, 2016",2016-05-16,"Earnings Calls","Agilent Technologies, Inc.","Executives","Shared services.",2,"Shared services."
154924,333332053,986953,"Agilent Technologies, Inc., Q2 2016 Earnings Call, May 16, 2016",2016-05-16,"Earnings Calls","Agilent Technologies, Inc.","Executives","Shared services.",2,"Shared services."
154924,333332053,986953,"Agilent Technologies, Inc., Q2 2016 Earnings Call, May 16, 2016",2016-05-16,"Earnings Calls","Agilent Technologies, Inc.","Executives","Yes, shared services.",3,"Yes, shared services."
154924,333332053,986953,"Agilent Technologies, Inc., Q2 2016 Earnings Call, May 16, 2016",2016-05-16,"Earnings Calls","Agilent Technologies, Inc.","Operator","And our final question comes from the line of the Dane Leone of BTIG.",14,"And our final question comes from the line of the Dane Leone of BTIG."
154924,333332053,986953,"Agilent Technologies, Inc., Q2 2016 Earnings Call, May 16, 2016",2016-05-16,"Earnings Calls","Agilent Technologies, Inc.","Analysts","I just had a quick clarification from earlier. So you're talking about the replacement cycle in biopharma and quoted, I think, 150,000 LC systems based on the 1100, 1200 platform. Did you -- can you clarify if that's what you think the opportunity is ahea",67,"I just had a quick clarification from earlier. So you're talking about the replacement cycle in biopharma and quoted, I think, 150,000 LC systems based on the 1100, 1200 platform. Did you -- can you clarify if that's what you think the opportunity is ahead of you or if that's an opportunity in progress? And if so, kind of what -- how far are you into that?"
154924,333332053,986953,"Agilent Technologies, Inc., Q2 2016 Earnings Call, May 16, 2016",2016-05-16,"Earnings Calls","Agilent Technologies, Inc.","Executives","This is Patrick. Let me answer this question. So first and foremost, this is not biopharma at all. This is pharma and biopharma combined. And when I talk about 150,000 systems out there, it's the installed base of LC systems in all markets. So it's not on",132,"This is Patrick. Let me answer this question. So first and foremost, this is not biopharma at all. This is pharma and biopharma combined. And when I talk about 150,000 systems out there, it's the installed base of LC systems in all markets. So it's not only in pharma and biopharma. But we think the biggest push is actually right now, coming from pharma and biopharma, and I would still say we are in the midst of the replacement cycle. We don't see that to be over -- in the next couple of quarters. There's a healthy demand and we are in negotiation with a lot of our core customers on upcoming replacements and how we place these systems and how we plan it out for them so it works for them."
154924,333332053,986953,"Agilent Technologies, Inc., Q2 2016 Earnings Call, May 16, 2016",2016-05-16,"Earnings Calls","Agilent Technologies, Inc.","Executives","And Dane, if I could add this one other comment to Patrick's response. We've been focused a lot today -- in today's call on pharma and biopharma, but keep in mind that the replacement cycles have been very, very subdued on the implied market side in liqui",89,"And Dane, if I could add this one other comment to Patrick's response. We've been focused a lot today -- in today's call on pharma and biopharma, but keep in mind that the replacement cycles have been very, very subdued on the implied market side in liquid chromatography. So we have several -- we have tens of thousands of systems on that side of the house as well. And again, this is why when we look out into '17 and '18, we think that our growth rates are sustainable."
154924,333332053,986953,"Agilent Technologies, Inc., Q2 2016 Earnings Call, May 16, 2016",2016-05-16,"Earnings Calls","Agilent Technologies, Inc.","Analysts","Any way you could handicap using a baseball analogy or something like that, like what inning you think you're at?",20,"Any way you could handicap using a baseball analogy or something like that, like what inning you think you're at?"
154924,333332053,986953,"Agilent Technologies, Inc., Q2 2016 Earnings Call, May 16, 2016",2016-05-16,"Earnings Calls","Agilent Technologies, Inc.","Executives","No, don't ask a German about a baseball analogy.",9,"No, don't ask a German about a baseball analogy."
154924,333332053,986953,"Agilent Technologies, Inc., Q2 2016 Earnings Call, May 16, 2016",2016-05-16,"Earnings Calls","Agilent Technologies, Inc.","Executives","I'd say, on the pharma side, you're probably innings 5 or 6. I mean, if there's a way through, maybe 2/3. I think -- and my point would be that I think the ballgame is just getting started. We may be in the first inning. We hope to be in the first inning",63,"I'd say, on the pharma side, you're probably innings 5 or 6. I mean, if there's a way through, maybe 2/3. I think -- and my point would be that I think the ballgame is just getting started. We may be in the first inning. We hope to be in the first inning soon of that cycle on the implied market side."
154924,333332053,986953,"Agilent Technologies, Inc., Q2 2016 Earnings Call, May 16, 2016",2016-05-16,"Earnings Calls","Agilent Technologies, Inc.","Operator","And I'm showing no further questions at this time. I'd now like to turn the conference back to Alicia Rodriguez for closing remarks.",24,"And I'm showing no further questions at this time. I'd now like to turn the conference back to Alicia Rodriguez for closing remarks."
154924,333332053,986953,"Agilent Technologies, Inc., Q2 2016 Earnings Call, May 16, 2016",2016-05-16,"Earnings Calls","Agilent Technologies, Inc.","Executives","Thank you, everybody, and I'd like to thank you all for joining us today on the call. If you have any questions, of course, please give us a call in IR. And just would hope that we'll see you next week at our Analyst Day in New York City. Thanks again. By",52,"Thank you, everybody, and I'd like to thank you all for joining us today on the call. If you have any questions, of course, please give us a call in IR. And just would hope that we'll see you next week at our Analyst Day in New York City. Thanks again. Bye-bye."
154924,333332053,986953,"Agilent Technologies, Inc., Q2 2016 Earnings Call, May 16, 2016",2016-05-16,"Earnings Calls","Agilent Technologies, Inc.","Operator","Ladies and gentlemen, thank you for participating in today's conference. This does conclude the program. You may all disconnect. Everyone, have a great day.",24,"Ladies and gentlemen, thank you for participating in today's conference. This does conclude the program. You may all disconnect. Everyone, have a great day."
154924,374881090,1036615,"Agilent Technologies, Inc., Q3 2016 Earnings Call, Aug 17, 2016",2016-08-17,"Earnings Calls","Agilent Technologies, Inc.","Operator","Good day ladies and gentlemen, and welcome to the Third Quarter 2016 Agilent Technologies Earnings Conference Call. [Operator Instructions] As a reminder, today's program is being recorded. I would now like to introduce your host for today's program, Alic",48,"Good day ladies and gentlemen, and welcome to the Third Quarter 2016 Agilent Technologies Earnings Conference Call. [Operator Instructions] As a reminder, today's program is being recorded. I would now like to introduce your host for today's program, Alicia Rodriguez, Vice President of Investor Relations. Please go ahead."
154924,374881090,1036615,"Agilent Technologies, Inc., Q3 2016 Earnings Call, Aug 17, 2016",2016-08-17,"Earnings Calls","Agilent Technologies, Inc.","Executives","Thank you, Jonathan and welcome, everyone, to Agilent's Third Quarter Conference Call for Fiscal Year 2016. With me are Mike McMullen, Agilent's President and CEO; and Didier Hirsch, Agilent's Senior Vice President and CFO.Joining in the Q&A after Didie",340,"Thank you, Jonathan and welcome, everyone, to Agilent's Third Quarter Conference Call for Fiscal Year 2016. With me are Mike McMullen, Agilent's President and CEO; and Didier Hirsch, Agilent's Senior Vice President and CFO.
Joining in the Q&A after Didier's comments will be Patrick Kaltenbach, President of Agilent's Life Sciences and Applied Markets Group; Jacob Thaysen, President of Agilent's Diagnostics and Genomics Group; and Mark Doak, President of the Agilent CrossLab Group.
You can find the press release and information to supplement today's discussion on our website at www.investor.agilent.com. While there, please click on the link for financial results under the Financial Information tab. You will find an investor presentation along with revenue breakouts and currency impacts, business segment results and historical financials for Agilent's operations. We will also post a copy of the prepared remarks following this call. 
Today's comments by Mike and Didier will refer to non-GAAP financial measures. You will find the most directly comparable GAAP financial metrics and reconciliations on our website. We will refer to core revenue growth, which excludes the impact of currency, the NMR business and acquisitions and divestitures within the past 12 months. Please note that we are reporting results for the Americas, Europe and Asia on a ship-to basis. Previously, we assign revenue to these regions based on where the order was placed. This change aligns with individual country reporting, which has always been on a ship-to basis. Historical restatements are available on the Investor Relations website. Unless otherwise noted, all references to increases or decreases in financial metrics are year-over-year. Guidance is based on exchange rates as of the last day of the reported quarter. 
We will also make forward-looking statements about the financial performance of the company. These statements are subject to risks and uncertainties and are only valid as of today. The company assumes no obligation to update them. Please look at the company's recent SEC filings for a more complete picture of our risks and other factors. And now let me turn the call over to Mike."
154924,374881090,1036615,"Agilent Technologies, Inc., Q3 2016 Earnings Call, Aug 17, 2016",2016-08-17,"Earnings Calls","Agilent Technologies, Inc.","Executives","Thanks, Alicia, and hello, everyone. Thank you for joining us on today's call. I'm pleased to report that the Agilent team delivered another quarter above expectations. Now let me highlight 3 key results. First, core -- Q3 core revenue growth of 3% was ab",1425,"Thanks, Alicia, and hello, everyone. Thank you for joining us on today's call. I'm pleased to report that the Agilent team delivered another quarter above expectations. Now let me highlight 3 key results. First, core -- Q3 core revenue growth of 3% was above the high end of our May guidance. Second, EPS of $0.49 was also above the high end of our guidance of $0.45 to $0.47. Finally, we delivered adjusted operating margin of 20.6%, an increase of 70 basis points from a year ago. As for the third quarter results echo many of the the same themes we saw last quarter. The pharma, food, clinical and diagnostics end markets remain strong. In the chemical engineering market while demand for services and consumables was strong, capital expenditures for new equipment purchases remain challenged. Geographically, Asia, led by China's double-digit growth, drove Agilent third quarter core growth with strength across all business segments. 
Let me highlight our Q3 results by business group. In line with our expectations, Life Sciences and Applied Markets Group core revenues were down 2%. Our strong growth in pharma, environmental food markets was offset by continued weakness in chemical energy capital expenditures. Academia and government revenues were also down across regions. Despite this mixed market environment, LSAG operating margin for the quarter was 19.1%, up 40 basis points from a year ago. Let me shift gears and talk about some of LSAG's new products. We are seeing very strong demand the new release 1260 and the 1290 Infinity II LC systems. The 1260 systems are part of the launch of the Infinity lab portfolio and analytica in May. Infinity lab portfolio consists of this new line of LC instruments along with columns, supplies and services. In Q3, LSAG also introduced the new -- 2 new 7000 Series Triple Quad DCMS analyzers, one for pesticides and another one for environmental pollutants. And we continue to strengthen our a leadership with a new Agilent 8900 Triple Quad ICP-MS system. This new system offers customers improved speed and accuracy of analysis.
Turning to the Agilent CrossLab Group. The business delivered another strong quarter with 8% [ph] core revenue growth. This growth is driven by strength in the food, pharma and environmental markets. ACGs operating margin over the quarter was 22.7%, up 10 basis points from a year ago. Portfolio expansion efforts also continued at ACG. In Q3, Agilent signed a definitive agreement to acquire the assets of iLab, and we just closed the transaction in early August. iLab is the market leader in cloud-based solutions for core laboratory management and provide services to leading universities, research hospitals and independent institutions around the world. This acquisition further strengthens Agilent's academia and government markets. iLab enables Agilent to deliver value in this market segment. We also see an opportunity to expand the iLab business both geographically and into the pharma market.
Finally, we saw a continued momentum in the Diagnostics and Genomics Group where the business delivered 8% [ph] core growth in Q3. We saw strength across all DGG business, driven by growth in the pharma and clinical and diagnostics market. Our pathology business continues on a steady trajectory of improved growth. This was highlighted by demand for our new PD-L1 companion diagnostics. Growth in genomics reflect a strong market performance in the U.S. and China across our array CGH target enrichment and SureSelect products. We also saw healthy demand for new clinic asset solutions offering. DGG's operating margin for the quarter was 18.8%, up 200 basis points from a year ago. Q3 highlights for DGG with the announcement of an expense of a intended use of our PD-L1 pharma test in Europe for patients with melanoma. This test was proven in the U.S. and available in Europe for patients with nonsquamous, nonsmall lung cancer in the U.S. and patients with melanoma. We also announced a $120 million investment over the next 3 years to expand production capacity for our new clinic asset solutions business. This includes the purchase of 20 acres of land in Colorado. We plan to build a factory in this land that will double our manufacturing capacity for nucleic acid active pharmaceutical ingredients and grow our business.
Now I'll provide an overview of Agilent's core revenues by end market. In our Life Sciences market, pharma saw sixth consecutive quarter of double-digit growth with core revenue up 10%. Academia and government core revenues were down 5%, down across most geographies except China. Clinical diagnostics grew 4% with strength in North America and Asia and led by growth in pathology. Applied end market performance was mixed was up 11% with strong demand in China and Americas. These regions also drove growth in environmental market for both instruments and aftermarket products. This performance was offset by a continued challenge in the chemical and energy market, down 4% globally with only Asia posting growth on a regional basis. The overall result was due to prolonged effects of the macroeconomic concerns and lower oil prices. 
Now I'll turn an update on our operating margin improvement initiatives. Q3 marked a major step in simplifying our company's infrastructure. In May, we completed the migration of the company's financial systems on to a single SAP platform. This was a culmination of a 20-month cross-company effort and represents a major step in simplifying Agilent's systems infrastructure that will deliver income cost savings as planned in fiscal 2017. In summary, our multiyear Agile Agilent program continues to solidify the company's business processes. This program is designed to make us more nimble and lower our cost. It will continue to deliver incremental savings in 2017.
On the capital deployment front, we purchased iLab paid $37 million in dividends and repurchased $94 million of Agilent stock. We continue to deliver on our strategy to drive sustainable growth while expanding operating margins and balancing deployment of our capital to drive shareholder value creation. 
At our recent Minneapolis meeting, I described a shareholder value creation model: outgrow the market, expand operating markets, balance capital deployment. Let's look at our Q3 results in the context of these longer-term goals and shareholder value creation model. In 2015, we delivered our highest annual growth rate in 4 years while increasing operating margin of 170 basis points and completely offsetting the $40 million of de-synergies from the company split. We have sustained this trajectory of improved operating results in fiscal 2016. In the first 3 quarters of 2016, the team had delivered strong growth and earnings above our initial expectation despite a challenging chemical energy market environment and global macroeconomic concerns.
We have continued to leverage our balance sheet and deploy capital in a balanced matter, buying companies that are bringing new capabilities to Agilent while repurchasing our stock and increasing cash dividends. The new leadership team continues to transform the business and deliver results. We continue to demonstrate our ability to deliver above-industry organic growth while expanding margins and leveraging our balance sheet strength. Our Q3 results in a challenging global economic environment reflect the strength of our team combined with the Agilent's scale and broad differentiated portfolio of products and services. Looking at today's overall market environment, we expect continued strength in pharma, along with growth in the food, environmental and clinical research and diagnostics markets and in China on a regional basis. As I highlighted in our last call, we experienced a steeper and more prolonged slowdown in the chemical and energy market than initially projected entering fiscal 2016. We subsequently revise our forecast for this market segment last quarter to overall low single-digit market declines for the year. While there are some signs of an impending [indiscernible] end market, we remain cautious in our outlook and expect Q4 to be in the similar range as the past quarter. Against this market drop, we are well positioned to capture growth in these end market segments and geographies where growth is expected to remain strong. The combination of our expanding our customer channel reach and our continued strength in our portfolio positions us well to achieve our previously raised full year guidance of 2016 and our longer-term goals. Our one Agilent team continues to work well together and is energized to win in the market. Overall, we remain on track with our 2017 goal to outgrow the market and improve our operating margin to 22%. Thank you for being on the call today. I will now turn it over to Didier who will provide additional insights on our financial results and guidance for the remainder of 2016. Didier?"
154924,374881090,1036615,"Agilent Technologies, Inc., Q3 2016 Earnings Call, Aug 17, 2016",2016-08-17,"Earnings Calls","Agilent Technologies, Inc.","Executives","Thank you, Mike, and hello, everyone. As mentioned by Mike, we delivered higher core revenue growth operating margin and earnings per share than the high end of our guidance. Earnings per share grew 11% in the quarter versus a year ago. We also generated",324,"Thank you, Mike, and hello, everyone. As mentioned by Mike, we delivered higher core revenue growth operating margin and earnings per share than the high end of our guidance. Earnings per share grew 11% in the quarter versus a year ago. We also generated $194 million in operating cash flow, more than double last year's amounts, which gives us increased confidence that we'll achieve our previously raised operating cash flow guidance for the full year. FX had a negative impact on revenue of about $10 million or 1% versus previous guidance and $7 million or 0.7% versus last year. It had a negative impact on operating profit of $3 million versus previous guidance and $1 million versus last year.
I'll now turn to the guidance for our fourth quarter. We expect Q4 revenues of $1.05 billion to $1.07 billion and earnings per share of $0.50 to $0.52. At midpoint, revenue is expected to grow 1.2% on a core basis. Versus previous guidance, FX is estimated to have a negative impact of $9 million on revenue and $2 million on operating profit. Our 21.3% adjusted operating margin at midpoint will be up 70 basis points sequentially.
Now to the guidance for fiscal year 2016. The Q4 guidance results in the following fiscal year guidance. At midpoint, revenue is projected to grow 4.5% on a core basis, no change from the previous guidance. Our earnings per share guidance of $1.90 at midpoint is also unchanged from previous guidance and corresponds to a 9% year-over-year increase.
Adjusted operating margin for the year is expected to be 20.4 basis points or 80 basis points higher than in fiscal year '15. And finally, FX is estimated to have a negative impact on a year-over-year basis of $68 million of revenue, $10 million on operating profit related to currency translation and an additional $21 million related to currency hedging. With that, I'll turn it over to Alicia for the Q&A."
154924,374881090,1036615,"Agilent Technologies, Inc., Q3 2016 Earnings Call, Aug 17, 2016",2016-08-17,"Earnings Calls","Agilent Technologies, Inc.","Executives","Thank you, Didier. Jonathan, will you please give the instructions for the Q&A?",13,"Thank you, Didier. Jonathan, will you please give the instructions for the Q&A?"
154924,374881090,1036615,"Agilent Technologies, Inc., Q3 2016 Earnings Call, Aug 17, 2016",2016-08-17,"Earnings Calls","Agilent Technologies, Inc.","Operator","[Operator Instructions] Our first question comes from the line of Brandon Cooley from Jefferies. Our next question comes from the line of Steve Beuchaw from Morgan Stanley.",27,"[Operator Instructions] Our first question comes from the line of Brandon Cooley from Jefferies. 
Our next question comes from the line of Steve Beuchaw from Morgan Stanley."
154924,374881090,1036615,"Agilent Technologies, Inc., Q3 2016 Earnings Call, Aug 17, 2016",2016-08-17,"Earnings Calls","Agilent Technologies, Inc.","Analysts","I want to start with the -- one regional trend that seems to be on many people's minds, which is what's going on in Europe. I wonder if you could speak to the trends that you saw in Europe over the course of the quarter. To some extent, it's a macro quest",98,"I want to start with the -- one regional trend that seems to be on many people's minds, which is what's going on in Europe. I wonder if you could speak to the trends that you saw in Europe over the course of the quarter. To some extent, it's a macro question. To some extent, it's a research question. And of course, there's -- the U.K. referendum that's still out there. So I apologize for the nebulous nature of it all. But any color on how Europe progressed over the course of the quarter would be really helpful."
154924,374881090,1036615,"Agilent Technologies, Inc., Q3 2016 Earnings Call, Aug 17, 2016",2016-08-17,"Earnings Calls","Agilent Technologies, Inc.","Executives","Yes, sure. led to provide some insight there, and I'm actually going to have Patrick jump in on this presentation, given his recent travels in the region.But what we saw in the quarter was, obviously, a lot of big macro events, the Brexit, Turkey. There",182,"Yes, sure. led to provide some insight there, and I'm actually going to have Patrick jump in on this presentation, given his recent travels in the region.
But what we saw in the quarter was, obviously, a lot of big macro events, the Brexit, Turkey. There's a number that developed in the quarter. We did not see any material impact from those events in our performance in the third quarter. What I will say though is it an increased level of uncertainty amongst our customers in Europe, and we've seen the questions around when will budgets be released. So it's more of an uncertainty of question right out there people are just sort of wait and see out there to see how it's going to develop. Again, no material effect on the third quarter results. But as we thought about our guidance for the fourth quarter, obviously, it has influenced us to think about how will Europe developed through the quarter. And Patrick, I know you had a pretty deep conversation about this yesterday. So any additional thoughts you'd like to add?"
154924,374881090,1036615,"Agilent Technologies, Inc., Q3 2016 Earnings Call, Aug 17, 2016",2016-08-17,"Earnings Calls","Agilent Technologies, Inc.","Executives","Yes. Thanks, Mike. In talking to a [indiscernible] in Europe to get the feedback there is some uncertainty as Mike -- as you said. The Brexit had that some of the government in traditional deals have some minor impacts. I think what's concerning us here a",93,"Yes. Thanks, Mike. In talking to a [indiscernible] in Europe to get the feedback there is some uncertainty as Mike -- as you said. The Brexit had that some of the government in traditional deals have some minor impacts. I think what's concerning us here a little bit is there are a couple of other countries standing in the sidelines and had other referendums this year. So we are cautious right now looking at Europe and the growth in Europe for the remainder of the year and also going to fiscal year '17."
154924,374881090,1036615,"Agilent Technologies, Inc., Q3 2016 Earnings Call, Aug 17, 2016",2016-08-17,"Earnings Calls","Agilent Technologies, Inc.","Executives","Thanks, Patrick.",2,"Thanks, Patrick."
154924,374881090,1036615,"Agilent Technologies, Inc., Q3 2016 Earnings Call, Aug 17, 2016",2016-08-17,"Earnings Calls","Agilent Technologies, Inc.","Analysts","And then one bigger picture question, Mike. You've made a pretty significant investment with a pretty long-term horizon on this facility in Colorado. So it speaks to your confidence in the long-term outlook for and the scale of the opportunity there. Can",76,"And then one bigger picture question, Mike. You've made a pretty significant investment with a pretty long-term horizon on this facility in Colorado. So it speaks to your confidence in the long-term outlook for and the scale of the opportunity there. Can you just talk us through how you frame the opportunity, remind us how big that business is today, and how do you think about the medium-term drivers that you're investing in the pursuit of?"
154924,374881090,1036615,"Agilent Technologies, Inc., Q3 2016 Earnings Call, Aug 17, 2016",2016-08-17,"Earnings Calls","Agilent Technologies, Inc.","Executives","Great. So I'm going to handle -- I'm going to handle the first part of your question that I'm going to turn it over to Jacob, and he'll reassure you about the long-term growth potential, which is the reason why is part of the investment. But just as a rem",183,"Great. So I'm going to handle -- I'm going to handle the first part of your question that I'm going to turn it over to Jacob, and he'll reassure you about the long-term growth potential, which is the reason why is part of the investment. But just as a reminder, I think this is roughly about roughly 5% or so of DGG's revenues in the range of maybe 16-plus-million dollars or so. We still have capacity at the current site. But we've got more demand that we can handle in terms of long-term outlook from our customers. So we can't bring on this capacity fast enough to satisfy the customer demand. We think this will be a bigger part of our growth story as we talked to you about 2017 and 2018. And I think as you hear from Jacob, there's a high degree of confidence that the business is going to be there and perhaps you can have a context on what exactly is this business and why are we so confident that the market is going to be there for us."
154924,374881090,1036615,"Agilent Technologies, Inc., Q3 2016 Earnings Call, Aug 17, 2016",2016-08-17,"Earnings Calls","Agilent Technologies, Inc.","Executives","Yes, let me try to provide a little bit more color there. So first of all, a reminder that the nuclear gas solutions division is providing API that constitute any type of drugs with significant potential. These drugs are primarily right now opportunities",289,"Yes, let me try to provide a little bit more color there. So first of all, a reminder that the nuclear gas solutions division is providing API that constitute any type of drugs with significant potential. These drugs are primarily right now opportunities within genetic diseases that today there's been no treatment and have devastating outcomes. And these drugs have the opportunity to change the expectancy all, you could say, the survival and also the quality of life for such patients. And we are working with the leaders in pharma the drugs again and again due to a deep technical experience to optimize all those performance and consistency combined with our ability to scale in GMP. We have seen a significant demand accelerated over the last few years. And as Mike mentioned, we're current expanding our current site to actually take up double capacity. But we also see that, that will run out -- that opportunity is really limited and will run out in a few years from now and that by the new investment in the new site will allow us to further double our capacity and even double again if we choose to do so. We have decided and based on a deep dive into the strategy and so on to place the site in close proximity to the other site approximately 20 minutes drive away from the highly-experienced staff that we already have an capabilities and processes. The overall market is in the hundreds of million dollar business right now, and it's growing somewhere between 20% to 30%. However, when you commercialize the drug, this might be a significant step up, but we see a lot of demand right now just in the clinical trial studies."
154924,374881090,1036615,"Agilent Technologies, Inc., Q3 2016 Earnings Call, Aug 17, 2016",2016-08-17,"Earnings Calls","Agilent Technologies, Inc.","Operator","Our next question comes from the line of Jonathan Groberg from UBS.",12,"Our next question comes from the line of Jonathan Groberg from UBS."
154924,374881090,1036615,"Agilent Technologies, Inc., Q3 2016 Earnings Call, Aug 17, 2016",2016-08-17,"Earnings Calls","Agilent Technologies, Inc.","Analysts","I know you have one more quarter to go here. But any initial thoughts on the puts and takes you're seeing on how we should be thinking about fiscal '17?",30,"I know you have one more quarter to go here. But any initial thoughts on the puts and takes you're seeing on how we should be thinking about fiscal '17?"
154924,374881090,1036615,"Agilent Technologies, Inc., Q3 2016 Earnings Call, Aug 17, 2016",2016-08-17,"Earnings Calls","Agilent Technologies, Inc.","Executives","Yes, Jonathan. I'd be happy to share my thoughts here. And in fact, I -- perhaps will build on some of the comments that I made in my prepared remarks. But we're still -- we are still seeing ourselves in the same path that we talked about just a month or",495,"Yes, Jonathan. I'd be happy to share my thoughts here. And in fact, I -- perhaps will build on some of the comments that I made in my prepared remarks. But we're still -- we are still seeing ourselves in the same path that we talked about just a month or so ago in New York. It's actually 2 months ago when I think about it. But our position remains the same. We are still confident that we are going to be able to achieve the overall projected core growth of 4.5%. And there's some new -- there really are some new factors that support this level of growth. First of all, we've -- we have a rich pipeline of new product introductions coming in Q4 and in FY '17 on top of what we've already introduced this year. Now we think our customers are going to be real excited about what we're bringing to market, and that's going to help drive share. So we know we've got going through on the system right now with releases coming up in the several [ph] quarters on top of what will be done. The second thing, we also have recognized the fact that the Agilent business model has really changed a lot over the last 18 months or so. We have a lot more recurring revenue. And if you look at the ACG and DGG business, which now represent over half -- I think it's 52%, last time I did the math, of Agilent's revenue. These are just inherently much more predictable revenue streams and then you sign our Q3 results how both groups delivered high single-digit growth, and they're not subject the same types of issues we're seeing in the capital-intensive chemical energy market, for example. And then the third thing I'd say is when you think about our LSAG instrument business, in addition to the impact of the impacts I mentioned, we do expect that pharma and China market is going to remain significant growth drivers, although I think they will be below these double-digit levels we've seen in 2016. And as mentioned in our last call, we still expect that the chemical energy will have bottomed to by the end of calendar year 2017. We're not ready to -- sorry, excuse me, I got my ears confused there -- by the end of calendar year 2016, we're not ready to call bottom, but we do see in 2017 that we're forecasting that we could be in low single digits growth. In our markets, we just had 18 to 24 months of pent-up demand for equipment that supports the production process. So there are 3 factors that's going into our thinking as we have thought about the 2017's growth rate. Honestly, we'll give you the official guidance at our next call. But I would just reinforce our view today is that we're still on track to what we told you in May in New York."
154924,374881090,1036615,"Agilent Technologies, Inc., Q3 2016 Earnings Call, Aug 17, 2016",2016-08-17,"Earnings Calls","Agilent Technologies, Inc.","Analysts","Great. That's helpful. And then just one follow-up, on the capital equipment business I know you mentioned going into the quarter last time you guided, you thought there would be a little bit of pull forward and you highlighted by thought it would be a li",75,"Great. That's helpful. And then just one follow-up, on the capital equipment business I know you mentioned going into the quarter last time you guided, you thought there would be a little bit of pull forward and you highlighted by thought it would be a little weaker. I'm just curious. Was it in line with what you thought? Or was there anything in unique in the quarter that was not right along what you saw?"
154924,374881090,1036615,"Agilent Technologies, Inc., Q3 2016 Earnings Call, Aug 17, 2016",2016-08-17,"Earnings Calls","Agilent Technologies, Inc.","Executives","Absolutely. I think the quarter was in line actually a little bit better than we had anticipated coming in the quarter. So no major surprises in our Q3 results. And as you can imagine, we were delighted with the ability to deliver above our expectations,",50,"Absolutely. I think the quarter was in line actually a little bit better than we had anticipated coming in the quarter. So no major surprises in our Q3 results. And as you can imagine, we were delighted with the ability to deliver above our expectations, both top and bottom line."
154924,374881090,1036615,"Agilent Technologies, Inc., Q3 2016 Earnings Call, Aug 17, 2016",2016-08-17,"Earnings Calls","Agilent Technologies, Inc.","Operator","Our next question comes from the line of Jack Meehan of Barclays.",12,"Our next question comes from the line of Jack Meehan of Barclays."
154924,374881090,1036615,"Agilent Technologies, Inc., Q3 2016 Earnings Call, Aug 17, 2016",2016-08-17,"Earnings Calls","Agilent Technologies, Inc.","Analysts","So I just wanted to ask about the LSAG business and some of the moving parts there? And can you just maybe talk about the chromatography market? A couple of your peers have had really nice results there. what you're seeing there will be helpful.",45,"So I just wanted to ask about the LSAG business and some of the moving parts there? And can you just maybe talk about the chromatography market? A couple of your peers have had really nice results there. what you're seeing there will be helpful."
154924,374881090,1036615,"Agilent Technologies, Inc., Q3 2016 Earnings Call, Aug 17, 2016",2016-08-17,"Earnings Calls","Agilent Technologies, Inc.","Executives","Yes, absolutely. And Patrick if you could break it out obviously, between [indiscernible] as well.",15,"Yes, absolutely. And Patrick if you could break it out obviously, between [indiscernible] as well."
154924,374881090,1036615,"Agilent Technologies, Inc., Q3 2016 Earnings Call, Aug 17, 2016",2016-08-17,"Earnings Calls","Agilent Technologies, Inc.","Executives","Yes, absolutely. Happy to do so. As Mike mentioned earlier in his remarks, we definitely see very strong growth right now in the liquid chromatography business, which has been [indiscernible] double-digits. And that is what we see, clearly, also taking ma",247,"Yes, absolutely. Happy to do so. As Mike mentioned earlier in his remarks, we definitely see very strong growth right now in the liquid chromatography business, which has been [indiscernible] double-digits. And that is what we see, clearly, also taking market share right now. We had a very strong launch of very strong waves of the Infinity series starting in 2009 and 2012 on average [ph] and now this year we move to 1260 series but not a big round of its and solutions for Liquid Chromatography that is very well received by the end markets. We see very healthy replacement businesses as well. And it's driven by the fact that these solutions are 100% backwards compatible and also compatible with some of our competitors' instrumentation, which makes very simple and seamless for the customer. So -- and we project this cycle to continue for several more quarters. We don't see yet a loss of momentum. What we see, of course, is that we're getting now with quarters tough compare the double-digit growth for several quarters now. On the the Gas Chromatography side, again, very strong portfolio as well. The issue we're seeing there is that the core market of one of the big markets for Gas Chromatography is the energy space. And that, of course, pull some of our results down at this point in time. If the market comes back, we think we are in an exceptional position to pick up this pent-up demand [indiscernible]"
154924,374881090,1036615,"Agilent Technologies, Inc., Q3 2016 Earnings Call, Aug 17, 2016",2016-08-17,"Earnings Calls","Agilent Technologies, Inc.","Executives","When the market comes back.",5,"When the market comes back."
154924,374881090,1036615,"Agilent Technologies, Inc., Q3 2016 Earnings Call, Aug 17, 2016",2016-08-17,"Earnings Calls","Agilent Technologies, Inc.","Executives","Yes, when the market comes back. Sorry. So I think we are in a great situation there as well. We have an outstanding product portfolio and ability to capture the growth when it gets back.",35,"Yes, when the market comes back. Sorry. So I think we are in a great situation there as well. We have an outstanding product portfolio and ability to capture the growth when it gets back."
154924,374881090,1036615,"Agilent Technologies, Inc., Q3 2016 Earnings Call, Aug 17, 2016",2016-08-17,"Earnings Calls","Agilent Technologies, Inc.","Executives","Yes. And the reason I asked Patrick to segment his remarks in Liquid Chromatography from Gas Chromatography, we have an outsized exposure in Gas Chromatography. And when -- the relative to the #2 competitors base, we're at least 2x the #2 person. And so w",88,"Yes. And the reason I asked Patrick to segment his remarks in Liquid Chromatography from Gas Chromatography, we have an outsized exposure in Gas Chromatography. And when -- the relative to the #2 competitors base, we're at least 2x the #2 person. And so when our major market is down, it really hits us. And that's why, again, we're really quite pleased we were able to deliver the growth we've done so far with our #2 market actually being down below our initial expectations coming into this year."
154924,374881090,1036615,"Agilent Technologies, Inc., Q3 2016 Earnings Call, Aug 17, 2016",2016-08-17,"Earnings Calls","Agilent Technologies, Inc.","Analysts","Yes, that's really helpful. And I appreciate all the details in the different segments. If I can just follow up with one more. The Americas growth, negative 1% in the quarter. I know it's not a tougher comp relative to last year. But can you maybe just ta",67,"Yes, that's really helpful. And I appreciate all the details in the different segments. If I can just follow up with one more. The Americas growth, negative 1% in the quarter. I know it's not a tougher comp relative to last year. But can you maybe just talk about the mix of the end markets there and whether there was any other notable changes worth pointing out."
154924,374881090,1036615,"Agilent Technologies, Inc., Q3 2016 Earnings Call, Aug 17, 2016",2016-08-17,"Earnings Calls","Agilent Technologies, Inc.","Executives","I think the big one there is the chemical energy market. So it's down pretty sharply. And I think that's bringing down the overall numbers as well as our academia and government business was down over last year. Although we think some of that the way we'r",72,"I think the big one there is the chemical energy market. So it's down pretty sharply. And I think that's bringing down the overall numbers as well as our academia and government business was down over last year. Although we think some of that the way we're set thinking about our plan for the rest of this year, we think the federal money will be there in the fourth quarter for us."
154924,374881090,1036615,"Agilent Technologies, Inc., Q3 2016 Earnings Call, Aug 17, 2016",2016-08-17,"Earnings Calls","Agilent Technologies, Inc.","Executives","Yes. And in addition if I may add, we had a very strong quarter in Q3 in the Americas. So it's a tough compare.",24,"Yes. And in addition if I may add, we had a very strong quarter in Q3 in the Americas. So it's a tough compare."
154924,374881090,1036615,"Agilent Technologies, Inc., Q3 2016 Earnings Call, Aug 17, 2016",2016-08-17,"Earnings Calls","Agilent Technologies, Inc.","Executives","Yes, not always going to let my guys do the tough compare argument, but thanks, Patrick.",16,"Yes, not always going to let my guys do the tough compare argument, but thanks, Patrick."
154924,374881090,1036615,"Agilent Technologies, Inc., Q3 2016 Earnings Call, Aug 17, 2016",2016-08-17,"Earnings Calls","Agilent Technologies, Inc.","Operator","Our next question comes from the line of Tycho Peterson from JPMorgan.",12,"Our next question comes from the line of Tycho Peterson from JPMorgan."
154924,374881090,1036615,"Agilent Technologies, Inc., Q3 2016 Earnings Call, Aug 17, 2016",2016-08-17,"Earnings Calls","Agilent Technologies, Inc.","Analysts","Maybe first just on the academic trend because it is a big swing from what you reported last quarter I understand the Europe dynamic. But in fact, that we hear from you is little bit different from what of the Life Sciences peers. So can you maybe just ta",67,"Maybe first just on the academic trend because it is a big swing from what you reported last quarter I understand the Europe dynamic. But in fact, that we hear from you is little bit different from what of the Life Sciences peers. So can you maybe just talk a little bit about why you felt more pressure in Europe academic than maybe most of your peers?"
154924,374881090,1036615,"Agilent Technologies, Inc., Q3 2016 Earnings Call, Aug 17, 2016",2016-08-17,"Earnings Calls","Agilent Technologies, Inc.","Executives","I think it's -- I'd point to 2 factors. I'm not sure exactly what all our peers are saying about Europe. I think they're probably saying the same thing, which are the European budgets are constrained, and the funding has not been released, and it's actual",132,"I think it's -- I'd point to 2 factors. I'm not sure exactly what all our peers are saying about Europe. I think they're probably saying the same thing, which are the European budgets are constrained, and the funding has not been released, and it's actually been [indiscernible] in some situations. I also think you may be hearing more positive spin on the U.S. environment because of many of our competitors have many business coming from NIH. So there's a lot of positive view on the NIH budget, but we pick up a relatively small piece of that overall budget. The agencies where we do a lot of our business in the U.S. government, we know the money is coming in the fourth quarter. Anything else you add to that, Patrick?"
154924,374881090,1036615,"Agilent Technologies, Inc., Q3 2016 Earnings Call, Aug 17, 2016",2016-08-17,"Earnings Calls","Agilent Technologies, Inc.","Executives","Not a lot. As you said, a lot of our competitors are definitely mixed bag, on average, I would say.",20,"Not a lot. As you said, a lot of our competitors are definitely mixed bag, on average, I would say."
154924,374881090,1036615,"Agilent Technologies, Inc., Q3 2016 Earnings Call, Aug 17, 2016",2016-08-17,"Earnings Calls","Agilent Technologies, Inc.","Analysts","And similarly to environmental is flat after growing 6% last quarter. Can you maybe just comment on the dynamics there?",20,"And similarly to environmental is flat after growing 6% last quarter. Can you maybe just comment on the dynamics there?"
154924,374881090,1036615,"Agilent Technologies, Inc., Q3 2016 Earnings Call, Aug 17, 2016",2016-08-17,"Earnings Calls","Agilent Technologies, Inc.","Executives","Yes. I think the biggest dynamic there is subsegment where we stick of our forensic segment. And we reported externally just a total Environmental Business. But a lot of big deal activity in forensic. So last year, we had a lot of big deals at this point",101,"Yes. I think the biggest dynamic there is subsegment where we stick of our forensic segment. And we reported externally just a total Environmental Business. But a lot of big deal activity in forensic. So last year, we had a lot of big deals at this point in time. Our environmental market is -- it's going to be a big deal in the second quarter. So it's really a forensic-driven phenomena, which is where we didn't have as many big deals in the third quarter. And this business tends to be a little bit more lumpy than our base Environmental Business."
154924,374881090,1036615,"Agilent Technologies, Inc., Q3 2016 Earnings Call, Aug 17, 2016",2016-08-17,"Earnings Calls","Agilent Technologies, Inc.","Analysts","Okay. And last one, a little bit of an question. But on the PD-L1 datasets on the front lines on, can you just talk about whether there is kind of any change in your outlook. Obviously, Bristol is happy to go without a companion work is doing a companion.",68,"Okay. And last one, a little bit of an question. But on the PD-L1 datasets on the front lines on, can you just talk about whether there is kind of any change in your outlook. Obviously, Bristol is happy to go without a companion work is doing a companion. So been used talk about whether some of those developments have changed your view of the market opportunity overall?"
154924,374881090,1036615,"Agilent Technologies, Inc., Q3 2016 Earnings Call, Aug 17, 2016",2016-08-17,"Earnings Calls","Agilent Technologies, Inc.","Executives","Sure. In fact, we have the conversation on this yesterday. So Pat, why don't you share your latest thoughts on Agilent on the topic.",24,"Sure. In fact, we have the conversation on this yesterday. So Pat, why don't you share your latest thoughts on Agilent on the topic."
154924,374881090,1036615,"Agilent Technologies, Inc., Q3 2016 Earnings Call, Aug 17, 2016",2016-08-17,"Earnings Calls","Agilent Technologies, Inc.","Executives","Yes, I would say, first and foremost, we're very pleased with the performance that we have seen on PD-L1 over the last 10 months, and we continue to see a strong traction. You're right, there has been some announcement recently on some studies that has co",119,"Yes, I would say, first and foremost, we're very pleased with the performance that we have seen on PD-L1 over the last 10 months, and we continue to see a strong traction. You're right, there has been some announcement recently on some studies that has come out as expected. It's really supports our thesis about the importance of and really that you need to make sure you strategize your patient group group the right way. So clearly, there is a short-term opportunity, at least from one of our customers that is a little less than we hoped for. But I don't think that, that overall change is the thesis, and we will continue to see a big opportunity here."
154924,374881090,1036615,"Agilent Technologies, Inc., Q3 2016 Earnings Call, Aug 17, 2016",2016-08-17,"Earnings Calls","Agilent Technologies, Inc.","Operator","Our next question comes from the line of Ross Muken from Evercore.",12,"Our next question comes from the line of Ross Muken from Evercore."
154924,374881090,1036615,"Agilent Technologies, Inc., Q3 2016 Earnings Call, Aug 17, 2016",2016-08-17,"Earnings Calls","Agilent Technologies, Inc.","Analysts","So it seems like most of the confusion we're hearing is sort of on the sequential progression of core revenues. And so I look at the last 2 years, and it looks like, sequentially, the comp is roughly, I don't know, 200 basis points easier on core. And it",121,"So it seems like most of the confusion we're hearing is sort of on the sequential progression of core revenues. And so I look at the last 2 years, and it looks like, sequentially, the comp is roughly, I don't know, 200 basis points easier on core. And it looks like you had a little bit heavier of an NMR headwind in 4Q than you did in 3Q. So one, could you confirm that? And two, as we think about the crosswalk, what are some of the underlying assumptions what is different sequentially versus 3Q whether it's end markets or any of the segments? And then where have you built in, I guess, some conservatism or some of that uncertainty?"
154924,374881090,1036615,"Agilent Technologies, Inc., Q3 2016 Earnings Call, Aug 17, 2016",2016-08-17,"Earnings Calls","Agilent Technologies, Inc.","Executives","Yes. Thanks for the question, Ross. And why don't I go ahead and just share with you some thoughts about the Q4 guidance. And then Didier, maybe could take your notes on the NMR impact. But I think it's important for me to share with the audience here tod",271,"Yes. Thanks for the question, Ross. And why don't I go ahead and just share with you some thoughts about the Q4 guidance. And then Didier, maybe could take your notes on the NMR impact. But I think it's important for me to share with the audience here today about how we thought about our Q4 guidance. I think this may get to the root of some of your questions. As you heard on our call, first of all, we're quite pleased with the higher-than-guided core revenue growth that we delivered for Q3 after having raised last -- in last call. I think we got's this increased confidence achieved our previously raised core growth guidance for the year. And listen, we realized by not raising our core guidance for this year that this question could arise. But the way we look at it was, so listen, there was a raised level of uncertainty in the markets centered around Europe. And we saw some weak European government budgets in the third quarter. Is this going to continue? We've seen some downward revisions in terms of market overall economic forecast for Europe. So we're not really sure exactly how it's going to develop. So we just thought it's prudent to reflect some of this uncertainty by not raising it again the full year guidance. So that's how we thought about the process. We really didn't look over the years sequentially. But we did know that last year though, I said I don't like the tough compare, although we did have a blowout and fourth quarter last year. But anything else, Didier, you remember"
154924,374881090,1036615,"Agilent Technologies, Inc., Q3 2016 Earnings Call, Aug 17, 2016",2016-08-17,"Earnings Calls","Agilent Technologies, Inc.","Executives","NMR is not a factor. You pointed out really what we intended to do. We've maintained overall core revenue growth for the whole year, and that's we derive the Q4.",30,"NMR is not a factor. You pointed out really what we intended to do. We've maintained overall core revenue growth for the whole year, and that's we derive the Q4."
154924,374881090,1036615,"Agilent Technologies, Inc., Q3 2016 Earnings Call, Aug 17, 2016",2016-08-17,"Earnings Calls","Agilent Technologies, Inc.","Executives","Yes. And I know we raised last quarter and business is developing in the third quarter actually better than we had thought as you saw in our results. And as you look in the fourth quarter, listen, we don't know how this year is going to play out. So let's",61,"Yes. And I know we raised last quarter and business is developing in the third quarter actually better than we had thought as you saw in our results. And as you look in the fourth quarter, listen, we don't know how this year is going to play out. So let's just be cautious as opposed to raising again for the quarter."
154924,374881090,1036615,"Agilent Technologies, Inc., Q3 2016 Earnings Call, Aug 17, 2016",2016-08-17,"Earnings Calls","Agilent Technologies, Inc.","Analysts","That makes total sense to me, Mike. I mean, I think given some of the uncertainty, certainly, don't want to get in front of your skis. And you guys had been beating numbers, and that's good. I guess, as you think about the key product cycles for the busin",132,"That makes total sense to me, Mike. I mean, I think given some of the uncertainty, certainly, don't want to get in front of your skis. And you guys had been beating numbers, and that's good. I guess, as you think about the key product cycles for the business, how do you think about the cadence now that you've had some releases of when we could start seeing that also drop the core growth overall? And then secondarily, when do we start to comp through? We've now, I guess, comped through some easier compares on the diagnostics business, which has been going hot, I don't know, 4, 6 quarters now. How long do you think we've got left on that trajectory of sort of high-single to almost double-digit growth in that business?"
154924,374881090,1036615,"Agilent Technologies, Inc., Q3 2016 Earnings Call, Aug 17, 2016",2016-08-17,"Earnings Calls","Agilent Technologies, Inc.","Executives","I think that for the forseeable future, we're highly confident on the growth rates in this business. And that's why I made the comment earlier about, ""Hey, when you think about Agilent's long-term growth perspective, you think about '17, think about that",155,"I think that for the forseeable future, we're highly confident on the growth rates in this business. And that's why I made the comment earlier about, ""Hey, when you think about Agilent's long-term growth perspective, you think about '17, think about that we've got over half of our revenue in markets that are going to have a steady trajectory of growth."" And you heard Jacob talk about what's going on in the companion diagnostic PD-L1. That's why wanted to highlight the investments and break in NASD, which is part of the business we probably haven't talked a lot about with you. So I think a lot of genomics, Seahorse there's a lot of fundamental very attractive markets that we have a strong position in. So Jacob, I don't want to speak for you but I guess, I have that we expected this growth rate will be sustain. Anything else you to add to my story."
154924,374881090,1036615,"Agilent Technologies, Inc., Q3 2016 Earnings Call, Aug 17, 2016",2016-08-17,"Earnings Calls","Agilent Technologies, Inc.","Executives","You're absolutely right. And I'm definitely pleased with a interesting growth. Last quarter, we had 5%. So I really want to make sure that you saw that we were when I -- when we talked also at the Analyst Day, we believe the right -- the direction is 6% t",79,"You're absolutely right. And I'm definitely pleased with a interesting growth. Last quarter, we had 5%. So I really want to make sure that you saw that we were when I -- when we talked also at the Analyst Day, we believe the right -- the direction is 6% to 7%. I'm happy to beat that. But we do not see any change in trajectory right now. And we continue in those high single-digit growth rates going forward."
154924,374881090,1036615,"Agilent Technologies, Inc., Q3 2016 Earnings Call, Aug 17, 2016",2016-08-17,"Earnings Calls","Agilent Technologies, Inc.","Analysts","And Ross, I think perhaps the earlier question was around product cycle replacement?  So I think, as you may know, when I came into the role a little over 1.5 years ago, we had really spent a lot of time redirecting our R&D program. We restructured the co",182,"And Ross, I think perhaps the earlier question was around product cycle replacement?  So I think, as you may know, when I came into the role a little over 1.5 years ago, we had really spent a lot of time redirecting our R&D program. We restructured the company. We reorganized our R&D programs. And I think you're starting to see the cadence. So you're seeing some of the product come out we highlighted earlier on the chromatography side, some updates and new products around ICP-MS. And we know this cadence going to continue throughout the next quarter and into '17. So that's why when I got the question about, ""hey, whether you thinking about in terms of '17? I know what's in the roadmap. I know what's coming to the market over the next 12 months. And I know it's already come to the market, and I know how customers are responding, and that's why we have this level of confidence about our ability to continue to grow this company in what has been very mixed market conditions, to say the least."
154924,374881090,1036615,"Agilent Technologies, Inc., Q3 2016 Earnings Call, Aug 17, 2016",2016-08-17,"Earnings Calls","Agilent Technologies, Inc.","Operator","Our next question comes from the line of Doug Schenkel of Cowen and Company.",14,"Our next question comes from the line of Doug Schenkel of Cowen and Company."
154924,374881090,1036615,"Agilent Technologies, Inc., Q3 2016 Earnings Call, Aug 17, 2016",2016-08-17,"Earnings Calls","Agilent Technologies, Inc.","Analysts","My first question -- I guess both are going to be on guidance. So fiscal Q4, your guidance essentially tells us that you're assuming operational margin decline year-over-year in fiscal year Q4 in spite of but seems like could be a, I guess, mix-wise, a pr",81,"My first question -- I guess both are going to be on guidance. So fiscal Q4, your guidance essentially tells us that you're assuming operational margin decline year-over-year in fiscal year Q4 in spite of but seems like could be a, I guess, mix-wise, a pretty favorable quarter year-over-year, based on your commentary. So keeping that in mind and the fact that you've actually expanded operating margin year-over-year, I believe 6 straight quarters, can you just explain why this makes sense?"
154924,374881090,1036615,"Agilent Technologies, Inc., Q3 2016 Earnings Call, Aug 17, 2016",2016-08-17,"Earnings Calls","Agilent Technologies, Inc.","Executives","Yes. I think you've got the string of consecutive quarters, the 6 quarters in a row. Didier, can you look at this. I think it's purely volume-related. But ...",29,"Yes. I think you've got the string of consecutive quarters, the 6 quarters in a row. Didier, can you look at this. I think it's purely volume-related. But ..."
154924,374881090,1036615,"Agilent Technologies, Inc., Q3 2016 Earnings Call, Aug 17, 2016",2016-08-17,"Earnings Calls","Agilent Technologies, Inc.","Executives","Yes, absolutely. Same thing for operating margin. Our approach as for revenue, our approach is we wanted to maintain our full year operating margin because, obviously, it's linked to revenue. So we maintain our core revenue growth assumption of 4.5% and o",136,"Yes, absolutely. Same thing for operating margin. Our approach as for revenue, our approach is we wanted to maintain our full year operating margin because, obviously, it's linked to revenue. So we maintain our core revenue growth assumption of 4.5% and our operating margin assumption of 20.4%. Now you are absolutely correct that it would mean that 50 basis points reduction from the significant operating margin we had in Q4 of last year of 21.5%, still a significant 70 basis point sequential improvement. And you have to take into account, as Mike said, that this is based on only 1.2% top line growth. So a slight reduction in operating margin still very significant increase sequentially but slight reduction related to the one -- the assumption that you made in the top line growth of only 1.2%."
154924,374881090,1036615,"Agilent Technologies, Inc., Q3 2016 Earnings Call, Aug 17, 2016",2016-08-17,"Earnings Calls","Agilent Technologies, Inc.","Executives","Yes, we'll do better in the volume, we'll do better on the margin.",13,"Yes, we'll do better in the volume, we'll do better on the margin."
154924,374881090,1036615,"Agilent Technologies, Inc., Q3 2016 Earnings Call, Aug 17, 2016",2016-08-17,"Earnings Calls","Agilent Technologies, Inc.","Analysts","So I guess that's a segue to, I guess, the second guidance question. And I don't mean to be redundant here because there's been a lot of questions on this already. But I'm going to ask anyway. I mean, your guidance is for around 1.2% core revenue growth i",217,"So I guess that's a segue to, I guess, the second guidance question. And I don't mean to be redundant here because there's been a lot of questions on this already. But I'm going to ask anyway. I mean, your guidance is for around 1.2% core revenue growth in the quarter. If we think about this by end market, it -- you actually have an easier compare in environmental, forensics, academic, environment and food relative to certainly what you had in fiscal Q3. Diagnostics a little tougher, but you had some real momentum there. So if we kind of make it simple end markets grow 3% to 5%, and chemical and energy is down mid-singles, it would imply that you guys are thinking that pharma is going to grow low single digits maybe at best in Q4. It's a tough compare in pharma in the quarter, but you've talked about continued strength in pharma in fiscal '17 in response to an earlier question. Again, recognizing the uncertainty you talked about the in Europe, this is -- I guess this is hard to reconcile. Can you help out a little bit? What are you assuming for pharma in the quarter? Is that because of the compare? And what's the assumption growth for Europe growth in the quarter?"
154924,374881090,1036615,"Agilent Technologies, Inc., Q3 2016 Earnings Call, Aug 17, 2016",2016-08-17,"Earnings Calls","Agilent Technologies, Inc.","Executives","Yes. Sure. to walk with you on this We spend a lot of time working in revenues for the rest of the year. Anticipating that this might be a question that would arise. And as I recall, Didier, I think that we had a less optimistic view relative to academia",94,"Yes. Sure. to walk with you on this We spend a lot of time working in revenues for the rest of the year. Anticipating that this might be a question that would arise. And as I recall, Didier, I think that we had a less optimistic view relative to academia and government than, I think, Doug's math was was where we were concerned about Europe. And we had a -- we basically have a flat for the year, and we still have pharma rolling double-digit, so if you want to do a little walk-through."
154924,374881090,1036615,"Agilent Technologies, Inc., Q3 2016 Earnings Call, Aug 17, 2016",2016-08-17,"Earnings Calls","Agilent Technologies, Inc.","Executives","Yes, the -- maybe, I mean, considering how we came up with the Q4 guidance, the makeup of the Q4 guidance by market in that academic and government and chemical and energy will show the same core revenue growth reduction year-over-year as in Q3. So minus",98,"Yes, the -- maybe, I mean, considering how we came up with the Q4 guidance, the makeup of the Q4 guidance by market in that academic and government and chemical and energy will show the same core revenue growth reduction year-over-year as in Q3. So minus 5% for academic and government, minus 4% for chemical energy. So the assumption is no change between Q3 and Q4. And then for the rest, pharma, you mentioned pharma, we're assuming mid-single digits. And again, on a very tough compare and to -- in line with how we been very conservative with."
154924,374881090,1036615,"Agilent Technologies, Inc., Q3 2016 Earnings Call, Aug 17, 2016",2016-08-17,"Earnings Calls","Agilent Technologies, Inc.","Executives","And just to be clear, my comment on double-digit pharma, that's for the full year.",15,"And just to be clear, my comment on double-digit pharma, that's for the full year."
154924,374881090,1036615,"Agilent Technologies, Inc., Q3 2016 Earnings Call, Aug 17, 2016",2016-08-17,"Earnings Calls","Agilent Technologies, Inc.","Executives","Timing for the full year, yes, double-digit absolutely.",8,"Timing for the full year, yes, double-digit absolutely."
154924,374881090,1036615,"Agilent Technologies, Inc., Q3 2016 Earnings Call, Aug 17, 2016",2016-08-17,"Earnings Calls","Agilent Technologies, Inc.","Executives","Yes, Doug, the company coming in, I think that the company growth would be lower. We thought China would be lower. We thought chemical would be higher. In fact, what's happened is pharma has actually been stronger, and China has been stronger than we init",56,"Yes, Doug, the company coming in, I think that the company growth would be lower. We thought China would be lower. We thought chemical would be higher. In fact, what's happened is pharma has actually been stronger, and China has been stronger than we initially you forecasted. And you know the story on chemical and energy."
154924,374881090,1036615,"Agilent Technologies, Inc., Q3 2016 Earnings Call, Aug 17, 2016",2016-08-17,"Earnings Calls","Agilent Technologies, Inc.","Analysts","Okay. The only thing I don't think we got there was, and maybe I missed it. But what is the assumption for Europe in the quarter?",26,"Okay. The only thing I don't think we got there was, and maybe I missed it. But what is the assumption for Europe in the quarter?"
154924,374881090,1036615,"Agilent Technologies, Inc., Q3 2016 Earnings Call, Aug 17, 2016",2016-08-17,"Earnings Calls","Agilent Technologies, Inc.","Executives","It's about -- that is down low single digits, mostly on the basis of chemical and energy.",18,"It's about -- that is down low single digits, mostly on the basis of chemical and energy."
154924,374881090,1036615,"Agilent Technologies, Inc., Q3 2016 Earnings Call, Aug 17, 2016",2016-08-17,"Earnings Calls","Agilent Technologies, Inc.","Executives","And the academia.",3,"And the academia."
154924,374881090,1036615,"Agilent Technologies, Inc., Q3 2016 Earnings Call, Aug 17, 2016",2016-08-17,"Earnings Calls","Agilent Technologies, Inc.","Executives","And the academia growing.",4,"And the academia growing."
154924,374881090,1036615,"Agilent Technologies, Inc., Q3 2016 Earnings Call, Aug 17, 2016",2016-08-17,"Earnings Calls","Agilent Technologies, Inc.","Operator","The next question comes from the line of Tim Evans with Wells Fargo Securities.",14,"The next question comes from the line of Tim Evans with Wells Fargo Securities."
154924,374881090,1036615,"Agilent Technologies, Inc., Q3 2016 Earnings Call, Aug 17, 2016",2016-08-17,"Earnings Calls","Agilent Technologies, Inc.","Analysts","This one is for Didier. It seems like cash flow is something that's going better than I expected or better than our expectations at least. Wondered if you could talk a little bit about the remaining leverage that you have to pull on that as you go into 20",86,"This one is for Didier. It seems like cash flow is something that's going better than I expected or better than our expectations at least. Wondered if you could talk a little bit about the remaining leverage that you have to pull on that as you go into 2017. Do you think that free cash flow growth in 2017 is really going to be a matter of earnings growth? Or is there more than you can do there to improve free cash flow faster than earnings?"
154924,374881090,1036615,"Agilent Technologies, Inc., Q3 2016 Earnings Call, Aug 17, 2016",2016-08-17,"Earnings Calls","Agilent Technologies, Inc.","Executives","Yes. There is more than we can do. I -- certainly, the profit before tax is going to be a factor. But Henrik who heads our order fulfillment and the supply chain organization has also committed to a material decrease in inventories.",42,"Yes. There is more than we can do. I -- certainly, the profit before tax is going to be a factor. But Henrik who heads our order fulfillment and the supply chain organization has also committed to a material decrease in inventories."
154924,374881090,1036615,"Agilent Technologies, Inc., Q3 2016 Earnings Call, Aug 17, 2016",2016-08-17,"Earnings Calls","Agilent Technologies, Inc.","Executives","And he's here in the room to hear that directly.",11,"And he's here in the room to hear that directly."
154924,374881090,1036615,"Agilent Technologies, Inc., Q3 2016 Earnings Call, Aug 17, 2016",2016-08-17,"Earnings Calls","Agilent Technologies, Inc.","Executives","So that is also something that we are counting on that will help us continue expanding our operating cash flow as a percentage of revenue or percentage of profit.",29,"So that is also something that we are counting on that will help us continue expanding our operating cash flow as a percentage of revenue or percentage of profit."
154924,374881090,1036615,"Agilent Technologies, Inc., Q3 2016 Earnings Call, Aug 17, 2016",2016-08-17,"Earnings Calls","Agilent Technologies, Inc.","Analysts","Okay. And then a quick one going back to one of questions on the forensics end market. Of that 12% slice of pie that's environmental and forensics, would you be willing to tell us how much is forensics?",38,"Okay. And then a quick one going back to one of questions on the forensics end market. Of that 12% slice of pie that's environmental and forensics, would you be willing to tell us how much is forensics?"
154924,374881090,1036615,"Agilent Technologies, Inc., Q3 2016 Earnings Call, Aug 17, 2016",2016-08-17,"Earnings Calls","Agilent Technologies, Inc.","Executives","I don't think we disclose that. Yes, it's fairly small, but enough to move it directly when big deals happen.",21,"I don't think we disclose that. Yes, it's fairly small, but enough to move it directly when big deals happen."
154924,374881090,1036615,"Agilent Technologies, Inc., Q3 2016 Earnings Call, Aug 17, 2016",2016-08-17,"Earnings Calls","Agilent Technologies, Inc.","Operator","Our second question comes from the line of Isaac Ro from Goldman Sachs.",13,"Our second question comes from the line of Isaac Ro from Goldman Sachs."
154924,374881090,1036615,"Agilent Technologies, Inc., Q3 2016 Earnings Call, Aug 17, 2016",2016-08-17,"Earnings Calls","Agilent Technologies, Inc.","Analysts","Just had a question on margins and then a follow-up on Europe. On the margin side -- thanks, on the margin side, if I look at sort of the components of gross margin, it's interesting, LSAG division is your highest growth margin segment most quarters. But",90,"Just had a question on margins and then a follow-up on Europe. On the margin side -- thanks, on the margin side, if I look at sort of the components of gross margin, it's interesting, LSAG division is your highest growth margin segment most quarters. But that was one where you saw a little pressure. So can you help us about a little bit kind of the key initiatives you guys have under the hood there to continue driving better gross margin versus expectations? And same goes through SG&A."
154924,374881090,1036615,"Agilent Technologies, Inc., Q3 2016 Earnings Call, Aug 17, 2016",2016-08-17,"Earnings Calls","Agilent Technologies, Inc.","Executives","What -- the question was what are the initiatives we have? I just want to make trying to so the question.",21,"What -- the question was what are the initiatives we have? I just want to make trying to so the question."
154924,374881090,1036615,"Agilent Technologies, Inc., Q3 2016 Earnings Call, Aug 17, 2016",2016-08-17,"Earnings Calls","Agilent Technologies, Inc.","Analysts","Yes. Over the last, I don't know 12 to 18 months, you guys have talked a lot about to drive gross margin higher what do your in this particular quarter, you had little bit of weakness in your most profitable segment. So I'm going to ring kind of aside fro",80,"Yes. Over the last, I don't know 12 to 18 months, you guys have talked a lot about to drive gross margin higher what do your in this particular quarter, you had little bit of weakness in your most profitable segment. So I'm going to ring kind of aside from the top line contribution, what you guys are kind of able to achieve this quarter on the gross margin my that allowed you to put out the slightly better result."
154924,374881090,1036615,"Agilent Technologies, Inc., Q3 2016 Earnings Call, Aug 17, 2016",2016-08-17,"Earnings Calls","Agilent Technologies, Inc.","Executives","Great. Thanks for the question. So what we've been focusing on our really 3 dimensions around what we call our value engineering programs, our logistics model and also our strategic procurement approach with our suppliers. And as I look at the results in",393,"Great. Thanks for the question. So what we've been focusing on our really 3 dimensions around what we call our value engineering programs, our logistics model and also our strategic procurement approach with our suppliers. And as I look at the results in '16, the program that is driving across this company is the biggest thing we've reached out so far in our improved logistics model. And you recall we talked about logistic cost as being problematic in 2015. That's no longer the case. In fact, we've benchmarked ourselves and we caught ourselves down to the best in our space. And there actually is more to come, which is the other 2 elements of the program are having a little bit more longer tail end terms of payoff, which is value reengineering when you're reengineer product platforms to ensure both the continuation of the high performance at a lower cost and then as we also continued to transform our supplier engagement model and how we leverage the scale of Agilent. So I think those -- of the latter 2 parts of the program carry us forward in the '17 and '18 beyond. So that's really how we work in the gross margin side. And by the way, this while your comments have been focused on the LSAG a lot of the logistics costs and and ACG business as well. And then relative to the SG&A, couple of things that you may recall I highlighted I would just emphasize again major focus on our systems infrastructure. So as you heard in my prepared remarks, we're now on one SAP systems a lot of our work on the financial team and taking a lot of our cost of the system. The next big wave will be when we move the company in 2017 where we can really start to leverage the scale and take out costs and have improved customer experience there. So there's a couple of big initiatives as well when we look at -- we're looking at other aspects of our benefit structures. We've made some changes. You may note earlier the U.S. pension plan and that the Agile Agilent program that I mentioned is live and we have a lot of initiatives underway to ensure that we can continue to take cost out while signifying the company. Didier, anything else you that?"
154924,374881090,1036615,"Agilent Technologies, Inc., Q3 2016 Earnings Call, Aug 17, 2016",2016-08-17,"Earnings Calls","Agilent Technologies, Inc.","Executives","I would just mentioned the currency hedging. I -- it had a big impact. It will have a big impact on a year-over-year basis. It's all impacts to gross margin. And ACG and DGG are -- because of their footprint, are -- have been more penalized. so ACG on a y",101,"I would just mentioned the currency hedging. I -- it had a big impact. It will have a big impact on a year-over-year basis. It's all impacts to gross margin. And ACG and DGG are -- because of their footprint, are -- have been more penalized. so ACG on a year-over-year basis lost $6 million in gross margin just because of the hedging programs. And DGG, $2 million. That also explains the difference between ACG, DGG and LSAG. LSAG has a different footprint, obviously, with stronger presence in Europe for example. So that can be stored a little bit the percentages."
154924,374881090,1036615,"Agilent Technologies, Inc., Q3 2016 Earnings Call, Aug 17, 2016",2016-08-17,"Earnings Calls","Agilent Technologies, Inc.","Analysts","That's helpful. Just to follow-up on Europe. Want to make sure I understand kind of how you're seeing that to the guidance. And there's 2 items there. One is the weakness in Europe, that take up in the month of July just given you guys off calendar versus",79,"That's helpful. Just to follow-up on Europe. Want to make sure I understand kind of how you're seeing that to the guidance. And there's 2 items there. One is the weakness in Europe, that take up in the month of July just given you guys off calendar versus the peer group. And secondly, because your guidance assumed that the academic end market in Europe weakens further as the year progresses? Or that it sort of stabilizes from here?"
154924,374881090,1036615,"Agilent Technologies, Inc., Q3 2016 Earnings Call, Aug 17, 2016",2016-08-17,"Earnings Calls","Agilent Technologies, Inc.","Executives","Yes, so nothing unusual in July. And I think the assumption of the Q4 is basically a continuation, not any worse but not any better. And we just thought that was a prudent way to think about the company performance fourth quarter. I would love to be wrong",76,"Yes, so nothing unusual in July. And I think the assumption of the Q4 is basically a continuation, not any worse but not any better. And we just thought that was a prudent way to think about the company performance fourth quarter. I would love to be wrong. I hope I'm wrong. We bought from a planning and guidance standpoint, we should be prudent in terms of how we look at the European market over all."
154924,374881090,1036615,"Agilent Technologies, Inc., Q3 2016 Earnings Call, Aug 17, 2016",2016-08-17,"Earnings Calls","Agilent Technologies, Inc.","Operator","Our next question comes from the line of Derik De Bruin from Bank of America Merrill Lynch.",17,"Our next question comes from the line of Derik De Bruin from Bank of America Merrill Lynch."
154924,374881090,1036615,"Agilent Technologies, Inc., Q3 2016 Earnings Call, Aug 17, 2016",2016-08-17,"Earnings Calls","Agilent Technologies, Inc.","Analysts","So a lot of the revenue question have been asked. And I mean, it certainly seems prudent to mere guidance just given your Europe even on their -- even in a good year this -- the calendar third quarter is choppy there's some year is it's proven to be a lit",96,"So a lot of the revenue question have been asked. And I mean, it certainly seems prudent to mere guidance just given your Europe even on their -- even in a good year this -- the calendar third quarter is choppy there's some year is it's proven to be a little bit conservative. But could you just talk a little bit about some of that I know the share count was a little bit higher in this quarter in which we previously guided to your sort of looking at buying out 1% of shares going forward?"
154924,374881090,1036615,"Agilent Technologies, Inc., Q3 2016 Earnings Call, Aug 17, 2016",2016-08-17,"Earnings Calls","Agilent Technologies, Inc.","Executives","Why don't you talk a little bit about the share repurchase activity in the quarter and how we're thinking about it going forward, Didier?",25,"Why don't you talk a little bit about the share repurchase activity in the quarter and how we're thinking about it going forward, Didier?"
154924,374881090,1036615,"Agilent Technologies, Inc., Q3 2016 Earnings Call, Aug 17, 2016",2016-08-17,"Earnings Calls","Agilent Technologies, Inc.","Executives","Yes, we filed it back in November 2015 [ph] I think of last year the 10b5-1 on an annual basis and we intend to file a new want to register a new one also in November of this year. And it's a formula-based instructions that we have provided between buying",133,"Yes, we filed it back in November 2015 [ph] I think of last year the 10b5-1 on an annual basis and we intend to file a new want to register a new one also in November of this year. And it's a formula-based instructions that we have provided between buying 350,000 [ph] shares a day under certain conditions buying kind of thing with a cap, as you can imagine. So we don't know exactly how it's going to play out in Q4. And the only thing that we know is that if there's any kind of shortfall at all in our intended buying in Q4 because of the formula in the 10b5-1, it will all be carried over into the following year. So we intend to spend exactly what we plan to spend."
154924,374881090,1036615,"Agilent Technologies, Inc., Q3 2016 Earnings Call, Aug 17, 2016",2016-08-17,"Earnings Calls","Agilent Technologies, Inc.","Analysts","Great. That's really helpful. And could you just give us a metric on what instruments versus consumable growth was in the quarter as an overall number for the company.",29,"Great. That's really helpful. And could you just give us a metric on what instruments versus consumable growth was in the quarter as an overall number for the company."
154924,374881090,1036615,"Agilent Technologies, Inc., Q3 2016 Earnings Call, Aug 17, 2016",2016-08-17,"Earnings Calls","Agilent Technologies, Inc.","Executives","I think, probably, the best way to think about it is probably just look at the respective business group. So you had the LSAG result was down 2.",28,"I think, probably, the best way to think about it is probably just look at the respective business group. So you had the LSAG result was down 2."
154924,374881090,1036615,"Agilent Technologies, Inc., Q3 2016 Earnings Call, Aug 17, 2016",2016-08-17,"Earnings Calls","Agilent Technologies, Inc.","Executives","And then ACG up 8 also.",6,"And then ACG up 8 also."
154924,374881090,1036615,"Agilent Technologies, Inc., Q3 2016 Earnings Call, Aug 17, 2016",2016-08-17,"Earnings Calls","Agilent Technologies, Inc.","Executives","And then minus 2 plus 8. And that's why I -- again, as you think about '17 for the company, would you really want to look at the growth rates of those 2 business units in the recurring revenue space, ACG and DGG perhaps differently you might think about h",65,"And then minus 2 plus 8. And that's why I -- again, as you think about '17 for the company, would you really want to look at the growth rates of those 2 business units in the recurring revenue space, ACG and DGG perhaps differently you might think about how you model the risk profile for revenue projections for the instrument side of the company."
154924,374881090,1036615,"Agilent Technologies, Inc., Q3 2016 Earnings Call, Aug 17, 2016",2016-08-17,"Earnings Calls","Agilent Technologies, Inc.","Analysts","Great. That's really helpful. And I guess, could you -- when you sort of you're still feeling good about the margin target for '17. And it sounds like that your IT initiatives are well underway or finished to do you feel so confident about what you're exp",54,"Great. That's really helpful. And I guess, could you -- when you sort of you're still feeling good about the margin target for '17. And it sounds like that your IT initiatives are well underway or finished to do you feel so confident about what you're expecting for next year for the margin improvement?"
154924,374881090,1036615,"Agilent Technologies, Inc., Q3 2016 Earnings Call, Aug 17, 2016",2016-08-17,"Earnings Calls","Agilent Technologies, Inc.","Executives","Absolutely. So that's why I made comments earlier because as we said, if we can be in 4.5%, 5% kind of growth range is mix of those bit more challenging. But we can see the path to 22, it's not just around margins. I mean, especially not around margin imp",192,"Absolutely. So that's why I made comments earlier because as we said, if we can be in 4.5%, 5% kind of growth range is mix of those bit more challenging. But we can see the path to 22, it's not just around margins. I mean, especially not around margin improvement from volume, but there are specific real programs. It's something that we review once a month then we have active programs in the cost will continue to come out and some of these new programs. Actually, I must say I'm really pleased with the team because we've went through and did what we called the project new new is the finance program that we just financed up. Right on the heels of that, we're going to go live in early '17 with our integration of Dako. So the team is still energized and that we are going to have a material impact on our results in '17. And that's why we have confidence assuming no major changes in terms of the macro environment that we can reach what we think are pretty challenging goals. But you've got to pass to get there."
154924,374881090,1036615,"Agilent Technologies, Inc., Q3 2016 Earnings Call, Aug 17, 2016",2016-08-17,"Earnings Calls","Agilent Technologies, Inc.","Operator","Our next question comes from the line of Dan Arias from Citigroup.",12,"Our next question comes from the line of Dan Arias from Citigroup."
154924,374881090,1036615,"Agilent Technologies, Inc., Q3 2016 Earnings Call, Aug 17, 2016",2016-08-17,"Earnings Calls","Agilent Technologies, Inc.","Analysts","Patrick, just going back to your comments on share gains in LC I know you don't like to get to specifically winners and losers. But as mentioned, all major players are doing fairly well there. So who would you say are taking share from there? Would with t",57,"Patrick, just going back to your comments on share gains in LC I know you don't like to get to specifically winners and losers. But as mentioned, all major players are doing fairly well there. So who would you say are taking share from there? Would with that the some of the box companies there as well?"
154924,374881090,1036615,"Agilent Technologies, Inc., Q3 2016 Earnings Call, Aug 17, 2016",2016-08-17,"Earnings Calls","Agilent Technologies, Inc.","Executives","Well, thanks, for the question. I can give you only a general flavor here on what we think is going on in the market. I will not comment on the individual contributors but your assumption probably take a larger hit is also our observation.",44,"Well, thanks, for the question. I can give you only a general flavor here on what we think is going on in the market. I will not comment on the individual contributors but your assumption probably take a larger hit is also our observation."
154924,374881090,1036615,"Agilent Technologies, Inc., Q3 2016 Earnings Call, Aug 17, 2016",2016-08-17,"Earnings Calls","Agilent Technologies, Inc.","Analysts","Okay. And then maybe a specific one on Mike that Analyst Day you talked about Saudi Arabia in refinery build out that was getting going. On we started to see some demand there? And that something that you think contributed also the back half of the year?",47,"Okay. And then maybe a specific one on Mike that Analyst Day you talked about Saudi Arabia in refinery build out that was getting going. On we started to see some demand there? And that something that you think contributed also the back half of the year?"
154924,374881090,1036615,"Agilent Technologies, Inc., Q3 2016 Earnings Call, Aug 17, 2016",2016-08-17,"Earnings Calls","Agilent Technologies, Inc.","Executives","Yes. The major partners that are underway haven't been canceled, but we're not seeing any major new projects underway. There's a lot of -- there's actually a lot of positive news by a lot of studies about where this market is going. But we're not seeing.",144,"Yes. The major partners that are underway haven't been canceled, but we're not seeing any major new projects underway. There's a lot of -- there's actually a lot of positive news by a lot of studies about where this market is going. But we're not seeing. What we're -- just to clarify here, a major project we knew about, whether it be the one that I mentioned in Saudi or whether there is a major project down in Texas, these programs come online. So people aren't canceling capacity increase projects, but we're not seeing a lot of new projects. And that's why we've taken a fairly conservative albeit pragmatic view of that marketplace. Again I'll remind everybody, too, that when we talk about energy where 50% or so is actually chemicals -- chemical processing not directly tied to the exploration and production of oil."
154924,374881090,1036615,"Agilent Technologies, Inc., Q3 2016 Earnings Call, Aug 17, 2016",2016-08-17,"Earnings Calls","Agilent Technologies, Inc.","Operator","Our next question comes from the line of Paul Knight from Janney Montgomery Scott.",14,"Our next question comes from the line of Paul Knight from Janney Montgomery Scott."
154924,374881090,1036615,"Agilent Technologies, Inc., Q3 2016 Earnings Call, Aug 17, 2016",2016-08-17,"Earnings Calls","Agilent Technologies, Inc.","Analysts","I guess, specifically, what is the GC business doing? What's its growth rate? What's it doing in the July quarter? And what's the backlog? Or what the -- what's July or August look like I guess?",36,"I guess, specifically, what is the GC business doing? What's its growth rate? What's it doing in the July quarter? And what's the backlog? Or what the -- what's July or August look like I guess?"
154924,374881090,1036615,"Agilent Technologies, Inc., Q3 2016 Earnings Call, Aug 17, 2016",2016-08-17,"Earnings Calls","Agilent Technologies, Inc.","Executives","Thanks, Paul. I appreciate the question. As you probably will understand, I'll give you more high-level result because we don't actually comment specifically at a product category level. Beyond, I think, I'll just reemphasize the point that Patrick when y",131,"Thanks, Paul. I appreciate the question. As you probably will understand, I'll give you more high-level result because we don't actually comment specifically at a product category level. Beyond, I think, I'll just reemphasize the point that Patrick when you characterize the market, that business is down relative to last year because the chemical energy is down. And we have seen no movement at all downward pressure in our share position. It's really a market phenomena we're dealing with right now. And that's why when we place the market does turn and we've been through these cycles before, when it does turn, we're going to be in a strong position to capture that growth as given the strength of our position in that market, which right now happens to be down."
154924,374881090,1036615,"Agilent Technologies, Inc., Q3 2016 Earnings Call, Aug 17, 2016",2016-08-17,"Earnings Calls","Agilent Technologies, Inc.","Analysts","And then last on the applied market in a broader sense, do you think it's still a GDP growth rate normalized? Or what you think the applied market should be for Agilent?",32,"And then last on the applied market in a broader sense, do you think it's still a GDP growth rate normalized? Or what you think the applied market should be for Agilent?"
154924,374881090,1036615,"Agilent Technologies, Inc., Q3 2016 Earnings Call, Aug 17, 2016",2016-08-17,"Earnings Calls","Agilent Technologies, Inc.","Executives","We actually don't think about it that way because the -- the segment that -- the big segments of the market, like your food and your environmental testing, we think are independent, to some extent, of the GDP. The only thing that we really think about tha",147,"We actually don't think about it that way because the -- the segment that -- the big segments of the market, like your food and your environmental testing, we think are independent, to some extent, of the GDP. The only thing that we really think about that a relative to it is our chemical energy space. So if you can just kind of think about tying GDP to that subsegment of the company, I think that would be good place to start but I would not apply to the whole market because these are being driven by quality of life investments in the food and environment area. And I think that's why we're -- I think this composition of our end markets is the reason why we've been able to put up these kind of growth rates even when the #2 market has shrunk this year."
154924,374881090,1036615,"Agilent Technologies, Inc., Q3 2016 Earnings Call, Aug 17, 2016",2016-08-17,"Earnings Calls","Agilent Technologies, Inc.","Analysts","And then last on -- you had your Analyst Day, obviously, you've been talking about a 22% operating margin. Are you more or less confident in that number for FY '17 at this juncture?",34,"And then last on -- you had your Analyst Day, obviously, you've been talking about a 22% operating margin. Are you more or less confident in that number for FY '17 at this juncture?"
154924,374881090,1036615,"Agilent Technologies, Inc., Q3 2016 Earnings Call, Aug 17, 2016",2016-08-17,"Earnings Calls","Agilent Technologies, Inc.","Executives","Yes. I think the confidence level is the same as it was back in May. And then maybe I'll just share a few points here. We've had some comments on the delivery on that, given our belief that we can get that growth rate, putting that growth rate territory.",232,"Yes. I think the confidence level is the same as it was back in May. And then maybe I'll just share a few points here. We've had some comments on the delivery on that, given our belief that we can get that growth rate, putting that growth rate territory. We've got this nice recurring revenue stream with ACG and DGG that will carry its momentum in 2017. And that the instrument business the pharma looks good. Of course, you have a double-digit compare issues. China continue to be strong. And chemical energy has got to turn at some point in time because the market requires these tools for production. Our thinking is when you look at chemical energy is we know our customers are looking for productivity improvements to help improve the company's profitability. We think it's a value proposition that Agilent has. We think as they go through their budget justification process budgets start in calendar 2017 that this is a decline in this business after 18 to 24 months will start to turn. We could see low single digits by the end of 2017 for the chemical energy market. If that happens, which we believe it will, that gives us the confidence to get the growth. And then know when we get the margin given both the volume, but also in gross margin initiatives as well as our SG&A costs."
154924,374881090,1036615,"Agilent Technologies, Inc., Q3 2016 Earnings Call, Aug 17, 2016",2016-08-17,"Earnings Calls","Agilent Technologies, Inc.","Operator","And our final question comes from the line of Catherine Ramsey from W Baird.",14,"And our final question comes from the line of Catherine Ramsey from W Baird."
154924,374881090,1036615,"Agilent Technologies, Inc., Q3 2016 Earnings Call, Aug 17, 2016",2016-08-17,"Earnings Calls","Agilent Technologies, Inc.","Analysts","We've heard a lot of commentary from your peers on Japan, strong pharma environment, weak academicc environment. So I was wondering if you could ask your exposure by end market there and what you're seeing across those customer groups?",40,"We've heard a lot of commentary from your peers on Japan, strong pharma environment, weak academicc environment. So I was wondering if you could ask your exposure by end market there and what you're seeing across those customer groups?"
154924,374881090,1036615,"Agilent Technologies, Inc., Q3 2016 Earnings Call, Aug 17, 2016",2016-08-17,"Earnings Calls","Agilent Technologies, Inc.","Executives","Didier, you remember the total Japan numbers.",7,"Didier, you remember the total Japan numbers."
154924,374881090,1036615,"Agilent Technologies, Inc., Q3 2016 Earnings Call, Aug 17, 2016",2016-08-17,"Earnings Calls","Agilent Technologies, Inc.","Executives","5% [ph] overall.",3,"5% [ph] overall."
154924,374881090,1036615,"Agilent Technologies, Inc., Q3 2016 Earnings Call, Aug 17, 2016",2016-08-17,"Earnings Calls","Agilent Technologies, Inc.","Executives","Yes. [indiscernible] 5% of the total market. Historically, we've been stronger. And I can share this from my experience having been the country manager in Japan for a few years in the early part of my career. We tend to be stronger in the chemical energy",122,"Yes. [indiscernible] 5% of the total market. Historically, we've been stronger. And I can share this from my experience having been the country manager in Japan for a few years in the early part of my career. We tend to be stronger in the chemical energy segment of that we are doing well in the life science research and genomics. But the majority of the business sits in the chemical energy space, which is -- has been down. I think Japan has been part of that story. Pharma, the pharma business for us is a relatively smaller portion of the market for us. I think we're doing well in pharma but not enough to really drive significant overall growth rates for Japan."
154924,374881090,1036615,"Agilent Technologies, Inc., Q3 2016 Earnings Call, Aug 17, 2016",2016-08-17,"Earnings Calls","Agilent Technologies, Inc.","Analysts","Okay. Great. And then any color on the progress of the Dako integration? What's left to do there? Had some nice margin expansion in DGG this quarter. So are you still thinking that 20% in fiscal '17 or could there be upside to that number?",45,"Okay. Great. And then any color on the progress of the Dako integration? What's left to do there? Had some nice margin expansion in DGG this quarter. So are you still thinking that 20% in fiscal '17 or could there be upside to that number?"
154924,374881090,1036615,"Agilent Technologies, Inc., Q3 2016 Earnings Call, Aug 17, 2016",2016-08-17,"Earnings Calls","Agilent Technologies, Inc.","Executives","Jacob has to be sitting right next to me in this conference, but I don't think we is ready to sign up for more than 20% because it is quite an improvement from where we started up. I think he will remain quite confident in the 20% achievement of that goal",178,"Jacob has to be sitting right next to me in this conference, but I don't think we is ready to sign up for more than 20% because it is quite an improvement from where we started up. I think he will remain quite confident in the 20% achievement of that goal an O&M perspective. You saw we had 18 28% [ph] operating margin this quarter, 200 basis points over last year. And the big next wave of integration efforts will really be starting in our Q1 '17. So we have a major programming called Project We seem to like a lot of these French names, Didier, I'm not sure why this would be the case. And that really will be the next big step to move the former Dako Company into the Agilent environment and take a little bit of to get the cost out. But as you go as you think about exiting '17, you're going to have a much lower SG&A spend than you started the year. And Jacob, I don't think you share anything else?"
154924,374881090,1036615,"Agilent Technologies, Inc., Q3 2016 Earnings Call, Aug 17, 2016",2016-08-17,"Earnings Calls","Agilent Technologies, Inc.","Executives","No, I think you captured it I just want to reinforce the what's left that the part [ph] 20% actually delivering 20% in 2017 is a significant turnaround of where we were a few years ago. So right now, that's our flame and I'm very happy with where the team",56,"No, I think you captured it I just want to reinforce the what's left that the part [ph] 20% actually delivering 20% in 2017 is a significant turnaround of where we were a few years ago. So right now, that's our flame and I'm very happy with where the team is and excluding this right now."
154924,374881090,1036615,"Agilent Technologies, Inc., Q3 2016 Earnings Call, Aug 17, 2016",2016-08-17,"Earnings Calls","Agilent Technologies, Inc.","Executives","Thanks, Jacob.",2,"Thanks, Jacob."
154924,374881090,1036615,"Agilent Technologies, Inc., Q3 2016 Earnings Call, Aug 17, 2016",2016-08-17,"Earnings Calls","Agilent Technologies, Inc.","Operator","Thank you. And this does conclude the question-and-answer session of today's program. I'd like to hand the program back to Alicia Rodriguez ready for the remarks.",26,"Thank you. And this does conclude the question-and-answer session of today's program. I'd like to hand the program back to Alicia Rodriguez ready for the remarks."
154924,374881090,1036615,"Agilent Technologies, Inc., Q3 2016 Earnings Call, Aug 17, 2016",2016-08-17,"Earnings Calls","Agilent Technologies, Inc.","Executives","Thank you, Jonathan. And on behalf of the entire mentioned team, I'd like to thank everybody for joining us today. If you have any questions, please give us a call at IR. Thanks again. Bye bye.",36,"Thank you, Jonathan. And on behalf of the entire mentioned team, I'd like to thank everybody for joining us today. If you have any questions, please give us a call at IR. Thanks again. Bye bye."
154924,374881090,1036615,"Agilent Technologies, Inc., Q3 2016 Earnings Call, Aug 17, 2016",2016-08-17,"Earnings Calls","Agilent Technologies, Inc.","Operator","Thank you. Ladies and gentlemen, for your today's conference. This does conclude the program. You may now disconnect. Good day.",20,"Thank you. Ladies and gentlemen, for your today's conference. This does conclude the program. You may now disconnect. Good day."
154924,374881090,1036665,"Agilent Technologies, Inc., Q3 2016 Earnings Call, Aug 17, 2016",2016-08-17,"Earnings Calls","Agilent Technologies, Inc.","Operator","Good day ladies and gentlemen, and welcome to the Third Quarter 2016 Agilent Technologies Earnings Conference Call. [Operator Instructions] As a reminder, today's program is being recorded. I would now like to introduce your host for today's program, Alic",48,"Good day ladies and gentlemen, and welcome to the Third Quarter 2016 Agilent Technologies Earnings Conference Call. [Operator Instructions] As a reminder, today's program is being recorded. I would now like to introduce your host for today's program, Alicia Rodriguez, Vice President of Investor Relations. Please go ahead."
154924,374881090,1036665,"Agilent Technologies, Inc., Q3 2016 Earnings Call, Aug 17, 2016",2016-08-17,"Earnings Calls","Agilent Technologies, Inc.","Executives","Thank you, Jonathan, and welcome, everyone, to Agilent's Third Quarter Conference Call for Fiscal Year 2016. With me are Mike McMullen, Agilent's President and CEO; and Didier Hirsch, Agilent's Vice -- Senior Vice President and CFO.Joining in the Q&A af",342,"Thank you, Jonathan, and welcome, everyone, to Agilent's Third Quarter Conference Call for Fiscal Year 2016. With me are Mike McMullen, Agilent's President and CEO; and Didier Hirsch, Agilent's Vice -- Senior Vice President and CFO.
Joining in the Q&A after Didier's comments will be Patrick Kaltenbach, President of Agilent's Life Sciences and Applied Markets Group; Jacob Thaysen, President of Agilent's Diagnostics and Genomics Group; and Mark Doak, President of the Agilent CrossLab Group.
You can find the press release and information to supplement today's discussion on our website at www.investor.agilent.com. While there, please click on the link for financial results under the Financial Information tab. You will find an investor presentation along with revenue breakouts and currency impacts, business segment results and historical financials for Agilent's operations. We will also post a copy of the prepared remarks following this call. 
Today's comments by Mike and Didier will refer to non-GAAP financial measures. You will find the most directly comparable GAAP financial metrics and reconciliations on our website. We will refer to core revenue growth, which excludes the impact of currency, the NMR business and acquisitions and divestitures within the past 12 months. Please note that we are reporting results for the Americas, Europe and Asia on a ship-to basis. Previously, we assigned revenue to these regions based on where the order was placed. This change aligns with individual country reporting, which has always been on a ship-to basis. Historical restatements are available on the Investor Relations website. Unless otherwise noted, all references to increases or decreases in financial metrics are year-over-year. Guidance is based on exchange rates as of the last day of the reported quarter. 
We will also make forward-looking statements about the financial performance of the company. These statements are subject to risks and uncertainties and are only valid as of today. The company assumes no obligation to update them. Please look at the company's recent SEC filings for a more complete picture of our risks and other factors. 
And now let me turn the call over to Mike."
154924,374881090,1036665,"Agilent Technologies, Inc., Q3 2016 Earnings Call, Aug 17, 2016",2016-08-17,"Earnings Calls","Agilent Technologies, Inc.","Executives","Thanks, Alicia, and hello, everyone. Thank you for joining us on today's call. I'm pleased to report that the Agilent team delivered another quarter above expectations. Now let me highlight 3 key results: First, core -- Q3 core revenue growth of 3% was",1440,"Thanks, Alicia, and hello, everyone. Thank you for joining us on today's call. I'm pleased to report that the Agilent team delivered another quarter above expectations. 
Now let me highlight 3 key results: First, core -- Q3 core revenue growth of 3% was above the high end of our May guidance. Second, EPS of $0.49 was also above the high end of our guidance of $0.45 to $0.47. Finally, we delivered adjusted operating margin of 20.6%, an increase of 70 basis points from a year ago. As the third quarter results echo many of the same themes that we saw last quarter, the pharma, food, clinical and diagnostics end markets remain strong. In the chemical engineering market, while demand for our services and consumables was strong, capital expenditures for new equipment purchases remain challenged. Geographically, Asia, led by China's double-digit growth, drove Agilent third quarter core growth with strength across all business segments. 
Let me highlight our Q3 results by business group. In line with our expectations, Life Sciences and Applied Markets Group core revenues were down 2%. Our strong growth in pharma, environmental and food markets was offset by continued weakness in chemical and energy capital expenditures. Academia and government revenues were also down across most regions. Despite this mixed market environment, LSAG's operating margin for the quarter was 19.1%, up 40 basis points from a year ago. 
Let me shift gears and talk about some of LSAG's new products. We are seeing very strong demand, the newly released 1260 and the 1290 Infinity II LC systems. The 1260 systems are part of the launch of the InfinityLab portfolio at Analytica in May. The InfinityLab portfolio consists of this new line of LC instruments along with columns, supplies and services. In Q3, LSAG also introduced the new -- 2 new 7000 Series Triple Quad GC/MS analyzers, one for pesticides and another  for environmental pollutants. And we continue to strengthen our ICP-MS market leadership with the new Agilent 8900 Triple Quad ICP-MS system. This new system offers customers improved speed and accuracy of analysis.
Turning to the Agilent CrossLab Group. The business delivered another strong quarter with 8% core revenue growth. This growth is driven by strength in the food, pharma and environmental markets. ACG's operating margin for the quarter was 22.7%, up 10 basis points from a year ago. 
Portfolio expansion efforts also continued at ACG. In Q3, Agilent signed a definitive agreement to acquire the assets of iLab, and we just closed the transaction in early August. iLab is the market leader in cloud-based solutions for core laboratory management and provide services to leading universities, research hospitals and independent institutions around the world. This acquisition further expands Agilent's portfolio in the academia and government market. iLab enables Agilent to deliver broader value for our customers in this market segment. We also see an opportunity to expand the iLab business both geographically and into the pharma market.
Finally, we saw a continued momentum in the Diagnostics and Genomics Group where the business delivered 8% core growth in Q3. We saw strength across all DGG businesses, driven by growth in the pharma and clinical and diagnostics market. Our pathology business continues on a steady trajectory of improved growth. This was highlighted by demand for our new PD-L1 companion diagnostics. Growth in genomics reflect a strong market performance in the U.S. and China across our Array CGH, Target Enrichment and SureSelect products. We also saw healthy demand for our new clinic assets solutions offering. DGG's operating margin for the quarter was 18.8%, up 200 basis points from a year ago. 
Q3 highlights for DGG with the announcement of an expansion of the intended use of our PD-L1 pharmDX test in Europe for patients with melanoma. This test was previously proven in the U.S. and available in Europe for patients with non-squamous, non-small-cell lung cancer and in the U.S. with patients with melanoma. We also announced a $120 million investment over the next 3 years to expand production capacity for our new clinic assets solutions business. This includes the purchase of 20 acres of land in Colorado. We plan to build our factory on this land that will double our manufacturing capacity for nucleic acid active pharmaceutical ingredients and grow our business.
Now I'll provide an overview of Agilent's core revenues by end market. In our life sciences market, pharma saw its sixth consecutive quarter of double-digit growth with core revenue up 10%. Academia and government core revenues were down 5%, down across most geographies except China. Clinical and diagnostics grew 4% with strength in North America and Asia and led by growth in pathology. Applied end market performance was mixed. Food was up 11% with strong demand in China and the Americas. These regions also drove growth in environmental market for both instruments and aftermarket products. This performance was offset by continued challenges in the chemical and energy market, down 4% globally, with only Asia posting growth on a regional basis. The overall result was due to prolonged effects of the macroeconomic concerns and lower oil prices. 
Now I'll turn an update on our operating margin improvement initiatives. Q3 marked a major step forward in simplifying our company's infrastructure. In May, we completed the migration of the company's financial systems onto a single SAP platform. This was a culmination of a 20-month cross-company effort and represents a major step in simplifying Agilent's systems infrastructure that will deliver incremental cost savings as planned in fiscal 2017. 
In summary, our multiyear Agile Agilent program continues to simplify the company's business processes. This program is designed to make us more nimble and lower our costs. It will continue to deliver incremental savings in 2017.
On the capital deployment front, we purchased iLab, paid $37 million in dividends and repurchased $94 million of Agilent stock. We continue to deliver on our strategy to drive sustainable growth while expanding operating margins and balancing deployment of our capital to drive shareholder value creation. 
At our recent May Analyst Meeting, I described our shareholder value creation model: outgrow the market, expand operating margins, balance capital deployment. Let's look at our Q3 results in the context of these longer-term goals and shareholder value creation model. 
In 2015, we delivered our highest annual growth rate in 4 years while increasing adjusted operating margin of 170 basis points and completely offsetting the $40 million of dyssynergies from the company split. We have sustained this trajectory of improved operating results in fiscal 2016. In the first 3 quarters of 2016, the team had delivered strong growth and earnings above our initial expectation despite a challenging chemical and energy market environment and global macroeconomic concerns.
We have continued to leverage our balance sheet and deployed capital in a balanced manner, buying companies that are bringing new capabilities to Agilent while repurchasing our stock and increasing cash dividends. The new leadership team continues to transform the business and deliver results. We continue to demonstrate our ability to deliver above-industry organic growth while expanding margins and leveraging our balance sheet strength. Our Q3 results in a challenging global economic environment reflect the strength of our team combined with Agilent's scale and broad differentiated portfolio of products and services. Looking at today's overall market environment, we expect continued strength in pharma, along with growth in the food, environmental and clinical research and diagnostics markets and in China on a regional basis. 
As I highlighted in our last call, we are experiencing a steeper and more prolonged slowdown in the chemical and energy market than initially projected entering fiscal 2016. We subsequently revised our forecast for this market segment last quarter to overall low single-digit market declines for the year. While there are some signs of an impending bottoming end market, we remain cautious in our outlook and expect Q4 to be in a similar range as the past quarter. Against this market drop, we are well positioned to capture growth in these end market segments and geographies where growth is expected to remain strong. The combination of our expanding our customer channel reach and continual strengthening of our portfolio positions us well to achieve our previously raised full year guidance of 2016 and our longer-term goals. Our One Agilent team continues to work well together and is energized to win in the market. Overall, we remain on track with our 2017 goal to outgrow the market and improve our operating margin to 22%. 
Thank you for being on the call today. I will now turn it over to Didier who will provide additional insights on our financial results and guidance for the remainder of 2016. Didier?"
154924,374881090,1036665,"Agilent Technologies, Inc., Q3 2016 Earnings Call, Aug 17, 2016",2016-08-17,"Earnings Calls","Agilent Technologies, Inc.","Executives","Thank you, Mike, and hello, everyone. As mentioned by Mike, we delivered higher core revenue growth, operating margin and earnings per share than the high end of our guidance. Earnings per share grew 11% in the quarter versus a year ago. We also generated",324,"Thank you, Mike, and hello, everyone. As mentioned by Mike, we delivered higher core revenue growth, operating margin and earnings per share than the high end of our guidance. Earnings per share grew 11% in the quarter versus a year ago. We also generated $194 million in operating cash flow, more than double last year's amount, which gives us increased confidence that we'll achieve our previously raised operating cash flow guidance for the full year. FX had a negative impact on revenue of about $10 million or 1% versus previous guidance and $7 million or 0.7% versus last year. It had a negative impact on operating profit of $3 million versus previous guidance and $1 million versus last year.
I'll now turn to the guidance for our fourth quarter. We expect Q4 revenues of $1.05 billion to $1.07 billion and earnings per share of $0.50 to $0.52. At midpoint, revenue is expected to grow 1.2% on a core basis. Versus previous guidance, FX is estimated to have a negative impact of $9 million on revenue and $2 million on operating profit. Our 21.3% adjusted operating margin at midpoint will be up 70 basis points sequentially.
Now to the guidance for fiscal year 2016. The Q4 guidance results in the following fiscal year guidance. At midpoint, revenue is projected to grow 4.5% on a core basis, no change from the previous guidance. Our earnings per share guidance of $1.90 at midpoint is also unchanged from previous guidance and corresponds to a 9% year-over-year increase. Adjusted operating margin for the year is expected to be 20.4 basis points or 80 basis points higher than in fiscal year '15. And finally, FX is estimated to have a negative impact on a year-over-year basis of $68 million on revenue, $10 million on operating profit related to currency translation and an additional $21 million related to currency hedging. 
With that, I'll turn it over to Alicia for the Q&A."
154924,374881090,1036665,"Agilent Technologies, Inc., Q3 2016 Earnings Call, Aug 17, 2016",2016-08-17,"Earnings Calls","Agilent Technologies, Inc.","Executives","Thank you, Didier. Jonathan, will you please give the instructions for the Q&A?",13,"Thank you, Didier. Jonathan, will you please give the instructions for the Q&A?"
154924,374881090,1036665,"Agilent Technologies, Inc., Q3 2016 Earnings Call, Aug 17, 2016",2016-08-17,"Earnings Calls","Agilent Technologies, Inc.","Operator","[Operator Instructions] Our first question comes from the line of Brandon Couillard from Jefferies. Our next question comes from the line of Steve Beuchaw from Morgan Stanley.",27,"[Operator Instructions] Our first question comes from the line of Brandon Couillard from Jefferies. 
Our next question comes from the line of Steve Beuchaw from Morgan Stanley."
154924,374881090,1036665,"Agilent Technologies, Inc., Q3 2016 Earnings Call, Aug 17, 2016",2016-08-17,"Earnings Calls","Agilent Technologies, Inc.","Analysts","I want to start with the -- one regional trend that seems to be on many people's minds, which is what's going on in Europe. I wonder if you could speak to the trends that you saw in Europe over the course of the quarter. To some extent, it's a macro quest",99,"I want to start with the -- one regional trend that seems to be on many people's minds, which is what's going on in Europe. I wonder if you could speak to the trends that you saw in Europe over the course of the quarter. To some extent, it's a macro question. To some extent, it's a research question. And of course, there's the -- their U.K. referendum that's still out there. So I apologize for the nebulous nature of it all, but any color on how Europe progressed over the course of the quarter would be really helpful."
154924,374881090,1036665,"Agilent Technologies, Inc., Q3 2016 Earnings Call, Aug 17, 2016",2016-08-17,"Earnings Calls","Agilent Technologies, Inc.","Executives","Yes, sure. Glad to provide some insight there, and then I'm going to actually have Patrick jump in on this conversation, given the recent travels in the region. But what we saw in the quarter was, obviously, a lot of big macro events, the Brexit, Turkey.",181,"Yes, sure. Glad to provide some insight there, and then I'm going to actually have Patrick jump in on this conversation, given the recent travels in the region. But what we saw in the quarter was, obviously, a lot of big macro events, the Brexit, Turkey. There's a number of development [ph] in the quarter. We did not see any material impact from those events in our performance in the third quarter. What I will say, though, it -- is -- raised an increased level of uncertainty amongst our customers in Europe, and we've seen the questions around when will budgets be released. So it's more of an uncertainty question right out there. People are just sort of wait and see how it's going to develop. Again, no material effect on the third quarter results. But as we thought about our guidance for the fourth quarter, obviously, it's influenced us to think about how will Europe develop through the quarter. And Patrick, I know you had a pretty deep conversation about this yesterday. So any additional thoughts you'd like to add?"
154924,374881090,1036665,"Agilent Technologies, Inc., Q3 2016 Earnings Call, Aug 17, 2016",2016-08-17,"Earnings Calls","Agilent Technologies, Inc.","Executives","Yes. Thanks, Mike. In talking to our field, local field in Europe is certainly get the feedback there is some uncertainty as Mike -- as you said. The Brexit had -- with some of the government in traditional [ph] deals had probably some minor impacts. I th",101,"Yes. Thanks, Mike. In talking to our field, local field in Europe is certainly get the feedback there is some uncertainty as Mike -- as you said. The Brexit had -- with some of the government in traditional [ph] deals had probably some minor impacts. I think what's concerning us here a little bit is also there are a couple of other countries standing on the sidelines and have other referendums this year. So we are cautious right now, looking at Europe and the growth scenario for Europe for the remainder of the year and also going into fiscal year '17."
154924,374881090,1036665,"Agilent Technologies, Inc., Q3 2016 Earnings Call, Aug 17, 2016",2016-08-17,"Earnings Calls","Agilent Technologies, Inc.","Executives","Thanks, Patrick.",2,"Thanks, Patrick."
154924,374881090,1036665,"Agilent Technologies, Inc., Q3 2016 Earnings Call, Aug 17, 2016",2016-08-17,"Earnings Calls","Agilent Technologies, Inc.","Analysts","And then one bigger-picture question, Mike. You made a pretty significant investment with a pretty long horizon -- long-term horizon on this facility in Colorado. So it speaks to your confidence in the long-term outlook for and the scale of the opportunit",78,"And then one bigger-picture question, Mike. You made a pretty significant investment with a pretty long horizon -- long-term horizon on this facility in Colorado. So it speaks to your confidence in the long-term outlook for and the scale of the opportunity there. Can you just talk us through how you frame the opportunity, remind us how big that business is today, and how you think about the medium-term drivers that you're investing in the pursuit of?"
154924,374881090,1036665,"Agilent Technologies, Inc., Q3 2016 Earnings Call, Aug 17, 2016",2016-08-17,"Earnings Calls","Agilent Technologies, Inc.","Executives","Great. So I'm going to handle your -- well, I'm going to handle the first part of this question. And then I'm going to turn it over to Jacob, and he'll reassure you about the long-term growth potential, which is the reason why I supported the investment.",189,"Great. So I'm going to handle your -- well, I'm going to handle the first part of this question. And then I'm going to turn it over to Jacob, and he'll reassure you about the long-term growth potential, which is the reason why I supported the investment. But just as a reminder, I think this is roughly about 5% or so of DGG's overall revenues in the range of maybe $16 plus million or so. We still have capacity at the current site, but we've got a -- more demand than we can handle in terms of long-term outlook from our customers. So we can't bring on this capacity fast enough to satisfy the customer demand. We think this will be a bigger part of our growth story as we talk to you about 2017 and 2018. And I think as you'll hear from Jacob, there's a high degree of confidence that the business is going to be there. And perhaps you can provide a little context of what exactly is this business and why are we so confident that the market is going to be there for us."
154924,374881090,1036665,"Agilent Technologies, Inc., Q3 2016 Earnings Call, Aug 17, 2016",2016-08-17,"Earnings Calls","Agilent Technologies, Inc.","Executives","Yes, let me try to provide a little more color there. So first of all, a reminder that the Nucleic Acid Solutions Division business out in Boulder is providing oligo APIs that constitute a new type of drugs with a significant potential. These drugs are pr",320,"Yes, let me try to provide a little more color there. So first of all, a reminder that the Nucleic Acid Solutions Division business out in Boulder is providing oligo APIs that constitute a new type of drugs with a significant potential. These drugs are primarily, right now, opportunities within orphan genetic diseases that today there has been no treatment and have devastating outcomes. And these drugs have actually the opportunity to change the expectancy of -- you could say the survival and also the quality of life for such patients. We are working with the leaders in pharma within these new type of drugs, and Agilent is chosen again and again due to our deep technical experience to optimize oligos for performance and consistency, combined with our ability to scale in DNP. We have seen a significant demand accelerated over the last few years. And as Mike mentioned, we're currently expanding our current site to actually take up double capacity. But we also see that, that will run out -- that opportunity is really limited and will run out in a few years from now; and thereby, the new investment in the new site will allow us to further double our capacity and even double again if we choose to do so. We have decided, and based on a deep dive into the strategy and so on, to place the site in close proximity to the other Boulder site at approximately 20 minutes drive away so we can releverage [ph] critical mass, high -- the highly experienced staff we already have and capabilities and processes. The overall market is in the hundreds of million dollar business right now, and it's growing somewhere between 20% to 30%. However, when you commercialize drugs -- when you get the commercialized drugs, this might be a significant step-ups, but we see a lot of demand right now just in the clinical trial studies."
154924,374881090,1036665,"Agilent Technologies, Inc., Q3 2016 Earnings Call, Aug 17, 2016",2016-08-17,"Earnings Calls","Agilent Technologies, Inc.","Operator","Our next question comes from the line of Jonathan Groberg from UBS.",12,"Our next question comes from the line of Jonathan Groberg from UBS."
154924,374881090,1036665,"Agilent Technologies, Inc., Q3 2016 Earnings Call, Aug 17, 2016",2016-08-17,"Earnings Calls","Agilent Technologies, Inc.","Analysts","I know you have one more quarter to go here, but any initial thoughts on the puts and takes you're seeing on how we should be thinking about fiscal '17?",30,"I know you have one more quarter to go here, but any initial thoughts on the puts and takes you're seeing on how we should be thinking about fiscal '17?"
154924,374881090,1036665,"Agilent Technologies, Inc., Q3 2016 Earnings Call, Aug 17, 2016",2016-08-17,"Earnings Calls","Agilent Technologies, Inc.","Executives","Yes. Jonathan, I'd be happy to share my thoughts here. And in fact, I, perhaps, will build on some of the comments I made in my prepared remarks. But we're still -- we are still seeing ourselves in the same path that we talked about just a month or so ago",385,"Yes. Jonathan, I'd be happy to share my thoughts here. And in fact, I, perhaps, will build on some of the comments I made in my prepared remarks. But we're still -- we are still seeing ourselves in the same path that we talked about just a month or so ago in New York. It actually was 2 months ago when I think about it, but our position remains the same. We are still confident we're going to be able to achieve the overall projected core growth of 4.5%. And there's some new -- there really are some new factors that, we think, support this level of growth. First of all, we've -- we have a rich pipeline of new product introductions coming in Q4 and in FY '17 on top of what we've already introduced this year. Now we think our customers are going to be really excited about what we're bringing to market, and that's going to help drive share. So we know we got this NPI [indiscernible] going through the system right now with releases coming up in several quarters on top of what we've done. The second thing, I -- we also have recognized the fact that the Agilent business model has really changed a lot over the last 18 months or so. We have a lot more recurring revenue. And if you look at the ACG and DGG business, which now represent over half -- I think it's 52% the last time I did the math, of Agilent's revenue. These are just inherently much more predictable revenue streams, and you saw in our Q3 results how both groups delivered high single-digit growth. And they're not subject to the same types of issues we're seeing in the capital-intensive chemical and energy market, for example. And then the third thing I'd say is when you think about our LSAG instrument business, in addition to the impact of these new product introductions I mentioned, we do expect that pharma and China market is going to remain significant growth drivers, although I think they will be below these double-digit levels we've seen in 2016. And as mentioned in our last call, we still expect that the chemical and energy market will have bottomed by the end of calendar year 2017. We're not ready to..."
154924,374881090,1036665,"Agilent Technologies, Inc., Q3 2016 Earnings Call, Aug 17, 2016",2016-08-17,"Earnings Calls","Agilent Technologies, Inc.","Executives","'16.",1,"'16."
154924,374881090,1036665,"Agilent Technologies, Inc., Q3 2016 Earnings Call, Aug 17, 2016",2016-08-17,"Earnings Calls","Agilent Technologies, Inc.","Executives","Excuse me. Sorry. Thanks, Didier. Got my ears confused there -- by the end of the calendar year 2016. We're not ready to call bottom, but we do see in 2017 that we're forecasting that we could be in low single digits growth in a market, which just had 18",119,"Excuse me. Sorry. Thanks, Didier. Got my ears confused there -- by the end of the calendar year 2016. We're not ready to call bottom, but we do see in 2017 that we're forecasting that we could be in low single digits growth in a market, which just had 18 to 24 months of pent-up demand for equipment that supports the production process. So they are the 3 factors that have gone into our thinking as we have thought about the 2017's growth rate. Honestly, we'll give you the official guidance at our next call. But I would just reinforce our view today is that we're still on track to what we told you in May in New York."
154924,374881090,1036665,"Agilent Technologies, Inc., Q3 2016 Earnings Call, Aug 17, 2016",2016-08-17,"Earnings Calls","Agilent Technologies, Inc.","Analysts","Great. That's helpful. And just one quick follow-up, on the capital equipment business, I know you mentioned going into the quarter, last time when you gave guidance, you thought there'd been a little bit of pull forward and you highlighted why you though",79,"Great. That's helpful. And just one quick follow-up, on the capital equipment business, I know you mentioned going into the quarter, last time when you gave guidance, you thought there'd been a little bit of pull forward and you highlighted why you thought it would be a little weaker. I'm just curious, was it in line with what you thought? Or was there anything unique in the quarter that maybe wasn't right along the lines of what you saw?"
154924,374881090,1036665,"Agilent Technologies, Inc., Q3 2016 Earnings Call, Aug 17, 2016",2016-08-17,"Earnings Calls","Agilent Technologies, Inc.","Executives","Absolutely. I think the quarter was actually in line and actually a little bit better than we had anticipated coming in the quarter, so no major surprises in our Q3 results. And as you can imagine, we were delighted with the ability to deliver above our e",52,"Absolutely. I think the quarter was actually in line and actually a little bit better than we had anticipated coming in the quarter, so no major surprises in our Q3 results. And as you can imagine, we were delighted with the ability to deliver above our expectations, both top and bottom line."
154924,374881090,1036665,"Agilent Technologies, Inc., Q3 2016 Earnings Call, Aug 17, 2016",2016-08-17,"Earnings Calls","Agilent Technologies, Inc.","Operator","Our next question comes from the line of Jack Meehan from Barclays.",12,"Our next question comes from the line of Jack Meehan from Barclays."
154924,374881090,1036665,"Agilent Technologies, Inc., Q3 2016 Earnings Call, Aug 17, 2016",2016-08-17,"Earnings Calls","Agilent Technologies, Inc.","Analysts","So I just wanted to ask about the LSAG business and some of the moving parts there. And could you maybe just talk about the chromatography markets? A couple of your peers have had really nice results there. Just what you're seeing there would be helpful.",46,"So I just wanted to ask about the LSAG business and some of the moving parts there. And could you maybe just talk about the chromatography markets? A couple of your peers have had really nice results there. Just what you're seeing there would be helpful."
154924,374881090,1036665,"Agilent Technologies, Inc., Q3 2016 Earnings Call, Aug 17, 2016",2016-08-17,"Earnings Calls","Agilent Technologies, Inc.","Executives","Yes, absolutely. And Patrick, if you could break it out, obviously, between liquid chromatography and gas chromatography as well.",19,"Yes, absolutely. And Patrick, if you could break it out, obviously, between liquid chromatography and gas chromatography as well."
154924,374881090,1036665,"Agilent Technologies, Inc., Q3 2016 Earnings Call, Aug 17, 2016",2016-08-17,"Earnings Calls","Agilent Technologies, Inc.","Executives","Yes, absolutely. Happy to do so. As Mike mentioned earlier in his remarks, we definitely see very strong growth right now in the liquid chromatography business, which has been, for the entire year, double digits. And that is what we see, clearly, also tak",249,"Yes, absolutely. Happy to do so. As Mike mentioned earlier in his remarks, we definitely see very strong growth right now in the liquid chromatography business, which has been, for the entire year, double digits. And that is what we see, clearly, also taking market share right now. We had a very strong launch of several waves of the Infinity series starting in 2009 and 2012. And now this year with the 1260 series with another big round of instrumentation and solutions in liquid chromatography, that is very well received by the end markets. We see very healthy replacement business as well, and it's driven by the fact that these solutions are 100% backwards compatible and also compatible with some of our competitors' instrumentations, which makes method transfer very simple and seamless for our customers. So -- and we project this cycle to continue for several more quarters. We don't see yet a loss of momentum. What we see, of course, is that they're getting now into quarters with tougher compare because we have double-digit growth for several quarters now. On the gas chromatography side, again, very strong portfolio as well. The issue we're seeing there is that the core market of one of the big markets for gas chromatography is the energy space. And that, of course, pull some of our results down at this point in time. If the market comes back, we think we are in an exceptional position to pick up this pent-up demand [indiscernible]."
154924,374881090,1036665,"Agilent Technologies, Inc., Q3 2016 Earnings Call, Aug 17, 2016",2016-08-17,"Earnings Calls","Agilent Technologies, Inc.","Executives","When the market comes back.",5,"When the market comes back."
154924,374881090,1036665,"Agilent Technologies, Inc., Q3 2016 Earnings Call, Aug 17, 2016",2016-08-17,"Earnings Calls","Agilent Technologies, Inc.","Executives","Yes, when the market comes back. Yes, when the market comes back, sorry. So I think we are in a great situation there as well. We have an outstanding product portfolio and ability to capture the growth when it gets back.",41,"Yes, when the market comes back. Yes, when the market comes back, sorry. So I think we are in a great situation there as well. We have an outstanding product portfolio and ability to capture the growth when it gets back."
154924,374881090,1036665,"Agilent Technologies, Inc., Q3 2016 Earnings Call, Aug 17, 2016",2016-08-17,"Earnings Calls","Agilent Technologies, Inc.","Executives","Yes. And the reason why I asked Patrick to segment his remarks in liquid chromatography from gas chromatography, we have an outsized exposure in gas chromatography. And when the -- relative to the #2 competitor space, we're at least 2x the #2 person. And",91,"Yes. And the reason why I asked Patrick to segment his remarks in liquid chromatography from gas chromatography, we have an outsized exposure in gas chromatography. And when the -- relative to the #2 competitor space, we're at least 2x the #2 person. And so when our major market is down, it really hits us. And that's why, again, we were really quite pleased that we were able to deliver the growth we've done so far, with our #2 market actually being down below our initial expectations coming into this year."
154924,374881090,1036665,"Agilent Technologies, Inc., Q3 2016 Earnings Call, Aug 17, 2016",2016-08-17,"Earnings Calls","Agilent Technologies, Inc.","Analysts","Yes, that's really helpful, and I appreciate all the details in the different segments. If I can just follow up with one more. The Americas growth, negative 1% in the quarter, I know it's not a tougher comp relative to last year. But can you maybe just ta",67,"Yes, that's really helpful, and I appreciate all the details in the different segments. If I can just follow up with one more. The Americas growth, negative 1% in the quarter, I know it's not a tougher comp relative to last year. But can you maybe just talk about the mix of the end markets there and whether there was any other notable changes worth pointing out?"
154924,374881090,1036665,"Agilent Technologies, Inc., Q3 2016 Earnings Call, Aug 17, 2016",2016-08-17,"Earnings Calls","Agilent Technologies, Inc.","Executives","I think the big one there is the chemical and energy market. So it's down pretty sharply, and I think that's bringing down the overall numbers as well as our academia and government business was down over last year. Although we think some of that -- the w",73,"I think the big one there is the chemical and energy market. So it's down pretty sharply, and I think that's bringing down the overall numbers as well as our academia and government business was down over last year. Although we think some of that -- the way we're thinking about our plan for the rest of this year, we think the federal money will be there in the fourth quarter for us."
154924,374881090,1036665,"Agilent Technologies, Inc., Q3 2016 Earnings Call, Aug 17, 2016",2016-08-17,"Earnings Calls","Agilent Technologies, Inc.","Executives","Yes. And in addition, if I may add, we had a very strong quarter in Q3 last year in Americas. So it's a tough compare.",25,"Yes. And in addition, if I may add, we had a very strong quarter in Q3 last year in Americas. So it's a tough compare."
154924,374881090,1036665,"Agilent Technologies, Inc., Q3 2016 Earnings Call, Aug 17, 2016",2016-08-17,"Earnings Calls","Agilent Technologies, Inc.","Executives","Yes. I'm not always willing to let my guys do the tough compare argument, but thanks, Patrick.",17,"Yes. I'm not always willing to let my guys do the tough compare argument, but thanks, Patrick."
154924,374881090,1036665,"Agilent Technologies, Inc., Q3 2016 Earnings Call, Aug 17, 2016",2016-08-17,"Earnings Calls","Agilent Technologies, Inc.","Operator","Our next question comes from the line of Tycho Peterson from JPMorgan.",12,"Our next question comes from the line of Tycho Peterson from JPMorgan."
154924,374881090,1036665,"Agilent Technologies, Inc., Q3 2016 Earnings Call, Aug 17, 2016",2016-08-17,"Earnings Calls","Agilent Technologies, Inc.","Analysts","Maybe first on -- just on the academic front because it is a big swing from what you reported last quarter. I understand the Europe dynamic, but frankly, what we hear from you is a little bit different than we've heard from most of the other life science",73,"Maybe first on -- just on the academic front because it is a big swing from what you reported last quarter. I understand the Europe dynamic, but frankly, what we hear from you is a little bit different than we've heard from most of the other life science peers. So can you maybe just talk a little bit about why you felt more pressure in Europe academic than maybe most of your peers?"
154924,374881090,1036665,"Agilent Technologies, Inc., Q3 2016 Earnings Call, Aug 17, 2016",2016-08-17,"Earnings Calls","Agilent Technologies, Inc.","Executives","I think it's -- I think -- I'd point to 2 factors. I'm not sure exactly what all our peers are saying about Europe. I think they're probably saying the same thing, which are the European budgets are constrained and funding has not been released, and it's",136,"I think it's -- I think -- I'd point to 2 factors. I'm not sure exactly what all our peers are saying about Europe. I think they're probably saying the same thing, which are the European budgets are constrained and funding has not been released, and it's actually been [indiscernible] in some situations. I also think you may be hearing more positive spin on the U.S. environment because of -- many of our competitors have much more business coming from NIH. So there's a lot of positive view of the NIH budget, but we pick up a relatively small piece of that overall budget. The agencies where we do a lot of our business in the U.S. government, we know the money is coming in the fourth quarter. Anything else you'd add to that, Patrick?"
154924,374881090,1036665,"Agilent Technologies, Inc., Q3 2016 Earnings Call, Aug 17, 2016",2016-08-17,"Earnings Calls","Agilent Technologies, Inc.","Executives","Not a lot. And as you said, there's -- a lot of our competitors definitely have also a mixed bag, on average, I would say.",25,"Not a lot. And as you said, there's -- a lot of our competitors definitely have also a mixed bag, on average, I would say."
154924,374881090,1036665,"Agilent Technologies, Inc., Q3 2016 Earnings Call, Aug 17, 2016",2016-08-17,"Earnings Calls","Agilent Technologies, Inc.","Analysts","And then similarly, environmental is flat after growing 6% last quarter. Can you maybe just comment on dynamics there?",19,"And then similarly, environmental is flat after growing 6% last quarter. Can you maybe just comment on dynamics there?"
154924,374881090,1036665,"Agilent Technologies, Inc., Q3 2016 Earnings Call, Aug 17, 2016",2016-08-17,"Earnings Calls","Agilent Technologies, Inc.","Executives","I think the biggest dynamic there is there's a subsegment within environmental [indiscernible] where we pick up our forensic business. And we report externally just the total environmental business, but a lot of big deal activity in forensic. So last year",103,"I think the biggest dynamic there is there's a subsegment within environmental [indiscernible] where we pick up our forensic business. And we report externally just the total environmental business, but a lot of big deal activity in forensic. So last year, we had a lot of big deals at this point in time. The overall environmental market has given me big deals in the second quarter. So it's really a forensic-driven phenomena, which is where we didn't have as many big deals in the third quarter. And this business tends to be a little bit more lumpy than our base environmental business."
154924,374881090,1036665,"Agilent Technologies, Inc., Q3 2016 Earnings Call, Aug 17, 2016",2016-08-17,"Earnings Calls","Agilent Technologies, Inc.","Analysts","Okay. And then -- and last one, a little bit of an esoteric question. But on the PD-L1 data sets [indiscernible] along, can you maybe just talk about whether there's kind of any change in your outlook? Obviously, Bristol attempted to go without a companio",73,"Okay. And then -- and last one, a little bit of an esoteric question. But on the PD-L1 data sets [indiscernible] along, can you maybe just talk about whether there's kind of any change in your outlook? Obviously, Bristol attempted to go without a companion and failed. Merck is doing a companion. So can you maybe just talk about whether some of those developments have changed your view of the market opportunity overall?"
154924,374881090,1036665,"Agilent Technologies, Inc., Q3 2016 Earnings Call, Aug 17, 2016",2016-08-17,"Earnings Calls","Agilent Technologies, Inc.","Executives","Sure. Sure, Tycho. In fact, we just had a conversation on this yesterday. So Pat -- I mean, Jacob, why don't you share the latest thoughts from Agilent on this topic?",31,"Sure. Sure, Tycho. In fact, we just had a conversation on this yesterday. So Pat -- I mean, Jacob, why don't you share the latest thoughts from Agilent on this topic?"
154924,374881090,1036665,"Agilent Technologies, Inc., Q3 2016 Earnings Call, Aug 17, 2016",2016-08-17,"Earnings Calls","Agilent Technologies, Inc.","Executives","Yes, I will say, first and foremost, we are very pleased with the performance we have seen on PD-L1 over the last 10 months, and we continue to see a strong traction. You're right. There has been some announcement recently on some studies that has not com",120,"Yes, I will say, first and foremost, we are very pleased with the performance we have seen on PD-L1 over the last 10 months, and we continue to see a strong traction. You're right. There has been some announcement recently on some studies that has not come out as expected. It really supports our thesis about the importancy of CDx and, really, that you need to make sure you stratify your patient group the right way. So clearly, there is a short-term opportunity, at least from one of our customers that is a little less than we hoped for. But I don't think that, that overall change is really the thesis, and we continue to see a big opportunity here."
154924,374881090,1036665,"Agilent Technologies, Inc., Q3 2016 Earnings Call, Aug 17, 2016",2016-08-17,"Earnings Calls","Agilent Technologies, Inc.","Operator","Our next question comes from the line of Ross Muken from Evercore.",12,"Our next question comes from the line of Ross Muken from Evercore."
154924,374881090,1036665,"Agilent Technologies, Inc., Q3 2016 Earnings Call, Aug 17, 2016",2016-08-17,"Earnings Calls","Agilent Technologies, Inc.","Analysts","So it seems like most of the confusion we're hearing is sort of on the sequential progression of core revenues. And so I look at the last 2 years, and looks like, sequentially, the comp is roughly, I don't know, 200 basis points easier on core. And it loo",126,"So it seems like most of the confusion we're hearing is sort of on the sequential progression of core revenues. And so I look at the last 2 years, and looks like, sequentially, the comp is roughly, I don't know, 200 basis points easier on core. And it looks like you have a little bit heavier of an NMR headwind in 4Q than you did in 3Q. So one, can you confirm that? And then two, as we just think about the crosswalk, what are the other sort of underlying assumptions in terms what is different sequentially versus 3Q, whether it's end markets or any of the key segments? And then where have you built in, I guess, some conservatism or some of that uncertainty?"
154924,374881090,1036665,"Agilent Technologies, Inc., Q3 2016 Earnings Call, Aug 17, 2016",2016-08-17,"Earnings Calls","Agilent Technologies, Inc.","Executives","Yes. Thanks for the question, Ross. And why don't I go ahead and just share some thoughts about the Q4 guidance. And then Didier, maybe you can dig through your notes on the NMR impact. But I think it's important for me to share with the audience here tod",268,"Yes. Thanks for the question, Ross. And why don't I go ahead and just share some thoughts about the Q4 guidance. And then Didier, maybe you can dig through your notes on the NMR impact. But I think it's important for me to share with the audience here today about how we thought about our Q4 guidance. I think this may get to the root of some of your questions. As you heard on our call, first of all, we're quite pleased with the higher-than-guided core revenue growth that we delivered for Q3 after having raised last -- in last call. I think we've got this increased confidence to achieve our previously raised core growth guidance for the year. And listen, we realized by not raising our core guidance for this year that this question could arise. But the way we look at that, so listen, there's a raised level uncertainty in the markets centered around Europe. And we saw some weak European government budgets in the third quarter. Is this going to continue? We've seen some downward revisions in terms of market overall economic forecast for Europe so really not sure exactly how it's going to develop. So we just thought it's prudent to reflect some of this uncertainty by not raising again the full year guidance. So that's how we thought about the process. We really didn't look over the years sequentially. We do know that last year, though, I said I don't like the tough compare, although we did have a blowout fourth quarter last year. But anything else -- Didier, can you remember unusual..."
154924,374881090,1036665,"Agilent Technologies, Inc., Q3 2016 Earnings Call, Aug 17, 2016",2016-08-17,"Earnings Calls","Agilent Technologies, Inc.","Executives","No. And NMR is not a factor.",7,"No. And NMR is not a factor."
154924,374881090,1036665,"Agilent Technologies, Inc., Q3 2016 Earnings Call, Aug 17, 2016",2016-08-17,"Earnings Calls","Agilent Technologies, Inc.","Executives","NMR is not a factor.",5,"NMR is not a factor."
154924,374881090,1036665,"Agilent Technologies, Inc., Q3 2016 Earnings Call, Aug 17, 2016",2016-08-17,"Earnings Calls","Agilent Technologies, Inc.","Executives","You pointed out really what we intended to do. We've maintained the overall core revenue growth for the whole year, and that's how derive the Q4.",26,"You pointed out really what we intended to do. We've maintained the overall core revenue growth for the whole year, and that's how derive the Q4."
154924,374881090,1036665,"Agilent Technologies, Inc., Q3 2016 Earnings Call, Aug 17, 2016",2016-08-17,"Earnings Calls","Agilent Technologies, Inc.","Executives","Yes. And we'd raised last quarter, and the business is developing in the third quarter actually better than we had thought as you saw in our results. And as you look in the fourth quarter, listen, we don't know how does Europe is going to play out, so let",60,"Yes. And we'd raised last quarter, and the business is developing in the third quarter actually better than we had thought as you saw in our results. And as you look in the fourth quarter, listen, we don't know how does Europe is going to play out, so let's just be cautious as opposed to raising again for the quarter."
154924,374881090,1036665,"Agilent Technologies, Inc., Q3 2016 Earnings Call, Aug 17, 2016",2016-08-17,"Earnings Calls","Agilent Technologies, Inc.","Analysts","That makes total sense to me, Mike. I mean, I think given some of the uncertainty, I certainly don't want to get in front of your skis. And you guys have been beating numbers, and that's good. I guess as you think about the key product cycles for the busi",136,"That makes total sense to me, Mike. I mean, I think given some of the uncertainty, I certainly don't want to get in front of your skis. And you guys have been beating numbers, and that's good. I guess as you think about the key product cycles for the business, how do you think about the cadence now that you've had some releases of when we could start seeing that also drop the core growth overall? And then secondarily, when do we start to comp through? We have now, I guess, comped through some easier compares on the Diagnostics business, which has been going hot for, I don't know, 4 or 6 quarters now. How long do you think we've got left on that trajectory of sort of high-single to almost double-digit growth in that business?"
154924,374881090,1036665,"Agilent Technologies, Inc., Q3 2016 Earnings Call, Aug 17, 2016",2016-08-17,"Earnings Calls","Agilent Technologies, Inc.","Executives","I think longer, but I think there for the foreseeable future, we're highly confident on the growth rates in this business. And that's why I made the comment earlier about, ""Hey, when you think about Agilent's long-term growth perspective, if you think abo",171,"I think longer, but I think there for the foreseeable future, we're highly confident on the growth rates in this business. And that's why I made the comment earlier about, ""Hey, when you think about Agilent's long-term growth perspective, if you think about '17, think about that we've got over half of our revenue in markets that are going to have a steady trajectory of growth."" And you heard Jacob talk about what's going on in the companion diagnostic PD-L1. We talked -- that's why I wanted to highlight the investments that we're making in NASD, which is a part of the business we haven't really talked a lot about with you. So I think there are a lot of genomics, there's SureSelect next-gen sequencing. There's a lot of fundamental, very attractive markets that we have a strong position in. So Jacob, I don't want to necessarily speak for you, but I guess I have that we expected this growth rate will be sustained. Anything else you'd add to my story?"
154924,374881090,1036665,"Agilent Technologies, Inc., Q3 2016 Earnings Call, Aug 17, 2016",2016-08-17,"Earnings Calls","Agilent Technologies, Inc.","Executives","You're absolutely right, and I'm definitely pleased with the excellent growth. Last quarter, we had 5%. So I really want to make sure that you saw that we were -- when I -- when we talked also at the Analyst Day, we believe the right -- the direction is 6",81,"You're absolutely right, and I'm definitely pleased with the excellent growth. Last quarter, we had 5%. So I really want to make sure that you saw that we were -- when I -- when we talked also at the Analyst Day, we believe the right -- the direction is 6% to 7%,  and I'm happy to beat that. But we do not see any change in trajectory right now, and we'll continue in those high single-digit growth rates going forward."
154924,374881090,1036665,"Agilent Technologies, Inc., Q3 2016 Earnings Call, Aug 17, 2016",2016-08-17,"Earnings Calls","Agilent Technologies, Inc.","Executives","And Ross, I think perhaps your earlier question was around product cycle -- Yes. So I think, as you may know, when I came into the role a little over 1.5 years ago, we had really spent a lot of time redirecting our R&D program. We restructured the company",188,"And Ross, I think perhaps your earlier question was around product cycle -- Yes. So I think, as you may know, when I came into the role a little over 1.5 years ago, we had really spent a lot of time redirecting our R&D program. We restructured the company. We reorganized our R&D programs, and I think you're starting to see the cadence. So you're seeing some of the product come out. We highlighted earlier on the chromatography side, some updates and new products around spectroscopy, ICP-MS. And we know this cadence is going to continue throughout the next quarter and into '17. So that's why when I got the earlier question about, hey, what are you thinking about in terms of '17. I know what's in our road maps, and I know what's coming to the market over the next 12 months. And I know it's already come to the market, and I know how customers are responding. That's why we have this level of confidence about our ability to continue to grow this company in what has been very mixed market conditions, to say the least."
154924,374881090,1036665,"Agilent Technologies, Inc., Q3 2016 Earnings Call, Aug 17, 2016",2016-08-17,"Earnings Calls","Agilent Technologies, Inc.","Operator","Our next question comes from the line of Doug Schenkel from Cowen.",12,"Our next question comes from the line of Doug Schenkel from Cowen."
154924,374881090,1036665,"Agilent Technologies, Inc., Q3 2016 Earnings Call, Aug 17, 2016",2016-08-17,"Earnings Calls","Agilent Technologies, Inc.","Analysts","My first question -- I guess both are going to be on guidance. So for fiscal Q4, your guidance essentially tells us that you're assuming operating margin decline year-over-year in fiscal year Q4 in spite of what seems like could be, I guess mix-wise, a pr",81,"My first question -- I guess both are going to be on guidance. So for fiscal Q4, your guidance essentially tells us that you're assuming operating margin decline year-over-year in fiscal year Q4 in spite of what seems like could be, I guess mix-wise, a pretty favorable quarter year-over-year based on your commentary. So keeping that in mind and the fact that you've actually expanded operating margin year-over-year, I believe 6 straight quarters, can you just explain why this makes sense?"
154924,374881090,1036665,"Agilent Technologies, Inc., Q3 2016 Earnings Call, Aug 17, 2016",2016-08-17,"Earnings Calls","Agilent Technologies, Inc.","Executives","Yes. I think you've got the string of consecutive quarters. It's been 6 quarters in a row. And Didier, we looked at this. I think it's purely volume related, but ...",31,"Yes. I think you've got the string of consecutive quarters. It's been 6 quarters in a row. And Didier, we looked at this. I think it's purely volume related, but ..."
154924,374881090,1036665,"Agilent Technologies, Inc., Q3 2016 Earnings Call, Aug 17, 2016",2016-08-17,"Earnings Calls","Agilent Technologies, Inc.","Executives","Yes, absolutely. Same thing for operating margin. Our approach as for revenue approach is we didn't -- we wanted to maintain our full year operating margin because obviously it's linked to a revenue, so we maintain our core revenue growth assumption of 4.",139,"Yes, absolutely. Same thing for operating margin. Our approach as for revenue approach is we didn't -- we wanted to maintain our full year operating margin because obviously it's linked to a revenue, so we maintain our core revenue growth assumption of 4.5% and our operating margin assumption of 20.4%. Now you are absolutely correct that, that would mean that 50 basis points reduction from the significant operating margin we had in Q4 of last year of 21.5%, still a significant 70 basis point sequential improvement. And you have to take into account, as Mike said, that this is based on only 1.2% top line growth. So a slight reduction in operating margin still very significant increase sequentially but slight reduction related to the one -- the assumption that we'd made on the top line growth of only 1.2%."
154924,374881090,1036665,"Agilent Technologies, Inc., Q3 2016 Earnings Call, Aug 17, 2016",2016-08-17,"Earnings Calls","Agilent Technologies, Inc.","Executives","Right. We do better on the volume, we'll do better on the margin.",13,"Right. We do better on the volume, we'll do better on the margin."
154924,374881090,1036665,"Agilent Technologies, Inc., Q3 2016 Earnings Call, Aug 17, 2016",2016-08-17,"Earnings Calls","Agilent Technologies, Inc.","Analysts","So I guess that's a segue to, I guess, the second guidance question. And I don't mean to be redundant here because there's been a lot of questions on this already. But I'm going to ask you anyway. I mean, your guidance is for around 1.2% core revenue grow",229,"So I guess that's a segue to, I guess, the second guidance question. And I don't mean to be redundant here because there's been a lot of questions on this already. But I'm going to ask you anyway. I mean, your guidance is for around 1.2% core revenue growth in the quarter. If we think about this by end market, it -- you actually have an easier compare in environmental forensics, academic, environment and food relative to certainly what you had in fiscal Q3. Diagnostics is a little tougher, but you have some real momentum there. So if we just kind of to make it simple assume all those end markets grow 3% to 5% and that chemical and energy is down mid-singles, it would imply that you guys are thinking pharma is only going to grow low single digits maybe at best in Q4. It's a tough compare in pharma in the quarter, but you've talked about continued strength in pharma in fiscal '17 in response to an earlier question. Again, recognizing the uncertainty you talked about in Europe, this is -- I guess some of this is hard to reconcile. Can you help out a little bit? And specifically again What, are you assuming for pharma in the quarter? Is that because of the compare? And what's your assumption growth for Europe growth in the quarter?"
154924,374881090,1036665,"Agilent Technologies, Inc., Q3 2016 Earnings Call, Aug 17, 2016",2016-08-17,"Earnings Calls","Agilent Technologies, Inc.","Executives","Yes. Sure. glad to walk through this, Doug. In fact, we spend a lot of time modeling our end market views for the rest of the year. Anticipating that this might be a question that would arise. And as I recall, Didier, I think that we had a less optimistic",105,"Yes. Sure. glad to walk through this, Doug. In fact, we spend a lot of time modeling our end market views for the rest of the year. Anticipating that this might be a question that would arise. And as I recall, Didier, I think that we had a less optimistic view relative to academia and government than I think Doug's math was where we were seeing where we were concerned about Europe. And we had -- we basically have it flat for the year, and I think we still have pharma overall double digits. So if you want to do just do a little walk-through."
154924,374881090,1036665,"Agilent Technologies, Inc., Q3 2016 Earnings Call, Aug 17, 2016",2016-08-17,"Earnings Calls","Agilent Technologies, Inc.","Executives","Yes. The -- maybe, I mean, again, considering how we explained how we came up with the Q4 guidance, the makeup of the Q4 guidance by market in that academic and government and chemical and energy will show the same core revenue growth reduction year-over-",105,"Yes. The -- maybe, I mean, again, considering how we explained how we came up with the Q4 guidance, the makeup of the Q4 guidance by market in that academic and government and chemical and energy will show the same core revenue growth reduction year-over-year as in Q3, so minus 5% for academic and government, minus 4% for chemical and energy. So the assumption is no change between Q3 and Q4. And then for the rest, pharma, you mentioned pharma, we're assuming mid-single digit. And again, on a very tough compare and to -- in line with the way we've been very conservative on the..."
154924,374881090,1036665,"Agilent Technologies, Inc., Q3 2016 Earnings Call, Aug 17, 2016",2016-08-17,"Earnings Calls","Agilent Technologies, Inc.","Executives","Yes. And just to be clear, my comment earlier about double-digit pharma, that's for the full year.",17,"Yes. And just to be clear, my comment earlier about double-digit pharma, that's for the full year."
154924,374881090,1036665,"Agilent Technologies, Inc., Q3 2016 Earnings Call, Aug 17, 2016",2016-08-17,"Earnings Calls","Agilent Technologies, Inc.","Executives","For the full year or -- yes, double digit, absolutely.",10,"For the full year or -- yes, double digit, absolutely."
154924,374881090,1036665,"Agilent Technologies, Inc., Q3 2016 Earnings Call, Aug 17, 2016",2016-08-17,"Earnings Calls","Agilent Technologies, Inc.","Executives","Yes, Doug, maybe just one of -- as we've thought about the company coming in, I think we'd thought that the pharma growth would be lower. We thought China would be lower, and we thought chemical and energy would be higher. And in fact, what's happened is",68,"Yes, Doug, maybe just one of -- as we've thought about the company coming in, I think we'd thought that the pharma growth would be lower. We thought China would be lower, and we thought chemical and energy would be higher. And in fact, what's happened is pharma has actually been stronger, and China is stronger than initially forecasted. And you know the story on chemical and energy."
154924,374881090,1036665,"Agilent Technologies, Inc., Q3 2016 Earnings Call, Aug 17, 2016",2016-08-17,"Earnings Calls","Agilent Technologies, Inc.","Analysts","Okay. The only thing I don't think we got there was just -- and maybe I missed it. But what is the assumption for Europe in the quarter?",28,"Okay. The only thing I don't think we got there was just -- and maybe I missed it. But what is the assumption for Europe in the quarter?"
154924,374881090,1036665,"Agilent Technologies, Inc., Q3 2016 Earnings Call, Aug 17, 2016",2016-08-17,"Earnings Calls","Agilent Technologies, Inc.","Executives","It's about -- that is down low-single digits, mostly on the basis of chemical and energy.",17,"It's about -- that is down low-single digits, mostly on the basis of chemical and energy."
154924,374881090,1036665,"Agilent Technologies, Inc., Q3 2016 Earnings Call, Aug 17, 2016",2016-08-17,"Earnings Calls","Agilent Technologies, Inc.","Analysts","Yes. And the academia.",4,"Yes. And the academia."
154924,374881090,1036665,"Agilent Technologies, Inc., Q3 2016 Earnings Call, Aug 17, 2016",2016-08-17,"Earnings Calls","Agilent Technologies, Inc.","Executives","And the academia growing.",4,"And the academia growing."
154924,374881090,1036665,"Agilent Technologies, Inc., Q3 2016 Earnings Call, Aug 17, 2016",2016-08-17,"Earnings Calls","Agilent Technologies, Inc.","Operator","Your next question comes from the line of Tim Evans from Wells Fargo Securities.",14,"Your next question comes from the line of Tim Evans from Wells Fargo Securities."
154924,374881090,1036665,"Agilent Technologies, Inc., Q3 2016 Earnings Call, Aug 17, 2016",2016-08-17,"Earnings Calls","Agilent Technologies, Inc.","Analysts","This one's for Didier. It seems like cash flow is something that's going better than our expectations or better than our expectations at least. Wondered if you could talk a little bit about the remaining levers that you have to pull on that as you go into",87,"This one's for Didier. It seems like cash flow is something that's going better than our expectations or better than our expectations at least. Wondered if you could talk a little bit about the remaining levers that you have to pull on that as you go into 2017. Do you think that free cash flow growth in 2017 is really just going to be a matter of earnings growth? Or is there more than you can do there to improve free cash flow faster than earnings?"
154924,374881090,1036665,"Agilent Technologies, Inc., Q3 2016 Earnings Call, Aug 17, 2016",2016-08-17,"Earnings Calls","Agilent Technologies, Inc.","Executives","Yes. There is more that we can do. Certainly, the profit before tax is going to be a factor. But Henrik who heads our order fulfillment and the supply chain organization is also committed to a material decrease in inventories.",40,"Yes. There is more that we can do. Certainly, the profit before tax is going to be a factor. But Henrik who heads our order fulfillment and the supply chain organization is also committed to a material decrease in inventories."
154924,374881090,1036665,"Agilent Technologies, Inc., Q3 2016 Earnings Call, Aug 17, 2016",2016-08-17,"Earnings Calls","Agilent Technologies, Inc.","Executives","And he's not here in the room to hear that directly.",12,"And he's not here in the room to hear that directly."
154924,374881090,1036665,"Agilent Technologies, Inc., Q3 2016 Earnings Call, Aug 17, 2016",2016-08-17,"Earnings Calls","Agilent Technologies, Inc.","Executives","So that is also something that we are counting on that will help us continue expanding our operating cash flow as a percentage of revenue or percentage of profits.",29,"So that is also something that we are counting on that will help us continue expanding our operating cash flow as a percentage of revenue or percentage of profits."
154924,374881090,1036665,"Agilent Technologies, Inc., Q3 2016 Earnings Call, Aug 17, 2016",2016-08-17,"Earnings Calls","Agilent Technologies, Inc.","Analysts","Okay. And then a quick one, going back to one of Tycho's questions on the forensics end market. Of that 12% slice of pie that's environmental and forensics, would you be willing to tell us how much is forensics?",39,"Okay. And then a quick one, going back to one of Tycho's questions on the forensics end market. Of that 12% slice of pie that's environmental and forensics, would you be willing to tell us how much is forensics?"
154924,374881090,1036665,"Agilent Technologies, Inc., Q3 2016 Earnings Call, Aug 17, 2016",2016-08-17,"Earnings Calls","Agilent Technologies, Inc.","Executives","I don't think we disclose that. It's fairly small but enough to move it directly when big deals happen.",20,"I don't think we disclose that. It's fairly small but enough to move it directly when big deals happen."
154924,374881090,1036665,"Agilent Technologies, Inc., Q3 2016 Earnings Call, Aug 17, 2016",2016-08-17,"Earnings Calls","Agilent Technologies, Inc.","Operator","Our next question comes from the line of Isaac Ro from Goldman Sachs.",13,"Our next question comes from the line of Isaac Ro from Goldman Sachs."
154924,374881090,1036665,"Agilent Technologies, Inc., Q3 2016 Earnings Call, Aug 17, 2016",2016-08-17,"Earnings Calls","Agilent Technologies, Inc.","Analysts","Just had a question on margins and then a follow-up on Europe. On the margin side, if I look at sort of the components of gross margin, it's interesting that the LSAG division is your highest growth margin segment in most quarters, but that was one where",88,"Just had a question on margins and then a follow-up on Europe. On the margin side, if I look at sort of the components of gross margin, it's interesting that the LSAG division is your highest growth margin segment in most quarters, but that was one where you saw a little pressure. So can you help us think a little bit about kind of the key initiatives you guys have under the hood there to continue driving better gross margin versus expectations and same goes through SG&A?"
154924,374881090,1036665,"Agilent Technologies, Inc., Q3 2016 Earnings Call, Aug 17, 2016",2016-08-17,"Earnings Calls","Agilent Technologies, Inc.","Executives","The question was what are the initiatives we have? I just want to make sure I understood the question.",19,"The question was what are the initiatives we have? I just want to make sure I understood the question."
154924,374881090,1036665,"Agilent Technologies, Inc., Q3 2016 Earnings Call, Aug 17, 2016",2016-08-17,"Earnings Calls","Agilent Technologies, Inc.","Analysts","Yes. Over the last, I don't know, 12 or 18 months, you guys talked a lot about some of the things you're doing to drive gross margin higher. This particular quarter, you had a little weakness in your most profitable segment. So I'm wondering kind of, asid",77,"Yes. Over the last, I don't know, 12 or 18 months, you guys talked a lot about some of the things you're doing to drive gross margin higher. This particular quarter, you had a little weakness in your most profitable segment. So I'm wondering kind of, aside from just the top line contribution, what you guys were able to achieve this quarter on the gross margin line that allowed you to put up a slightly better result."
154924,374881090,1036665,"Agilent Technologies, Inc., Q3 2016 Earnings Call, Aug 17, 2016",2016-08-17,"Earnings Calls","Agilent Technologies, Inc.","Executives","Great, great. Thanks for the question. So what we've been focusing on are really 3 dimensions around what we call our value-engineering program, our logistics model and also our strategic procurement approach with our suppliers. And as I look at the resul",425,"Great, great. Thanks for the question. So what we've been focusing on are really 3 dimensions around what we call our value-engineering program, our logistics model and also our strategic procurement approach with our suppliers. And as I look at the results in '16, the program that Henrik is driving across this company, I think we probably have seen the biggest impact so far in our improved logistics model. And you may recall we talked about logistics costs as being problematic in 2015. That's no longer the case. In fact, we've benchmarked ourselves, and we've got ourselves down to the best in our space. And there actually is more to come, which is the other 2 elements of the program have a little bit more longer tail in terms of payoff, which is value engineering when you're reengineering product platforms to ensure both the continuation of a high performance but a lower cost and then as we also continue to transform our supplier engagement model and how we leverage the scale of Agilent. So I think those latter 2 parts of the program are going to carry us forward into '17 and '18 beyond, so I think that's how we're really working the gross margin side. And by the way, I also -- one of your comments were focused on LSAG. A lot of logistics costs and some of these other factors I mentioned, procurement, show up as impacts on the DDG and ACG business as well. And then relative to the SG&A, couple of things that you may recall I highlighted in the Europe and I just reemphasize again, major focus on our systems infrastructure. So as you heard in my prepared remarks, we're now on one SAP instance, simplifying a lot of our work for our financial team and taking a lot of cost out of the system. The next big wave will be when we move the former Dako company into the Agilent environment in 2017 where we can really start to leverage the scale and take out costs and have improved customer experience there. So there's a couple of big initiatives as well as we look at -- we're looking at other aspects of our benefit structures. We've made some changes. You may know earlier that's where our U.S. pension plan and that the Agile Agilent program I mentioned is live. And we have a lot of initiatives underway to ensure that we can continue to take costs out while simplifying the company. Didier, anything else you would add to that?"
154924,374881090,1036665,"Agilent Technologies, Inc., Q3 2016 Earnings Call, Aug 17, 2016",2016-08-17,"Earnings Calls","Agilent Technologies, Inc.","Executives","I'll just mention the currency hedging. It had a big impact. It will have a big impact on a year-over-year basis. It's all impacts to gross margin. And ACG and DGG are -- because of their footprint, are -- have been more penalized. So ACG on a year-over-y",100,"I'll just mention the currency hedging. It had a big impact. It will have a big impact on a year-over-year basis. It's all impacts to gross margin. And ACG and DGG are -- because of their footprint, are -- have been more penalized. So ACG on a year-over-year basis lost $6 million in gross margin just because of the hedging programs; and DGG, $2 million. That also explains the difference between ACG, DGG and LSAG. LSAG has a different footprint, obviously with a stronger presence in Europe, for example. And so that can distort a little bit the percentages."
154924,374881090,1036665,"Agilent Technologies, Inc., Q3 2016 Earnings Call, Aug 17, 2016",2016-08-17,"Earnings Calls","Agilent Technologies, Inc.","Analysts","That's helpful. Let me just follow-up on Europe. I want to make sure I understand kind of how -- what you're seeing [indiscernible] to the guidance end. So 2 items there. One is did the weakness in Europe, did that tick up in the month of July, just given",86,"That's helpful. Let me just follow-up on Europe. I want to make sure I understand kind of how -- what you're seeing [indiscernible] to the guidance end. So 2 items there. One is did the weakness in Europe, did that tick up in the month of July, just given you guys were off calendar versus the peer group? And secondly, did your guidance assume that the academic end market in Europe weakens further as the year progresses or that it sort of stabilizes from here?"
154924,374881090,1036665,"Agilent Technologies, Inc., Q3 2016 Earnings Call, Aug 17, 2016",2016-08-17,"Earnings Calls","Agilent Technologies, Inc.","Executives","Yes. So nothing unusual in July, and I think the assumption of the Q4 is basically a continuation, not any worse but not any better. And we just thought that was a prudent way to think about the company's performance fourth quarter. I would love to be wro",77,"Yes. So nothing unusual in July, and I think the assumption of the Q4 is basically a continuation, not any worse but not any better. And we just thought that was a prudent way to think about the company's performance fourth quarter. I would love to be wrong, and I hope I'm wrong. But we thought from a planning and guidance standpoint, we should be prudent in terms of how we look at the European market overall."
154924,374881090,1036665,"Agilent Technologies, Inc., Q3 2016 Earnings Call, Aug 17, 2016",2016-08-17,"Earnings Calls","Agilent Technologies, Inc.","Operator","Our next question comes from the line of Derik De Bruin from Bank of America.",15,"Our next question comes from the line of Derik De Bruin from Bank of America."
154924,374881090,1036665,"Agilent Technologies, Inc., Q3 2016 Earnings Call, Aug 17, 2016",2016-08-17,"Earnings Calls","Agilent Technologies, Inc.","Analysts","So a lot of the revenue questions have been asked. And I mean, it certainly seems prudent to me your guidance, just given that Europe, even under a good -- even in a good year this -- the calendar third quarter is always a little bit choppy anyway, so the",117,"So a lot of the revenue questions have been asked. And I mean, it certainly seems prudent to me your guidance, just given that Europe, even under a good -- even in a good year this -- the calendar third quarter is always a little bit choppy anyway, so there's clearly some heightened uncertainty this year. So I think it's prudent to be a little bit conservative. But could you just talk a bit about some of the -- I know the share count was a little bit higher this quarter than what you previously guided to. Are you still looking at buying back 1% of the outstanding shares as we go into the -- going forward?"
154924,374881090,1036665,"Agilent Technologies, Inc., Q3 2016 Earnings Call, Aug 17, 2016",2016-08-17,"Earnings Calls","Agilent Technologies, Inc.","Executives","Yes. Why don't you talk a little bit about the -- our share repurchase activity in the quarter and how we're thinking about it going forward, Didier?",27,"Yes. Why don't you talk a little bit about the -- our share repurchase activity in the quarter and how we're thinking about it going forward, Didier?"
154924,374881090,1036665,"Agilent Technologies, Inc., Q3 2016 Earnings Call, Aug 17, 2016",2016-08-17,"Earnings Calls","Agilent Technologies, Inc.","Executives","Yes. We filed it back in November 28, I think, of last year a 10b5-1 on an annual basis, and we intend to file a new one to register a new one also in November of this year. And it's a formula-based instructions that we have provided between buying 350,00",133,"Yes. We filed it back in November 28, I think, of last year a 10b5-1 on an annual basis, and we intend to file a new one to register a new one also in November of this year. And it's a formula-based instructions that we have provided between buying 350,000 shares a day under certain conditions to buying 0 kind of thing with a cap as you can imagine. So we don't know exactly how it's going to play out in Q4. And the only thing that we know is that if there's any kind of shortfall at all in our intended buying in Q4 because of the formula in the 10b5-1, it will all be carried over into the following year. So we intend to spend exactly what we committed to spend."
154924,374881090,1036665,"Agilent Technologies, Inc., Q3 2016 Earnings Call, Aug 17, 2016",2016-08-17,"Earnings Calls","Agilent Technologies, Inc.","Analysts","Great. That's really helpful. And could you just give us a metric on what instruments versus consumable growth was in the quarter as an overall number for the company?",29,"Great. That's really helpful. And could you just give us a metric on what instruments versus consumable growth was in the quarter as an overall number for the company?"
154924,374881090,1036665,"Agilent Technologies, Inc., Q3 2016 Earnings Call, Aug 17, 2016",2016-08-17,"Earnings Calls","Agilent Technologies, Inc.","Executives","I think probably the best way to think about it is just look at the respective business groups. So you have the LSAG results of down 2%, and then the...",30,"I think probably the best way to think about it is just look at the respective business groups. So you have the LSAG results of down 2%, and then the..."
154924,374881090,1036665,"Agilent Technologies, Inc., Q3 2016 Earnings Call, Aug 17, 2016",2016-08-17,"Earnings Calls","Agilent Technologies, Inc.","Executives","ACG up 8%; and DGG, up 8% also.",9,"ACG up 8%; and DGG, up 8% also."
154924,374881090,1036665,"Agilent Technologies, Inc., Q3 2016 Earnings Call, Aug 17, 2016",2016-08-17,"Earnings Calls","Agilent Technologies, Inc.","Executives","Minus 2%, plus 8%. And that's why I -- again as you think about '17 for the company, if you really want to look at the growth rates of those 2 business units in the recurring revenue space, ACG and DGG, are perhaps differently than you might think about h",66,"Minus 2%, plus 8%. And that's why I -- again as you think about '17 for the company, if you really want to look at the growth rates of those 2 business units in the recurring revenue space, ACG and DGG, are perhaps differently than you might think about how you model the risk profile for revenue projections for the instrument side of the company."
154924,374881090,1036665,"Agilent Technologies, Inc., Q3 2016 Earnings Call, Aug 17, 2016",2016-08-17,"Earnings Calls","Agilent Technologies, Inc.","Analysts","Great. That's really helpful. And I guess, could you -- when you sort of -- you're still feeling good about the margin target for '17, and it sounds like that your IT initiatives are well underway or finished to do like that. Are you -- do you still feel",62,"Great. That's really helpful. And I guess, could you -- when you sort of -- you're still feeling good about the margin target for '17, and it sounds like that your IT initiatives are well underway or finished to do like that. Are you -- do you still feel confident about getting what you're expecting for next year for the margin improvement?"
154924,374881090,1036665,"Agilent Technologies, Inc., Q3 2016 Earnings Call, Aug 17, 2016",2016-08-17,"Earnings Calls","Agilent Technologies, Inc.","Executives","Absolutely. So that's why I made a few comments about it earlier because as we said, if we can be in a 4.5%, 5% kind of growth range, perhaps even lower [ph], it makes it a little bit more challenging. But we can see -- we see the path to 22%. It's not ju",215,"Absolutely. So that's why I made a few comments about it earlier because as we said, if we can be in a 4.5%, 5% kind of growth range, perhaps even lower [ph], it makes it a little bit more challenging. But we can see -- we see the path to 22%. It's not just around margins. I mean, especially not just around margin improvement from volume. But there are specific real programs. It's something we review once a month, then we have active programs, and the costs will continue to come out in some of these big programs. Actually, I must say I'm really pleased with the team because we've -- we went through and did the -- we call project Nunu [ph]. It's the finance program we just finished up. And then right on the heels of that, we're going to go live in early '17 with our integration of Dako. So the teams are still energized and working hard, and I think this can have a material impact on our results in '17. And that's why we have confidence about the -- assuming no major changes in terms of the macro environment that we can reach what we think are pretty challenging goals, but they're -- we've got to pass to get there."
154924,374881090,1036665,"Agilent Technologies, Inc., Q3 2016 Earnings Call, Aug 17, 2016",2016-08-17,"Earnings Calls","Agilent Technologies, Inc.","Operator","Our next question comes from the line of Dan Arias from Citigroup.",12,"Our next question comes from the line of Dan Arias from Citigroup."
154924,374881090,1036665,"Agilent Technologies, Inc., Q3 2016 Earnings Call, Aug 17, 2016",2016-08-17,"Earnings Calls","Agilent Technologies, Inc.","Analysts","Patrick, just going back to your comments on share gains in LC. I know you guys don't like to get too specific on winners and losers. But as was mentioned, it does look like all of the major players are doing fairly well there. So who would you say you're",72,"Patrick, just going back to your comments on share gains in LC. I know you guys don't like to get too specific on winners and losers. But as was mentioned, it does look like all of the major players are doing fairly well there. So who would you say you're taking share from? Is it the small column providers or does that actually extend into some of the box companies as well?"
154924,374881090,1036665,"Agilent Technologies, Inc., Q3 2016 Earnings Call, Aug 17, 2016",2016-08-17,"Earnings Calls","Agilent Technologies, Inc.","Executives","Well, I -- thanks for the question. I can give you only a general flavor here on what we think is going on in the market. I will not comment on the individual competitors, but your assumption that the small providers probably take a larger hit is also our",50,"Well, I -- thanks for the question. I can give you only a general flavor here on what we think is going on in the market. I will not comment on the individual competitors, but your assumption that the small providers probably take a larger hit is also our observation."
154924,374881090,1036665,"Agilent Technologies, Inc., Q3 2016 Earnings Call, Aug 17, 2016",2016-08-17,"Earnings Calls","Agilent Technologies, Inc.","Analysts","Okay. And then maybe a specific one on C&E. Mike, at the Analyst Day, you called out a Saudi Arabian refinery build-out that was getting going. Have you started to see some demand there? And is that something that you think contribute at all to the back h",51,"Okay. And then maybe a specific one on C&E. Mike, at the Analyst Day, you called out a Saudi Arabian refinery build-out that was getting going. Have you started to see some demand there? And is that something that you think contribute at all to the back half of the year?"
154924,374881090,1036665,"Agilent Technologies, Inc., Q3 2016 Earnings Call, Aug 17, 2016",2016-08-17,"Earnings Calls","Agilent Technologies, Inc.","Executives","The major projects that were underway haven't been canceled, so -- but we're not seeing any major new projects underway. There's a lot of -- there are actually a lot of positive news by a lot of studies about where this market is going, but we're not seei",157,"The major projects that were underway haven't been canceled, so -- but we're not seeing any major new projects underway. There's a lot of -- there are actually a lot of positive news by a lot of studies about where this market is going, but we're not seeing -- what we're -- just to clarify here, the major project that we knew about, whether it be the one I mentioned in Saudi or the -- there's a major project down in Texas. These programs, they're going to come online. So people aren't canceling capacity increase projects, but we're not seeing a lot of new projects. And that's why we have taken a fairly conservative sort of a little bit pragmatic view of that marketplace. Again, I'll remind everybody, too, that when we talk about chemical and energy, 50% or so is actually chemicals -- chemical processing not directly tied to the exploration and production of oil."
154924,374881090,1036665,"Agilent Technologies, Inc., Q3 2016 Earnings Call, Aug 17, 2016",2016-08-17,"Earnings Calls","Agilent Technologies, Inc.","Operator","Our next question comes from the line of Paul Knight from Janney Montgomery Scott.",14,"Our next question comes from the line of Paul Knight from Janney Montgomery Scott."
154924,374881090,1036665,"Agilent Technologies, Inc., Q3 2016 Earnings Call, Aug 17, 2016",2016-08-17,"Earnings Calls","Agilent Technologies, Inc.","Analysts","I guess specifically what is the GC business doing? What's its growth rate? What was it doing in the July quarter? And what's the backlog or what are the -- what's July or August look like, I guess?",38,"I guess specifically what is the GC business doing? What's its growth rate? What was it doing in the July quarter? And what's the backlog or what are the -- what's July or August look like, I guess?"
154924,374881090,1036665,"Agilent Technologies, Inc., Q3 2016 Earnings Call, Aug 17, 2016",2016-08-17,"Earnings Calls","Agilent Technologies, Inc.","Executives","Thanks, Paul, appreciate the question. As you probably will understand, I'll give you more high-level result because we don't actually comment specifically at a product category level beyond, I think, I'll just reemphasize the point that Patrick made when",134,"Thanks, Paul, appreciate the question. As you probably will understand, I'll give you more high-level result because we don't actually comment specifically at a product category level beyond, I think, I'll just reemphasize the point that Patrick made when he characterized the chromatography market. That business is down relative to last year because the chemical and energy market is down. And we have seen no movement at all, downward pressure on our share position. It's really a market phenomena we're dealing with right now. And that's why when that replaced [ph] the market, it does turn, and we've been through these cycles before. When it does turn, we'll be in a strong position to capture that growth as given the strength of our position in that market, which right now happens to be down."
154924,374881090,1036665,"Agilent Technologies, Inc., Q3 2016 Earnings Call, Aug 17, 2016",2016-08-17,"Earnings Calls","Agilent Technologies, Inc.","Analysts","And then last on the applied market in a broader sense, do you think it's still a GDP growth rate normalized or what do you think the applied market should be for Agilent?",33,"And then last on the applied market in a broader sense, do you think it's still a GDP growth rate normalized or what do you think the applied market should be for Agilent?"
154924,374881090,1036665,"Agilent Technologies, Inc., Q3 2016 Earnings Call, Aug 17, 2016",2016-08-17,"Earnings Calls","Agilent Technologies, Inc.","Executives","We actually don't think about it that way because the segments that -- big segments of the market like your food and environmental testing, we think are independent to some extent of GDP. So the only way I think that we really think about that as relative",152,"We actually don't think about it that way because the segments that -- big segments of the market like your food and environmental testing, we think are independent to some extent of GDP. So the only way I think that we really think about that as relative to it is our chemical and energy space. So if you could just kind of think about tying GDP to that subsegment of the company, I think that's -- would be good place to start. But I would not apply it to the whole what we call applied markets because these are being driven by quality-of-life investments in the food and environmental area. And I think that's why -- I think this composition of our end markets is the reason why we've been able to put up these kind of growth rates even when a #2 market as a company has shrunk this year."
154924,374881090,1036665,"Agilent Technologies, Inc., Q3 2016 Earnings Call, Aug 17, 2016",2016-08-17,"Earnings Calls","Agilent Technologies, Inc.","Analysts","And then last on -- you had your Analyst Day, obviously. You've been talking about a 22% operating margin. Are you more or less confident in that number for FY '17 at this juncture?",34,"And then last on -- you had your Analyst Day, obviously. You've been talking about a 22% operating margin. Are you more or less confident in that number for FY '17 at this juncture?"
154924,374881090,1036665,"Agilent Technologies, Inc., Q3 2016 Earnings Call, Aug 17, 2016",2016-08-17,"Earnings Calls","Agilent Technologies, Inc.","Executives","Yes. I think the confidence level is the same as it was back in May. And again maybe this is -- I'll just share a few points here, which as you know, we have this confidence of delivery on that given our belief that we can get that growth rate that we're",277,"Yes. I think the confidence level is the same as it was back in May. And again maybe this is -- I'll just share a few points here, which as you know, we have this confidence of delivery on that given our belief that we can get that growth rate that we're putting up growth rates right now in that territory. We've got this pipeline of new products coming out. We've got this nice recurring revenue stream with ACG and DDG that will carry this momentum into '17 and that where our instrument business is going. Hey, pharma looks -- still looks good. Of course, you have these double-digit compare issues. China looks -- continue to be strong. And chemical and energy has got to turn at some point in time because the market requires these tools as -- for production. Our thinking is when we look at chemical and energy is we know our customers are looking for productivity improvements to help improve their company profitability. We think that's a value proposition that Agilent has. We think as they go through their budget justification processes and their budgets start in calendar 2017 that this is why we can say, ""Listen, the decline in this business after 18 to 24 months will start to turn,"" and we could see low single digits by the end of 2017 for the chemical and energy market. If that happens, which we believe it will, that will give us the confidence to get the growth and then know we'll get the margin, given both the volume but also in terms of gross margin improvement initiatives as well as our SG&A cost."
154924,374881090,1036665,"Agilent Technologies, Inc., Q3 2016 Earnings Call, Aug 17, 2016",2016-08-17,"Earnings Calls","Agilent Technologies, Inc.","Operator","And our final question today comes from the line of Catherine Ramsey from Robert W. Baird.",16,"And our final question today comes from the line of Catherine Ramsey from Robert W. Baird."
154924,374881090,1036665,"Agilent Technologies, Inc., Q3 2016 Earnings Call, Aug 17, 2016",2016-08-17,"Earnings Calls","Agilent Technologies, Inc.","Analysts","We've heard a lot of commentary from your peers on Japan, strong pharma environment, weak academic government. So I was wondering if you could walk through your exposure by end market there and what you're seeing across those customer groups.",41,"We've heard a lot of commentary from your peers on Japan, strong pharma environment, weak academic government. So I was wondering if you could walk through your exposure by end market there and what you're seeing across those customer groups."
154924,374881090,1036665,"Agilent Technologies, Inc., Q3 2016 Earnings Call, Aug 17, 2016",2016-08-17,"Earnings Calls","Agilent Technologies, Inc.","Executives","Didier, do you remember the total Japan numbers? I think...",10,"Didier, do you remember the total Japan numbers? I think..."
154924,374881090,1036665,"Agilent Technologies, Inc., Q3 2016 Earnings Call, Aug 17, 2016",2016-08-17,"Earnings Calls","Agilent Technologies, Inc.","Executives","About 5% of overall...",4,"About 5% of overall..."
154924,374881090,1036665,"Agilent Technologies, Inc., Q3 2016 Earnings Call, Aug 17, 2016",2016-08-17,"Earnings Calls","Agilent Technologies, Inc.","Executives","Yes. About 5%, yes. Just to give you a sense of -- 5% of the total market. Historically, we've been stronger, and I can share this from my experience having been the country manager over in Japan for a few years and early part of my career. We tend to be",137,"Yes. About 5%, yes. Just to give you a sense of -- 5% of the total market. Historically, we've been stronger, and I can share this from my experience having been the country manager over in Japan for a few years and early part of my career. We tend to be much stronger in the chemical and energy segment of that marketplace. We are doing well in the life science research and in genomics, but the majority of the business sits in the chemical and energy space, which is -- has been down. I think Japan has been part of that story. Pharma, the pharma business for us is a relatively smaller portion of the market for us. I think they're doing well in pharma but not enough to really drive significant overall growth rates for Japan."
154924,374881090,1036665,"Agilent Technologies, Inc., Q3 2016 Earnings Call, Aug 17, 2016",2016-08-17,"Earnings Calls","Agilent Technologies, Inc.","Analysts","Okay, great. And then any color on the progress of Dako integration? What's left to do there? Had some nice up margin expansion in DGG this quarter, so are you still thinking that 20% in fiscal '17 or could there be upside to that number?",45,"Okay, great. And then any color on the progress of Dako integration? What's left to do there? Had some nice up margin expansion in DGG this quarter, so are you still thinking that 20% in fiscal '17 or could there be upside to that number?"
154924,374881090,1036665,"Agilent Technologies, Inc., Q3 2016 Earnings Call, Aug 17, 2016",2016-08-17,"Earnings Calls","Agilent Technologies, Inc.","Executives","Jacob has to be sitting right next to me in this conference, but I don't think he's ready to sign up for more than 20% because it is quite an improvement from where we started. But I think he remains quite confident in the 20% achievement of that goal of",186,"Jacob has to be sitting right next to me in this conference, but I don't think he's ready to sign up for more than 20% because it is quite an improvement from where we started. But I think he remains quite confident in the 20% achievement of that goal of an O&M perspective. You saw we had 18.8% operating margin this quarter, 200 basis points over last year. And the big next wave of integration efforts will really be starting in our Q1 '17, so we have a major program we call project de Gaulle [ph]. We seem to like a lot of these French names, Didier. I'm not sure why that may be the case, but -- and that really will be the next big step to move the former Dako company into the Agilent environment. And it will take a little bit of a while to get the cost out, but as you go -- as you think about exiting '17, you're going to have a much lower SG&A spend than you started the year. And Jacob, I don't think you'd share anything else?"
154924,374881090,1036665,"Agilent Technologies, Inc., Q3 2016 Earnings Call, Aug 17, 2016",2016-08-17,"Earnings Calls","Agilent Technologies, Inc.","Executives","No. I think you captured it correctly. I just want to reinforce what's left that the part 20%, actually delivering 20% in 2017 is a significant turnaround of where we were a few years ago. So right now, that's our flame, and I'm very happy where the team",54,"No. I think you captured it correctly. I just want to reinforce what's left that the part 20%, actually delivering 20% in 2017 is a significant turnaround of where we were a few years ago. So right now, that's our flame, and I'm very happy where the team is and excluding this right now."
154924,374881090,1036665,"Agilent Technologies, Inc., Q3 2016 Earnings Call, Aug 17, 2016",2016-08-17,"Earnings Calls","Agilent Technologies, Inc.","Executives","Thanks, Jacob.",2,"Thanks, Jacob."
154924,374881090,1036665,"Agilent Technologies, Inc., Q3 2016 Earnings Call, Aug 17, 2016",2016-08-17,"Earnings Calls","Agilent Technologies, Inc.","Operator","And this does conclude the question-and-answer session of today's program. I'd like to hand the program back to Alicia Rodriguez for any further remarks.",25,"And this does conclude the question-and-answer session of today's program. I'd like to hand the program back to Alicia Rodriguez for any further remarks."
154924,374881090,1036665,"Agilent Technologies, Inc., Q3 2016 Earnings Call, Aug 17, 2016",2016-08-17,"Earnings Calls","Agilent Technologies, Inc.","Executives","Thank you, Jonathan. And on behalf of the entire management team, I'd like to thank everybody for joining us today. If you have any questions, please give us a call at IR. Thanks again. Bye-bye.",35,"Thank you, Jonathan. And on behalf of the entire management team, I'd like to thank everybody for joining us today. If you have any questions, please give us a call at IR. Thanks again. Bye-bye."
154924,374881090,1036665,"Agilent Technologies, Inc., Q3 2016 Earnings Call, Aug 17, 2016",2016-08-17,"Earnings Calls","Agilent Technologies, Inc.","Operator","Thank you, ladies and gentlemen, for your participation in today's conference. This does conclude the program. You may now disconnect. Good day.",22,"Thank you, ladies and gentlemen, for your participation in today's conference. This does conclude the program. You may now disconnect. Good day."
154924,374881090,1036742,"Agilent Technologies, Inc., Q3 2016 Earnings Call, Aug 17, 2016",2016-08-17,"Earnings Calls","Agilent Technologies, Inc.","Operator","Good day ladies and gentlemen, and welcome to the Third Quarter 2016 Agilent Technologies Earnings Conference Call. [Operator Instructions] As a reminder, today's program is being recorded. I would now like to introduce your host for today's program, Al",48,"Good day ladies and gentlemen, and welcome to the Third Quarter 2016 Agilent Technologies Earnings Conference Call. [Operator Instructions] As a reminder, today's program is being recorded. 
I would now like to introduce your host for today's program, Alicia Rodriguez, Vice President of Investor Relations. Please go ahead."
154924,374881090,1036742,"Agilent Technologies, Inc., Q3 2016 Earnings Call, Aug 17, 2016",2016-08-17,"Earnings Calls","Agilent Technologies, Inc.","Executives","Thank you, Jonathan, and welcome, everyone, to Agilent's Third Quarter Conference Call for Fiscal Year 2016. With me are Mike McMullen, Agilent's President and CEO; and Didier Hirsch, Agilent's Vice -- Senior Vice President and CFO.Joining in the Q&A af",342,"Thank you, Jonathan, and welcome, everyone, to Agilent's Third Quarter Conference Call for Fiscal Year 2016. With me are Mike McMullen, Agilent's President and CEO; and Didier Hirsch, Agilent's Vice -- Senior Vice President and CFO.
Joining in the Q&A after Didier's comments will be Patrick Kaltenbach, President of Agilent's Life Sciences and Applied Markets Group; Jacob Thaysen, President of Agilent's Diagnostics and Genomics Group; and Mark Doak, President of the Agilent CrossLab Group.
You can find the press release and information to supplement today's discussion on our website at www.investor.agilent.com. While there, please click on the link for financial results under the Financial Information tab. You will find an investor presentation along with revenue breakouts and currency impacts, business segment results and historical financials for Agilent's operations. We will also post a copy of the prepared remarks following this call. 
Today's comments by Mike and Didier will refer to non-GAAP financial measures. You will find the most directly comparable GAAP financial metrics and reconciliations on our website. We will refer to core revenue growth, which excludes the impact of currency, the NMR business and acquisitions and divestitures within the past 12 months. 
Please note that we are reporting results for the Americas, Europe and Asia on a ship-to basis. Previously, we assigned revenue to these regions based on where the order was placed. This change aligns with individual country reporting, which has always been on a ship-to basis. Historical restatements are available on the Investor Relations website. 
Unless otherwise noted, all references to increases or decreases in financial metrics are year-over-year. Guidance is based on exchange rates as of the last day of the reported quarter. 
We will also make forward-looking statements about the financial performance of the company. These statements are subject to risks and uncertainties and are only valid as of today. The company assumes no obligation to update them. Please look at the company's recent SEC filings for a more complete picture of our risks and other factors. 
And now let me turn the call over to Mike."
154924,374881090,1036742,"Agilent Technologies, Inc., Q3 2016 Earnings Call, Aug 17, 2016",2016-08-17,"Earnings Calls","Agilent Technologies, Inc.","Executives","Thanks, Alicia, and hello, everyone. Thank you for joining us on today's call. I'm pleased to report that the Agilent team delivered another quarter above expectations. Now let me highlight 3 key results: First, core -- Q3 core revenue growth of 3% was",1442,"Thanks, Alicia, and hello, everyone. Thank you for joining us on today's call. I'm pleased to report that the Agilent team delivered another quarter above expectations. 
Now let me highlight 3 key results: First, core -- Q3 core revenue growth of 3% was above the high end of our May guidance. Second, EPS of $0.49 was also above the high end of our guidance of $0.45 to $0.47. Finally, we delivered adjusted operating margin of 20.6%, an increase of 70 basis points from a year ago. 
Agilent's third quarter results echo many of the same themes that we saw last quarter. The pharma, food, clinical and diagnostics end markets remain strong. In the chemical and energy market, while demand for our services and consumables was strong, capital expenditures for new equipment purchases remain challenged. Geographically, Asia, led by China's double-digit growth, drove Agilent third quarter core growth with strength across all business segments. 
Let me highlight our Q3 results by business group. In line with our expectations, Life Sciences and Applied Markets Group core revenues were down 2%. Our strong growth in pharma, environmental and food markets was offset by continued weakness in chemical and energy capital expenditures. Academia and government revenues were also down across most regions. Despite this mixed market environment, LSAG's operating margin for the quarter was 19.1%, up 40 basis points from a year ago. 
Let me shift gears and talk about some of LSAG's new products. We are seeing very strong demand for the newly released 1260 and the 1290 Infinity II LC systems. The 1260 systems are part of the launch of the InfinityLab portfolio at Analytica in May. The InfinityLab portfolio consists of this new line of LC instruments along with columns, supplies and services. In Q3, LSAG also introduced the new -- 2 new 7000 Series Triple Quad GC/MS analyzers, one for pesticides and another for environmental pollutants. And we continued to strengthen our ICP-MS market leadership with the new Agilent 8900 Triple Quad ICP-MS system. This new system offers customers improved speed and accuracy of analysis.
Turning to the Agilent CrossLab Group. The business delivered another strong quarter with 8% core revenue growth. This growth is driven by strength in the food, pharma and environmental markets. ACG's operating margin for the quarter was 22.7%, up 10 basis points from a year ago. 
Portfolio expansion efforts also continued in ACG. In Q3, Agilent signed a definitive agreement to acquire the assets of iLab, and we just closed the transaction in early August. iLab is the market leader in cloud-based solutions for core laboratory management and provide services to leading universities, research hospitals and independent institutions around the world. This acquisition further expands Agilent's portfolio in the academia and government market. iLab enables Agilent to deliver broader value for our customers in this market segment. We also see an opportunity to expand the iLab business both geographically and into the pharma market.
Finally, we saw a continued momentum in the Diagnostics and Genomics Group where the business delivered 8% core growth in Q3. We saw strength across all DGG businesses, driven by growth in the pharma and clinical and diagnostics markets. Our pathology business continues on its steady trajectory of improved growth. This was highlighted by demand for our new PD-L1 companion diagnostics. Growth in Genomics reflect a strong market performance in the U.S. and China across our array CGH, Target Enrichment and SureSelect products. We also saw healthy demand for our Nucleic Acid Solutions offering. DGG's operating margin for the quarter was 18.8%, up 200 basis points from a year ago. 
Q3 highlights for DGG include the announcement of an expansion of the intended use of our PD-L1 pharmDX test in Europe for patients with melanoma. This test was previously proven in the U.S. and available in Europe for patients with non-squamous, non-small-cell lung cancer and in the U.S. with patients -- for patients with melanoma. We also announced a $120 million investment over the next 3 years to expand production capacity for our Nucleic Acid Solutions business. This includes the purchase of 20 acres of land in Colorado. We plan to build our factory on this land that will double our manufacturing capacity for nucleic acid active pharmaceutical ingredients and grow our business.
Now I'll provide an overview of Agilent's core revenues by end market. In our life sciences market, pharma saw its sixth consecutive quarter of double-digit growth with core revenue up 10%. Academia and government core revenues were down 5%, down across most geographies except China. Clinical and diagnostics grew 4% with strength in North America and Asia and led by growth in pathology. 
Applied end-market performance was mixed. Food was up 11% with strong demand in China and the Americas. These regions also drove growth in the environmental market for both instruments and aftermarket products. 
This performance was offset by continued challenges in the chemical and energy market, down 4% globally, with only Asia posting growth on a regional basis. The overall result was due to prolonged effects of the macroeconomic concerns and lower oil prices. 
Now I'll turn an update on our operating margin improvement initiatives. Q3 marked a major step forward in simplifying our company's infrastructure. In May, we completed the migration of the company's financial systems onto a single SAP platform. This was a culmination of a 20-month cross-company effort and represents a major step in simplifying Agilent's systems infrastructure that will deliver incremental cost savings as planned in fiscal 2017. 
In summary, our multiyear Agile Agilent program continues to simplify the company's business processes. This program is designed to make us more nimble and lower our costs. It will continue to deliver incremental savings in 2017.
On the capital deployment front, we purchased iLab, paid $37 million in dividends and repurchased $94 million of Agilent stock. We continue to deliver on our strategy to drive sustainable growth while expanding operating margins and balancing deployment of our capital to drive shareholder value creation. 
At our recent May Analyst Meeting, I described our shareholder value creation model: outgrow the market; expand operating margins; balance capital deployment. Let's look at our Q3 results in the context of these longer-term goals and shareholder value creation model. 
In 2015, we delivered our highest annual growth rate in 4 years while increasing adjusted operating margin 170 basis points and completely offsetting the $40 million of dissynergies from the company split. We have sustained this trajectory of improved operating results in fiscal 2016. In the first 3 quarters of 2016, the team has delivered strong growth and earnings above our initial expectations despite a challenging chemical and energy market environment and global macroeconomic concerns.
We have continued to leverage our balance sheet and deployed capital in a balanced manner, buying companies that bring new capabilities to Agilent while repurchasing our stock and increasing cash dividends. 
The new leadership team continues to transform the business and deliver results. We continue to demonstrate our ability to deliver above-industry organic growth while expanding margins and leveraging our balance sheet strength. Our Q3 results in a challenging global economic environment reflect the strength of our team combined with Agilent's scale and broad differentiated portfolio of products and services. 
Looking at today's overall market environment, we expect continued strength in pharma, along with growth in the food, environmental and clinical research and diagnostics markets and in China on a regional basis. 
As I highlighted in our last call, we are experiencing a steeper and more prolonged slowdown in the chemical and energy market than initially projected entering fiscal 2016. We subsequently revised our forecast for this market segment last quarter to overall low single-digit market declines for the year. While there are some signs of an impending bottom in the market, we remain cautious in our outlook and expect Q4 to be in a similar range as the past quarter. 
Against this market drop (sic) [backdrop], we are well positioned to capture growth in these end-market segments and geographies where growth is expected to remain strong. The combination of our expanding our customer channel reach and continual strengthening of our portfolio positions us well to achieve our previously raised full year guidance of 2016 and our longer-term goals. Our One Agilent team continues to work well together and is energized to win in the market. Overall, we remain on track with our 2017 goal to outgrow the market and improve our operating margin to 22%. 
Thank you for being on the call today. I will now turn it over to Didier who will provide additional insights on our financial results and guidance for the remainder of 2016. Didier?"
154924,374881090,1036742,"Agilent Technologies, Inc., Q3 2016 Earnings Call, Aug 17, 2016",2016-08-17,"Earnings Calls","Agilent Technologies, Inc.","Executives","Thank you, Mike, and hello, everyone. As mentioned by Mike, we delivered higher core revenue growth, operating margin and earnings per share than the high end of our guidance. Earnings per share grew 11% in the quarter versus a year ago. We also generated",326,"Thank you, Mike, and hello, everyone. As mentioned by Mike, we delivered higher core revenue growth, operating margin and earnings per share than the high end of our guidance. Earnings per share grew 11% in the quarter versus a year ago. We also generated $194 million in operating cash flow, more than double last year's amount, which gives us increased confidence that we will achieve our previously raised operating cash flow guidance for the full year. FX had a negative impact on revenue of about $10 million or 1% versus previous guidance and $7 million or 0.7% versus last year. It had a negative impact on operating profit of $3 million versus previous guidance and $1 million versus last year.
I'll now turn to the guidance for our fourth quarter. We expect Q4 revenues of $1.05 billion to $1.07 billion and earnings per share of $0.50 to $0.52. At the midpoint, revenue is expected to grow 1.2% on a core basis. Versus previous guidance, FX is estimated to have a negative impact of $9 million on revenue and $2 million on operating profit. Our 21.3% adjusted operating margin at midpoint will be up 70 basis points sequentially.
Now to the guidance for fiscal year 2016. The Q4 guidance results in the following fiscal year guidance. At midpoint, revenue is projected to grow 4.5% on a core basis, no change from the previous guidance. Our earnings per share guidance of $1.90 at midpoint is also unchanged from previous guidance and corresponds to a 9% year-over-year increase. Adjusted operating margin for the year is expected to be 20.4 basis points or 80 basis points higher than in fiscal year '15. And finally, FX is estimated to have a negative impact on a year-over-year basis of $68 million on revenue, $10 million on operating profit related to currency translation and an additional $21 million related to currency hedging. 
With that, I'll turn it over to Alicia for the Q&A."
154924,374881090,1036742,"Agilent Technologies, Inc., Q3 2016 Earnings Call, Aug 17, 2016",2016-08-17,"Earnings Calls","Agilent Technologies, Inc.","Executives","Thank you, Didier. Jonathan, will you please give the instructions for the Q&A?",13,"Thank you, Didier. Jonathan, will you please give the instructions for the Q&A?"
154924,374881090,1036742,"Agilent Technologies, Inc., Q3 2016 Earnings Call, Aug 17, 2016",2016-08-17,"Earnings Calls","Agilent Technologies, Inc.","Operator","[Operator Instructions] Our first question comes from the line of Brandon Couillard from Jefferies. Our next question comes from the line of Steve Beuchaw from Morgan Stanley.",27,"[Operator Instructions] Our first question comes from the line of Brandon Couillard from Jefferies. Our next question comes from the line of Steve Beuchaw from Morgan Stanley."
154924,374881090,1036742,"Agilent Technologies, Inc., Q3 2016 Earnings Call, Aug 17, 2016",2016-08-17,"Earnings Calls","Agilent Technologies, Inc.","Analysts","I want to start with the one regional trend that seems to be on many people's minds, which is what's going on in Europe. I wonder if you could speak to the trends that you saw in Europe over the course of the quarter. To some extent, it's a macro question",99,"I want to start with the one regional trend that seems to be on many people's minds, which is what's going on in Europe. I wonder if you could speak to the trends that you saw in Europe over the course of the quarter. To some extent, it's a macro question. To some extent, it's a research question. And of course, there's the -- their U.K. referendum that's still out there. So I apologize for the nebulous nature of it all, but any color on how Europe progressed over the course of the quarter would be really helpful."
154924,374881090,1036742,"Agilent Technologies, Inc., Q3 2016 Earnings Call, Aug 17, 2016",2016-08-17,"Earnings Calls","Agilent Technologies, Inc.","Executives","Yes, sure. Glad to provide some insight there, and then I'm going to actually have Patrick jump in on this conversation, given your recent travels in the region. But what we saw in the quarter was, obviously, a lot of big macro events, the Brexit, Turkey.",178,"Yes, sure. Glad to provide some insight there, and then I'm going to actually have Patrick jump in on this conversation, given your recent travels in the region. But what we saw in the quarter was, obviously, a lot of big macro events, the Brexit, Turkey. There's a number developed [ph] in the quarter. We did not see any material impact from those events in our performance in the third quarter. What I will say, though, it is raising an increased level of uncertainty amongst our customers in Europe, and we've seen the questions around when will budgets be released. So it's more of an uncertainty question right out there. People are just sort of waiting to see how it's going to develop. Again, no material effect on the third quarter results. But as we thought about our guidance for the fourth quarter, obviously, it's influenced us to think about how will Europe develop through the quarter. And, Patrick, I know you had a pretty deep conversation about this yesterday. So any additional thoughts you'd like to add?"
154924,374881090,1036742,"Agilent Technologies, Inc., Q3 2016 Earnings Call, Aug 17, 2016",2016-08-17,"Earnings Calls","Agilent Technologies, Inc.","Executives","Yes. Thanks, Mike. In talking to our field, local field in Europe, you certainly get the feedback there is some uncertainty as Mike -- as you said. The Brexit had -- with some of the government in traditional [ph] deals had probably some minor impacts. I",101,"Yes. Thanks, Mike. In talking to our field, local field in Europe, you certainly get the feedback there is some uncertainty as Mike -- as you said. The Brexit had -- with some of the government in traditional [ph] deals had probably some minor impacts. I think what's concerning us here a little bit is also there are a couple of other countries standing on the sidelines and have other referendums this year. So we are cautious right now, looking at Europe and the growth scenario for Europe for the remainder of the year and also going into fiscal year '17."
154924,374881090,1036742,"Agilent Technologies, Inc., Q3 2016 Earnings Call, Aug 17, 2016",2016-08-17,"Earnings Calls","Agilent Technologies, Inc.","Executives","Thanks, Patrick.",2,"Thanks, Patrick."
154924,374881090,1036742,"Agilent Technologies, Inc., Q3 2016 Earnings Call, Aug 17, 2016",2016-08-17,"Earnings Calls","Agilent Technologies, Inc.","Analysts","And then one bigger-picture question, Mike. I mean you made a pretty significant investment with a pretty long horizon -- long-term horizon on this facility in Colorado. So it speaks to your confidence in the long-term outlook for and the scale of the opp",80,"And then one bigger-picture question, Mike. I mean you made a pretty significant investment with a pretty long horizon -- long-term horizon on this facility in Colorado. So it speaks to your confidence in the long-term outlook for and the scale of the opportunity there. Can you just talk us through how you frame the opportunity, remind us how big that business is today, and how you think about the medium-term drivers that you're investing in the pursuit of?"
154924,374881090,1036742,"Agilent Technologies, Inc., Q3 2016 Earnings Call, Aug 17, 2016",2016-08-17,"Earnings Calls","Agilent Technologies, Inc.","Executives","Great. So I'm going to handle your -- well, I'm going to handle the first part of this question. And then I'm going to turn it over to Jacob, and he'll reassure you about the long-term growth potential, which is the reason why I supported the investment.",189,"Great. So I'm going to handle your -- well, I'm going to handle the first part of this question. And then I'm going to turn it over to Jacob, and he'll reassure you about the long-term growth potential, which is the reason why I supported the investment. But just as a reminder, I think this is roughly about 5% or so of DGG's overall revenues in the range of maybe $16 plus million or so. We still have capacity at the current site, but we've got a -- more demand than we can handle in terms of long-term outlook from our customers. So we can't bring on this capacity fast enough to satisfy the customer demand. We think this will be a bigger part of our growth story as we talk to you about 2017 and 2018. And I think as you'll hear from Jacob, there's a high degree of confidence that the business is going to be there. And perhaps you can provide a little context of what exactly is this business and why are we so confident that the market is going to be there for us."
154924,374881090,1036742,"Agilent Technologies, Inc., Q3 2016 Earnings Call, Aug 17, 2016",2016-08-17,"Earnings Calls","Agilent Technologies, Inc.","Executives","Yes, let me try to provide a little more color there. So first of all, a reminder that the Nucleic Acid Solutions Division business out in Boulder is providing oligo APIs that constitute a new type of drugs with a significant potential. These drugs are, p",317,"Yes, let me try to provide a little more color there. So first of all, a reminder that the Nucleic Acid Solutions Division business out in Boulder is providing oligo APIs that constitute a new type of drugs with a significant potential. These drugs are, primarily, right now, opportunities within orphan genetic diseases that today there has been no treatment and have devastating outcomes. And these drugs have actually the opportunity to change the expectancy of, you could say, the survival and also the quality of life for such patients. We are working with the leaders in pharma within these new type of drugs, and Agilent is chosen again and again due to our deep technical experience to optimize oligos for performance and consistency, combined with our ability to scale in DNP. We have seen a significant demand accelerated over the last few years. And as Mike mentioned, we're currently expanding our current site to actually take up double capacity. But we also see that, that will run out. That opportunity is really limited and will run out in a few years from now; and thereby, the new investment in the new site will allow us to further double our capacity and even double again if we choose to do so. We have decided, and based on a deep dive into the strategy and so on, to place the site in close proximity to the other Boulder site at approximately 20 minutes' drive away so we can releverage critical mass, high -- the highly experienced staff we already have and capabilities and processes. The overall market is in the hundreds of million dollar business right now, and it's growing something between 20% to 30%. However, when you commercialize drugs -- when you get the commercialized drugs, this might be a significant step-ups, but we see a lot of demand right now just in the clinical trial studies."
154924,374881090,1036742,"Agilent Technologies, Inc., Q3 2016 Earnings Call, Aug 17, 2016",2016-08-17,"Earnings Calls","Agilent Technologies, Inc.","Operator","Our next question comes from the line of Jonathan Groberg from UBS.",12,"Our next question comes from the line of Jonathan Groberg from UBS."
154924,374881090,1036742,"Agilent Technologies, Inc., Q3 2016 Earnings Call, Aug 17, 2016",2016-08-17,"Earnings Calls","Agilent Technologies, Inc.","Analysts","I know you have one more quarter to go here, but any initial thoughts on the puts and takes you're seeing on how we should be thinking about fiscal '17?",30,"I know you have one more quarter to go here, but any initial thoughts on the puts and takes you're seeing on how we should be thinking about fiscal '17?"
154924,374881090,1036742,"Agilent Technologies, Inc., Q3 2016 Earnings Call, Aug 17, 2016",2016-08-17,"Earnings Calls","Agilent Technologies, Inc.","Executives","Yes. Jonathan, I'd be happy to share my thoughts here. And in fact, I, perhaps, will build on some of the comments I made in my prepared remarks. But we're still -- we are still seeing ourselves on the same path that we talked about just a month or so ago",386,"Yes. Jonathan, I'd be happy to share my thoughts here. And in fact, I, perhaps, will build on some of the comments I made in my prepared remarks. But we're still -- we are still seeing ourselves on the same path that we talked about just a month or so ago in New York. I think it actually was 2 months ago when I think about it, but our position remains the same. We are still confident we're going to be able to achieve the overall projected core growth of 4.5%. And there's some new -- there really are some new factors that we think support this level of growth. First of all, we've -- we have a rich pipeline of new product introductions coming in Q4 and in FY '17, on top of what we've already introduced this year. We think our customers are going to be really excited about what we're bringing to market, and that's going to help drive share. So we know we got this NPI pipe going through the system right now with releases coming up in the several quarters on top of what we've done. The second thing, I -- we also have recognized the fact that the Agilent business model has really changed a lot over the last 18 months or so. We have a lot more recurring revenue. And if you look at the ACG and DGG business, which now represent over half, I think it's 52% the last time I did the math, of Agilent's revenue. These are just inherently much more predictable revenue streams, and you saw in our Q3 results how both groups delivered high single-digit growth. And they're not subject to the same types of issues we're seeing in the capital-intensive chemical and energy market, for example. And then the third thing I'd say is when you think about our LSAG instrument business, in addition to the impact of these new product introductions I mentioned, we do expect that pharma and China market is going to remain significant growth drivers, although I think they will be below these double-digit levels we've seen in 2016. And as mentioned in our last call, we still expect that the chemical and energy market will have bottomed by the end of calendar year 2017. We're not ready to..."
154924,374881090,1036742,"Agilent Technologies, Inc., Q3 2016 Earnings Call, Aug 17, 2016",2016-08-17,"Earnings Calls","Agilent Technologies, Inc.","Executives","'16.",1,"'16."
154924,374881090,1036742,"Agilent Technologies, Inc., Q3 2016 Earnings Call, Aug 17, 2016",2016-08-17,"Earnings Calls","Agilent Technologies, Inc.","Executives","Excuse me. Sorry. Thanks, Didier. I got my ears confused there -- by the end of the calendar year 2016. We're not ready to call bottom, but we do see in 2017 that we're forecasting that we could be in low single-digits growth in a market which has had 18",118,"Excuse me. Sorry. Thanks, Didier. I got my ears confused there -- by the end of the calendar year 2016. We're not ready to call bottom, but we do see in 2017 that we're forecasting that we could be in low single-digits growth in a market which has had 18 to 24 months of pent-up demand for equipment that supports the production process. So they're the 3 factors that have gone into our thinking as we have thought about the 2017's growth rate. Honestly, we'll give you the official guidance at our next call. But I would just reinforce our view today is that we're still on track to what we told you in May in New York."
154924,374881090,1036742,"Agilent Technologies, Inc., Q3 2016 Earnings Call, Aug 17, 2016",2016-08-17,"Earnings Calls","Agilent Technologies, Inc.","Analysts","Great. That's helpful. And just one quick follow-up, on the capital equipment business, I know you mentioned going into the quarter, last time when you gave guidance, you thought there'd been a little bit of pull forward and you highlighted why you though",79,"Great. That's helpful. And just one quick follow-up, on the capital equipment business, I know you mentioned going into the quarter, last time when you gave guidance, you thought there'd been a little bit of pull forward and you highlighted why you thought it would be a little weaker. I'm just curious, was it in line with what you thought? Or was there anything unique in the quarter that maybe wasn't right along the lines of what you thought?"
154924,374881090,1036742,"Agilent Technologies, Inc., Q3 2016 Earnings Call, Aug 17, 2016",2016-08-17,"Earnings Calls","Agilent Technologies, Inc.","Executives","Absolutely. I think the quarter was actually in line and actually a little bit better than we had anticipated coming into the quarter, so no major surprises in our Q3 results. And as you can imagine, we were delighted with the ability to deliver above our",52,"Absolutely. I think the quarter was actually in line and actually a little bit better than we had anticipated coming into the quarter, so no major surprises in our Q3 results. And as you can imagine, we were delighted with the ability to deliver above our expectations, both top and bottom line."
154924,374881090,1036742,"Agilent Technologies, Inc., Q3 2016 Earnings Call, Aug 17, 2016",2016-08-17,"Earnings Calls","Agilent Technologies, Inc.","Operator","Our next question comes from the line of Jack Meehan from Barclays.",12,"Our next question comes from the line of Jack Meehan from Barclays."
154924,374881090,1036742,"Agilent Technologies, Inc., Q3 2016 Earnings Call, Aug 17, 2016",2016-08-17,"Earnings Calls","Agilent Technologies, Inc.","Analysts","So I just wanted to ask about the LSAG business and some of the moving parts there. And could you maybe just talk about the chromatography markets? A couple of your peers have had really nice results there. Just what you're seeing there would be helpful.",46,"So I just wanted to ask about the LSAG business and some of the moving parts there. And could you maybe just talk about the chromatography markets? A couple of your peers have had really nice results there. Just what you're seeing there would be helpful."
154924,374881090,1036742,"Agilent Technologies, Inc., Q3 2016 Earnings Call, Aug 17, 2016",2016-08-17,"Earnings Calls","Agilent Technologies, Inc.","Executives","Yes, absolutely. And then, Patrick, if you could break it out, obviously, between liquid chromatography and gas chromatography as well?",20,"Yes, absolutely. And then, Patrick, if you could break it out, obviously, between liquid chromatography and gas chromatography as well?"
154924,374881090,1036742,"Agilent Technologies, Inc., Q3 2016 Earnings Call, Aug 17, 2016",2016-08-17,"Earnings Calls","Agilent Technologies, Inc.","Executives","Yes, absolutely. Happy to do so. As Mike mentioned earlier in his remarks, we definitely see very strong growth right now in the liquid chromatography business, which has been, for the entire year, double digits. And that is what we see, clearly, also tak",251,"Yes, absolutely. Happy to do so. As Mike mentioned earlier in his remarks, we definitely see very strong growth right now in the liquid chromatography business, which has been, for the entire year, double digits. And that is what we see, clearly, also taking market share right now. We had a very strong launch of several waves of the Infinity series starting in 2009 and 2012. And now this year with the 1260 series with another big round of instrumentation and solutions in liquid chromatography, that is very well received by the end markets. We see very healthy replacement business as well, and it's driven by the fact that these solutions are 100% backwards compatible and also compatible with some of our competitors' instrumentations, which makes method transfer very simple and seamless for our customers. So -- and we project this cycle to continue for several more quarters. We don't see yet a loss of momentum. What we see, of course, is that we're getting now into quarters with tougher compare because we have double-digit growth for several quarters now. On the gas chromatography side, again, very strong portfolio as well. The issue we're seeing there is that the core market or one of the big markets for gas chromatography is the energy space. And that, of course, pulled some of our results down at this point in time. If the market comes back, we think we are in an exceptional position to pick up this pent-up demand that we see."
154924,374881090,1036742,"Agilent Technologies, Inc., Q3 2016 Earnings Call, Aug 17, 2016",2016-08-17,"Earnings Calls","Agilent Technologies, Inc.","Executives","When the market comes back.",5,"When the market comes back."
154924,374881090,1036742,"Agilent Technologies, Inc., Q3 2016 Earnings Call, Aug 17, 2016",2016-08-17,"Earnings Calls","Agilent Technologies, Inc.","Executives","Yes, when the market comes back. Yes, when the market comes back, sorry. So I think we are in a great situation there as well. We have an outstanding product portfolio and ability to capture the growth when it gets back.",41,"Yes, when the market comes back. Yes, when the market comes back, sorry. So I think we are in a great situation there as well. We have an outstanding product portfolio and ability to capture the growth when it gets back."
154924,374881090,1036742,"Agilent Technologies, Inc., Q3 2016 Earnings Call, Aug 17, 2016",2016-08-17,"Earnings Calls","Agilent Technologies, Inc.","Executives","Yes. And the reason why I asked Patrick to segment his remarks in liquid chromatography from gas chromatography, we have an outsized exposure in gas chromatography, and when the -- relative to the #2 competitor space, we're at least 2x the #2 person. And",91,"Yes. And the reason why I asked Patrick to segment his remarks in liquid chromatography from gas chromatography, we have an outsized exposure in gas chromatography, and when the -- relative to the #2 competitor space, we're at least 2x the #2 person. And so when our major market is down, it really hits us. And that's why, again, we were really quite pleased that we were able to deliver the growth we've done so far, with our #2 market actually being down below our initial expectations coming into this year."
154924,374881090,1036742,"Agilent Technologies, Inc., Q3 2016 Earnings Call, Aug 17, 2016",2016-08-17,"Earnings Calls","Agilent Technologies, Inc.","Analysts","Yes, that's really helpful, and I appreciate all the details in the different segments. If I could just follow up with one more. The Americas growth, negative 1% in the quarter, I know it's on a tougher comp relative to last year. But could you maybe just",67,"Yes, that's really helpful, and I appreciate all the details in the different segments. If I could just follow up with one more. The Americas growth, negative 1% in the quarter, I know it's on a tougher comp relative to last year. But could you maybe just talk about the mix of the end markets there and whether there was any other notable changes worth pointing out?"
154924,374881090,1036742,"Agilent Technologies, Inc., Q3 2016 Earnings Call, Aug 17, 2016",2016-08-17,"Earnings Calls","Agilent Technologies, Inc.","Executives","I think the big one there is the chemical and energy market. So it's down pretty sharply, and I think that's bringing down the overall numbers as well as our academia and government business was down over last year. Although we think some of that -- the w",73,"I think the big one there is the chemical and energy market. So it's down pretty sharply, and I think that's bringing down the overall numbers as well as our academia and government business was down over last year. Although we think some of that -- the way we're thinking about our plan for the rest of this year, we think the federal money will be there in the fourth quarter for us."
154924,374881090,1036742,"Agilent Technologies, Inc., Q3 2016 Earnings Call, Aug 17, 2016",2016-08-17,"Earnings Calls","Agilent Technologies, Inc.","Executives","Yes. And in addition, if I may add, we had a very strong quarter Q3 last year in Americas. So it's a tough compare.",24,"Yes. And in addition, if I may add, we had a very strong quarter Q3 last year in Americas. So it's a tough compare."
154924,374881090,1036742,"Agilent Technologies, Inc., Q3 2016 Earnings Call, Aug 17, 2016",2016-08-17,"Earnings Calls","Agilent Technologies, Inc.","Executives","Yes. I'm not always willing to let my guys do the tough compare argument, but thanks, Patrick.",17,"Yes. I'm not always willing to let my guys do the tough compare argument, but thanks, Patrick."
154924,374881090,1036742,"Agilent Technologies, Inc., Q3 2016 Earnings Call, Aug 17, 2016",2016-08-17,"Earnings Calls","Agilent Technologies, Inc.","Operator","Our next question comes from the line of Tycho Peterson from JPMorgan.",12,"Our next question comes from the line of Tycho Peterson from JPMorgan."
154924,374881090,1036742,"Agilent Technologies, Inc., Q3 2016 Earnings Call, Aug 17, 2016",2016-08-17,"Earnings Calls","Agilent Technologies, Inc.","Analysts","Maybe first on -- just on the academic front because it is a big swing from what you reported last quarter. I understand the Europe dynamic, but frankly, what we hear from you is a little bit different than we've heard from most of the other life science",73,"Maybe first on -- just on the academic front because it is a big swing from what you reported last quarter. I understand the Europe dynamic, but frankly, what we hear from you is a little bit different than we've heard from most of the other life science peers. So can you maybe just talk a little bit about why you felt more pressure in Europe academic than maybe most of your peers?"
154924,374881090,1036742,"Agilent Technologies, Inc., Q3 2016 Earnings Call, Aug 17, 2016",2016-08-17,"Earnings Calls","Agilent Technologies, Inc.","Executives","I think it's -- I think -- I'd point to 2 factors. I'm not sure exactly what all our peers are saying about Europe. I think they're probably saying the same thing, which are the European budgets are constrained and funding has not been released, and has a",136,"I think it's -- I think -- I'd point to 2 factors. I'm not sure exactly what all our peers are saying about Europe. I think they're probably saying the same thing, which are the European budgets are constrained and funding has not been released, and has actually been withheld in some situations. I also think you may be hearing a more positive spin on the U.S. environment because of many of our competitors have much more business coming from NIH. So there's a lot of positive view of the NIH budget, but we pick up a relatively small piece of that overall budget. The agencies where we do a lot of our business in the U.S. government, we know the money is coming in the fourth quarter. Anything else you'd add to that, Patrick?"
154924,374881090,1036742,"Agilent Technologies, Inc., Q3 2016 Earnings Call, Aug 17, 2016",2016-08-17,"Earnings Calls","Agilent Technologies, Inc.","Executives","Not a lot. And as you said, there's -- a lot of our competitors definitely have also a mixed bag, on average, I would say.",25,"Not a lot. And as you said, there's -- a lot of our competitors definitely have also a mixed bag, on average, I would say."
154924,374881090,1036742,"Agilent Technologies, Inc., Q3 2016 Earnings Call, Aug 17, 2016",2016-08-17,"Earnings Calls","Agilent Technologies, Inc.","Analysts","And then similarly, environmental is flat after growing 6% last quarter. Can you maybe just comment on dynamics there?",19,"And then similarly, environmental is flat after growing 6% last quarter. Can you maybe just comment on dynamics there?"
154924,374881090,1036742,"Agilent Technologies, Inc., Q3 2016 Earnings Call, Aug 17, 2016",2016-08-17,"Earnings Calls","Agilent Technologies, Inc.","Executives","I think the biggest dynamic there is there's a subsegment within environmental as well where we pick up our forensics business. And we report externally just the total environmental business, but a lot of big deal activity in forensics. So last year, we h",104,"I think the biggest dynamic there is there's a subsegment within environmental as well where we pick up our forensics business. And we report externally just the total environmental business, but a lot of big deal activity in forensics. So last year, we had a lot of big deals at this point in time. The overall environmental market has given me big deals in the second quarter. So it's really a forensic-driven phenomena, which is where we didn't have as many big deals in the third quarter. And this business tends to be a little bit more lumpy than our base environmental business."
154924,374881090,1036742,"Agilent Technologies, Inc., Q3 2016 Earnings Call, Aug 17, 2016",2016-08-17,"Earnings Calls","Agilent Technologies, Inc.","Analysts","Okay. And then -- and last one, a little bit of an esoteric question. But on the PD-L1 data sets in frontline lung, can you maybe just talk about whether there's kind of any change in your outlook? Obviously, Bristol attempted to go without a companion an",74,"Okay. And then -- and last one, a little bit of an esoteric question. But on the PD-L1 data sets in frontline lung, can you maybe just talk about whether there's kind of any change in your outlook? Obviously, Bristol attempted to go without a companion and failed. Merck is doing a companion. So can you maybe just talk about whether some of those developments have changed your view of the market opportunity overall?"
154924,374881090,1036742,"Agilent Technologies, Inc., Q3 2016 Earnings Call, Aug 17, 2016",2016-08-17,"Earnings Calls","Agilent Technologies, Inc.","Executives","Sure. Sure, Tycho. In fact, we just had a conversation on this yesterday. So Pat -- I mean, Jacob, why don't you share the latest thoughts from Agilent on this topic?",31,"Sure. Sure, Tycho. In fact, we just had a conversation on this yesterday. So Pat -- I mean, Jacob, why don't you share the latest thoughts from Agilent on this topic?"
154924,374881090,1036742,"Agilent Technologies, Inc., Q3 2016 Earnings Call, Aug 17, 2016",2016-08-17,"Earnings Calls","Agilent Technologies, Inc.","Executives","Yes, I will say, first and foremost, we are very pleased with the performance we have seen on PD-L1 over the last 10 months, and we continue to see strong traction. You're right. There has been some announcement recently on some studies that has not come",120,"Yes, I will say, first and foremost, we are very pleased with the performance we have seen on PD-L1 over the last 10 months, and we continue to see strong traction. You're right. There has been some announcement recently on some studies that has not come out as expected. It really supports our thesis about the importance here of CDx and, really, that you need to make sure you stratify your patient group the right way. So clearly, there is a short-term opportunity, at least from one of our customers that is a little less than we hoped for. But I don't think that, that overall change is really the thesis, and we continue to see a big opportunity here."
154924,374881090,1036742,"Agilent Technologies, Inc., Q3 2016 Earnings Call, Aug 17, 2016",2016-08-17,"Earnings Calls","Agilent Technologies, Inc.","Operator","Our next question comes from the line of Ross Muken from Evercore.",12,"Our next question comes from the line of Ross Muken from Evercore."
154924,374881090,1036742,"Agilent Technologies, Inc., Q3 2016 Earnings Call, Aug 17, 2016",2016-08-17,"Earnings Calls","Agilent Technologies, Inc.","Analysts","So it seems like most of the confusion we're hearing is sort of on the sequential progression of core revenues. And so I look at the last 2 years, and it looks like, sequentially, the comp is roughly, I don't know, 200 basis points easier on core. And it",128,"So it seems like most of the confusion we're hearing is sort of on the sequential progression of core revenues. And so I look at the last 2 years, and it looks like, sequentially, the comp is roughly, I don't know, 200 basis points easier on core. And it looks like you have a little bit heavier of an NMR headwind in 4Q than you did in 3Q. So one, can you confirm that? And then two, as we just think about the crosswalk, what are the other sort of underlying assumptions in terms of what is different sequentially versus 3Q, whether it's end markets or any of the key segments? And then where have you built in, I guess, some conservatism or some of that uncertainty?"
154924,374881090,1036742,"Agilent Technologies, Inc., Q3 2016 Earnings Call, Aug 17, 2016",2016-08-17,"Earnings Calls","Agilent Technologies, Inc.","Executives","Yes. Thanks for the question, Ross. And why don't I go ahead and just share some thoughts about the Q4 guidance. And then, Didier, maybe you can dig through your notes on the NMR impact. But I think it's important for me to share with the audience here to",271,"Yes. Thanks for the question, Ross. And why don't I go ahead and just share some thoughts about the Q4 guidance. And then, Didier, maybe you can dig through your notes on the NMR impact. But I think it's important for me to share with the audience here today about how we thought about our Q4 guidance. I think this may get to the root of some of your questions. As you heard on our call, first of all, we're quite pleased with the higher-than-guided core revenue growth that we delivered for Q3 after having raised last -- in last call. And I think we've got this increased confidence to achieve our previously raised core growth guidance for the year. And listen, we realize by not raising our core guidance for this year that this question could arise. But the way we looked at it, we said, listen, there's a raised level uncertainty in the markets centered around Europe. And we saw some weak European government budgets in the third quarter. Is this going to continue? We've seen some downward revisions in terms of market overall economic forecasts for Europe, so we're really not sure exactly how it's going to develop. So we just thought it's prudent to reflect some of this uncertainty by not raising again the full year guidance. So that's how we thought about the process. We really didn't look over the years sequentially. We do know that last year, though, I said I don't like the tough compare argument, we did have a blowout fourth quarter last year. But anything else, Didier, you can remember unusual or..."
154924,374881090,1036742,"Agilent Technologies, Inc., Q3 2016 Earnings Call, Aug 17, 2016",2016-08-17,"Earnings Calls","Agilent Technologies, Inc.","Executives","No. NMR is not a factor.",6,"No. NMR is not a factor."
154924,374881090,1036742,"Agilent Technologies, Inc., Q3 2016 Earnings Call, Aug 17, 2016",2016-08-17,"Earnings Calls","Agilent Technologies, Inc.","Executives","NMR is not a factor.",5,"NMR is not a factor."
154924,374881090,1036742,"Agilent Technologies, Inc., Q3 2016 Earnings Call, Aug 17, 2016",2016-08-17,"Earnings Calls","Agilent Technologies, Inc.","Executives","You pointed out really what we intended to do is maintain the overall core revenue growth for the whole year, and that's how we derived Q4.",26,"You pointed out really what we intended to do is maintain the overall core revenue growth for the whole year, and that's how we derived Q4."
154924,374881090,1036742,"Agilent Technologies, Inc., Q3 2016 Earnings Call, Aug 17, 2016",2016-08-17,"Earnings Calls","Agilent Technologies, Inc.","Executives","Yes. We'd raised last quarter, and the business is developing in the third quarter actually better than we had thought as you saw in our results. And as we look to the fourth quarter, listen, we don't know how this Europe's going to play out, so let's jus",58,"Yes. We'd raised last quarter, and the business is developing in the third quarter actually better than we had thought as you saw in our results. And as we look to the fourth quarter, listen, we don't know how this Europe's going to play out, so let's just be cautious as opposed to raising again for the quarter."
154924,374881090,1036742,"Agilent Technologies, Inc., Q3 2016 Earnings Call, Aug 17, 2016",2016-08-17,"Earnings Calls","Agilent Technologies, Inc.","Analysts","So that makes total sense to me, Mike. I mean, I think given some of the uncertainty, I certainly don't want to get in front of your skis. And you guys have been beating numbers, so that's good. I guess as you think about the key product cycles for the bu",137,"So that makes total sense to me, Mike. I mean, I think given some of the uncertainty, I certainly don't want to get in front of your skis. And you guys have been beating numbers, so that's good. I guess as you think about the key product cycles for the business, how do you think about the cadence now that you've had some releases of when we could start seeing that also draw up the core growth overall? And then secondarily, when do we start to comp through? We've now, I guess, comp-ed through some easier compares on the Diagnostics business, which has been going hot for, I don't know, 4 or 6 quarters now. How long do you think we've got left on that trajectory of sort of high-single to almost double-digit growth in that business?"
154924,374881090,1036742,"Agilent Technologies, Inc., Q3 2016 Earnings Call, Aug 17, 2016",2016-08-17,"Earnings Calls","Agilent Technologies, Inc.","Executives","I think longer, but I think that for the foreseeable future, we're highly confident on the growth rates in this business. And that's why I made the comment earlier about, hey, when you think about Agilent's long-term growth perspective, if you think about",170,"I think longer, but I think that for the foreseeable future, we're highly confident on the growth rates in this business. And that's why I made the comment earlier about, hey, when you think about Agilent's long-term growth perspective, if you think about '17, think about that we've got over half of our revenue in markets that are going to have a steady trajectory of growth. And you heard Jacob talk about what's going on in the companion diagnostic PD-L1. We talked -- that's why I wanted to highlight the investments we're making in NASD, which is a part of the business we haven't really talked a lot about with you. So I think there are a lot of genomics, there's SureSelect next-gen sequencing. There's a lot of fundamental, very attractive markets we have a strong position in. So Jacob, I don't want to necessarily speak for you, but I guess I have that we expect that this growth rate will be sustained. Anything else you'd add to my story?"
154924,374881090,1036742,"Agilent Technologies, Inc., Q3 2016 Earnings Call, Aug 17, 2016",2016-08-17,"Earnings Calls","Agilent Technologies, Inc.","Executives","You're absolutely right, and I'm definitely pleased with the excellent growth. Last quarter, we had 5%. So I really want to make sure that you saw that we were -- when I -- when we talked also at the Analyst Day, we believe the right -- the direction is 6",80,"You're absolutely right, and I'm definitely pleased with the excellent growth. Last quarter, we had 5%. So I really want to make sure that you saw that we were -- when I -- when we talked also at the Analyst Day, we believe the right -- the direction is 6% to 7%. I'm happy to beat that. But we do not see any change in trajectory right now, and we'll continue in those high single-digit growth rates going forward."
154924,374881090,1036742,"Agilent Technologies, Inc., Q3 2016 Earnings Call, Aug 17, 2016",2016-08-17,"Earnings Calls","Agilent Technologies, Inc.","Executives","And, Ross, I think perhaps your earlier question was around product cycle replacement. Yes. So I think, as you may know, when I came into the role a little over 1.5 years ago, we had really spent a lot of time redirecting our R&D programs. We restructured",188,"And, Ross, I think perhaps your earlier question was around product cycle replacement. Yes. So I think, as you may know, when I came into the role a little over 1.5 years ago, we had really spent a lot of time redirecting our R&D programs. We restructured the company. We reorganized our R&D programs, and I think you're starting to see the cadence. So you've seen some of the product come out. We highlighted earlier on the chromatography side some updates and new products around spectroscopy, ICP-MS. And we know this cadence is going to continue throughout the next quarter and into '17. So that's why when I got the earlier question about, hey, what are you thinking about in terms of '17, I know what's in our road maps, and I know what's coming to the market over the next 12 months. And I know what's already come to the market, and I know how customers are responding. That's why we have this level of confidence about our ability to continue to grow this company in what has been very mixed market conditions, to say the least."
154924,374881090,1036742,"Agilent Technologies, Inc., Q3 2016 Earnings Call, Aug 17, 2016",2016-08-17,"Earnings Calls","Agilent Technologies, Inc.","Operator","Our next question comes from the line of Doug Schenkel from Cowen.",12,"Our next question comes from the line of Doug Schenkel from Cowen."
154924,374881090,1036742,"Agilent Technologies, Inc., Q3 2016 Earnings Call, Aug 17, 2016",2016-08-17,"Earnings Calls","Agilent Technologies, Inc.","Analysts","My first question -- I guess both are going to be on guidance. So for fiscal Q4, your guidance essentially tells us that you're assuming operating margin declines year-over-year in fiscal year Q4 in spite of what seems like could be, I guess mix-wise, a p",81,"My first question -- I guess both are going to be on guidance. So for fiscal Q4, your guidance essentially tells us that you're assuming operating margin declines year-over-year in fiscal year Q4 in spite of what seems like could be, I guess mix-wise, a pretty favorable quarter year-over-year based on your commentary. So keeping that in mind and the fact that you've actually expanded operating margin year-over-year, I believe 6 straight quarters, can you just explain why this makes sense?"
154924,374881090,1036742,"Agilent Technologies, Inc., Q3 2016 Earnings Call, Aug 17, 2016",2016-08-17,"Earnings Calls","Agilent Technologies, Inc.","Executives","Yes. I think you've got the string of consecutive quarters. It's been 6 quarters in a row. And, Didier, we looked at this. I think it's purely volume related, but...",30,"Yes. I think you've got the string of consecutive quarters. It's been 6 quarters in a row. And, Didier, we looked at this. I think it's purely volume related, but..."
154924,374881090,1036742,"Agilent Technologies, Inc., Q3 2016 Earnings Call, Aug 17, 2016",2016-08-17,"Earnings Calls","Agilent Technologies, Inc.","Executives","Yes, absolutely. As same thing for operating margin, our approach -- as for revenue, our approach is we didn't -- we wanted to maintain our full year operating margin because, obviously, it's linked to revenue. So we maintain our core revenue growth assum",141,"Yes, absolutely. As same thing for operating margin, our approach -- as for revenue, our approach is we didn't -- we wanted to maintain our full year operating margin because, obviously, it's linked to revenue. So we maintain our core revenue growth assumption of 4.5% and our operating margin assumption of 20.4%. Now, you are absolutely correct that, that would mean that 50 basis points reduction from the significant operating margin we had in Q4 of last year of 21.5%, still a significant 70 basis point sequential improvement. And you have to take into account, as Mike said, that this is based on only 1.2% top line growth. So a slight reduction in operating margin, still very significant increase sequentially, but slight reduction related to the one -- the assumption that we'd made on the top line growth of only 1.2%."
154924,374881090,1036742,"Agilent Technologies, Inc., Q3 2016 Earnings Call, Aug 17, 2016",2016-08-17,"Earnings Calls","Agilent Technologies, Inc.","Executives","Right. And if we do better on the volume, we'll do better on the margin.",15,"Right. And if we do better on the volume, we'll do better on the margin."
154924,374881090,1036742,"Agilent Technologies, Inc., Q3 2016 Earnings Call, Aug 17, 2016",2016-08-17,"Earnings Calls","Agilent Technologies, Inc.","Analysts","So I guess that's a segue to, I guess, the second guidance question. And I don't mean to be redundant here because there's been a lot of questions on this already. But I'm going to ask anyway. I mean, your guidance is for around 1.2% core revenue growth i",225,"So I guess that's a segue to, I guess, the second guidance question. And I don't mean to be redundant here because there's been a lot of questions on this already. But I'm going to ask anyway. I mean, your guidance is for around 1.2% core revenue growth in the quarter. If we think about this by end market, you actually have an easier compare in environmental forensics, academic government and food relative to certainly what you had in fiscal Q3. Diagnostics is a little tougher, but you have some real momentum there. So if we just, kind of to make it simple, assume all those end markets grow 3% to 5% and that chemical and energy is down mid-singles, it would imply that you guys are thinking pharma is only going to grow low single digits maybe at best in Q4. It's a tough compare in pharma in the quarter, but you've talked about continued strength in pharma in fiscal '17 in response to an earlier question. Again, recognizing the uncertainty you talked about in Europe, this is -- I guess some of this is hard to reconcile. Can you help out a little bit? And specifically again what are you assuming for pharma in the quarter? Is that because of the compare? And what's your assumption for Europe growth in the quarter?"
154924,374881090,1036742,"Agilent Technologies, Inc., Q3 2016 Earnings Call, Aug 17, 2016",2016-08-17,"Earnings Calls","Agilent Technologies, Inc.","Executives","Yes, sure. Glad to walk through this, Doug. In fact, we spent a lot of time modeling our end market views for the rest of the year, anticipating that this might be a question that would arise. And as I recall, Didier, I think that we had a less optimistic",106,"Yes, sure. Glad to walk through this, Doug. In fact, we spent a lot of time modeling our end market views for the rest of the year, anticipating that this might be a question that would arise. And as I recall, Didier, I think that we had a less optimistic view relative to academia and government than I think Doug's math was, where we were seeing -- where we were concerned about Europe. And we had -- we basically have it flat for the year, and I think we still have pharma overall double digits. So if you want to just maybe do a little walk-through?"
154924,374881090,1036742,"Agilent Technologies, Inc., Q3 2016 Earnings Call, Aug 17, 2016",2016-08-17,"Earnings Calls","Agilent Technologies, Inc.","Executives","Yes. The -- maybe, I mean, again, considering how we explained how we came up with the Q4 guidance, the makeup of the Q4 guidance by market in that academic and government and chemical and energy will show the same core revenue growth reduction year-over-",105,"Yes. The -- maybe, I mean, again, considering how we explained how we came up with the Q4 guidance, the makeup of the Q4 guidance by market in that academic and government and chemical and energy will show the same core revenue growth reduction year-over-year as in Q3, so minus 5% for academic and government, minus 4% for chemical and energy. So the assumption is no change between Q3 and Q4. And then for the rest, pharma, you mentioned pharma, we're assuming mid-single digit. And again, on a very tough compare and to -- in line with the way we've been very conservative on the..."
154924,374881090,1036742,"Agilent Technologies, Inc., Q3 2016 Earnings Call, Aug 17, 2016",2016-08-17,"Earnings Calls","Agilent Technologies, Inc.","Executives","Yes. And just to be clear, my comment earlier about double-digit pharma, that's for the full year.",17,"Yes. And just to be clear, my comment earlier about double-digit pharma, that's for the full year."
154924,374881090,1036742,"Agilent Technologies, Inc., Q3 2016 Earnings Call, Aug 17, 2016",2016-08-17,"Earnings Calls","Agilent Technologies, Inc.","Executives","For the full year or -- yes, double digit, absolutely.",10,"For the full year or -- yes, double digit, absolutely."
154924,374881090,1036742,"Agilent Technologies, Inc., Q3 2016 Earnings Call, Aug 17, 2016",2016-08-17,"Earnings Calls","Agilent Technologies, Inc.","Executives","Yes, Doug, maybe just one of -- as we thought about the company coming in, I think we thought that the pharma growth would be lower. We thought China would be lower, and we thought chemical and energy would be higher. And in fact, what's happened is pharm",68,"Yes, Doug, maybe just one of -- as we thought about the company coming in, I think we thought that the pharma growth would be lower. We thought China would be lower, and we thought chemical and energy would be higher. And in fact, what's happened is pharma has actually been stronger, and China is stronger than initially forecasted. And you know the story on chemical and energy."
154924,374881090,1036742,"Agilent Technologies, Inc., Q3 2016 Earnings Call, Aug 17, 2016",2016-08-17,"Earnings Calls","Agilent Technologies, Inc.","Analysts","Okay. The only thing I don't think we got there was just -- and maybe I missed it. But what is the assumption for Europe in the quarter?",28,"Okay. The only thing I don't think we got there was just -- and maybe I missed it. But what is the assumption for Europe in the quarter?"
154924,374881090,1036742,"Agilent Technologies, Inc., Q3 2016 Earnings Call, Aug 17, 2016",2016-08-17,"Earnings Calls","Agilent Technologies, Inc.","Executives","It's about flattish, down low-single digits, mostly on the basis of chemical and energy.",15,"It's about flattish, down low-single digits, mostly on the basis of chemical and energy."
154924,374881090,1036742,"Agilent Technologies, Inc., Q3 2016 Earnings Call, Aug 17, 2016",2016-08-17,"Earnings Calls","Agilent Technologies, Inc.","Executives","Yes. And the academia and government.",6,"Yes. And the academia and government."
154924,374881090,1036742,"Agilent Technologies, Inc., Q3 2016 Earnings Call, Aug 17, 2016",2016-08-17,"Earnings Calls","Agilent Technologies, Inc.","Executives","And academia and government, yes.",5,"And academia and government, yes."
154924,374881090,1036742,"Agilent Technologies, Inc., Q3 2016 Earnings Call, Aug 17, 2016",2016-08-17,"Earnings Calls","Agilent Technologies, Inc.","Operator","Our next question comes from the line of Tim Evans from Wells Fargo Securities.",14,"Our next question comes from the line of Tim Evans from Wells Fargo Securities."
154924,374881090,1036742,"Agilent Technologies, Inc., Q3 2016 Earnings Call, Aug 17, 2016",2016-08-17,"Earnings Calls","Agilent Technologies, Inc.","Analysts","This one's for Didier. It seems like cash flow is something that's going better than expectations or better than our expectations at least. Wondered if you could talk a little bit about the remaining levers that you have to pull on that as you go into 201",86,"This one's for Didier. It seems like cash flow is something that's going better than expectations or better than our expectations at least. Wondered if you could talk a little bit about the remaining levers that you have to pull on that as you go into 2017. Do you think that free cash flow growth in 2017 is really just going to be a matter of earnings growth? Or is there more than you can do there to improve free cash flow faster than earnings?"
154924,374881090,1036742,"Agilent Technologies, Inc., Q3 2016 Earnings Call, Aug 17, 2016",2016-08-17,"Earnings Calls","Agilent Technologies, Inc.","Executives","Yes. There is more that we can do. Certainly, the profit before tax is going to be a factor. But Henrik, who heads our order fulfillment and the supply chain organization has also committed to a material decrease in inventories.",40,"Yes. There is more that we can do. Certainly, the profit before tax is going to be a factor. But Henrik, who heads our order fulfillment and the supply chain organization has also committed to a material decrease in inventories."
154924,374881090,1036742,"Agilent Technologies, Inc., Q3 2016 Earnings Call, Aug 17, 2016",2016-08-17,"Earnings Calls","Agilent Technologies, Inc.","Executives","And he's here in the room to hear that directly.",11,"And he's here in the room to hear that directly."
154924,374881090,1036742,"Agilent Technologies, Inc., Q3 2016 Earnings Call, Aug 17, 2016",2016-08-17,"Earnings Calls","Agilent Technologies, Inc.","Executives","So that is also something that we are counting on that will help us continue expanding our operating cash flow as a percentage of revenue or percentage of profits.",29,"So that is also something that we are counting on that will help us continue expanding our operating cash flow as a percentage of revenue or percentage of profits."
154924,374881090,1036742,"Agilent Technologies, Inc., Q3 2016 Earnings Call, Aug 17, 2016",2016-08-17,"Earnings Calls","Agilent Technologies, Inc.","Analysts","Okay. And then a quick one, going back to one of Tycho's questions on the forensics end market. Of that 12% slice of pie that's environmental and forensics, would you be willing to tell us how much is forensics?",39,"Okay. And then a quick one, going back to one of Tycho's questions on the forensics end market. Of that 12% slice of pie that's environmental and forensics, would you be willing to tell us how much is forensics?"
154924,374881090,1036742,"Agilent Technologies, Inc., Q3 2016 Earnings Call, Aug 17, 2016",2016-08-17,"Earnings Calls","Agilent Technologies, Inc.","Executives","I don't think we disclose that and it's fairly small but enough to move it directly when big deals happen.",21,"I don't think we disclose that and it's fairly small but enough to move it directly when big deals happen."
154924,374881090,1036742,"Agilent Technologies, Inc., Q3 2016 Earnings Call, Aug 17, 2016",2016-08-17,"Earnings Calls","Agilent Technologies, Inc.","Operator","Our next question comes from the line of Isaac Ro from Goldman Sachs.",13,"Our next question comes from the line of Isaac Ro from Goldman Sachs."
154924,374881090,1036742,"Agilent Technologies, Inc., Q3 2016 Earnings Call, Aug 17, 2016",2016-08-17,"Earnings Calls","Agilent Technologies, Inc.","Analysts","Just had a question on margins and then a follow-up on Europe. On the margin side, if I look at sort of the components of gross margin, it's interesting that the LSAG division is your highest gross margin segment in most quarters, but that was one where y",88,"Just had a question on margins and then a follow-up on Europe. On the margin side, if I look at sort of the components of gross margin, it's interesting that the LSAG division is your highest gross margin segment in most quarters, but that was one where you saw a little pressure. So can you help us think a little bit about kind of the key initiatives you guys have under the hood there to continue driving better gross margin versus expectations and same goes through SG&A?"
154924,374881090,1036742,"Agilent Technologies, Inc., Q3 2016 Earnings Call, Aug 17, 2016",2016-08-17,"Earnings Calls","Agilent Technologies, Inc.","Executives","The question was what are the initiatives we have? I just want to make sure I understood the question.",19,"The question was what are the initiatives we have? I just want to make sure I understood the question."
154924,374881090,1036742,"Agilent Technologies, Inc., Q3 2016 Earnings Call, Aug 17, 2016",2016-08-17,"Earnings Calls","Agilent Technologies, Inc.","Analysts","Yes. Over the last, I don't know, 12 or 18 months, you guys talked a lot about some of the things you're doing to drive gross margin higher. This particular quarter, you had a little weakness in your most profitable segment. So I'm wondering kind of, asid",77,"Yes. Over the last, I don't know, 12 or 18 months, you guys talked a lot about some of the things you're doing to drive gross margin higher. This particular quarter, you had a little weakness in your most profitable segment. So I'm wondering kind of, aside from just the top line contribution, what you guys were able to achieve this quarter on the gross margin line that allowed you to put up a slightly better result."
154924,374881090,1036742,"Agilent Technologies, Inc., Q3 2016 Earnings Call, Aug 17, 2016",2016-08-17,"Earnings Calls","Agilent Technologies, Inc.","Executives","Great, great. Thanks for the question. So what we've been focusing on are really 3 dimensions around what we call our value-engineering program, our logistics model and also our strategic procurement approach with our suppliers. And as I look at the resul",427,"Great, great. Thanks for the question. So what we've been focusing on are really 3 dimensions around what we call our value-engineering program, our logistics model and also our strategic procurement approach with our suppliers. And as I look at the results in '16, the program that Henrik is driving across this company, I think we probably have seen the biggest impact so far in our improved logistics model. And you may recall we talked about logistics costs as being problematic in 2015. That's no longer the case. In fact, we've benchmarked ourselves, and we've got ourselves down to the best in our space. And there actually is more to come, which is the other 2 elements of the program have a little bit more longer tail in terms of payoff, which is value engineering, when you're reengineering product platforms to ensure both the continuation of the high performance but at a lower cost. And then as we also continue to transform our supplier engagement model and how we leverage the scale of Agilent. So I think those latter 2 parts of the program are going to carry us forward into '17 and '18 beyond, so I think that's how we're really working the gross margin side. And by the way, I also [indiscernible] of your comments were focused on LSAG. A lot of logistics costs and some of these other factors I mentioned, procurement, show up as impacts on the DDG and ACG business as well. And then relative to the SG&A, a couple of things that you may recall I highlighted in New York and I just reemphasize again, major focus on our systems infrastructure. So as you heard in my prepared remarks, we're now on one SAP instance, simplifying a lot of our work for our financial team and taking a lot of cost out of the system. The next big wave will be when we move the former Dako company into the Agilent environment in 2017 where we can really start to leverage the scale and take out costs and have an improved customer experience there. So there's a couple of big initiatives as well as we look at -- we're looking at other aspects of our benefit structure as we made some change, as you may know, earlier to our U.S. pension plan and the Agile Agilent program I mentioned is live. And we have a lot of initiatives underway to ensure that we can continue to take costs out while simplifying the company. Didier, anything else you would add to that?"
154924,374881090,1036742,"Agilent Technologies, Inc., Q3 2016 Earnings Call, Aug 17, 2016",2016-08-17,"Earnings Calls","Agilent Technologies, Inc.","Executives","I'd just mention the currency hedging. It had a big impact. It will have a big impact on a year-over-year basis. It's all impacts to gross margin. And ACG and DGG, because of their footprint, have been more penalized. So ACG on a year-over-year basis lost",97,"I'd just mention the currency hedging. It had a big impact. It will have a big impact on a year-over-year basis. It's all impacts to gross margin. And ACG and DGG, because of their footprint, have been more penalized. So ACG on a year-over-year basis lost $6 million in gross margin just because of the hedging programs; and DGG, $2 million. So that also explains the difference between ACG, DGG and LSAG. LSAG has a different footprint, obviously with a stronger presence in Europe, for example. And so that can distort a little bit the percentages."
154924,374881090,1036742,"Agilent Technologies, Inc., Q3 2016 Earnings Call, Aug 17, 2016",2016-08-17,"Earnings Calls","Agilent Technologies, Inc.","Analysts","That's helpful. Let me just follow-up on Europe. I want to make sure I understand kind of how -- what you're seeing now in that respect to the guidance end. So 2 items there. One is did the weakness in Europe, did that pick up in the month of July, just g",89,"That's helpful. Let me just follow-up on Europe. I want to make sure I understand kind of how -- what you're seeing now in that respect to the guidance end. So 2 items there. One is did the weakness in Europe, did that pick up in the month of July, just given you guys are off calendar versus the peer group? And secondly, does your guidance assume that the academic end market in Europe weakens further as the year progresses or that it sort of stabilizes from here?"
154924,374881090,1036742,"Agilent Technologies, Inc., Q3 2016 Earnings Call, Aug 17, 2016",2016-08-17,"Earnings Calls","Agilent Technologies, Inc.","Executives","Yes. So nothing unusual in July, and I think the assumption of the Q4 is basically a continuation, not any worse but not any better. And we just thought that was a prudent way to think about the company's performance fourth quarter. I would love to be wro",77,"Yes. So nothing unusual in July, and I think the assumption of the Q4 is basically a continuation, not any worse but not any better. And we just thought that was a prudent way to think about the company's performance fourth quarter. I would love to be wrong, and I hope I'm wrong. But we thought from a planning and guidance standpoint, we should be prudent in terms of how we looked at the European market overall."
154924,374881090,1036742,"Agilent Technologies, Inc., Q3 2016 Earnings Call, Aug 17, 2016",2016-08-17,"Earnings Calls","Agilent Technologies, Inc.","Operator","Our next question comes from the line of Derik De Bruin from Bank of America.",15,"Our next question comes from the line of Derik De Bruin from Bank of America."
154924,374881090,1036742,"Agilent Technologies, Inc., Q3 2016 Earnings Call, Aug 17, 2016",2016-08-17,"Earnings Calls","Agilent Technologies, Inc.","Analysts","So a lot of the revenue questions have been asked. And I mean, it certainly seems prudent to me your guidance, just given that Europe, even under a good -- even in a good year, this -- the calendar third quarter is always a little bit choppy anyway, so th",119,"So a lot of the revenue questions have been asked. And I mean, it certainly seems prudent to me your guidance, just given that Europe, even under a good -- even in a good year, this -- the calendar third quarter is always a little bit choppy anyway, so there's clearly some heightened uncertainty this year. So I think it's prudent to be a little bit conservative. But could you just talk a bit about some of the -- I noticed the share count was a little bit higher this quarter than what you previously guided to. Are you still looking at buying back 1% of the outstanding shares as we sort of go into the -- going forward?"
154924,374881090,1036742,"Agilent Technologies, Inc., Q3 2016 Earnings Call, Aug 17, 2016",2016-08-17,"Earnings Calls","Agilent Technologies, Inc.","Executives","Yes. Why don't you talk a little bit about the -- our share repurchase activity in the quarter and how we're thinking about it going forward, Didier?",27,"Yes. Why don't you talk a little bit about the -- our share repurchase activity in the quarter and how we're thinking about it going forward, Didier?"
154924,374881090,1036742,"Agilent Technologies, Inc., Q3 2016 Earnings Call, Aug 17, 2016",2016-08-17,"Earnings Calls","Agilent Technologies, Inc.","Executives","Yes. We filed back in, what, November 20, I think, of last year a 10b5-1 on an annual basis, and we intend to file a new one, to register a new one also in November of this year. And it's a formula-based instructions that we have provided between buying 3",133,"Yes. We filed back in, what, November 20, I think, of last year a 10b5-1 on an annual basis, and we intend to file a new one, to register a new one also in November of this year. And it's a formula-based instructions that we have provided between buying 350,000 shares a day under certain conditions to buying 0 kind of thing with a cap as you can imagine. So we don't know exactly how it's going to play out in Q4. And the only thing that we know is that if there's any kind of shortfall at all in our intended buying in Q4 because of the formula in the 10b5-1, it will all be carried over into the following year. So we intend to spend exactly what we committed to spend."
154924,374881090,1036742,"Agilent Technologies, Inc., Q3 2016 Earnings Call, Aug 17, 2016",2016-08-17,"Earnings Calls","Agilent Technologies, Inc.","Analysts","Great. That's really helpful. And could you just give us a metric on what instruments versus consumable growth was in the quarter as an overall number for the company?",29,"Great. That's really helpful. And could you just give us a metric on what instruments versus consumable growth was in the quarter as an overall number for the company?"
154924,374881090,1036742,"Agilent Technologies, Inc., Q3 2016 Earnings Call, Aug 17, 2016",2016-08-17,"Earnings Calls","Agilent Technologies, Inc.","Executives","I think probably the best way to think about it is just look at the respective business groups. So you have the LSAG results of down 2%, and then the...",30,"I think probably the best way to think about it is just look at the respective business groups. So you have the LSAG results of down 2%, and then the..."
154924,374881090,1036742,"Agilent Technologies, Inc., Q3 2016 Earnings Call, Aug 17, 2016",2016-08-17,"Earnings Calls","Agilent Technologies, Inc.","Executives","ACG up 8%; and DGG, up 8% also.",9,"ACG up 8%; and DGG, up 8% also."
154924,374881090,1036742,"Agilent Technologies, Inc., Q3 2016 Earnings Call, Aug 17, 2016",2016-08-17,"Earnings Calls","Agilent Technologies, Inc.","Executives","And Dako. So minus 2%, plus 8%. And that's why I -- again, as you think about '17 for the company, if you really want to look at the growth rates of those 2 business units in the recurring revenue space, ACG and DGG, perhaps differently than you might thi",67,"And Dako. So minus 2%, plus 8%. And that's why I -- again, as you think about '17 for the company, if you really want to look at the growth rates of those 2 business units in the recurring revenue space, ACG and DGG, perhaps differently than you might think about how you model the risk profile for revenue projections for the instruments side of the company."
154924,374881090,1036742,"Agilent Technologies, Inc., Q3 2016 Earnings Call, Aug 17, 2016",2016-08-17,"Earnings Calls","Agilent Technologies, Inc.","Analysts","Great. That's really helpful. And I guess, could you -- when you sort of -- you're still feeling good about the margin target for '17, and it sounds like that your IT initiatives are well underway or finished to do like that. Are you -- do you still feel",62,"Great. That's really helpful. And I guess, could you -- when you sort of -- you're still feeling good about the margin target for '17, and it sounds like that your IT initiatives are well underway or finished to do like that. Are you -- do you still feel confident about getting what you're expecting for next year for the margin improvement?"
154924,374881090,1036742,"Agilent Technologies, Inc., Q3 2016 Earnings Call, Aug 17, 2016",2016-08-17,"Earnings Calls","Agilent Technologies, Inc.","Executives","Yes, absolutely. So that's why I made a few comments about it earlier because as we said, if we can be in a 4.5%, 5% kind of growth range, perhaps even low 4%, it makes it a little bit more challenging. But we can see -- we see the path to 22%. It's not j",218,"Yes, absolutely. So that's why I made a few comments about it earlier because as we said, if we can be in a 4.5%, 5% kind of growth range, perhaps even low 4%, it makes it a little bit more challenging. But we can see -- we see the path to 22%. It's not just around margins. I mean, especially not just around margin improvement from volume. But there are specific real programs. It's something we review once a month, then we have active programs, and the costs will continue to come out on some of these big programs. Actually, I must say I'm really pleased with the team because we've -- we went through and did the -- we call project Nunu [ph] is the finance program we just finished up. And then right on the heels of that, we're going to go live in early '17 with our integration of Dako. So the teams are still energized and working hard, and I think these are going to have a material impact on our results in '17. And that's why we have confidence about the -- assuming no major change in terms of the macro environment that we can reach what we think are pretty challenging goals, but they're -- we've got a path to get there."
154924,374881090,1036742,"Agilent Technologies, Inc., Q3 2016 Earnings Call, Aug 17, 2016",2016-08-17,"Earnings Calls","Agilent Technologies, Inc.","Operator","Our next question comes from the line of Dan Arias from Citigroup.",12,"Our next question comes from the line of Dan Arias from Citigroup."
154924,374881090,1036742,"Agilent Technologies, Inc., Q3 2016 Earnings Call, Aug 17, 2016",2016-08-17,"Earnings Calls","Agilent Technologies, Inc.","Analysts","Patrick, just going back to your comments on share gains in LC. I know you guys don't like to get too specific on winners and losers. But as was mentioned, it does look like all of the major players are doing fairly well there. So who would you say you're",72,"Patrick, just going back to your comments on share gains in LC. I know you guys don't like to get too specific on winners and losers. But as was mentioned, it does look like all of the major players are doing fairly well there. So who would you say you're taking share from? Is it the small column providers or does that actually extend into some of the box companies as well?"
154924,374881090,1036742,"Agilent Technologies, Inc., Q3 2016 Earnings Call, Aug 17, 2016",2016-08-17,"Earnings Calls","Agilent Technologies, Inc.","Executives","Well, I -- thanks for the question. I can give you only a general flavor here on what we think is going on in the market. I will not comment on the individual competitors, but your assumption that the smaller suppliers probably take a larger hit is also o",50,"Well, I -- thanks for the question. I can give you only a general flavor here on what we think is going on in the market. I will not comment on the individual competitors, but your assumption that the smaller suppliers probably take a larger hit is also our observation."
154924,374881090,1036742,"Agilent Technologies, Inc., Q3 2016 Earnings Call, Aug 17, 2016",2016-08-17,"Earnings Calls","Agilent Technologies, Inc.","Analysts","Okay. And then maybe a specific one on C&E. Mike, at the Analyst Day, you called out a Saudi Arabian refinery build-out that was getting going. Have you started to see some demand there? And is that something that you think contributes at all to the back",51,"Okay. And then maybe a specific one on C&E. Mike, at the Analyst Day, you called out a Saudi Arabian refinery build-out that was getting going. Have you started to see some demand there? And is that something that you think contributes at all to the back half of the year?"
154924,374881090,1036742,"Agilent Technologies, Inc., Q3 2016 Earnings Call, Aug 17, 2016",2016-08-17,"Earnings Calls","Agilent Technologies, Inc.","Executives","The major projects that were underway haven't been canceled, so -- but we're not seeing any major new projects underway. There's a lot of -- there's actually a lot of positive news by a lot of studies about where this market's going, but we're not seeing",156,"The major projects that were underway haven't been canceled, so -- but we're not seeing any major new projects underway. There's a lot of -- there's actually a lot of positive news by a lot of studies about where this market's going, but we're not seeing -- what we're -- just to clarify here, the major project that we knew about, whether it be the one I mentioned in Saudi or the -- there's a major project down in Texas. These programs, they're going to come online. So people aren't canceling capacity increase projects, but we're not seeing a lot of new projects. And that's why we have taken a fairly conservative -- probably be a bit pragmatic view of that marketplace. Again, I would remind everybody, too, that when we talk about chemical and energy, 50% or so is actually chemicals -- chemical processing not directly tied to the exploration and production of oil."
154924,374881090,1036742,"Agilent Technologies, Inc., Q3 2016 Earnings Call, Aug 17, 2016",2016-08-17,"Earnings Calls","Agilent Technologies, Inc.","Operator","Our next question comes from the line of Paul Knight from Janney Montgomery Scott.",14,"Our next question comes from the line of Paul Knight from Janney Montgomery Scott."
154924,374881090,1036742,"Agilent Technologies, Inc., Q3 2016 Earnings Call, Aug 17, 2016",2016-08-17,"Earnings Calls","Agilent Technologies, Inc.","Analysts","I guess specifically what is the GC business doing? What's its growth rate? What was it doing in the July quarter? And what's the backlog or what are the -- what's July or August look like, I guess?",38,"I guess specifically what is the GC business doing? What's its growth rate? What was it doing in the July quarter? And what's the backlog or what are the -- what's July or August look like, I guess?"
154924,374881090,1036742,"Agilent Technologies, Inc., Q3 2016 Earnings Call, Aug 17, 2016",2016-08-17,"Earnings Calls","Agilent Technologies, Inc.","Executives","Well, thanks, Paul, I appreciate the question. As you probably will understand, I'll give you more a high-level result because we don't actually comment specifically at a product category level, beyond, I think, I would just reemphasize the point that Pat",135,"Well, thanks, Paul, I appreciate the question. As you probably will understand, I'll give you more a high-level result because we don't actually comment specifically at a product category level, beyond, I think, I would just reemphasize the point that Patrick made when he characterized the chromatography market. That business is down relative to last year because the chemical and energy market is down. And we have seen no movement at all, downward pressure on our share position. It's really a market phenomena we're dealing with right now. And that's why when that replacement market does turn, and we've been through these cycles before, when it does turn, we'll be in a strong position to capture that growth as given the strength of our position in that market, which right now happens to be down."
154924,374881090,1036742,"Agilent Technologies, Inc., Q3 2016 Earnings Call, Aug 17, 2016",2016-08-17,"Earnings Calls","Agilent Technologies, Inc.","Analysts","And then last, on the applied markets in a broader sense, do you think it's still a GDP growth rate normalized or what do you think the applied markets should be for Agilent?",33,"And then last, on the applied markets in a broader sense, do you think it's still a GDP growth rate normalized or what do you think the applied markets should be for Agilent?"
154924,374881090,1036742,"Agilent Technologies, Inc., Q3 2016 Earnings Call, Aug 17, 2016",2016-08-17,"Earnings Calls","Agilent Technologies, Inc.","Executives","We actually don't think about it that way because the segments that -- or big segments of the market like your food and environmental testing, we think are independent to some extent of GDP. So the only way I think that we really think about that as relat",152,"We actually don't think about it that way because the segments that -- or big segments of the market like your food and environmental testing, we think are independent to some extent of GDP. So the only way I think that we really think about that as relative to is our chemical and energy space. So if you could just kind of think about tying GDP to that subsegment of the company, I think that's -- would be good place to start. But I would not apply it to the whole what we call Applied Markets because these are being driven by quality-of-life investments in the food and environmental area. And I think that's why -- I think this composition of our end markets is the reason why we're being able to put up these kind of growth rates even when our #2 market as a company has shrunk this year."
154924,374881090,1036742,"Agilent Technologies, Inc., Q3 2016 Earnings Call, Aug 17, 2016",2016-08-17,"Earnings Calls","Agilent Technologies, Inc.","Analysts","And then last on -- you had your Analyst Day, obviously. You've been talking about a 22% operating margin. Are you more or less confident in that number for FY '17 at this juncture?",34,"And then last on -- you had your Analyst Day, obviously. You've been talking about a 22% operating margin. Are you more or less confident in that number for FY '17 at this juncture?"
154924,374881090,1036742,"Agilent Technologies, Inc., Q3 2016 Earnings Call, Aug 17, 2016",2016-08-17,"Earnings Calls","Agilent Technologies, Inc.","Executives","Yes. I think the confidence level is the same as it was back in May. And again, I'd maybe just share a few points here, which as you know, we have this confidence of delivery on that given our belief that we can get that growth rate that we're putting up",274,"Yes. I think the confidence level is the same as it was back in May. And again, I'd maybe just share a few points here, which as you know, we have this confidence of delivery on that given our belief that we can get that growth rate that we're putting up growth rates right now in that territory. We've got this pipeline of new products coming out. We've got this nice recurring revenue stream with ACG and DDG that will carry this momentum into '17 and that where our instrument business is going, hey, pharma looks -- still looks good. Of course, you have these double-digit compare issues. China looks to continue to be strong. And chemical and energy has got to turn at some point in time because the market requires these tools to support production. Our thinking is when we look at chemical and energy is we know our customers are looking for productivity improvements to help improve their company profitability. We think that's a value proposition that Agilent has. We think as they go through their budget justification processes and their budgets start in calendar 2017, that this is why we can say, ""Listen, the decline in this business after 18 to 24 months will start to turn,"" and we could see low single digits by the end of 2017 for the chemical and energy market. If that happens, which we believe it will, that will give us the confidence to get the growth and then we know we'll get the margin, given both the volume but also in terms of gross margin improvement initiatives as well as our SG&A cost."
154924,374881090,1036742,"Agilent Technologies, Inc., Q3 2016 Earnings Call, Aug 17, 2016",2016-08-17,"Earnings Calls","Agilent Technologies, Inc.","Operator","And our final question today comes from the line of Catherine Ramsey from Robert W. Baird.",16,"And our final question today comes from the line of Catherine Ramsey from Robert W. Baird."
154924,374881090,1036742,"Agilent Technologies, Inc., Q3 2016 Earnings Call, Aug 17, 2016",2016-08-17,"Earnings Calls","Agilent Technologies, Inc.","Analysts","We've heard a lot of commentary from your peers on Japan; strong pharma environment, weak academic government. So I was wondering if you could walk through your exposure by end market there and what you're seeing across those customer groups.",41,"We've heard a lot of commentary from your peers on Japan; strong pharma environment, weak academic government. So I was wondering if you could walk through your exposure by end market there and what you're seeing across those customer groups."
154924,374881090,1036742,"Agilent Technologies, Inc., Q3 2016 Earnings Call, Aug 17, 2016",2016-08-17,"Earnings Calls","Agilent Technologies, Inc.","Executives","Didier, do you remember the total Japan numbers? I think were...",11,"Didier, do you remember the total Japan numbers? I think were..."
154924,374881090,1036742,"Agilent Technologies, Inc., Q3 2016 Earnings Call, Aug 17, 2016",2016-08-17,"Earnings Calls","Agilent Technologies, Inc.","Executives","About 5% of overall...",4,"About 5% of overall..."
154924,374881090,1036742,"Agilent Technologies, Inc., Q3 2016 Earnings Call, Aug 17, 2016",2016-08-17,"Earnings Calls","Agilent Technologies, Inc.","Executives","5%. Yes, just to give you a sense of -- 5% of the total market. Historically, we've been stronger, and I can share this from my experience having been the country manager for Japan for a few years in the early part of my career. We tend to be much stronge",137,"5%. Yes, just to give you a sense of -- 5% of the total market. Historically, we've been stronger, and I can share this from my experience having been the country manager for Japan for a few years in the early part of my career. We tend to be much stronger in the chemical and energy segment of that marketplace. We are doing well in the life science research and in genomics, but the majority of the business sits in the chemical and energy space, which is -- which has been down. I think Japan has been part of that story. Pharma, the pharma business for us is a relatively smaller portion of the market for us. I think they're doing well in pharma but not enough to really drive significant overall growth rates for Japan."
154924,374881090,1036742,"Agilent Technologies, Inc., Q3 2016 Earnings Call, Aug 17, 2016",2016-08-17,"Earnings Calls","Agilent Technologies, Inc.","Analysts","Okay, great. And then any color on the progress of Dako integration? What's left to do there? Had some nice op margin expansion in DGG this quarter, so are you still thinking that 20% in fiscal '17 or could there be upside to that number?",45,"Okay, great. And then any color on the progress of Dako integration? What's left to do there? Had some nice op margin expansion in DGG this quarter, so are you still thinking that 20% in fiscal '17 or could there be upside to that number?"
154924,374881090,1036742,"Agilent Technologies, Inc., Q3 2016 Earnings Call, Aug 17, 2016",2016-08-17,"Earnings Calls","Agilent Technologies, Inc.","Executives","Jacob happens to be sitting right next to me in this conference room. I don't think he's ready to sign up for more than 20% because it is quite a improvement from where we started. But I think he remains quite confident in the 20% achievement of that goal",186,"Jacob happens to be sitting right next to me in this conference room. I don't think he's ready to sign up for more than 20% because it is quite a improvement from where we started. But I think he remains quite confident in the 20% achievement of that goal of an O&M perspective. You saw we had 18.8% operating margin this quarter, 200 basis points over last year. And the big next wave of integration efforts will really be starting in our Q1 '17, So we have a major program we call it project de Gaulle [ph]. We seem to like a lot of these French names, Didier. I'm not sure why that may be the case, but -- and that really will be the next big step to move the former Dako company into the Agilent environment. And it will take a little bit of while to get the cost out, but as you go -- as you think about exiting '17, you're going to have a much lower SG&A spend than you started the year. And, Jacob, I don't think you'd share anything else?"
154924,374881090,1036742,"Agilent Technologies, Inc., Q3 2016 Earnings Call, Aug 17, 2016",2016-08-17,"Earnings Calls","Agilent Technologies, Inc.","Executives","No. I think you captured it correctly. I just want to reinforce what you said, that the path to 20%, actually delivering 20% in 2017 is a significant turnaround of where we were a few years ago. So right now, that's our full aim, and I'm very happy where",57,"No. I think you captured it correctly. I just want to reinforce what you said, that the path to 20%, actually delivering 20% in 2017 is a significant turnaround of where we were a few years ago. So right now, that's our full aim, and I'm very happy where the team is and executing this right now."
154924,374881090,1036742,"Agilent Technologies, Inc., Q3 2016 Earnings Call, Aug 17, 2016",2016-08-17,"Earnings Calls","Agilent Technologies, Inc.","Executives","Thanks, Jacob.",2,"Thanks, Jacob."
154924,374881090,1036742,"Agilent Technologies, Inc., Q3 2016 Earnings Call, Aug 17, 2016",2016-08-17,"Earnings Calls","Agilent Technologies, Inc.","Operator","And this does conclude the question-and-answer session of today's program. I'd like to hand the program back to Alicia Rodriguez for any further remarks.",25,"And this does conclude the question-and-answer session of today's program. I'd like to hand the program back to Alicia Rodriguez for any further remarks."
154924,374881090,1036742,"Agilent Technologies, Inc., Q3 2016 Earnings Call, Aug 17, 2016",2016-08-17,"Earnings Calls","Agilent Technologies, Inc.","Executives","Thank you, Jonathan. And on behalf of the entire management team, I'd like to thank everybody for joining us today. If you have any questions, please give us a call at IR. Thanks again. Bye-bye.",35,"Thank you, Jonathan. And on behalf of the entire management team, I'd like to thank everybody for joining us today. If you have any questions, please give us a call at IR. Thanks again. Bye-bye."
154924,374881090,1036742,"Agilent Technologies, Inc., Q3 2016 Earnings Call, Aug 17, 2016",2016-08-17,"Earnings Calls","Agilent Technologies, Inc.","Operator","Thank you, ladies and gentlemen, for your participation in today's conference. This does conclude the program. You may now disconnect. Good day.",22,"Thank you, ladies and gentlemen, for your participation in today's conference. This does conclude the program. You may now disconnect. Good day."
154924,374881090,1037210,"Agilent Technologies, Inc., Q3 2016 Earnings Call, Aug 17, 2016",2016-08-17,"Earnings Calls","Agilent Technologies, Inc.","Operator","Good day ladies and gentlemen, and welcome to the Third Quarter 2016 Agilent Technologies Earnings Conference Call. [Operator Instructions] As a reminder, today's program is being recorded. I would now like to introduce your host for today's program, Al",48,"Good day ladies and gentlemen, and welcome to the Third Quarter 2016 Agilent Technologies Earnings Conference Call. [Operator Instructions] As a reminder, today's program is being recorded. 
I would now like to introduce your host for today's program, Alicia Rodriguez, Vice President of Investor Relations. Please go ahead."
154924,374881090,1037210,"Agilent Technologies, Inc., Q3 2016 Earnings Call, Aug 17, 2016",2016-08-17,"Earnings Calls","Agilent Technologies, Inc.","Executives","Thank you, Jonathan, and welcome, everyone, to Agilent's Third Quarter Conference Call for Fiscal Year 2016. With me are Mike McMullen, Agilent's President and CEO; and Didier Hirsch, Agilent's Vice -- Senior Vice President and CFO.Joining in the Q&A af",342,"Thank you, Jonathan, and welcome, everyone, to Agilent's Third Quarter Conference Call for Fiscal Year 2016. With me are Mike McMullen, Agilent's President and CEO; and Didier Hirsch, Agilent's Vice -- Senior Vice President and CFO.
Joining in the Q&A after Didier's comments will be Patrick Kaltenbach, President of Agilent's Life Sciences and Applied Markets Group; Jacob Thaysen, President of Agilent's Diagnostics and Genomics Group; and Mark Doak, President of the Agilent CrossLab Group.
You can find the press release and information to supplement today's discussion on our website at www.investor.agilent.com. While there, please click on the link for financial results under the Financial Information tab. You will find an investor presentation along with revenue breakouts and currency impacts, business segment results and historical financials for Agilent's operations. We will also post a copy of the prepared remarks following this call. 
Today's comments by Mike and Didier will refer to non-GAAP financial measures. You will find the most directly comparable GAAP financial metrics and reconciliations on our website. We will refer to core revenue growth, which excludes the impact of currency, the NMR business and acquisitions and divestitures within the past 12 months. 
Please note that we are reporting results for the Americas, Europe and Asia on a ship-to basis. Previously, we assigned revenue to these regions based on where the order was placed. This change aligns with individual country reporting, which has always been on a ship-to basis. Historical restatements are available on the Investor Relations website. 
Unless otherwise noted, all references to increases or decreases in financial metrics are year-over-year. Guidance is based on exchange rates as of the last day of the reported quarter. 
We will also make forward-looking statements about the financial performance of the company. These statements are subject to risks and uncertainties and are only valid as of today. The company assumes no obligation to update them. Please look at the company's recent SEC filings for a more complete picture of our risks and other factors. 
And now let me turn the call over to Mike."
154924,374881090,1037210,"Agilent Technologies, Inc., Q3 2016 Earnings Call, Aug 17, 2016",2016-08-17,"Earnings Calls","Agilent Technologies, Inc.","Executives","Thanks, Alicia, and hello, everyone. Thank you for joining us on today's call. I'm pleased to report that the Agilent team delivered another quarter above expectations. Now let me highlight 3 key results: First, core -- Q3 core revenue growth of 3% was",1442,"Thanks, Alicia, and hello, everyone. Thank you for joining us on today's call. I'm pleased to report that the Agilent team delivered another quarter above expectations. 
Now let me highlight 3 key results: First, core -- Q3 core revenue growth of 3% was above the high end of our May guidance. Second, EPS of $0.49 was also above the high end of our guidance of $0.45 to $0.47. Finally, we delivered adjusted operating margin of 20.6%, an increase of 70 basis points from a year ago. 
Agilent's third quarter results echo many of the same themes that we saw last quarter. The pharma, food, clinical and diagnostics end markets remain strong. In the chemical and energy market, while demand for our services and consumables was strong, capital expenditures for new equipment purchases remain challenged. Geographically, Asia, led by China's double-digit growth, drove Agilent third quarter core growth with strength across all business segments. 
Let me highlight our Q3 results by business group. In line with our expectations, Life Sciences and Applied Markets Group core revenues were down 2%. Our strong growth in pharma, environmental and food markets was offset by continued weakness in chemical and energy capital expenditures. Academia and government revenues were also down across most regions. Despite this mixed market environment, LSAG's operating margin for the quarter was 19.1%, up 40 basis points from a year ago. 
Let me shift gears and talk about some of LSAG's new products. We are seeing very strong demand for the newly released 1260 and the 1290 Infinity II LC systems. The 1260 systems are part of the launch of the InfinityLab portfolio at Analytica in May. The InfinityLab portfolio consists of this new line of LC instruments along with columns, supplies and services. In Q3, LSAG also introduced the new -- 2 new 7000 Series Triple Quad GC/MS analyzers, one for pesticides and another for environmental pollutants. And we continued to strengthen our ICP-MS market leadership with the new Agilent 8900 Triple Quad ICP-MS system. This new system offers customers improved speed and accuracy of analysis.
Turning to the Agilent CrossLab Group. The business delivered another strong quarter with 8% core revenue growth. This growth is driven by strength in the food, pharma and environmental markets. ACG's operating margin for the quarter was 22.7%, up 10 basis points from a year ago. 
Portfolio expansion efforts also continued in ACG. In Q3, Agilent signed a definitive agreement to acquire the assets of iLab, and we just closed the transaction in early August. iLab is the market leader in cloud-based solutions for core laboratory management and provide services to leading universities, research hospitals and independent institutions around the world. This acquisition further expands Agilent's portfolio in the academia and government market. iLab enables Agilent to deliver broader value for our customers in this market segment. We also see an opportunity to expand the iLab business both geographically and into the pharma market.
Finally, we saw a continued momentum in the Diagnostics and Genomics Group where the business delivered 8% core growth in Q3. We saw strength across all DGG businesses, driven by growth in the pharma and clinical and diagnostics markets. Our pathology business continues on its steady trajectory of improved growth. This was highlighted by demand for our new PD-L1 companion diagnostics. Growth in Genomics reflect a strong market performance in the U.S. and China across our array CGH, Target Enrichment and SureSelect products. We also saw healthy demand for our Nucleic Acid Solutions offering. DGG's operating margin for the quarter was 18.8%, up 200 basis points from a year ago. 
Q3 highlights for DGG include the announcement of an expansion of the intended use of our PD-L1 pharmDX test in Europe for patients with melanoma. This test was previously proven in the U.S. and available in Europe for patients with non-squamous, non-small-cell lung cancer and in the U.S. with patients -- for patients with melanoma. We also announced a $120 million investment over the next 3 years to expand production capacity for our Nucleic Acid Solutions business. This includes the purchase of 20 acres of land in Colorado. We plan to build our factory on this land that will double our manufacturing capacity for nucleic acid active pharmaceutical ingredients and grow our business.
Now I'll provide an overview of Agilent's core revenues by end market. In our life sciences market, pharma saw its sixth consecutive quarter of double-digit growth with core revenue up 10%. Academia and government core revenues were down 5%, down across most geographies except China. Clinical and diagnostics grew 4% with strength in North America and Asia and led by growth in pathology. 
Applied end-market performance was mixed. Food was up 11% with strong demand in China and the Americas. These regions also drove growth in the environmental market for both instruments and aftermarket products. 
This performance was offset by continued challenges in the chemical and energy market, down 4% globally, with only Asia posting growth on a regional basis. The overall result was due to prolonged effects of the macroeconomic concerns and lower oil prices. 
Now I'll turn an update on our operating margin improvement initiatives. Q3 marked a major step forward in simplifying our company's infrastructure. In May, we completed the migration of the company's financial systems onto a single SAP platform. This was a culmination of a 20-month cross-company effort and represents a major step in simplifying Agilent's systems infrastructure that will deliver incremental cost savings as planned in fiscal 2017. 
In summary, our multiyear Agile Agilent program continues to simplify the company's business processes. This program is designed to make us more nimble and lower our costs. It will continue to deliver incremental savings in 2017.
On the capital deployment front, we purchased iLab, paid $37 million in dividends and repurchased $94 million of Agilent stock. We continue to deliver on our strategy to drive sustainable growth while expanding operating margins and balancing deployment of our capital to drive shareholder value creation. 
At our recent May Analyst Meeting, I described our shareholder value creation model: outgrow the market; expand operating margins; balance capital deployment. Let's look at our Q3 results in the context of these longer-term goals and shareholder value creation model. 
In 2015, we delivered our highest annual growth rate in 4 years while increasing adjusted operating margin 170 basis points and completely offsetting the $40 million of dissynergies from the company split. We have sustained this trajectory of improved operating results in fiscal 2016. In the first 3 quarters of 2016, the team has delivered strong growth and earnings above our initial expectations despite a challenging chemical and energy market environment and global macroeconomic concerns.
We have continued to leverage our balance sheet and deployed capital in a balanced manner, buying companies that bring new capabilities to Agilent while repurchasing our stock and increasing cash dividends. 
The new leadership team continues to transform the business and deliver results. We continue to demonstrate our ability to deliver above-industry organic growth while expanding margins and leveraging our balance sheet strength. Our Q3 results in a challenging global economic environment reflect the strength of our team combined with Agilent's scale and broad differentiated portfolio of products and services. 
Looking at today's overall market environment, we expect continued strength in pharma, along with growth in the food, environmental and clinical research and diagnostics markets and in China on a regional basis. 
As I highlighted in our last call, we are experiencing a steeper and more prolonged slowdown in the chemical and energy market than initially projected entering fiscal 2016. We subsequently revised our forecast for this market segment last quarter to overall low single-digit market declines for the year. While there are some signs of an impending bottom in the market, we remain cautious in our outlook and expect Q4 to be in a similar range as the past quarter. 
Against this market drop (sic) [backdrop], we are well positioned to capture growth in these end-market segments and geographies where growth is expected to remain strong. The combination of our expanding our customer channel reach and continual strengthening of our portfolio positions us well to achieve our previously raised full year guidance of 2016 and our longer-term goals. Our One Agilent team continues to work well together and is energized to win in the market. Overall, we remain on track with our 2017 goal to outgrow the market and improve our operating margin to 22%. 
Thank you for being on the call today. I will now turn it over to Didier who will provide additional insights on our financial results and guidance for the remainder of 2016. Didier?"
154924,374881090,1037210,"Agilent Technologies, Inc., Q3 2016 Earnings Call, Aug 17, 2016",2016-08-17,"Earnings Calls","Agilent Technologies, Inc.","Executives","Thank you, Mike, and hello, everyone. As mentioned by Mike, we delivered higher core revenue growth, operating margin and earnings per share than the high end of our guidance. Earnings per share grew 11% in the quarter versus a year ago. We also generated",326,"Thank you, Mike, and hello, everyone. As mentioned by Mike, we delivered higher core revenue growth, operating margin and earnings per share than the high end of our guidance. Earnings per share grew 11% in the quarter versus a year ago. We also generated $194 million in operating cash flow, more than double last year's amount, which gives us increased confidence that we will achieve our previously raised operating cash flow guidance for the full year. FX had a negative impact on revenue of about $10 million or 1% versus previous guidance and $7 million or 0.7% versus last year. It had a negative impact on operating profit of $3 million versus previous guidance and $1 million versus last year.
I'll now turn to the guidance for our fourth quarter. We expect Q4 revenues of $1.05 billion to $1.07 billion and earnings per share of $0.50 to $0.52. At the midpoint, revenue is expected to grow 1.2% on a core basis. Versus previous guidance, FX is estimated to have a negative impact of $9 million on revenue and $2 million on operating profit. Our 21.3% adjusted operating margin at midpoint will be up 70 basis points sequentially.
Now to the guidance for fiscal year 2016. The Q4 guidance results in the following fiscal year guidance. At midpoint, revenue is projected to grow 4.5% on a core basis, no change from the previous guidance. Our earnings per share guidance of $1.90 at midpoint is also unchanged from previous guidance and corresponds to a 9% year-over-year increase. Adjusted operating margin for the year is expected to be 20.4 basis points or 80 basis points higher than in fiscal year '15. And finally, FX is estimated to have a negative impact on a year-over-year basis of $68 million on revenue, $10 million on operating profit related to currency translation and an additional $21 million related to currency hedging. 
With that, I'll turn it over to Alicia for the Q&A."
154924,374881090,1037210,"Agilent Technologies, Inc., Q3 2016 Earnings Call, Aug 17, 2016",2016-08-17,"Earnings Calls","Agilent Technologies, Inc.","Executives","Thank you, Didier. Jonathan, will you please give the instructions for the Q&A?",13,"Thank you, Didier. Jonathan, will you please give the instructions for the Q&A?"
154924,374881090,1037210,"Agilent Technologies, Inc., Q3 2016 Earnings Call, Aug 17, 2016",2016-08-17,"Earnings Calls","Agilent Technologies, Inc.","Operator","[Operator Instructions] Our first question comes from the line of Brandon Couillard from Jefferies. Our next question comes from the line of Steve Beuchaw from Morgan Stanley.",27,"[Operator Instructions] Our first question comes from the line of Brandon Couillard from Jefferies. Our next question comes from the line of Steve Beuchaw from Morgan Stanley."
154924,374881090,1037210,"Agilent Technologies, Inc., Q3 2016 Earnings Call, Aug 17, 2016",2016-08-17,"Earnings Calls","Agilent Technologies, Inc.","Analysts","I want to start with the one regional trend that seems to be on many people's minds, which is what's going on in Europe. I wonder if you could speak to the trends that you saw in Europe over the course of the quarter. To some extent, it's a macro question",99,"I want to start with the one regional trend that seems to be on many people's minds, which is what's going on in Europe. I wonder if you could speak to the trends that you saw in Europe over the course of the quarter. To some extent, it's a macro question. To some extent, it's a research question. And of course, there's the -- their U.K. referendum that's still out there. So I apologize for the nebulous nature of it all, but any color on how Europe progressed over the course of the quarter would be really helpful."
154924,374881090,1037210,"Agilent Technologies, Inc., Q3 2016 Earnings Call, Aug 17, 2016",2016-08-17,"Earnings Calls","Agilent Technologies, Inc.","Executives","Yes, sure. Glad to provide some insight there, and then I'm going to actually have Patrick jump in on this conversation, given your recent travels in the region. But what we saw in the quarter was, obviously, a lot of big macro events, the Brexit, Turkey.",178,"Yes, sure. Glad to provide some insight there, and then I'm going to actually have Patrick jump in on this conversation, given your recent travels in the region. But what we saw in the quarter was, obviously, a lot of big macro events, the Brexit, Turkey. There's a number developed [ph] in the quarter. We did not see any material impact from those events in our performance in the third quarter. What I will say, though, it is raising an increased level of uncertainty amongst our customers in Europe, and we've seen the questions around when will budgets be released. So it's more of an uncertainty question right out there. People are just sort of waiting to see how it's going to develop. Again, no material effect on the third quarter results. But as we thought about our guidance for the fourth quarter, obviously, it's influenced us to think about how will Europe develop through the quarter. And, Patrick, I know you had a pretty deep conversation about this yesterday. So any additional thoughts you'd like to add?"
154924,374881090,1037210,"Agilent Technologies, Inc., Q3 2016 Earnings Call, Aug 17, 2016",2016-08-17,"Earnings Calls","Agilent Technologies, Inc.","Executives","Yes. Thanks, Mike. In talking to our field, local field in Europe, you certainly get the feedback there is some uncertainty as Mike -- as you said. The Brexit had -- with some of the government in traditional [ph] deals had probably some minor impacts. I",101,"Yes. Thanks, Mike. In talking to our field, local field in Europe, you certainly get the feedback there is some uncertainty as Mike -- as you said. The Brexit had -- with some of the government in traditional [ph] deals had probably some minor impacts. I think what's concerning us here a little bit is also there are a couple of other countries standing on the sidelines and have other referendums this year. So we are cautious right now, looking at Europe and the growth scenario for Europe for the remainder of the year and also going into fiscal year '17."
154924,374881090,1037210,"Agilent Technologies, Inc., Q3 2016 Earnings Call, Aug 17, 2016",2016-08-17,"Earnings Calls","Agilent Technologies, Inc.","Executives","Thanks, Patrick.",2,"Thanks, Patrick."
154924,374881090,1037210,"Agilent Technologies, Inc., Q3 2016 Earnings Call, Aug 17, 2016",2016-08-17,"Earnings Calls","Agilent Technologies, Inc.","Analysts","And then one bigger-picture question, Mike. I mean you made a pretty significant investment with a pretty long horizon -- long-term horizon on this facility in Colorado. So it speaks to your confidence in the long-term outlook for and the scale of the opp",80,"And then one bigger-picture question, Mike. I mean you made a pretty significant investment with a pretty long horizon -- long-term horizon on this facility in Colorado. So it speaks to your confidence in the long-term outlook for and the scale of the opportunity there. Can you just talk us through how you frame the opportunity, remind us how big that business is today, and how you think about the medium-term drivers that you're investing in the pursuit of?"
154924,374881090,1037210,"Agilent Technologies, Inc., Q3 2016 Earnings Call, Aug 17, 2016",2016-08-17,"Earnings Calls","Agilent Technologies, Inc.","Executives","Great. So I'm going to handle your -- well, I'm going to handle the first part of this question. And then I'm going to turn it over to Jacob, and he'll reassure you about the long-term growth potential, which is the reason why I supported the investment.",189,"Great. So I'm going to handle your -- well, I'm going to handle the first part of this question. And then I'm going to turn it over to Jacob, and he'll reassure you about the long-term growth potential, which is the reason why I supported the investment. But just as a reminder, I think this is roughly about 5% or so of DGG's overall revenues in the range of maybe $16 plus million or so. We still have capacity at the current site, but we've got a -- more demand than we can handle in terms of long-term outlook from our customers. So we can't bring on this capacity fast enough to satisfy the customer demand. We think this will be a bigger part of our growth story as we talk to you about 2017 and 2018. And I think as you'll hear from Jacob, there's a high degree of confidence that the business is going to be there. And perhaps you can provide a little context of what exactly is this business and why are we so confident that the market is going to be there for us."
154924,374881090,1037210,"Agilent Technologies, Inc., Q3 2016 Earnings Call, Aug 17, 2016",2016-08-17,"Earnings Calls","Agilent Technologies, Inc.","Executives","Yes, let me try to provide a little more color there. So first of all, a reminder that the Nucleic Acid Solutions Division business out in Boulder is providing oligo APIs that constitute a new type of drugs with a significant potential. These drugs are, p",317,"Yes, let me try to provide a little more color there. So first of all, a reminder that the Nucleic Acid Solutions Division business out in Boulder is providing oligo APIs that constitute a new type of drugs with a significant potential. These drugs are, primarily, right now, opportunities within orphan genetic diseases that today there has been no treatment and have devastating outcomes. And these drugs have actually the opportunity to change the expectancy of, you could say, the survival and also the quality of life for such patients. We are working with the leaders in pharma within these new type of drugs, and Agilent is chosen again and again due to our deep technical experience to optimize oligos for performance and consistency, combined with our ability to scale in DNP. We have seen a significant demand accelerated over the last few years. And as Mike mentioned, we're currently expanding our current site to actually take up double capacity. But we also see that, that will run out. That opportunity is really limited and will run out in a few years from now; and thereby, the new investment in the new site will allow us to further double our capacity and even double again if we choose to do so. We have decided, and based on a deep dive into the strategy and so on, to place the site in close proximity to the other Boulder site at approximately 20 minutes' drive away so we can releverage critical mass, high -- the highly experienced staff we already have and capabilities and processes. The overall market is in the hundreds of million dollar business right now, and it's growing something between 20% to 30%. However, when you commercialize drugs -- when you get the commercialized drugs, this might be a significant step-ups, but we see a lot of demand right now just in the clinical trial studies."
154924,374881090,1037210,"Agilent Technologies, Inc., Q3 2016 Earnings Call, Aug 17, 2016",2016-08-17,"Earnings Calls","Agilent Technologies, Inc.","Operator","Our next question comes from the line of Jonathan Groberg from UBS.",12,"Our next question comes from the line of Jonathan Groberg from UBS."
154924,374881090,1037210,"Agilent Technologies, Inc., Q3 2016 Earnings Call, Aug 17, 2016",2016-08-17,"Earnings Calls","Agilent Technologies, Inc.","Analysts","I know you have one more quarter to go here, but any initial thoughts on the puts and takes you're seeing on how we should be thinking about fiscal '17?",30,"I know you have one more quarter to go here, but any initial thoughts on the puts and takes you're seeing on how we should be thinking about fiscal '17?"
154924,374881090,1037210,"Agilent Technologies, Inc., Q3 2016 Earnings Call, Aug 17, 2016",2016-08-17,"Earnings Calls","Agilent Technologies, Inc.","Executives","Yes. Jonathan, I'd be happy to share my thoughts here. And in fact, I, perhaps, will build on some of the comments I made in my prepared remarks. But we're still -- we are still seeing ourselves on the same path that we talked about just a month or so ago",386,"Yes. Jonathan, I'd be happy to share my thoughts here. And in fact, I, perhaps, will build on some of the comments I made in my prepared remarks. But we're still -- we are still seeing ourselves on the same path that we talked about just a month or so ago in New York. I think it actually was 2 months ago when I think about it, but our position remains the same. We are still confident we're going to be able to achieve the overall projected core growth of 4.5%. And there's some new -- there really are some new factors that we think support this level of growth. First of all, we've -- we have a rich pipeline of new product introductions coming in Q4 and in FY '17, on top of what we've already introduced this year. We think our customers are going to be really excited about what we're bringing to market, and that's going to help drive share. So we know we got this NPI pipe going through the system right now with releases coming up in the several quarters on top of what we've done. The second thing, I -- we also have recognized the fact that the Agilent business model has really changed a lot over the last 18 months or so. We have a lot more recurring revenue. And if you look at the ACG and DGG business, which now represent over half, I think it's 52% the last time I did the math, of Agilent's revenue. These are just inherently much more predictable revenue streams, and you saw in our Q3 results how both groups delivered high single-digit growth. And they're not subject to the same types of issues we're seeing in the capital-intensive chemical and energy market, for example. And then the third thing I'd say is when you think about our LSAG instrument business, in addition to the impact of these new product introductions I mentioned, we do expect that pharma and China market is going to remain significant growth drivers, although I think they will be below these double-digit levels we've seen in 2016. And as mentioned in our last call, we still expect that the chemical and energy market will have bottomed by the end of calendar year 2017. We're not ready to..."
154924,374881090,1037210,"Agilent Technologies, Inc., Q3 2016 Earnings Call, Aug 17, 2016",2016-08-17,"Earnings Calls","Agilent Technologies, Inc.","Executives","'16.",1,"'16."
154924,374881090,1037210,"Agilent Technologies, Inc., Q3 2016 Earnings Call, Aug 17, 2016",2016-08-17,"Earnings Calls","Agilent Technologies, Inc.","Executives","Excuse me. Sorry. Thanks, Didier. I got my ears confused there -- by the end of the calendar year 2016. We're not ready to call bottom, but we do see in 2017 that we're forecasting that we could be in low single-digits growth in a market which has had 18",118,"Excuse me. Sorry. Thanks, Didier. I got my ears confused there -- by the end of the calendar year 2016. We're not ready to call bottom, but we do see in 2017 that we're forecasting that we could be in low single-digits growth in a market which has had 18 to 24 months of pent-up demand for equipment that supports the production process. So they're the 3 factors that have gone into our thinking as we have thought about the 2017's growth rate. Honestly, we'll give you the official guidance at our next call. But I would just reinforce our view today is that we're still on track to what we told you in May in New York."
154924,374881090,1037210,"Agilent Technologies, Inc., Q3 2016 Earnings Call, Aug 17, 2016",2016-08-17,"Earnings Calls","Agilent Technologies, Inc.","Analysts","Great. That's helpful. And just one quick follow-up, on the capital equipment business, I know you mentioned going into the quarter, last time when you gave guidance, you thought there'd been a little bit of pull forward and you highlighted why you though",79,"Great. That's helpful. And just one quick follow-up, on the capital equipment business, I know you mentioned going into the quarter, last time when you gave guidance, you thought there'd been a little bit of pull forward and you highlighted why you thought it would be a little weaker. I'm just curious, was it in line with what you thought? Or was there anything unique in the quarter that maybe wasn't right along the lines of what you thought?"
154924,374881090,1037210,"Agilent Technologies, Inc., Q3 2016 Earnings Call, Aug 17, 2016",2016-08-17,"Earnings Calls","Agilent Technologies, Inc.","Executives","Absolutely. I think the quarter was actually in line and actually a little bit better than we had anticipated coming into the quarter, so no major surprises in our Q3 results. And as you can imagine, we were delighted with the ability to deliver above our",52,"Absolutely. I think the quarter was actually in line and actually a little bit better than we had anticipated coming into the quarter, so no major surprises in our Q3 results. And as you can imagine, we were delighted with the ability to deliver above our expectations, both top and bottom line."
154924,374881090,1037210,"Agilent Technologies, Inc., Q3 2016 Earnings Call, Aug 17, 2016",2016-08-17,"Earnings Calls","Agilent Technologies, Inc.","Operator","Our next question comes from the line of Jack Meehan from Barclays.",12,"Our next question comes from the line of Jack Meehan from Barclays."
154924,374881090,1037210,"Agilent Technologies, Inc., Q3 2016 Earnings Call, Aug 17, 2016",2016-08-17,"Earnings Calls","Agilent Technologies, Inc.","Analysts","So I just wanted to ask about the LSAG business and some of the moving parts there. And could you maybe just talk about the chromatography markets? A couple of your peers have had really nice results there. Just what you're seeing there would be helpful.",46,"So I just wanted to ask about the LSAG business and some of the moving parts there. And could you maybe just talk about the chromatography markets? A couple of your peers have had really nice results there. Just what you're seeing there would be helpful."
154924,374881090,1037210,"Agilent Technologies, Inc., Q3 2016 Earnings Call, Aug 17, 2016",2016-08-17,"Earnings Calls","Agilent Technologies, Inc.","Executives","Yes, absolutely. And then, Patrick, if you could break it out, obviously, between liquid chromatography and gas chromatography as well?",20,"Yes, absolutely. And then, Patrick, if you could break it out, obviously, between liquid chromatography and gas chromatography as well?"
154924,374881090,1037210,"Agilent Technologies, Inc., Q3 2016 Earnings Call, Aug 17, 2016",2016-08-17,"Earnings Calls","Agilent Technologies, Inc.","Executives","Yes, absolutely. Happy to do so. As Mike mentioned earlier in his remarks, we definitely see very strong growth right now in the liquid chromatography business, which has been, for the entire year, double digits. And that is what we see, clearly, also tak",251,"Yes, absolutely. Happy to do so. As Mike mentioned earlier in his remarks, we definitely see very strong growth right now in the liquid chromatography business, which has been, for the entire year, double digits. And that is what we see, clearly, also taking market share right now. We had a very strong launch of several waves of the Infinity series starting in 2009 and 2012. And now this year with the 1260 series with another big round of instrumentation and solutions in liquid chromatography, that is very well received by the end markets. We see very healthy replacement business as well, and it's driven by the fact that these solutions are 100% backwards compatible and also compatible with some of our competitors' instrumentations, which makes method transfer very simple and seamless for our customers. So -- and we project this cycle to continue for several more quarters. We don't see yet a loss of momentum. What we see, of course, is that we're getting now into quarters with tougher compare because we have double-digit growth for several quarters now. On the gas chromatography side, again, very strong portfolio as well. The issue we're seeing there is that the core market or one of the big markets for gas chromatography is the energy space. And that, of course, pulled some of our results down at this point in time. If the market comes back, we think we are in an exceptional position to pick up this pent-up demand that we see."
154924,374881090,1037210,"Agilent Technologies, Inc., Q3 2016 Earnings Call, Aug 17, 2016",2016-08-17,"Earnings Calls","Agilent Technologies, Inc.","Executives","When the market comes back.",5,"When the market comes back."
154924,374881090,1037210,"Agilent Technologies, Inc., Q3 2016 Earnings Call, Aug 17, 2016",2016-08-17,"Earnings Calls","Agilent Technologies, Inc.","Executives","Yes, when the market comes back. Yes, when the market comes back, sorry. So I think we are in a great situation there as well. We have an outstanding product portfolio and ability to capture the growth when it gets back.",41,"Yes, when the market comes back. Yes, when the market comes back, sorry. So I think we are in a great situation there as well. We have an outstanding product portfolio and ability to capture the growth when it gets back."
154924,374881090,1037210,"Agilent Technologies, Inc., Q3 2016 Earnings Call, Aug 17, 2016",2016-08-17,"Earnings Calls","Agilent Technologies, Inc.","Executives","Yes. And the reason why I asked Patrick to segment his remarks in liquid chromatography from gas chromatography, we have an outsized exposure in gas chromatography, and when the -- relative to the #2 competitor space, we're at least 2x the #2 person. And",91,"Yes. And the reason why I asked Patrick to segment his remarks in liquid chromatography from gas chromatography, we have an outsized exposure in gas chromatography, and when the -- relative to the #2 competitor space, we're at least 2x the #2 person. And so when our major market is down, it really hits us. And that's why, again, we were really quite pleased that we were able to deliver the growth we've done so far, with our #2 market actually being down below our initial expectations coming into this year."
154924,374881090,1037210,"Agilent Technologies, Inc., Q3 2016 Earnings Call, Aug 17, 2016",2016-08-17,"Earnings Calls","Agilent Technologies, Inc.","Analysts","Yes, that's really helpful, and I appreciate all the details in the different segments. If I could just follow up with one more. The Americas growth, negative 1% in the quarter, I know it's on a tougher comp relative to last year. But could you maybe just",67,"Yes, that's really helpful, and I appreciate all the details in the different segments. If I could just follow up with one more. The Americas growth, negative 1% in the quarter, I know it's on a tougher comp relative to last year. But could you maybe just talk about the mix of the end markets there and whether there was any other notable changes worth pointing out?"
154924,374881090,1037210,"Agilent Technologies, Inc., Q3 2016 Earnings Call, Aug 17, 2016",2016-08-17,"Earnings Calls","Agilent Technologies, Inc.","Executives","I think the big one there is the chemical and energy market. So it's down pretty sharply, and I think that's bringing down the overall numbers as well as our academia and government business was down over last year. Although we think some of that -- the w",73,"I think the big one there is the chemical and energy market. So it's down pretty sharply, and I think that's bringing down the overall numbers as well as our academia and government business was down over last year. Although we think some of that -- the way we're thinking about our plan for the rest of this year, we think the federal money will be there in the fourth quarter for us."
154924,374881090,1037210,"Agilent Technologies, Inc., Q3 2016 Earnings Call, Aug 17, 2016",2016-08-17,"Earnings Calls","Agilent Technologies, Inc.","Executives","Yes. And in addition, if I may add, we had a very strong quarter Q3 last year in Americas. So it's a tough compare.",24,"Yes. And in addition, if I may add, we had a very strong quarter Q3 last year in Americas. So it's a tough compare."
154924,374881090,1037210,"Agilent Technologies, Inc., Q3 2016 Earnings Call, Aug 17, 2016",2016-08-17,"Earnings Calls","Agilent Technologies, Inc.","Executives","Yes. I'm not always willing to let my guys do the tough compare argument, but thanks, Patrick.",17,"Yes. I'm not always willing to let my guys do the tough compare argument, but thanks, Patrick."
154924,374881090,1037210,"Agilent Technologies, Inc., Q3 2016 Earnings Call, Aug 17, 2016",2016-08-17,"Earnings Calls","Agilent Technologies, Inc.","Operator","Our next question comes from the line of Tycho Peterson from JPMorgan.",12,"Our next question comes from the line of Tycho Peterson from JPMorgan."
154924,374881090,1037210,"Agilent Technologies, Inc., Q3 2016 Earnings Call, Aug 17, 2016",2016-08-17,"Earnings Calls","Agilent Technologies, Inc.","Analysts","Maybe first on -- just on the academic front because it is a big swing from what you reported last quarter. I understand the Europe dynamic, but frankly, what we hear from you is a little bit different than we've heard from most of the other life science",73,"Maybe first on -- just on the academic front because it is a big swing from what you reported last quarter. I understand the Europe dynamic, but frankly, what we hear from you is a little bit different than we've heard from most of the other life science peers. So can you maybe just talk a little bit about why you felt more pressure in Europe academic than maybe most of your peers?"
154924,374881090,1037210,"Agilent Technologies, Inc., Q3 2016 Earnings Call, Aug 17, 2016",2016-08-17,"Earnings Calls","Agilent Technologies, Inc.","Executives","I think it's -- I think -- I'd point to 2 factors. I'm not sure exactly what all our peers are saying about Europe. I think they're probably saying the same thing, which are the European budgets are constrained and funding has not been released, and has a",136,"I think it's -- I think -- I'd point to 2 factors. I'm not sure exactly what all our peers are saying about Europe. I think they're probably saying the same thing, which are the European budgets are constrained and funding has not been released, and has actually been withheld in some situations. I also think you may be hearing a more positive spin on the U.S. environment because of many of our competitors have much more business coming from NIH. So there's a lot of positive view of the NIH budget, but we pick up a relatively small piece of that overall budget. The agencies where we do a lot of our business in the U.S. government, we know the money is coming in the fourth quarter. Anything else you'd add to that, Patrick?"
154924,374881090,1037210,"Agilent Technologies, Inc., Q3 2016 Earnings Call, Aug 17, 2016",2016-08-17,"Earnings Calls","Agilent Technologies, Inc.","Executives","Not a lot. And as you said, there's -- a lot of our competitors definitely have also a mixed bag, on average, I would say.",25,"Not a lot. And as you said, there's -- a lot of our competitors definitely have also a mixed bag, on average, I would say."
154924,374881090,1037210,"Agilent Technologies, Inc., Q3 2016 Earnings Call, Aug 17, 2016",2016-08-17,"Earnings Calls","Agilent Technologies, Inc.","Analysts","And then similarly, environmental is flat after growing 6% last quarter. Can you maybe just comment on dynamics there?",19,"And then similarly, environmental is flat after growing 6% last quarter. Can you maybe just comment on dynamics there?"
154924,374881090,1037210,"Agilent Technologies, Inc., Q3 2016 Earnings Call, Aug 17, 2016",2016-08-17,"Earnings Calls","Agilent Technologies, Inc.","Executives","I think the biggest dynamic there is there's a subsegment within environmental as well where we pick up our forensics business. And we report externally just the total environmental business, but a lot of big deal activity in forensics. So last year, we h",104,"I think the biggest dynamic there is there's a subsegment within environmental as well where we pick up our forensics business. And we report externally just the total environmental business, but a lot of big deal activity in forensics. So last year, we had a lot of big deals at this point in time. The overall environmental market has given me big deals in the second quarter. So it's really a forensic-driven phenomena, which is where we didn't have as many big deals in the third quarter. And this business tends to be a little bit more lumpy than our base environmental business."
154924,374881090,1037210,"Agilent Technologies, Inc., Q3 2016 Earnings Call, Aug 17, 2016",2016-08-17,"Earnings Calls","Agilent Technologies, Inc.","Analysts","Okay. And then -- and last one, a little bit of an esoteric question. But on the PD-L1 data sets in frontline lung, can you maybe just talk about whether there's kind of any change in your outlook? Obviously, Bristol attempted to go without a companion an",74,"Okay. And then -- and last one, a little bit of an esoteric question. But on the PD-L1 data sets in frontline lung, can you maybe just talk about whether there's kind of any change in your outlook? Obviously, Bristol attempted to go without a companion and failed. Merck is doing a companion. So can you maybe just talk about whether some of those developments have changed your view of the market opportunity overall?"
154924,374881090,1037210,"Agilent Technologies, Inc., Q3 2016 Earnings Call, Aug 17, 2016",2016-08-17,"Earnings Calls","Agilent Technologies, Inc.","Executives","Sure. Sure, Tycho. In fact, we just had a conversation on this yesterday. So Pat -- I mean, Jacob, why don't you share the latest thoughts from Agilent on this topic?",31,"Sure. Sure, Tycho. In fact, we just had a conversation on this yesterday. So Pat -- I mean, Jacob, why don't you share the latest thoughts from Agilent on this topic?"
154924,374881090,1037210,"Agilent Technologies, Inc., Q3 2016 Earnings Call, Aug 17, 2016",2016-08-17,"Earnings Calls","Agilent Technologies, Inc.","Executives","Yes, I will say, first and foremost, we are very pleased with the performance we have seen on PD-L1 over the last 10 months, and we continue to see strong traction. You're right. There has been some announcement recently on some studies that has not come",120,"Yes, I will say, first and foremost, we are very pleased with the performance we have seen on PD-L1 over the last 10 months, and we continue to see strong traction. You're right. There has been some announcement recently on some studies that has not come out as expected. It really supports our thesis about the importance here of CDx and, really, that you need to make sure you stratify your patient group the right way. So clearly, there is a short-term opportunity, at least from one of our customers that is a little less than we hoped for. But I don't think that, that overall change is really the thesis, and we continue to see a big opportunity here."
154924,374881090,1037210,"Agilent Technologies, Inc., Q3 2016 Earnings Call, Aug 17, 2016",2016-08-17,"Earnings Calls","Agilent Technologies, Inc.","Operator","Our next question comes from the line of Ross Muken from Evercore.",12,"Our next question comes from the line of Ross Muken from Evercore."
154924,374881090,1037210,"Agilent Technologies, Inc., Q3 2016 Earnings Call, Aug 17, 2016",2016-08-17,"Earnings Calls","Agilent Technologies, Inc.","Analysts","So it seems like most of the confusion we're hearing is sort of on the sequential progression of core revenues. And so I look at the last 2 years, and it looks like, sequentially, the comp is roughly, I don't know, 200 basis points easier on core. And it",128,"So it seems like most of the confusion we're hearing is sort of on the sequential progression of core revenues. And so I look at the last 2 years, and it looks like, sequentially, the comp is roughly, I don't know, 200 basis points easier on core. And it looks like you have a little bit heavier of an NMR headwind in 4Q than you did in 3Q. So one, can you confirm that? And then two, as we just think about the crosswalk, what are the other sort of underlying assumptions in terms of what is different sequentially versus 3Q, whether it's end markets or any of the key segments? And then where have you built in, I guess, some conservatism or some of that uncertainty?"
154924,374881090,1037210,"Agilent Technologies, Inc., Q3 2016 Earnings Call, Aug 17, 2016",2016-08-17,"Earnings Calls","Agilent Technologies, Inc.","Executives","Yes. Thanks for the question, Ross. And why don't I go ahead and just share some thoughts about the Q4 guidance. And then, Didier, maybe you can dig through your notes on the NMR impact. But I think it's important for me to share with the audience here to",271,"Yes. Thanks for the question, Ross. And why don't I go ahead and just share some thoughts about the Q4 guidance. And then, Didier, maybe you can dig through your notes on the NMR impact. But I think it's important for me to share with the audience here today about how we thought about our Q4 guidance. I think this may get to the root of some of your questions. As you heard on our call, first of all, we're quite pleased with the higher-than-guided core revenue growth that we delivered for Q3 after having raised last -- in last call. And I think we've got this increased confidence to achieve our previously raised core growth guidance for the year. And listen, we realize by not raising our core guidance for this year that this question could arise. But the way we looked at it, we said, listen, there's a raised level uncertainty in the markets centered around Europe. And we saw some weak European government budgets in the third quarter. Is this going to continue? We've seen some downward revisions in terms of market overall economic forecasts for Europe, so we're really not sure exactly how it's going to develop. So we just thought it's prudent to reflect some of this uncertainty by not raising again the full year guidance. So that's how we thought about the process. We really didn't look over the years sequentially. We do know that last year, though, I said I don't like the tough compare argument, we did have a blowout fourth quarter last year. But anything else, Didier, you can remember unusual or..."
154924,374881090,1037210,"Agilent Technologies, Inc., Q3 2016 Earnings Call, Aug 17, 2016",2016-08-17,"Earnings Calls","Agilent Technologies, Inc.","Executives","No. NMR is not a factor.",6,"No. NMR is not a factor."
154924,374881090,1037210,"Agilent Technologies, Inc., Q3 2016 Earnings Call, Aug 17, 2016",2016-08-17,"Earnings Calls","Agilent Technologies, Inc.","Executives","NMR is not a factor.",5,"NMR is not a factor."
154924,374881090,1037210,"Agilent Technologies, Inc., Q3 2016 Earnings Call, Aug 17, 2016",2016-08-17,"Earnings Calls","Agilent Technologies, Inc.","Executives","You pointed out really what we intended to do is maintain the overall core revenue growth for the whole year, and that's how we derived Q4.",26,"You pointed out really what we intended to do is maintain the overall core revenue growth for the whole year, and that's how we derived Q4."
154924,374881090,1037210,"Agilent Technologies, Inc., Q3 2016 Earnings Call, Aug 17, 2016",2016-08-17,"Earnings Calls","Agilent Technologies, Inc.","Executives","Yes. We'd raised last quarter, and the business is developing in the third quarter actually better than we had thought as you saw in our results. And as we look to the fourth quarter, listen, we don't know how this Europe's going to play out, so let's jus",58,"Yes. We'd raised last quarter, and the business is developing in the third quarter actually better than we had thought as you saw in our results. And as we look to the fourth quarter, listen, we don't know how this Europe's going to play out, so let's just be cautious as opposed to raising again for the quarter."
154924,374881090,1037210,"Agilent Technologies, Inc., Q3 2016 Earnings Call, Aug 17, 2016",2016-08-17,"Earnings Calls","Agilent Technologies, Inc.","Analysts","So that makes total sense to me, Mike. I mean, I think given some of the uncertainty, I certainly don't want to get in front of your skis. And you guys have been beating numbers, so that's good. I guess as you think about the key product cycles for the bu",137,"So that makes total sense to me, Mike. I mean, I think given some of the uncertainty, I certainly don't want to get in front of your skis. And you guys have been beating numbers, so that's good. I guess as you think about the key product cycles for the business, how do you think about the cadence now that you've had some releases of when we could start seeing that also draw up the core growth overall? And then secondarily, when do we start to comp through? We've now, I guess, comp-ed through some easier compares on the Diagnostics business, which has been going hot for, I don't know, 4 or 6 quarters now. How long do you think we've got left on that trajectory of sort of high-single to almost double-digit growth in that business?"
154924,374881090,1037210,"Agilent Technologies, Inc., Q3 2016 Earnings Call, Aug 17, 2016",2016-08-17,"Earnings Calls","Agilent Technologies, Inc.","Executives","I think longer, but I think that for the foreseeable future, we're highly confident on the growth rates in this business. And that's why I made the comment earlier about, hey, when you think about Agilent's long-term growth perspective, if you think about",170,"I think longer, but I think that for the foreseeable future, we're highly confident on the growth rates in this business. And that's why I made the comment earlier about, hey, when you think about Agilent's long-term growth perspective, if you think about '17, think about that we've got over half of our revenue in markets that are going to have a steady trajectory of growth. And you heard Jacob talk about what's going on in the companion diagnostic PD-L1. We talked -- that's why I wanted to highlight the investments we're making in NASD, which is a part of the business we haven't really talked a lot about with you. So I think there are a lot of genomics, there's SureSelect next-gen sequencing. There's a lot of fundamental, very attractive markets we have a strong position in. So Jacob, I don't want to necessarily speak for you, but I guess I have that we expect that this growth rate will be sustained. Anything else you'd add to my story?"
154924,374881090,1037210,"Agilent Technologies, Inc., Q3 2016 Earnings Call, Aug 17, 2016",2016-08-17,"Earnings Calls","Agilent Technologies, Inc.","Executives","You're absolutely right, and I'm definitely pleased with the excellent growth. Last quarter, we had 5%. So I really want to make sure that you saw that we were -- when I -- when we talked also at the Analyst Day, we believe the right -- the direction is 6",80,"You're absolutely right, and I'm definitely pleased with the excellent growth. Last quarter, we had 5%. So I really want to make sure that you saw that we were -- when I -- when we talked also at the Analyst Day, we believe the right -- the direction is 6% to 7%. I'm happy to beat that. But we do not see any change in trajectory right now, and we'll continue in those high single-digit growth rates going forward."
154924,374881090,1037210,"Agilent Technologies, Inc., Q3 2016 Earnings Call, Aug 17, 2016",2016-08-17,"Earnings Calls","Agilent Technologies, Inc.","Executives","And, Ross, I think perhaps your earlier question was around product cycle replacement. Yes. So I think, as you may know, when I came into the role a little over 1.5 years ago, we had really spent a lot of time redirecting our R&D programs. We restructured",188,"And, Ross, I think perhaps your earlier question was around product cycle replacement. Yes. So I think, as you may know, when I came into the role a little over 1.5 years ago, we had really spent a lot of time redirecting our R&D programs. We restructured the company. We reorganized our R&D programs, and I think you're starting to see the cadence. So you've seen some of the product come out. We highlighted earlier on the chromatography side some updates and new products around spectroscopy, ICP-MS. And we know this cadence is going to continue throughout the next quarter and into '17. So that's why when I got the earlier question about, hey, what are you thinking about in terms of '17, I know what's in our road maps, and I know what's coming to the market over the next 12 months. And I know what's already come to the market, and I know how customers are responding. That's why we have this level of confidence about our ability to continue to grow this company in what has been very mixed market conditions, to say the least."
154924,374881090,1037210,"Agilent Technologies, Inc., Q3 2016 Earnings Call, Aug 17, 2016",2016-08-17,"Earnings Calls","Agilent Technologies, Inc.","Operator","Our next question comes from the line of Doug Schenkel from Cowen.",12,"Our next question comes from the line of Doug Schenkel from Cowen."
154924,374881090,1037210,"Agilent Technologies, Inc., Q3 2016 Earnings Call, Aug 17, 2016",2016-08-17,"Earnings Calls","Agilent Technologies, Inc.","Analysts","My first question -- I guess both are going to be on guidance. So for fiscal Q4, your guidance essentially tells us that you're assuming operating margin declines year-over-year in fiscal year Q4 in spite of what seems like could be, I guess mix-wise, a p",81,"My first question -- I guess both are going to be on guidance. So for fiscal Q4, your guidance essentially tells us that you're assuming operating margin declines year-over-year in fiscal year Q4 in spite of what seems like could be, I guess mix-wise, a pretty favorable quarter year-over-year based on your commentary. So keeping that in mind and the fact that you've actually expanded operating margin year-over-year, I believe 6 straight quarters, can you just explain why this makes sense?"
154924,374881090,1037210,"Agilent Technologies, Inc., Q3 2016 Earnings Call, Aug 17, 2016",2016-08-17,"Earnings Calls","Agilent Technologies, Inc.","Executives","Yes. I think you've got the string of consecutive quarters. It's been 6 quarters in a row. And, Didier, we looked at this. I think it's purely volume related, but...",30,"Yes. I think you've got the string of consecutive quarters. It's been 6 quarters in a row. And, Didier, we looked at this. I think it's purely volume related, but..."
154924,374881090,1037210,"Agilent Technologies, Inc., Q3 2016 Earnings Call, Aug 17, 2016",2016-08-17,"Earnings Calls","Agilent Technologies, Inc.","Executives","Yes, absolutely. As same thing for operating margin, our approach -- as for revenue, our approach is we didn't -- we wanted to maintain our full year operating margin because, obviously, it's linked to revenue. So we maintain our core revenue growth assum",141,"Yes, absolutely. As same thing for operating margin, our approach -- as for revenue, our approach is we didn't -- we wanted to maintain our full year operating margin because, obviously, it's linked to revenue. So we maintain our core revenue growth assumption of 4.5% and our operating margin assumption of 20.4%. Now, you are absolutely correct that, that would mean that 50 basis points reduction from the significant operating margin we had in Q4 of last year of 21.5%, still a significant 70 basis point sequential improvement. And you have to take into account, as Mike said, that this is based on only 1.2% top line growth. So a slight reduction in operating margin, still very significant increase sequentially, but slight reduction related to the one -- the assumption that we'd made on the top line growth of only 1.2%."
154924,374881090,1037210,"Agilent Technologies, Inc., Q3 2016 Earnings Call, Aug 17, 2016",2016-08-17,"Earnings Calls","Agilent Technologies, Inc.","Executives","Right. And if we do better on the volume, we'll do better on the margin.",15,"Right. And if we do better on the volume, we'll do better on the margin."
154924,374881090,1037210,"Agilent Technologies, Inc., Q3 2016 Earnings Call, Aug 17, 2016",2016-08-17,"Earnings Calls","Agilent Technologies, Inc.","Analysts","So I guess that's a segue to, I guess, the second guidance question. And I don't mean to be redundant here because there's been a lot of questions on this already. But I'm going to ask anyway. I mean, your guidance is for around 1.2% core revenue growth i",225,"So I guess that's a segue to, I guess, the second guidance question. And I don't mean to be redundant here because there's been a lot of questions on this already. But I'm going to ask anyway. I mean, your guidance is for around 1.2% core revenue growth in the quarter. If we think about this by end market, you actually have an easier compare in environmental forensics, academic government and food relative to certainly what you had in fiscal Q3. Diagnostics is a little tougher, but you have some real momentum there. So if we just, kind of to make it simple, assume all those end markets grow 3% to 5% and that chemical and energy is down mid-singles, it would imply that you guys are thinking pharma is only going to grow low single digits maybe at best in Q4. It's a tough compare in pharma in the quarter, but you've talked about continued strength in pharma in fiscal '17 in response to an earlier question. Again, recognizing the uncertainty you talked about in Europe, this is -- I guess some of this is hard to reconcile. Can you help out a little bit? And specifically again what are you assuming for pharma in the quarter? Is that because of the compare? And what's your assumption for Europe growth in the quarter?"
154924,374881090,1037210,"Agilent Technologies, Inc., Q3 2016 Earnings Call, Aug 17, 2016",2016-08-17,"Earnings Calls","Agilent Technologies, Inc.","Executives","Yes, sure. Glad to walk through this, Doug. In fact, we spent a lot of time modeling our end market views for the rest of the year, anticipating that this might be a question that would arise. And as I recall, Didier, I think that we had a less optimistic",106,"Yes, sure. Glad to walk through this, Doug. In fact, we spent a lot of time modeling our end market views for the rest of the year, anticipating that this might be a question that would arise. And as I recall, Didier, I think that we had a less optimistic view relative to academia and government than I think Doug's math was, where we were seeing -- where we were concerned about Europe. And we had -- we basically have it flat for the year, and I think we still have pharma overall double digits. So if you want to just maybe do a little walk-through?"
154924,374881090,1037210,"Agilent Technologies, Inc., Q3 2016 Earnings Call, Aug 17, 2016",2016-08-17,"Earnings Calls","Agilent Technologies, Inc.","Executives","Yes. The -- maybe, I mean, again, considering how we explained how we came up with the Q4 guidance, the makeup of the Q4 guidance by market in that academic and government and chemical and energy will show the same core revenue growth reduction year-over-",105,"Yes. The -- maybe, I mean, again, considering how we explained how we came up with the Q4 guidance, the makeup of the Q4 guidance by market in that academic and government and chemical and energy will show the same core revenue growth reduction year-over-year as in Q3, so minus 5% for academic and government, minus 4% for chemical and energy. So the assumption is no change between Q3 and Q4. And then for the rest, pharma, you mentioned pharma, we're assuming mid-single digit. And again, on a very tough compare and to -- in line with the way we've been very conservative on the..."
154924,374881090,1037210,"Agilent Technologies, Inc., Q3 2016 Earnings Call, Aug 17, 2016",2016-08-17,"Earnings Calls","Agilent Technologies, Inc.","Executives","Yes. And just to be clear, my comment earlier about double-digit pharma, that's for the full year.",17,"Yes. And just to be clear, my comment earlier about double-digit pharma, that's for the full year."
154924,374881090,1037210,"Agilent Technologies, Inc., Q3 2016 Earnings Call, Aug 17, 2016",2016-08-17,"Earnings Calls","Agilent Technologies, Inc.","Executives","For the full year or -- yes, double digit, absolutely.",10,"For the full year or -- yes, double digit, absolutely."
154924,374881090,1037210,"Agilent Technologies, Inc., Q3 2016 Earnings Call, Aug 17, 2016",2016-08-17,"Earnings Calls","Agilent Technologies, Inc.","Executives","Yes, Doug, maybe just one of -- as we thought about the company coming in, I think we thought that the pharma growth would be lower. We thought China would be lower, and we thought chemical and energy would be higher. And in fact, what's happened is pharm",68,"Yes, Doug, maybe just one of -- as we thought about the company coming in, I think we thought that the pharma growth would be lower. We thought China would be lower, and we thought chemical and energy would be higher. And in fact, what's happened is pharma has actually been stronger, and China is stronger than initially forecasted. And you know the story on chemical and energy."
154924,374881090,1037210,"Agilent Technologies, Inc., Q3 2016 Earnings Call, Aug 17, 2016",2016-08-17,"Earnings Calls","Agilent Technologies, Inc.","Analysts","Okay. The only thing I don't think we got there was just -- and maybe I missed it. But what is the assumption for Europe in the quarter?",28,"Okay. The only thing I don't think we got there was just -- and maybe I missed it. But what is the assumption for Europe in the quarter?"
154924,374881090,1037210,"Agilent Technologies, Inc., Q3 2016 Earnings Call, Aug 17, 2016",2016-08-17,"Earnings Calls","Agilent Technologies, Inc.","Executives","It's about flattish, down low-single digits, mostly on the basis of chemical and energy.",15,"It's about flattish, down low-single digits, mostly on the basis of chemical and energy."
154924,374881090,1037210,"Agilent Technologies, Inc., Q3 2016 Earnings Call, Aug 17, 2016",2016-08-17,"Earnings Calls","Agilent Technologies, Inc.","Executives","Yes. And the academia and government.",6,"Yes. And the academia and government."
154924,374881090,1037210,"Agilent Technologies, Inc., Q3 2016 Earnings Call, Aug 17, 2016",2016-08-17,"Earnings Calls","Agilent Technologies, Inc.","Executives","And academia and government, yes.",5,"And academia and government, yes."
154924,374881090,1037210,"Agilent Technologies, Inc., Q3 2016 Earnings Call, Aug 17, 2016",2016-08-17,"Earnings Calls","Agilent Technologies, Inc.","Operator","Our next question comes from the line of Tim Evans from Wells Fargo Securities.",14,"Our next question comes from the line of Tim Evans from Wells Fargo Securities."
154924,374881090,1037210,"Agilent Technologies, Inc., Q3 2016 Earnings Call, Aug 17, 2016",2016-08-17,"Earnings Calls","Agilent Technologies, Inc.","Analysts","This one's for Didier. It seems like cash flow is something that's going better than expectations or better than our expectations at least. Wondered if you could talk a little bit about the remaining levers that you have to pull on that as you go into 201",86,"This one's for Didier. It seems like cash flow is something that's going better than expectations or better than our expectations at least. Wondered if you could talk a little bit about the remaining levers that you have to pull on that as you go into 2017. Do you think that free cash flow growth in 2017 is really just going to be a matter of earnings growth? Or is there more than you can do there to improve free cash flow faster than earnings?"
154924,374881090,1037210,"Agilent Technologies, Inc., Q3 2016 Earnings Call, Aug 17, 2016",2016-08-17,"Earnings Calls","Agilent Technologies, Inc.","Executives","Yes. There is more that we can do. Certainly, the profit before tax is going to be a factor. But Henrik, who heads our order fulfillment and the supply chain organization has also committed to a material decrease in inventories.",40,"Yes. There is more that we can do. Certainly, the profit before tax is going to be a factor. But Henrik, who heads our order fulfillment and the supply chain organization has also committed to a material decrease in inventories."
154924,374881090,1037210,"Agilent Technologies, Inc., Q3 2016 Earnings Call, Aug 17, 2016",2016-08-17,"Earnings Calls","Agilent Technologies, Inc.","Executives","And he's here in the room to hear that directly.",11,"And he's here in the room to hear that directly."
154924,374881090,1037210,"Agilent Technologies, Inc., Q3 2016 Earnings Call, Aug 17, 2016",2016-08-17,"Earnings Calls","Agilent Technologies, Inc.","Executives","So that is also something that we are counting on that will help us continue expanding our operating cash flow as a percentage of revenue or percentage of profits.",29,"So that is also something that we are counting on that will help us continue expanding our operating cash flow as a percentage of revenue or percentage of profits."
154924,374881090,1037210,"Agilent Technologies, Inc., Q3 2016 Earnings Call, Aug 17, 2016",2016-08-17,"Earnings Calls","Agilent Technologies, Inc.","Analysts","Okay. And then a quick one, going back to one of Tycho's questions on the forensics end market. Of that 12% slice of pie that's environmental and forensics, would you be willing to tell us how much is forensics?",39,"Okay. And then a quick one, going back to one of Tycho's questions on the forensics end market. Of that 12% slice of pie that's environmental and forensics, would you be willing to tell us how much is forensics?"
154924,374881090,1037210,"Agilent Technologies, Inc., Q3 2016 Earnings Call, Aug 17, 2016",2016-08-17,"Earnings Calls","Agilent Technologies, Inc.","Executives","I don't think we disclose that and it's fairly small but enough to move it directly when big deals happen.",21,"I don't think we disclose that and it's fairly small but enough to move it directly when big deals happen."
154924,374881090,1037210,"Agilent Technologies, Inc., Q3 2016 Earnings Call, Aug 17, 2016",2016-08-17,"Earnings Calls","Agilent Technologies, Inc.","Operator","Our next question comes from the line of Isaac Ro from Goldman Sachs.",13,"Our next question comes from the line of Isaac Ro from Goldman Sachs."
154924,374881090,1037210,"Agilent Technologies, Inc., Q3 2016 Earnings Call, Aug 17, 2016",2016-08-17,"Earnings Calls","Agilent Technologies, Inc.","Analysts","Just had a question on margins and then a follow-up on Europe. On the margin side, if I look at sort of the components of gross margin, it's interesting that the LSAG division is your highest gross margin segment in most quarters, but that was one where y",88,"Just had a question on margins and then a follow-up on Europe. On the margin side, if I look at sort of the components of gross margin, it's interesting that the LSAG division is your highest gross margin segment in most quarters, but that was one where you saw a little pressure. So can you help us think a little bit about kind of the key initiatives you guys have under the hood there to continue driving better gross margin versus expectations and same goes through SG&A?"
154924,374881090,1037210,"Agilent Technologies, Inc., Q3 2016 Earnings Call, Aug 17, 2016",2016-08-17,"Earnings Calls","Agilent Technologies, Inc.","Executives","The question was what are the initiatives we have? I just want to make sure I understood the question.",19,"The question was what are the initiatives we have? I just want to make sure I understood the question."
154924,374881090,1037210,"Agilent Technologies, Inc., Q3 2016 Earnings Call, Aug 17, 2016",2016-08-17,"Earnings Calls","Agilent Technologies, Inc.","Analysts","Yes. Over the last, I don't know, 12 or 18 months, you guys talked a lot about some of the things you're doing to drive gross margin higher. This particular quarter, you had a little weakness in your most profitable segment. So I'm wondering kind of, asid",77,"Yes. Over the last, I don't know, 12 or 18 months, you guys talked a lot about some of the things you're doing to drive gross margin higher. This particular quarter, you had a little weakness in your most profitable segment. So I'm wondering kind of, aside from just the top line contribution, what you guys were able to achieve this quarter on the gross margin line that allowed you to put up a slightly better result."
154924,374881090,1037210,"Agilent Technologies, Inc., Q3 2016 Earnings Call, Aug 17, 2016",2016-08-17,"Earnings Calls","Agilent Technologies, Inc.","Executives","Great, great. Thanks for the question. So what we've been focusing on are really 3 dimensions around what we call our value-engineering program, our logistics model and also our strategic procurement approach with our suppliers. And as I look at the resul",427,"Great, great. Thanks for the question. So what we've been focusing on are really 3 dimensions around what we call our value-engineering program, our logistics model and also our strategic procurement approach with our suppliers. And as I look at the results in '16, the program that Henrik is driving across this company, I think we probably have seen the biggest impact so far in our improved logistics model. And you may recall we talked about logistics costs as being problematic in 2015. That's no longer the case. In fact, we've benchmarked ourselves, and we've got ourselves down to the best in our space. And there actually is more to come, which is the other 2 elements of the program have a little bit more longer tail in terms of payoff, which is value engineering, when you're reengineering product platforms to ensure both the continuation of the high performance but at a lower cost. And then as we also continue to transform our supplier engagement model and how we leverage the scale of Agilent. So I think those latter 2 parts of the program are going to carry us forward into '17 and '18 beyond, so I think that's how we're really working the gross margin side. And by the way, I also [indiscernible] of your comments were focused on LSAG. A lot of logistics costs and some of these other factors I mentioned, procurement, show up as impacts on the DDG and ACG business as well. And then relative to the SG&A, a couple of things that you may recall I highlighted in New York and I just reemphasize again, major focus on our systems infrastructure. So as you heard in my prepared remarks, we're now on one SAP instance, simplifying a lot of our work for our financial team and taking a lot of cost out of the system. The next big wave will be when we move the former Dako company into the Agilent environment in 2017 where we can really start to leverage the scale and take out costs and have an improved customer experience there. So there's a couple of big initiatives as well as we look at -- we're looking at other aspects of our benefit structure as we made some change, as you may know, earlier to our U.S. pension plan and the Agile Agilent program I mentioned is live. And we have a lot of initiatives underway to ensure that we can continue to take costs out while simplifying the company. Didier, anything else you would add to that?"
154924,374881090,1037210,"Agilent Technologies, Inc., Q3 2016 Earnings Call, Aug 17, 2016",2016-08-17,"Earnings Calls","Agilent Technologies, Inc.","Executives","I'd just mention the currency hedging. It had a big impact. It will have a big impact on a year-over-year basis. It's all impacts to gross margin. And ACG and DGG, because of their footprint, have been more penalized. So ACG on a year-over-year basis lost",97,"I'd just mention the currency hedging. It had a big impact. It will have a big impact on a year-over-year basis. It's all impacts to gross margin. And ACG and DGG, because of their footprint, have been more penalized. So ACG on a year-over-year basis lost $6 million in gross margin just because of the hedging programs; and DGG, $2 million. So that also explains the difference between ACG, DGG and LSAG. LSAG has a different footprint, obviously with a stronger presence in Europe, for example. And so that can distort a little bit the percentages."
154924,374881090,1037210,"Agilent Technologies, Inc., Q3 2016 Earnings Call, Aug 17, 2016",2016-08-17,"Earnings Calls","Agilent Technologies, Inc.","Analysts","That's helpful. Let me just follow-up on Europe. I want to make sure I understand kind of how -- what you're seeing now in that respect to the guidance end. So 2 items there. One is did the weakness in Europe, did that pick up in the month of July, just g",89,"That's helpful. Let me just follow-up on Europe. I want to make sure I understand kind of how -- what you're seeing now in that respect to the guidance end. So 2 items there. One is did the weakness in Europe, did that pick up in the month of July, just given you guys are off calendar versus the peer group? And secondly, does your guidance assume that the academic end market in Europe weakens further as the year progresses or that it sort of stabilizes from here?"
154924,374881090,1037210,"Agilent Technologies, Inc., Q3 2016 Earnings Call, Aug 17, 2016",2016-08-17,"Earnings Calls","Agilent Technologies, Inc.","Executives","Yes. So nothing unusual in July, and I think the assumption of the Q4 is basically a continuation, not any worse but not any better. And we just thought that was a prudent way to think about the company's performance fourth quarter. I would love to be wro",77,"Yes. So nothing unusual in July, and I think the assumption of the Q4 is basically a continuation, not any worse but not any better. And we just thought that was a prudent way to think about the company's performance fourth quarter. I would love to be wrong, and I hope I'm wrong. But we thought from a planning and guidance standpoint, we should be prudent in terms of how we looked at the European market overall."
154924,374881090,1037210,"Agilent Technologies, Inc., Q3 2016 Earnings Call, Aug 17, 2016",2016-08-17,"Earnings Calls","Agilent Technologies, Inc.","Operator","Our next question comes from the line of Derik De Bruin from Bank of America.",15,"Our next question comes from the line of Derik De Bruin from Bank of America."
154924,374881090,1037210,"Agilent Technologies, Inc., Q3 2016 Earnings Call, Aug 17, 2016",2016-08-17,"Earnings Calls","Agilent Technologies, Inc.","Analysts","So a lot of the revenue questions have been asked. And I mean, it certainly seems prudent to me your guidance, just given that Europe, even under a good -- even in a good year, this -- the calendar third quarter is always a little bit choppy anyway, so th",119,"So a lot of the revenue questions have been asked. And I mean, it certainly seems prudent to me your guidance, just given that Europe, even under a good -- even in a good year, this -- the calendar third quarter is always a little bit choppy anyway, so there's clearly some heightened uncertainty this year. So I think it's prudent to be a little bit conservative. But could you just talk a bit about some of the -- I noticed the share count was a little bit higher this quarter than what you previously guided to. Are you still looking at buying back 1% of the outstanding shares as we sort of go into the -- going forward?"
154924,374881090,1037210,"Agilent Technologies, Inc., Q3 2016 Earnings Call, Aug 17, 2016",2016-08-17,"Earnings Calls","Agilent Technologies, Inc.","Executives","Yes. Why don't you talk a little bit about the -- our share repurchase activity in the quarter and how we're thinking about it going forward, Didier?",27,"Yes. Why don't you talk a little bit about the -- our share repurchase activity in the quarter and how we're thinking about it going forward, Didier?"
154924,374881090,1037210,"Agilent Technologies, Inc., Q3 2016 Earnings Call, Aug 17, 2016",2016-08-17,"Earnings Calls","Agilent Technologies, Inc.","Executives","Yes. We filed back in, what, November 20, I think, of last year a 10b5-1 on an annual basis, and we intend to file a new one, to register a new one also in November of this year. And it's a formula-based instructions that we have provided between buying 3",133,"Yes. We filed back in, what, November 20, I think, of last year a 10b5-1 on an annual basis, and we intend to file a new one, to register a new one also in November of this year. And it's a formula-based instructions that we have provided between buying 350,000 shares a day under certain conditions to buying 0 kind of thing with a cap as you can imagine. So we don't know exactly how it's going to play out in Q4. And the only thing that we know is that if there's any kind of shortfall at all in our intended buying in Q4 because of the formula in the 10b5-1, it will all be carried over into the following year. So we intend to spend exactly what we committed to spend."
154924,374881090,1037210,"Agilent Technologies, Inc., Q3 2016 Earnings Call, Aug 17, 2016",2016-08-17,"Earnings Calls","Agilent Technologies, Inc.","Analysts","Great. That's really helpful. And could you just give us a metric on what instruments versus consumable growth was in the quarter as an overall number for the company?",29,"Great. That's really helpful. And could you just give us a metric on what instruments versus consumable growth was in the quarter as an overall number for the company?"
154924,374881090,1037210,"Agilent Technologies, Inc., Q3 2016 Earnings Call, Aug 17, 2016",2016-08-17,"Earnings Calls","Agilent Technologies, Inc.","Executives","I think probably the best way to think about it is just look at the respective business groups. So you have the LSAG results of down 2%, and then the...",30,"I think probably the best way to think about it is just look at the respective business groups. So you have the LSAG results of down 2%, and then the..."
154924,374881090,1037210,"Agilent Technologies, Inc., Q3 2016 Earnings Call, Aug 17, 2016",2016-08-17,"Earnings Calls","Agilent Technologies, Inc.","Executives","ACG up 8%; and DGG, up 8% also.",9,"ACG up 8%; and DGG, up 8% also."
154924,374881090,1037210,"Agilent Technologies, Inc., Q3 2016 Earnings Call, Aug 17, 2016",2016-08-17,"Earnings Calls","Agilent Technologies, Inc.","Executives","And Dako. So minus 2%, plus 8%. And that's why I -- again, as you think about '17 for the company, if you really want to look at the growth rates of those 2 business units in the recurring revenue space, ACG and DGG, perhaps differently than you might thi",67,"And Dako. So minus 2%, plus 8%. And that's why I -- again, as you think about '17 for the company, if you really want to look at the growth rates of those 2 business units in the recurring revenue space, ACG and DGG, perhaps differently than you might think about how you model the risk profile for revenue projections for the instruments side of the company."
154924,374881090,1037210,"Agilent Technologies, Inc., Q3 2016 Earnings Call, Aug 17, 2016",2016-08-17,"Earnings Calls","Agilent Technologies, Inc.","Analysts","Great. That's really helpful. And I guess, could you -- when you sort of -- you're still feeling good about the margin target for '17, and it sounds like that your IT initiatives are well underway or finished to do like that. Are you -- do you still feel",62,"Great. That's really helpful. And I guess, could you -- when you sort of -- you're still feeling good about the margin target for '17, and it sounds like that your IT initiatives are well underway or finished to do like that. Are you -- do you still feel confident about getting what you're expecting for next year for the margin improvement?"
154924,374881090,1037210,"Agilent Technologies, Inc., Q3 2016 Earnings Call, Aug 17, 2016",2016-08-17,"Earnings Calls","Agilent Technologies, Inc.","Executives","Yes, absolutely. So that's why I made a few comments about it earlier because as we said, if we can be in a 4.5%, 5% kind of growth range, perhaps even low 4%, it makes it a little bit more challenging. But we can see -- we see the path to 22%. It's not j",218,"Yes, absolutely. So that's why I made a few comments about it earlier because as we said, if we can be in a 4.5%, 5% kind of growth range, perhaps even low 4%, it makes it a little bit more challenging. But we can see -- we see the path to 22%. It's not just around margins. I mean, especially not just around margin improvement from volume. But there are specific real programs. It's something we review once a month, then we have active programs, and the costs will continue to come out on some of these big programs. Actually, I must say I'm really pleased with the team because we've -- we went through and did the -- we call project Nunu [ph] is the finance program we just finished up. And then right on the heels of that, we're going to go live in early '17 with our integration of Dako. So the teams are still energized and working hard, and I think these are going to have a material impact on our results in '17. And that's why we have confidence about the -- assuming no major change in terms of the macro environment that we can reach what we think are pretty challenging goals, but they're -- we've got a path to get there."
154924,374881090,1037210,"Agilent Technologies, Inc., Q3 2016 Earnings Call, Aug 17, 2016",2016-08-17,"Earnings Calls","Agilent Technologies, Inc.","Operator","Our next question comes from the line of Dan Arias from Citigroup.",12,"Our next question comes from the line of Dan Arias from Citigroup."
154924,374881090,1037210,"Agilent Technologies, Inc., Q3 2016 Earnings Call, Aug 17, 2016",2016-08-17,"Earnings Calls","Agilent Technologies, Inc.","Analysts","Patrick, just going back to your comments on share gains in LC. I know you guys don't like to get too specific on winners and losers. But as was mentioned, it does look like all of the major players are doing fairly well there. So who would you say you're",72,"Patrick, just going back to your comments on share gains in LC. I know you guys don't like to get too specific on winners and losers. But as was mentioned, it does look like all of the major players are doing fairly well there. So who would you say you're taking share from? Is it the small column providers or does that actually extend into some of the box companies as well?"
154924,374881090,1037210,"Agilent Technologies, Inc., Q3 2016 Earnings Call, Aug 17, 2016",2016-08-17,"Earnings Calls","Agilent Technologies, Inc.","Executives","Well, I -- thanks for the question. I can give you only a general flavor here on what we think is going on in the market. I will not comment on the individual competitors, but your assumption that the smaller suppliers probably take a larger hit is also o",50,"Well, I -- thanks for the question. I can give you only a general flavor here on what we think is going on in the market. I will not comment on the individual competitors, but your assumption that the smaller suppliers probably take a larger hit is also our observation."
154924,374881090,1037210,"Agilent Technologies, Inc., Q3 2016 Earnings Call, Aug 17, 2016",2016-08-17,"Earnings Calls","Agilent Technologies, Inc.","Analysts","Okay. And then maybe a specific one on C&E. Mike, at the Analyst Day, you called out a Saudi Arabian refinery build-out that was getting going. Have you started to see some demand there? And is that something that you think contributes at all to the back",51,"Okay. And then maybe a specific one on C&E. Mike, at the Analyst Day, you called out a Saudi Arabian refinery build-out that was getting going. Have you started to see some demand there? And is that something that you think contributes at all to the back half of the year?"
154924,374881090,1037210,"Agilent Technologies, Inc., Q3 2016 Earnings Call, Aug 17, 2016",2016-08-17,"Earnings Calls","Agilent Technologies, Inc.","Executives","The major projects that were underway haven't been canceled, so -- but we're not seeing any major new projects underway. There's a lot of -- there's actually a lot of positive news by a lot of studies about where this market's going, but we're not seeing",156,"The major projects that were underway haven't been canceled, so -- but we're not seeing any major new projects underway. There's a lot of -- there's actually a lot of positive news by a lot of studies about where this market's going, but we're not seeing -- what we're -- just to clarify here, the major project that we knew about, whether it be the one I mentioned in Saudi or the -- there's a major project down in Texas. These programs, they're going to come online. So people aren't canceling capacity increase projects, but we're not seeing a lot of new projects. And that's why we have taken a fairly conservative -- probably be a bit pragmatic view of that marketplace. Again, I would remind everybody, too, that when we talk about chemical and energy, 50% or so is actually chemicals -- chemical processing not directly tied to the exploration and production of oil."
154924,374881090,1037210,"Agilent Technologies, Inc., Q3 2016 Earnings Call, Aug 17, 2016",2016-08-17,"Earnings Calls","Agilent Technologies, Inc.","Operator","Our next question comes from the line of Paul Knight from Janney Montgomery Scott.",14,"Our next question comes from the line of Paul Knight from Janney Montgomery Scott."
154924,374881090,1037210,"Agilent Technologies, Inc., Q3 2016 Earnings Call, Aug 17, 2016",2016-08-17,"Earnings Calls","Agilent Technologies, Inc.","Analysts","I guess specifically what is the GC business doing? What's its growth rate? What was it doing in the July quarter? And what's the backlog or what are the -- what's July or August look like, I guess?",38,"I guess specifically what is the GC business doing? What's its growth rate? What was it doing in the July quarter? And what's the backlog or what are the -- what's July or August look like, I guess?"
154924,374881090,1037210,"Agilent Technologies, Inc., Q3 2016 Earnings Call, Aug 17, 2016",2016-08-17,"Earnings Calls","Agilent Technologies, Inc.","Executives","Well, thanks, Paul, I appreciate the question. As you probably will understand, I'll give you more a high-level result because we don't actually comment specifically at a product category level, beyond, I think, I would just reemphasize the point that Pat",135,"Well, thanks, Paul, I appreciate the question. As you probably will understand, I'll give you more a high-level result because we don't actually comment specifically at a product category level, beyond, I think, I would just reemphasize the point that Patrick made when he characterized the chromatography market. That business is down relative to last year because the chemical and energy market is down. And we have seen no movement at all, downward pressure on our share position. It's really a market phenomena we're dealing with right now. And that's why when that replacement market does turn, and we've been through these cycles before, when it does turn, we'll be in a strong position to capture that growth as given the strength of our position in that market, which right now happens to be down."
154924,374881090,1037210,"Agilent Technologies, Inc., Q3 2016 Earnings Call, Aug 17, 2016",2016-08-17,"Earnings Calls","Agilent Technologies, Inc.","Analysts","And then last, on the applied markets in a broader sense, do you think it's still a GDP growth rate normalized or what do you think the applied markets should be for Agilent?",33,"And then last, on the applied markets in a broader sense, do you think it's still a GDP growth rate normalized or what do you think the applied markets should be for Agilent?"
154924,374881090,1037210,"Agilent Technologies, Inc., Q3 2016 Earnings Call, Aug 17, 2016",2016-08-17,"Earnings Calls","Agilent Technologies, Inc.","Executives","We actually don't think about it that way because the segments that -- or big segments of the market like your food and environmental testing, we think are independent to some extent of GDP. So the only way I think that we really think about that as relat",152,"We actually don't think about it that way because the segments that -- or big segments of the market like your food and environmental testing, we think are independent to some extent of GDP. So the only way I think that we really think about that as relative to is our chemical and energy space. So if you could just kind of think about tying GDP to that subsegment of the company, I think that's -- would be good place to start. But I would not apply it to the whole what we call Applied Markets because these are being driven by quality-of-life investments in the food and environmental area. And I think that's why -- I think this composition of our end markets is the reason why we're being able to put up these kind of growth rates even when our #2 market as a company has shrunk this year."
154924,374881090,1037210,"Agilent Technologies, Inc., Q3 2016 Earnings Call, Aug 17, 2016",2016-08-17,"Earnings Calls","Agilent Technologies, Inc.","Analysts","And then last on -- you had your Analyst Day, obviously. You've been talking about a 22% operating margin. Are you more or less confident in that number for FY '17 at this juncture?",34,"And then last on -- you had your Analyst Day, obviously. You've been talking about a 22% operating margin. Are you more or less confident in that number for FY '17 at this juncture?"
154924,374881090,1037210,"Agilent Technologies, Inc., Q3 2016 Earnings Call, Aug 17, 2016",2016-08-17,"Earnings Calls","Agilent Technologies, Inc.","Executives","Yes. I think the confidence level is the same as it was back in May. And again, I'd maybe just share a few points here, which as you know, we have this confidence of delivery on that given our belief that we can get that growth rate that we're putting up",274,"Yes. I think the confidence level is the same as it was back in May. And again, I'd maybe just share a few points here, which as you know, we have this confidence of delivery on that given our belief that we can get that growth rate that we're putting up growth rates right now in that territory. We've got this pipeline of new products coming out. We've got this nice recurring revenue stream with ACG and DDG that will carry this momentum into '17 and that where our instrument business is going, hey, pharma looks -- still looks good. Of course, you have these double-digit compare issues. China looks to continue to be strong. And chemical and energy has got to turn at some point in time because the market requires these tools to support production. Our thinking is when we look at chemical and energy is we know our customers are looking for productivity improvements to help improve their company profitability. We think that's a value proposition that Agilent has. We think as they go through their budget justification processes and their budgets start in calendar 2017, that this is why we can say, ""Listen, the decline in this business after 18 to 24 months will start to turn,"" and we could see low single digits by the end of 2017 for the chemical and energy market. If that happens, which we believe it will, that will give us the confidence to get the growth and then we know we'll get the margin, given both the volume but also in terms of gross margin improvement initiatives as well as our SG&A cost."
154924,374881090,1037210,"Agilent Technologies, Inc., Q3 2016 Earnings Call, Aug 17, 2016",2016-08-17,"Earnings Calls","Agilent Technologies, Inc.","Operator","And our final question today comes from the line of Catherine Ramsey from Robert W. Baird.",16,"And our final question today comes from the line of Catherine Ramsey from Robert W. Baird."
154924,374881090,1037210,"Agilent Technologies, Inc., Q3 2016 Earnings Call, Aug 17, 2016",2016-08-17,"Earnings Calls","Agilent Technologies, Inc.","Analysts","We've heard a lot of commentary from your peers on Japan; strong pharma environment, weak academic government. So I was wondering if you could walk through your exposure by end market there and what you're seeing across those customer groups.",41,"We've heard a lot of commentary from your peers on Japan; strong pharma environment, weak academic government. So I was wondering if you could walk through your exposure by end market there and what you're seeing across those customer groups."
154924,374881090,1037210,"Agilent Technologies, Inc., Q3 2016 Earnings Call, Aug 17, 2016",2016-08-17,"Earnings Calls","Agilent Technologies, Inc.","Executives","Didier, do you remember the total Japan numbers? I think were...",11,"Didier, do you remember the total Japan numbers? I think were..."
154924,374881090,1037210,"Agilent Technologies, Inc., Q3 2016 Earnings Call, Aug 17, 2016",2016-08-17,"Earnings Calls","Agilent Technologies, Inc.","Executives","About 5% of overall...",4,"About 5% of overall..."
154924,374881090,1037210,"Agilent Technologies, Inc., Q3 2016 Earnings Call, Aug 17, 2016",2016-08-17,"Earnings Calls","Agilent Technologies, Inc.","Executives","5%. Yes, just to give you a sense of -- 5% of the total market. Historically, we've been stronger, and I can share this from my experience having been the country manager for Japan for a few years in the early part of my career. We tend to be much stronge",137,"5%. Yes, just to give you a sense of -- 5% of the total market. Historically, we've been stronger, and I can share this from my experience having been the country manager for Japan for a few years in the early part of my career. We tend to be much stronger in the chemical and energy segment of that marketplace. We are doing well in the life science research and in genomics, but the majority of the business sits in the chemical and energy space, which is -- which has been down. I think Japan has been part of that story. Pharma, the pharma business for us is a relatively smaller portion of the market for us. I think they're doing well in pharma but not enough to really drive significant overall growth rates for Japan."
154924,374881090,1037210,"Agilent Technologies, Inc., Q3 2016 Earnings Call, Aug 17, 2016",2016-08-17,"Earnings Calls","Agilent Technologies, Inc.","Analysts","Okay, great. And then any color on the progress of Dako integration? What's left to do there? Had some nice op margin expansion in DGG this quarter, so are you still thinking that 20% in fiscal '17 or could there be upside to that number?",45,"Okay, great. And then any color on the progress of Dako integration? What's left to do there? Had some nice op margin expansion in DGG this quarter, so are you still thinking that 20% in fiscal '17 or could there be upside to that number?"
154924,374881090,1037210,"Agilent Technologies, Inc., Q3 2016 Earnings Call, Aug 17, 2016",2016-08-17,"Earnings Calls","Agilent Technologies, Inc.","Executives","Jacob happens to be sitting right next to me in this conference room. I don't think he's ready to sign up for more than 20% because it is quite a improvement from where we started. But I think he remains quite confident in the 20% achievement of that goal",186,"Jacob happens to be sitting right next to me in this conference room. I don't think he's ready to sign up for more than 20% because it is quite a improvement from where we started. But I think he remains quite confident in the 20% achievement of that goal of an O&M perspective. You saw we had 18.8% operating margin this quarter, 200 basis points over last year. And the big next wave of integration efforts will really be starting in our Q1 '17, So we have a major program we call it project de Gaulle [ph]. We seem to like a lot of these French names, Didier. I'm not sure why that may be the case, but -- and that really will be the next big step to move the former Dako company into the Agilent environment. And it will take a little bit of while to get the cost out, but as you go -- as you think about exiting '17, you're going to have a much lower SG&A spend than you started the year. And, Jacob, I don't think you'd share anything else?"
154924,374881090,1037210,"Agilent Technologies, Inc., Q3 2016 Earnings Call, Aug 17, 2016",2016-08-17,"Earnings Calls","Agilent Technologies, Inc.","Executives","No. I think you captured it correctly. I just want to reinforce what you said, that the path to 20%, actually delivering 20% in 2017 is a significant turnaround of where we were a few years ago. So right now, that's our full aim, and I'm very happy where",57,"No. I think you captured it correctly. I just want to reinforce what you said, that the path to 20%, actually delivering 20% in 2017 is a significant turnaround of where we were a few years ago. So right now, that's our full aim, and I'm very happy where the team is and executing this right now."
154924,374881090,1037210,"Agilent Technologies, Inc., Q3 2016 Earnings Call, Aug 17, 2016",2016-08-17,"Earnings Calls","Agilent Technologies, Inc.","Executives","Thanks, Jacob.",2,"Thanks, Jacob."
154924,374881090,1037210,"Agilent Technologies, Inc., Q3 2016 Earnings Call, Aug 17, 2016",2016-08-17,"Earnings Calls","Agilent Technologies, Inc.","Operator","And this does conclude the question-and-answer session of today's program. I'd like to hand the program back to Alicia Rodriguez for any further remarks.",25,"And this does conclude the question-and-answer session of today's program. I'd like to hand the program back to Alicia Rodriguez for any further remarks."
154924,374881090,1037210,"Agilent Technologies, Inc., Q3 2016 Earnings Call, Aug 17, 2016",2016-08-17,"Earnings Calls","Agilent Technologies, Inc.","Executives","Thank you, Jonathan. And on behalf of the entire management team, I'd like to thank everybody for joining us today. If you have any questions, please give us a call at IR. Thanks again. Bye-bye.",35,"Thank you, Jonathan. And on behalf of the entire management team, I'd like to thank everybody for joining us today. If you have any questions, please give us a call at IR. Thanks again. Bye-bye."
154924,374881090,1037210,"Agilent Technologies, Inc., Q3 2016 Earnings Call, Aug 17, 2016",2016-08-17,"Earnings Calls","Agilent Technologies, Inc.","Operator","Thank you, ladies and gentlemen, for your participation in today's conference. This does conclude the program. You may now disconnect. Good day.",22,"Thank you, ladies and gentlemen, for your participation in today's conference. This does conclude the program. You may now disconnect. Good day."
154924,374881090,1037613,"Agilent Technologies, Inc., Q3 2016 Earnings Call, Aug 17, 2016",2016-08-17,"Earnings Calls","Agilent Technologies, Inc.","Operator","Good day ladies and gentlemen, and welcome to the Third Quarter 2016 Agilent Technologies Earnings Conference Call. [Operator Instructions] As a reminder, today's program is being recorded. I would now like to introduce your host for today's program, Al",48,"Good day ladies and gentlemen, and welcome to the Third Quarter 2016 Agilent Technologies Earnings Conference Call. [Operator Instructions] As a reminder, today's program is being recorded. 
I would now like to introduce your host for today's program, Alicia Rodriguez, Vice President of Investor Relations. Please go ahead."
154924,374881090,1037613,"Agilent Technologies, Inc., Q3 2016 Earnings Call, Aug 17, 2016",2016-08-17,"Earnings Calls","Agilent Technologies, Inc.","Executives","Thank you, Jonathan, and welcome, everyone, to Agilent's Third Quarter Conference Call for Fiscal Year 2016. With me are Mike McMullen, Agilent's President and CEO; and Didier Hirsch, Agilent's Vice -- Senior Vice President and CFO.Joining in the Q&A af",342,"Thank you, Jonathan, and welcome, everyone, to Agilent's Third Quarter Conference Call for Fiscal Year 2016. With me are Mike McMullen, Agilent's President and CEO; and Didier Hirsch, Agilent's Vice -- Senior Vice President and CFO.
Joining in the Q&A after Didier's comments will be Patrick Kaltenbach, President of Agilent's Life Sciences and Applied Markets Group; Jacob Thaysen, President of Agilent's Diagnostics and Genomics Group; and Mark Doak, President of the Agilent CrossLab Group.
You can find the press release and information to supplement today's discussion on our website at www.investor.agilent.com. While there, please click on the link for financial results under the Financial Information tab. You will find an investor presentation along with revenue breakouts and currency impacts, business segment results and historical financials for Agilent's operations. We will also post a copy of the prepared remarks following this call. 
Today's comments by Mike and Didier will refer to non-GAAP financial measures. You will find the most directly comparable GAAP financial metrics and reconciliations on our website. We will refer to core revenue growth, which excludes the impact of currency, the NMR business and acquisitions and divestitures within the past 12 months. 
Please note that we are reporting results for the Americas, Europe and Asia on a ship-to basis. Previously, we assigned revenue to these regions based on where the order was placed. This change aligns with individual country reporting, which has always been on a ship-to basis. Historical restatements are available on the Investor Relations website. 
Unless otherwise noted, all references to increases or decreases in financial metrics are year-over-year. Guidance is based on exchange rates as of the last day of the reported quarter. 
We will also make forward-looking statements about the financial performance of the company. These statements are subject to risks and uncertainties and are only valid as of today. The company assumes no obligation to update them. Please look at the company's recent SEC filings for a more complete picture of our risks and other factors. 
And now let me turn the call over to Mike."
154924,374881090,1037613,"Agilent Technologies, Inc., Q3 2016 Earnings Call, Aug 17, 2016",2016-08-17,"Earnings Calls","Agilent Technologies, Inc.","Executives","Thanks, Alicia, and hello, everyone. Thank you for joining us on today's call. I'm pleased to report that the Agilent team delivered another quarter above expectations. Now let me highlight 3 key results: First, core -- Q3 core revenue growth of 3% was",1444,"Thanks, Alicia, and hello, everyone. Thank you for joining us on today's call. I'm pleased to report that the Agilent team delivered another quarter above expectations. 
Now let me highlight 3 key results: First, core -- Q3 core revenue growth of 3% was above the high end of our May guidance. Second, EPS of $0.49 was also above the high end of our guidance of $0.45 to $0.47. Finally, we delivered adjusted operating margin of 20.6%, an increase of 70 basis points from a year ago. 
As for the third quarter results echo many of the same themes that we saw last quarter, the pharma, food, clinical and diagnostics end markets remain strong. In the chemical and energy market, while demand for our services and consumables was strong, capital expenditures for new equipment purchases remain challenged. Geographically, Asia, led by China's double-digit growth, drove Agilent third quarter core growth with strength across all business segments. 
Let me highlight our Q3 results by business group. In line with our expectations, Life Sciences and Applied Markets Group core revenues were down 2%. Our strong growth in pharma, environmental and food markets was offset by continued weakness in chemical and energy capital expenditures. Academia and government revenues were also down across most regions. Despite this mixed market environment, LSAG's operating margin for the quarter was 19.1%, up 40 basis points from a year ago. 
Let me shift gears and talk about some of LSAG's new products. We are seeing very strong demand, the newly released 1260 and the 1290 Infinity II LC systems. The 1260 systems are part of the launch of the InfinityLab portfolio at Analytica in May. The InfinityLab portfolio consists of this new line of LC instruments along with columns, supplies and services. In Q3, LSAG also introduced the new -- 2 new 7000 Series Triple Quad GC/MS analyzers, one for pesticides and another for environmental pollutants. And we continue to strengthen our ICP-MS market leadership with the new Agilent 8900 Triple Quad ICP-MS system. This new system offers customers improved speed and accuracy of analysis.
Turning to the Agilent CrossLab Group. The business delivered another strong quarter with 8% core revenue growth. This growth is driven by strength in the food, pharma and environmental markets. ACG's operating margin for the quarter was 22.7%, up 10 basis points from a year ago. 
Portfolio expansion efforts also continued in ACG. In Q3, Agilent signed a definitive agreement to acquire the assets of iLab, and we just closed the transaction in early August. iLab is the market leader in cloud-based solutions for core laboratory management and provide services to leading universities, research hospitals and independent institutions around the world. This acquisition further expands Agilent's portfolio in the academia and government market. iLab enables Agilent to deliver broader value for our customers in this market segment. We also see an opportunity to expand the iLab business both geographically and into the pharma market.
Finally, we saw a continued momentum in the Diagnostics and Genomics Group where the business delivered 8% core growth in Q3. We saw strength across all DGG businesses, driven by growth in the pharma and clinical and diagnostics market. Our pathology business continues on a steady trajectory of improved growth. This was highlighted by demand for our new PD-L1 companion diagnostics. Growth in genomics reflect a strong market performance in the U.S. and China across our Array CGH, Target Enrichment and SureSelect products. We also saw healthy demand for our Nucleic Acid Solutions offering. DGG's operating margin for the quarter was 18.8%, up 200 basis points from a year ago. 
Q3 highlights for DGG include the announcement of an expansion of the intended use of our PD-L1 pharmDX test in Europe for patients with melanoma. This test was previously proven in the U.S. and available in Europe for patients with non-squamous, non-small-cell lung cancer and in the U.S. with patients -- for patients with melanoma. We also announced a $120 million investment over the next 3 years to expand production capacity for our Nucleic Acid Solutions business. This includes the purchase of 20 acres of land in Colorado. We plan to build our factory on this land that will double our manufacturing capacity for nucleic acid active pharmaceutical ingredients and grow our business.
Now I'll provide an overview of Agilent's core revenues by end market. In our life sciences market, pharma saw its sixth consecutive quarter of double-digit growth with core revenue up 10%. Academia and government core revenues were down 5%, down across most geographies except China. Clinical and diagnostics grew 4% with strength in North America and Asia and led by growth in pathology. 
Applied end-market performance was mixed. Food was up 11% with strong demand in China and the Americas. These regions also drove growth in environmental market for both instruments and aftermarket products. 
This performance was offset by continued challenges in the chemical and energy market, down 4% globally, with only Asia posting growth on a regional basis. The overall result was due to prolonged effects of the macroeconomic concerns and lower oil prices. 
Now I'll turn an update on our operating margin improvement initiatives. Q3 marked a major step forward in simplifying our company's infrastructure. In May, we completed the migration of the company's financial systems onto a single SAP platform. This was a culmination of a 20-month cross-company effort and represents a major step in simplifying Agilent's systems infrastructure that will deliver incremental cost savings as planned in fiscal 2017. 
In summary, our multiyear Agile Agilent program continues to simplify the company's business processes. This program is designed to make us more nimble and lower our costs. It will continue to deliver incremental savings in 2017.
On the capital deployment front, we purchased iLab, paid $37 million in dividends and repurchased $94 million of Agilent stock. We continue to deliver on our strategy to drive sustainable growth while expanding operating margins and balancing deployment of our capital to drive shareholder value creation. 
At our recent May Analyst Meeting, I described our shareholder value creation model: outgrow the market, expand operating margins, balance capital deployment. Let's look at our Q3 results in the context of these longer-term goals and shareholder value creation model. 
In 2015, we delivered our highest annual growth rate in 4 years while increasing adjusted operating margin 170 basis points and completely offsetting the $40 million of dissynergies from the company split. We have sustained this trajectory of improved operating results in fiscal 2016. In the first 3 quarters of 2016, the team has delivered strong growth and earnings above our initial expectation despite a challenging chemical and energy market environment and global macroeconomic concerns.
We have continued to leverage our balance sheet and deployed capital in a balanced manner, buying companies that bring new capabilities to Agilent while repurchasing our stock and increasing cash dividends. 
The new leadership team continues to transform the business and deliver results. We continue to demonstrate our ability to deliver above-industry organic growth while expanding margins and leveraging our balance sheet strength. Our Q3 results in a challenging global economic environment reflect the strength of our team combined with Agilent's scale and broad differentiated portfolio of products and services. 
Looking at today's overall market environment, we expect continued strength in pharma, along with growth in the food, environmental and clinical research and diagnostics markets and in China on a regional basis. 
As I highlighted in our last call, we are experiencing a steeper and more prolonged slowdown in the chemical and energy market than initially projected entering fiscal 2016. We subsequently revised our forecast for this market segment last quarter to overall low single-digit market declines for the year. While there are some signs of an impending bottom in the market, we remain cautious in our outlook and expect Q4 to be in a similar range as the past quarter. 
Against this market drop (sic) [ backdrop ], we are well positioned to capture growth in these end-market segments and geographies where growth is expected to remain strong. The combination of our expanding our customer channel reach and continual strengthening of our portfolio positions us well to achieve our previously raised full year guidance of 2016 and our longer-term goals. Our One Agilent team continues to work well together and is energized to win in the market. Overall, we remain on track with our 2017 goal to outgrow the market and improve our operating margin to 22%. 
Thank you for being on the call today. I will now turn it over to Didier who will provide additional insights on our financial results and guidance for the remainder of 2016. Didier?"
154924,374881090,1037613,"Agilent Technologies, Inc., Q3 2016 Earnings Call, Aug 17, 2016",2016-08-17,"Earnings Calls","Agilent Technologies, Inc.","Executives","Thank you, Mike, and hello, everyone. As mentioned by Mike, we delivered higher core revenue growth, operating margin and earnings per share than the high end of our guidance. Earnings per share grew 11% in the quarter versus a year ago. We also generated",325,"Thank you, Mike, and hello, everyone. As mentioned by Mike, we delivered higher core revenue growth, operating margin and earnings per share than the high end of our guidance. Earnings per share grew 11% in the quarter versus a year ago. We also generated $194 million in operating cash flow, more than double last year's amount, which gives us increased confidence that we will achieve our previously raised operating cash flow guidance for the full year. FX had a negative impact on revenue of about $10 million or 1% versus previous guidance and $7 million or 0.7% versus last year. It had a negative impact on operating profit of $3 million versus previous guidance and $1 million versus last year.
I'll now turn to the guidance for our fourth quarter. We expect Q4 revenues of $1.05 billion to $1.07 billion and earnings per share of $0.50 to $0.52. At midpoint, revenue is expected to grow 1.2% on a core basis. Versus previous guidance, FX is estimated to have a negative impact of $9 million on revenue and $2 million on operating profit. Our 21.3% adjusted operating margin at midpoint will be up 70 basis points sequentially.
Now to the guidance for fiscal year 2016. The Q4 guidance results in the following fiscal year guidance. At midpoint, revenue is projected to grow 4.5% on a core basis, no change from the previous guidance. Our earnings per share guidance of $1.90 at midpoint is also unchanged from previous guidance and corresponds to a 9% year-over-year increase. Adjusted operating margin for the year is expected to be 20.4 basis points or 80 basis points higher than in fiscal year '15. And finally, FX is estimated to have a negative impact on a year-over-year basis of $68 million on revenue, $10 million on operating profit related to currency translation and an additional $21 million related to currency hedging. 
With that, I'll turn it over to Alicia for the Q&A."
154924,374881090,1037613,"Agilent Technologies, Inc., Q3 2016 Earnings Call, Aug 17, 2016",2016-08-17,"Earnings Calls","Agilent Technologies, Inc.","Executives","Thank you, Didier. Jonathan, will you please give the instructions for the Q&A?",13,"Thank you, Didier. Jonathan, will you please give the instructions for the Q&A?"
154924,374881090,1037613,"Agilent Technologies, Inc., Q3 2016 Earnings Call, Aug 17, 2016",2016-08-17,"Earnings Calls","Agilent Technologies, Inc.","Operator","[Operator Instructions] Our first question comes from the line of Brandon Couillard from Jefferies. Our next question comes from the line of Steve Beuchaw from Morgan Stanley.",27,"[Operator Instructions] Our first question comes from the line of Brandon Couillard from Jefferies. Our next question comes from the line of Steve Beuchaw from Morgan Stanley."
154924,374881090,1037613,"Agilent Technologies, Inc., Q3 2016 Earnings Call, Aug 17, 2016",2016-08-17,"Earnings Calls","Agilent Technologies, Inc.","Analysts","I want to start with the one regional trend that seems to be on many people's minds, which is what's going on in Europe. I wonder if you could speak to the trends that you saw in Europe over the course of the quarter. To some extent, it's a macro question",99,"I want to start with the one regional trend that seems to be on many people's minds, which is what's going on in Europe. I wonder if you could speak to the trends that you saw in Europe over the course of the quarter. To some extent, it's a macro question. To some extent, it's a research question. And of course, there's the -- their U.K. referendum that's still out there. So I apologize for the nebulous nature of it all, but any color on how Europe progressed over the course of the quarter would be really helpful."
154924,374881090,1037613,"Agilent Technologies, Inc., Q3 2016 Earnings Call, Aug 17, 2016",2016-08-17,"Earnings Calls","Agilent Technologies, Inc.","Executives","Yes, sure. Glad to provide some insight there, and then I'm going to actually have Patrick jump in on this conversation, given your recent travels in the region. But what we saw in the quarter was, obviously, a lot of big macro events, the Brexit, Turkey.",178,"Yes, sure. Glad to provide some insight there, and then I'm going to actually have Patrick jump in on this conversation, given your recent travels in the region. But what we saw in the quarter was, obviously, a lot of big macro events, the Brexit, Turkey. There's a number developed [ph] in the quarter. We did not see any material impact from those events in our performance in the third quarter. What I will say, though, it is raising an increased level of uncertainty amongst our customers in Europe, and we've seen the questions around when will budgets be released. So it's more of an uncertainty question right out there. People are just sort of waiting to see how it's going to develop. Again, no material effect on the third quarter results. But as we thought about our guidance for the fourth quarter, obviously, it's influenced us to think about how will Europe develop through the quarter. And Patrick, I know you had a pretty deep conversation about this yesterday. So any additional thoughts you'd like to add?"
154924,374881090,1037613,"Agilent Technologies, Inc., Q3 2016 Earnings Call, Aug 17, 2016",2016-08-17,"Earnings Calls","Agilent Technologies, Inc.","Executives","Yes. Thanks, Mike. In talking to our field, local field in Europe, you certainly get the feedback there is some uncertainty as Mike -- as you said. The Brexit had -- with some of the government in traditional [ph] deals had probably some minor impacts. I",101,"Yes. Thanks, Mike. In talking to our field, local field in Europe, you certainly get the feedback there is some uncertainty as Mike -- as you said. The Brexit had -- with some of the government in traditional [ph] deals had probably some minor impacts. I think what's concerning us here a little bit is also there are a couple of other countries standing on the sidelines and have other referendums this year. So we are cautious right now, looking at Europe and the growth scenario for Europe for the remainder of the year and also going into fiscal year '17."
154924,374881090,1037613,"Agilent Technologies, Inc., Q3 2016 Earnings Call, Aug 17, 2016",2016-08-17,"Earnings Calls","Agilent Technologies, Inc.","Executives","Thanks, Patrick.",2,"Thanks, Patrick."
154924,374881090,1037613,"Agilent Technologies, Inc., Q3 2016 Earnings Call, Aug 17, 2016",2016-08-17,"Earnings Calls","Agilent Technologies, Inc.","Analysts","And then one bigger-picture question, Mike. I mean you made a pretty significant investment with a pretty long horizon -- long-term horizon on this facility in Colorado. So it speaks to your confidence in the long-term outlook for and the scale of the opp",80,"And then one bigger-picture question, Mike. I mean you made a pretty significant investment with a pretty long horizon -- long-term horizon on this facility in Colorado. So it speaks to your confidence in the long-term outlook for and the scale of the opportunity there. Can you just talk us through how you frame the opportunity, remind us how big that business is today, and how you think about the medium-term drivers that you're investing in the pursuit of?"
154924,374881090,1037613,"Agilent Technologies, Inc., Q3 2016 Earnings Call, Aug 17, 2016",2016-08-17,"Earnings Calls","Agilent Technologies, Inc.","Executives","Great. So I'm going to handle your -- well, I'm going to handle the first part of this question. And then I'm going to turn it over to Jacob, and he'll reassure you about the long-term growth potential, which is the reason why I supported the investment.",189,"Great. So I'm going to handle your -- well, I'm going to handle the first part of this question. And then I'm going to turn it over to Jacob, and he'll reassure you about the long-term growth potential, which is the reason why I supported the investment. But just as a reminder, I think this is roughly about 5% or so of DGG's overall revenues in the range of maybe $16 plus million or so. We still have capacity at the current site, but we've got a -- more demand than we can handle in terms of long-term outlook from our customers. So we can't bring on this capacity fast enough to satisfy the customer demand. We think this will be a bigger part of our growth story as we talk to you about 2017 and 2018. And I think as you'll hear from Jacob, there's a high degree of confidence that the business is going to be there. And perhaps you can provide a little context of what exactly is this business and why are we so confident that the market is going to be there for us."
154924,374881090,1037613,"Agilent Technologies, Inc., Q3 2016 Earnings Call, Aug 17, 2016",2016-08-17,"Earnings Calls","Agilent Technologies, Inc.","Executives","Yes, let me try to provide a little more color there. So first of all, a reminder that the Nucleic Acid Solutions Division business out in Boulder is providing oligo APIs that constitute a new type of drugs with a significant potential. These drugs are pr",317,"Yes, let me try to provide a little more color there. So first of all, a reminder that the Nucleic Acid Solutions Division business out in Boulder is providing oligo APIs that constitute a new type of drugs with a significant potential. These drugs are primarily, right now, opportunities within orphan genetic diseases that today there has been no treatment and have devastating outcomes. And these drugs have actually the opportunity to change the expectancy of, you could say the survival and also the quality of life for such patients. We are working with the leaders in pharma within these new type of drugs, and Agilent is chosen again and again due to our deep technical experience to optimize oligos for performance and consistency, combined with our ability to scale in DNP. We have seen a significant demand accelerated over the last few years. And as Mike mentioned, we're currently expanding our current site to actually take up double capacity. But we also see that, that will run out. That opportunity is really limited and will run out in a few years from now; and thereby, the new investment in the new site will allow us to further double our capacity and even double again if we choose to do so. We have decided, and based on a deep dive into the strategy and so on, to place the site in close proximity to the other Boulder site at approximately 20 minutes' drive away so we can releverage critical mass, high -- the highly experienced staff we already have and capabilities and processes. The overall market is in the hundreds of million dollar business right now, and it's growing something between 20% to 30%. However, when you commercialize drugs -- when you get the commercialized drugs, this might be a significant step-ups, but we see a lot of demand right now just in the clinical trial studies."
154924,374881090,1037613,"Agilent Technologies, Inc., Q3 2016 Earnings Call, Aug 17, 2016",2016-08-17,"Earnings Calls","Agilent Technologies, Inc.","Operator","Our next question comes from the line of Jonathan Groberg from UBS.",12,"Our next question comes from the line of Jonathan Groberg from UBS."
154924,374881090,1037613,"Agilent Technologies, Inc., Q3 2016 Earnings Call, Aug 17, 2016",2016-08-17,"Earnings Calls","Agilent Technologies, Inc.","Analysts","I know you have one more quarter to go here, but any initial thoughts on the puts and takes you're seeing on how we should be thinking about fiscal '17?",30,"I know you have one more quarter to go here, but any initial thoughts on the puts and takes you're seeing on how we should be thinking about fiscal '17?"
154924,374881090,1037613,"Agilent Technologies, Inc., Q3 2016 Earnings Call, Aug 17, 2016",2016-08-17,"Earnings Calls","Agilent Technologies, Inc.","Executives","Yes. Jonathan, I'd be happy to share my thoughts here. And in fact, I, perhaps, will build on some of the comments I made in my prepared remarks. But we're still -- we are still seeing ourselves on the same path that we talked about just a month or so ago",386,"Yes. Jonathan, I'd be happy to share my thoughts here. And in fact, I, perhaps, will build on some of the comments I made in my prepared remarks. But we're still -- we are still seeing ourselves on the same path that we talked about just a month or so ago in New York. I think it actually was 2 months ago when I think about it, but our position remains the same. We are still confident we're going to be able to achieve the overall projected core growth of 4.5%. And there's some new -- there really are some new factors that we think support this level of growth. First of all, we've -- we have a rich pipeline of new product introductions coming in Q4 and in FY '17 on top of what we've already introduced this year. We think our customers are going to be really excited about what we're bringing to market, and that's going to help drive share. So we know we got this NPI pipe going through the system right now with releases coming up in the several quarters on top of what we've done. The second thing, I -- we also have recognized the fact that the Agilent business model has really changed a lot over the last 18 months or so. We have a lot more recurring revenue. And if you look at the ACG and DGG business, which now represent over half, I think it's 52% the last time I did the math, of Agilent's revenue. These are just inherently much more predictable revenue streams, and you saw in our Q3 results how both groups delivered high single-digit growth. And they're not subject to the same types of issues we're seeing in the capital-intensive chemical and energy market, for example. And then the third thing I'd say is when you think about our LSAG instrument business, in addition to the impact of these new product introductions I mentioned, we do expect that pharma and China market is going to remain significant growth drivers, although I think they will be below these double-digit levels we've seen in 2016. And as mentioned in our last call, we still expect that the chemical and energy market will have bottomed by the end of calendar year 2017. We're not ready to..."
154924,374881090,1037613,"Agilent Technologies, Inc., Q3 2016 Earnings Call, Aug 17, 2016",2016-08-17,"Earnings Calls","Agilent Technologies, Inc.","Executives","'16.",1,"'16."
154924,374881090,1037613,"Agilent Technologies, Inc., Q3 2016 Earnings Call, Aug 17, 2016",2016-08-17,"Earnings Calls","Agilent Technologies, Inc.","Executives","Excuse me. Sorry. Thanks, Didier. I got my ears confused there -- by the end of the calendar year 2016. We're not ready to call bottom, but we do see in 2017 that we're forecasting that we could be in low single-digits growth in a market which has had 18",118,"Excuse me. Sorry. Thanks, Didier. I got my ears confused there -- by the end of the calendar year 2016. We're not ready to call bottom, but we do see in 2017 that we're forecasting that we could be in low single-digits growth in a market which has had 18 to 24 months of pent-up demand for equipment that supports the production process. So they're the 3 factors that have gone into our thinking as we have thought about the 2017's growth rate. Honestly, we'll give you the official guidance at our next call. But I would just reinforce our view today is that we're still on track to what we told you in May in New York."
154924,374881090,1037613,"Agilent Technologies, Inc., Q3 2016 Earnings Call, Aug 17, 2016",2016-08-17,"Earnings Calls","Agilent Technologies, Inc.","Analysts","Great. That's helpful. And just one quick follow-up, on the capital equipment business, I know you mentioned going into the quarter, last time when you gave guidance, you thought there'd been a little bit of pull forward and you highlighted why you though",79,"Great. That's helpful. And just one quick follow-up, on the capital equipment business, I know you mentioned going into the quarter, last time when you gave guidance, you thought there'd been a little bit of pull forward and you highlighted why you thought it would be a little weaker. I'm just curious, was it in line with what you thought? Or was there anything unique in the quarter that maybe wasn't right along the lines of what you thought?"
154924,374881090,1037613,"Agilent Technologies, Inc., Q3 2016 Earnings Call, Aug 17, 2016",2016-08-17,"Earnings Calls","Agilent Technologies, Inc.","Executives","Absolutely. I think the quarter was actually in line and actually a little bit better than we had anticipated coming into the quarter, so no major surprises in our Q3 results. And as you can imagine, we were delighted with the ability to deliver above our",52,"Absolutely. I think the quarter was actually in line and actually a little bit better than we had anticipated coming into the quarter, so no major surprises in our Q3 results. And as you can imagine, we were delighted with the ability to deliver above our expectations, both top and bottom line."
154924,374881090,1037613,"Agilent Technologies, Inc., Q3 2016 Earnings Call, Aug 17, 2016",2016-08-17,"Earnings Calls","Agilent Technologies, Inc.","Operator","Our next question comes from the line of Jack Meehan from Barclays.",12,"Our next question comes from the line of Jack Meehan from Barclays."
154924,374881090,1037613,"Agilent Technologies, Inc., Q3 2016 Earnings Call, Aug 17, 2016",2016-08-17,"Earnings Calls","Agilent Technologies, Inc.","Analysts","So I just wanted to ask about the LSAG business and some of the moving parts there. And could you maybe just talk about the chromatography markets? A couple of your peers have had really nice results there. Just what you're seeing there would be helpful.",46,"So I just wanted to ask about the LSAG business and some of the moving parts there. And could you maybe just talk about the chromatography markets? A couple of your peers have had really nice results there. Just what you're seeing there would be helpful."
154924,374881090,1037613,"Agilent Technologies, Inc., Q3 2016 Earnings Call, Aug 17, 2016",2016-08-17,"Earnings Calls","Agilent Technologies, Inc.","Executives","Yes, absolutely. And then, Patrick, if you could break it out, obviously, between liquid chromatography and gas chromatography as well.",20,"Yes, absolutely. And then, Patrick, if you could break it out, obviously, between liquid chromatography and gas chromatography as well."
154924,374881090,1037613,"Agilent Technologies, Inc., Q3 2016 Earnings Call, Aug 17, 2016",2016-08-17,"Earnings Calls","Agilent Technologies, Inc.","Executives","Yes, absolutely. Happy to do so. As Mike mentioned earlier in his remarks, we definitely see very strong growth right now in the liquid chromatography business, which has been, for the entire year, double digits. And that is what we see, clearly, also tak",251,"Yes, absolutely. Happy to do so. As Mike mentioned earlier in his remarks, we definitely see very strong growth right now in the liquid chromatography business, which has been, for the entire year, double digits. And that is what we see, clearly, also taking market share right now. We had a very strong launch of several waves of the Infinity series starting in 2009 and 2012. And now this year with the 1260 series with another big round of instrumentation and solutions in liquid chromatography, that is very well received by the end markets. We see very healthy replacement business as well, and it's driven by the fact that these solutions are 100% backwards compatible and also compatible with some of our competitors' instrumentations, which makes method transfer very simple and seamless for our customers. So -- and we project this cycle to continue for several more quarters. We don't see yet a loss of momentum. What we see, of course, is that we're getting now into quarters with tougher compare because we have double-digit growth for several quarters now. On the gas chromatography side, again, very strong portfolio as well. The issue we're seeing there is that the core market or one of the big markets for gas chromatography is the energy space. And that, of course, pulled some of our results down at this point in time. If the market comes back, we think we are in an exceptional position to pick up this pent-up demand that we see."
154924,374881090,1037613,"Agilent Technologies, Inc., Q3 2016 Earnings Call, Aug 17, 2016",2016-08-17,"Earnings Calls","Agilent Technologies, Inc.","Executives","When the market comes back.",5,"When the market comes back."
154924,374881090,1037613,"Agilent Technologies, Inc., Q3 2016 Earnings Call, Aug 17, 2016",2016-08-17,"Earnings Calls","Agilent Technologies, Inc.","Executives","Yes, when the market comes back. Yes, when the market comes back, sorry. So I think we are in a great situation there as well. We have an outstanding product portfolio and ability to capture the growth when it gets back.",41,"Yes, when the market comes back. Yes, when the market comes back, sorry. So I think we are in a great situation there as well. We have an outstanding product portfolio and ability to capture the growth when it gets back."
154924,374881090,1037613,"Agilent Technologies, Inc., Q3 2016 Earnings Call, Aug 17, 2016",2016-08-17,"Earnings Calls","Agilent Technologies, Inc.","Executives","Yes. And the reason why I asked Patrick to segment his remarks in liquid chromatography from gas chromatography, we have an outsized exposure in gas chromatography. And when the -- relative to the #2 competitor space, we're at least 2x the #2 person. And",91,"Yes. And the reason why I asked Patrick to segment his remarks in liquid chromatography from gas chromatography, we have an outsized exposure in gas chromatography. And when the -- relative to the #2 competitor space, we're at least 2x the #2 person. And so when our major market is down, it really hits us. And that's why, again, we were really quite pleased that we were able to deliver the growth we've done so far, with our #2 market actually being down below our initial expectations coming into this year."
154924,374881090,1037613,"Agilent Technologies, Inc., Q3 2016 Earnings Call, Aug 17, 2016",2016-08-17,"Earnings Calls","Agilent Technologies, Inc.","Analysts","Yes, that's really helpful, and I appreciate all the details in the different segments. If I could just follow up with one more. The Americas growth, negative 1% in the quarter, I know it's on a tougher comp relative to last year. But could you maybe just",67,"Yes, that's really helpful, and I appreciate all the details in the different segments. If I could just follow up with one more. The Americas growth, negative 1% in the quarter, I know it's on a tougher comp relative to last year. But could you maybe just talk about the mix of the end markets there and whether there was any other notable changes worth pointing out?"
154924,374881090,1037613,"Agilent Technologies, Inc., Q3 2016 Earnings Call, Aug 17, 2016",2016-08-17,"Earnings Calls","Agilent Technologies, Inc.","Executives","I think the big one there is the chemical and energy market. So it's down pretty sharply, and I think that's bringing down the overall numbers as well as our academia and government business was down over last year. Although we think some of that -- the w",73,"I think the big one there is the chemical and energy market. So it's down pretty sharply, and I think that's bringing down the overall numbers as well as our academia and government business was down over last year. Although we think some of that -- the way we're thinking about our plan for the rest of this year, we think the federal money will be there in the fourth quarter for us."
154924,374881090,1037613,"Agilent Technologies, Inc., Q3 2016 Earnings Call, Aug 17, 2016",2016-08-17,"Earnings Calls","Agilent Technologies, Inc.","Executives","Yes. And in addition, if I may add, we had a very strong quarter Q3 last year in Americas. So it's a tough compare.",24,"Yes. And in addition, if I may add, we had a very strong quarter Q3 last year in Americas. So it's a tough compare."
154924,374881090,1037613,"Agilent Technologies, Inc., Q3 2016 Earnings Call, Aug 17, 2016",2016-08-17,"Earnings Calls","Agilent Technologies, Inc.","Executives","Yes. I'm not always willing to let my guys do the tough compare argument, but thanks, Patrick.",17,"Yes. I'm not always willing to let my guys do the tough compare argument, but thanks, Patrick."
154924,374881090,1037613,"Agilent Technologies, Inc., Q3 2016 Earnings Call, Aug 17, 2016",2016-08-17,"Earnings Calls","Agilent Technologies, Inc.","Operator","Our next question comes from the line of Tycho Peterson from JPMorgan.",12,"Our next question comes from the line of Tycho Peterson from JPMorgan."
154924,374881090,1037613,"Agilent Technologies, Inc., Q3 2016 Earnings Call, Aug 17, 2016",2016-08-17,"Earnings Calls","Agilent Technologies, Inc.","Analysts","Maybe first on -- just on the academic front because it is a big swing from what you reported last quarter. I understand the Europe dynamic, but frankly, what we hear from you is a little bit different than we've heard from most of the other life science",73,"Maybe first on -- just on the academic front because it is a big swing from what you reported last quarter. I understand the Europe dynamic, but frankly, what we hear from you is a little bit different than we've heard from most of the other life science peers. So can you maybe just talk a little bit about why you felt more pressure in Europe academic than maybe most of your peers?"
154924,374881090,1037613,"Agilent Technologies, Inc., Q3 2016 Earnings Call, Aug 17, 2016",2016-08-17,"Earnings Calls","Agilent Technologies, Inc.","Executives","I think it's -- I think -- I'd point to 2 factors. I'm not sure exactly what all our peers are saying about Europe. I think they're probably saying the same thing, which are the European budgets are constrained and funding has not been released, and has a",136,"I think it's -- I think -- I'd point to 2 factors. I'm not sure exactly what all our peers are saying about Europe. I think they're probably saying the same thing, which are the European budgets are constrained and funding has not been released, and has actually been withheld in some situations. I also think you may be hearing a more positive spin on the U.S. environment because of many of our competitors have much more business coming from NIH. So there's a lot of positive view of the NIH budget, but we pick up a relatively small piece of that overall budget. The agencies where we do a lot of our business in the U.S. government, we know the money is coming in the fourth quarter. Anything else you'd add to that, Patrick?"
154924,374881090,1037613,"Agilent Technologies, Inc., Q3 2016 Earnings Call, Aug 17, 2016",2016-08-17,"Earnings Calls","Agilent Technologies, Inc.","Executives","Not a lot. And as you said, there's -- a lot of our competitors definitely have also a mixed bag, on average, I would say.",25,"Not a lot. And as you said, there's -- a lot of our competitors definitely have also a mixed bag, on average, I would say."
154924,374881090,1037613,"Agilent Technologies, Inc., Q3 2016 Earnings Call, Aug 17, 2016",2016-08-17,"Earnings Calls","Agilent Technologies, Inc.","Analysts","And then similarly, environmental is flat after growing 6% last quarter. Can you maybe just comment on dynamics there?",19,"And then similarly, environmental is flat after growing 6% last quarter. Can you maybe just comment on dynamics there?"
154924,374881090,1037613,"Agilent Technologies, Inc., Q3 2016 Earnings Call, Aug 17, 2016",2016-08-17,"Earnings Calls","Agilent Technologies, Inc.","Executives","I think the biggest dynamic there is there's a subsegment within environmental as well where we pick up our forensics business. And we report externally just the total environmental business, but a lot of big deal activity in forensics. So last year, we h",104,"I think the biggest dynamic there is there's a subsegment within environmental as well where we pick up our forensics business. And we report externally just the total environmental business, but a lot of big deal activity in forensics. So last year, we had a lot of big deals at this point in time. The overall environmental market has given me big deals in the second quarter. So it's really a forensic-driven phenomena, which is where we didn't have as many big deals in the third quarter. And this business tends to be a little bit more lumpy than our base environmental business."
154924,374881090,1037613,"Agilent Technologies, Inc., Q3 2016 Earnings Call, Aug 17, 2016",2016-08-17,"Earnings Calls","Agilent Technologies, Inc.","Analysts","Okay. And then -- and last one, a little bit of an esoteric question. But on the PD-L1 data sets in frontline lung, can you maybe just talk about whether there's kind of any change in your outlook? Obviously, Bristol attempted to go without a companion an",74,"Okay. And then -- and last one, a little bit of an esoteric question. But on the PD-L1 data sets in frontline lung, can you maybe just talk about whether there's kind of any change in your outlook? Obviously, Bristol attempted to go without a companion and failed. Merck is doing a companion. So can you maybe just talk about whether some of those developments have changed your view of the market opportunity overall?"
154924,374881090,1037613,"Agilent Technologies, Inc., Q3 2016 Earnings Call, Aug 17, 2016",2016-08-17,"Earnings Calls","Agilent Technologies, Inc.","Executives","Sure. Sure, Tycho. In fact, we just had a conversation on this yesterday. So Pat -- I mean, Jacob, why don't you share the latest thoughts from Agilent on this topic?",31,"Sure. Sure, Tycho. In fact, we just had a conversation on this yesterday. So Pat -- I mean, Jacob, why don't you share the latest thoughts from Agilent on this topic?"
154924,374881090,1037613,"Agilent Technologies, Inc., Q3 2016 Earnings Call, Aug 17, 2016",2016-08-17,"Earnings Calls","Agilent Technologies, Inc.","Executives","Yes, I will say, first and foremost, we are very pleased with the performance we have seen on PD-L1 over the last 10 months, and we continue to see strong traction. You're right. There has been some announcement recently on some studies that has not come",120,"Yes, I will say, first and foremost, we are very pleased with the performance we have seen on PD-L1 over the last 10 months, and we continue to see strong traction. You're right. There has been some announcement recently on some studies that has not come out as expected. It really supports our thesis about the importance here of CDx and, really, that you need to make sure you stratify your patient group the right way. So clearly, there is a short-term opportunity, at least from one of our customers that is a little less than we hoped for. But I don't think that, that overall change is really the thesis, and we continue to see a big opportunity here."
154924,374881090,1037613,"Agilent Technologies, Inc., Q3 2016 Earnings Call, Aug 17, 2016",2016-08-17,"Earnings Calls","Agilent Technologies, Inc.","Operator","Our next question comes from the line of Ross Muken from Evercore.",12,"Our next question comes from the line of Ross Muken from Evercore."
154924,374881090,1037613,"Agilent Technologies, Inc., Q3 2016 Earnings Call, Aug 17, 2016",2016-08-17,"Earnings Calls","Agilent Technologies, Inc.","Analysts","So it seems like most of the confusion we're hearing is sort of on the sequential progression of core revenues. And so I look at the last 2 years, and it looks like, sequentially, the comp is roughly, I don't know, 200 basis points easier on core. And it",128,"So it seems like most of the confusion we're hearing is sort of on the sequential progression of core revenues. And so I look at the last 2 years, and it looks like, sequentially, the comp is roughly, I don't know, 200 basis points easier on core. And it looks like you have a little bit heavier of an NMR headwind in 4Q than you did in 3Q. So one, can you confirm that? And then two, as we just think about the crosswalk, what are the other sort of underlying assumptions in terms of what is different sequentially versus 3Q, whether it's end markets or any of the key segments? And then where have you built in, I guess, some conservatism or some of that uncertainty?"
154924,374881090,1037613,"Agilent Technologies, Inc., Q3 2016 Earnings Call, Aug 17, 2016",2016-08-17,"Earnings Calls","Agilent Technologies, Inc.","Executives","Yes. Thanks for the question, Ross. And why don't I go ahead and just share some thoughts about the Q4 guidance. And then, Didier, maybe you can dig through your notes on the NMR impact. But I think it's important for me to share with the audience here to",271,"Yes. Thanks for the question, Ross. And why don't I go ahead and just share some thoughts about the Q4 guidance. And then, Didier, maybe you can dig through your notes on the NMR impact. But I think it's important for me to share with the audience here today about how we thought about our Q4 guidance. I think this may get to the root of some of your questions. As you heard on our call, first of all, we're quite pleased with the higher-than-guided core revenue growth that we delivered for Q3 after having raised last -- in last call. And I think we've got this increased confidence to achieve our previously raised core growth guidance for the year. And listen, we realize by not raising our core guidance for this year that this question could arise. But the way we looked at it, we said, listen, there's a raised level uncertainty in the markets centered around Europe. And we saw some weak European government budgets in the third quarter. Is this going to continue? We've seen some downward revisions in terms of market overall economic forecasts for Europe, so we're really not sure exactly how it's going to develop. So we just thought it's prudent to reflect some of this uncertainty by not raising again the full year guidance. So that's how we thought about the process. We really didn't look over the years sequentially. We do know that last year, though, I said I don't like the tough compare argument, we did have a blowout fourth quarter last year. But anything else, Didier, you can remember unusual or..."
154924,374881090,1037613,"Agilent Technologies, Inc., Q3 2016 Earnings Call, Aug 17, 2016",2016-08-17,"Earnings Calls","Agilent Technologies, Inc.","Executives","No. NMR is not a factor.",6,"No. NMR is not a factor."
154924,374881090,1037613,"Agilent Technologies, Inc., Q3 2016 Earnings Call, Aug 17, 2016",2016-08-17,"Earnings Calls","Agilent Technologies, Inc.","Executives","NMR is not a factor.",5,"NMR is not a factor."
154924,374881090,1037613,"Agilent Technologies, Inc., Q3 2016 Earnings Call, Aug 17, 2016",2016-08-17,"Earnings Calls","Agilent Technologies, Inc.","Executives","You pointed out really what we intended to do is maintain the overall core revenue growth for the whole year, and that's how we derived Q4.",26,"You pointed out really what we intended to do is maintain the overall core revenue growth for the whole year, and that's how we derived Q4."
154924,374881090,1037613,"Agilent Technologies, Inc., Q3 2016 Earnings Call, Aug 17, 2016",2016-08-17,"Earnings Calls","Agilent Technologies, Inc.","Executives","Yes. We'd raised last quarter, and the business is developing in the third quarter actually better than we had thought as you saw in our results. And as we look to the fourth quarter, listen, we don't know how this Europe's going to play out, so let's jus",58,"Yes. We'd raised last quarter, and the business is developing in the third quarter actually better than we had thought as you saw in our results. And as we look to the fourth quarter, listen, we don't know how this Europe's going to play out, so let's just be cautious as opposed to raising again for the quarter."
154924,374881090,1037613,"Agilent Technologies, Inc., Q3 2016 Earnings Call, Aug 17, 2016",2016-08-17,"Earnings Calls","Agilent Technologies, Inc.","Analysts","So that makes total sense to me, Mike. I mean, I think given some of the uncertainty, I certainly don't want to get in front of your skis. And you guys have been beating numbers, so that's good. I guess as you think about the key product cycles for the bu",137,"So that makes total sense to me, Mike. I mean, I think given some of the uncertainty, I certainly don't want to get in front of your skis. And you guys have been beating numbers, so that's good. I guess as you think about the key product cycles for the business, how do you think about the cadence now that you've had some releases of when we could start seeing that also draw up the core growth overall? And then secondarily, when do we start to comp through? We've now, I guess, comp-ed through some easier compares on the Diagnostics business, which has been going hot for, I don't know, 4 or 6 quarters now. How long do you think we've got left on that trajectory of sort of high-single to almost double-digit growth in that business?"
154924,374881090,1037613,"Agilent Technologies, Inc., Q3 2016 Earnings Call, Aug 17, 2016",2016-08-17,"Earnings Calls","Agilent Technologies, Inc.","Executives","I think longer, but I think that for the foreseeable future, we're highly confident on the growth rates in this business. And that's why I made the comment earlier about, hey, when you think about Agilent's long-term growth perspective, if you think about",170,"I think longer, but I think that for the foreseeable future, we're highly confident on the growth rates in this business. And that's why I made the comment earlier about, hey, when you think about Agilent's long-term growth perspective, if you think about '17, think about that we've got over half of our revenue in markets that are going to have a steady trajectory of growth. And you heard Jacob talk about what's going on in the companion diagnostic PD-L1. We talked -- that's why I wanted to highlight the investments we're making in NASD, which is a part of the business we haven't really talked a lot about with you. So I think there are a lot of genomics, there's SureSelect next-gen sequencing. There's a lot of fundamental, very attractive markets we have a strong position in. So Jacob, I don't want to necessarily speak for you, but I guess I have that we expect that this growth rate will be sustained. Anything else you'd add to my story?"
154924,374881090,1037613,"Agilent Technologies, Inc., Q3 2016 Earnings Call, Aug 17, 2016",2016-08-17,"Earnings Calls","Agilent Technologies, Inc.","Executives","You're absolutely right, and I'm definitely pleased with the excellent growth. Last quarter, we had 5%. So I really want to make sure that you saw that we were -- when I -- when we talked also at the Analyst Day, we believe the right -- the direction is 6",80,"You're absolutely right, and I'm definitely pleased with the excellent growth. Last quarter, we had 5%. So I really want to make sure that you saw that we were -- when I -- when we talked also at the Analyst Day, we believe the right -- the direction is 6% to 7%. I'm happy to beat that. But we do not see any change in trajectory right now, and we'll continue in those high single-digit growth rates going forward."
154924,374881090,1037613,"Agilent Technologies, Inc., Q3 2016 Earnings Call, Aug 17, 2016",2016-08-17,"Earnings Calls","Agilent Technologies, Inc.","Executives","And Ross, I think perhaps your earlier question was around product cycle replacement. Yes. So I think, as you may know, when I came into the role a little over 1.5 years ago, we had really spent a lot of time redirecting our R&D programs. We restructured",188,"And Ross, I think perhaps your earlier question was around product cycle replacement. Yes. So I think, as you may know, when I came into the role a little over 1.5 years ago, we had really spent a lot of time redirecting our R&D programs. We restructured the company. We reorganized our R&D programs, and I think you're starting to see the cadence. So you've seen some of the product come out. We highlighted earlier on the chromatography side some updates and new products around spectroscopy, ICP-MS. And we know this cadence is going to continue throughout the next quarter and into '17. So that's why when I got the earlier question about, hey, what are you thinking about in terms of '17, I know what's in our road maps, and I know what's coming to the market over the next 12 months. And I know what's already come to the market, and I know how customers are responding. That's why we have this level of confidence about our ability to continue to grow this company in what has been very mixed market conditions, to say the least."
154924,374881090,1037613,"Agilent Technologies, Inc., Q3 2016 Earnings Call, Aug 17, 2016",2016-08-17,"Earnings Calls","Agilent Technologies, Inc.","Operator","Our next question comes from the line of Doug Schenkel from Cowen.",12,"Our next question comes from the line of Doug Schenkel from Cowen."
154924,374881090,1037613,"Agilent Technologies, Inc., Q3 2016 Earnings Call, Aug 17, 2016",2016-08-17,"Earnings Calls","Agilent Technologies, Inc.","Analysts","My first question -- I guess both are going to be on guidance. So for fiscal Q4, your guidance essentially tells us that you're assuming operating margin declines year-over-year in fiscal year Q4 in spite of what seems like could be, I guess mix-wise, a p",81,"My first question -- I guess both are going to be on guidance. So for fiscal Q4, your guidance essentially tells us that you're assuming operating margin declines year-over-year in fiscal year Q4 in spite of what seems like could be, I guess mix-wise, a pretty favorable quarter year-over-year based on your commentary. So keeping that in mind and the fact that you've actually expanded operating margin year-over-year, I believe 6 straight quarters, can you just explain why this makes sense?"
154924,374881090,1037613,"Agilent Technologies, Inc., Q3 2016 Earnings Call, Aug 17, 2016",2016-08-17,"Earnings Calls","Agilent Technologies, Inc.","Executives","Yes. I think you've got the string of consecutive quarters. It's been 6 quarters in a row. And Didier, we looked at this. I think it's purely volume related, but...",30,"Yes. I think you've got the string of consecutive quarters. It's been 6 quarters in a row. And Didier, we looked at this. I think it's purely volume related, but..."
154924,374881090,1037613,"Agilent Technologies, Inc., Q3 2016 Earnings Call, Aug 17, 2016",2016-08-17,"Earnings Calls","Agilent Technologies, Inc.","Executives","Yes, absolutely. As same thing for operating margin, our approach -- as for revenue, our approach is we didn't -- we wanted to maintain our full year operating margin because, obviously, it's linked to revenue. So we maintain our core revenue growth assum",141,"Yes, absolutely. As same thing for operating margin, our approach -- as for revenue, our approach is we didn't -- we wanted to maintain our full year operating margin because, obviously, it's linked to revenue. So we maintain our core revenue growth assumption of 4.5% and our operating margin assumption of 20.4%. Now you are absolutely correct that, that would mean that 50 basis points reduction from the significant operating margin we had in Q4 of last year of 21.5%, still a significant 70 basis point sequential improvement. And you have to take into account, as Mike said, that this is based on only 1.2% top line growth. So a slight reduction in operating margin, still very significant increase sequentially, but slight reduction related to the one -- the assumption that we'd made on the top line growth of only 1.2%."
154924,374881090,1037613,"Agilent Technologies, Inc., Q3 2016 Earnings Call, Aug 17, 2016",2016-08-17,"Earnings Calls","Agilent Technologies, Inc.","Executives","Right. And if we do better on the volume, we'll do better on the margin.",15,"Right. And if we do better on the volume, we'll do better on the margin."
154924,374881090,1037613,"Agilent Technologies, Inc., Q3 2016 Earnings Call, Aug 17, 2016",2016-08-17,"Earnings Calls","Agilent Technologies, Inc.","Analysts","So I guess that's a segue to, I guess, the second guidance question. And I don't mean to be redundant here because there's been a lot of questions on this already. But I'm going to ask anyway. I mean, your guidance is for around 1.2% core revenue growth i",225,"So I guess that's a segue to, I guess, the second guidance question. And I don't mean to be redundant here because there's been a lot of questions on this already. But I'm going to ask anyway. I mean, your guidance is for around 1.2% core revenue growth in the quarter. If we think about this by end market, you actually have an easier compare in environmental forensics, academic government and food relative to certainly what you had in fiscal Q3. Diagnostics is a little tougher, but you have some real momentum there. So if we just, kind of to make it simple, assume all those end markets grow 3% to 5% and that chemical and energy is down mid-singles, it would imply that you guys are thinking pharma is only going to grow low single digits maybe at best in Q4. It's a tough compare in pharma in the quarter, but you've talked about continued strength in pharma in fiscal '17 in response to an earlier question. Again, recognizing the uncertainty you talked about in Europe, this is -- I guess some of this is hard to reconcile. Can you help out a little bit? And specifically again what are you assuming for pharma in the quarter? Is that because of the compare? And what's your assumption for Europe growth in the quarter?"
154924,374881090,1037613,"Agilent Technologies, Inc., Q3 2016 Earnings Call, Aug 17, 2016",2016-08-17,"Earnings Calls","Agilent Technologies, Inc.","Executives","Yes, sure. Glad to walk through this, Doug. In fact, we spent a lot of time modeling our end market views for the rest of the year, anticipating that this might be a question that would arise. And as I recall, Didier, I think that we had a less optimistic",106,"Yes, sure. Glad to walk through this, Doug. In fact, we spent a lot of time modeling our end market views for the rest of the year, anticipating that this might be a question that would arise. And as I recall, Didier, I think that we had a less optimistic view relative to academia and government than I think Doug's math was, where we were seeing -- where we were concerned about Europe. And we had -- we basically have it flat for the year, and I think we still have pharma overall double digits. So if you want to just maybe do a little walk-through?"
154924,374881090,1037613,"Agilent Technologies, Inc., Q3 2016 Earnings Call, Aug 17, 2016",2016-08-17,"Earnings Calls","Agilent Technologies, Inc.","Executives","Yes. The -- maybe, I mean, again, considering how we explained how we came up with the Q4 guidance, the makeup of the Q4 guidance by market in that academic and government and chemical and energy will show the same core revenue growth reduction year-over-",105,"Yes. The -- maybe, I mean, again, considering how we explained how we came up with the Q4 guidance, the makeup of the Q4 guidance by market in that academic and government and chemical and energy will show the same core revenue growth reduction year-over-year as in Q3, so minus 5% for academic and government, minus 4% for chemical and energy. So the assumption is no change between Q3 and Q4. And then for the rest, pharma, you mentioned pharma, we're assuming mid-single digit. And again, on a very tough compare and to -- in line with the way we've been very conservative on the..."
154924,374881090,1037613,"Agilent Technologies, Inc., Q3 2016 Earnings Call, Aug 17, 2016",2016-08-17,"Earnings Calls","Agilent Technologies, Inc.","Executives","Yes. And just to be clear, my comment earlier about double-digit pharma, that's for the full year.",17,"Yes. And just to be clear, my comment earlier about double-digit pharma, that's for the full year."
154924,374881090,1037613,"Agilent Technologies, Inc., Q3 2016 Earnings Call, Aug 17, 2016",2016-08-17,"Earnings Calls","Agilent Technologies, Inc.","Executives","For the full year or -- yes, double digit, absolutely.",10,"For the full year or -- yes, double digit, absolutely."
154924,374881090,1037613,"Agilent Technologies, Inc., Q3 2016 Earnings Call, Aug 17, 2016",2016-08-17,"Earnings Calls","Agilent Technologies, Inc.","Executives","Yes, Doug, maybe just one of -- as we thought about the company coming in, I think we thought that the pharma growth would be lower. We thought China would be lower, and we thought chemical and energy would be higher. And in fact, what's happened is pharm",68,"Yes, Doug, maybe just one of -- as we thought about the company coming in, I think we thought that the pharma growth would be lower. We thought China would be lower, and we thought chemical and energy would be higher. And in fact, what's happened is pharma has actually been stronger, and China is stronger than initially forecasted. And you know the story on chemical and energy."
154924,374881090,1037613,"Agilent Technologies, Inc., Q3 2016 Earnings Call, Aug 17, 2016",2016-08-17,"Earnings Calls","Agilent Technologies, Inc.","Analysts","Okay. The only thing I don't think we got there was just -- and maybe I missed it. But what is the assumption for Europe in the quarter?",28,"Okay. The only thing I don't think we got there was just -- and maybe I missed it. But what is the assumption for Europe in the quarter?"
154924,374881090,1037613,"Agilent Technologies, Inc., Q3 2016 Earnings Call, Aug 17, 2016",2016-08-17,"Earnings Calls","Agilent Technologies, Inc.","Executives","It's about flattish, down low-single digits, mostly on the basis of chemical and energy.",15,"It's about flattish, down low-single digits, mostly on the basis of chemical and energy."
154924,374881090,1037613,"Agilent Technologies, Inc., Q3 2016 Earnings Call, Aug 17, 2016",2016-08-17,"Earnings Calls","Agilent Technologies, Inc.","Executives","Yes. And the academia and government.",6,"Yes. And the academia and government."
154924,374881090,1037613,"Agilent Technologies, Inc., Q3 2016 Earnings Call, Aug 17, 2016",2016-08-17,"Earnings Calls","Agilent Technologies, Inc.","Executives","And academia and government, yes.",5,"And academia and government, yes."
154924,374881090,1037613,"Agilent Technologies, Inc., Q3 2016 Earnings Call, Aug 17, 2016",2016-08-17,"Earnings Calls","Agilent Technologies, Inc.","Operator","Our next question comes from the line of Tim Evans from Wells Fargo Securities.",14,"Our next question comes from the line of Tim Evans from Wells Fargo Securities."
154924,374881090,1037613,"Agilent Technologies, Inc., Q3 2016 Earnings Call, Aug 17, 2016",2016-08-17,"Earnings Calls","Agilent Technologies, Inc.","Analysts","This one's for Didier. It seems like cash flow is something that's going better than expectations or better than our expectations at least. Wondered if you could talk a little bit about the remaining levers that you have to pull on that as you go into 201",86,"This one's for Didier. It seems like cash flow is something that's going better than expectations or better than our expectations at least. Wondered if you could talk a little bit about the remaining levers that you have to pull on that as you go into 2017. Do you think that free cash flow growth in 2017 is really just going to be a matter of earnings growth? Or is there more than you can do there to improve free cash flow faster than earnings?"
154924,374881090,1037613,"Agilent Technologies, Inc., Q3 2016 Earnings Call, Aug 17, 2016",2016-08-17,"Earnings Calls","Agilent Technologies, Inc.","Executives","Yes. There is more that we can do. Certainly, the profit before tax is going to be a factor. But Henrik, who heads our order fulfillment and the supply chain organization has also committed to a material decrease in inventories.",40,"Yes. There is more that we can do. Certainly, the profit before tax is going to be a factor. But Henrik, who heads our order fulfillment and the supply chain organization has also committed to a material decrease in inventories."
154924,374881090,1037613,"Agilent Technologies, Inc., Q3 2016 Earnings Call, Aug 17, 2016",2016-08-17,"Earnings Calls","Agilent Technologies, Inc.","Executives","And he's here in the room to hear that directly.",11,"And he's here in the room to hear that directly."
154924,374881090,1037613,"Agilent Technologies, Inc., Q3 2016 Earnings Call, Aug 17, 2016",2016-08-17,"Earnings Calls","Agilent Technologies, Inc.","Executives","So that is also something that we are counting on that will help us continue expanding our operating cash flow as a percentage of revenue or percentage of profits.",29,"So that is also something that we are counting on that will help us continue expanding our operating cash flow as a percentage of revenue or percentage of profits."
154924,374881090,1037613,"Agilent Technologies, Inc., Q3 2016 Earnings Call, Aug 17, 2016",2016-08-17,"Earnings Calls","Agilent Technologies, Inc.","Analysts","Okay. And then a quick one, going back to one of Tycho's questions on the forensics end market. Of that 12% slice of pie that's environmental and forensics, would you be willing to tell us how much is forensics?",39,"Okay. And then a quick one, going back to one of Tycho's questions on the forensics end market. Of that 12% slice of pie that's environmental and forensics, would you be willing to tell us how much is forensics?"
154924,374881090,1037613,"Agilent Technologies, Inc., Q3 2016 Earnings Call, Aug 17, 2016",2016-08-17,"Earnings Calls","Agilent Technologies, Inc.","Executives","I don't think we disclose that and it's fairly small but enough to move it directly when big deals happen.",21,"I don't think we disclose that and it's fairly small but enough to move it directly when big deals happen."
154924,374881090,1037613,"Agilent Technologies, Inc., Q3 2016 Earnings Call, Aug 17, 2016",2016-08-17,"Earnings Calls","Agilent Technologies, Inc.","Operator","Our next question comes from the line of Isaac Ro from Goldman Sachs.",13,"Our next question comes from the line of Isaac Ro from Goldman Sachs."
154924,374881090,1037613,"Agilent Technologies, Inc., Q3 2016 Earnings Call, Aug 17, 2016",2016-08-17,"Earnings Calls","Agilent Technologies, Inc.","Analysts","Just had a question on margins and then a follow-up on Europe. On the margin side, if I look at sort of the components of gross margin, it's interesting that the LSAG division is your highest gross margin segment in most quarters, but that was one where y",88,"Just had a question on margins and then a follow-up on Europe. On the margin side, if I look at sort of the components of gross margin, it's interesting that the LSAG division is your highest gross margin segment in most quarters, but that was one where you saw a little pressure. So can you help us think a little bit about kind of the key initiatives you guys have under the hood there to continue driving better gross margin versus expectations and same goes through SG&A?"
154924,374881090,1037613,"Agilent Technologies, Inc., Q3 2016 Earnings Call, Aug 17, 2016",2016-08-17,"Earnings Calls","Agilent Technologies, Inc.","Executives","The question was what are the initiatives we have? I just want to make sure I understood the question.",19,"The question was what are the initiatives we have? I just want to make sure I understood the question."
154924,374881090,1037613,"Agilent Technologies, Inc., Q3 2016 Earnings Call, Aug 17, 2016",2016-08-17,"Earnings Calls","Agilent Technologies, Inc.","Analysts","Yes. Over the last, I don't know, 12 or 18 months, you guys talked a lot about some of the things you're doing to drive gross margin higher. This particular quarter, you had a little weakness in your most profitable segment. So I'm wondering kind of, asid",77,"Yes. Over the last, I don't know, 12 or 18 months, you guys talked a lot about some of the things you're doing to drive gross margin higher. This particular quarter, you had a little weakness in your most profitable segment. So I'm wondering kind of, aside from just the top line contribution, what you guys were able to achieve this quarter on the gross margin line that allowed you to put up a slightly better result."
154924,374881090,1037613,"Agilent Technologies, Inc., Q3 2016 Earnings Call, Aug 17, 2016",2016-08-17,"Earnings Calls","Agilent Technologies, Inc.","Executives","Great, great. Thanks for the question. So what we've been focusing on are really 3 dimensions around what we call our value-engineering program, our logistics model and also our strategic procurement approach with our suppliers. And as I look at the resul",427,"Great, great. Thanks for the question. So what we've been focusing on are really 3 dimensions around what we call our value-engineering program, our logistics model and also our strategic procurement approach with our suppliers. And as I look at the results in '16, the program that Henrik is driving across this company, I think we probably have seen the biggest impact so far in our improved logistics model. And you may recall we talked about logistics costs as being problematic in 2015. That's no longer the case. In fact, we've benchmarked ourselves, and we've got ourselves down to the best in our space. And there actually is more to come, which is the other 2 elements of the program have a little bit more longer tail in terms of payoff, which is value engineering, when you're reengineering product platforms to ensure both the continuation of the high performance but at a lower cost. And then as we also continue to transform our supplier engagement model and how we leverage the scale of Agilent. So I think those latter 2 parts of the program are going to carry us forward into '17 and '18 beyond, so I think that's how we're really working the gross margin side. And by the way, I also [indiscernible] of your comments were focused on LSAG. A lot of logistics costs and some of these other factors I mentioned, procurement, show up as impacts on the DDG and ACG business as well. And then relative to the SG&A, a couple of things that you may recall I highlighted in New York and I just reemphasize again, major focus on our systems infrastructure. So as you heard in my prepared remarks, we're now on one SAP instance, simplifying a lot of our work for our financial team and taking a lot of cost out of the system. The next big wave will be when we move the former Dako company into the Agilent environment in 2017 where we can really start to leverage the scale and take out costs and have an improved customer experience there. So there's a couple of big initiatives as well as we look at -- we're looking at other aspects of our benefit structure as we made some change, as you may know, earlier to our U.S. pension plan and the Agile Agilent program I mentioned is live. And we have a lot of initiatives underway to ensure that we can continue to take costs out while simplifying the company. Didier, anything else you would add to that?"
154924,374881090,1037613,"Agilent Technologies, Inc., Q3 2016 Earnings Call, Aug 17, 2016",2016-08-17,"Earnings Calls","Agilent Technologies, Inc.","Executives","I'd just mention the currency hedging. It had a big impact. It will have a big impact on a year-over-year basis. It's all impacts to gross margin. And ACG and DGG, because of their footprint, have been more penalized. So ACG on a year-over-year basis lost",97,"I'd just mention the currency hedging. It had a big impact. It will have a big impact on a year-over-year basis. It's all impacts to gross margin. And ACG and DGG, because of their footprint, have been more penalized. So ACG on a year-over-year basis lost $6 million in gross margin just because of the hedging programs; and DGG, $2 million. So that also explains the difference between ACG, DGG and LSAG. LSAG has a different footprint, obviously with a stronger presence in Europe, for example. And so that can distort a little bit the percentages."
154924,374881090,1037613,"Agilent Technologies, Inc., Q3 2016 Earnings Call, Aug 17, 2016",2016-08-17,"Earnings Calls","Agilent Technologies, Inc.","Analysts","That's helpful. Let me just follow-up on Europe. I want to make sure I understand kind of how -- what you're seeing now in that respect to the guidance end. So 2 items there. One is did the weakness in Europe, did that pick up in the month of July, just g",89,"That's helpful. Let me just follow-up on Europe. I want to make sure I understand kind of how -- what you're seeing now in that respect to the guidance end. So 2 items there. One is did the weakness in Europe, did that pick up in the month of July, just given you guys are off calendar versus the peer group? And secondly, does your guidance assume that the academic end market in Europe weakens further as the year progresses or that it sort of stabilizes from here?"
154924,374881090,1037613,"Agilent Technologies, Inc., Q3 2016 Earnings Call, Aug 17, 2016",2016-08-17,"Earnings Calls","Agilent Technologies, Inc.","Executives","Yes. So nothing unusual in July, and I think the assumption of the Q4 is basically a continuation, not any worse but not any better. And we just thought that was a prudent way to think about the company's performance fourth quarter. I would love to be wro",77,"Yes. So nothing unusual in July, and I think the assumption of the Q4 is basically a continuation, not any worse but not any better. And we just thought that was a prudent way to think about the company's performance fourth quarter. I would love to be wrong, and I hope I'm wrong. But we thought from a planning and guidance standpoint, we should be prudent in terms of how we looked at the European market overall."
154924,374881090,1037613,"Agilent Technologies, Inc., Q3 2016 Earnings Call, Aug 17, 2016",2016-08-17,"Earnings Calls","Agilent Technologies, Inc.","Operator","Our next question comes from the line of Derik De Bruin from Bank of America.",15,"Our next question comes from the line of Derik De Bruin from Bank of America."
154924,374881090,1037613,"Agilent Technologies, Inc., Q3 2016 Earnings Call, Aug 17, 2016",2016-08-17,"Earnings Calls","Agilent Technologies, Inc.","Analysts","So a lot of the revenue questions have been asked. And I mean, it certainly seems prudent to me your guidance, just given that Europe, even under a good -- even in a good year, this -- the calendar third quarter is always a little bit choppy anyway, so th",119,"So a lot of the revenue questions have been asked. And I mean, it certainly seems prudent to me your guidance, just given that Europe, even under a good -- even in a good year, this -- the calendar third quarter is always a little bit choppy anyway, so there's clearly some heightened uncertainty this year. So I think it's prudent to be a little bit conservative. But could you just talk a bit about some of the -- I noticed the share count was a little bit higher this quarter than what you previously guided to. Are you still looking at buying back 1% of the outstanding shares as we sort of go into the -- going forward?"
154924,374881090,1037613,"Agilent Technologies, Inc., Q3 2016 Earnings Call, Aug 17, 2016",2016-08-17,"Earnings Calls","Agilent Technologies, Inc.","Executives","Yes. Why don't you talk a little bit about the -- our share repurchase activity in the quarter and how we're thinking about it going forward, Didier?",27,"Yes. Why don't you talk a little bit about the -- our share repurchase activity in the quarter and how we're thinking about it going forward, Didier?"
154924,374881090,1037613,"Agilent Technologies, Inc., Q3 2016 Earnings Call, Aug 17, 2016",2016-08-17,"Earnings Calls","Agilent Technologies, Inc.","Executives","Yes. We filed back in, what, November 20, I think, of last year a 10b5-1 on an annual basis, and we intend to file a new one, to register a new one also in November of this year. And it's a formula-based instructions that we have provided between buying 3",133,"Yes. We filed back in, what, November 20, I think, of last year a 10b5-1 on an annual basis, and we intend to file a new one, to register a new one also in November of this year. And it's a formula-based instructions that we have provided between buying 350,000 shares a day under certain conditions to buying 0 kind of thing with a cap as you can imagine. So we don't know exactly how it's going to play out in Q4. And the only thing that we know is that if there's any kind of shortfall at all in our intended buying in Q4 because of the formula in the 10b5-1, it will all be carried over into the following year. So we intend to spend exactly what we committed to spend."
154924,374881090,1037613,"Agilent Technologies, Inc., Q3 2016 Earnings Call, Aug 17, 2016",2016-08-17,"Earnings Calls","Agilent Technologies, Inc.","Analysts","Great. That's really helpful. And could you just give us a metric on what instruments versus consumable growth was in the quarter as an overall number for the company?",29,"Great. That's really helpful. And could you just give us a metric on what instruments versus consumable growth was in the quarter as an overall number for the company?"
154924,374881090,1037613,"Agilent Technologies, Inc., Q3 2016 Earnings Call, Aug 17, 2016",2016-08-17,"Earnings Calls","Agilent Technologies, Inc.","Executives","I think probably the best way to think about it is just look at the respective business groups. So you have the LSAG results of down 2%, and then the...",30,"I think probably the best way to think about it is just look at the respective business groups. So you have the LSAG results of down 2%, and then the..."
154924,374881090,1037613,"Agilent Technologies, Inc., Q3 2016 Earnings Call, Aug 17, 2016",2016-08-17,"Earnings Calls","Agilent Technologies, Inc.","Executives","ACG up 8%; and DGG, up 8% also.",9,"ACG up 8%; and DGG, up 8% also."
154924,374881090,1037613,"Agilent Technologies, Inc., Q3 2016 Earnings Call, Aug 17, 2016",2016-08-17,"Earnings Calls","Agilent Technologies, Inc.","Executives","And Dako. So minus 2%, plus 8%. And that's why I -- again, as you think about '17 for the company, if you really want to look at the growth rates of those 2 business units in the recurring revenue space, ACG and DGG, perhaps differently than you might thi",67,"And Dako. So minus 2%, plus 8%. And that's why I -- again, as you think about '17 for the company, if you really want to look at the growth rates of those 2 business units in the recurring revenue space, ACG and DGG, perhaps differently than you might think about how you model the risk profile for revenue projections for the instruments side of the company."
154924,374881090,1037613,"Agilent Technologies, Inc., Q3 2016 Earnings Call, Aug 17, 2016",2016-08-17,"Earnings Calls","Agilent Technologies, Inc.","Analysts","Great. That's really helpful. And I guess, could you -- when you sort of -- you're still feeling good about the margin target for '17, and it sounds like that your IT initiatives are well underway or finished to do like that. Are you -- do you still feel",62,"Great. That's really helpful. And I guess, could you -- when you sort of -- you're still feeling good about the margin target for '17, and it sounds like that your IT initiatives are well underway or finished to do like that. Are you -- do you still feel confident about getting what you're expecting for next year for the margin improvement?"
154924,374881090,1037613,"Agilent Technologies, Inc., Q3 2016 Earnings Call, Aug 17, 2016",2016-08-17,"Earnings Calls","Agilent Technologies, Inc.","Executives","Yes, absolutely. So that's why I made a few comments about it earlier because as we said, if we can be in a 4.5%, 5% kind of growth range, perhaps even low 4%, it makes it a little bit more challenging. But we can see -- we see the path to 22%. It's not j",218,"Yes, absolutely. So that's why I made a few comments about it earlier because as we said, if we can be in a 4.5%, 5% kind of growth range, perhaps even low 4%, it makes it a little bit more challenging. But we can see -- we see the path to 22%. It's not just around margins. I mean, especially not just around margin improvement from volume. But there are specific real programs. It's something we review once a month, then we have active programs, and the costs will continue to come out on some of these big programs. Actually, I must say I'm really pleased with the team because we've -- we went through and did the -- we call project Nunu [ph] is the finance program we just finished up. And then right on the heels of that, we're going to go live in early '17 with our integration of Dako. So the teams are still energized and working hard, and I think these are going to have a material impact on our results in '17. And that's why we have confidence about the -- assuming no major change in terms of the macro environment that we can reach what we think are pretty challenging goals, but they're -- we've got a path to get there."
154924,374881090,1037613,"Agilent Technologies, Inc., Q3 2016 Earnings Call, Aug 17, 2016",2016-08-17,"Earnings Calls","Agilent Technologies, Inc.","Operator","Our next question comes from the line of Dan Arias from Citigroup.",12,"Our next question comes from the line of Dan Arias from Citigroup."
154924,374881090,1037613,"Agilent Technologies, Inc., Q3 2016 Earnings Call, Aug 17, 2016",2016-08-17,"Earnings Calls","Agilent Technologies, Inc.","Analysts","Patrick, just going back to your comments on share gains in LC. I know you guys don't like to get too specific on winners and losers. But as was mentioned, it does look like all of the major players are doing fairly well there. So who would you say you're",72,"Patrick, just going back to your comments on share gains in LC. I know you guys don't like to get too specific on winners and losers. But as was mentioned, it does look like all of the major players are doing fairly well there. So who would you say you're taking share from? Is it the small column providers or does that actually extend into some of the box companies as well?"
154924,374881090,1037613,"Agilent Technologies, Inc., Q3 2016 Earnings Call, Aug 17, 2016",2016-08-17,"Earnings Calls","Agilent Technologies, Inc.","Executives","Well, I -- thanks for the question. I can give you only a general flavor here on what we think is going on in the market. I will not comment on the individual competitors, but your assumption that the smaller suppliers probably take a larger hit is also o",50,"Well, I -- thanks for the question. I can give you only a general flavor here on what we think is going on in the market. I will not comment on the individual competitors, but your assumption that the smaller suppliers probably take a larger hit is also our observation."
154924,374881090,1037613,"Agilent Technologies, Inc., Q3 2016 Earnings Call, Aug 17, 2016",2016-08-17,"Earnings Calls","Agilent Technologies, Inc.","Analysts","Okay. And then maybe a specific one on C&E. Mike, at the Analyst Day, you called out a Saudi Arabian refinery build-out that was getting going. Have you started to see some demand there? And is that something that you think contributes at all to the back",51,"Okay. And then maybe a specific one on C&E. Mike, at the Analyst Day, you called out a Saudi Arabian refinery build-out that was getting going. Have you started to see some demand there? And is that something that you think contributes at all to the back half of the year?"
154924,374881090,1037613,"Agilent Technologies, Inc., Q3 2016 Earnings Call, Aug 17, 2016",2016-08-17,"Earnings Calls","Agilent Technologies, Inc.","Executives","The major projects that were underway haven't been canceled, so -- but we're not seeing any major new projects underway. There's a lot of -- there's actually a lot of positive news by a lot of studies about where this market's going, but we're not seeing",156,"The major projects that were underway haven't been canceled, so -- but we're not seeing any major new projects underway. There's a lot of -- there's actually a lot of positive news by a lot of studies about where this market's going, but we're not seeing -- what we're -- just to clarify here, the major project that we knew about, whether it be the one I mentioned in Saudi or the -- there's a major project down in Texas. These programs, they're going to come online. So people aren't canceling capacity increase projects, but we're not seeing a lot of new projects. And that's why we have taken a fairly conservative -- probably be a bit pragmatic view of that marketplace. Again, I would remind everybody, too, that when we talk about chemical and energy, 50% or so is actually chemicals -- chemical processing not directly tied to the exploration and production of oil."
154924,374881090,1037613,"Agilent Technologies, Inc., Q3 2016 Earnings Call, Aug 17, 2016",2016-08-17,"Earnings Calls","Agilent Technologies, Inc.","Operator","Our next question comes from the line of Paul Knight from Janney Montgomery Scott.",14,"Our next question comes from the line of Paul Knight from Janney Montgomery Scott."
154924,374881090,1037613,"Agilent Technologies, Inc., Q3 2016 Earnings Call, Aug 17, 2016",2016-08-17,"Earnings Calls","Agilent Technologies, Inc.","Analysts","I guess specifically what is the GC business doing? What's its growth rate? What was it doing in the July quarter? And what's the backlog or what are the -- what's July or August look like, I guess?",38,"I guess specifically what is the GC business doing? What's its growth rate? What was it doing in the July quarter? And what's the backlog or what are the -- what's July or August look like, I guess?"
154924,374881090,1037613,"Agilent Technologies, Inc., Q3 2016 Earnings Call, Aug 17, 2016",2016-08-17,"Earnings Calls","Agilent Technologies, Inc.","Executives","Well, thanks, Paul, I appreciate the question. As you probably will understand, I'll give you more a high-level result because we don't actually comment specifically at a product category level, beyond, I think, I would just reemphasize the point that Pat",135,"Well, thanks, Paul, I appreciate the question. As you probably will understand, I'll give you more a high-level result because we don't actually comment specifically at a product category level, beyond, I think, I would just reemphasize the point that Patrick made when he characterized the chromatography market. That business is down relative to last year because the chemical and energy market is down. And we have seen no movement at all, downward pressure on our share position. It's really a market phenomena we're dealing with right now. And that's why when that replacement market does turn, and we've been through these cycles before, when it does turn, we'll be in a strong position to capture that growth as given the strength of our position in that market, which right now happens to be down."
154924,374881090,1037613,"Agilent Technologies, Inc., Q3 2016 Earnings Call, Aug 17, 2016",2016-08-17,"Earnings Calls","Agilent Technologies, Inc.","Analysts","And then last, on the applied markets in a broader sense, do you think it's still a GDP growth rate normalized or what do you think the applied markets should be for Agilent?",33,"And then last, on the applied markets in a broader sense, do you think it's still a GDP growth rate normalized or what do you think the applied markets should be for Agilent?"
154924,374881090,1037613,"Agilent Technologies, Inc., Q3 2016 Earnings Call, Aug 17, 2016",2016-08-17,"Earnings Calls","Agilent Technologies, Inc.","Executives","We actually don't think about it that way because the segments that -- or big segments of the market like your food and environmental testing, we think are independent to some extent of GDP. So the only way I think that we really think about that as relat",152,"We actually don't think about it that way because the segments that -- or big segments of the market like your food and environmental testing, we think are independent to some extent of GDP. So the only way I think that we really think about that as relative to is our chemical and energy space. So if you could just kind of think about tying GDP to that subsegment of the company, I think that's -- would be good place to start. But I would not apply it to the whole what we call Applied Markets because these are being driven by quality-of-life investments in the food and environmental area. And I think that's why -- I think this composition of our end markets is the reason why we're being able to put up these kind of growth rates even when our #2 market as a company has shrunk this year."
154924,374881090,1037613,"Agilent Technologies, Inc., Q3 2016 Earnings Call, Aug 17, 2016",2016-08-17,"Earnings Calls","Agilent Technologies, Inc.","Analysts","And then last on -- you had your Analyst Day, obviously. You've been talking about a 22% operating margin. Are you more or less confident in that number for FY '17 at this juncture?",34,"And then last on -- you had your Analyst Day, obviously. You've been talking about a 22% operating margin. Are you more or less confident in that number for FY '17 at this juncture?"
154924,374881090,1037613,"Agilent Technologies, Inc., Q3 2016 Earnings Call, Aug 17, 2016",2016-08-17,"Earnings Calls","Agilent Technologies, Inc.","Executives","Yes. I think the confidence level is the same as it was back in May. And again, I'd maybe just share a few points here, which as you know, we have this confidence of delivery on that given our belief that we can get that growth rate that we're putting up",274,"Yes. I think the confidence level is the same as it was back in May. And again, I'd maybe just share a few points here, which as you know, we have this confidence of delivery on that given our belief that we can get that growth rate that we're putting up growth rates right now in that territory. We've got this pipeline of new products coming out. We've got this nice recurring revenue stream with ACG and DDG that will carry this momentum into '17 and that where our instrument business is going, hey, pharma looks -- still looks good. Of course, you have these double-digit compare issues. China looks to continue to be strong. And chemical and energy has got to turn at some point in time because the market requires these tools to support production. Our thinking is when we look at chemical and energy is we know our customers are looking for productivity improvements to help improve their company profitability. We think that's a value proposition that Agilent has. We think as they go through their budget justification processes and their budgets start in calendar 2017, that this is why we can say, ""Listen, the decline in this business after 18 to 24 months will start to turn,"" and we could see low single digits by the end of 2017 for the chemical and energy market. If that happens, which we believe it will, that will give us the confidence to get the growth and then we know we'll get the margin, given both the volume but also in terms of gross margin improvement initiatives as well as our SG&A cost."
154924,374881090,1037613,"Agilent Technologies, Inc., Q3 2016 Earnings Call, Aug 17, 2016",2016-08-17,"Earnings Calls","Agilent Technologies, Inc.","Operator","And our final question today comes from the line of Catherine Ramsey from Robert W. Baird.",16,"And our final question today comes from the line of Catherine Ramsey from Robert W. Baird."
154924,374881090,1037613,"Agilent Technologies, Inc., Q3 2016 Earnings Call, Aug 17, 2016",2016-08-17,"Earnings Calls","Agilent Technologies, Inc.","Analysts","We've heard a lot of commentary from your peers on Japan; strong pharma environment, weak academic government. So I was wondering if you could walk through your exposure by end market there and what you're seeing across those customer groups.",41,"We've heard a lot of commentary from your peers on Japan; strong pharma environment, weak academic government. So I was wondering if you could walk through your exposure by end market there and what you're seeing across those customer groups."
154924,374881090,1037613,"Agilent Technologies, Inc., Q3 2016 Earnings Call, Aug 17, 2016",2016-08-17,"Earnings Calls","Agilent Technologies, Inc.","Executives","Didier, do you remember the total Japan numbers? I think were...",11,"Didier, do you remember the total Japan numbers? I think were..."
154924,374881090,1037613,"Agilent Technologies, Inc., Q3 2016 Earnings Call, Aug 17, 2016",2016-08-17,"Earnings Calls","Agilent Technologies, Inc.","Executives","About 5% of overall...",4,"About 5% of overall..."
154924,374881090,1037613,"Agilent Technologies, Inc., Q3 2016 Earnings Call, Aug 17, 2016",2016-08-17,"Earnings Calls","Agilent Technologies, Inc.","Executives","5%. Yes, just to give you a sense of -- 5% of the total market. Historically, we've been stronger, and I can share this from my experience having been the country manager for Japan for a few years in the early part of my career. We tend to be much stronge",137,"5%. Yes, just to give you a sense of -- 5% of the total market. Historically, we've been stronger, and I can share this from my experience having been the country manager for Japan for a few years in the early part of my career. We tend to be much stronger in the chemical and energy segment of that marketplace. We are doing well in the life science research and in genomics, but the majority of the business sits in the chemical and energy space, which is -- which has been down. I think Japan has been part of that story. Pharma, the pharma business for us is a relatively smaller portion of the market for us. I think they're doing well in pharma but not enough to really drive significant overall growth rates for Japan."
154924,374881090,1037613,"Agilent Technologies, Inc., Q3 2016 Earnings Call, Aug 17, 2016",2016-08-17,"Earnings Calls","Agilent Technologies, Inc.","Analysts","Okay, great. And then any color on the progress of Dako integration? What's left to do there? Had some nice op margin expansion in DGG this quarter, so are you still thinking that 20% in fiscal '17 or could there be upside to that number?",45,"Okay, great. And then any color on the progress of Dako integration? What's left to do there? Had some nice op margin expansion in DGG this quarter, so are you still thinking that 20% in fiscal '17 or could there be upside to that number?"
154924,374881090,1037613,"Agilent Technologies, Inc., Q3 2016 Earnings Call, Aug 17, 2016",2016-08-17,"Earnings Calls","Agilent Technologies, Inc.","Executives","Jacob happens to be sitting right next to me in this conference room. I don't think he's ready to sign up for more than 20% because it is quite a improvement from where we started. But I think he remains quite confident in the 20% achievement of that goal",186,"Jacob happens to be sitting right next to me in this conference room. I don't think he's ready to sign up for more than 20% because it is quite a improvement from where we started. But I think he remains quite confident in the 20% achievement of that goal of an O&M perspective. You saw we had 18.8% operating margin this quarter, 200 basis points over last year. And the big next wave of integration efforts will really be starting in our Q1 '17, So we have a major program we call it project de Gaulle [ph]. We seem to like a lot of these French names, Didier. I'm not sure why that may be the case, but -- and that really will be the next big step to move the former Dako company into the Agilent environment. And it will take a little bit of while to get the cost out, but as you go -- as you think about exiting '17, you're going to have a much lower SG&A spend than you started the year. And Jacob, I don't think you'd share anything else?"
154924,374881090,1037613,"Agilent Technologies, Inc., Q3 2016 Earnings Call, Aug 17, 2016",2016-08-17,"Earnings Calls","Agilent Technologies, Inc.","Executives","No. I think you captured it correctly. I just want to reinforce what you said, that the path to 20%, actually delivering 20% in 2017 is a significant turnaround of where we were a few years ago. So right now, that's our full aim, and I'm very happy where",57,"No. I think you captured it correctly. I just want to reinforce what you said, that the path to 20%, actually delivering 20% in 2017 is a significant turnaround of where we were a few years ago. So right now, that's our full aim, and I'm very happy where the team is and executing this right now."
154924,374881090,1037613,"Agilent Technologies, Inc., Q3 2016 Earnings Call, Aug 17, 2016",2016-08-17,"Earnings Calls","Agilent Technologies, Inc.","Executives","Thanks, Jacob.",2,"Thanks, Jacob."
154924,374881090,1037613,"Agilent Technologies, Inc., Q3 2016 Earnings Call, Aug 17, 2016",2016-08-17,"Earnings Calls","Agilent Technologies, Inc.","Operator","And this does conclude the question-and-answer session of today's program. I'd like to hand the program back to Alicia Rodriguez for any further remarks.",25,"And this does conclude the question-and-answer session of today's program. I'd like to hand the program back to Alicia Rodriguez for any further remarks."
154924,374881090,1037613,"Agilent Technologies, Inc., Q3 2016 Earnings Call, Aug 17, 2016",2016-08-17,"Earnings Calls","Agilent Technologies, Inc.","Executives","Thank you, Jonathan. And on behalf of the entire management team, I'd like to thank everybody for joining us today. If you have any questions, please give us a call at IR. Thanks again. Bye-bye.",35,"Thank you, Jonathan. And on behalf of the entire management team, I'd like to thank everybody for joining us today. If you have any questions, please give us a call at IR. Thanks again. Bye-bye."
154924,374881090,1037613,"Agilent Technologies, Inc., Q3 2016 Earnings Call, Aug 17, 2016",2016-08-17,"Earnings Calls","Agilent Technologies, Inc.","Operator","Thank you, ladies and gentlemen, for your participation in today's conference. This does conclude the program. You may now disconnect. Good day.",22,"Thank you, ladies and gentlemen, for your participation in today's conference. This does conclude the program. You may now disconnect. Good day."
154924,407124595,1087095,"Agilent Technologies, Inc., Q4 2016 Earnings Call, Nov 15, 2016",2016-11-15,"Earnings Calls","Agilent Technologies, Inc.","Operator","Good day, ladies and gentlemen, and welcome to the Agilent Technologies Fourth Quarter 2016 Earnings Conference Call. [Operator Instructions] As a reminder, this conference is being recorded. I would now like to hand the floor over to Alicia Rodriguez, Vi",47,"Good day, ladies and gentlemen, and welcome to the Agilent Technologies Fourth Quarter 2016 Earnings Conference Call. [Operator Instructions] As a reminder, this conference is being recorded. I would now like to hand the floor over to Alicia Rodriguez, Vice President of Investor Relations. Please go ahead."
154924,407124595,1087095,"Agilent Technologies, Inc., Q4 2016 Earnings Call, Nov 15, 2016",2016-11-15,"Earnings Calls","Agilent Technologies, Inc.","Executives","Thank you, Karen, and welcome, everyone, to Agilent's Fourth Quarter Conference Call for Fiscal Year 2016. With me are Mike McMullen, Agilent's President and CEO; and Didier Hirsch, Agilent's Senior Vice President and CFO. Joining in the Q&A after Didier'",285,"Thank you, Karen, and welcome, everyone, to Agilent's Fourth Quarter Conference Call for Fiscal Year 2016. With me are Mike McMullen, Agilent's President and CEO; and Didier Hirsch, Agilent's Senior Vice President and CFO. Joining in the Q&A after Didier's comments will be Patrick Kaltenbach, President of Agilent's Life Sciences and Applied Markets Group; Jacob Thaysen, President of Agilent's Diagnostics and Genomics Group; and Mark Doak, President of the Agilent CrossLab Group.
You can find the press release and information to supplement today's discussion on our website at www.investor.agilent.com. While there, please click on the link for financial results under the Financial Information tab. You will find an investor presentation along with revenue breakouts and currency impacts, business segment results and historical financials for Agilent's operations. We will also post a copy of the prepared remarks following this call.
Today's comments by Mike and Didier will refer to non-GAAP financial measures. You will find the most directly comparable GAAP financial metrics and reconciliations on our website. We will refer to core revenue growth, which excludes the impact of currency, the NMR business and acquisitions and divestitures within the past 12 months. Unless otherwise noted, all references to increases or decreases in financial metrics are year-over-year. Guidance is based on exchange rates as of the last day of the reported quarter.
We will also make forward-looking statements about the financial performance of the company. These statements are subject to risks and uncertainties and are only valid as of today. The company assumes no obligation to update them. Please look at the company's recent SEC filings for a more complete picture of our risks and other factors.
And now let me turn the call over to Mike"
154924,407124595,1087095,"Agilent Technologies, Inc., Q4 2016 Earnings Call, Nov 15, 2016",2016-11-15,"Earnings Calls","Agilent Technologies, Inc.","Executives","Thanks, Alicia, and hello, everyone. I'm very pleased to announce that our Agilent team ended 2016 with another strong quarter of excellent results. I will start by looking at our key numbers from the quarter. First, we continue to deliver above market",2022,"Thanks, Alicia, and hello, everyone. I'm very pleased to announce that our Agilent team ended 2016 with another strong quarter of excellent results. I will start by looking at our key numbers from the quarter. 
First, we continue to deliver above market growth. Revenues of $1.1 billion exceeded the high end of the guidance by a size [ph] of $41 million and were up 6.3% on a core basis. We were then [ph] first surprised by the strength of our instrument business in pharma, China and Europe, which far exceeded our expectations. 
Second, our adjusted EPS of $0.59 was $0.07 above the high end of our guidance. Finally, we continued our track record of improving profitability as we delivered another quarter of operating margin expansion. Adjusted operating margin of 22.5% was up 60 basis points from Q4 of fiscal 2015. 
Turning to our full year results. Core revenue continued to outperform the market, growing 5.9%. We increased operating margins 110 basis points to 20.7% from 2015. These results drove a 14% increase in adjusted earnings per share for the full year. We are capping off the second year of our company transformation with stellar performance by the Agilent team. Our fourth quarter and full year results demonstrate our continued ability to win in the market. 
We are outgrowing the market while expanding margins and fully leveraging our strong balance sheet. In the past year, we distributed $150 million in cash dividends, repurchased $434 million of our shares and invested $480 million directly into the business through M&A, strategic transactions and capital expenditures. Let me now address what happened in our end markets and business groups. I'll start with the end markets.
Our Q4 trends were similar to what we experienced last quarter with pharma and academia and government being the exceptions. We had expected [ph] continued strength in pharma, but our 16% growth on a difficult compare exceeded our expectations. Growth is being driven by strong customer acceptance of our new products and enterprise service offerings. Academia and government's decline of 2% was less than expected. European spending is holding up better than projected while our U.S. government vestments [ph] continue to lag 2015 spending levels. Clinical diagnostics grew 8% over last year, led by continued growth in reagents.
Within our applied end markets, food is up 10% with strong demand in China and Americas. China also drove growth in environmental market up [ph] 3%. Chemical energy declined 3% in line with expectations due to continued effect of crude oil prices and macroeconomic uncertainties. We expect this market to remain challenging for the rest of calendar year 2016 and into 2017 with no significant downward or upward movements.
Geographically, Asia, led by China and Europe, was stronger than forecast. Our Asia business, excluding Japan, grew double digit, driven by greater than 25% growth in China. While the overall European market remains challenged, we delivered solid mid-single-digit growth. European pharma and food markets were strong and academia and government funding was stable with Q3. Japan and Americas were flat with growth strained [ph] by continued chemical energy market weakness and specific to the U.S., slow U.S. government funding. 
Moving on to the business groups. Life Sciences and Applied Markets Group delivered core revenue growth of 5%. Better-than-expected revenues from our analytical lab instrument business was driven by an attractive combination of introducing new products into growing markets. This applied in particular to our new lineup of chromatography and mass spectrometry products targeted [ph] to pharma in applied food, environmental and forensics markets. LSAG's operating margin for the quarter was 22.8%, up 280 basis points from a year ago.
We are building for the future. In August, we introduced a transformational Intuvo 9000 GC system. Building on our recognized GC leadership, the Intuvo system revolutionized the way user perform gas chromatography. Industry experts recognize unique innovation being delivered by Agilent with press coverage at 100% positive. Intuvo is featured this month on the cover LCGC magazine and major trade publication. Customer response is also very positive introduction, confirming our undisputed market leadership in gas chromatography. We anticipate a measured uptick in revenue. Limited international shipments are expected in Q1 of fiscal 2017 with [indiscernible] expected to increase over subsequent quarters.
Another industry unique product, the Agilent 8900 Triple Quad ICP-MS system, which we just introduced in Q3, is also being well received in the market. This instrument is rapidly becoming the solution of choice in lab to [ph] demand the highest standards of performance. 
Next, the Agilent CrossLab Group continue to deliver strong, sustained growth with core revenue up [ph] 8%. Growth is healthy in both services and consumables. ACG's operating margin for the quarter was 22.7%, down 240 basis points from a year ago and in line with expectations.
ACG result was driven by strong pharma, food, clinical and diagnostic markets, where our CrossLab customer value proposition is being well received. Unlike our instrument business, ACG also grew in the chemical and energy markets. Laboratory supporting strong production levels drove demand for consumables. There is also continued demand for services as customers focus on keeping their older instruments operational.
We are investing for the future in ACG. We just introduced a new range of innovative and differentiated supplies. These new offerings enable the Agilent Intuvo 9000 GC to be the most efficient and cost-effective premium GC to own and operate. We continue to successfully integrate the recently acquired iLab business, which brings differentiated capabilities to core lab managers. 
Last but certainly, not least in terms of impact, the momentum in the Diagnostics and Genomics Group continued with delivery of 8% core growth. Our laser focused on improving the previously acquired dock [ph] of business is paying off before. The pathology business continues its steady climb back to market growth rates with strong through a [ph] strength in reagent and companion diagnostics.
Our nucleic acid solutions business for which we recently announced a significant production capacity grew double digit. This growth reflects the increase in demand for oligonucleotides for RNA-based drugs. DDG's operating margin for the quarter was 19.6%, up 40 basis points from a year ago. 
In October, there were some exciting news from Merck for lung cancer patients and for Agilent. Merck's KEYTRUDA is now approved by the FDA for first-line treatment for metastatic nonsmall cell lung cancer for patients with high rates of PD-L1 expression. In conjunction, Agilent's pharma DS [ph] companion diagnostics, PD-L1 test, is now approved for expanded use. This is the first time an Agilent's PD-L1 companion diagnostic is approved for first-line testing.
The female requesting [ph] for our future is also evident in DDG. We launched a comprehensive offering of pool crystal [ph] libraries for functional genomics. This will help accelerate research into complex diseases and drug discovery. We signed an agreement with the [indiscernible] of the world cancer diagnostics [ph] in China based on Agilent SureSelect solutions. And we broke ground, initiated construction on the previously announced $120 million investment in a new factory in Colorado to expand nucleic acid production capacity.
Turning now to operating margin. We remain focused on operating margin improvement. Since the new Agilent leadership team was appointed, we have delivered 7 consecutive quarters of improved operating margin and strong growth. Despite continued challenges in the chemical and energy business, we have improved adjusted operating margin by 280 basis points in the first 2 years of the company's transformation. We have completely absorbed and offset the $40 million of the synergy costs due to the spill-off [ph] of key site.
On the operations front, our Agile Agilent program continues to simplify the company and lower operating costs. This program is designed to keep us nimble, improve our interaction with customers and lower our cost.
It is having [ph] an impact and will continue to deliver savings in 2017 and beyond. In the coming year, we will realize cost savings from the completion of the integration of doctrine [ph] in early 2017, a simplified enterprise IT systems environment and other cost savings initiatives.
Turning to our FY '17 market and company outlook.
As a reminder, our shareholder value creation model [ph] for superior earnings growth is to outgrow the market and expand operating margins with a balanced deployment of our capital. Didier will go to the specifics of our Q1 '17 and full year guidance. I want to share our thinking about end markets and our initial guidance philosophy, given an environment of increased uncertainty.
This is a change in our last call and in May 2016 Analyst Investor Day. In our end markets, we expect continued strength in pharma, accompanied by continued solid growth in the food, environmental and clinical research and diagnostics markets. Geographically, China and India are expected to grow at significantly higher rates than other countries. There remains considerable uncertainty about European markets. We are forecasting moderate growth in the United States with the U.S. government policies and spending and chemical energy markets being the wildcards.
Chemical and energy, while [ph] it appear an easier compares and improved oil prices has not yet returned the growth. We expect a continued subdued academic and government research market in the coming year until uncertainties resulting from Brexit and the U.S. elections play out. We are also keeping a watchful eye on how potential new U.S. government driven trade and currency evaluation discussions could impact our business.
We finished 2016 very strongly and we are well positioned for future growth with a pipeline of new offerings. In our initial revenue guidance for 2017, however, we want to be on the cautious side. We want to see some more clarity on U.S. and European government actions and have better indicators on when we will return to growth in our industrial end markets. 
Predicting end market growth in today's uncertain political and economic environment is challenging. However, I can predict quite confidently that we will continue our track record of outgrowing the market whatever market environment we encounter. We continue to expand our customer channel reach and fortify our portfolio, which strengthen us well for the coming year and beyond. 
The transformation of asset we discuss of the May Analyst and Investor Day is a full force. The new leadership team, put in place in early 2015 continued to deliver strong operating results each and every quarter. We are building momentum for future growth. We have improved our adjusted operating margins by 200 basis points over the past 2 years and our march to improve operating margins will continue in 2017.
However, in our initial operating margin and earnings per share guidance for 2017, we want to be on the cautious side. Since our May Analyst and Investor Day meeting, change in exchange rate, pension expenses and the recent iLab acquisition are having a short-term dilutive impact in our operating margins of 0.5%. The Agilent team, however, is laser-focused on improving another 130 basis points of operating margin. We have an internal action plan, in line with achieving a 22% operating margin goal in fiscal 2017 excluding M&A impact. This is the primary goal for our executive team's compensation. We continue to hold ourselves to a higher level of performance, expectations than reflected in our initial full year earnings guidance.
As you assess our future possibilities, I will leave you with a few thoughts. We are expanding our product portfolio and extended into adjacent markets. We're improving the customer experience by streamlining processes and modernizing the systems, making the company more efficient and customer friendly. Our Agile Agilent program has and will continue to deliver incremental improvements and operating margin. The One Agilent team continues to work well together and is determined to win in the market. We believe we are well positioned in staying [ph] our strong operational performance and achieve our long-term goals. The entire Agilent team is energized and committed to deliver future growth. 
Thank you for being on the call today. I will now turn it over to Didier, who will provide initial insights on our financial results and initial guidance for our fiscal Q1 and full year 2017. Didier?"
154924,407124595,1087095,"Agilent Technologies, Inc., Q4 2016 Earnings Call, Nov 15, 2016",2016-11-15,"Earnings Calls","Agilent Technologies, Inc.","Executives","Thank you, Mike, and hello, everyone. As Mike stated, we are very pleased with our Q4 and full year performance, both well over the high end of our guidance. We delivered above [ph] market core revenue growth of 6.3% and 5.9%, respectively, and our operat",576,"Thank you, Mike, and hello, everyone. As Mike stated, we are very pleased with our Q4 and full year performance, both well over the high end of our guidance. We delivered above [ph] market core revenue growth of 6.3% and 5.9%, respectively, and our operating margin adjusted for income from key site was up 60 basis points, 110 basis points, respectively. 
Our full year EPS at $1.98 is 14% higher than the previous year. Please note that we have reduced our pro forma tax rate by 1 percentage points, which had a $0.02 impact on our EPS. Our operating cash flow for the full year at $793 million reflects our strong overall performance. And turning to capital returns.
For the first -- for the year, we returned $584 million to shareholders in the form of dividends and buybacks or 89% of our free cash flow. I'll now turn to the guidance for fiscal year 2017. 
As Mike stated, our initial guidance, like last year, assumes that what we believe to be appropriate caution. Our fiscal year '17 revenue guidance of $4.35 billion to $4.37 billion corresponds to core revenue growth of 4% to 4.5%. It is based on October 31 [indiscernible] rates and currency had a 0.6 percentage foreign impact, negative impact on revenues.
We project fiscal year '17 adjusted operating margin of 21% to 21.5% and fiscal year '17 EPS of $2.10 to $2.16, growing 8% at mid-point. As you update your models for fiscal year '17, please consider the following 10 points. First, annual salary increases will be effective December 1, 2016. Second, stock-based compensation will be about $59 million and as we front end the recognition of stock-based compensation, the Q1 expense will be about $23 million. Third, the reduction in bond yields is negatively impacting our annual pension expenses by about $12 million.
Fourth, depreciation is projected to be $104 million for the fiscal year. Fifth, the non-GAAP effective tax rate is projected to remain at 19%. Sixth, we plan to return approximately $600 million in capital to shareholders, including $170 million in dividends and $430 million in buybacks, subject to customary conditions. Seventh, we plan to buy [ph] $250 million in the second half to fund a portion of our capital returns. Eighth, net interest expense is forecasted at $71 million and other income at $11 million. Ninth, for purpose of our EPS guidance, we have assumed a diluted share count of 324 million shares, 5 million shares less than the average diluted share count in fiscal year '16. And finally, tenth, we expect operating cash flow of $825 million and capital expenditures of $200 million, about $60 million over fiscal year '16, mostly due to the investment in the second nucleic acid facility.
Now finally, moving to the guidance for our first quarter. First, please note that lunar new year falls in Q1 this year versus Q2 last year. Meaning, about $15 million of revenue shifting from Q1 to Q2. 
We expect Q1 revenues of $1.04 billion to $1.06 billion and EPS of $0.48 to $0.50. At mid-point, revenue will grow 2.2% on a core basis and EPS will grow 7%.
And as customary, Q1 EPS is negatively impacted by the December salary increase, front loading of stock-based compensation and the increase in payroll taxes due to the disbursement of the variable and incentive pay of the previous year. 
With that, I'll turn it over to Alicia for the Q&A."
154924,407124595,1087095,"Agilent Technologies, Inc., Q4 2016 Earnings Call, Nov 15, 2016",2016-11-15,"Earnings Calls","Agilent Technologies, Inc.","Executives","Thank you, Didier. Karen, will you please give the instructions for the Q&A.",13,"Thank you, Didier. Karen, will you please give the instructions for the Q&A."
154924,407124595,1087095,"Agilent Technologies, Inc., Q4 2016 Earnings Call, Nov 15, 2016",2016-11-15,"Earnings Calls","Agilent Technologies, Inc.","Operator","[Operator Instructions] Our first question comes from the line of Steve Beuchaw from Morgan Stanley.",15,"[Operator Instructions] Our first question comes from the line of Steve Beuchaw from Morgan Stanley."
154924,407124595,1087095,"Agilent Technologies, Inc., Q4 2016 Earnings Call, Nov 15, 2016",2016-11-15,"Earnings Calls","Agilent Technologies, Inc.","Analysts","First question for me is I wonder if you could just juxtapose your results against what we've heard from others in the category over the last several weeks. I mean, it sounds like a particularly strong category by number -- quarter by number of metrics. Y",99,"First question for me is I wonder if you could just juxtapose your results against what we've heard from others in the category over the last several weeks. I mean, it sounds like a particularly strong category by number -- quarter by number of metrics. You actually accelerated or we saw a number of others decelerate in terms of organic growth in the quarter. Can you give us, from a high level, what you think are the keys there in terms of positioning? Why it is the quarter were so good for you guys relative to the market?"
154924,407124595,1087095,"Agilent Technologies, Inc., Q4 2016 Earnings Call, Nov 15, 2016",2016-11-15,"Earnings Calls","Agilent Technologies, Inc.","Executives","Yes, thanks, Steve. The headline for me was as we look grow the quarter, we were winning more of [ph] the business than we plan. So we're winning a lot of business in our core markets. I think some of the end market strength that we plan to is actually fa",140,"Yes, thanks, Steve. The headline for me was as we look grow the quarter, we were winning more of [ph] the business than we plan. So we're winning a lot of business in our core markets. I think some of the end market strength that we plan to is actually fairly similar to what I've seen other people comment on relative to the strength of China, strength of pharma, continued, subdued, but kind of a stable actually even [ph] government environment. And for us, I think we were just delighted by our performance, in particular, in our analytical instrument business where we seem to be winning more business than we planned and we think that bodes well for the strength of our portfolio and some of the things we've been doing over the last year in our channels as well."
154924,407124595,1087095,"Agilent Technologies, Inc., Q4 2016 Earnings Call, Nov 15, 2016",2016-11-15,"Earnings Calls","Agilent Technologies, Inc.","Analysts","And then so the follow-up, I guess, just to dig a little deeper would be, did you notice anything in terms of instrument trends relative to consumables trends accelerating or decelerating? And what is that telling you about end of year, I should say end o",51,"And then so the follow-up, I guess, just to dig a little deeper would be, did you notice anything in terms of instrument trends relative to consumables trends accelerating or decelerating? And what is that telling you about end of year, I should say end of calendar year budget flush?"
154924,407124595,1087095,"Agilent Technologies, Inc., Q4 2016 Earnings Call, Nov 15, 2016",2016-11-15,"Earnings Calls","Agilent Technologies, Inc.","Executives","Yes, we were talking a bit about this yesterday with the team. And if you look at our performance through the quarter, we got off to a strong start in August and it continued throughout the quarter. And sometimes, it's hard to tell either [ph] first month",94,"Yes, we were talking a bit about this yesterday with the team. And if you look at our performance through the quarter, we got off to a strong start in August and it continued throughout the quarter. And sometimes, it's hard to tell either [ph] first month, where things align [ph] for the quarter. But I'd say by the end of September, we knew we are winning more business than we plan. And this really shaping up to be a strong quarter for us and really position us well for us going into 2017."
154924,407124595,1087095,"Agilent Technologies, Inc., Q4 2016 Earnings Call, Nov 15, 2016",2016-11-15,"Earnings Calls","Agilent Technologies, Inc.","Operator","And our next question comes from the line of Tycho Peterson from JPMorgan.",13,"And our next question comes from the line of Tycho Peterson from JPMorgan."
154924,407124595,1087095,"Agilent Technologies, Inc., Q4 2016 Earnings Call, Nov 15, 2016",2016-11-15,"Earnings Calls","Agilent Technologies, Inc.","Analysts","Mike, just hoping for a little bit more color on some of the expectations and guidance in particular around pharma. Are you still assuming that's kind of double-digit growth next year? Or are you factoring in a moderation? And on environmental, you manage",69,"Mike, just hoping for a little bit more color on some of the expectations and guidance in particular around pharma. Are you still assuming that's kind of double-digit growth next year? Or are you factoring in a moderation? And on environmental, you managed to grow that business in contrast peers last week. So maybe talk a bit about contributions from the DC replacement cycle for next year as well."
154924,407124595,1087095,"Agilent Technologies, Inc., Q4 2016 Earnings Call, Nov 15, 2016",2016-11-15,"Earnings Calls","Agilent Technologies, Inc.","Executives","Yes, sure. Tycho, you broke up a bit on the cost. So if I don't got to the specific questions, please come back to me. But I think relative to the expectations for end market kind of thinking for growth rate, we had pharma below the double-digit growth th",101,"Yes, sure. Tycho, you broke up a bit on the cost. So if I don't got to the specific questions, please come back to me. But I think relative to the expectations for end market kind of thinking for growth rate, we had pharma below the double-digit growth that have been placed in '16. So as we look at our end markets, we would expect a moderation of growth, not because the expense, but you really going to script out to get into tough compares. And Didier, if I remember quickly, we were in the mid-to high single-digit growth for pharma?"
154924,407124595,1087095,"Agilent Technologies, Inc., Q4 2016 Earnings Call, Nov 15, 2016",2016-11-15,"Earnings Calls","Agilent Technologies, Inc.","Executives","Yes.",1,"Yes."
154924,407124595,1087095,"Agilent Technologies, Inc., Q4 2016 Earnings Call, Nov 15, 2016",2016-11-15,"Earnings Calls","Agilent Technologies, Inc.","Executives","And then I think the story -- I think Tycho the question was around environmental.",15,"And then I think the story -- I think Tycho the question was around environmental."
154924,407124595,1087095,"Agilent Technologies, Inc., Q4 2016 Earnings Call, Nov 15, 2016",2016-11-15,"Earnings Calls","Agilent Technologies, Inc.","Analysts","Yes, the GC replacement.",4,"Yes, the GC replacement."
154924,407124595,1087095,"Agilent Technologies, Inc., Q4 2016 Earnings Call, Nov 15, 2016",2016-11-15,"Earnings Calls","Agilent Technologies, Inc.","Executives","So environmental, the story really there is China. And we think that's got many quarters in front of us of growth in China. And we, as you know, I'm fairly bullish on the prospects of that market. And I think with that kind of a perfect storm here going o",195,"So environmental, the story really there is China. And we think that's got many quarters in front of us of growth in China. And we, as you know, I'm fairly bullish on the prospects of that market. And I think with that kind of a perfect storm here going on where we have strong products going into the growing markets. Relative to the GC replacement cycle. This is really about what's going to happen in the chemical and energy market. And I'll make a few comments here then, Patrick, you may want to provide your perspective as well. So may have noticed in my call script, I went kind of out over my we to talk about a measured ramp-up of our new Intubo GC because we think we've got a winner products in our hands. And now there's lot of interest from customers. But we also recognize the reality of constraints they may have in their capital budgets. Now the work in the -- with their own management teams internally of this company's about what they may get in terms of funding in 2017. But what are your thoughts, Patrick on that as well?"
154924,407124595,1087095,"Agilent Technologies, Inc., Q4 2016 Earnings Call, Nov 15, 2016",2016-11-15,"Earnings Calls","Agilent Technologies, Inc.","Executives","Yes, thanks, Mike. Looking at the GC market, we definitely are positioned very well to capture in a growth opportunity there. We have launched the Intubo, which is a strong message so our customers that were standing we had a minute comes a drive for lowe",159,"Yes, thanks, Mike. Looking at the GC market, we definitely are positioned very well to capture in a growth opportunity there. We have launched the Intubo, which is a strong message so our customers that were standing we had a minute comes a drive for lower cost of measurement, when it comes to lower cost of ownership, when it comes to increase productivity below the positions us clearly asked the market leader in gas chromatography. There will be a lot of discussions of time, not only interpret, but I think whether turbo logic for us. We also -- it also spent lot of discussion again about other part of portfolio to 78 90 and other products, which are were market-leading products. And again, the discussion with the customers in the suppress market is all about how can we help them increase their productivity, driving their cost of analysis down and business where we are exceptionally positioned with this portfolio."
154924,407124595,1087095,"Agilent Technologies, Inc., Q4 2016 Earnings Call, Nov 15, 2016",2016-11-15,"Earnings Calls","Agilent Technologies, Inc.","Executives","Yes, maybe just to up an exclamation point on this. Is that we know that the installed base is at historic levels of aging. We know that equipment is being used. And it's just a matter time for that replacement cycle is going to turn on. But as you saw in",61,"Yes, maybe just to up an exclamation point on this. Is that we know that the installed base is at historic levels of aging. We know that equipment is being used. And it's just a matter time for that replacement cycle is going to turn on. But as you saw in my call comments, we're not ready to call that yet."
154924,407124595,1087095,"Agilent Technologies, Inc., Q4 2016 Earnings Call, Nov 15, 2016",2016-11-15,"Earnings Calls","Agilent Technologies, Inc.","Analysts","Okay. And just one clarification on the operating margin guidance. Half of the cut you're down at 1% that you what you to talk service just conservatism, and kind of the macro?",32,"Okay. And just one clarification on the operating margin guidance. Half of the cut you're down at 1% that you what you to talk service just conservatism, and kind of the macro?"
154924,407124595,1087095,"Agilent Technologies, Inc., Q4 2016 Earnings Call, Nov 15, 2016",2016-11-15,"Earnings Calls","Agilent Technologies, Inc.","Executives","Yes, actually I think where we had was the high in our guidance was around 21.5, right, Didier? And...",19,"Yes, actually I think where we had was the high in our guidance was around 21.5, right, Didier? And..."
154924,407124595,1087095,"Agilent Technologies, Inc., Q4 2016 Earnings Call, Nov 15, 2016",2016-11-15,"Earnings Calls","Agilent Technologies, Inc.","Executives","So yes, with the high end at 21.5 and we are losing about 50 basis points related to the 3 items that were mentioned: Currency, acquisition and pension expenses. And the other thing to note is as Mike has clearly stated, we are still being measured on ach",55,"So yes, with the high end at 21.5 and we are losing about 50 basis points related to the 3 items that were mentioned: Currency, acquisition and pension expenses. And the other thing to note is as Mike has clearly stated, we are still being measured on achieving 22% in terms of our variable compensation."
154924,407124595,1087095,"Agilent Technologies, Inc., Q4 2016 Earnings Call, Nov 15, 2016",2016-11-15,"Earnings Calls","Agilent Technologies, Inc.","Executives","Yes, the way Didier and I talked about this one is listen, we think we've got a path to 22%. But there's lost higher risks than it was back in the last call and at the May AIDs. So we thought it was prudent for us to guide as well. But we're all out insid",64,"Yes, the way Didier and I talked about this one is listen, we think we've got a path to 22%. But there's lost higher risks than it was back in the last call and at the May AIDs. So we thought it was prudent for us to guide as well. But we're all out inside, all our comp is tied to the 22% number."
154924,407124595,1087095,"Agilent Technologies, Inc., Q4 2016 Earnings Call, Nov 15, 2016",2016-11-15,"Earnings Calls","Agilent Technologies, Inc.","Executives","The 3 elements were headwinds.",5,"The 3 elements were headwinds."
154924,407124595,1087095,"Agilent Technologies, Inc., Q4 2016 Earnings Call, Nov 15, 2016",2016-11-15,"Earnings Calls","Agilent Technologies, Inc.","Operator","And our next question comes from the line of Ross Muken from Evercore ISI.",14,"And our next question comes from the line of Ross Muken from Evercore ISI."
154924,407124595,1087095,"Agilent Technologies, Inc., Q4 2016 Earnings Call, Nov 15, 2016",2016-11-15,"Earnings Calls","Agilent Technologies, Inc.","Analysts","Just hoping you can give our more color on your margin assumption for next year? Where do you guys think about basing the FX headwinds, if any, was going to be the operational, pricing, et cetera?",36,"Just hoping you can give our more color on your margin assumption for next year? Where do you guys think about basing the FX headwinds, if any, was going to be the operational, pricing, et cetera?"
154924,407124595,1087095,"Agilent Technologies, Inc., Q4 2016 Earnings Call, Nov 15, 2016",2016-11-15,"Earnings Calls","Agilent Technologies, Inc.","Executives","I think the question, Didier a was relative to the composition of our operating margin improvements for next year. And perhaps we can start to the mix between volume and OpEx and gross margins.",34,"I think the question, Didier a was relative to the composition of our operating margin improvements for next year. And perhaps we can start to the mix between volume and OpEx and gross margins."
154924,407124595,1087095,"Agilent Technologies, Inc., Q4 2016 Earnings Call, Nov 15, 2016",2016-11-15,"Earnings Calls","Agilent Technologies, Inc.","Executives","Yes, I mean, the -- I mean, I'm not going to give you the full bridge. I mean, when we provided the guidance of 21% to 21.5%, we took into account obviously, the -- all the impact that I've mentioned. So there is -- it's based on the 4.3% core revenue gro",157,"Yes, I mean, the -- I mean, I'm not going to give you the full bridge. I mean, when we provided the guidance of 21% to 21.5%, we took into account obviously, the -- all the impact that I've mentioned. So there is -- it's based on the 4.3% core revenue growth. So there is a clearly an operating leverage impact. And a lot of actions that are taking place to offset inflation and other headwinds that partly I have mentioned. The guidance assumes some level of increase improvements in gross margins as well as the reduction in terms of our -- of the OpEx as a percentage of revenue. So have a pretty much, on all fronts, some improvements, not as much as we had initially abated because of the 3 headwinds that they mentioned. Some of it related to operating leverage and some of it is related to the continuation of our Agile Agilent programs."
154924,407124595,1087095,"Agilent Technologies, Inc., Q4 2016 Earnings Call, Nov 15, 2016",2016-11-15,"Earnings Calls","Agilent Technologies, Inc.","Executives","And maybe just reminding the audience, Didier. When we first started in March almost 2 years ago to go to the 22%, we laid out a path, which is really around 50% been volatile, the other 40% was going to be on OpEx improvement in gross margin. And I think",60,"And maybe just reminding the audience, Didier. When we first started in March almost 2 years ago to go to the 22%, we laid out a path, which is really around 50% been volatile, the other 40% was going to be on OpEx improvement in gross margin. And I think were thinking about the same kind of mix for 2017."
154924,407124595,1087095,"Agilent Technologies, Inc., Q4 2016 Earnings Call, Nov 15, 2016",2016-11-15,"Earnings Calls","Agilent Technologies, Inc.","Analysts","Okay, great. And then I guess just one more. New you guys are built on low cash flow in '16. I think 6 47 and you're guiding for 6 25. Is there any timing impact on that '17 guide? And then, I guess, on the tax of '17, kind of what are you baking into tha",59,"Okay, great. And then I guess just one more. New you guys are built on low cash flow in '16. I think 6 47 and you're guiding for 6 25. Is there any timing impact on that '17 guide? And then, I guess, on the tax of '17, kind of what are you baking into that benefit down there?"
154924,407124595,1087095,"Agilent Technologies, Inc., Q4 2016 Earnings Call, Nov 15, 2016",2016-11-15,"Earnings Calls","Agilent Technologies, Inc.","Executives","So I some when you refer to timing impact, you referring to special, mean between '16, '17, some cash out [indiscernible].",21,"So I some when you refer to timing impact, you referring to special, mean between '16, '17, some cash out [indiscernible]."
154924,407124595,1087095,"Agilent Technologies, Inc., Q4 2016 Earnings Call, Nov 15, 2016",2016-11-15,"Earnings Calls","Agilent Technologies, Inc.","Analysts","Yes, correct.",2,"Yes, correct."
154924,407124595,1087095,"Agilent Technologies, Inc., Q4 2016 Earnings Call, Nov 15, 2016",2016-11-15,"Earnings Calls","Agilent Technologies, Inc.","Executives","Yes, there's a little bit. I mean, let me just highlight 2 potentially. This -- in fiscal year '16, we dispersed $66 million for overall Agilent variable pay and pay for results. Next year, we -- but we've changed our program so that we now know do a lot",218,"Yes, there's a little bit. I mean, let me just highlight 2 potentially. This -- in fiscal year '16, we dispersed $66 million for overall Agilent variable pay and pay for results. Next year, we -- but we've changed our program so that we now know do a lot of the cash outlays in an annual basis in terms of some minor. So we have a full breadth in '17 of improvements and '16 and the fact that we're going to be in '17 something that is more than pertaining to '16. As it's going to be $91 million going from $66 million to $91 million. So a increased capital cash outlook. 
And then second, we did not fund our twist pension plan in '16. So our overall contributions to our worldwide pension plan was $24 million. We intend to fund our U.S. pension plan more in '17 and the contribution to the pension plan will move to $45 million. So an increase from 24 to 45. So that -- those are the 2 things that come to mind in terms of explaining some of the variance between '16 and 17. But even with this to headwinds, we're still concern, in our initial guidance, a nice increase of $30 million on a year-over-year basis. And your second question"
154924,407124595,1087095,"Agilent Technologies, Inc., Q4 2016 Earnings Call, Nov 15, 2016",2016-11-15,"Earnings Calls","Agilent Technologies, Inc.","Executives","Related to tax rate.",4,"Related to tax rate."
154924,407124595,1087095,"Agilent Technologies, Inc., Q4 2016 Earnings Call, Nov 15, 2016",2016-11-15,"Earnings Calls","Agilent Technologies, Inc.","Executives","Yes, on the tax rates, I did mention that may Analyst Day that we -- we're going to work really hard on the reducing our tax rate by 2 percentage points over the course of the next 2 to 3 years. We are very happy to be able to deliver already 1 percentage",150,"Yes, on the tax rates, I did mention that may Analyst Day that we -- we're going to work really hard on the reducing our tax rate by 2 percentage points over the course of the next 2 to 3 years. We are very happy to be able to deliver already 1 percentage point in this fiscal year '16. We still are aiming to reduce our effective tax rate by other 1 percentage points over the course of the next 24 months as committed to or as indicated, I would say, in fiscal year -- in -- at the ID. But it's prudent to assume that the reduction will come in fiscal year '18 and not in fiscal year '17. So in your models, we advise you to put a 1 percentage points reduction in tax rate from 19 to 18 in fiscal year '18, not in fiscal year '17."
154924,407124595,1087095,"Agilent Technologies, Inc., Q4 2016 Earnings Call, Nov 15, 2016",2016-11-15,"Earnings Calls","Agilent Technologies, Inc.","Analysts","And does that include the to 16 09 benefit?",9,"And does that include the to 16 09 benefit?"
154924,407124595,1087095,"Agilent Technologies, Inc., Q4 2016 Earnings Call, Nov 15, 2016",2016-11-15,"Earnings Calls","Agilent Technologies, Inc.","Executives","It includes everything.",3,"It includes everything."
154924,407124595,1087095,"Agilent Technologies, Inc., Q4 2016 Earnings Call, Nov 15, 2016",2016-11-15,"Earnings Calls","Agilent Technologies, Inc.","Operator","And our next question comes from the line of Doug Schenkel from Cowen and Company.",15,"And our next question comes from the line of Doug Schenkel from Cowen and Company."
154924,407124595,1087095,"Agilent Technologies, Inc., Q4 2016 Earnings Call, Nov 15, 2016",2016-11-15,"Earnings Calls","Agilent Technologies, Inc.","Analysts","Hi, this is Ryan Blicker on for Doug. Would you be willing to provide what your LCMS growth for the quarter and how that was impacted by the comparisons relative to recent quarters and maybe where your annual growth was there?",41,"Hi, this is Ryan Blicker on for Doug. Would you be willing to provide what your LCMS growth for the quarter and how that was impacted by the comparisons relative to recent quarters and maybe where your annual growth was there?"
154924,407124595,1087095,"Agilent Technologies, Inc., Q4 2016 Earnings Call, Nov 15, 2016",2016-11-15,"Earnings Calls","Agilent Technologies, Inc.","Executives","What I can tell you is that, back to our statement comp is that we're bringing more business that plan. So we're quite pleased with how we've been doing with the LC/MS portfolio. And Patrick, you may just want to remind the audience some of the new stuff",95,"What I can tell you is that, back to our statement comp is that we're bringing more business that plan. So we're quite pleased with how we've been doing with the LC/MS portfolio. And Patrick, you may just want to remind the audience some of the new stuff that will come out with. So I guess, I'm not comfortable with giving the space of the growth rates. But just to give you a sense of the trend of the business maybe a few point the way we believe is going as well as it is."
154924,407124595,1087095,"Agilent Technologies, Inc., Q4 2016 Earnings Call, Nov 15, 2016",2016-11-15,"Earnings Calls","Agilent Technologies, Inc.","Executives","Sure, again, I'm confident that we are of growing the markets on many fronts. And we have a very strong LC/MS portfolio we have lunched a lot of exciting product set and I think the perception of the market just underlines our strength. The completion of",108,"Sure, again, I'm confident that we are of growing the markets on many fronts. And we have a very strong LC/MS portfolio we have lunched a lot of exciting product set and I think the perception of the market just underlines our strength. The completion of LC/MS anything both are winning platforms. See strong reduction across all the end markets. If there was one market where we have seen some headwind, then it was probably at the pain management market segment. But that is also in line with what we probably have for some of our competitors. But overall, we have very please with a result in Q4."
154924,407124595,1087095,"Agilent Technologies, Inc., Q4 2016 Earnings Call, Nov 15, 2016",2016-11-15,"Earnings Calls","Agilent Technologies, Inc.","Analysts","Okay, that's helpful. And then it seems like there could be a repatriation holiday of some sort in 2017. I believe over 90% of your cash is currently trapped internationally. Can you provide any initial thoughts on how you would you prioritize repatriated",53,"Okay, that's helpful. And then it seems like there could be a repatriation holiday of some sort in 2017. I believe over 90% of your cash is currently trapped internationally. Can you provide any initial thoughts on how you would you prioritize repatriated cash, specifically on M&A opportunities and returning capital to shareholders?"
154924,407124595,1087095,"Agilent Technologies, Inc., Q4 2016 Earnings Call, Nov 15, 2016",2016-11-15,"Earnings Calls","Agilent Technologies, Inc.","Executives","Yes, sure, Ross. So Didier, will have to make a few additional comments. Than first, I think we did caveats on my response because we really don't know what this might look like. Was rigs might be attached to, how you can use it, whether you could use cas",273,"Yes, sure, Ross. So Didier, will have to make a few additional comments. Than first, I think we did caveats on my response because we really don't know what this might look like. Was rigs might be attached to, how you can use it, whether you could use cash in a certain way. But obviously, we would welcome this type of development including a move to a more permanent reduction in U.S. corporate tax rates. That being said, I think if you go beyond the theory, I assume -- of those caveats, I think what you'd expect us to do is handle the return to cash very much along the lines of how we're managing our current use of capital. So we would want to use it for U.S. based M&A, and we'd like to use that in situation where we've been using debt, such as our share repurchases so we would able to finance our share repurchases. And then we might look at our debt structure. But I think what we want to do is, for several, understand what are the restrictions that could be tied to it. Also remind the group that some of the cash does need to remain permanently investment overseas. But we were -- if that particular situation with the fall, we would likely would bring it back use of the cash pretty much along the lines how we've been using cash with the exception of us need to borrow money like of the on in the past for U.S. base M&A or stock repurchases. I guess that you're okay with that, Didier. You didn't say anything else."
154924,407124595,1087095,"Agilent Technologies, Inc., Q4 2016 Earnings Call, Nov 15, 2016",2016-11-15,"Earnings Calls","Agilent Technologies, Inc.","Executives","Obviously. We're just waiting and waiting breadth for the fine lines on any chance, but yes.",16,"Obviously. We're just waiting and waiting breadth for the fine lines on any chance, but yes."
154924,407124595,1087095,"Agilent Technologies, Inc., Q4 2016 Earnings Call, Nov 15, 2016",2016-11-15,"Earnings Calls","Agilent Technologies, Inc.","Operator","And our next question comes from the line of Jonathan Groberg from UBS.",13,"And our next question comes from the line of Jonathan Groberg from UBS."
154924,407124595,1087095,"Agilent Technologies, Inc., Q4 2016 Earnings Call, Nov 15, 2016",2016-11-15,"Earnings Calls","Agilent Technologies, Inc.","Analysts","Mike i was just going back and looking, you did 6% growth organically for last year 6% this year in '16. Is it a high level, have some pretty tough, tough businesses and some of the industrial business this year, we still put up 6%. I guess I'm wondering,",103,"Mike i was just going back and looking, you did 6% growth organically for last year 6% this year in '16. Is it a high level, have some pretty tough, tough businesses and some of the industrial business this year, we still put up 6%. I guess I'm wondering, as you look out to '17, are there some initial thoughts you have are under the election from an end market standpoint, outside of tax, that make you incremental it concerned? Is there -- maybe just a high-level kind of what makes you think you're going to get kind of 150 bp slowdown year-over-year."
154924,407124595,1087095,"Agilent Technologies, Inc., Q4 2016 Earnings Call, Nov 15, 2016",2016-11-15,"Earnings Calls","Agilent Technologies, Inc.","Executives","Yes, so great question, John and thanks for that obviously, you spent a lot of time talking about this as a team and I mentioned to Alicia before the call, I think we maybe the first company our space that had to do guidance after the U.S. election. So wh",502,"Yes, so great question, John and thanks for that obviously, you spent a lot of time talking about this as a team and I mentioned to Alicia before the call, I think we maybe the first company our space that had to do guidance after the U.S. election. So what I'm going to tell you is kind of factors were thinking about. And then also give you maybe some a little bit more thinking about why we guided the growth rate we did as a company. But we don't yet have a position on these issues. What we do know is there's a multitude of factors that we need to pay attention to. Regulated markets, what's going to happen to other customers in the food markets, environmental markets, the drug -- the FDA regulatory markets. So we know there could be a custom impact. What's going to happen with the U.S. government-funded? A lot of our business is driven by U.S. government funding. What's going to happen with trade agreements. This been a lot of noise about Chinese currency. Just talk about the tax and all of the M&A environment change in terms of -- a so I can say right now, Donovan is perhaps, like everybody else on this call, we kind of, on a sense of issues, but we don't know these things are going to go yet so or not going to call them. And that's one of the reasons why we took what we believe to be a prudent, cautious initial guide to FY '17. 
If I look at the end markets, I mean, pharma's going to continue to be strong. But we don't believe that it continued to grow double digits throughout all of FY '17. So we tapered down our expectations a bit about the pharma. We also think that China has been this fantastic for us. I think our number for the U.S. Senate percent growth for the year to come down that back a bit to double digit. So what we're doing is really just trying to moderate our view of growth for next year based on what you've seen to be some pretty difficult comparisons in some markets that really have been driving the business. As I mentioned to you, the wildcard is the term on a G. One of the things that you point out Jonathan and what I'm really delighted is we've had 6%, close to 6% growth, 2 years in a row with our number 2 market declining for 8 quarters. When that market turns, that obviously will help us in that growth. So -- but I learned over the first 2 years in this job, it's really hard to call terms of a merger market. So I'm not going to. And we'll just kind of keep an eye on it and we'll update you as we go through the. By that's our thinking about how reviewing the your selection and the thought behind our aftermarket guidance for next year."
154924,407124595,1087095,"Agilent Technologies, Inc., Q4 2016 Earnings Call, Nov 15, 2016",2016-11-15,"Earnings Calls","Agilent Technologies, Inc.","Analysts","And if I could just one more on the diagnostic and clinical market.",13,"And if I could just one more on the diagnostic and clinical market."
154924,407124595,1087095,"Agilent Technologies, Inc., Q4 2016 Earnings Call, Nov 15, 2016",2016-11-15,"Earnings Calls","Agilent Technologies, Inc.","Executives","Yes, Jacob and Daya and our answer to question. Was you have 85 growth there. Obviously, you're probably going to say to think about how hospitals may react to the potential repeal of the ACA. But although PD-L1 testing business, how much of your growth w",61,"Yes, Jacob and Daya and our answer to question. Was you have 85 growth there. Obviously, you're probably going to say to think about how hospitals may react to the potential repeal of the ACA. But although PD-L1 testing business, how much of your growth was driven by that market? And any -- can you size that market for us yet?"
154924,407124595,1087095,"Agilent Technologies, Inc., Q4 2016 Earnings Call, Nov 15, 2016",2016-11-15,"Earnings Calls","Agilent Technologies, Inc.","Executives","Well, it's -- I can start by saying that we have been very pleased with the performance of the PD-L1 over the last 12 months, I think it's 13 months now. And it has grown, if not, to our, above even. And we expect that to continue to grow now based on a 1",234,"Well, it's -- I can start by saying that we have been very pleased with the performance of the PD-L1 over the last 12 months, I think it's 13 months now. And it has grown, if not, to our, above even. And we expect that to continue to grow now based on a 12 first-line and obviously, know that comparing diagnostic. We will see a bigger demand for U.S, Europe and in other  regions. In the market itself is very difficult to size, as you know, that both been a companion with one drug and then has been the complementary with another drug, and those have very different sizes at this point of time. I still believe that the overall PD-L1 market might end up in the same size after that market. But the difference is that too is only one. One, basically one drug together with as one diagnostics by the PD-L1 will be up to 5 different drugs, maybe more in 5 different diagnostic, maybe even more and a lot of indications also. So this is as close as I can get to right now. The market we place in is -- the 2 companion diagnostics that we had today continued to grow strongly. I won't say that that's the overall margin driver for the 8%. Basically, all of our businesses today have a very nice growth performance but it's definitely contributing."
154924,407124595,1087095,"Agilent Technologies, Inc., Q4 2016 Earnings Call, Nov 15, 2016",2016-11-15,"Earnings Calls","Agilent Technologies, Inc.","Operator","And our next question comes from line of Derik De Bruin from Bank of America.",15,"And our next question comes from line of Derik De Bruin from Bank of America."
154924,407124595,1087095,"Agilent Technologies, Inc., Q4 2016 Earnings Call, Nov 15, 2016",2016-11-15,"Earnings Calls","Agilent Technologies, Inc.","Analysts","The pacing in the quarter was very good. Can you talk a little bit about backlog and, I guess, did you pull -- are you mortgage pull anything from the first quarter and I mean, anything usual spending patterns that you thought?",42,"The pacing in the quarter was very good. Can you talk a little bit about backlog and, I guess, did you pull -- are you mortgage pull anything from the first quarter and I mean, anything usual spending patterns that you thought?"
154924,407124595,1087095,"Agilent Technologies, Inc., Q4 2016 Earnings Call, Nov 15, 2016",2016-11-15,"Earnings Calls","Agilent Technologies, Inc.","Executives","Yes, thanks for the question, Derik. So as I mentioned earlier, we saw strength throughout the quarter. And we were quite, quite delighted with the results. And we're not specifically comment about orders or backlogs. But I did say in my early comments th",157,"Yes, thanks for the question, Derik. So as I mentioned earlier, we saw strength throughout the quarter. And we were quite, quite delighted with the results. And we're not specifically comment about orders or backlogs. But I did say in my early comments that we're well-positioned for 2017. I would ask you to think about these Q1, particularly the impact of Chinese lunar new year. I told Didier, I said, don't want to talk about it in the Q1 call. So let's make sure that we included in our guide. So that is the one thing that I would ask you to think about in terms of the next 3 months of the company's performance. Because we think we'll probably push about a week's worth of revenue or so from Q1 to Q2 because customers just won't be there to take delivery and as you saw the growth rates have been really exceptional for us in China."
154924,407124595,1087095,"Agilent Technologies, Inc., Q4 2016 Earnings Call, Nov 15, 2016",2016-11-15,"Earnings Calls","Agilent Technologies, Inc.","Analysts","So I'm going to -- I appreciate the nearest comments. I think I should just follow that up with another question. Have you had any conversations to our customers so that mean obviously, are not doing what's right figure out with a new world order is in te",90,"So I'm going to -- I appreciate the nearest comments. I think I should just follow that up with another question. Have you had any conversations to our customers so that mean obviously, are not doing what's right figure out with a new world order is in terms of how spendings going to be. Are you worried about all about potential in terms of lower CapEx spend, lower spending beginning of the year as people try to get their arms around what exactly the new administration has in store?"
154924,407124595,1087095,"Agilent Technologies, Inc., Q4 2016 Earnings Call, Nov 15, 2016",2016-11-15,"Earnings Calls","Agilent Technologies, Inc.","Executives","No, actually, we don't have that concern. What they have been more thinking about is where is this thing going long-term. So -- but in the next quarter, we don't have any real concerns about that. So -- that's why we are doing full guide here in November.",78,"No, actually, we don't have that concern. What they have been more thinking about is where is this thing going long-term. So -- but in the next quarter, we don't have any real concerns about that. So -- that's why we are doing full guide here in November. But it's really hard to see what's going to happen longer-term throughout the year. But in the next quarter or so, we wouldn't expect that to have any significant impact."
154924,407124595,1087095,"Agilent Technologies, Inc., Q4 2016 Earnings Call, Nov 15, 2016",2016-11-15,"Earnings Calls","Agilent Technologies, Inc.","Operator","And our next question comes from the line of Paul Knight from Janney.",13,"And our next question comes from the line of Paul Knight from Janney."
154924,407124595,1087095,"Agilent Technologies, Inc., Q4 2016 Earnings Call, Nov 15, 2016",2016-11-15,"Earnings Calls","Agilent Technologies, Inc.","Analysts","This is actually Bill on for. Maybe just touching on China again. Could you maybe talk about what your underlying trends have been driving the outsize growth for the company. Is it biopharma? Is it food? Is it environmental? And how does that impact as yo",50,"This is actually Bill on for. Maybe just touching on China again. Could you maybe talk about what your underlying trends have been driving the outsize growth for the company. Is it biopharma? Is it food? Is it environmental? And how does that impact as you look to next year?"
154924,407124595,1087095,"Agilent Technologies, Inc., Q4 2016 Earnings Call, Nov 15, 2016",2016-11-15,"Earnings Calls","Agilent Technologies, Inc.","Executives","Yes, thanks for the question. I had to say it really was across the board with one exception, which is the chemical and energy market. So all the other markets were up quite substantially for us. And I think this is consistent with what they talked about",240,"Yes, thanks for the question. I had to say it really was across the board with one exception, which is the chemical and energy market. So all the other markets were up quite substantially for us. And I think this is consistent with what they talked about in prior calls, which is really there is going to be a level of investment in China relative to qualitative life issue and environmental common food, line objective the with their 5-year plan that they're in the midst of a major improvement in their overall pharma industry and that there's a lot of money going on to research. So -- and then I think the reason Agilent has been able to do so well here is they've got this combination of working the organizational structure, the -- our channel model country. We had a lot of stability of the last 18 months. So we've got a really strong team there. And that combination of the team are historical strength in China and the new products we have is all coming together in terms of growth. And I guess, I maybe just add one thing and Mark, perhaps, you can comment here. We often talk about the strength of end markets and the new products going to these and markets, but I think there's something going on relative to your business fair and move to services I think is worth coming on as well."
154924,407124595,1087095,"Agilent Technologies, Inc., Q4 2016 Earnings Call, Nov 15, 2016",2016-11-15,"Earnings Calls","Agilent Technologies, Inc.","Executives","Thanks, Mike, and thanks, Bill. To add a little color to that, as we're seeing a fundamental shift in buying behaviors in China, largely shifting from the core areas at around Shanghai, Beijing to some of the more Tier 2, Tier 3 cities, where services now",150,"Thanks, Mike, and thanks, Bill. To add a little color to that, as we're seeing a fundamental shift in buying behaviors in China, largely shifting from the core areas at around Shanghai, Beijing to some of the more Tier 2, Tier 3 cities, where services now is viewed as the commonplace purchasing item in China, and it's certainly driving the growth. But the breadth of services, I think, in China, source of the consumables business now is the rest of the story, where they have reached the size and scale that they have the same interest that we find in Western markets around enterprise services and consumables all coming together. So starting, as you mentioned, Mike, with our extraordinarily strong position to start with, the installed base of China is just allowed us to build the business and truly of grow our expectations in the second half around this, too."
154924,407124595,1087095,"Agilent Technologies, Inc., Q4 2016 Earnings Call, Nov 15, 2016",2016-11-15,"Earnings Calls","Agilent Technologies, Inc.","Executives","Yes, I mentioned I ask Mark to comment on that because as you may recall, we really have change the portfolio of composition of the company, doing much for the after markets. So CapEx instruments are actually less than 50% now with total company's of reve",65,"Yes, I mentioned I ask Mark to comment on that because as you may recall, we really have change the portfolio of composition of the company, doing much for the after markets. So CapEx instruments are actually less than 50% now with total company's of revenue. And historically, China's been driven by new instrument purchases. Are seeing increasing growth also coming in services and consumables."
154924,407124595,1087095,"Agilent Technologies, Inc., Q4 2016 Earnings Call, Nov 15, 2016",2016-11-15,"Earnings Calls","Agilent Technologies, Inc.","Analysts","Great. And then just a follow-up for Didier on the guidance. CapEx up to about $200 million this year. Could you maybe just talk about where the incremental dollars are going and maybe what you think the maintenance CapEx is for Agilent as a whole?",45,"Great. And then just a follow-up for Didier on the guidance. CapEx up to about $200 million this year. Could you maybe just talk about where the incremental dollars are going and maybe what you think the maintenance CapEx is for Agilent as a whole?"
154924,407124595,1087095,"Agilent Technologies, Inc., Q4 2016 Earnings Call, Nov 15, 2016",2016-11-15,"Earnings Calls","Agilent Technologies, Inc.","Executives","Yes, the main reason for the increase, which is about $60 million from $139 million this year to $200 million next year is really the significant increase that we're planning to -- in terms of our metric asset facilities, RNA-based, therapeutics and [indi",146,"Yes, the main reason for the increase, which is about $60 million from $139 million this year to $200 million next year is really the significant increase that we're planning to -- in terms of our metric asset facilities, RNA-based, therapeutics and [indiscernible]. So we had one facility. We're still expanding the capacity of that facility, but we are building and we just started the few weeks ago 20 miles away a second facility that we're kind of doubled the capacity when it will be put in production end of 2018, 2019. So that is the main reason for the increase in starting in 2018, we should start -- we will see a reduction in the CapEx. This is not the run rate. Our CapEx run rate is still between like between $100 million, $120 million per year. So this is way above our run rate."
154924,407124595,1087095,"Agilent Technologies, Inc., Q4 2016 Earnings Call, Nov 15, 2016",2016-11-15,"Earnings Calls","Agilent Technologies, Inc.","Operator","And our next question comes from the line of Jack Meehan from Barclays.",13,"And our next question comes from the line of Jack Meehan from Barclays."
154924,407124595,1087095,"Agilent Technologies, Inc., Q4 2016 Earnings Call, Nov 15, 2016",2016-11-15,"Earnings Calls","Agilent Technologies, Inc.","Analysts","I wanted to follow up on the diagnostics this is really I thought it was a nice quarter at a tough comp I know you talked about the PO 1. But just any -- I wanted to focus on the Omnis and just whether you think you're picking up steam in the 2017 and the",64,"I wanted to follow up on the diagnostics this is really I thought it was a nice quarter at a tough comp I know you talked about the PO 1. But just any -- I wanted to focus on the Omnis and just whether you think you're picking up steam in the 2017 and then anything worth watching on the reimbursement side with that?"
154924,407124595,1087095,"Agilent Technologies, Inc., Q4 2016 Earnings Call, Nov 15, 2016",2016-11-15,"Earnings Calls","Agilent Technologies, Inc.","Executives","Yes, jack, thanks for the question. I think I'll pass it over to Jacob to give you a little bit more quarter on the quarter results.",26,"Yes, jack, thanks for the question. I think I'll pass it over to Jacob to give you a little bit more quarter on the quarter results."
154924,407124595,1087095,"Agilent Technologies, Inc., Q4 2016 Earnings Call, Nov 15, 2016",2016-11-15,"Earnings Calls","Agilent Technologies, Inc.","Executives","Yes, it's -- we really continue to see overall in our ratings pick up today differently by Omnibus that we see the growth is coming back. It's a nice momentum racing and it continues to basically -- it will continue to increase over -- during '16. So that",117,"Yes, it's -- we really continue to see overall in our ratings pick up today differently by Omnibus that we see the growth is coming back. It's a nice momentum racing and it continues to basically -- it will continue to increase over -- during '16. So that momentum, we expect that we will continue to see a good performance into '17 also. From a reimbursement perspective, obviously, there are already some expectation how that will look like into '17 and '18 with the and so on. But now we have to see what happens under the new administration here whether that will change everything. But so far, we actually don't expect any significant changes into '17."
154924,407124595,1087095,"Agilent Technologies, Inc., Q4 2016 Earnings Call, Nov 15, 2016",2016-11-15,"Earnings Calls","Agilent Technologies, Inc.","Analysts","Great, that's helpful. Then just wanted to follow up on the margin again just from our seat, what we should be watching? And what would push you to the 22% above level for this year? What are some of the actions that you think are going to be critical for",52,"Great, that's helpful. Then just wanted to follow up on the margin again just from our seat, what we should be watching? And what would push you to the 22% above level for this year? What are some of the actions that you think are going to be critical for doing that?"
154924,407124595,1087095,"Agilent Technologies, Inc., Q4 2016 Earnings Call, Nov 15, 2016",2016-11-15,"Earnings Calls","Agilent Technologies, Inc.","Executives","Yes, I mean, Didier, feel free to of been the response here. But I think, obviously, it's going to be volume, which is about 60% of the margin. Improvement comes from volume. In the things that we can control, we're on top of. So it's really -- that's the",159,"Yes, I mean, Didier, feel free to of been the response here. But I think, obviously, it's going to be volume, which is about 60% of the margin. Improvement comes from volume. In the things that we can control, we're on top of. So it's really -- that's the one thing I can control is what's going to happen in the market. So obviously, there's that 60% tied to margin. And then we've got some pretty big initiatives in the gross margin area that overall fulfillment team. I think you may have heard me speak previously about some of our work in value engineering, material cost reductions and logistics. And I think also keep an eye on our gross margins as we look through the year. Some of the things that collided to actually start coming through the P&L. But once they're there, they're there for an extended it appeared of tempo Didier, anything else you'd add to that?"
154924,407124595,1087095,"Agilent Technologies, Inc., Q4 2016 Earnings Call, Nov 15, 2016",2016-11-15,"Earnings Calls","Agilent Technologies, Inc.","Executives","No, I mean, just that, I mean, we do have stretch goals. As we mentioned, we are paid internally on achieving 22%. And that means all of us has a stretch goals to make -- to achieve that -- to contribute to 22%. And OSS, the Hendrick for supply chain orga",74,"No, I mean, just that, I mean, we do have stretch goals. As we mentioned, we are paid internally on achieving 22%. And that means all of us has a stretch goals to make -- to achieve that -- to contribute to 22%. And OSS, the Hendrick for supply chain organization, which has delivered greatly in '16 is looking at opportunities to deliver even more in '17, which would help us bridge the gap."
154924,407124595,1087095,"Agilent Technologies, Inc., Q4 2016 Earnings Call, Nov 15, 2016",2016-11-15,"Earnings Calls","Agilent Technologies, Inc.","Executives","And thanks, Didier. One additional thought here is I think it's important to everyone some of the things that might help in '17 have already been finished in '16. So things such as our simple vacation of our financial systems infrastructure. So it's done.",52,"And thanks, Didier. One additional thought here is I think it's important to everyone some of the things that might help in '17 have already been finished in '16. So things such as our simple vacation of our financial systems infrastructure. So it's done. And now the same will shop in '17."
154924,407124595,1087095,"Agilent Technologies, Inc., Q4 2016 Earnings Call, Nov 15, 2016",2016-11-15,"Earnings Calls","Agilent Technologies, Inc.","Operator","And our our next question comes from the line of Isaac Ro from Goldman Sachs.",15,"And our our next question comes from the line of Isaac Ro from Goldman Sachs."
154924,407124595,1087095,"Agilent Technologies, Inc., Q4 2016 Earnings Call, Nov 15, 2016",2016-11-15,"Earnings Calls","Agilent Technologies, Inc.","Analysts","First question just quickly on the quarter. Curious if you could comment on pacing. You guys have the off cycle calendar there with October. Trevor once curious. If whether it was on the capital spending side or in any particular market you saw a meaningf",65,"First question just quickly on the quarter. Curious if you could comment on pacing. You guys have the off cycle calendar there with October. Trevor once curious. If whether it was on the capital spending side or in any particular market you saw a meaningful solution or dissolution of the month of October to the extent that pretense to the rest of the calendar year."
154924,407124595,1087095,"Agilent Technologies, Inc., Q4 2016 Earnings Call, Nov 15, 2016",2016-11-15,"Earnings Calls","Agilent Technologies, Inc.","Executives","No, Isaiah, I just mentioned that what we saw was really strong pacing throughout the quarter. So it wasn't -- didn't see something happen also in the last 4, 5 weeks. We had -- and we had the strength all through 3 quarters of our fiscal year close.",48,"No, Isaiah, I just mentioned that what we saw was really strong pacing throughout the quarter. So it wasn't -- didn't see something happen also in the last 4, 5 weeks. We had -- and we had the strength all through 3 quarters of our fiscal year close."
154924,407124595,1087095,"Agilent Technologies, Inc., Q4 2016 Earnings Call, Nov 15, 2016",2016-11-15,"Earnings Calls","Agilent Technologies, Inc.","Analysts","And then maybe a longer year Mike you guys have spent a lot of time over the last couple this talk about emphasis on here margin goals and you guys have done that pretty well. So as you move pass that 22% number, I was wondering how you think about evolvi",89,"And then maybe a longer year Mike you guys have spent a lot of time over the last couple this talk about emphasis on here margin goals and you guys have done that pretty well. So as you move pass that 22% number, I was wondering how you think about evolving instead of structure for the management team? And should we assume that the types of incentives you have in place is same place maybe with slightly different targets? Or could the overall composition evolve a little bit here?"
154924,407124595,1087095,"Agilent Technologies, Inc., Q4 2016 Earnings Call, Nov 15, 2016",2016-11-15,"Earnings Calls","Agilent Technologies, Inc.","Executives","Yes, Isaac, great, great question. And I would point back to what we discussed back in May AID where this is really all about this generating superior earnings growth, right? So if you think about that we're trying to do here is we're trying to outgrow th",217,"Yes, Isaac, great, great question. And I would point back to what we discussed back in May AID where this is really all about this generating superior earnings growth, right? So if you think about that we're trying to do here is we're trying to outgrow the market, extent the operation margins to keep driving up adjusted earnings per share growth. So what we like to be able to do is really that should be the focus of the team as we go forward. Operating margin expansion and capital deployment and your growth and market are all ways to get there. So we like to really be that have become the cornerstone of our long-term focus. And we want Agilent flip as a company who grows their earnings faster than revenue. 
But as I mentioned the AID is, I really want to also make sure that we don't get so focused on continuing to drive up the operating margin year in year out that you pass on things that immediately say accretive, maybe did dilutive on your margins but with good M&A additions to the business. So I think the way we're going to talk about the company post '17 is very consistent with what we had talked about back in the spring in New York City."
154924,407124595,1087095,"Agilent Technologies, Inc., Q4 2016 Earnings Call, Nov 15, 2016",2016-11-15,"Earnings Calls","Agilent Technologies, Inc.","Operator","And our next question comes from the line of Brendan Couillard from Jefferies.",13,"And our next question comes from the line of Brendan Couillard from Jefferies."
154924,407124595,1087095,"Agilent Technologies, Inc., Q4 2016 Earnings Call, Nov 15, 2016",2016-11-15,"Earnings Calls","Agilent Technologies, Inc.","Analysts","Most of my questions have been addressed. Mike, just curious what your embedding for the government market globally for next year and any color you can give us sort of regionally would be helpful.",34,"Most of my questions have been addressed. Mike, just curious what your embedding for the government market globally for next year and any color you can give us sort of regionally would be helpful."
154924,407124595,1087095,"Agilent Technologies, Inc., Q4 2016 Earnings Call, Nov 15, 2016",2016-11-15,"Earnings Calls","Agilent Technologies, Inc.","Executives","Yes, sure, Brendan. As we -- as I look through my notes here, I think we're expecting low single-digit growth. And I think it's important to kind of parse it out by academia and government. So we think that the go by the major reasons why China is going t",268,"Yes, sure, Brendan. As we -- as I look through my notes here, I think we're expecting low single-digit growth. And I think it's important to kind of parse it out by academia and government. So we think that the go by the major reasons why China is going to be strong. And give actually helped me to get somewhat what's been happening in the U.S. and your. We're not expecting much in Europe. It's been down. It was down again, but not -- it was basically -- sort of almost fill that the chemical energy market, which is kind of chugging along at a reduced rate. We're not expecting the governments there to do anything in terms of more stimulus. In fact, one of things were watching us what are we going to do as a result of Brexit for those of things. So we expect a strong China, academia government. We expect the continuation of this current environment in Europe. In the United States, the academia side is not bad. It's what we've seen more has been more on the U.S. government side. The U.S. government -- our U.S. government business is down in 2016 relative to '15. And that's why in my call a mentioned, hey, we need to kind of see where this new administrative go with budget plans and investment priorities. So right now, we're kind of standing on the sideline as saying it's going to continue to be just like it is, but -- in the United States. But we could see something different in a few months, we just don't know."
154924,407124595,1087095,"Agilent Technologies, Inc., Q4 2016 Earnings Call, Nov 15, 2016",2016-11-15,"Earnings Calls","Agilent Technologies, Inc.","Operator","And our next question comes from the line of Dan Arias from Citigroup.",13,"And our next question comes from the line of Dan Arias from Citigroup."
154924,407124595,1087095,"Agilent Technologies, Inc., Q4 2016 Earnings Call, Nov 15, 2016",2016-11-15,"Earnings Calls","Agilent Technologies, Inc.","Analysts","Mike, just follow up on the outlook. How are you thinking about the pacing of growth in chemical and energy in '17? Is the assumption that you kind of see some sequential improvement through the year? Or are you basically flat lining the business across t",60,"Mike, just follow up on the outlook. How are you thinking about the pacing of growth in chemical and energy in '17? Is the assumption that you kind of see some sequential improvement through the year? Or are you basically flat lining the business across the quarter just given that we haven't seen much in the way of positive signals?"
154924,407124595,1087095,"Agilent Technologies, Inc., Q4 2016 Earnings Call, Nov 15, 2016",2016-11-15,"Earnings Calls","Agilent Technologies, Inc.","Executives","I think you anticipated my answer, so we basically have a flat line for the year. And it hasn't -- it's been shrinking for the last 7 or 8 quarters 2% to 3%. I think we ended up down about 3% for the full year. And we're basically saying it's going to be",201,"I think you anticipated my answer, so we basically have a flat line for the year. And it hasn't -- it's been shrinking for the last 7 or 8 quarters 2% to 3%. I think we ended up down about 3% for the full year. And we're basically saying it's going to be flattish for '17. If there's any good news to that story is the fundamental industries are still out there in terms of gasoline as being produced. We've seen record levels of production in the United States, for example. The plants are running. There's a lot of discussion. There's a lot of reports externally about a turn. Oil prices have been inching up. But our history here is that it's really hard to know exactly when it's going to turn. What I can say is that if you have a profitability productivity message associated with something you can bring to the laboratory, then they might listen to you. And we're hopeful that some of our new product introductions will hit the mark there. But in terms of our overall market assumption and growth assumption for the company, we're assuming flat for '17. No big movements one way or another."
154924,407124595,1087095,"Agilent Technologies, Inc., Q4 2016 Earnings Call, Nov 15, 2016",2016-11-15,"Earnings Calls","Agilent Technologies, Inc.","Analysts","Got it. okay, great. And then maybe just to go back to the M&A and the margin comments. As we sort of think of all the moving parts of the out margin guidance and just what you might look to do this year, how at risk is the current up margin outlook from",94,"Got it. okay, great. And then maybe just to go back to the M&A and the margin comments. As we sort of think of all the moving parts of the out margin guidance and just what you might look to do this year, how at risk is the current up margin outlook from additional M&A? I mean, obviously, it's tough to discuss these things in the abstract. But are you often to further diluted of the right asset comes along or do you kind of think you hold the line of the current forecasts?"
154924,407124595,1087095,"Agilent Technologies, Inc., Q4 2016 Earnings Call, Nov 15, 2016",2016-11-15,"Earnings Calls","Agilent Technologies, Inc.","Executives","Yes. No, I think what we've said, and I'm really trying to be have actions are consistent with our prior communication. We said we would look at acquisitions that could be short-term dilutive in nature, and we did one in the latter of '16. We just loved h",151,"Yes. No, I think what we've said, and I'm really trying to be have actions are consistent with our prior communication. We said we would look at acquisitions that could be short-term dilutive in nature, and we did one in the latter of '16. We just loved having iLab part portfolio. It's going to be -- it's a great addition to the business. But right now, it's not at the corporate average. We'll move it up. So if we saw there are opportunities like that, we know we would pursue them. But I think if you want to look at that type of the bills in the size, just look at what we've done so far a just to give you kind of the sense of the things that were looking at going forward. We like accretive deals, and we like ones that can move up -- move the margins up."
154924,407124595,1087095,"Agilent Technologies, Inc., Q4 2016 Earnings Call, Nov 15, 2016",2016-11-15,"Earnings Calls","Agilent Technologies, Inc.","Operator","And our next question comes from the line of Puneet Souda from Leerink Partners.",14,"And our next question comes from the line of Puneet Souda from Leerink Partners."
154924,407124595,1087095,"Agilent Technologies, Inc., Q4 2016 Earnings Call, Nov 15, 2016",2016-11-15,"Earnings Calls","Agilent Technologies, Inc.","Analysts","Just a quick follow-up, if I could, on the pharma. And just wanted to understand, there's clearly a solid contribution here. If you could maybe help us parse out the case. Is that more from service small molecule, macromolecules? Or is this -- are we thin",83,"Just a quick follow-up, if I could, on the pharma. And just wanted to understand, there's clearly a solid contribution here. If you could maybe help us parse out the case. Is that more from service small molecule, macromolecules? Or is this -- are we thinking about that incorrectly or maybe we should be thinking about in terms of the service contract share that you're gaining and why the CrossLab Group, help us if you could parse that out a little bit."
154924,407124595,1087095,"Agilent Technologies, Inc., Q4 2016 Earnings Call, Nov 15, 2016",2016-11-15,"Earnings Calls","Agilent Technologies, Inc.","Executives","Yes, sure. So there's a couple of things going on, which is in terms of the overall fundamental end markets growth rates, we think bio pharma and the small molecule side of pharma both growing quite strongly.Small molecule side is really being driven by",196,"Yes, sure. So there's a couple of things going on, which is in terms of the overall fundamental end markets growth rates, we think bio pharma and the small molecule side of pharma both growing quite strongly.
Small molecule side is really being driven by a conversion to the new technology and a good chromatography in particular. Also, an increasing interest in enterprise service, what we have to offer for ACG. So I think what's been going on here for Agilent, you've got the combination of really strong and market growth. There's a new market that has and will continue to develop in this services side, and we're doing well there, along with our new instruments in the pharma. When I look at '17, we think that the bio pharma side of that market is going to continue to go quite strongly. It's been an area of prioritization for us in terms of new solutions. But we do think that over time, that the small molecules will start to move back towards more long-term growth rates. And Patrick, I think what are the kind of think about our long-term growth rates in the small molecule side?"
154924,407124595,1087095,"Agilent Technologies, Inc., Q4 2016 Earnings Call, Nov 15, 2016",2016-11-15,"Earnings Calls","Agilent Technologies, Inc.","Executives","Well, on the small molecule side, I think we're more in the low- to mid-single digits range were as in by pharma it continues to be double digit. That's our projection right now.",33,"Well, on the small molecule side, I think we're more in the low- to mid-single digits range were as in by pharma it continues to be double digit. That's our projection right now."
154924,407124595,1087095,"Agilent Technologies, Inc., Q4 2016 Earnings Call, Nov 15, 2016",2016-11-15,"Earnings Calls","Agilent Technologies, Inc.","Analysts","Just one more. In terms of the chemical and energy market I mean, we get the view into 2017. But as you have conversation with the labs and lab directors, just help us understand how they are thinking about capital equipment in 2017 knowing these times an",68,"Just one more. In terms of the chemical and energy market I mean, we get the view into 2017. But as you have conversation with the labs and lab directors, just help us understand how they are thinking about capital equipment in 2017 knowing these times and knowing that the progression that's been? Or are they thinking more in 2018 terms in the -- on the capital equipment?"
154924,407124595,1087095,"Agilent Technologies, Inc., Q4 2016 Earnings Call, Nov 15, 2016",2016-11-15,"Earnings Calls","Agilent Technologies, Inc.","Executives","I have to say, I don't think they know yet as well. What they're doing right now is in their right in the midst of their capital budgeting process. So what I can tell you is -- so couple of conversations with customers over the last 2 or 3 weeks on this e",284,"I have to say, I don't think they know yet as well. What they're doing right now is in their right in the midst of their capital budgeting process. So what I can tell you is -- so couple of conversations with customers over the last 2 or 3 weeks on this exact topic. And one thing to describe for me is hey, our end -- these -- one customer was somebody who provide services into -- equipment into the energy markets. So listen, we're starting to get interest in quotes, but we're not sure where that's going to hit in '17 or '18 when we had our VIP large for the Intubo 9000 GC, a lot our customers chemical energy space. Listen, we love this productivity message you have here. I think there's a real economic ROI. I'm now right in the midst of my budgeting process inside the company. Maybe I'll be able to get this thing through this year or maybe the following year because there's still seems to be the sentiment particularly with a larger companies but they want to hold on to the equipment as long as they can before they have to replace it. So -- and again, that's why I pointed to the fact that not all negative because of the fact that we do have a strong service and consumables offerings into that space. But again, we just don't -- I don't think our customers know yet as well as can happen. We do know it's going to happen. History repeats itself.
There will be well-positioned of base good thing but again, which is not confident enough right now to say when that's going to occur."
154924,407124595,1087095,"Agilent Technologies, Inc., Q4 2016 Earnings Call, Nov 15, 2016",2016-11-15,"Earnings Calls","Agilent Technologies, Inc.","Operator","And that concludes our question-and-answer session for today. I would like to turn the conference back over to Alicia Rodriguez for any closing comments.",25,"And that concludes our question-and-answer session for today. I would like to turn the conference back over to Alicia Rodriguez for any closing comments."
154924,407124595,1087095,"Agilent Technologies, Inc., Q4 2016 Earnings Call, Nov 15, 2016",2016-11-15,"Earnings Calls","Agilent Technologies, Inc.","Executives","Thank you, everybody. And on behalf of the management team, I wanted to thank you for joining us on the call. If you have any questions, please feel free us to give us a call on IR. Appreciate it very much. Bye-bye.",42,"Thank you, everybody. And on behalf of the management team, I wanted to thank you for joining us on the call. If you have any questions, please feel free us to give us a call on IR. Appreciate it very much. Bye-bye."
154924,407124595,1087095,"Agilent Technologies, Inc., Q4 2016 Earnings Call, Nov 15, 2016",2016-11-15,"Earnings Calls","Agilent Technologies, Inc.","Operator","Ladies and gentlemen, thank you for your participation in today's conference. This does conclude the program, and you may now disconnect. Everyone, have a great day.",26,"Ladies and gentlemen, thank you for your participation in today's conference. This does conclude the program, and you may now disconnect. Everyone, have a great day."
154924,407124595,1087313,"Agilent Technologies, Inc., Q4 2016 Earnings Call, Nov 15, 2016",2016-11-15,"Earnings Calls","Agilent Technologies, Inc.","Operator","Good day, ladies and gentlemen, and welcome to the Agilent Technologies Fourth Quarter 2016 Earnings Conference Call. [Operator Instructions] As a reminder, this conference is being recorded. I would now like to hand the floor over to Alicia Rodriguez, Vi",47,"Good day, ladies and gentlemen, and welcome to the Agilent Technologies Fourth Quarter 2016 Earnings Conference Call. [Operator Instructions] As a reminder, this conference is being recorded. I would now like to hand the floor over to Alicia Rodriguez, Vice President of Investor Relations. Please go ahead."
154924,407124595,1087313,"Agilent Technologies, Inc., Q4 2016 Earnings Call, Nov 15, 2016",2016-11-15,"Earnings Calls","Agilent Technologies, Inc.","Executives","Thank you, Karen, and welcome, everyone, to Agilent's Fourth Quarter Conference Call for Fiscal Year 2016. With me are Mike McMullen, Agilent's President and CEO; and Didier Hirsch, Agilent's Senior Vice President and CFO. Joining in the Q&A after Didier'",285,"Thank you, Karen, and welcome, everyone, to Agilent's Fourth Quarter Conference Call for Fiscal Year 2016. With me are Mike McMullen, Agilent's President and CEO; and Didier Hirsch, Agilent's Senior Vice President and CFO. Joining in the Q&A after Didier's comments will be Patrick Kaltenbach, President of Agilent's Life Sciences and Applied Markets Group; Jacob Thaysen, President of Agilent's Diagnostics and Genomics Group; and Mark Doak, President of the Agilent CrossLab Group.
You can find the press release and information to supplement today's discussion on our website at www.investor.agilent.com. While there, please click on the link for financial results under the Financial Information tab. You will find an investor presentation along with revenue breakouts and currency impacts, business segment results and historical financials for Agilent's operations. We will also post a copy of the prepared remarks following this call.
Today's comments by Mike and Didier will refer to non-GAAP financial measures. You will find the most directly comparable GAAP financial metrics and reconciliations on our website. We will refer to core revenue growth, which excludes the impact of currency, the NMR business and acquisitions and divestitures within the past 12 months. Unless otherwise noted, all references to increases or decreases in financial metrics are year-over-year. Guidance is based on exchange rates as of the last day of the reported quarter.
We will also make forward-looking statements about the financial performance of the company. These statements are subject to risks and uncertainties and are only valid as of today. The company assumes no obligation to update them. Please look at the company's recent SEC filings for a more complete picture of our risks and other factors.
And now let me turn the call over to Mike"
154924,407124595,1087313,"Agilent Technologies, Inc., Q4 2016 Earnings Call, Nov 15, 2016",2016-11-15,"Earnings Calls","Agilent Technologies, Inc.","Executives","Thanks, Alicia, and hello, everyone. I'm very pleased to announce that our Agilent team ended 2016 with another strong quarter of excellent results. I will start by looking at our key numbers from the quarter. First, we continued to deliver above-market",2002,"Thanks, Alicia, and hello, everyone. I'm very pleased to announce that our Agilent team ended 2016 with another strong quarter of excellent results. I will start by looking at our key numbers from the quarter. 
First, we continued to deliver above-market growth. Revenues of $1.1 billion exceeded the high end of the guidance by a sizeable $41 million, and were up 6.3% on a core basis. We were the first surprised by the strength of our instrument business in pharma, China and Europe, which far exceeded our expectations. 
Second, our adjusted EPS of $0.59 was $0.07 above the high end of our guidance. Finally, we continued our track record of improving profitability as we delivered another quarter of operating margin expansion. Adjusted operating margin of 22.5% was up 60 basis points from Q4 of fiscal 2015. 
Turning to our full year results. Core revenue continued to outperform the market, growing 5.9%. We increased operating margins 110 basis points to 20.7% from 2015. These results drove a 14% increase in adjusted earnings per share for the full year. We are capping off the second year of our company transformation with stellar performance by the Agilent team. Our fourth quarter and full year results demonstrate our continued ability to win in the market. 
We are outgrowing the market while expanding margins and fully leveraging our strong balance sheet. In the past year, we distributed $150 million in cash dividends, repurchased $434 million of our shares and invested $480 million directly into the business through M&A, strategic transactions and capital expenditures. Let me now address what's happening in our end markets and business groups. I'll start with the end markets.
Our Q4 trends were similar to what we experienced last quarter with pharma and academia and government being the exceptions. We had expected continued strength in pharma, but our 16% growth on a difficult compare exceeded our expectations. Growth is being driven by strong customer acceptance of our new products and enterprise service offerings. Academia and government's decline of 2% was less than expected. European spending is holding up better than projected while our U.S. government investments continue to lag 2015 spending levels. Clinical and diagnostics grew 8% over last year, led by continued growth in reagents.
Within our applied end markets, food is up 10% with strong demand in China and Americas. China also drove growth in environmental market, up 3%. Chemical energy declined 3% in line with expectations due to continued effect of crude oil prices and macroeconomic uncertainties. We expect this market to remain challenging for the rest of calendar year 2016 and into 2017 with no significant downward or upward movements.
Geographically, Asia, led by China and Europe, was stronger than forecast. Our Asia business, excluding Japan, grew double digit, driven by greater than 25% growth in China. While the overall European market remains challenged, we delivered solid mid-single-digit growth. European pharma and food markets were strong and academia and government funding was stable with Q3. Japan and Americas were flat with growth constrained by continued chemical and energy market weakness and specific to the U.S., slow U.S. government funding. 
Moving on to the business groups. Life Sciences and Applied Markets Group delivered core revenue growth of 5%. Better-than-expected revenues from our analytical lab instrument business was driven by an attractive combination of introducing new products into growing markets. This applied in particular to our new lineup of chromatography and mass spectrometry products targeted at the pharma in applied food, environmental and forensics markets. LSAG's operating margin for the quarter was 22.8%, up 280 basis points from a year ago.
We are building for the future. In August, we introduced the transformational Intuvo 9000 GC system. Building on our recognized GC leadership, the Intuvo system revolutionized the way users perform gas chromatography. Industry experts recognize unique innovation being delivered by Agilent with press coverage at 100% positive. Intuvo is featured this month on the cover LCGC magazine, a major trade publication. 
Customer response is also very positive to this introduction, confirming our undisputed market leadership in gas chromatography. We anticipate a measured uptake in revenue. Limited international shipments are expected in Q1 of fiscal 2017, with volumes expected to increase over subsequent quarters.
Another industry-unique product, the Agilent 8900 Triple Quad ICP-MS system, which we just introduced in Q3, is also being well received in the market. This instrument is rapidly becoming the solution of choice in labs that demand the highest standards of performance. 
Next, the Agilent CrossLab Group continue to deliver strong, sustained growth with core revenue up 8%. Growth is healthy in both services and consumables. ACG's operating margin for the quarter was 22.7%, down 240 basis points from a year ago and in line with expectations.
ACG results were driven by strong pharma, food, clinical and diagnostic markets, where our CrossLab customer value proposition is being well received. Unlike our instrument business, ACG also grew in the chemical and energy markets. Laboratories supporting strong production levels drove demand for consumables. There is also continued demand for services, as customers focus on keeping their older instruments operational.
We are investing for the future in ACG. We just introduced a new range of innovative and differentiated supplies. These new offerings enable the Agilent Intuvo 9000 GC to be the most efficient and cost-effective premium GC to own and operate. We continue to successfully integrate the recently acquired iLab business, which brings differentiated capabilities to core lab managers. 
Last but certainly not least in terms of impact, the momentum in the Diagnostics and Genomics Group continued, with delivery of 8% core growth. Our laser focus on improving the previously acquired Dako business is paying off before. The pathology business continues its steady climb back to market growth rates, with strong -- with strength in reagents and companion diagnostics.
Our nucleic acid solutions business, for which we recently announced a significant production capacity, grew double digits. This growth reflects the increasing demand for oligonucleotides for RNA-based drugs. DDG's operating margin for the quarter was 19.6%, up 40 basis points from a year ago. 
In October, there were some exciting news from Merck for lung cancer patients and for Agilent. Merck's KEYTRUDA is now approved by the FDA for first-line treatment for metastatic non-small-cell lung cancer for patients with high rates of PD-L1 expression. In conjunction, Agilent's pharmDx companion diagnostics PD-L1 test is now approved for expanded use. This is the first time an Agilent's PD-L1 companion diagnostic is approved for first-line testing.
The theme of investing for our future is also evident in DDG. We launched a comprehensive offering of pooled CRISPR libraries for functional genomics. This will help accelerate research into complex diseases and drug discovery. We signed an agreement with the Burning Rock Biotech to develop cancer diagnostics in China based on Agilent SureSelect solutions. And we broke ground and initiated construction on the previously announced $120 million investment in a new factory in Colorado to expand nucleic acid production capacity.
Turning now to operating margin. We remain focused on operating margin improvement. Since the new Agilent leadership team was appointed, we have delivered 7 consecutive quarters of improved operating margin and strong growth. Despite continued challenges in the chemical and energy business, we have improved adjusted operating margin by 280 basis points in the first 2 years of the company's transformation. We have completely absorbed and offset the $40 million of the synergy costs due to the spin-off of Keysight.
On the operations front, our Agile Agilent program continues to simplify the company and lower operating costs. This program is designed to keep us nimble, improve our interaction with customers and lower our costs.
It is having an impact and will continue to deliver savings in 2017 and beyond. In the coming year, we will realize cost savings from the completion of the integration of Dako in early 2017, a simplified enterprise IT systems environment and other cost savings initiatives.
Turning to our FY '17 market and company outlook.
As a reminder, our shareholder value creation model for superior earnings growth is to outgrow the market and expand operating margins with a balanced deployment of our capital. Didier will go through the specifics of our Q1 '17 and full year guidance. I want to share our thinking about end markets and our initial guidance philosophy, given an environment of increased uncertainty.
This is a change in our last call and the May 2016 Analyst Investor Day. In our end markets, we expect continued strength in pharma, accompanied by continued solid growth in the food, environmental and clinical research and diagnostics markets. Geographically, China and India are expected to grow at significantly higher rates than other countries. There remains considerable uncertainty about European markets. We are forecasting moderate growth in the United States with the U.S. government policies and spending and chemical and energy markets being the wildcards.
Chemical and energy, while entering a period of easier compares and improved oil prices has not yet returned to growth. We expect a continued subdued academic and government research market in the coming year until uncertainties resulting from Brexit and the U.S. elections play out. We are also keeping a watchful eye on how potential new U.S. government driven trade and currency evaluation discussions could impact our business.
We finished 2016 very strongly, and we are well positioned for future growth with a pipeline of new offerings. In our initial revenue guidance for 2017, however, we want to be on the cautious side. We want to see some more clarity on U.S. and European government actions and have better indicators on when we will return to growth in our industrial end markets. 
Predicting end market growth in today's uncertain political and economic environment is challenging. However, I can predict quite confidently that we will continue our track record of outgrowing the market whatever market environment we encounter. We continue to expand our customer channel reach and fortify our portfolio, which strengthen us well for the coming year and beyond. 
The transformation of Agilent we discussed at the May Analyst and Investor Day is in full force. The new leadership team, put in place in early 2015 continued to deliver strong operating results each and every quarter. We are building momentum for future growth. We have improved our adjusted operating margins by 200 basis points over the past 2 years and our march to improved operating margins will continue in 2017.
However, in our initial operating margin and earnings per share guidance for 2017, we want to be on the cautious side. Since our May Analyst and Investor Day meeting, changes in exchange rate, pension expenses and the recent iLab acquisition are having a short-term dilutive impact on our operating margins of 0.5%. The Agilent team, however, is laser-focused on improving another 130 basis points of operating margin. We have an internal action plan aligned with achieving a 22% operating margin goal in fiscal 2017, excluding M&A impact. 
This is the primary goal for our executive team's compensation. We continue to hold ourselves to a higher level of performance, expectations than reflected in our initial full year earnings guidance.
As you assess our future possibilities, I will leave you with a few thoughts. We are expanding our product portfolio and extending into adjacent markets. We're improving the customer experience by streamlining processes and modernizing the systems, making the company more efficient and customer friendly. Our Agile Agilent program has and will continue to deliver incremental improvements in operating margin. The One Agilent team continues to work well together and is determined to win in the market. We believe we are well positioned to sustain our strong operational performance and achieve our long-term goals. The entire Agilent team is energized and committed to deliver future growth. 
Thank you for being on the call today. I will now turn it over to Didier, who will provide initial insights on our financial results and initial guidance for our fiscal Q1 and full year 2017. Didier?"
154924,407124595,1087313,"Agilent Technologies, Inc., Q4 2016 Earnings Call, Nov 15, 2016",2016-11-15,"Earnings Calls","Agilent Technologies, Inc.","Executives","Thank you, Mike, and hello, everyone. As Mike stated, we are very pleased with our Q4 and full year performance, both well over the high end of our guidance. We delivered above-market core revenue growth of 6.3% and 5.9%, respectively; and our operating m",575,"Thank you, Mike, and hello, everyone. As Mike stated, we are very pleased with our Q4 and full year performance, both well over the high end of our guidance. We delivered above-market core revenue growth of 6.3% and 5.9%, respectively; and our operating margin, adjusted for income from Keysight, was up 60 basis points and 110 basis points, respectively. 
Our full year EPS at $1.98 is 14% higher than the previous year. Please note that we have reduced our pro forma tax rate by 1 percentage points, which had a $0.02 impact on our EPS. Our operating cash flow for the full year, at $793 million, reflects our strong overall performance. 
And turning to capital returns. For the first -- for the year, we returned $584 million to shareholders in the form of dividends and buybacks or 89% of our free cash flow. 
I will now turn to the guidance for fiscal year 2017. As Mike stated, our initial guidance, like last year, assumes that what we believe to be appropriate caution. Our fiscal year '17 revenue guidance of $4.35 billion to $4.37 billion corresponds to core revenue growth of 4% to 4.5%. It is based on October 31 exchange rates and currency had a 0.6 percentage foreign impact -- negative impact on revenues. We project fiscal year '17 adjusted operating margin of 21% to 21.5% and fiscal year '17 EPS of $2.10 to $2.16, growing 8% at midpoint. 
As you update your models for fiscal year '17, please consider the following 10 points: First, annual salary increases will be effective December 1, 2016. Second, stock-based compensation will be about $59 million. And as we front end the recognition of stock-based compensation, the Q1 expense will be about $23 million. Third, the reduction in bond yields is negatively impacting our annual pension expenses by about $12 million. Fourth, depreciation is projected to be $104 million for the fiscal year. Fifth, the non-GAAP effective tax rate is projected to remain at 19%. Sixth, we plan to return approximately $600 million in capital to shareholders, including $170 million in dividends and $430 million in buybacks, subject to customary conditions. Seventh, we plan to borrow $250 million in the second half to fund a portion of our capital returns. Eighth, net interest expense is forecasted at $71 million and other income at $11 million. Ninth, for purpose of our EPS guidance, we have assumed a diluted share count of 324 million shares, 5 million shares less than the average diluted share count in fiscal year '16. And finally, tenth, we expect operating cash flow of $825 million and capital expenditures of $200 million, about $60 million over fiscal year '16, mostly due to the investment in the second nucleic acid facility.
Now finally, moving to the guidance for our first quarter. First, please note that Lunar New Year falls in Q1 this year versus Q2 last year. Meaning, about $15 million of revenue shifting from Q1 to Q2. 
We expect Q1 revenues of $1.04 billion to $1.06 billion and EPS of $0.48 to $0.50. At midpoint, revenue will grow 2.2% on a core basis and EPS will grow 7%.
And as customary, Q1 EPS is negatively impacted by the December salary increase, front loading of stock-based compensation and the increase in payroll taxes due to the disbursement of the variable and incentive pay of the previous year. 
With that, I'll turn it over to Alicia for the Q&A."
154924,407124595,1087313,"Agilent Technologies, Inc., Q4 2016 Earnings Call, Nov 15, 2016",2016-11-15,"Earnings Calls","Agilent Technologies, Inc.","Executives","Thank you, Didier. Karen, will you please give the instructions for the Q&A.",13,"Thank you, Didier. Karen, will you please give the instructions for the Q&A."
154924,407124595,1087313,"Agilent Technologies, Inc., Q4 2016 Earnings Call, Nov 15, 2016",2016-11-15,"Earnings Calls","Agilent Technologies, Inc.","Operator","[Operator Instructions] Our first question comes from the line of Steve Beuchaw from Morgan Stanley.",15,"[Operator Instructions] Our first question comes from the line of Steve Beuchaw from Morgan Stanley."
154924,407124595,1087313,"Agilent Technologies, Inc., Q4 2016 Earnings Call, Nov 15, 2016",2016-11-15,"Earnings Calls","Agilent Technologies, Inc.","Analysts","First question for me is I wonder if you could just juxtapose your results against what we've heard from others in the category over the last several weeks. I mean, it sounds like a particularly strong category by number -- quarter by number of metrics. Y",99,"First question for me is I wonder if you could just juxtapose your results against what we've heard from others in the category over the last several weeks. I mean, it sounds like a particularly strong category by number -- quarter by number of metrics. You actually accelerated or we saw a number of others decelerate in terms of organic growth in the quarter. Can you give us, from a high level, what you think are the keys there in terms of positioning? Why it is the quarter were so good for you guys relative to the market?"
154924,407124595,1087313,"Agilent Technologies, Inc., Q4 2016 Earnings Call, Nov 15, 2016",2016-11-15,"Earnings Calls","Agilent Technologies, Inc.","Executives","Yes, thanks, Steve. The headline for me was as we look grow the quarter, we were winning more business than we plan. So we're winning a lot of business in our core markets. I think some of the end market strength that we plan to is actually fairly similar",136,"Yes, thanks, Steve. The headline for me was as we look grow the quarter, we were winning more business than we plan. So we're winning a lot of business in our core markets. I think some of the end market strength that we plan to is actually fairly similar to what I've seen other people comment on relative to the strength of China, strength of pharma, continued, subdued, but kind of a stable academia and government environment. And for us, I think we were just delighted by our performance, in particular, in our analytical instrument business where we seem to be winning more business than we planned and we think that bodes well for the strength of our portfolio and some of the things we've been doing over the last year in our channels as well."
154924,407124595,1087313,"Agilent Technologies, Inc., Q4 2016 Earnings Call, Nov 15, 2016",2016-11-15,"Earnings Calls","Agilent Technologies, Inc.","Analysts","And then so the follow-up, I guess, just to dig a little deeper would be, did you notice anything in terms of instrument trends relative to consumables trends accelerating or decelerating? And what is that telling you about end of year, I should say end o",51,"And then so the follow-up, I guess, just to dig a little deeper would be, did you notice anything in terms of instrument trends relative to consumables trends accelerating or decelerating? And what is that telling you about end of year, I should say end of calendar year budget flush?"
154924,407124595,1087313,"Agilent Technologies, Inc., Q4 2016 Earnings Call, Nov 15, 2016",2016-11-15,"Earnings Calls","Agilent Technologies, Inc.","Executives","Yes, we were talking a bit about this yesterday with the team. And if you look at our performance through the quarter, we got off to a strong start in August and it continued throughout the quarter. And sometimes, it's hard to tell other, first month, whe",95,"Yes, we were talking a bit about this yesterday with the team. And if you look at our performance through the quarter, we got off to a strong start in August and it continued throughout the quarter. And sometimes, it's hard to tell other, first month, where things are going to land for the quarter. But I'd say by the end of September, we knew we are winning more business than we plan. And this really shaping up to be a strong quarter for us and really position us well for us going into 2017."
154924,407124595,1087313,"Agilent Technologies, Inc., Q4 2016 Earnings Call, Nov 15, 2016",2016-11-15,"Earnings Calls","Agilent Technologies, Inc.","Operator","And our next question comes from the line of Tycho Peterson from JPMorgan.",13,"And our next question comes from the line of Tycho Peterson from JPMorgan."
154924,407124595,1087313,"Agilent Technologies, Inc., Q4 2016 Earnings Call, Nov 15, 2016",2016-11-15,"Earnings Calls","Agilent Technologies, Inc.","Analysts","Mike, just hoping for a little bit more color on some of the expectations and guidance in particular around pharma. Are you still assuming that's kind of double-digit growth next year? Or are you factoring in a moderation? And on environmental, you manage",78,"Mike, just hoping for a little bit more color on some of the expectations and guidance in particular around pharma. Are you still assuming that's kind of double-digit growth next year? Or are you factoring in a moderation? And on environmental, you managed to grow that business in contrast to what we saw from one of your peers last week. So maybe talk a little bit about contributions from the DC replacement cycle for next year as well."
154924,407124595,1087313,"Agilent Technologies, Inc., Q4 2016 Earnings Call, Nov 15, 2016",2016-11-15,"Earnings Calls","Agilent Technologies, Inc.","Executives","Yes, sure. Tycho, you broke up a bit on the call. So if I don't get to the specific questions, please come back to me. But I think relative to the expectations for end market kind of thinking for growth rate, we had pharma below the double-digit growth th",107,"Yes, sure. Tycho, you broke up a bit on the call. So if I don't get to the specific questions, please come back to me. But I think relative to the expectations for end market kind of thinking for growth rate, we had pharma below the double-digit growth that have been placed in '16. So as we look at our end markets, we would expect a moderation of growth, not because the spends are going to go away, but you really are going to start to get into tough compares. And Didier, if I remember correctly, we were in the mid- to high single-digit growth for pharma?"
154924,407124595,1087313,"Agilent Technologies, Inc., Q4 2016 Earnings Call, Nov 15, 2016",2016-11-15,"Earnings Calls","Agilent Technologies, Inc.","Executives","Yes.",1,"Yes."
154924,407124595,1087313,"Agilent Technologies, Inc., Q4 2016 Earnings Call, Nov 15, 2016",2016-11-15,"Earnings Calls","Agilent Technologies, Inc.","Executives","And then I think the story -- I think, Tycho, the question was around environmental.",15,"And then I think the story -- I think, Tycho, the question was around environmental."
154924,407124595,1087313,"Agilent Technologies, Inc., Q4 2016 Earnings Call, Nov 15, 2016",2016-11-15,"Earnings Calls","Agilent Technologies, Inc.","Analysts","Yes, and the GC replacement cycle.",6,"Yes, and the GC replacement cycle."
154924,407124595,1087313,"Agilent Technologies, Inc., Q4 2016 Earnings Call, Nov 15, 2016",2016-11-15,"Earnings Calls","Agilent Technologies, Inc.","Executives","Yes, so environmental, the story really there is China. And we think that's got many quarters in front of us of growth in China. And we -- as you know, I'm fairly bullish on the prospects of that market. And I think with that kind of a perfect storm here",197,"Yes, so environmental, the story really there is China. And we think that's got many quarters in front of us of growth in China. And we -- as you know, I'm fairly bullish on the prospects of that market. And I think with that kind of a perfect storm here going on where we have strong products going into -- in the growing markets. Relative to the GC replacement cycle, this is really about what's going to happen in the chemical and energy market. And I'll make a few comments here, then, Patrick, you may want to provide your perspective as well. So you may have noticed in my call script, I went kind of out my way to talk about a measured ramp-up of our new Intuvo GC because we think we've got a winner product on our hands. We know there's a lot of interest from customers. But we also recognize the reality of constraints they may have in their capital budgets. I know they're working with their own management teams internally of this company's about what they may get in terms of funding in 2017. What are your thoughts, Patrick, on that as well?"
154924,407124595,1087313,"Agilent Technologies, Inc., Q4 2016 Earnings Call, Nov 15, 2016",2016-11-15,"Earnings Calls","Agilent Technologies, Inc.","Executives","Yes, thanks, Mike. Looking at the GC market, we definitely are positioned very well to capture any growth opportunity there. We have launched the Intuvo, which is a strong message to all the customers that we are standing behind them when it comes to driv",162,"Yes, thanks, Mike. Looking at the GC market, we definitely are positioned very well to capture any growth opportunity there. We have launched the Intuvo, which is a strong message to all the customers that we are standing behind them when it comes to drive for lower cost of measurement, when it comes to lower cost of ownership, when it comes to increase productivity and it positions us clearly as the market leader in gas chromatography. So we'll be in a lot of discussions this time, not only Intuvo, but I think whether Intuvo launch it for us, we also -- it also spread a lot of discussion again about other part of portfolio to 7890 and other products, which are market-leading products. And again, the discussion with the customers in the suppress market is all about how can we help them increasing their productivity, driving their cost of analysis down and business where we are exceptionally well positioned with this portfolio."
154924,407124595,1087313,"Agilent Technologies, Inc., Q4 2016 Earnings Call, Nov 15, 2016",2016-11-15,"Earnings Calls","Agilent Technologies, Inc.","Executives","Yes, maybe just to up an exclamation point on this. Is that we know that the installed base is at historic levels of aging. We know the equipment is being used. And it's just a matter time for that replacement cycle is going to turn on. But as you saw in",61,"Yes, maybe just to up an exclamation point on this. Is that we know that the installed base is at historic levels of aging. We know the equipment is being used. And it's just a matter time for that replacement cycle is going to turn on. But as you saw in my call comments, we're not ready to call that yet."
154924,407124595,1087313,"Agilent Technologies, Inc., Q4 2016 Earnings Call, Nov 15, 2016",2016-11-15,"Earnings Calls","Agilent Technologies, Inc.","Analysts","Okay. And then just one clarification on the operating margin guidance. Half of the cut you're down about 1% from what you talked about the analyst day, half of that is from iLab pension and FX, is the rest just conservatism, given kind of the macro?",46,"Okay. And then just one clarification on the operating margin guidance. Half of the cut you're down about 1% from what you talked about the analyst day, half of that is from iLab pension and FX, is the rest just conservatism, given kind of the macro?"
154924,407124595,1087313,"Agilent Technologies, Inc., Q4 2016 Earnings Call, Nov 15, 2016",2016-11-15,"Earnings Calls","Agilent Technologies, Inc.","Executives","Yes, actually, I think where we had was the high end of our guidance is around 21.5%, right, Didier? And...",20,"Yes, actually, I think where we had was the high end of our guidance is around 21.5%, right, Didier? And..."
154924,407124595,1087313,"Agilent Technologies, Inc., Q4 2016 Earnings Call, Nov 15, 2016",2016-11-15,"Earnings Calls","Agilent Technologies, Inc.","Executives","So yes, with the high end is at 21.5%, and we are losing about 50 basis points related to the 3 items that were mentioned: currency, acquisition and pension expenses. And the other thing to note is, as Mike has clearly stated, we are still being measured",56,"So yes, with the high end is at 21.5%, and we are losing about 50 basis points related to the 3 items that were mentioned: currency, acquisition and pension expenses. And the other thing to note is, as Mike has clearly stated, we are still being measured on achieving 22% in terms of our variable compensation."
154924,407124595,1087313,"Agilent Technologies, Inc., Q4 2016 Earnings Call, Nov 15, 2016",2016-11-15,"Earnings Calls","Agilent Technologies, Inc.","Executives","Yes, and the way Didier and I talked about this one is listen, we think we've got a path to 22%. But there's lot of higher risks than it was back at the last call and at the May AIDs. So we thought it was prudent for us to guide this way. But we're all ou",66,"Yes, and the way Didier and I talked about this one is listen, we think we've got a path to 22%. But there's lot of higher risks than it was back at the last call and at the May AIDs. So we thought it was prudent for us to guide this way. But we're all out inside, all our comp is tied to the 22% number."
154924,407124595,1087313,"Agilent Technologies, Inc., Q4 2016 Earnings Call, Nov 15, 2016",2016-11-15,"Earnings Calls","Agilent Technologies, Inc.","Executives","3 elements that were clear headwinds.",6,"3 elements that were clear headwinds."
154924,407124595,1087313,"Agilent Technologies, Inc., Q4 2016 Earnings Call, Nov 15, 2016",2016-11-15,"Earnings Calls","Agilent Technologies, Inc.","Operator","And our next question comes from the line of Ross Muken from Evercore ISI.",14,"And our next question comes from the line of Ross Muken from Evercore ISI."
154924,407124595,1087313,"Agilent Technologies, Inc., Q4 2016 Earnings Call, Nov 15, 2016",2016-11-15,"Earnings Calls","Agilent Technologies, Inc.","Analysts","This is Luke in for Ross. Just hoping you could give a little more color on your margin assumption for next year? Where do you guys think about pacing, the FX headwinds, if any, what's going to be operational with the pricing, et cetera?",44,"This is Luke in for Ross. Just hoping you could give a little more color on your margin assumption for next year? Where do you guys think about pacing, the FX headwinds, if any, what's going to be operational with the pricing, et cetera?"
154924,407124595,1087313,"Agilent Technologies, Inc., Q4 2016 Earnings Call, Nov 15, 2016",2016-11-15,"Earnings Calls","Agilent Technologies, Inc.","Executives","I think the question, Didier, was relative to the composition of our operating margin improvements for next year. And perhaps we can start with the mix between volume and OpEx and gross margins.",33,"I think the question, Didier, was relative to the composition of our operating margin improvements for next year. And perhaps we can start with the mix between volume and OpEx and gross margins."
154924,407124595,1087313,"Agilent Technologies, Inc., Q4 2016 Earnings Call, Nov 15, 2016",2016-11-15,"Earnings Calls","Agilent Technologies, Inc.","Executives","Yes, I mean, the -- I mean, I'm not going to give you the full bridge. I mean, when we provided the guidance of 21% to 21.5%, we took into account obviously, the -- all the impact that I've mentioned. So there is -- it's based on the 4.3% core revenue gro",160,"Yes, I mean, the -- I mean, I'm not going to give you the full bridge. I mean, when we provided the guidance of 21% to 21.5%, we took into account obviously, the -- all the impact that I've mentioned. So there is -- it's based on the 4.3% core revenue growth. So there is a clearly an operating leverage impact. And a lot, a lot of actions that are taking place to offset inflation and other headwinds that partly I have mentioned. The guidance assumes some level of increase improvements in gross margins as well as a reduction in terms of our -- of the OpEx as a percentage of revenue. So you have a pretty much on all fronts, some improvements, not as much as we had initially anticipated because of the 3 headwinds that I've mentioned. Some of it related to operating leverage and some of it is related to the continuation of our Agile Agilent programs."
154924,407124595,1087313,"Agilent Technologies, Inc., Q4 2016 Earnings Call, Nov 15, 2016",2016-11-15,"Earnings Calls","Agilent Technologies, Inc.","Executives","And maybe just reminding the audience, Didier. When we first started this march almost 2 years ago to go to the 22%, we laid out a path, which is really around 60% being volume, the other 40% was going to be on OpEx improvements in gross margin. I think w",59,"And maybe just reminding the audience, Didier. When we first started this march almost 2 years ago to go to the 22%, we laid out a path, which is really around 60% being volume, the other 40% was going to be on OpEx improvements in gross margin. I think we're thinking about the same kind of mix for 2017."
154924,407124595,1087313,"Agilent Technologies, Inc., Q4 2016 Earnings Call, Nov 15, 2016",2016-11-15,"Earnings Calls","Agilent Technologies, Inc.","Analysts","Okay, great. And I guess just one more. You guys did really well on the cash flow in '16. I think $647 million and you're guiding for $625 million. Is there any timing impact on that '17 guide? And then, I guess, on the tax of '17, kind of what are you ba",58,"Okay, great. And I guess just one more. You guys did really well on the cash flow in '16. I think $647 million and you're guiding for $625 million. Is there any timing impact on that '17 guide? And then, I guess, on the tax of '17, kind of what are you baking into that benefit down there?"
154924,407124595,1087313,"Agilent Technologies, Inc., Q4 2016 Earnings Call, Nov 15, 2016",2016-11-15,"Earnings Calls","Agilent Technologies, Inc.","Executives","So I assume when you refer to timing impact, you're referring to special --  I mean between '16 and '17, some cash outlays [indiscernible] that's good for us?",28,"So I assume when you refer to timing impact, you're referring to special --  I mean between '16 and '17, some cash outlays [indiscernible] that's good for us?"
154924,407124595,1087313,"Agilent Technologies, Inc., Q4 2016 Earnings Call, Nov 15, 2016",2016-11-15,"Earnings Calls","Agilent Technologies, Inc.","Analysts","Yes, correct.",2,"Yes, correct."
154924,407124595,1087313,"Agilent Technologies, Inc., Q4 2016 Earnings Call, Nov 15, 2016",2016-11-15,"Earnings Calls","Agilent Technologies, Inc.","Executives","Yes, there's a little bit. I mean, let me just highlight 2 potentially. This -- in fiscal year '16, we disbursed $66 million for overall Agilent variable pay and pay for results. Next year, we -- but we've changed our program so that we now do a lot of th",217,"Yes, there's a little bit. I mean, let me just highlight 2 potentially. This -- in fiscal year '16, we disbursed $66 million for overall Agilent variable pay and pay for results. Next year, we -- but we've changed our program so that we now do a lot of the cash outlays on an annual basis instead of semi-annual. So we have the full brunt in '17 of improvements in '16 and the fact that we're going to be in '17 something that is more than pertaining to '16. So it's going to be $91 million going from $66 million to $91 million. So an increased capital cash outlay. And then second, we did not fund our U.S. pension plan in '16. So our overall contributions to our worldwide pension plan was $24 million. We intend to fund our U.S. pension plan more in '17 and the contribution to the pension plan will move to $45 million. So an increase from $24 million to $45 million. So that -- those are the 2 things that come to mind in terms of explaining some of the variance between '16 and 17. But even with those 2 headwinds, we're still ensuring, in our initial guidance, a nice increase of $30 million on a year-over-year basis. And your second question?"
154924,407124595,1087313,"Agilent Technologies, Inc., Q4 2016 Earnings Call, Nov 15, 2016",2016-11-15,"Earnings Calls","Agilent Technologies, Inc.","Executives","Related to tax rate.",4,"Related to tax rate."
154924,407124595,1087313,"Agilent Technologies, Inc., Q4 2016 Earnings Call, Nov 15, 2016",2016-11-15,"Earnings Calls","Agilent Technologies, Inc.","Executives","Yes, on the tax rates, I did mention that May Analyst Day that we -- we're going to work really hard on the reducing our tax rate by 2 percentage points over the course of the next 2 to 3 years. We are very happy to be able to deliver already 1 percentage",150,"Yes, on the tax rates, I did mention that May Analyst Day that we -- we're going to work really hard on the reducing our tax rate by 2 percentage points over the course of the next 2 to 3 years. We are very happy to be able to deliver already 1 percentage point in this fiscal year '16. We still are aiming to reduce our effective tax rate by other 1 percentage points over the course of the next 24 months as committed to or as indicated, I would say, in fiscal year -- in -- at the AID. But it's prudent to assume that the reduction will come in fiscal year '18 and not in fiscal year '17. So in your models, we advise you to put a 1 percentage point's reduction in tax rate from 19 to 18 in fiscal year '18, not in fiscal year '17."
154924,407124595,1087313,"Agilent Technologies, Inc., Q4 2016 Earnings Call, Nov 15, 2016",2016-11-15,"Earnings Calls","Agilent Technologies, Inc.","Analysts","Okay. And does that include the FASB 2016-09 benefit?",9,"Okay. And does that include the FASB 2016-09 benefit?"
154924,407124595,1087313,"Agilent Technologies, Inc., Q4 2016 Earnings Call, Nov 15, 2016",2016-11-15,"Earnings Calls","Agilent Technologies, Inc.","Executives","It includes everything.",3,"It includes everything."
154924,407124595,1087313,"Agilent Technologies, Inc., Q4 2016 Earnings Call, Nov 15, 2016",2016-11-15,"Earnings Calls","Agilent Technologies, Inc.","Operator","And our next question comes from the line of Doug Schenkel from Cowen and Company.",15,"And our next question comes from the line of Doug Schenkel from Cowen and Company."
154924,407124595,1087313,"Agilent Technologies, Inc., Q4 2016 Earnings Call, Nov 15, 2016",2016-11-15,"Earnings Calls","Agilent Technologies, Inc.","Analysts","This is Ryan Blicker on for Doug. Would you be willing to provide what your LC/MS growth was in the quarter? And how that was impacted by the comparisons relative to recent quarters and maybe what your annual growth was there?",41,"This is Ryan Blicker on for Doug. Would you be willing to provide what your LC/MS growth was in the quarter? And how that was impacted by the comparisons relative to recent quarters and maybe what your annual growth was there?"
154924,407124595,1087313,"Agilent Technologies, Inc., Q4 2016 Earnings Call, Nov 15, 2016",2016-11-15,"Earnings Calls","Agilent Technologies, Inc.","Executives","What I can tell you is that, back to earlier statement is that we're winning more business that planned. So we're quite pleased with how we've been doing with the LC/MS portfolio. And Patrick, you may just want to remind the audience some of the new stuff",94,"What I can tell you is that, back to earlier statement is that we're winning more business that planned. So we're quite pleased with how we've been doing with the LC/MS portfolio. And Patrick, you may just want to remind the audience some of the new stuff that we've come out with. So I guess, I'm not comfortable giving the specific of the growth rate. But just to give you a sense of trend of the business and maybe a few proof point to why we believe it's going as well as it is."
154924,407124595,1087313,"Agilent Technologies, Inc., Q4 2016 Earnings Call, Nov 15, 2016",2016-11-15,"Earnings Calls","Agilent Technologies, Inc.","Executives","Sure, again, I'm confident that we are outgrowing the market on many fronts. And we have a very strong LC/MS portfolio. We have launched a lot of exciting products at ASMS this year. And I think the reception of the market just underlines our strength. Th",119,"Sure, again, I'm confident that we are outgrowing the market on many fronts. And we have a very strong LC/MS portfolio. We have launched a lot of exciting products at ASMS this year. And I think the reception of the market just underlines our strength. The combination of LC and LC/MS is important, and we think both are winning platforms. We see strong adoption across all the end markets. And if there was one market where we have seen some headwind, then it was probably at the pain management market segment. But that is also in line with what we probably have for some of our competitors. But overall, we have been very pleased with the result in Q4."
154924,407124595,1087313,"Agilent Technologies, Inc., Q4 2016 Earnings Call, Nov 15, 2016",2016-11-15,"Earnings Calls","Agilent Technologies, Inc.","Analysts","Okay, that's helpful. And then it seems like there could be a repatriation holiday of some sort in 2017. I believe over 90% of your cash is currently trapped internationally. Can you provide any initial thoughts on how you would you prioritize repatriated",53,"Okay, that's helpful. And then it seems like there could be a repatriation holiday of some sort in 2017. I believe over 90% of your cash is currently trapped internationally. Can you provide any initial thoughts on how you would you prioritize repatriated cash, specifically on M&A opportunities and returning capital to shareholders?"
154924,407124595,1087313,"Agilent Technologies, Inc., Q4 2016 Earnings Call, Nov 15, 2016",2016-11-15,"Earnings Calls","Agilent Technologies, Inc.","Executives","Yes, sure, Ryan. So Didier, I will have to make a few additional comments. And then if you want to add anything to it but, firstly, I think we also need to put a series of caveats on my response because we really don't know what this might look like. What",289,"Yes, sure, Ryan. So Didier, I will have to make a few additional comments. And then if you want to add anything to it but, firstly, I think we also need to put a series of caveats on my response because we really don't know what this might look like. What strings might be attached to, how you can use it, whether you can use cash in a certain way. But obviously, we would welcome this type of development, including a move to a more permanent reduction in U.S. corporate tax rates. That being said, I think if you go beyond the theory, I assume those caveats, I think what you'd expect us to do is handle the return to cash very much along the lines of how we're managing our current use of capital. So we would want to use it for U.S.-based M&A, and we'd like to use that in situation where we've been using debt, such as our share repurchases so we would able to finance our share repurchases. And then we might look at our debt structure. But I think what we want to do is, first of all, obviously, understand what are the restrictions that could be tied to it. Also remind the group that some of the cash does need to remain permanently investment overseas. But we were -- if that particular situation will develop, we would likely will bring it back and use the cash pretty much along the lines how we've been using cash with the exception is I won't need to borrow money like I've done in the past for U.S.-based M&A or stock repurchases. I guess you might be okay with that, Didier. You haven't said anything else. Okay."
154924,407124595,1087313,"Agilent Technologies, Inc., Q4 2016 Earnings Call, Nov 15, 2016",2016-11-15,"Earnings Calls","Agilent Technologies, Inc.","Executives","Obviously. We're just waiting [indiscernible] for the fine lines on any chance, but yes.",14,"Obviously. We're just waiting [indiscernible] for the fine lines on any chance, but yes."
154924,407124595,1087313,"Agilent Technologies, Inc., Q4 2016 Earnings Call, Nov 15, 2016",2016-11-15,"Earnings Calls","Agilent Technologies, Inc.","Operator","And our next question comes from the line of Jonathan Groberg from UBS.",13,"And our next question comes from the line of Jonathan Groberg from UBS."
154924,407124595,1087313,"Agilent Technologies, Inc., Q4 2016 Earnings Call, Nov 15, 2016",2016-11-15,"Earnings Calls","Agilent Technologies, Inc.","Analysts","Mike, so I was just going back and looking, you did 6% growth organically for last year, 6% this year in '16. Is it a high level, you have some pretty tough, tough businesses and some of the industrial business this year, still put up 6%. I guess I'm just",105,"Mike, so I was just going back and looking, you did 6% growth organically for last year, 6% this year in '16. Is it a high level, you have some pretty tough, tough businesses and some of the industrial business this year, still put up 6%. I guess I'm just wondering, as you look out to '17, are there some initial thoughts you have around the election from an end market standpoint, outside of tax, that make you incrementally concerned? Is there -- maybe just high level of kind of what makes you think you're going to get the kind of 150 bp slowdown year-over-year."
154924,407124595,1087313,"Agilent Technologies, Inc., Q4 2016 Earnings Call, Nov 15, 2016",2016-11-15,"Earnings Calls","Agilent Technologies, Inc.","Executives","Yes. So great question, Jon, and thanks for that and obviously, we've spent a lot of time talking about this as a team and I mentioned to Alicia before the call, I think we may be the first company in our space that had to do guidance after the U.S. elect",513,"Yes. So great question, Jon, and thanks for that and obviously, we've spent a lot of time talking about this as a team and I mentioned to Alicia before the call, I think we may be the first company in our space that had to do guidance after the U.S. election. So what I'm going to tell you is kind of factors we're thinking about. And then also give you maybe some a little bit more thinking about why we guided the growth rate we did as a company. But we don't yet have a position on these issues. What we do know is there's a multitude of factors that we need to pay attention to. Regulated markets, what's going to happen to other customers in the food markets, environmental markets, the drug -- the FDA regulatory markets. So we know there could be a custom impact. What's going to happen with the U.S. government funding? A lot of our business is driven by U.S. government funding. What's going to happen with trade agreements. There's been a lot of noise about Chinese currency. We just talked about the tax, and will the M&A environment change in terms of -- so I can say right now, Jonathan, is perhaps, like everybody else on this call, we kind of -- at a sense of the issues, but we don't know which ways these things are going to go yet, so we're not going to call them. And that's one of the reasons why we took what we believe to be a prudent, cautious initial guide to FY '17. If I look at the end markets, I mean, pharma's going to continue to be strong. But we don't believe that it continue to grow in double digits throughout all of FY '17. So we've tapered down our expectations a bit about pharma. We also think that China has been just a -- just fantastic for us. I think our number for the year was 21% growth for the year, I'm dialing that back a bit to double digit. So what we're doing is really just trying to moderate our view of growth for next year based on what we've seen to be some pretty difficult comparisons in some markets that really have been driving the business. As I mentioned to you, the wildcard is the turn on energy. One of the things that you pointed out, Jonathan, and what I'm really delighted is we've had 6%, close to 6% growth, 2 years in a row with our #2 market declining for 8 quarters. When that market turns, that obviously will help us in the growth.  So -- but I've learned over the first 2 years in this job, it's really hard to call in terms of a major market. So I'm not going to. And we'll just kind of keep an eye on it, and we'll update you as we go through the year, but that's our thinking about how we're viewing the U.S. election and the thought behind our end market guidance for next year."
154924,407124595,1087313,"Agilent Technologies, Inc., Q4 2016 Earnings Call, Nov 15, 2016",2016-11-15,"Earnings Calls","Agilent Technologies, Inc.","Analysts","And if I could just -- one more on the diagnostic and clinical market.",14,"And if I could just -- one more on the diagnostic and clinical market."
154924,407124595,1087313,"Agilent Technologies, Inc., Q4 2016 Earnings Call, Nov 15, 2016",2016-11-15,"Earnings Calls","Agilent Technologies, Inc.","Executives","Yes, Jacob has been dying to answer the question.",9,"Yes, Jacob has been dying to answer the question."
154924,407124595,1087313,"Agilent Technologies, Inc., Q4 2016 Earnings Call, Nov 15, 2016",2016-11-15,"Earnings Calls","Agilent Technologies, Inc.","Analysts","Yes, so obviously, we have 8% growth there. Obviously, you're probably going to say too early to think about how hospitals may react to the potential repeal of the ACA. But how about the PD-L1 testing business, how much of your growth was driven by that m",58,"Yes, so obviously, we have 8% growth there. Obviously, you're probably going to say too early to think about how hospitals may react to the potential repeal of the ACA. But how about the PD-L1 testing business, how much of your growth was driven by that market? And any -- can you size that market for us yet?"
154924,407124595,1087313,"Agilent Technologies, Inc., Q4 2016 Earnings Call, Nov 15, 2016",2016-11-15,"Earnings Calls","Agilent Technologies, Inc.","Executives","Well, it's -- I can start by saying that we have been very pleased with the performance of the PD-L1 over the last 12 months, I think it's 13 months now. And it has growing, if not to our expectation, then above even. And we expect that to continue to gro",246,"Well, it's -- I can start by saying that we have been very pleased with the performance of the PD-L1 over the last 12 months, I think it's 13 months now. And it has growing, if not to our expectation, then above even. And we expect that to continue to grow now based on KEYTRUDA going first line and obviously, now with our companion diagnostic. We will see a bigger demand for here in U.S., in Europe and in other regions. The market itself is very difficult to size, as you know, that both been the companion with one drug and then has been the complementary with another drug, and those have very different sizes at this point of time. I still believe that the overall PD-L1 market might end up in the same size as the HER2 market. But the difference is that HER2 is only one. One. Basically one drug, or one class of drug, together with one diagnostics whether the PD-L1 will be up to 5 different drugs, maybe more in 5 different diagnostic, maybe even for a lot of indications also. So this is as close as I can get to right now. And the market we place in is -- or the 2 companion diagnostics that we have today continues to grow strongly. I won't say that that's the overall, I think, driver for the 8%. Basically, all our businesses today have a very nice growth performance, but it's definitely contributing."
154924,407124595,1087313,"Agilent Technologies, Inc., Q4 2016 Earnings Call, Nov 15, 2016",2016-11-15,"Earnings Calls","Agilent Technologies, Inc.","Operator","And our next question comes from line of Derik De Bruin from Bank of America.",15,"And our next question comes from line of Derik De Bruin from Bank of America."
154924,407124595,1087313,"Agilent Technologies, Inc., Q4 2016 Earnings Call, Nov 15, 2016",2016-11-15,"Earnings Calls","Agilent Technologies, Inc.","Analysts","The pace in the quarter was very good. Can you talk a little bit about backlog and, I guess, did you pull -- are you worried that you pulled anything from the first quarter in? I mean, any unusual spending patterns that you thought?",44,"The pace in the quarter was very good. Can you talk a little bit about backlog and, I guess, did you pull -- are you worried that you pulled anything from the first quarter in? I mean, any unusual spending patterns that you thought?"
154924,407124595,1087313,"Agilent Technologies, Inc., Q4 2016 Earnings Call, Nov 15, 2016",2016-11-15,"Earnings Calls","Agilent Technologies, Inc.","Executives","Yes, thanks for the question, Derik. So as I mentioned earlier, we saw strength throughout the quarter. And we were quite delighted with the results. And we're not specifically commenting about orders or backlogs. But I did say in my early comments that w",157,"Yes, thanks for the question, Derik. So as I mentioned earlier, we saw strength throughout the quarter. And we were quite delighted with the results. And we're not specifically commenting about orders or backlogs. But I did say in my early comments that we're well positioned for 2017. I would ask you to think about these Q1, particularly the impact of Chinese Lunar New Year. I told Didier, I said, don't want to talk about it in the Q1 call. So let's make sure that we included in our guide. So that is the one thing that I would ask you to think about in terms of the next 3 months of the company's performance. Because we think we'll probably push about a week's worth of revenue or so from Q1 to Q2 because customers just won't be there to take delivery, and as you saw the growth rates have been really exceptional for us in China."
154924,407124595,1087313,"Agilent Technologies, Inc., Q4 2016 Earnings Call, Nov 15, 2016",2016-11-15,"Earnings Calls","Agilent Technologies, Inc.","Analysts","So I'm going to -- I appreciate the New Year's comment. So I think I'm just actually going to follow that up with another question. Have you had any conversations to your customers that -- I mean, obviously, you're not the only ones trying to figure out w",98,"So I'm going to -- I appreciate the New Year's comment. So I think I'm just actually going to follow that up with another question. Have you had any conversations to your customers that -- I mean, obviously, you're not the only ones trying to figure out what the new world order is in terms of how spending is going to be. Are you worried at all about potential in terms of lower CapEx spending, lower spending beginning of the year as people try to get their arms around what exactly the new administration has in store?"
154924,407124595,1087313,"Agilent Technologies, Inc., Q4 2016 Earnings Call, Nov 15, 2016",2016-11-15,"Earnings Calls","Agilent Technologies, Inc.","Executives","No, actually, we don't have that concern. What we've been more thinking about is where is the thing going long term. So -- but in the next quarter, we don't have any real concerns about that. So -- and that's why we are doing full year guide here in Novem",80,"No, actually, we don't have that concern. What we've been more thinking about is where is the thing going long term. So -- but in the next quarter, we don't have any real concerns about that. So -- and that's why we are doing full year guide here in November. It's really hard to see what's going to happen longer term throughout the year. But in the next quarter or so, we wouldn't expect that to have any significant impact."
154924,407124595,1087313,"Agilent Technologies, Inc., Q4 2016 Earnings Call, Nov 15, 2016",2016-11-15,"Earnings Calls","Agilent Technologies, Inc.","Operator","And our next question comes from the line of Paul Knight from Janney.",13,"And our next question comes from the line of Paul Knight from Janney."
154924,407124595,1087313,"Agilent Technologies, Inc., Q4 2016 Earnings Call, Nov 15, 2016",2016-11-15,"Earnings Calls","Agilent Technologies, Inc.","Analysts","This is actually Bill [ph] on behalf of Paul. Maybe just touching on China again. Could you maybe talk about what your underlying trends have been driving the outsize growth for the company. Is it biopharma? Is it food? Is it environmental? And how does t",53,"This is actually Bill [ph] on behalf of Paul. Maybe just touching on China again. Could you maybe talk about what your underlying trends have been driving the outsize growth for the company. Is it biopharma? Is it food? Is it environmental? And how does that impact as you look to next year?"
154924,407124595,1087313,"Agilent Technologies, Inc., Q4 2016 Earnings Call, Nov 15, 2016",2016-11-15,"Earnings Calls","Agilent Technologies, Inc.","Executives","Yes, thanks for the question. I had to say it really was across the board with one exception, which is the chemical and energy market. So all the other markets were up quite substantially for us. And I think this is consistent with what we had talked abou",246,"Yes, thanks for the question. I had to say it really was across the board with one exception, which is the chemical and energy market. So all the other markets were up quite substantially for us. And I think this is consistent with what we had talked about in prior calls, which is really there is going to be a level of investment in China relative to quality of life issues and environmental and food, line objectively with their 5-year plan that they're in the midst of a major improvement in their overall pharma industry and that there's a lot of money going on to research. So -- and then I think the reason Agilent has been able to do so well here is we've got this combination of we've been working the organizational structure, the -- our channel model in the country. We had a lot of stability over the last 18 months. So we've got a really strong team there. And that combination of the team are historical strength in China and the new products we have, it's all coming together in terms of growth. And I guess, I maybe just add one thing and Mark, perhaps, you can comment here. We often talk about the strength of end markets and the new products going to these end markets, but I think there's something going on relative to your business there and the move to services, I think, is worth coming on as well."
154924,407124595,1087313,"Agilent Technologies, Inc., Q4 2016 Earnings Call, Nov 15, 2016",2016-11-15,"Earnings Calls","Agilent Technologies, Inc.","Executives","Thanks, Mike, and thanks, Bill [ph]. To add a little color to that, as we're seeing a fundamental shift in buying behaviors in China, largely shifting from the core areas at around Shanghai, Beijing to some of the more Tier 2, Tier 3 cities, where service",152,"Thanks, Mike, and thanks, Bill [ph]. To add a little color to that, as we're seeing a fundamental shift in buying behaviors in China, largely shifting from the core areas at around Shanghai, Beijing to some of the more Tier 2, Tier 3 cities, where services now is viewed as the commonplace purchasing item in China, and it's certainly driving the growth. But the breadth of services, I think, in China, as well as the consumables business now, is the rest of the story, where they have reached the size and scale that they have the same interest that we'd find in the Western markets around enterprise services and consumables all coming together. So starting, as you've mentioned, Mike, with our extraordinarily strong position to start with, the installed base of China has just allowed us to build the business and truly outgrow our expectations in the second half around this, too."
154924,407124595,1087313,"Agilent Technologies, Inc., Q4 2016 Earnings Call, Nov 15, 2016",2016-11-15,"Earnings Calls","Agilent Technologies, Inc.","Executives","Yes, I mentioned I ask Mark to comment on that because as you may recall, we really have change the portfolio composition of the company, doing much more in the after markets. So CapEx instruments are actually less than 50% now with total company's revenu",64,"Yes, I mentioned I ask Mark to comment on that because as you may recall, we really have change the portfolio composition of the company, doing much more in the after markets. So CapEx instruments are actually less than 50% now with total company's revenue. And historically, China's been driven by new instrument purchases. We're seeing increasing growth also coming from services and consumables."
154924,407124595,1087313,"Agilent Technologies, Inc., Q4 2016 Earnings Call, Nov 15, 2016",2016-11-15,"Earnings Calls","Agilent Technologies, Inc.","Analysts","Great. And then just a follow-up for Didier on the guidance. CapEx up to about $200 million this year. Could you maybe just talk about where the incremental dollars are going and maybe what you think the maintenance CapEx is for Agilent as a whole?",45,"Great. And then just a follow-up for Didier on the guidance. CapEx up to about $200 million this year. Could you maybe just talk about where the incremental dollars are going and maybe what you think the maintenance CapEx is for Agilent as a whole?"
154924,407124595,1087313,"Agilent Technologies, Inc., Q4 2016 Earnings Call, Nov 15, 2016",2016-11-15,"Earnings Calls","Agilent Technologies, Inc.","Executives","Yes, the main reason for the increase, which is about $60 million, from $139 million this year to $200 million next year is really the significant increase that we're planning to -- in terms of our nucleic acid facilities, RNA-based therapeutics in Colora",148,"Yes, the main reason for the increase, which is about $60 million, from $139 million this year to $200 million next year is really the significant increase that we're planning to -- in terms of our nucleic acid facilities, RNA-based therapeutics in Colorado. So we had one facility. We're still expanding the capacity of that facility, but we are building and we just started a few weeks ago 20 miles away a second facility that we're kind of doubled the capacity when it will be put in production end of 2018, 2019. So that is the main reason for the increase and starting in 2018, we should start -- we will see a reduction in the CapEx. This is not the run rate. Our CapEx run rate is still between -- like between $100 million and $120 million per year. So this is way above our run rate."
154924,407124595,1087313,"Agilent Technologies, Inc., Q4 2016 Earnings Call, Nov 15, 2016",2016-11-15,"Earnings Calls","Agilent Technologies, Inc.","Operator","And our next question comes from the line of Jack Meehan from Barclays.",13,"And our next question comes from the line of Jack Meehan from Barclays."
154924,407124595,1087313,"Agilent Technologies, Inc., Q4 2016 Earnings Call, Nov 15, 2016",2016-11-15,"Earnings Calls","Agilent Technologies, Inc.","Analysts","I wanted to follow up on the diagnostics business really I thought it was a nice quarter on a tough comp. I know you talked about the PD-L1. But just any -- I wanted to focus on the Omnis and just whether you think you're picking up steam in the 2017 and",62,"I wanted to follow up on the diagnostics business really I thought it was a nice quarter on a tough comp. I know you talked about the PD-L1. But just any -- I wanted to focus on the Omnis and just whether you think you're picking up steam in the 2017 and then anything worth watching on the reimbursement side with that?"
154924,407124595,1087313,"Agilent Technologies, Inc., Q4 2016 Earnings Call, Nov 15, 2016",2016-11-15,"Earnings Calls","Agilent Technologies, Inc.","Executives","Yes, Jack, thanks for the question. I think I'll pass it over to Jacob, maybe a little bit more color on the quarter results.",24,"Yes, Jack, thanks for the question. I think I'll pass it over to Jacob, maybe a little bit more color on the quarter results."
154924,407124595,1087313,"Agilent Technologies, Inc., Q4 2016 Earnings Call, Nov 15, 2016",2016-11-15,"Earnings Calls","Agilent Technologies, Inc.","Executives","Yes, it's -- we really continue to see overall in our ratings pick up definitely by Omnibus that we see the growth is coming back. It's a nice momentum we're seeing and it continues to basically -- it has continued to increase over -- during '16. So with",121,"Yes, it's -- we really continue to see overall in our ratings pick up definitely by Omnibus that we see the growth is coming back. It's a nice momentum we're seeing and it continues to basically -- it has continued to increase over -- during '16. So with that momentum, we expect that we will continue to see a good performance into '17 also. From a reimbursement perspective, obviously, there are already some expectation how that will look like into '17 and '18 with the comment [ph] and so on. But now we will have to see what happens under the new administration here whether that will change anything. But so far, we actually don't expect any significant changes into '17."
154924,407124595,1087313,"Agilent Technologies, Inc., Q4 2016 Earnings Call, Nov 15, 2016",2016-11-15,"Earnings Calls","Agilent Technologies, Inc.","Analysts","Great, that's helpful. And then I just wanted to follow up on the margin again. And just from our seat, what we should be watching? And what would push you to the 22% above level for this year? What are some of the actions that you think are going to be c",55,"Great, that's helpful. And then I just wanted to follow up on the margin again. And just from our seat, what we should be watching? And what would push you to the 22% above level for this year? What are some of the actions that you think are going to be critical for doing that?"
154924,407124595,1087313,"Agilent Technologies, Inc., Q4 2016 Earnings Call, Nov 15, 2016",2016-11-15,"Earnings Calls","Agilent Technologies, Inc.","Executives","Yes, I mean, Didier, feel free to augment my response here. But I think, obviously, it's going to be volume, which is about 60% of the margin. Improvement comes from volume. And the things that we can control, we're on top of. So it's really -- that's the",161,"Yes, I mean, Didier, feel free to augment my response here. But I think, obviously, it's going to be volume, which is about 60% of the margin. Improvement comes from volume. And the things that we can control, we're on top of. So it's really -- that's the one thing I can't control is what's going to happen in the market. So obviously, there's that 60% tied to margin. And then we've got some pretty big initiatives in the gross margin area, water [ph] fulfillment team. I think you may have heard me speak previously about some of our work in value engineering, material cost, the reductions in logistics. So I think I'll also keep an eye on our gross margins as we work through the year. Some of the things take a while before they actually start coming through your P&L. But once they're there, they're there for extended period of time. And Didier, anything else you'd add to that?"
154924,407124595,1087313,"Agilent Technologies, Inc., Q4 2016 Earnings Call, Nov 15, 2016",2016-11-15,"Earnings Calls","Agilent Technologies, Inc.","Executives","No, I mean, just that -- I mean, we do have stretch goals. As we mentioned, we are paid internally on achieving 22%. And that means all of us has a stretch goals to make -- to achieve that -- to contribute to 22%. And OSS, under Hendrick [ph], the order f",79,"No, I mean, just that -- I mean, we do have stretch goals. As we mentioned, we are paid internally on achieving 22%. And that means all of us has a stretch goals to make -- to achieve that -- to contribute to 22%. And OSS, under Hendrick [ph], the order fulfillment and supply chain organization, which has delivered greatly in '16 is looking at opportunities to deliver even more in '17, which would help us bridge the gap."
154924,407124595,1087313,"Agilent Technologies, Inc., Q4 2016 Earnings Call, Nov 15, 2016",2016-11-15,"Earnings Calls","Agilent Technologies, Inc.","Executives","And thanks, Didier. One additional thought here is, I think, it's important to remind everyone is that some of the things that are going to help in '17 have already been finished in '16. So things such as our simplification of our financial systems infras",56,"And thanks, Didier. One additional thought here is, I think, it's important to remind everyone is that some of the things that are going to help in '17 have already been finished in '16. So things such as our simplification of our financial systems infrastructure. So it's done. And now the savings will start in '17."
154924,407124595,1087313,"Agilent Technologies, Inc., Q4 2016 Earnings Call, Nov 15, 2016",2016-11-15,"Earnings Calls","Agilent Technologies, Inc.","Operator","And our next question comes from the line of Isaac Ro from Goldman Sachs.",14,"And our next question comes from the line of Isaac Ro from Goldman Sachs."
154924,407124595,1087313,"Agilent Technologies, Inc., Q4 2016 Earnings Call, Nov 15, 2016",2016-11-15,"Earnings Calls","Agilent Technologies, Inc.","Analysts","First question just quickly on the quarter. Curious if you could comment on pacing. You guys have the off-cycle calendar there with October. I'm sure everyone is curious if whether it was on the capital spending side or in any particular end market you sa",66,"First question just quickly on the quarter. Curious if you could comment on pacing. You guys have the off-cycle calendar there with October. I'm sure everyone is curious if whether it was on the capital spending side or in any particular end market you saw a meaningful acceleration or deceleration in the month of October to the extent that portends the rest of the calendar year."
154924,407124595,1087313,"Agilent Technologies, Inc., Q4 2016 Earnings Call, Nov 15, 2016",2016-11-15,"Earnings Calls","Agilent Technologies, Inc.","Executives","No, Isaac, I just mentioned that what we saw was really strong pacing throughout the quarter. So it wasn't -- we didn't see something happen also in the last 4 or 5 weeks. We had -- we had strength all through 3 quarters of our fiscal year close.",48,"No, Isaac, I just mentioned that what we saw was really strong pacing throughout the quarter. So it wasn't -- we didn't see something happen also in the last 4 or 5 weeks. We had -- we had strength all through 3 quarters of our fiscal year close."
154924,407124595,1087313,"Agilent Technologies, Inc., Q4 2016 Earnings Call, Nov 15, 2016",2016-11-15,"Earnings Calls","Agilent Technologies, Inc.","Analysts","Got it. And then maybe a longer-term question, Mike, regarding management incentives, you guys have spent a lot of time over the last couple of years talking about the emphasis on hitting your margin goals and you guys have done that pretty well. So as yo",97,"Got it. And then maybe a longer-term question, Mike, regarding management incentives, you guys have spent a lot of time over the last couple of years talking about the emphasis on hitting your margin goals and you guys have done that pretty well. So as you move pass that 22% number, I was wondering how you think about evolving instead of structure for the management team? And should we assume that the types of incentives you have in place is same place maybe with slightly different targets? Or could the overall composition evolve a little bit here?"
154924,407124595,1087313,"Agilent Technologies, Inc., Q4 2016 Earnings Call, Nov 15, 2016",2016-11-15,"Earnings Calls","Agilent Technologies, Inc.","Executives","Yes, Isaac, great, great question. And I would point back to what we discussed back at the May AID, where we really say -- what this is all about is generating superior earnings growth, right? So if you think about what we're trying to do here is we're tr",225,"Yes, Isaac, great, great question. And I would point back to what we discussed back at the May AID, where we really say -- what this is all about is generating superior earnings growth, right? So if you think about what we're trying to do here is we're trying to outgrow the market, extend the operation margins to keep driving up our adjusted earnings per share growth. So what we like to be able to do is really that should be the focus of the team as we move forward. Operating margin expansion and capital deployment and your growth and market are all ways to get there. So we'd like to really be that, become the cornerstone of our long-term focus. And we want Agilent viewed as a company who grows their earnings faster than revenue. But as I mentioned in the AID is, I really want to also make sure that we don't get so focused on continuing to drive up the operating margin year in and year out that you pass on things that immediately you say accretive, maybe their dilutive on your margins but with good M&A additions to the business. So I think the way we're going to talk about the company post '17 is very consistent with what we had talked about back in the spring in New York City."
154924,407124595,1087313,"Agilent Technologies, Inc., Q4 2016 Earnings Call, Nov 15, 2016",2016-11-15,"Earnings Calls","Agilent Technologies, Inc.","Operator","And our next question comes from the line of Brandon Couillard from Jefferies.",13,"And our next question comes from the line of Brandon Couillard from Jefferies."
154924,407124595,1087313,"Agilent Technologies, Inc., Q4 2016 Earnings Call, Nov 15, 2016",2016-11-15,"Earnings Calls","Agilent Technologies, Inc.","Analysts","Most of my questions have been addressed. Mike, just curious what you're embedding for the government and academia market globally for next year and any color you can give us sort of regionally would be helpful.",36,"Most of my questions have been addressed. Mike, just curious what you're embedding for the government and academia market globally for next year and any color you can give us sort of regionally would be helpful."
154924,407124595,1087313,"Agilent Technologies, Inc., Q4 2016 Earnings Call, Nov 15, 2016",2016-11-15,"Earnings Calls","Agilent Technologies, Inc.","Executives","Yes, sure, Brandon. As we -- as I look through my notes here, I think we're expecting low single-digit growth. And I think it's important to kind of parse it out by academia and government. So we think that if we go by the major regions, right, China is g",271,"Yes, sure, Brandon. As we -- as I look through my notes here, I think we're expecting low single-digit growth. And I think it's important to kind of parse it out by academia and government. So we think that if we go by the major regions, right, China is going to be strong. And they've actually helped mitigate some of what's been happening in the U.S. and Europe. We're not expecting much in Europe. It's been down. It was down again, but not -- it was basically -- sort of almost feels like the chemical and energy market, which is kind of chugging along at a reduced rate. We're not expecting the governments there to do anything in terms of more stimulus. In fact, one of things we're watching is what are they going to do as a result of Brexit for those of things. So we expect a strong China, academia and government. We expect the continuation of this current environment in Europe. In the United States, the academia side is not bad. It's what we've seen more has been more on the U.S. government side. The U.S. government -- our U.S. government business is down in 2016 relative to '15. And that's why in my call I mentioned, hey, we need to kind of see where this new administrative goes with its budget plans and investment priorities. So right now, we're kind of standing on the sideline and saying, this going to continue to be just like it is, but -- in the United States. But we could see something different in a few months, we just don't know."
154924,407124595,1087313,"Agilent Technologies, Inc., Q4 2016 Earnings Call, Nov 15, 2016",2016-11-15,"Earnings Calls","Agilent Technologies, Inc.","Operator","And our next question comes from the line of Dan Arias from Citigroup.",13,"And our next question comes from the line of Dan Arias from Citigroup."
154924,407124595,1087313,"Agilent Technologies, Inc., Q4 2016 Earnings Call, Nov 15, 2016",2016-11-15,"Earnings Calls","Agilent Technologies, Inc.","Analysts","Mike, just following up on the outlook. How are you thinking about the pacing of growth in chemical and energy in '17? Is the assumption that you kind of see some sequential improvement through the year? Or are you basically flat lining the business acros",60,"Mike, just following up on the outlook. How are you thinking about the pacing of growth in chemical and energy in '17? Is the assumption that you kind of see some sequential improvement through the year? Or are you basically flat lining the business across the quarter just given that we haven't seen much in the way of positive signals?"
154924,407124595,1087313,"Agilent Technologies, Inc., Q4 2016 Earnings Call, Nov 15, 2016",2016-11-15,"Earnings Calls","Agilent Technologies, Inc.","Executives","I think you anticipated my answer, so we basically have a flat line for the year. And it hasn't -- it's been shrinking for the last 7 or 8 quarters 2% or 3%. I think we ended up down about 3% for the full year. And we're basically saying, it's going to be",201,"I think you anticipated my answer, so we basically have a flat line for the year. And it hasn't -- it's been shrinking for the last 7 or 8 quarters 2% or 3%. I think we ended up down about 3% for the full year. And we're basically saying, it's going to be flattish for '17. If there's any good news to that story is the fundamental industries are still out there in terms of gasoline as being produced. We've seen record levels of production in the United States, for example. The plants are running. There's a lot of discussion. There's a lot of reports externally about a turn. Oil prices have been inching up. But our history here is that it's really hard to know exactly when it's going to turn. What I can say is that if you have a profitability productivity message associated with something you can bring to the laboratory, then they might listen to you. And we're hopeful that some of our new product introductions will hit the mark there. But in terms of our overall market assumption and growth assumption for the company, we're assuming flat for '17. No big movements one way or another."
154924,407124595,1087313,"Agilent Technologies, Inc., Q4 2016 Earnings Call, Nov 15, 2016",2016-11-15,"Earnings Calls","Agilent Technologies, Inc.","Analysts","Got it. Okay, great. And then maybe just to go back to the M&A and the margin comments. As we sort of think about the moving parts on the op margin guidance and just what you might look to do this year, how at risk is the current op margin outlook from ad",93,"Got it. Okay, great. And then maybe just to go back to the M&A and the margin comments. As we sort of think about the moving parts on the op margin guidance and just what you might look to do this year, how at risk is the current op margin outlook from additional M&A? I mean, obviously, it's tough to discuss these things in the abstract. But are you open to further dilution if the right asset comes along? Or do you kind of think you hold the line of the current forecasts?"
154924,407124595,1087313,"Agilent Technologies, Inc., Q4 2016 Earnings Call, Nov 15, 2016",2016-11-15,"Earnings Calls","Agilent Technologies, Inc.","Executives","Yes. No, I think what we've said, and I'm really trying to be -- have actions that are consistent with our prior communication. We said we would look at acquisitions that could be short-term dilutive in nature, and we did one in latter part of '16. We jus",153,"Yes. No, I think what we've said, and I'm really trying to be -- have actions that are consistent with our prior communication. We said we would look at acquisitions that could be short-term dilutive in nature, and we did one in latter part of '16. We just love having iLab part of the portfolio. It's going to be -- it's a great addition to the business. But right now, it's not at the corporate average. We'll move it up. So if we saw there are opportunities like that, we know we would pursue them. But I think if you want to look at that type of the deals and the size, just look at what we've done so far to give you kind of a sense of the things that we're looking at going forward. We like accretive deals, and we like ones that can move up -- move the margins up."
154924,407124595,1087313,"Agilent Technologies, Inc., Q4 2016 Earnings Call, Nov 15, 2016",2016-11-15,"Earnings Calls","Agilent Technologies, Inc.","Operator","And our next question comes from the line of Puneet Souda from Leerink Partners.",14,"And our next question comes from the line of Puneet Souda from Leerink Partners."
154924,407124595,1087313,"Agilent Technologies, Inc., Q4 2016 Earnings Call, Nov 15, 2016",2016-11-15,"Earnings Calls","Agilent Technologies, Inc.","Analysts","Just a quick follow-up, if I could, on the pharma. And I just wanted to understand, there's clearly a solid contribution here. If you could maybe help us parse out. Is that more coming from sort of a small molecule or macro molecules? Or is this -- are we",87,"Just a quick follow-up, if I could, on the pharma. And I just wanted to understand, there's clearly a solid contribution here. If you could maybe help us parse out. Is that more coming from sort of a small molecule or macro molecules? Or is this -- are we thinking about them correctly? Or maybe we should be thinking about in terms of the service contract share that you're gaining and why the CrossLab Group? Help us, if you could parse that out a little bit."
154924,407124595,1087313,"Agilent Technologies, Inc., Q4 2016 Earnings Call, Nov 15, 2016",2016-11-15,"Earnings Calls","Agilent Technologies, Inc.","Executives","Yes, sure. So there's a couple of things going on, which is in terms of the overall fundamental end markets growth rates, we think biopharma and the small molecule side of pharma, both growing quite strongly. Small molecule side is really being driven by",195,"Yes, sure. So there's a couple of things going on, which is in terms of the overall fundamental end markets growth rates, we think biopharma and the small molecule side of pharma, both growing quite strongly. Small molecule side is really being driven by a conversion to the new technology and a good chromatography in particular. Also, an increasing interest in enterprise service, what we have to offer for ACG. So I think what's been going on here for Agilent, we've had a combination of really strong end market growth. There's a new market that has and will continue to develop in the services side, and we're doing well there, along with our new instruments in the pharma. When I look at '17, we think that the biopharma side of that market is going to continue to go quite strongly. It's been an area of prioritization for us in terms of new solutions. But we do think that over time, that the small molecules will start to move back towards more of long-term growth rates. And Patrick, I think, what are we kind of think about our long-term growth rates in the small molecule side?"
154924,407124595,1087313,"Agilent Technologies, Inc., Q4 2016 Earnings Call, Nov 15, 2016",2016-11-15,"Earnings Calls","Agilent Technologies, Inc.","Executives","Well, on the small molecule side, I think we're more in the low- to mid-single-digits range whereas in biopharma we're more optimistic, and it continues to be double digit. That's our projection right now.",34,"Well, on the small molecule side, I think we're more in the low- to mid-single-digits range whereas in biopharma we're more optimistic, and it continues to be double digit. That's our projection right now."
154924,407124595,1087313,"Agilent Technologies, Inc., Q4 2016 Earnings Call, Nov 15, 2016",2016-11-15,"Earnings Calls","Agilent Technologies, Inc.","Analysts","Just one more. In terms of the chemical and energy market side, I mean, we get the view into 2017. But as you have conversation with the labs and lab directors, just help us understand how they're thinking about capital equipment in 2017 knowing these tim",68,"Just one more. In terms of the chemical and energy market side, I mean, we get the view into 2017. But as you have conversation with the labs and lab directors, just help us understand how they're thinking about capital equipment in 2017 knowing these times and knowing that the progression that's been? Or are they thinking more in 2018 terms in the -- on the capital equipment?"
154924,407124595,1087313,"Agilent Technologies, Inc., Q4 2016 Earnings Call, Nov 15, 2016",2016-11-15,"Earnings Calls","Agilent Technologies, Inc.","Executives","I have to say, I don't think they really know yet as well. What they're doing right now is in their right in the midst of their capital budgeting process. So what I can tell you is -- so a couple of conversations with customers over the last 2 or 3 weeks",293,"I have to say, I don't think they really know yet as well. What they're doing right now is in their right in the midst of their capital budgeting process. So what I can tell you is -- so a couple of conversations with customers over the last 2 or 3 weeks on this exact topic. And what they described for me is, hey, our end -- these are -- one customer was somebody who provide services into -- equipment into the energy market. So listen, we're starting to get interest in quotes, but we're not sure whether it's going to hit in '17 or '18 when we had our VIP launch for the Intuvo 9000 GC, a lot our customers were in the chemical and energy space. Listen, we love this productivity message you have here. I think there's a real economic ROI. I'm now right in the midst of my budgeting process inside the company. Maybe I'll be able to get this thing through this year or maybe the following year because there's still seems to be the sentiment, particularly with the larger companies that they want to hold on to the equipment as long as they can before they have to replace it. So -- and again, that's why I pointed to the fact that it's not all negative because of the fact that we do have a strong service and consumables offerings into that space. But again, we just don't -- I don't think our customers know yet as well what's going to happen. We do know it's going to happen. History will repeat itself. There will be a replenishment of aged equipment. But again, we're just not confident enough right now to say when that's going to occur."
154924,407124595,1087313,"Agilent Technologies, Inc., Q4 2016 Earnings Call, Nov 15, 2016",2016-11-15,"Earnings Calls","Agilent Technologies, Inc.","Operator","And that concludes our question-and-answer session for today. I would like to turn the conference back over to Alicia Rodriguez for any closing comments.",25,"And that concludes our question-and-answer session for today. I would like to turn the conference back over to Alicia Rodriguez for any closing comments."
154924,407124595,1087313,"Agilent Technologies, Inc., Q4 2016 Earnings Call, Nov 15, 2016",2016-11-15,"Earnings Calls","Agilent Technologies, Inc.","Executives","Thank you, everybody. And on behalf of the management team, I wanted to thank you for joining us on the call. If you have any questions, feel free to give us a call in IR. Appreciate it very much. Bye-bye.",40,"Thank you, everybody. And on behalf of the management team, I wanted to thank you for joining us on the call. If you have any questions, feel free to give us a call in IR. Appreciate it very much. Bye-bye."
154924,407124595,1087313,"Agilent Technologies, Inc., Q4 2016 Earnings Call, Nov 15, 2016",2016-11-15,"Earnings Calls","Agilent Technologies, Inc.","Operator","Ladies and gentlemen, thank you for your participation in today's conference. This does conclude the program, and you may now disconnect. Everyone, have a great day.",26,"Ladies and gentlemen, thank you for your participation in today's conference. This does conclude the program, and you may now disconnect. Everyone, have a great day."
154924,407124595,1087336,"Agilent Technologies, Inc., Q4 2016 Earnings Call, Nov 15, 2016",2016-11-15,"Earnings Calls","Agilent Technologies, Inc.","Operator","Good day, ladies and gentlemen, and welcome to the Agilent Technologies Fourth Quarter 2016 Earnings Conference Call. [Operator Instructions] As a reminder, this conference is being recorded. I would now like to hand the floor over to Alicia Rodriguez,",47,"Good day, ladies and gentlemen, and welcome to the Agilent Technologies Fourth Quarter 2016 Earnings Conference Call. [Operator Instructions] As a reminder, this conference is being recorded. 
I would now like to hand the floor over to Alicia Rodriguez, Vice President of Investor Relations. Please go ahead."
154924,407124595,1087336,"Agilent Technologies, Inc., Q4 2016 Earnings Call, Nov 15, 2016",2016-11-15,"Earnings Calls","Agilent Technologies, Inc.","Executives","Thank you, Karen, and welcome, everyone, to Agilent's Fourth Quarter Conference Call for Fiscal Year 2016. With me are Mike McMullen, Agilent's President and CEO; and Didier Hirsch, Agilent's Senior Vice President and CFO. Joining in the Q&A after Didier'",285,"Thank you, Karen, and welcome, everyone, to Agilent's Fourth Quarter Conference Call for Fiscal Year 2016. With me are Mike McMullen, Agilent's President and CEO; and Didier Hirsch, Agilent's Senior Vice President and CFO. Joining in the Q&A after Didier's comments will be Patrick Kaltenbach, President of Agilent's Life Sciences and Applied Markets Group; Jacob Thaysen, President of Agilent's Diagnostics and Genomics Group; and Mark Doak, President of the Agilent CrossLab Group.
You can find the press release and information to supplement today's discussion on our website at www.investor.agilent.com. While there, please click on the link for financial results under the Financial Information tab. You will find an investor presentation along with revenue breakouts and currency impacts, business segment results and historical financials for Agilent's operations. We will also post a copy of the prepared remarks following this call.
Today's comments by Mike and Didier will refer to non-GAAP financial measures. You will find the most directly comparable GAAP financial metrics and reconciliations on our website. We will refer to core revenue growth, which excludes the impact of currency, the NMR business and acquisitions and divestitures within the past 12 months. Unless otherwise noted, all references to increases or decreases in financial metrics are year-over-year. Guidance is based on exchange rates as of the last day of the reported quarter.
We will also make forward-looking statements about the financial performance of the company. These statements are subject to risks and uncertainties and are only valid as of today. The company assumes no obligation to update them. Please look at the company's recent SEC filings for a more complete picture of our risks and other factors.
And now let me turn the call over to Mike."
154924,407124595,1087336,"Agilent Technologies, Inc., Q4 2016 Earnings Call, Nov 15, 2016",2016-11-15,"Earnings Calls","Agilent Technologies, Inc.","Executives","Thanks, Alicia, and hello, everyone. I'm very pleased to announce that our Agilent team ended 2016 with another strong quarter of excellent results. I will start by looking at our key numbers from the quarter. First, we continued to deliver above-market",1998,"Thanks, Alicia, and hello, everyone. I'm very pleased to announce that our Agilent team ended 2016 with another strong quarter of excellent results. 
I will start by looking at our key numbers from the quarter. First, we continued to deliver above-market growth. Revenues of $1.1 billion exceeded the high end of the guidance by a sizeable $41 million and were up 6.3% on a core basis. We were the first surprised by the strength of our instrument business in pharma, China and Europe, which far exceeded our expectations. 
Second, our adjusted EPS of $0.59 was $0.07 above the high end of our guidance. 
Finally, we continued our track record of improving profitability as we delivered another quarter of operating margin expansion. Adjusted operating margin of 22.5% was up 60 basis points from Q4 of fiscal 2015. 
Turning to our full year results. Core revenue continued to outperform the market, growing 5.9%. We increased operating margins 110 basis points to 20.7% from 2015. These results drove a 14% increase in adjusted earnings per share for the full year. 
We are capping off the second year of our company transformation with stellar performance by the Agilent team. Our fourth quarter and full year results demonstrate our continued ability to win in the market. We are outgrowing the market while expanding margins and fully leveraging our strong balance sheet. 
In the past year, we distributed $150 million in cash dividends, repurchased $434 million of our shares and invested $480 million directly into the business through M&A, strategic transactions and capital expenditures. 
Let me now address what's happening in our end markets and business groups. I'll start with the end markets. Our Q4 trends were similar to what we experienced last quarter with pharma and academia and government being the exceptions. We had expected continued strength in pharma, but our 16% growth on a difficult compare exceeded our expectations. Growth is being driven by strong customer acceptance of our new products and enterprise service offerings. Academia and government's decline of 2% was less than expected. European spending is holding up better than projected, while our U.S. government investments continue to lag 2015 spending levels. 
Clinical and diagnostics grew 8% over last year, led by continued growth in reagents.
Within our applied end markets, food is up 10% with strong demand in China and Americas. China also drove growth in environmental market, up 3%. 
Chemical and energy declined 3% in line with expectations due to continued effect of crude oil prices and macroeconomic uncertainties. We expect this market to remain challenging for the rest of calendar year 2016 and into 2017, with no significant downward or upward movements.
Geographically, Asia, led by China, and Europe were stronger than forecast. Our Asia business, excluding Japan, grew double digit, driven by greater than 25% growth in China. While the overall European market remains challenged, we delivered solid mid-single-digit growth. European pharma and food markets were strong and academia and government funding was stable with Q3. Japan and Americas were flat with growth constrained by continued chemical and energy market weakness and specific to the U.S., slow U.S. government funding. 
Moving on to the business groups. Life Sciences and Applied Markets Group delivered core revenue growth of 5%. Better-than-expected revenues from our analytical lab instruments business was driven by an attractive combination of introducing new products into growing markets. This applied in particular to our new lineup of chromatography and mass spectrometry products targeted at the pharma in applied food, environmental and forensics markets. LSAG's operating margin for the quarter was 22.8%, up 280 basis points from a year ago.
We are building for the future. In August, we introduced the transformational Intuvo 9000 GC system. Building on our recognized GC leadership, the Intuvo system revolutionized the way users perform gas chromatography. Industry experts recognize unique innovation being delivered by Agilent with press coverage at 100% positive. Intuvo is featured this month on the cover LCGC magazine, a major trade publication. 
Customer response is also very positive to this introduction, confirming our undisputed market leadership in gas chromatography. We anticipate a measured uptake in revenue. Limited international shipments are expected in Q1 of fiscal 2017, with volumes expected to increase over subsequent quarters.
Another industry-unique product, the Agilent 8900 Triple Quad ICP-MS system, which we just introduced in Q3, is also being well received in the market. This instrument is rapidly becoming the solution of choice in labs that demand the highest standards of performance. 
Next, the Agilent CrossLab Group continues to deliver strong, sustained growth with core revenue up 8%. Growth is healthy in both services and consumables. ACG's operating margin for the quarter was 22.7%, down 240 basis points from a year ago and in line with expectations.
ACG results were driven by strong pharma, food, clinical and diagnostic markets, where our CrossLab customer value proposition is being well received. Unlike our instrument business, ACG also grew in the chemical and energy markets. Laboratories supporting strong production levels drove demand for consumables. There is also continued demand for services, as customers focus on keeping their older instruments operational.
We are investing for the future in ACG. We just introduced a new range of innovative and differentiated supplies. These new offerings enable the Agilent Intuvo 9000 GC to be the most efficient and cost-effective premium GC to own and operate. We continue to successfully integrate the recently acquired iLab business, which brings differentiated capabilities to core lab managers. 
Last, but certainly not least in terms of impact, the momentum in the Diagnostics and Genomics Group continued, with delivery of 8% core growth. Our laser focus on improving the previously acquired Dako business is paying off. The pathology business continues its steady climb back to market growth rates, with strong -- with strength in reagents and companion diagnostics.
Our nucleic acid solutions business, for which we recently announced a significant production capacity, grew double digits. This growth reflects the increasing demand for oligonucleotides for RNA-based drugs. DDG's operating margin for the quarter was 19.6%, up 40 basis points from a year ago. 
In October, there was some exciting news from Merck for lung cancer patients and for Agilent. Merck's KEYTRUDA is now approved by the FDA for first-line treatment for metastatic non-small-cell lung cancer for patients with high rates of PD-L1 expression. In conjunction, Agilent's pharmDx companion diagnostics PD-L1 test is now approved for expanded use. This is the first time an Agilent's PD-L1 companion diagnostic is approved for first-line testing.
The theme of investing for our future is also evident in DDG. We launched a comprehensive offering of pooled CRISPR libraries for functional genomics. This will help accelerate research into complex diseases and drug discovery. We signed an agreement with the Burning Rock Biotech to develop cancer diagnostics in China based on Agilent SureSelect solutions. And we broke ground and initiated construction on the previously announced $120 million investment in a new factory in Colorado to expand nucleic acid production capacity.
Turning now to operating margin. We remain focused on operating margin improvement. Since the new Agilent leadership team was appointed, we have delivered 7 consecutive quarters of improved operating margin and strong growth. Despite continued challenges in the chemical and energy business, we have improved adjusted operating margin by 280 basis points in the first 2 years of the company's transformation. We have completely absorbed and offset the $40 million of dis-synergy costs due to the spin-off of Keysight.
On the operations front, our Agile Agilent program continues to simplify the company and lower operating costs. This program is designed to keep us nimble, improve our interaction with customers and lower our costs. It is having an impact and will continue to deliver savings in 2017 and beyond. 
In the coming year, we will realize cost savings from the completion of the integration of Dako in early 2017, a simplified enterprise IT systems environment and other cost-savings initiatives.
Turning to our FY '17 market and company outlook. As a reminder, our shareholder value creation model for superior earnings growth is to outgrow the market and expand operating margins with a balanced deployment of our capital. Didier will go through the specifics of our Q1 '17 and full year guidance. I want to share our thinking about end markets and our initial guidance philosophy, given an environment of increased uncertainty. This is a change since our last call and the May 2016 Analyst Investor Day. 
In our end markets, we expect continued strength in pharma, accompanied by continued solid growth in the food, environmental and clinical research and diagnostics markets. Geographically, China and India are expected to grow at significantly higher rates than other countries. There remains considerable uncertainty about European markets. We are forecasting moderate growth in the United States with the U.S. government policies and spending and chemical and energy markets being the wildcards.
Chemical and energy, while entering a period of easier compares and improved oil prices, has not yet returned to growth. We expect a continued subdued academic and government research market in the coming year until uncertainties resulting from Brexit and the U.S. elections play out. We are also keeping a watchful eye on how potential new U.S. government driven trade and currency evaluation discussions could impact our business.
We finished 2016 very strongly, and we are well positioned for future growth with a pipeline of new offerings. In our initial revenue guidance for 2017, however, we want to be on the cautious side. We want to see some more clarity on U.S. and European government actions and have better indicators of when we will return to growth in our industrial end markets. 
Predicting end-market growth in today's uncertain political and economic environment is challenging. However, I can predict quite confidently that we will continue our track record of outgrowing the market whatever market environment we encounter. We continue to expand our customer channel reach and fortify our portfolio, which strengthens us well for the coming year and beyond. 
The transformation of Agilent we discussed at the May Analyst and Investor Day is in full force. The new leadership team, put in place in early 2015, continues to deliver strong operating results each and every quarter. We are building momentum for future growth. 
We have improved our adjusted operating margins by 200 basis points over the past 2 years and our march to improved operating margins will continue in 2017. However, in our initial operating margin and earnings per share guidance for 2017, we want to be on the cautious side. Since our May Analyst and Investor Day meeting, changes in exchange rate, pension expenses and the recent iLab acquisition are having a short-term dilutive impact on our operating margins of 0.5%. The Agilent team, however, is laser-focused on improving another 130 basis points of operating margin. We have an internal action plan aligned with achieving a 22% operating margin goal in fiscal 2017, excluding M&A impact. This is the primary goal for our executive team's compensation. We continue to hold ourselves to a higher level of performance, expectations than reflected in our initial full year earnings guidance.
As you assess our future possibilities, I will leave you with a few thoughts. We are expanding our product portfolio and extending into adjacent markets. We're improving the customer experience by streamlining processes and modernizing systems, making the company more efficient and customer friendly. Our Agile Agilent program has and will continue to deliver incremental improvements in operating margin. The One Agilent team continues to work well together and is determined to win in the market. We believe we are well positioned to sustain our strong operational performance and achieve our long-term goals. The entire Agilent team is energized and committed to deliver future growth. 
Thank you for being on the call today. I will now turn it over to Didier, who will provide initial insights on our financial results and initial guidance for our fiscal Q1 and full year 2017. Didier?"
154924,407124595,1087336,"Agilent Technologies, Inc., Q4 2016 Earnings Call, Nov 15, 2016",2016-11-15,"Earnings Calls","Agilent Technologies, Inc.","Executives","Thank you, Mike, and hello, everyone. As Mike stated, we are very pleased with our Q4 and full year performance, both well over the high end of our guidance. We delivered above-market core revenue growth of 6.3% and 5.9%, respectively; and our operating",577,"Thank you, Mike, and hello, everyone. As Mike stated, we are very pleased with our Q4 and full year performance, both well over the high end of our guidance. 
We delivered above-market core revenue growth of 6.3% and 5.9%, respectively; and our operating margin, adjusted for income from Keysight, was up 60 basis points and 110 basis points, respectively. 
Our full year EPS at $1.98 is 14% higher than the previous year. Please note that we have reduced our pro forma tax rate by 1 percentage points, which had a $0.02 impact on our EPS. Our operating cash flow for the full year, at $793 million, reflects our strong overall performance. 
And turning to capital returns. For the first -- for the year, we returned $584 million to shareholders in the form of dividends and buybacks or 89% of our free cash flow. 
I will now turn to the guidance for fiscal year 2017. As Mike stated, our initial guidance, like last year, assumes that -- what we believe to be appropriate caution. Our fiscal year '17 revenue guidance of $4.35 billion to $4.37 billion corresponds to a core revenue growth of 4% to 4.5%. It is based on October 31 exchange rates and currency had a 0.6 percentage point impact -- negative impact on revenues. We project fiscal year '17 adjusted operating margin of 21% to 21.5% and fiscal year '17 EPS of $2.10 to $2.16, growing 8% at midpoint. 
As you update your models for fiscal year '17, please consider the following 10 points: First, annual salary increases will be effective December 1, 2016. Second, stock-based compensation will be about $59 million. And as we front end the recognition of stock-based compensation, the Q1 expense will be about $23 million. Third, the reduction in bond yields is negatively impacting our annual pension expenses by about $12 million. Fourth, depreciation is projected to be $104 million for the fiscal year. Fifth, the non-GAAP effective tax rate is projected to remain at 19%. Sixth, we plan to return approximately $600 million in capital to shareholders, including $170 million in dividends and $430 million in buybacks, subject to customary conditions. Seventh, we plan to borrow $250 million in the second half to fund a portion of our capital returns. Eighth, net interest expense is forecasted at $71 million and other income at $11 million. Ninth, for purpose of our EPS guidance, we have assumed a diluted share count of 324 million shares, 5 million shares less than the average diluted share count in fiscal year '16. And finally, tenth, we expect operating cash flow of $825 million and capital expenditures of $200 million, about $60 million over fiscal year '16, mostly due to the investment in the second nucleic acid facility.
Now finally, moving to the guidance for our first quarter. First, please note that Lunar New Year falls in Q1 this year versus Q2 last year, meaning about $15 million of revenue shifting from Q1 to Q2. We expect Q1 revenues of $1.04 billion to $1.06 billion and EPS of $0.48 to $0.50. At midpoint, revenue will grow 2.2% on a core basis and EPS will grow 7%. And as customary, Q1 EPS is negatively impacted by the December salary increase, front loading of stock-based compensation and the increase in payroll taxes due to the disbursement of the variable and incentive pay of the previous year. 
With that, I'll turn it over to Alicia for the Q&A."
154924,407124595,1087336,"Agilent Technologies, Inc., Q4 2016 Earnings Call, Nov 15, 2016",2016-11-15,"Earnings Calls","Agilent Technologies, Inc.","Executives","Thank you, Didier. Karen, will you please give the instructions for the Q&A.",13,"Thank you, Didier. Karen, will you please give the instructions for the Q&A."
154924,407124595,1087336,"Agilent Technologies, Inc., Q4 2016 Earnings Call, Nov 15, 2016",2016-11-15,"Earnings Calls","Agilent Technologies, Inc.","Operator","[Operator Instructions] Our first question comes from the line of Steve Beuchaw from Morgan Stanley.",15,"[Operator Instructions] Our first question comes from the line of Steve Beuchaw from Morgan Stanley."
154924,407124595,1087336,"Agilent Technologies, Inc., Q4 2016 Earnings Call, Nov 15, 2016",2016-11-15,"Earnings Calls","Agilent Technologies, Inc.","Analysts","First question for me is I wonder if you could just juxtapose your results against what we've heard from others in the category over the last several weeks. I mean, it sounds like a particularly strong category by number -- quarter by number of metrics. Y",99,"First question for me is I wonder if you could just juxtapose your results against what we've heard from others in the category over the last several weeks. I mean, it sounds like a particularly strong category by number -- quarter by number of metrics. You actually accelerated while we saw a number of others decelerate in terms of organic growth in the quarter. Can you give us, from a high level, what you think are the keys there in terms of positioning? Why it is the quarter was so good for you guys relative to the market?"
154924,407124595,1087336,"Agilent Technologies, Inc., Q4 2016 Earnings Call, Nov 15, 2016",2016-11-15,"Earnings Calls","Agilent Technologies, Inc.","Executives","Yes, thanks, Steve. The headline for me was as we looked throughout the quarter, we were winning more business than we planned. So we're winning a lot of business in our core markets. I think some of the end-market strength that we planned too was actuall",135,"Yes, thanks, Steve. The headline for me was as we looked throughout the quarter, we were winning more business than we planned. So we're winning a lot of business in our core markets. I think some of the end-market strength that we planned too was actually fairly similar to what I've seen other people comment on relative to the strength of China, strength of pharma, continued subdued but kind of a stable academia and government environment. And for us, I think we were just delighted by our performance, in particular, in our analytical instrument business where we seem to be winning more business than we planned and we think that bodes well for the strength of our portfolio and some of the things we've been doing over the last year in our channels as well."
154924,407124595,1087336,"Agilent Technologies, Inc., Q4 2016 Earnings Call, Nov 15, 2016",2016-11-15,"Earnings Calls","Agilent Technologies, Inc.","Analysts","And then so the follow-up, I guess, just to dig a little deeper would be, did you notice anything in terms of instrument trends relative to consumables trends accelerating or decelerating? And what is that telling you about end of year, I should say end o",51,"And then so the follow-up, I guess, just to dig a little deeper would be, did you notice anything in terms of instrument trends relative to consumables trends accelerating or decelerating? And what is that telling you about end of year, I should say end of calendar year budget flush?"
154924,407124595,1087336,"Agilent Technologies, Inc., Q4 2016 Earnings Call, Nov 15, 2016",2016-11-15,"Earnings Calls","Agilent Technologies, Inc.","Executives","Yes, we were talking a bit about this yesterday with the team. And if you look at our performance through the quarter, we got off to a strong start in August and it continued throughout the quarter. And sometimes, it's hard to tell over first month where",95,"Yes, we were talking a bit about this yesterday with the team. And if you look at our performance through the quarter, we got off to a strong start in August and it continued throughout the quarter. And sometimes, it's hard to tell over first month where things are going to land for the quarter. But I'd say by the end of September, we knew we are winning more business than we planned. And it's really shaping up to be a strong quarter for us and really position us well for us going into 2017."
154924,407124595,1087336,"Agilent Technologies, Inc., Q4 2016 Earnings Call, Nov 15, 2016",2016-11-15,"Earnings Calls","Agilent Technologies, Inc.","Operator","And our next question comes from the line of Tycho Peterson from JPMorgan.",13,"And our next question comes from the line of Tycho Peterson from JPMorgan."
154924,407124595,1087336,"Agilent Technologies, Inc., Q4 2016 Earnings Call, Nov 15, 2016",2016-11-15,"Earnings Calls","Agilent Technologies, Inc.","Analysts","Mike, just hoping for a little bit more color on some of the expectations and guidance in particular around pharma. Are you still assuming that's kind of double-digit growth next year? Or are you factoring in a moderation? And on environmental, you manage",78,"Mike, just hoping for a little bit more color on some of the expectations and guidance in particular around pharma. Are you still assuming that's kind of double-digit growth next year? Or are you factoring in a moderation? And on environmental, you managed to grow that business in contrast to what we saw from one of your peers last week. So maybe talk a little bit about contributions from the DC replacement cycle for next year as well."
154924,407124595,1087336,"Agilent Technologies, Inc., Q4 2016 Earnings Call, Nov 15, 2016",2016-11-15,"Earnings Calls","Agilent Technologies, Inc.","Executives","Yes, sure. Tycho, you broke up a bit on the call. So if I don't get to the specific questions, please come back to me. But I think relative to the expectations for end market kind of thinking for growth rate, we had pharma below the double-digit growth th",107,"Yes, sure. Tycho, you broke up a bit on the call. So if I don't get to the specific questions, please come back to me. But I think relative to the expectations for end market kind of thinking for growth rate, we had pharma below the double-digit growth that have been placed in '16. So as we look at our end markets, we would expect a moderation of growth, not because the spends are going to go away, but you really are going to start to get into tough compares. And, Didier, if I remember correctly, we were in the mid- to high single-digit growth for pharma?"
154924,407124595,1087336,"Agilent Technologies, Inc., Q4 2016 Earnings Call, Nov 15, 2016",2016-11-15,"Earnings Calls","Agilent Technologies, Inc.","Executives","Yes.",1,"Yes."
154924,407124595,1087336,"Agilent Technologies, Inc., Q4 2016 Earnings Call, Nov 15, 2016",2016-11-15,"Earnings Calls","Agilent Technologies, Inc.","Executives","And then I think the story -- I think, Tycho, the question was around environmental.",15,"And then I think the story -- I think, Tycho, the question was around environmental."
154924,407124595,1087336,"Agilent Technologies, Inc., Q4 2016 Earnings Call, Nov 15, 2016",2016-11-15,"Earnings Calls","Agilent Technologies, Inc.","Analysts","Yes, and the GC replacement cycle.",6,"Yes, and the GC replacement cycle."
154924,407124595,1087336,"Agilent Technologies, Inc., Q4 2016 Earnings Call, Nov 15, 2016",2016-11-15,"Earnings Calls","Agilent Technologies, Inc.","Executives","Yes, so in environmental, the story really there is China. And we think that's got many quarters in front of us of growth in China. And we -- as you know, I'm fairly bullish on the prospects of that market. And I think we've got kind of a perfect storm he",198,"Yes, so in environmental, the story really there is China. And we think that's got many quarters in front of us of growth in China. And we -- as you know, I'm fairly bullish on the prospects of that market. And I think we've got kind of a perfect storm here going on where we have strong products going into -- in the growing markets. Relative to the GC replacement cycle, this is really about what's going to happen in the chemical and energy market. And I'll make a few comments here, then, Patrick, you may want to provide your perspective as well. So you may have noticed in my call script, I went kind of out my way to talk about a measured ramp-up of our new Intuvo GC because we think we've got a winner product on our hands. We know there's a lot of interest from customers. But we also recognize the reality of constraints they may have in their capital budgets. I know they're working with their own management teams internally of these companies about what they may get in terms of funding in 2017. What are your thoughts, Patrick, on that as well?"
154924,407124595,1087336,"Agilent Technologies, Inc., Q4 2016 Earnings Call, Nov 15, 2016",2016-11-15,"Earnings Calls","Agilent Technologies, Inc.","Executives","Yes, thanks, Mike. Looking at the GC market, we definitely are positioned very well to capture any growth opportunity there. We have launched the Intuvo, which is a strong message to all our customers that we are standing behind them when it comes to driv",169,"Yes, thanks, Mike. Looking at the GC market, we definitely are positioned very well to capture any growth opportunity there. We have launched the Intuvo, which is a strong message to all our customers that we are standing behind them when it comes to drive for lower cost of measurement, when it comes to lower cost of ownership, when it comes to increased productivity and it positions us clearly as the market leader in gas chromatography. So we are in a lot of discussions with them, not only on Intuvo, but I think what the Intuvo launch did for us, we also -- it also spread a lot of discussion again about other -- of our other part of portfolio to 7890 and other products, which are market-leading products. And again, the discussion with the customers in the suppressed market is all about how can we help them increasing their productivity, driving their cost of analysis down and this is where we are exceptionally well positioned with this portfolio."
154924,407124595,1087336,"Agilent Technologies, Inc., Q4 2016 Earnings Call, Nov 15, 2016",2016-11-15,"Earnings Calls","Agilent Technologies, Inc.","Executives","Yes, maybe just to up an exclamation point on this is that we know that the installed base is at historic levels of aging. We know the equipment is being used. And it's just a matter time for that replacement cycle is going to turn on. But as you saw in m",61,"Yes, maybe just to up an exclamation point on this is that we know that the installed base is at historic levels of aging. We know the equipment is being used. And it's just a matter time for that replacement cycle is going to turn on. But as you saw in my call comments, we're not ready to call that yet."
154924,407124595,1087336,"Agilent Technologies, Inc., Q4 2016 Earnings Call, Nov 15, 2016",2016-11-15,"Earnings Calls","Agilent Technologies, Inc.","Analysts","Okay. And then just one clarification on the operating margin guidance. Half of the cut, you're down about 1% from what you talked about the Analyst Day, half of that is from iLab, pension and FX, is the rest just conservatism, given kind of the macro?",46,"Okay. And then just one clarification on the operating margin guidance. Half of the cut, you're down about 1% from what you talked about the Analyst Day, half of that is from iLab, pension and FX, is the rest just conservatism, given kind of the macro?"
154924,407124595,1087336,"Agilent Technologies, Inc., Q4 2016 Earnings Call, Nov 15, 2016",2016-11-15,"Earnings Calls","Agilent Technologies, Inc.","Executives","Yes, actually, I think where we had was the high end of our guidance is around 21.5%, right, Didier? And...",20,"Yes, actually, I think where we had was the high end of our guidance is around 21.5%, right, Didier? And..."
154924,407124595,1087336,"Agilent Technologies, Inc., Q4 2016 Earnings Call, Nov 15, 2016",2016-11-15,"Earnings Calls","Agilent Technologies, Inc.","Executives","So yes, we -- with the high end is at 21.5%, and we are losing about 50 basis points related to the 3 items that were mentioned: currency, acquisition and pension expenses. And the other thing to note is, as Mike has clearly stated, we are still being mea",58,"So yes, we -- with the high end is at 21.5%, and we are losing about 50 basis points related to the 3 items that were mentioned: currency, acquisition and pension expenses. And the other thing to note is, as Mike has clearly stated, we are still being measured on achieving 22% in terms of our variable compensation."
154924,407124595,1087336,"Agilent Technologies, Inc., Q4 2016 Earnings Call, Nov 15, 2016",2016-11-15,"Earnings Calls","Agilent Technologies, Inc.","Executives","Yes, and the way Didier and I talked about this one was listen, we think we've got a path to 22%. But there's lot of higher risks than there was back at the last call and at the May AID. So we thought it was prudent for us to guide this way. But we're all",66,"Yes, and the way Didier and I talked about this one was listen, we think we've got a path to 22%. But there's lot of higher risks than there was back at the last call and at the May AID. So we thought it was prudent for us to guide this way. But we're all out inside, all our comp is tied to the 22% number."
154924,407124595,1087336,"Agilent Technologies, Inc., Q4 2016 Earnings Call, Nov 15, 2016",2016-11-15,"Earnings Calls","Agilent Technologies, Inc.","Executives","With the 3 elements that were clear headwinds.",8,"With the 3 elements that were clear headwinds."
154924,407124595,1087336,"Agilent Technologies, Inc., Q4 2016 Earnings Call, Nov 15, 2016",2016-11-15,"Earnings Calls","Agilent Technologies, Inc.","Operator","And our next question comes from the line of Ross Muken from Evercore ISI.",14,"And our next question comes from the line of Ross Muken from Evercore ISI."
154924,407124595,1087336,"Agilent Technologies, Inc., Q4 2016 Earnings Call, Nov 15, 2016",2016-11-15,"Earnings Calls","Agilent Technologies, Inc.","Analysts","This is Luke in for Ross. Just hoping you could give a little more color on your margin assumption for next year? What you guys are thinking about pacing the FX headwinds, if any, what's going to be operational, what's pricing, et cetera?",43,"This is Luke in for Ross. Just hoping you could give a little more color on your margin assumption for next year? What you guys are thinking about pacing the FX headwinds, if any, what's going to be operational, what's pricing, et cetera?"
154924,407124595,1087336,"Agilent Technologies, Inc., Q4 2016 Earnings Call, Nov 15, 2016",2016-11-15,"Earnings Calls","Agilent Technologies, Inc.","Executives","I think the question, Didier, was relative to the composition of our operating margin improvements for next year. And perhaps we can start with the mix between volume and OpEx and gross margins.",33,"I think the question, Didier, was relative to the composition of our operating margin improvements for next year. And perhaps we can start with the mix between volume and OpEx and gross margins."
154924,407124595,1087336,"Agilent Technologies, Inc., Q4 2016 Earnings Call, Nov 15, 2016",2016-11-15,"Earnings Calls","Agilent Technologies, Inc.","Executives","Yes, I mean, the -- I mean, I'm not going to give you the full bridge. I mean, when we provided the guidance of 21% to 21.5%, we took into account obviously, the -- all the impacts that I've mentioned. So there is -- it's based on the 4.3% core revenue gr",157,"Yes, I mean, the -- I mean, I'm not going to give you the full bridge. I mean, when we provided the guidance of 21% to 21.5%, we took into account obviously, the -- all the impacts that I've mentioned. So there is -- it's based on the 4.3% core revenue growth. So there is clearly an operating leverage impact. And a lot, a lot of actions that are taking place to offset inflation and other headwinds that partly I have mentioned. The guidance assumes some level of increase improvements in gross margins as well as a reduction in terms of our -- the OpEx as a percentage of revenue. So you have a pretty much on all fronts, some improvements, not as much as we had initially anticipated because of the 3 headwinds that I've mentioned. Some of it related to operating leverage and some of it related to the continuation of our Agile Agilent programs."
154924,407124595,1087336,"Agilent Technologies, Inc., Q4 2016 Earnings Call, Nov 15, 2016",2016-11-15,"Earnings Calls","Agilent Technologies, Inc.","Executives","And maybe just reminding the audience, Didier. When we first started this march almost 2 years ago to go to the 22%, we laid out a path, which is really around 60% was going to be on volume, the other 40% was going to be on OpEx improvements in gross marg",64,"And maybe just reminding the audience, Didier. When we first started this march almost 2 years ago to go to the 22%, we laid out a path, which is really around 60% was going to be on volume, the other 40% was going to be on OpEx improvements in gross margin. And I think we're thinking about the same kind of mix for 2017."
154924,407124595,1087336,"Agilent Technologies, Inc., Q4 2016 Earnings Call, Nov 15, 2016",2016-11-15,"Earnings Calls","Agilent Technologies, Inc.","Executives","That's right, yes. Absolutely.",5,"That's right, yes. Absolutely."
154924,407124595,1087336,"Agilent Technologies, Inc., Q4 2016 Earnings Call, Nov 15, 2016",2016-11-15,"Earnings Calls","Agilent Technologies, Inc.","Analysts","Okay, great. And I guess just one more. You guys did really well on the cash flow in '16. I think $647 million and you're guiding for $625 million. Is there any timing impact on that '17 guide? And then, I guess, on the tax of '17, kind of what are you ba",58,"Okay, great. And I guess just one more. You guys did really well on the cash flow in '16. I think $647 million and you're guiding for $625 million. Is there any timing impact on that '17 guide? And then, I guess, on the tax of '17, kind of what are you baking into that benefit down there?"
154924,407124595,1087336,"Agilent Technologies, Inc., Q4 2016 Earnings Call, Nov 15, 2016",2016-11-15,"Earnings Calls","Agilent Technologies, Inc.","Executives","So I assume when you refer to timing impact, you're referring to special -- I mean between '16 and '17, some cash outlays only that couldâ¦",26,"So I assume when you refer to timing impact, you're referring to special -- I mean between '16 and '17, some cash outlays only that couldâ¦"
154924,407124595,1087336,"Agilent Technologies, Inc., Q4 2016 Earnings Call, Nov 15, 2016",2016-11-15,"Earnings Calls","Agilent Technologies, Inc.","Analysts","Yes, correct.",2,"Yes, correct."
154924,407124595,1087336,"Agilent Technologies, Inc., Q4 2016 Earnings Call, Nov 15, 2016",2016-11-15,"Earnings Calls","Agilent Technologies, Inc.","Executives","Yes, there's a little bit. I mean, let me just highlight 2 potentially. This -- in fiscal year '16, we disbursed $66 million for overall Agilent variable pay and pay for results. Next year, we -- but we've changed our program so that we now do a lot of th",218,"Yes, there's a little bit. I mean, let me just highlight 2 potentially. This -- in fiscal year '16, we disbursed $66 million for overall Agilent variable pay and pay for results. Next year, we -- but we've changed our program so that we now do a lot of the cash outlays on an annual basis instead of semi-annual. So we have the full brunt in '17 of improvements in '16 and the fact that we're going to pay in '17 something that is more than pertaining to '16. So it's going to be $91 million; going from $66 million to $91 million. So an increased capital cash outlay. And then second, we did not fund our U.S. pension plan in '16. So our overall contributions to our worldwide pension plan was $24 million. We intend to fund our U.S. pension plan more in '17 and the contribution to the pension plan will move to $45 million. So an increase from $24 million to $45 million. So that -- those are the 2 things that come to mind in terms of explaining some of the variance between '16 and 17. But even with those 2 headwinds, we are still showing, in our initial guidance, a nice increase of $30 million on a year-over-year basis. And your second question?"
154924,407124595,1087336,"Agilent Technologies, Inc., Q4 2016 Earnings Call, Nov 15, 2016",2016-11-15,"Earnings Calls","Agilent Technologies, Inc.","Executives","Related to tax rates.",4,"Related to tax rates."
154924,407124595,1087336,"Agilent Technologies, Inc., Q4 2016 Earnings Call, Nov 15, 2016",2016-11-15,"Earnings Calls","Agilent Technologies, Inc.","Executives","Yes, on the tax rates, I did mention at the May Analyst Day that we were going to work really hard on the reducing our tax rate by 2 percentage points over the course of the next 2 to 3 years. We are very happy to be able to deliver already 1 percentage p",150,"Yes, on the tax rates, I did mention at the May Analyst Day that we were going to work really hard on the reducing our tax rate by 2 percentage points over the course of the next 2 to 3 years. We are very happy to be able to deliver already 1 percentage point in this fiscal year '16. We still are aiming to reduce our effective tax rate by other 1 percentage points over the course of the next 24 months as committed to or as indicated, I would say, in fiscal year -- in -- at the AID. But it's prudent to assume that the reduction will come in fiscal year '18 and not in fiscal year '17. So in your models, we advise you to put a 1 percentage point's reduction in tax rate from 19% to 18% in fiscal year '18, not in fiscal year '17."
154924,407124595,1087336,"Agilent Technologies, Inc., Q4 2016 Earnings Call, Nov 15, 2016",2016-11-15,"Earnings Calls","Agilent Technologies, Inc.","Analysts","Okay. And does that include the FASB 2016-09 benefit?",9,"Okay. And does that include the FASB 2016-09 benefit?"
154924,407124595,1087336,"Agilent Technologies, Inc., Q4 2016 Earnings Call, Nov 15, 2016",2016-11-15,"Earnings Calls","Agilent Technologies, Inc.","Executives","It includes everything.",3,"It includes everything."
154924,407124595,1087336,"Agilent Technologies, Inc., Q4 2016 Earnings Call, Nov 15, 2016",2016-11-15,"Earnings Calls","Agilent Technologies, Inc.","Operator","And our next question comes from the line of Doug Schenkel from Cowen and Company.",15,"And our next question comes from the line of Doug Schenkel from Cowen and Company."
154924,407124595,1087336,"Agilent Technologies, Inc., Q4 2016 Earnings Call, Nov 15, 2016",2016-11-15,"Earnings Calls","Agilent Technologies, Inc.","Analysts","This is Ryan Blicker on for Doug. Would you be willing to provide what your LC/MS growth was in the quarter? And how that was impacted by the comparison relative to recent quarters and maybe what your annual growth was there?",41,"This is Ryan Blicker on for Doug. Would you be willing to provide what your LC/MS growth was in the quarter? And how that was impacted by the comparison relative to recent quarters and maybe what your annual growth was there?"
154924,407124595,1087336,"Agilent Technologies, Inc., Q4 2016 Earnings Call, Nov 15, 2016",2016-11-15,"Earnings Calls","Agilent Technologies, Inc.","Executives","What I can tell you is that -- back to my earlier statement, is that we're winning more business that planned. So we're quite pleased with how we've been doing with the LC/MS portfolio. And, Patrick, you may just want to remind the audience of some of the",96,"What I can tell you is that -- back to my earlier statement, is that we're winning more business that planned. So we're quite pleased with how we've been doing with the LC/MS portfolio. And, Patrick, you may just want to remind the audience of some of the new stuff that we've come out with. So I guess, I'm not comfortable giving the specific of the growth rate. But just giving you a sense of trend of the business and maybe a few proof points of why we believe it's going as well as it is."
154924,407124595,1087336,"Agilent Technologies, Inc., Q4 2016 Earnings Call, Nov 15, 2016",2016-11-15,"Earnings Calls","Agilent Technologies, Inc.","Executives","Sure, again, I'm confident that we are outgrowing the market on many fronts. And we have a very strong LC/MS portfolio. We launched a lot of exciting products at ASMS this year. And I think the reception of the market just underlines our strength. The com",118,"Sure, again, I'm confident that we are outgrowing the market on many fronts. And we have a very strong LC/MS portfolio. We launched a lot of exciting products at ASMS this year. And I think the reception of the market just underlines our strength. The combination of LC and LC/MS is important, and we think both are winning platforms. We see strong adoption across all the end markets. If there was one market where we have seen some headwind, then it was probably at the pain management market segment. But that is also in line with what you probably have heard with some of our competitors. But overall, we have been very pleased with the result in Q4."
154924,407124595,1087336,"Agilent Technologies, Inc., Q4 2016 Earnings Call, Nov 15, 2016",2016-11-15,"Earnings Calls","Agilent Technologies, Inc.","Analysts","Okay, that's helpful. And then it seems like there could be a repatriation holiday of some sort in 2017. I believe over 90% of your cash is currently trapped internationally. Can you provide any initial thoughts on how you would you prioritize repatriated",53,"Okay, that's helpful. And then it seems like there could be a repatriation holiday of some sort in 2017. I believe over 90% of your cash is currently trapped internationally. Can you provide any initial thoughts on how you would you prioritize repatriated cash, specifically on M&A opportunities and returning capital to shareholders?"
154924,407124595,1087336,"Agilent Technologies, Inc., Q4 2016 Earnings Call, Nov 15, 2016",2016-11-15,"Earnings Calls","Agilent Technologies, Inc.","Executives","Yes, sure, Ryan. So Didier, how about I make a few initial comments and then if you wanted to add anything to it. But, firstly, I think we also need to put a series of caveats on my response because we really don't know what this might look like. What str",291,"Yes, sure, Ryan. So Didier, how about I make a few initial comments and then if you wanted to add anything to it. But, firstly, I think we also need to put a series of caveats on my response because we really don't know what this might look like. What strings might be attached to, how you can use it, whether you can use cash in a certain way. But obviously, we would welcome this type of development, including a move to a more permanent reduction in U.S. corporate tax rates. That being said, I think if you go beyond the theory, I assume with those caveats, I think what you'd expect us to do is handle the return to cash very much along the lines of how we're managing our current use of capital. So we would want to use it for U.S.-based M&A, and we'd like to use that in situation where we've been using debt, such as our share repurchases so we would able to finance our share repurchases. And then we might look at our debt structure. But I think what we want to do is, first of all, obviously, understand what are the restrictions that could be tied to it. Also remind the group that some of the cash does need to remain permanently investment overseas. But we were -- if that particular situation would develop, we would like -- we would bring it back and use the cash very much along the lines how we've been using cash with the exception is I won't need to borrow money like I've done in the past for U.S.-based M&A or stock repurchases. I guess you might be okay with that, Didier. You haven't said anything else. Okay."
154924,407124595,1087336,"Agilent Technologies, Inc., Q4 2016 Earnings Call, Nov 15, 2016",2016-11-15,"Earnings Calls","Agilent Technologies, Inc.","Executives","Absolutely. Absolutely. I was just waiting for his bated breath for the fine lines on the -- any chance, but yes.",21,"Absolutely. Absolutely. I was just waiting for his bated breath for the fine lines on the -- any chance, but yes."
154924,407124595,1087336,"Agilent Technologies, Inc., Q4 2016 Earnings Call, Nov 15, 2016",2016-11-15,"Earnings Calls","Agilent Technologies, Inc.","Operator","And our next question comes from the line of Jonathan Groberg from UBS.",13,"And our next question comes from the line of Jonathan Groberg from UBS."
154924,407124595,1087336,"Agilent Technologies, Inc., Q4 2016 Earnings Call, Nov 15, 2016",2016-11-15,"Earnings Calls","Agilent Technologies, Inc.","Analysts","Mike, so I was just going back and looking, you did 6% growth organically for last year, 6% this year in '16. Just at a high level, you had some pretty tough, tough businesses and some of the industrial business this year and still put up 6%. I guess I'm",105,"Mike, so I was just going back and looking, you did 6% growth organically for last year, 6% this year in '16. Just at a high level, you had some pretty tough, tough businesses and some of the industrial business this year and still put up 6%. I guess I'm just wondering, as you look out to '17, are there some initial thoughts you have around the election from an end-market standpoint, outside of tax, that make you incrementally concerned? Is there -- maybe just high level of kind of what makes you think you're going to get that kind of 150 bps slowdown year-over-year."
154924,407124595,1087336,"Agilent Technologies, Inc., Q4 2016 Earnings Call, Nov 15, 2016",2016-11-15,"Earnings Calls","Agilent Technologies, Inc.","Executives","Yes. So great question, Jon, and thanks for that and obviously, we've spent a lot of time talking about this as a team and I mentioned to Alicia before the call, I think we may be the first company in our space that had to do guidance after the U.S. elect",519,"Yes. So great question, Jon, and thanks for that and obviously, we've spent a lot of time talking about this as a team and I mentioned to Alicia before the call, I think we may be the first company in our space that had to do guidance after the U.S. election. So what I'm going to tell you is the kind of factors we're thinking about. And then also give you maybe some little bit more thinking about why we guided the growth rate we did as a company. But we don't yet have a position on these issues. What we do know is there's a multitude of factors that we need to pay attention to. Regulated markets, what's going to happen to other customers in the food markets, the environmental markets, the drug -- the FDA regulatory markets? So we know there's going to be a customer impact. What's going to happen with U.S. government funding? A lot of our business is driven by U.S. government funding. What's going to happen with trade agreements? There's been a lot of noise about Chinese currency. We just talked about the tax. And will the M&A environment change in terms of -- so all I can say right now, Jonathan, is perhaps, like everybody else on this call, we kind of had a sense of the issues, but we don't know which ways these things are going to go yet, so we're not going to call them. And we're just going to -- and that's one of the reasons why we took what we believe to be a prudent, cautious initial guide to FY '17. If I look at the end markets, I mean, pharma's going to continue to be strong. But we don't believe that it can continue to grow in double digits throughout all of FY '17. So we've tapered down our expectations a bit about pharma. We also think that China has been just a -- just fantastic for us. I think our number for the year was 21% growth for the year; I'm dialing that back a bit to double digit. So what we're doing is really just trying to moderate our view of growth for next year based on what we've seen to be some pretty difficult comparisons in some markets that really have been driving the business. As I mentioned to you, the wildcard is the turn on energy. One of the things that you pointed out, Jonathan, and what I'm really delighted is, we've had 6%, close to 6% growth, 2 years in a row with our #2 market declining for 8 quarters. When that market turns, that obviously will help us in the growth.  So -- but I've learned over the first 2 years in this job, it's really hard to call in terms of major markets. So I'm not going to. And we'll just kind of keep an eye on it, and we'll update you as we go through the year, but that's our thinking about how we're viewing the U.S. election and the thought behind our end-market guidance for next year."
154924,407124595,1087336,"Agilent Technologies, Inc., Q4 2016 Earnings Call, Nov 15, 2016",2016-11-15,"Earnings Calls","Agilent Technologies, Inc.","Analysts","And if I could just -- one more on the diagnostic and clinical market?",14,"And if I could just -- one more on the diagnostic and clinical market?"
154924,407124595,1087336,"Agilent Technologies, Inc., Q4 2016 Earnings Call, Nov 15, 2016",2016-11-15,"Earnings Calls","Agilent Technologies, Inc.","Executives","Yes, Jacob's been dying to answer a question.",8,"Yes, Jacob's been dying to answer a question."
154924,407124595,1087336,"Agilent Technologies, Inc., Q4 2016 Earnings Call, Nov 15, 2016",2016-11-15,"Earnings Calls","Agilent Technologies, Inc.","Analysts","Yes, so obviously, another -- you have 8% growth there. Obviously, you're probably going to say too early to think about how hospitals may react to the potential repeal of the ACA. But how about the PD-L1 testing business, how much of your growth was driv",60,"Yes, so obviously, another -- you have 8% growth there. Obviously, you're probably going to say too early to think about how hospitals may react to the potential repeal of the ACA. But how about the PD-L1 testing business, how much of your growth was driven by that market? And any -- can you size that market for us yet?"
154924,407124595,1087336,"Agilent Technologies, Inc., Q4 2016 Earnings Call, Nov 15, 2016",2016-11-15,"Earnings Calls","Agilent Technologies, Inc.","Executives","Well, it's -- I can start by saying that we have been very pleased with the performance of the PD-L1 over the last 12 months, I think it's 13 months now. And it has growing, if not to our expectation, then above even. And we expect that to continue to gro",248,"Well, it's -- I can start by saying that we have been very pleased with the performance of the PD-L1 over the last 12 months, I think it's 13 months now. And it has growing, if not to our expectation, then above even. And we expect that to continue to grow now based on KEYTRUDA going first line. And obviously, now with our companion diagnostic, we will see a bigger demand for it here in U.S., in Europe and in other regions. The market itself is very difficult to size. As you know, there's both been the companion with 1 drug and then there has been the complementary with another drug, and those have very different sizes at this point of time. I still believe that the overall PD-L1 market might end up in the same size as the HER2 market. But the difference is that HER2 is the only one -- one -- basically, one drug, one class of drug, together with one diagnostics, where the PD-L1 will be up to 5 different drugs, maybe more and 5 different diagnostic, maybe even for a lot of indications also. So this is as close as I can get to right now. The market we place in is -- or the 2 companion diagnostics that we have today continues to grow strongly. I won't say that that's the overall arching driver for the 8%. Basically, all our businesses today have a very nice growth performance, but it's definitely contributing."
154924,407124595,1087336,"Agilent Technologies, Inc., Q4 2016 Earnings Call, Nov 15, 2016",2016-11-15,"Earnings Calls","Agilent Technologies, Inc.","Operator","And our next question comes from line of Derik De Bruin from Bank of America.",15,"And our next question comes from line of Derik De Bruin from Bank of America."
154924,407124595,1087336,"Agilent Technologies, Inc., Q4 2016 Earnings Call, Nov 15, 2016",2016-11-15,"Earnings Calls","Agilent Technologies, Inc.","Analysts","The pace in the quarter was very good. Can you talk a little bit about backlog and, I guess, did you pull -- are you worried that you pulled anything from the first quarter in? I mean, any unusual spending patterns that you thought?",44,"The pace in the quarter was very good. Can you talk a little bit about backlog and, I guess, did you pull -- are you worried that you pulled anything from the first quarter in? I mean, any unusual spending patterns that you thought?"
154924,407124595,1087336,"Agilent Technologies, Inc., Q4 2016 Earnings Call, Nov 15, 2016",2016-11-15,"Earnings Calls","Agilent Technologies, Inc.","Executives","Yes, thanks for the question, Derik. So as I mentioned earlier, we saw strength throughout the quarter. And we were quite delighted with the results. And we're not specifically commenting about orders or backlogs. But I did say in my early comments that w",158,"Yes, thanks for the question, Derik. So as I mentioned earlier, we saw strength throughout the quarter. And we were quite delighted with the results. And we're not specifically commenting about orders or backlogs. But I did say in my early comments that we're well positioned for 2017. I would ask you to think about the Q1, particularly the impact of Chinese Lunar New Year. I told Didier, I said, don't want to talk about it in the Q1 call. So let's make sure that we include it in our guide. So that is the one thing that I would ask you to think about in terms of the next 3 months of the company's performance. Because we think we'll probably push about a week's worth of revenue or so from Q1 to Q2 because customers just won't be there to take delivery, and as you saw, the growth rates have been really exceptional for us in China."
154924,407124595,1087336,"Agilent Technologies, Inc., Q4 2016 Earnings Call, Nov 15, 2016",2016-11-15,"Earnings Calls","Agilent Technologies, Inc.","Analysts","So I'm going to -- I appreciate the New Year's comment. So I'm actually going to follow that up with another question. It's like are you -- have you had any conversations with your customers that -- I mean, obviously, you're not the only ones trying to fi",100,"So I'm going to -- I appreciate the New Year's comment. So I'm actually going to follow that up with another question. It's like are you -- have you had any conversations with your customers that -- I mean, obviously, you're not the only ones trying to figure out what the new world order is in terms of how spending is going to be. Are you worried at all about potential in terms of lower CapEx spending, lower spending beginning of the year as people try to get their arms around what exactly the new administration has in store?"
154924,407124595,1087336,"Agilent Technologies, Inc., Q4 2016 Earnings Call, Nov 15, 2016",2016-11-15,"Earnings Calls","Agilent Technologies, Inc.","Executives","No, actually, we don't have that concern. What we've been more thinking about is where's the thing going long term. So -- but in the next quarter, we don't have any real concerns about that. So -- and that's why we are doing a full year guidance here in N",81,"No, actually, we don't have that concern. What we've been more thinking about is where's the thing going long term. So -- but in the next quarter, we don't have any real concerns about that. So -- and that's why we are doing a full year guidance here in November. And it's really hard to see what's going to happen longer term throughout the year. But in the next quarter or so, we wouldn't expect that to have any significant impact."
154924,407124595,1087336,"Agilent Technologies, Inc., Q4 2016 Earnings Call, Nov 15, 2016",2016-11-15,"Earnings Calls","Agilent Technologies, Inc.","Operator","And our next question comes from the line of Paul Knight from Janney.",13,"And our next question comes from the line of Paul Knight from Janney."
154924,407124595,1087336,"Agilent Technologies, Inc., Q4 2016 Earnings Call, Nov 15, 2016",2016-11-15,"Earnings Calls","Agilent Technologies, Inc.","Analysts","This is actually Bill [ph] on behalf of Paul. Maybe just touching on China again. Could you maybe talk about what your underlying trends have been driving the outsize growth for the company. Is it biopharma? Is it food? Is it environmental? And how does t",53,"This is actually Bill [ph] on behalf of Paul. Maybe just touching on China again. Could you maybe talk about what your underlying trends have been driving the outsize growth for the company. Is it biopharma? Is it food? Is it environmental? And how does that impact as you look to next year?"
154924,407124595,1087336,"Agilent Technologies, Inc., Q4 2016 Earnings Call, Nov 15, 2016",2016-11-15,"Earnings Calls","Agilent Technologies, Inc.","Executives","Yes, thanks for the question. I have to say it really was across the board with one exception, which is the chemical and energy market. So all the other markets were up quite substantially for us. And I think this is consistent with what we had talked abo",248,"Yes, thanks for the question. I have to say it really was across the board with one exception, which is the chemical and energy market. So all the other markets were up quite substantially for us. And I think this is consistent with what we had talked about in prior calls, which is really there's going to be a level of investment in China relative to quality of life issues and in environmental, in food, lined up directly with their 5-year plan that they're in the midst of a major improvement in their overall pharma industry and that there's a lot of money going on to research. So -- and then I think the reason Agilent has been able to do so well here is we've got this combination of we've been working the organizational structure, the -- our channel model in the country. We've had a lot of stability over the last 18 months. So we've got a really strong team there. And that combination of the team, our historical strength in China and the new products we have, it's all coming together in terms of growth. And I guess, I maybe just add one thing and, Mark, perhaps, you can comment here. We often talk about the strength of end markets and the new products going to these end markets, but I think there's something going on relative to your business there and the move to services, I think, is worth a comment on as well."
154924,407124595,1087336,"Agilent Technologies, Inc., Q4 2016 Earnings Call, Nov 15, 2016",2016-11-15,"Earnings Calls","Agilent Technologies, Inc.","Executives","Thanks, Mike, and thanks, Bill [ph]. To add a little color to that is we've seen a fundamental shift in buying behaviors in China, largely shifting from the core areas and around Shanghai, Beijing, to some of the more Tier 2, Tier 3 cities, where services",152,"Thanks, Mike, and thanks, Bill [ph]. To add a little color to that is we've seen a fundamental shift in buying behaviors in China, largely shifting from the core areas and around Shanghai, Beijing, to some of the more Tier 2, Tier 3 cities, where services now is viewed as the commonplace purchasing item in China, and it's certainly driving the growth. But the breadth of services, I think, in China, as well as the consumables business now, is the rest of the story, where they have reached the size and scale that they have the same interest that we'd find in the Western markets around enterprise services and consumables all coming together. So starting, as you've mentioned, Mike, with our extraordinarily strong position to start with, the installed base of China has just allowed us to build the business and truly outgrow our expectations in the second half around this, too."
154924,407124595,1087336,"Agilent Technologies, Inc., Q4 2016 Earnings Call, Nov 15, 2016",2016-11-15,"Earnings Calls","Agilent Technologies, Inc.","Executives","Yes, I mentioned -- I ask Mark to comment on that because as you may recall, we really have changed the portfolio composition of the company, doing much more in the aftermarket. So cath lab instruments are actually less than 50% now of total company's rev",66,"Yes, I mentioned -- I ask Mark to comment on that because as you may recall, we really have changed the portfolio composition of the company, doing much more in the aftermarket. So cath lab instruments are actually less than 50% now of total company's revenue. And historically, China has been driven by new instrument purchases. We're seeing increasing growth also coming from services and consumables."
154924,407124595,1087336,"Agilent Technologies, Inc., Q4 2016 Earnings Call, Nov 15, 2016",2016-11-15,"Earnings Calls","Agilent Technologies, Inc.","Analysts","Great. And then just a follow-up for Didier on the guidance. CapEx up to about $200 million this year. Could you maybe just talk about where the incremental dollars are going and maybe what you think the maintenance CapEx is for Agilent as a whole?",45,"Great. And then just a follow-up for Didier on the guidance. CapEx up to about $200 million this year. Could you maybe just talk about where the incremental dollars are going and maybe what you think the maintenance CapEx is for Agilent as a whole?"
154924,407124595,1087336,"Agilent Technologies, Inc., Q4 2016 Earnings Call, Nov 15, 2016",2016-11-15,"Earnings Calls","Agilent Technologies, Inc.","Executives","Yes, the main reason for the increase, which is about $60 million, from $139 million this year to $200 million next year, is really the significant increase that we're planning in terms of our nucleic acid facilities, RNA-based therapeutics and -- in Colo",148,"Yes, the main reason for the increase, which is about $60 million, from $139 million this year to $200 million next year, is really the significant increase that we're planning in terms of our nucleic acid facilities, RNA-based therapeutics and -- in Colorado. So we had one facility. We're still expanding the capacity of that facility, but we are building and we just started a few weeks ago 20 miles away a second facility that will kind of double the capacity when it will be put in production end of 2018, 2019. So that is the main reason for the increase. And starting in 2018, we should start -- we will see a reduction in the CapEx. This is not the run rate. Our CapEx run rate is still between -- like between $100 million and $120 million per year. So this is way above our run rate."
154924,407124595,1087336,"Agilent Technologies, Inc., Q4 2016 Earnings Call, Nov 15, 2016",2016-11-15,"Earnings Calls","Agilent Technologies, Inc.","Operator","And our next question comes from the line of Jack Meehan from Barclays.",13,"And our next question comes from the line of Jack Meehan from Barclays."
154924,407124595,1087336,"Agilent Technologies, Inc., Q4 2016 Earnings Call, Nov 15, 2016",2016-11-15,"Earnings Calls","Agilent Technologies, Inc.","Analysts","I wanted to follow up on the diagnostics business. Really, I thought it was a nice quarter on a tough comp. I know you talked about the PD-L1. But just any -- I wanted to focus on the Omnis and just whether you think you're picking up steam into 2017 and",60,"I wanted to follow up on the diagnostics business. Really, I thought it was a nice quarter on a tough comp. I know you talked about the PD-L1. But just any -- I wanted to focus on the Omnis and just whether you think you're picking up steam into 2017 and anything worth watching on the reimbursement side with that?"
154924,407124595,1087336,"Agilent Technologies, Inc., Q4 2016 Earnings Call, Nov 15, 2016",2016-11-15,"Earnings Calls","Agilent Technologies, Inc.","Executives","Yes, Jack, thanks for the question. I think I'll pass it over to Jacob, maybe a little bit more color on the quarter results.",24,"Yes, Jack, thanks for the question. I think I'll pass it over to Jacob, maybe a little bit more color on the quarter results."
154924,407124595,1087336,"Agilent Technologies, Inc., Q4 2016 Earnings Call, Nov 15, 2016",2016-11-15,"Earnings Calls","Agilent Technologies, Inc.","Executives","Yes, it's -- we really continue to see overall in our ratings pickup definitely by Omnis that we see the growth is coming back. It's a nice momentum we're seeing and it continues to -- basically, it has continued to increase over -- during '16. So with th",119,"Yes, it's -- we really continue to see overall in our ratings pickup definitely by Omnis that we see the growth is coming back. It's a nice momentum we're seeing and it continues to -- basically, it has continued to increase over -- during '16. So with that momentum, we expect that we will continue to see a good performance into '17 also. From a reimbursement perspective, obviously, there are already some expectation how that will look like into '17 and '18 with the pharma and so on. But now we will have to see what happens under the new administration here whether that will change anything. But so far, we actually don't expect any significant changes into '17."
154924,407124595,1087336,"Agilent Technologies, Inc., Q4 2016 Earnings Call, Nov 15, 2016",2016-11-15,"Earnings Calls","Agilent Technologies, Inc.","Analysts","Great, that's helpful. And then I just wanted to follow up on the margin again. And just from our seat, what we should be watching? And what would push you to the 22% above level for this year? What are some of the actions that you think are going to be c",55,"Great, that's helpful. And then I just wanted to follow up on the margin again. And just from our seat, what we should be watching? And what would push you to the 22% above level for this year? What are some of the actions that you think are going to be critical for doing that?"
154924,407124595,1087336,"Agilent Technologies, Inc., Q4 2016 Earnings Call, Nov 15, 2016",2016-11-15,"Earnings Calls","Agilent Technologies, Inc.","Executives","Yes, I mean, Didier, feel free to augment my response here. But I think, obviously, it's going to be volume, which is about 60% of the margin improvement comes from volume. And the things that we can control, we're on top of. So it's really -- that's the",161,"Yes, I mean, Didier, feel free to augment my response here. But I think, obviously, it's going to be volume, which is about 60% of the margin improvement comes from volume. And the things that we can control, we're on top of. So it's really -- that's the one thing I can't control is what's going to happen in the market. So obviously, there's that 60% tied to margin. And then we've got some pretty big initiatives in the gross margin area, with our water fulfillment team. I think you may have heard me speak previously about some of our work in value engineering, material cost, reductions in logistics. So I think also we keep an eye on our gross margins as we work through the year. Some of the things take a while until actually they start coming through your P&L. But once they're there, they're there for extended period of time. And, Didier, anything else you'd add to that?"
154924,407124595,1087336,"Agilent Technologies, Inc., Q4 2016 Earnings Call, Nov 15, 2016",2016-11-15,"Earnings Calls","Agilent Technologies, Inc.","Executives","No, I mean, just that, I mean, we do have stretch goals. As we mentioned, we are paid internally on achieving 22%. And that means all of us have stretch goals to make -- to achieve that -- to contribute to the 22%. And OSS, under Henrik, the order fulfill",77,"No, I mean, just that, I mean, we do have stretch goals. As we mentioned, we are paid internally on achieving 22%. And that means all of us have stretch goals to make -- to achieve that -- to contribute to the 22%. And OSS, under Henrik, the order fulfillment and supply chain organization, which has delivered greatly in '16 is looking at opportunities to deliver even more in '17, which would help us bridge the gap."
154924,407124595,1087336,"Agilent Technologies, Inc., Q4 2016 Earnings Call, Nov 15, 2016",2016-11-15,"Earnings Calls","Agilent Technologies, Inc.","Executives","Yes. And thanks, Didier. I had one additional thought here is, I think it's important to remind everyone is that some of the things that are going to help in '17 have already been finished in '16. So things such as our simplification of our financial syst",60,"Yes. And thanks, Didier. I had one additional thought here is, I think it's important to remind everyone is that some of the things that are going to help in '17 have already been finished in '16. So things such as our simplification of our financial systems infrastructure. So it's done. And now the savings will show up in '17."
154924,407124595,1087336,"Agilent Technologies, Inc., Q4 2016 Earnings Call, Nov 15, 2016",2016-11-15,"Earnings Calls","Agilent Technologies, Inc.","Operator","And our next question comes from the line of Isaac Ro from Goldman Sachs.",14,"And our next question comes from the line of Isaac Ro from Goldman Sachs."
154924,407124595,1087336,"Agilent Technologies, Inc., Q4 2016 Earnings Call, Nov 15, 2016",2016-11-15,"Earnings Calls","Agilent Technologies, Inc.","Analysts","First question just quickly on the quarter. Curious if you could comment on pacing. You guys have the off-cycle calendar there with October. I'm sure everyone is curious if whether it was on the capital spending side or any particular end market you saw a",65,"First question just quickly on the quarter. Curious if you could comment on pacing. You guys have the off-cycle calendar there with October. I'm sure everyone is curious if whether it was on the capital spending side or any particular end market you saw a meaningful acceleration or deceleration in the month of October to the extent that portends the rest of the calendar year."
154924,407124595,1087336,"Agilent Technologies, Inc., Q4 2016 Earnings Call, Nov 15, 2016",2016-11-15,"Earnings Calls","Agilent Technologies, Inc.","Executives","No, Isaac, I just mentioned that what we saw was really strong pacing throughout the quarter. So it wasn't -- we didn't see something happen all of a sudden in the last 4 or 5 weeks. We had -- we had strength all through 3 quarters of our fiscal year clos",51,"No, Isaac, I just mentioned that what we saw was really strong pacing throughout the quarter. So it wasn't -- we didn't see something happen all of a sudden in the last 4 or 5 weeks. We had -- we had strength all through 3 quarters of our fiscal year close."
154924,407124595,1087336,"Agilent Technologies, Inc., Q4 2016 Earnings Call, Nov 15, 2016",2016-11-15,"Earnings Calls","Agilent Technologies, Inc.","Analysts","Got it. And then maybe a longer-term question, Mike, regarding management incentives. You guys have spent a lot of time over the last couple of years talking about the emphasis on hitting your margin goals and you guys have done that pretty well. So as yo",97,"Got it. And then maybe a longer-term question, Mike, regarding management incentives. You guys have spent a lot of time over the last couple of years talking about the emphasis on hitting your margin goals and you guys have done that pretty well. So as you move pass that 22% number, I was wondering how you think about evolving inside of structure for the management team? And should we assume that the types of incentives you have in place stay in place maybe with slightly different targets? Or could the overall composition evolve a little bit here?"
154924,407124595,1087336,"Agilent Technologies, Inc., Q4 2016 Earnings Call, Nov 15, 2016",2016-11-15,"Earnings Calls","Agilent Technologies, Inc.","Executives","Yes, Isaac, great, great question. And I would point back to what we discussed back at the May AID, where we really said, what this is really all about is generating superior earnings growth, right. So if you think about what we're trying to do here is we",226,"Yes, Isaac, great, great question. And I would point back to what we discussed back at the May AID, where we really said, what this is really all about is generating superior earnings growth, right. So if you think about what we're trying to do here is we're trying to outgrow the market, extend the operation margin to keep driving up our adjusted earnings per share growth. So what we'd like to be able to do is really that should be the focus of the team as we move forward. Operating margin expansion and capital deployment and your growth and market are all ways to get there. So we'd like to really be that have become the cornerstone of our long-term focus. And we want Agilent viewed as a company who grows their earnings faster than revenue. But as I mentioned in the AID is, I really want to also make sure that we don't get so focused on continuing to drive up the operating margin year in and year out that you pass on things that are immediately, say, accretive, maybe they're dilutive on your margins, but with good M&A additions to the business. So I think the way we're going to talk about the company post '17 is very consistent with what we had talked about back in the spring in New York City."
154924,407124595,1087336,"Agilent Technologies, Inc., Q4 2016 Earnings Call, Nov 15, 2016",2016-11-15,"Earnings Calls","Agilent Technologies, Inc.","Operator","And our next question comes from the line of Brandon Couillard from Jefferies.",13,"And our next question comes from the line of Brandon Couillard from Jefferies."
154924,407124595,1087336,"Agilent Technologies, Inc., Q4 2016 Earnings Call, Nov 15, 2016",2016-11-15,"Earnings Calls","Agilent Technologies, Inc.","Analysts","Most of my questions have been addressed. Mike, just curious what you're embedding for the government and academia market globally for next year and any color you can give us sort of regionally would be helpful.",36,"Most of my questions have been addressed. Mike, just curious what you're embedding for the government and academia market globally for next year and any color you can give us sort of regionally would be helpful."
154924,407124595,1087336,"Agilent Technologies, Inc., Q4 2016 Earnings Call, Nov 15, 2016",2016-11-15,"Earnings Calls","Agilent Technologies, Inc.","Executives","Yes, sure, Brandon. As we -- as I look through my notes here, I think we're expecting low single-digit growth. And I think it's important to kind of parse it out by academia and government. So we think that if we go by the major regions, right, China is g",271,"Yes, sure, Brandon. As we -- as I look through my notes here, I think we're expecting low single-digit growth. And I think it's important to kind of parse it out by academia and government. So we think that if we go by the major regions, right, China is going to be strong. And they've actually helped mitigate some of what's been happening in the U.S. and Europe. We're not expecting much in Europe. It's been down. It was down again, but not -- it was basically -- sort of almost feels like the chemical and energy market, which is kind of chugging along at a reduced rate. We're not expecting the governments there to do anything in terms of more stimulus. In fact, one of things we're watching is what are they going to do as a result of Brexit, for those of things. So we expect a strong China, academia and government. We expect a continuation of this current environment in Europe. In the United States, the academia side is not bad. It's what we've seen more has been more on the U.S. government side. The U.S. government -- our U.S. government business is down in 2016 relative to '15. And that's why in my call I mentioned, hey, we need to kind of see where this new administration goes with its budget plans and investment priorities. So right now, we're kind of standing on the sideline just saying it's going to continue to be just like it is, but -- in the United States. But we could see something different in a few months, we just don't know."
154924,407124595,1087336,"Agilent Technologies, Inc., Q4 2016 Earnings Call, Nov 15, 2016",2016-11-15,"Earnings Calls","Agilent Technologies, Inc.","Operator","And our next question comes from the line of Dan Arias from Citigroup.",13,"And our next question comes from the line of Dan Arias from Citigroup."
154924,407124595,1087336,"Agilent Technologies, Inc., Q4 2016 Earnings Call, Nov 15, 2016",2016-11-15,"Earnings Calls","Agilent Technologies, Inc.","Analysts","Mike, just sort of following up on the outlook. Kind of like how are you thinking about the pacing of growth in chemical and energy in '17? Is the assumption that you kind of see some sequential improvement through the year? Or are you basically flat lini",65,"Mike, just sort of following up on the outlook. Kind of like how are you thinking about the pacing of growth in chemical and energy in '17? Is the assumption that you kind of see some sequential improvement through the year? Or are you basically flat lining the business across the quarter just given that we haven't seen much in the way of positive signals?"
154924,407124595,1087336,"Agilent Technologies, Inc., Q4 2016 Earnings Call, Nov 15, 2016",2016-11-15,"Earnings Calls","Agilent Technologies, Inc.","Executives","I think you anticipated my answer. So we basically have a flat line for the year. And it hasn't -- it's been shrinking for the last 7 or 8 quarters 2% or 3%. I think we ended up down about 3% for the full year. And we're basically saying, it's going to be",201,"I think you anticipated my answer. So we basically have a flat line for the year. And it hasn't -- it's been shrinking for the last 7 or 8 quarters 2% or 3%. I think we ended up down about 3% for the full year. And we're basically saying, it's going to be flattish for '17. If there's any good news to that story is the fundamental industries are still out there in terms of gasoline is being produced. We've seen record levels of production in the United States, for example. The plants are running. There's a lot of discussion. There's a lot of reports externally about a turn. Oil prices have been inching up. But our history here is that it's really hard to know exactly when it's going to turn. What I can say is that if you have a profitability productivity message associated with something you can bring to the laboratory, then they might listen to you. And we're hopeful that some of our new product introductions will hit the mark there. But in terms of our overall market assumption and growth assumption for the company, we're assuming flat for '17. No big movements one way or another."
154924,407124595,1087336,"Agilent Technologies, Inc., Q4 2016 Earnings Call, Nov 15, 2016",2016-11-15,"Earnings Calls","Agilent Technologies, Inc.","Analysts","Got it. Okay, great. And then maybe just to go back to the M&A and the margin comments. As we sort of think about the moving parts on the op margin guidance and just what you might look to do this year, how at risk is the current op margin outlook from ad",93,"Got it. Okay, great. And then maybe just to go back to the M&A and the margin comments. As we sort of think about the moving parts on the op margin guidance and just what you might look to do this year, how at risk is the current op margin outlook from additional M&A? I mean, obviously, it's tough to discuss these things in the abstract. But are you open to further dilution if the right asset comes along? Or do you kind of think you hold the line with the current forecasts?"
154924,407124595,1087336,"Agilent Technologies, Inc., Q4 2016 Earnings Call, Nov 15, 2016",2016-11-15,"Earnings Calls","Agilent Technologies, Inc.","Executives","Yes. No, I think what we've said, and I'm really trying to be -- have actions that are consistent with our prior communication. We said we would look at acquisitions that could be short-term dilutive in nature, and we did one the latter part of '16. And w",154,"Yes. No, I think what we've said, and I'm really trying to be -- have actions that are consistent with our prior communication. We said we would look at acquisitions that could be short-term dilutive in nature, and we did one the latter part of '16. And we just love having iLab part of the portfolio. It's going to be -- it's a great addition to the business. But right now, it's not at the corporate average. We'll move it up. So if we saw other opportunities like that, we would pursue them. But I think if you want to look at the type of the deals and the size and other things, just look at what we've done so far to give you kind of a sense of the things that we're looking at going forward. We like accretive deals, and we like ones that can move up -- move the margins up."
154924,407124595,1087336,"Agilent Technologies, Inc., Q4 2016 Earnings Call, Nov 15, 2016",2016-11-15,"Earnings Calls","Agilent Technologies, Inc.","Operator","And our next question comes from the line of Puneet Souda from Leerink Partners.",14,"And our next question comes from the line of Puneet Souda from Leerink Partners."
154924,407124595,1087336,"Agilent Technologies, Inc., Q4 2016 Earnings Call, Nov 15, 2016",2016-11-15,"Earnings Calls","Agilent Technologies, Inc.","Analysts","Just a quick follow-up, if I could, on the pharma. And just wanted to understand, there's clearly a solid contribution here. If you could maybe help us parse out. Is that more coming from sort of a small molecules or macro molecules? Or is this -- are we",86,"Just a quick follow-up, if I could, on the pharma. And just wanted to understand, there's clearly a solid contribution here. If you could maybe help us parse out. Is that more coming from sort of a small molecules or macro molecules? Or is this -- are we thinking about them correctly? Or maybe we should be thinking about in terms of the service contract share that you're gaining and via the CrossLab Group? Help us, if you could parse that out a little bit."
154924,407124595,1087336,"Agilent Technologies, Inc., Q4 2016 Earnings Call, Nov 15, 2016",2016-11-15,"Earnings Calls","Agilent Technologies, Inc.","Executives","Yes, sure. So there's a couple of things going on, which is in terms of the overall fundamental end-market growth rates, we think biopharma and the small molecule side of pharma are both growing quite strongly. The small molecule side is really being driv",196,"Yes, sure. So there's a couple of things going on, which is in terms of the overall fundamental end-market growth rates, we think biopharma and the small molecule side of pharma are both growing quite strongly. The small molecule side is really being driven by a conversion to the new technology, the liquid chromatography in particular. Also, an increasing interest in enterprise service, what we have to offer from ACG. So I think what's been going on here for Agilent, we've had a combination of really strong end-market growth. There's a new market that has and will continue to develop in the services side, and we're doing well there, along with our new instruments in the pharma. When I look at '17, we think that the biopharma side of that market is going to continue to go quite strongly. It's been an area of prioritization for us in terms of new solutions. But we do think that over time, that the small molecule stuff will start to move back towards more of its long-term growth rates. And, Patrick, I think what do we kind of think about our long-term growth rates in the small molecule side?"
154924,407124595,1087336,"Agilent Technologies, Inc., Q4 2016 Earnings Call, Nov 15, 2016",2016-11-15,"Earnings Calls","Agilent Technologies, Inc.","Executives","Well, on the small molecule side, I think we are more in the low- to mid-single-digits range; whereas in biopharma we're more optimistic, and it continues to be double digit. That's our projection right now.",35,"Well, on the small molecule side, I think we are more in the low- to mid-single-digits range; whereas in biopharma we're more optimistic, and it continues to be double digit. That's our projection right now."
154924,407124595,1087336,"Agilent Technologies, Inc., Q4 2016 Earnings Call, Nov 15, 2016",2016-11-15,"Earnings Calls","Agilent Technologies, Inc.","Analysts","All right. Great. Just one more. In terms of the chemical and energy market side, I mean, we get the view into 2017. But as you have conversation with the labs and lab directors, just help us understand how they're thinking about capital equipment in 2017",71,"All right. Great. Just one more. In terms of the chemical and energy market side, I mean, we get the view into 2017. But as you have conversation with the labs and lab directors, just help us understand how they're thinking about capital equipment in 2017 knowing these times and knowing that the progression that's been? Or are they thinking more in 2018 terms in the -- on the capital equipment?"
154924,407124595,1087336,"Agilent Technologies, Inc., Q4 2016 Earnings Call, Nov 15, 2016",2016-11-15,"Earnings Calls","Agilent Technologies, Inc.","Executives","I have to say, I don't think they really know yet as well. What they're doing right now is in they're right in the midst of their capital budgeting process. So what I can tell you is I've had a couple conversations with customers over the last 2 or 3 week",295,"I have to say, I don't think they really know yet as well. What they're doing right now is in they're right in the midst of their capital budgeting process. So what I can tell you is I've had a couple conversations with customers over the last 2 or 3 weeks on this exact topic. And what they described for me is, hey, our end -- these are -- one customer was somebody who provides services into -- and equipment into the energy market. So listen, we're starting to get interest in quotes, but we're not sure whether it's going to hit in '17 or '18. When we had our VIP launch for the Intuvo 9000 GC, a lot our customers were in the chemical and energy space. And it's, ""Listen, we love this productivity message you have here. I think there's a real economic ROI. I'm now right in the midst of my budgeting process inside the company. Maybe I'll be able to get this thing through this year or maybe the following year."" Because there still seems to be the sentiment, particularly with the larger companies that they want to hold on to the equipment as long as they can before they have to replace it. So -- and again, that's why I pointed to the fact that it's not all negative because of the fact that we do have a strong service and consumables offerings into that space. But again, we just don't -- I don't think our customers know yet as well what's going to happen. We do know it's going to happen. History will repeat itself. There will be a replenishment of aged equipment. But again, we're just not confident enough right now to say when that's going to occur."
154924,407124595,1087336,"Agilent Technologies, Inc., Q4 2016 Earnings Call, Nov 15, 2016",2016-11-15,"Earnings Calls","Agilent Technologies, Inc.","Operator","And that concludes our question-and-answer session for today. I would like to turn the conference back over to Alicia Rodriguez for any closing comments.",25,"And that concludes our question-and-answer session for today. I would like to turn the conference back over to Alicia Rodriguez for any closing comments."
154924,407124595,1087336,"Agilent Technologies, Inc., Q4 2016 Earnings Call, Nov 15, 2016",2016-11-15,"Earnings Calls","Agilent Technologies, Inc.","Executives","Thank you, everybody. And on behalf of the management team, I wanted to thank you for joining us on the call. If you have any questions, feel free to give us a call in IR. Appreciate it very much. Bye-bye.",40,"Thank you, everybody. And on behalf of the management team, I wanted to thank you for joining us on the call. If you have any questions, feel free to give us a call in IR. Appreciate it very much. Bye-bye."
154924,407124595,1087336,"Agilent Technologies, Inc., Q4 2016 Earnings Call, Nov 15, 2016",2016-11-15,"Earnings Calls","Agilent Technologies, Inc.","Operator","Ladies and gentlemen, thank you for your participation in today's conference. This does conclude the program, and you may now disconnect. Everyone, have a great day.",26,"Ladies and gentlemen, thank you for your participation in today's conference. This does conclude the program, and you may now disconnect. Everyone, have a great day."
154924,407124595,1088180,"Agilent Technologies, Inc., Q4 2016 Earnings Call, Nov 15, 2016",2016-11-15,"Earnings Calls","Agilent Technologies, Inc.","Operator","Good day, ladies and gentlemen, and welcome to the Agilent Technologies Fourth Quarter 2016 Earnings Conference Call. [Operator Instructions] As a reminder, this conference is being recorded. I would now like to hand the floor over to Alicia Rodriguez,",47,"Good day, ladies and gentlemen, and welcome to the Agilent Technologies Fourth Quarter 2016 Earnings Conference Call. [Operator Instructions] As a reminder, this conference is being recorded. 
I would now like to hand the floor over to Alicia Rodriguez, Vice President of Investor Relations. Please go ahead."
154924,407124595,1088180,"Agilent Technologies, Inc., Q4 2016 Earnings Call, Nov 15, 2016",2016-11-15,"Earnings Calls","Agilent Technologies, Inc.","Executives","Thank you, Karen, and welcome, everyone, to Agilent's Fourth Quarter Conference Call for Fiscal Year 2016. With me are Mike McMullen, Agilent's President and CEO; and Didier Hirsch, Agilent's Senior Vice President and CFO. Joining in the Q&A after Didier'",285,"Thank you, Karen, and welcome, everyone, to Agilent's Fourth Quarter Conference Call for Fiscal Year 2016. With me are Mike McMullen, Agilent's President and CEO; and Didier Hirsch, Agilent's Senior Vice President and CFO. Joining in the Q&A after Didier's comments will be Patrick Kaltenbach, President of Agilent's Life Sciences and Applied Markets Group; Jacob Thaysen, President of Agilent's Diagnostics and Genomics Group; and Mark Doak, President of the Agilent CrossLab Group.
You can find the press release and information to supplement today's discussion on our website at www.investor.agilent.com. While there, please click on the link for financial results under the Financial Information tab. You will find an investor presentation along with revenue breakouts and currency impacts, business segment results and historical financials for Agilent's operations. We will also post a copy of the prepared remarks following this call.
Today's comments by Mike and Didier will refer to non-GAAP financial measures. You will find the most directly comparable GAAP financial metrics and reconciliations on our website. We will refer to core revenue growth, which excludes the impact of currency, the NMR business and acquisitions and divestitures within the past 12 months. Unless otherwise noted, all references to increases or decreases in financial metrics are year-over-year. Guidance is based on exchange rates as of the last day of the reported quarter.
We will also make forward-looking statements about the financial performance of the company. These statements are subject to risks and uncertainties and are only valid as of today. The company assumes no obligation to update them. Please look at the company's recent SEC filings for a more complete picture of our risks and other factors.
And now let me turn the call over to Mike."
154924,407124595,1088180,"Agilent Technologies, Inc., Q4 2016 Earnings Call, Nov 15, 2016",2016-11-15,"Earnings Calls","Agilent Technologies, Inc.","Executives","Thanks, Alicia, and hello, everyone. I'm very pleased to announce that our Agilent team ended 2016 with another strong quarter of excellent results. I will start by looking at our key numbers from the quarter. First, we continued to deliver above-market",1998,"Thanks, Alicia, and hello, everyone. I'm very pleased to announce that our Agilent team ended 2016 with another strong quarter of excellent results. 
I will start by looking at our key numbers from the quarter. First, we continued to deliver above-market growth. Revenues of $1.1 billion exceeded the high end of the guidance by a sizeable $41 million and were up 6.3% on a core basis. We were the first surprised by the strength of our instrument business in pharma, China and Europe, which far exceeded our expectations. 
Second, our adjusted EPS of $0.59 was $0.07 above the high end of our guidance. 
Finally, we continued our track record of improving profitability as we delivered another quarter of operating margin expansion. Adjusted operating margin of 22.5% was up 60 basis points from Q4 of fiscal 2015. 
Turning to our full year results. Core revenue continued to outperform the market, growing 5.9%. We increased operating margins 110 basis points to 20.7% from 2015. These results drove a 14% increase in adjusted earnings per share for the full year. 
We are capping off the second year of our company transformation with stellar performance by the Agilent team. Our fourth quarter and full year results demonstrate our continued ability to win in the market. We are outgrowing the market while expanding margins and fully leveraging our strong balance sheet. 
In the past year, we distributed $150 million in cash dividends, repurchased $434 million of our shares and invested $480 million directly into the business through M&A, strategic transactions and capital expenditures. 
Let me now address what's happening in our end markets and business groups. I'll start with the end markets. Our Q4 trends were similar to what we experienced last quarter with pharma and academia and government being the exceptions. We had expected continued strength in pharma, but our 16% growth on a difficult compare exceeded our expectations. Growth is being driven by strong customer acceptance of our new products and enterprise service offerings. Academia and government's decline of 2% was less than expected. European spending is holding up better than projected, while our U.S. government investments continue to lag 2015 spending levels. 
Clinical and diagnostics grew 8% over last year, led by continued growth in reagents.
Within our applied end markets, food is up 10% with strong demand in China and Americas. China also drove growth in environmental market, up 3%. 
Chemical and energy declined 3% in line with expectations due to continued effect of crude oil prices and macroeconomic uncertainties. We expect this market to remain challenging for the rest of calendar year 2016 and into 2017, with no significant downward or upward movements.
Geographically, Asia, led by China, and Europe were stronger than forecast. Our Asia business, excluding Japan, grew double digit, driven by greater than 25% growth in China. While the overall European market remains challenged, we delivered solid mid-single-digit growth. European pharma and food markets were strong and academia and government funding was stable with Q3. Japan and Americas were flat with growth constrained by continued chemical and energy market weakness and specific to the U.S., slow U.S. government funding. 
Moving on to the business groups. Life Sciences and Applied Markets Group delivered core revenue growth of 5%. Better-than-expected revenues from our analytical lab instruments business was driven by an attractive combination of introducing new products into growing markets. This applied in particular to our new lineup of chromatography and mass spectrometry products targeted at the pharma in applied food, environmental and forensics markets. LSAG's operating margin for the quarter was 22.8%, up 280 basis points from a year ago.
We are building for the future. In August, we introduced the transformational Intuvo 9000 GC system. Building on our recognized GC leadership, the Intuvo system revolutionized the way users perform gas chromatography. Industry experts recognize unique innovation being delivered by Agilent with press coverage at 100% positive. Intuvo is featured this month on the cover LCGC magazine, a major trade publication. 
Customer response is also very positive to this introduction, confirming our undisputed market leadership in gas chromatography. We anticipate a measured uptake in revenue. Limited international shipments are expected in Q1 of fiscal 2017, with volumes expected to increase over subsequent quarters.
Another industry-unique product, the Agilent 8900 Triple Quad ICP-MS system, which we just introduced in Q3, is also being well received in the market. This instrument is rapidly becoming the solution of choice in labs that demand the highest standards of performance. 
Next, the Agilent CrossLab Group continues to deliver strong, sustained growth with core revenue up 8%. Growth is healthy in both services and consumables. ACG's operating margin for the quarter was 22.7%, down 240 basis points from a year ago and in line with expectations.
ACG results were driven by strong pharma, food, clinical and diagnostic markets, where our CrossLab customer value proposition is being well received. Unlike our instrument business, ACG also grew in the chemical and energy markets. Laboratories supporting strong production levels drove demand for consumables. There is also continued demand for services, as customers focus on keeping their older instruments operational.
We are investing for the future in ACG. We just introduced a new range of innovative and differentiated supplies. These new offerings enable the Agilent Intuvo 9000 GC to be the most efficient and cost-effective premium GC to own and operate. We continue to successfully integrate the recently acquired iLab business, which brings differentiated capabilities to core lab managers. 
Last, but certainly not least in terms of impact, the momentum in the Diagnostics and Genomics Group continued, with delivery of 8% core growth. Our laser focus on improving the previously acquired Dako business is paying off. The pathology business continues its steady climb back to market growth rates, with strong -- with strength in reagents and companion diagnostics.
Our nucleic acid solutions business, for which we recently announced a significant production capacity, grew double digits. This growth reflects the increasing demand for oligonucleotides for RNA-based drugs. DDG's operating margin for the quarter was 19.6%, up 40 basis points from a year ago. 
In October, there was some exciting news from Merck for lung cancer patients and for Agilent. Merck's KEYTRUDA is now approved by the FDA for first-line treatment for metastatic non-small-cell lung cancer for patients with high rates of PD-L1 expression. In conjunction, Agilent's pharmDx companion diagnostics PD-L1 test is now approved for expanded use. This is the first time an Agilent's PD-L1 companion diagnostic is approved for first-line testing.
The theme of investing for our future is also evident in DDG. We launched a comprehensive offering of pooled CRISPR libraries for functional genomics. This will help accelerate research into complex diseases and drug discovery. We signed an agreement with the Burning Rock Biotech to develop cancer diagnostics in China based on Agilent SureSelect solutions. And we broke ground and initiated construction on the previously announced $120 million investment in a new factory in Colorado to expand nucleic acid production capacity.
Turning now to operating margin. We remain focused on operating margin improvement. Since the new Agilent leadership team was appointed, we have delivered 7 consecutive quarters of improved operating margin and strong growth. Despite continued challenges in the chemical and energy business, we have improved adjusted operating margin by 280 basis points in the first 2 years of the company's transformation. We have completely absorbed and offset the $40 million of dis-synergy costs due to the spin-off of Keysight.
On the operations front, our Agile Agilent program continues to simplify the company and lower operating costs. This program is designed to keep us nimble, improve our interaction with customers and lower our costs. It is having an impact and will continue to deliver savings in 2017 and beyond. 
In the coming year, we will realize cost savings from the completion of the integration of Dako in early 2017, a simplified enterprise IT systems environment and other cost-savings initiatives.
Turning to our FY '17 market and company outlook. As a reminder, our shareholder value creation model for superior earnings growth is to outgrow the market and expand operating margins with a balanced deployment of our capital. Didier will go through the specifics of our Q1 '17 and full year guidance. I want to share our thinking about end markets and our initial guidance philosophy, given an environment of increased uncertainty. This is a change since our last call and the May 2016 Analyst Investor Day. 
In our end markets, we expect continued strength in pharma, accompanied by continued solid growth in the food, environmental and clinical research and diagnostics markets. Geographically, China and India are expected to grow at significantly higher rates than other countries. There remains considerable uncertainty about European markets. We are forecasting moderate growth in the United States with the U.S. government policies and spending and chemical and energy markets being the wildcards.
Chemical and energy, while entering a period of easier compares and improved oil prices, has not yet returned to growth. We expect a continued subdued academic and government research market in the coming year until uncertainties resulting from Brexit and the U.S. elections play out. We are also keeping a watchful eye on how potential new U.S. government driven trade and currency evaluation discussions could impact our business.
We finished 2016 very strongly, and we are well positioned for future growth with a pipeline of new offerings. In our initial revenue guidance for 2017, however, we want to be on the cautious side. We want to see some more clarity on U.S. and European government actions and have better indicators of when we will return to growth in our industrial end markets. 
Predicting end-market growth in today's uncertain political and economic environment is challenging. However, I can predict quite confidently that we will continue our track record of outgrowing the market whatever market environment we encounter. We continue to expand our customer channel reach and fortify our portfolio, which strengthens us well for the coming year and beyond. 
The transformation of Agilent we discussed at the May Analyst and Investor Day is in full force. The new leadership team, put in place in early 2015, continues to deliver strong operating results each and every quarter. We are building momentum for future growth. 
We have improved our adjusted operating margins by 200 basis points over the past 2 years and our march to improved operating margins will continue in 2017. However, in our initial operating margin and earnings per share guidance for 2017, we want to be on the cautious side. Since our May Analyst and Investor Day meeting, changes in exchange rate, pension expenses and the recent iLab acquisition are having a short-term dilutive impact on our operating margins of 0.5%. The Agilent team, however, is laser-focused on improving another 130 basis points of operating margin. We have an internal action plan aligned with achieving a 22% operating margin goal in fiscal 2017, excluding M&A impact. This is the primary goal for our executive team's compensation. We continue to hold ourselves to a higher level of performance, expectations than reflected in our initial full year earnings guidance.
As you assess our future possibilities, I will leave you with a few thoughts. We are expanding our product portfolio and extending into adjacent markets. We're improving the customer experience by streamlining processes and modernizing systems, making the company more efficient and customer friendly. Our Agile Agilent program has and will continue to deliver incremental improvements in operating margin. The One Agilent team continues to work well together and is determined to win in the market. We believe we are well positioned to sustain our strong operational performance and achieve our long-term goals. The entire Agilent team is energized and committed to deliver future growth. 
Thank you for being on the call today. I will now turn it over to Didier, who will provide initial insights on our financial results and initial guidance for our fiscal Q1 and full year 2017. Didier?"
154924,407124595,1088180,"Agilent Technologies, Inc., Q4 2016 Earnings Call, Nov 15, 2016",2016-11-15,"Earnings Calls","Agilent Technologies, Inc.","Executives","Thank you, Mike, and hello, everyone. As Mike stated, we are very pleased with our Q4 and full year performance, both well over the high end of our guidance. We delivered above-market core revenue growth of 6.3% and 5.9%, respectively; and our operating",577,"Thank you, Mike, and hello, everyone. As Mike stated, we are very pleased with our Q4 and full year performance, both well over the high end of our guidance. 
We delivered above-market core revenue growth of 6.3% and 5.9%, respectively; and our operating margin, adjusted for income from Keysight, was up 60 basis points and 110 basis points, respectively. 
Our full year EPS at $1.98 is 14% higher than the previous year. Please note that we have reduced our pro forma tax rate by 1 percentage points, which had a $0.02 impact on our EPS. Our operating cash flow for the full year, at $793 million, reflects our strong overall performance. 
And turning to capital returns. For the first -- for the year, we returned $584 million to shareholders in the form of dividends and buybacks or 89% of our free cash flow. 
I will now turn to the guidance for fiscal year 2017. As Mike stated, our initial guidance, like last year, assumes that -- what we believe to be appropriate caution. Our fiscal year '17 revenue guidance of $4.35 billion to $4.37 billion corresponds to a core revenue growth of 4% to 4.5%. It is based on October 31 exchange rates and currency had a 0.6 percentage point impact -- negative impact on revenues. We project fiscal year '17 adjusted operating margin of 21% to 21.5% and fiscal year '17 EPS of $2.10 to $2.16, growing 8% at midpoint. 
As you update your models for fiscal year '17, please consider the following 10 points: First, annual salary increases will be effective December 1, 2016. Second, stock-based compensation will be about $59 million. And as we front end the recognition of stock-based compensation, the Q1 expense will be about $23 million. Third, the reduction in bond yields is negatively impacting our annual pension expenses by about $12 million. Fourth, depreciation is projected to be $104 million for the fiscal year. Fifth, the non-GAAP effective tax rate is projected to remain at 19%. Sixth, we plan to return approximately $600 million in capital to shareholders, including $170 million in dividends and $430 million in buybacks, subject to customary conditions. Seventh, we plan to borrow $250 million in the second half to fund a portion of our capital returns. Eighth, net interest expense is forecasted at $71 million and other income at $11 million. Ninth, for purpose of our EPS guidance, we have assumed a diluted share count of 324 million shares, 5 million shares less than the average diluted share count in fiscal year '16. And finally, tenth, we expect operating cash flow of $825 million and capital expenditures of $200 million, about $60 million over fiscal year '16, mostly due to the investment in the second nucleic acid facility.
Now finally, moving to the guidance for our first quarter. First, please note that Lunar New Year falls in Q1 this year versus Q2 last year, meaning about $15 million of revenue shifting from Q1 to Q2. We expect Q1 revenues of $1.04 billion to $1.06 billion and EPS of $0.48 to $0.50. At midpoint, revenue will grow 2.2% on a core basis and EPS will grow 7%. And as customary, Q1 EPS is negatively impacted by the December salary increase, front loading of stock-based compensation and the increase in payroll taxes due to the disbursement of the variable and incentive pay of the previous year. 
With that, I'll turn it over to Alicia for the Q&A."
154924,407124595,1088180,"Agilent Technologies, Inc., Q4 2016 Earnings Call, Nov 15, 2016",2016-11-15,"Earnings Calls","Agilent Technologies, Inc.","Executives","Thank you, Didier. Karen, will you please give the instructions for the Q&A.",13,"Thank you, Didier. Karen, will you please give the instructions for the Q&A."
154924,407124595,1088180,"Agilent Technologies, Inc., Q4 2016 Earnings Call, Nov 15, 2016",2016-11-15,"Earnings Calls","Agilent Technologies, Inc.","Operator","[Operator Instructions] Our first question comes from the line of Steve Beuchaw from Morgan Stanley.",15,"[Operator Instructions] Our first question comes from the line of Steve Beuchaw from Morgan Stanley."
154924,407124595,1088180,"Agilent Technologies, Inc., Q4 2016 Earnings Call, Nov 15, 2016",2016-11-15,"Earnings Calls","Agilent Technologies, Inc.","Analysts","First question for me is I wonder if you could just juxtapose your results against what we've heard from others in the category over the last several weeks. I mean, it sounds like a particularly strong category by number -- quarter by number of metrics. Y",99,"First question for me is I wonder if you could just juxtapose your results against what we've heard from others in the category over the last several weeks. I mean, it sounds like a particularly strong category by number -- quarter by number of metrics. You actually accelerated while we saw a number of others decelerate in terms of organic growth in the quarter. Can you give us, from a high level, what you think are the keys there in terms of positioning? Why it is the quarter was so good for you guys relative to the market?"
154924,407124595,1088180,"Agilent Technologies, Inc., Q4 2016 Earnings Call, Nov 15, 2016",2016-11-15,"Earnings Calls","Agilent Technologies, Inc.","Executives","Yes, thanks, Steve. The headline for me was as we looked throughout the quarter, we were winning more business than we planned. So we're winning a lot of business in our core markets. I think some of the end-market strength that we planned too was actuall",135,"Yes, thanks, Steve. The headline for me was as we looked throughout the quarter, we were winning more business than we planned. So we're winning a lot of business in our core markets. I think some of the end-market strength that we planned too was actually fairly similar to what I've seen other people comment on relative to the strength of China, strength of pharma, continued subdued but kind of a stable academia and government environment. And for us, I think we were just delighted by our performance, in particular, in our analytical instrument business where we seem to be winning more business than we planned and we think that bodes well for the strength of our portfolio and some of the things we've been doing over the last year in our channels as well."
154924,407124595,1088180,"Agilent Technologies, Inc., Q4 2016 Earnings Call, Nov 15, 2016",2016-11-15,"Earnings Calls","Agilent Technologies, Inc.","Analysts","And then so the follow-up, I guess, just to dig a little deeper would be, did you notice anything in terms of instrument trends relative to consumables trends accelerating or decelerating? And what is that telling you about end of year, I should say end o",51,"And then so the follow-up, I guess, just to dig a little deeper would be, did you notice anything in terms of instrument trends relative to consumables trends accelerating or decelerating? And what is that telling you about end of year, I should say end of calendar year budget flush?"
154924,407124595,1088180,"Agilent Technologies, Inc., Q4 2016 Earnings Call, Nov 15, 2016",2016-11-15,"Earnings Calls","Agilent Technologies, Inc.","Executives","Yes, we were talking a bit about this yesterday with the team. And if you look at our performance through the quarter, we got off to a strong start in August and it continued throughout the quarter. And sometimes, it's hard to tell over first month where",95,"Yes, we were talking a bit about this yesterday with the team. And if you look at our performance through the quarter, we got off to a strong start in August and it continued throughout the quarter. And sometimes, it's hard to tell over first month where things are going to land for the quarter. But I'd say by the end of September, we knew we are winning more business than we planned. And it's really shaping up to be a strong quarter for us and really position us well for us going into 2017."
154924,407124595,1088180,"Agilent Technologies, Inc., Q4 2016 Earnings Call, Nov 15, 2016",2016-11-15,"Earnings Calls","Agilent Technologies, Inc.","Operator","And our next question comes from the line of Tycho Peterson from JPMorgan.",13,"And our next question comes from the line of Tycho Peterson from JPMorgan."
154924,407124595,1088180,"Agilent Technologies, Inc., Q4 2016 Earnings Call, Nov 15, 2016",2016-11-15,"Earnings Calls","Agilent Technologies, Inc.","Analysts","Mike, just hoping for a little bit more color on some of the expectations and guidance in particular around pharma. Are you still assuming that's kind of double-digit growth next year? Or are you factoring in a moderation? And on environmental, you manage",78,"Mike, just hoping for a little bit more color on some of the expectations and guidance in particular around pharma. Are you still assuming that's kind of double-digit growth next year? Or are you factoring in a moderation? And on environmental, you managed to grow that business in contrast to what we saw from one of your peers last week. So maybe talk a little bit about contributions from the DC replacement cycle for next year as well."
154924,407124595,1088180,"Agilent Technologies, Inc., Q4 2016 Earnings Call, Nov 15, 2016",2016-11-15,"Earnings Calls","Agilent Technologies, Inc.","Executives","Yes, sure. Tycho, you broke up a bit on the call. So if I don't get to the specific questions, please come back to me. But I think relative to the expectations for end market kind of thinking for growth rate, we had pharma below the double-digit growth th",107,"Yes, sure. Tycho, you broke up a bit on the call. So if I don't get to the specific questions, please come back to me. But I think relative to the expectations for end market kind of thinking for growth rate, we had pharma below the double-digit growth that have been placed in '16. So as we look at our end markets, we would expect a moderation of growth, not because the spends are going to go away, but you really are going to start to get into tough compares. And, Didier, if I remember correctly, we were in the mid- to high single-digit growth for pharma?"
154924,407124595,1088180,"Agilent Technologies, Inc., Q4 2016 Earnings Call, Nov 15, 2016",2016-11-15,"Earnings Calls","Agilent Technologies, Inc.","Executives","Yes.",1,"Yes."
154924,407124595,1088180,"Agilent Technologies, Inc., Q4 2016 Earnings Call, Nov 15, 2016",2016-11-15,"Earnings Calls","Agilent Technologies, Inc.","Executives","And then I think the story -- I think, Tycho, the question was around environmental.",15,"And then I think the story -- I think, Tycho, the question was around environmental."
154924,407124595,1088180,"Agilent Technologies, Inc., Q4 2016 Earnings Call, Nov 15, 2016",2016-11-15,"Earnings Calls","Agilent Technologies, Inc.","Analysts","Yes, and the GC replacement cycle.",6,"Yes, and the GC replacement cycle."
154924,407124595,1088180,"Agilent Technologies, Inc., Q4 2016 Earnings Call, Nov 15, 2016",2016-11-15,"Earnings Calls","Agilent Technologies, Inc.","Executives","Yes, so in environmental, the story really there is China. And we think that's got many quarters in front of us of growth in China. And we -- as you know, I'm fairly bullish on the prospects of that market. And I think we've got kind of a perfect storm he",198,"Yes, so in environmental, the story really there is China. And we think that's got many quarters in front of us of growth in China. And we -- as you know, I'm fairly bullish on the prospects of that market. And I think we've got kind of a perfect storm here going on where we have strong products going into -- in the growing markets. Relative to the GC replacement cycle, this is really about what's going to happen in the chemical and energy market. And I'll make a few comments here, then, Patrick, you may want to provide your perspective as well. So you may have noticed in my call script, I went kind of out my way to talk about a measured ramp-up of our new Intuvo GC because we think we've got a winner product on our hands. We know there's a lot of interest from customers. But we also recognize the reality of constraints they may have in their capital budgets. I know they're working with their own management teams internally of these companies about what they may get in terms of funding in 2017. What are your thoughts, Patrick, on that as well?"
154924,407124595,1088180,"Agilent Technologies, Inc., Q4 2016 Earnings Call, Nov 15, 2016",2016-11-15,"Earnings Calls","Agilent Technologies, Inc.","Executives","Yes, thanks, Mike. Looking at the GC market, we definitely are positioned very well to capture any growth opportunity there. We have launched the Intuvo, which is a strong message to all our customers that we are standing behind them when it comes to driv",169,"Yes, thanks, Mike. Looking at the GC market, we definitely are positioned very well to capture any growth opportunity there. We have launched the Intuvo, which is a strong message to all our customers that we are standing behind them when it comes to drive for lower cost of measurement, when it comes to lower cost of ownership, when it comes to increased productivity and it positions us clearly as the market leader in gas chromatography. So we are in a lot of discussions with them, not only on Intuvo, but I think what the Intuvo launch did for us, we also -- it also spread a lot of discussion again about other -- of our other part of portfolio to 7890 and other products, which are market-leading products. And again, the discussion with the customers in the suppressed market is all about how can we help them increasing their productivity, driving their cost of analysis down and this is where we are exceptionally well positioned with this portfolio."
154924,407124595,1088180,"Agilent Technologies, Inc., Q4 2016 Earnings Call, Nov 15, 2016",2016-11-15,"Earnings Calls","Agilent Technologies, Inc.","Executives","Yes, maybe just to up an exclamation point on this is that we know that the installed base is at historic levels of aging. We know the equipment is being used. And it's just a matter time for that replacement cycle is going to turn on. But as you saw in m",61,"Yes, maybe just to up an exclamation point on this is that we know that the installed base is at historic levels of aging. We know the equipment is being used. And it's just a matter time for that replacement cycle is going to turn on. But as you saw in my call comments, we're not ready to call that yet."
154924,407124595,1088180,"Agilent Technologies, Inc., Q4 2016 Earnings Call, Nov 15, 2016",2016-11-15,"Earnings Calls","Agilent Technologies, Inc.","Analysts","Okay. And then just one clarification on the operating margin guidance. Half of the cut, you're down about 1% from what you talked about the Analyst Day, half of that is from iLab, pension and FX, is the rest just conservatism, given kind of the macro?",46,"Okay. And then just one clarification on the operating margin guidance. Half of the cut, you're down about 1% from what you talked about the Analyst Day, half of that is from iLab, pension and FX, is the rest just conservatism, given kind of the macro?"
154924,407124595,1088180,"Agilent Technologies, Inc., Q4 2016 Earnings Call, Nov 15, 2016",2016-11-15,"Earnings Calls","Agilent Technologies, Inc.","Executives","Yes, actually, I think where we had was the high end of our guidance is around 21.5%, right, Didier? And...",20,"Yes, actually, I think where we had was the high end of our guidance is around 21.5%, right, Didier? And..."
154924,407124595,1088180,"Agilent Technologies, Inc., Q4 2016 Earnings Call, Nov 15, 2016",2016-11-15,"Earnings Calls","Agilent Technologies, Inc.","Executives","So yes, we -- with the high end is at 21.5%, and we are losing about 50 basis points related to the 3 items that were mentioned: currency, acquisition and pension expenses. And the other thing to note is, as Mike has clearly stated, we are still being mea",58,"So yes, we -- with the high end is at 21.5%, and we are losing about 50 basis points related to the 3 items that were mentioned: currency, acquisition and pension expenses. And the other thing to note is, as Mike has clearly stated, we are still being measured on achieving 22% in terms of our variable compensation."
154924,407124595,1088180,"Agilent Technologies, Inc., Q4 2016 Earnings Call, Nov 15, 2016",2016-11-15,"Earnings Calls","Agilent Technologies, Inc.","Executives","Yes, and the way Didier and I talked about this one was listen, we think we've got a path to 22%. But there's lot of higher risks than there was back at the last call and at the May AID. So we thought it was prudent for us to guide this way. But we're all",66,"Yes, and the way Didier and I talked about this one was listen, we think we've got a path to 22%. But there's lot of higher risks than there was back at the last call and at the May AID. So we thought it was prudent for us to guide this way. But we're all out inside, all our comp is tied to the 22% number."
154924,407124595,1088180,"Agilent Technologies, Inc., Q4 2016 Earnings Call, Nov 15, 2016",2016-11-15,"Earnings Calls","Agilent Technologies, Inc.","Executives","With the 3 elements that were clear headwinds.",8,"With the 3 elements that were clear headwinds."
154924,407124595,1088180,"Agilent Technologies, Inc., Q4 2016 Earnings Call, Nov 15, 2016",2016-11-15,"Earnings Calls","Agilent Technologies, Inc.","Operator","And our next question comes from the line of Ross Muken from Evercore ISI.",14,"And our next question comes from the line of Ross Muken from Evercore ISI."
154924,407124595,1088180,"Agilent Technologies, Inc., Q4 2016 Earnings Call, Nov 15, 2016",2016-11-15,"Earnings Calls","Agilent Technologies, Inc.","Analysts","This is Luke in for Ross. Just hoping you could give a little more color on your margin assumption for next year? What you guys are thinking about pacing the FX headwinds, if any, what's going to be operational, what's pricing, et cetera?",43,"This is Luke in for Ross. Just hoping you could give a little more color on your margin assumption for next year? What you guys are thinking about pacing the FX headwinds, if any, what's going to be operational, what's pricing, et cetera?"
154924,407124595,1088180,"Agilent Technologies, Inc., Q4 2016 Earnings Call, Nov 15, 2016",2016-11-15,"Earnings Calls","Agilent Technologies, Inc.","Executives","I think the question, Didier, was relative to the composition of our operating margin improvements for next year. And perhaps we can start with the mix between volume and OpEx and gross margins.",33,"I think the question, Didier, was relative to the composition of our operating margin improvements for next year. And perhaps we can start with the mix between volume and OpEx and gross margins."
154924,407124595,1088180,"Agilent Technologies, Inc., Q4 2016 Earnings Call, Nov 15, 2016",2016-11-15,"Earnings Calls","Agilent Technologies, Inc.","Executives","Yes, I mean, the -- I mean, I'm not going to give you the full bridge. I mean, when we provided the guidance of 21% to 21.5%, we took into account obviously, the -- all the impacts that I've mentioned. So there is -- it's based on the 4.3% core revenue gr",157,"Yes, I mean, the -- I mean, I'm not going to give you the full bridge. I mean, when we provided the guidance of 21% to 21.5%, we took into account obviously, the -- all the impacts that I've mentioned. So there is -- it's based on the 4.3% core revenue growth. So there is clearly an operating leverage impact. And a lot, a lot of actions that are taking place to offset inflation and other headwinds that partly I have mentioned. The guidance assumes some level of increase improvements in gross margins as well as a reduction in terms of our -- the OpEx as a percentage of revenue. So you have a pretty much on all fronts, some improvements, not as much as we had initially anticipated because of the 3 headwinds that I've mentioned. Some of it related to operating leverage and some of it related to the continuation of our Agile Agilent programs."
154924,407124595,1088180,"Agilent Technologies, Inc., Q4 2016 Earnings Call, Nov 15, 2016",2016-11-15,"Earnings Calls","Agilent Technologies, Inc.","Executives","And maybe just reminding the audience, Didier. When we first started this march almost 2 years ago to go to the 22%, we laid out a path, which is really around 60% was going to be on volume, the other 40% was going to be on OpEx improvements in gross marg",64,"And maybe just reminding the audience, Didier. When we first started this march almost 2 years ago to go to the 22%, we laid out a path, which is really around 60% was going to be on volume, the other 40% was going to be on OpEx improvements in gross margin. And I think we're thinking about the same kind of mix for 2017."
154924,407124595,1088180,"Agilent Technologies, Inc., Q4 2016 Earnings Call, Nov 15, 2016",2016-11-15,"Earnings Calls","Agilent Technologies, Inc.","Executives","That's right, yes. Absolutely.",5,"That's right, yes. Absolutely."
154924,407124595,1088180,"Agilent Technologies, Inc., Q4 2016 Earnings Call, Nov 15, 2016",2016-11-15,"Earnings Calls","Agilent Technologies, Inc.","Analysts","Okay, great. And I guess just one more. You guys did really well on the cash flow in '16. I think $647 million and you're guiding for $625 million. Is there any timing impact on that '17 guide? And then, I guess, on the tax of '17, kind of what are you ba",58,"Okay, great. And I guess just one more. You guys did really well on the cash flow in '16. I think $647 million and you're guiding for $625 million. Is there any timing impact on that '17 guide? And then, I guess, on the tax of '17, kind of what are you baking into that benefit down there?"
154924,407124595,1088180,"Agilent Technologies, Inc., Q4 2016 Earnings Call, Nov 15, 2016",2016-11-15,"Earnings Calls","Agilent Technologies, Inc.","Executives","So I assume when you refer to timing impact, you're referring to special -- I mean between '16 and '17, some cash outlays only that couldâ¦",26,"So I assume when you refer to timing impact, you're referring to special -- I mean between '16 and '17, some cash outlays only that couldâ¦"
154924,407124595,1088180,"Agilent Technologies, Inc., Q4 2016 Earnings Call, Nov 15, 2016",2016-11-15,"Earnings Calls","Agilent Technologies, Inc.","Analysts","Yes, correct.",2,"Yes, correct."
154924,407124595,1088180,"Agilent Technologies, Inc., Q4 2016 Earnings Call, Nov 15, 2016",2016-11-15,"Earnings Calls","Agilent Technologies, Inc.","Executives","Yes, there's a little bit. I mean, let me just highlight 2 potentially. This -- in fiscal year '16, we disbursed $66 million for overall Agilent variable pay and pay for results. Next year, we -- but we've changed our program so that we now do a lot of th",218,"Yes, there's a little bit. I mean, let me just highlight 2 potentially. This -- in fiscal year '16, we disbursed $66 million for overall Agilent variable pay and pay for results. Next year, we -- but we've changed our program so that we now do a lot of the cash outlays on an annual basis instead of semi-annual. So we have the full brunt in '17 of improvements in '16 and the fact that we're going to pay in '17 something that is more than pertaining to '16. So it's going to be $91 million; going from $66 million to $91 million. So an increased capital cash outlay. And then second, we did not fund our U.S. pension plan in '16. So our overall contributions to our worldwide pension plan was $24 million. We intend to fund our U.S. pension plan more in '17 and the contribution to the pension plan will move to $45 million. So an increase from $24 million to $45 million. So that -- those are the 2 things that come to mind in terms of explaining some of the variance between '16 and 17. But even with those 2 headwinds, we are still showing, in our initial guidance, a nice increase of $30 million on a year-over-year basis. And your second question?"
154924,407124595,1088180,"Agilent Technologies, Inc., Q4 2016 Earnings Call, Nov 15, 2016",2016-11-15,"Earnings Calls","Agilent Technologies, Inc.","Executives","Related to tax rates.",4,"Related to tax rates."
154924,407124595,1088180,"Agilent Technologies, Inc., Q4 2016 Earnings Call, Nov 15, 2016",2016-11-15,"Earnings Calls","Agilent Technologies, Inc.","Executives","Yes, on the tax rates, I did mention at the May Analyst Day that we were going to work really hard on the reducing our tax rate by 2 percentage points over the course of the next 2 to 3 years. We are very happy to be able to deliver already 1 percentage p",150,"Yes, on the tax rates, I did mention at the May Analyst Day that we were going to work really hard on the reducing our tax rate by 2 percentage points over the course of the next 2 to 3 years. We are very happy to be able to deliver already 1 percentage point in this fiscal year '16. We still are aiming to reduce our effective tax rate by other 1 percentage points over the course of the next 24 months as committed to or as indicated, I would say, in fiscal year -- in -- at the AID. But it's prudent to assume that the reduction will come in fiscal year '18 and not in fiscal year '17. So in your models, we advise you to put a 1 percentage point's reduction in tax rate from 19% to 18% in fiscal year '18, not in fiscal year '17."
154924,407124595,1088180,"Agilent Technologies, Inc., Q4 2016 Earnings Call, Nov 15, 2016",2016-11-15,"Earnings Calls","Agilent Technologies, Inc.","Analysts","Okay. And does that include the FASB 2016-09 benefit?",9,"Okay. And does that include the FASB 2016-09 benefit?"
154924,407124595,1088180,"Agilent Technologies, Inc., Q4 2016 Earnings Call, Nov 15, 2016",2016-11-15,"Earnings Calls","Agilent Technologies, Inc.","Executives","It includes everything.",3,"It includes everything."
154924,407124595,1088180,"Agilent Technologies, Inc., Q4 2016 Earnings Call, Nov 15, 2016",2016-11-15,"Earnings Calls","Agilent Technologies, Inc.","Operator","And our next question comes from the line of Doug Schenkel from Cowen and Company.",15,"And our next question comes from the line of Doug Schenkel from Cowen and Company."
154924,407124595,1088180,"Agilent Technologies, Inc., Q4 2016 Earnings Call, Nov 15, 2016",2016-11-15,"Earnings Calls","Agilent Technologies, Inc.","Analysts","This is Ryan Blicker on for Doug. Would you be willing to provide what your LC/MS growth was in the quarter? And how that was impacted by the comparison relative to recent quarters and maybe what your annual growth was there?",41,"This is Ryan Blicker on for Doug. Would you be willing to provide what your LC/MS growth was in the quarter? And how that was impacted by the comparison relative to recent quarters and maybe what your annual growth was there?"
154924,407124595,1088180,"Agilent Technologies, Inc., Q4 2016 Earnings Call, Nov 15, 2016",2016-11-15,"Earnings Calls","Agilent Technologies, Inc.","Executives","What I can tell you is that -- back to my earlier statement, is that we're winning more business that planned. So we're quite pleased with how we've been doing with the LC/MS portfolio. And, Patrick, you may just want to remind the audience of some of the",96,"What I can tell you is that -- back to my earlier statement, is that we're winning more business that planned. So we're quite pleased with how we've been doing with the LC/MS portfolio. And, Patrick, you may just want to remind the audience of some of the new stuff that we've come out with. So I guess, I'm not comfortable giving the specific of the growth rate. But just giving you a sense of trend of the business and maybe a few proof points of why we believe it's going as well as it is."
154924,407124595,1088180,"Agilent Technologies, Inc., Q4 2016 Earnings Call, Nov 15, 2016",2016-11-15,"Earnings Calls","Agilent Technologies, Inc.","Executives","Sure, again, I'm confident that we are outgrowing the market on many fronts. And we have a very strong LC/MS portfolio. We launched a lot of exciting products at ASMS this year. And I think the reception of the market just underlines our strength. The com",118,"Sure, again, I'm confident that we are outgrowing the market on many fronts. And we have a very strong LC/MS portfolio. We launched a lot of exciting products at ASMS this year. And I think the reception of the market just underlines our strength. The combination of LC and LC/MS is important, and we think both are winning platforms. We see strong adoption across all the end markets. If there was one market where we have seen some headwind, then it was probably at the pain management market segment. But that is also in line with what you probably have heard with some of our competitors. But overall, we have been very pleased with the result in Q4."
154924,407124595,1088180,"Agilent Technologies, Inc., Q4 2016 Earnings Call, Nov 15, 2016",2016-11-15,"Earnings Calls","Agilent Technologies, Inc.","Analysts","Okay, that's helpful. And then it seems like there could be a repatriation holiday of some sort in 2017. I believe over 90% of your cash is currently trapped internationally. Can you provide any initial thoughts on how you would you prioritize repatriated",53,"Okay, that's helpful. And then it seems like there could be a repatriation holiday of some sort in 2017. I believe over 90% of your cash is currently trapped internationally. Can you provide any initial thoughts on how you would you prioritize repatriated cash, specifically on M&A opportunities and returning capital to shareholders?"
154924,407124595,1088180,"Agilent Technologies, Inc., Q4 2016 Earnings Call, Nov 15, 2016",2016-11-15,"Earnings Calls","Agilent Technologies, Inc.","Executives","Yes, sure, Ryan. So Didier, how about I make a few initial comments and then if you wanted to add anything to it. But, firstly, I think we also need to put a series of caveats on my response because we really don't know what this might look like. What str",291,"Yes, sure, Ryan. So Didier, how about I make a few initial comments and then if you wanted to add anything to it. But, firstly, I think we also need to put a series of caveats on my response because we really don't know what this might look like. What strings might be attached to, how you can use it, whether you can use cash in a certain way. But obviously, we would welcome this type of development, including a move to a more permanent reduction in U.S. corporate tax rates. That being said, I think if you go beyond the theory, I assume with those caveats, I think what you'd expect us to do is handle the return to cash very much along the lines of how we're managing our current use of capital. So we would want to use it for U.S.-based M&A, and we'd like to use that in situation where we've been using debt, such as our share repurchases so we would able to finance our share repurchases. And then we might look at our debt structure. But I think what we want to do is, first of all, obviously, understand what are the restrictions that could be tied to it. Also remind the group that some of the cash does need to remain permanently investment overseas. But we were -- if that particular situation would develop, we would like -- we would bring it back and use the cash very much along the lines how we've been using cash with the exception is I won't need to borrow money like I've done in the past for U.S.-based M&A or stock repurchases. I guess you might be okay with that, Didier. You haven't said anything else. Okay."
154924,407124595,1088180,"Agilent Technologies, Inc., Q4 2016 Earnings Call, Nov 15, 2016",2016-11-15,"Earnings Calls","Agilent Technologies, Inc.","Executives","Absolutely. Absolutely. I was just waiting for his bated breath for the fine lines on the -- any chance, but yes.",21,"Absolutely. Absolutely. I was just waiting for his bated breath for the fine lines on the -- any chance, but yes."
154924,407124595,1088180,"Agilent Technologies, Inc., Q4 2016 Earnings Call, Nov 15, 2016",2016-11-15,"Earnings Calls","Agilent Technologies, Inc.","Operator","And our next question comes from the line of Jonathan Groberg from UBS.",13,"And our next question comes from the line of Jonathan Groberg from UBS."
154924,407124595,1088180,"Agilent Technologies, Inc., Q4 2016 Earnings Call, Nov 15, 2016",2016-11-15,"Earnings Calls","Agilent Technologies, Inc.","Analysts","Mike, so I was just going back and looking, you did 6% growth organically for last year, 6% this year in '16. Just at a high level, you had some pretty tough, tough businesses and some of the industrial business this year and still put up 6%. I guess I'm",105,"Mike, so I was just going back and looking, you did 6% growth organically for last year, 6% this year in '16. Just at a high level, you had some pretty tough, tough businesses and some of the industrial business this year and still put up 6%. I guess I'm just wondering, as you look out to '17, are there some initial thoughts you have around the election from an end-market standpoint, outside of tax, that make you incrementally concerned? Is there -- maybe just high level of kind of what makes you think you're going to get that kind of 150 bps slowdown year-over-year."
154924,407124595,1088180,"Agilent Technologies, Inc., Q4 2016 Earnings Call, Nov 15, 2016",2016-11-15,"Earnings Calls","Agilent Technologies, Inc.","Executives","Yes. So great question, Jon, and thanks for that and obviously, we've spent a lot of time talking about this as a team and I mentioned to Alicia before the call, I think we may be the first company in our space that had to do guidance after the U.S. elect",519,"Yes. So great question, Jon, and thanks for that and obviously, we've spent a lot of time talking about this as a team and I mentioned to Alicia before the call, I think we may be the first company in our space that had to do guidance after the U.S. election. So what I'm going to tell you is the kind of factors we're thinking about. And then also give you maybe some little bit more thinking about why we guided the growth rate we did as a company. But we don't yet have a position on these issues. What we do know is there's a multitude of factors that we need to pay attention to. Regulated markets, what's going to happen to other customers in the food markets, the environmental markets, the drug -- the FDA regulatory markets? So we know there's going to be a customer impact. What's going to happen with U.S. government funding? A lot of our business is driven by U.S. government funding. What's going to happen with trade agreements? There's been a lot of noise about Chinese currency. We just talked about the tax. And will the M&A environment change in terms of -- so all I can say right now, Jonathan, is perhaps, like everybody else on this call, we kind of had a sense of the issues, but we don't know which ways these things are going to go yet, so we're not going to call them. And we're just going to -- and that's one of the reasons why we took what we believe to be a prudent, cautious initial guide to FY '17. If I look at the end markets, I mean, pharma's going to continue to be strong. But we don't believe that it can continue to grow in double digits throughout all of FY '17. So we've tapered down our expectations a bit about pharma. We also think that China has been just a -- just fantastic for us. I think our number for the year was 21% growth for the year; I'm dialing that back a bit to double digit. So what we're doing is really just trying to moderate our view of growth for next year based on what we've seen to be some pretty difficult comparisons in some markets that really have been driving the business. As I mentioned to you, the wildcard is the turn on energy. One of the things that you pointed out, Jonathan, and what I'm really delighted is, we've had 6%, close to 6% growth, 2 years in a row with our #2 market declining for 8 quarters. When that market turns, that obviously will help us in the growth.  So -- but I've learned over the first 2 years in this job, it's really hard to call in terms of major markets. So I'm not going to. And we'll just kind of keep an eye on it, and we'll update you as we go through the year, but that's our thinking about how we're viewing the U.S. election and the thought behind our end-market guidance for next year."
154924,407124595,1088180,"Agilent Technologies, Inc., Q4 2016 Earnings Call, Nov 15, 2016",2016-11-15,"Earnings Calls","Agilent Technologies, Inc.","Analysts","And if I could just -- one more on the diagnostic and clinical market?",14,"And if I could just -- one more on the diagnostic and clinical market?"
154924,407124595,1088180,"Agilent Technologies, Inc., Q4 2016 Earnings Call, Nov 15, 2016",2016-11-15,"Earnings Calls","Agilent Technologies, Inc.","Executives","Yes, Jacob's been dying to answer a question.",8,"Yes, Jacob's been dying to answer a question."
154924,407124595,1088180,"Agilent Technologies, Inc., Q4 2016 Earnings Call, Nov 15, 2016",2016-11-15,"Earnings Calls","Agilent Technologies, Inc.","Analysts","Yes, so obviously, another -- you have 8% growth there. Obviously, you're probably going to say too early to think about how hospitals may react to the potential repeal of the ACA. But how about the PD-L1 testing business, how much of your growth was driv",60,"Yes, so obviously, another -- you have 8% growth there. Obviously, you're probably going to say too early to think about how hospitals may react to the potential repeal of the ACA. But how about the PD-L1 testing business, how much of your growth was driven by that market? And any -- can you size that market for us yet?"
154924,407124595,1088180,"Agilent Technologies, Inc., Q4 2016 Earnings Call, Nov 15, 2016",2016-11-15,"Earnings Calls","Agilent Technologies, Inc.","Executives","Well, it's -- I can start by saying that we have been very pleased with the performance of the PD-L1 over the last 12 months, I think it's 13 months now. And it has growing, if not to our expectation, then above even. And we expect that to continue to gro",248,"Well, it's -- I can start by saying that we have been very pleased with the performance of the PD-L1 over the last 12 months, I think it's 13 months now. And it has growing, if not to our expectation, then above even. And we expect that to continue to grow now based on KEYTRUDA going first line. And obviously, now with our companion diagnostic, we will see a bigger demand for it here in U.S., in Europe and in other regions. The market itself is very difficult to size. As you know, there's both been the companion with 1 drug and then there has been the complementary with another drug, and those have very different sizes at this point of time. I still believe that the overall PD-L1 market might end up in the same size as the HER2 market. But the difference is that HER2 is the only one -- one -- basically, one drug, one class of drug, together with one diagnostics, where the PD-L1 will be up to 5 different drugs, maybe more and 5 different diagnostic, maybe even for a lot of indications also. So this is as close as I can get to right now. The market we place in is -- or the 2 companion diagnostics that we have today continues to grow strongly. I won't say that that's the overall arching driver for the 8%. Basically, all our businesses today have a very nice growth performance, but it's definitely contributing."
154924,407124595,1088180,"Agilent Technologies, Inc., Q4 2016 Earnings Call, Nov 15, 2016",2016-11-15,"Earnings Calls","Agilent Technologies, Inc.","Operator","And our next question comes from line of Derik De Bruin from Bank of America.",15,"And our next question comes from line of Derik De Bruin from Bank of America."
154924,407124595,1088180,"Agilent Technologies, Inc., Q4 2016 Earnings Call, Nov 15, 2016",2016-11-15,"Earnings Calls","Agilent Technologies, Inc.","Analysts","The pace in the quarter was very good. Can you talk a little bit about backlog and, I guess, did you pull -- are you worried that you pulled anything from the first quarter in? I mean, any unusual spending patterns that you thought?",44,"The pace in the quarter was very good. Can you talk a little bit about backlog and, I guess, did you pull -- are you worried that you pulled anything from the first quarter in? I mean, any unusual spending patterns that you thought?"
154924,407124595,1088180,"Agilent Technologies, Inc., Q4 2016 Earnings Call, Nov 15, 2016",2016-11-15,"Earnings Calls","Agilent Technologies, Inc.","Executives","Yes, thanks for the question, Derik. So as I mentioned earlier, we saw strength throughout the quarter. And we were quite delighted with the results. And we're not specifically commenting about orders or backlogs. But I did say in my early comments that w",158,"Yes, thanks for the question, Derik. So as I mentioned earlier, we saw strength throughout the quarter. And we were quite delighted with the results. And we're not specifically commenting about orders or backlogs. But I did say in my early comments that we're well positioned for 2017. I would ask you to think about the Q1, particularly the impact of Chinese Lunar New Year. I told Didier, I said, don't want to talk about it in the Q1 call. So let's make sure that we include it in our guide. So that is the one thing that I would ask you to think about in terms of the next 3 months of the company's performance. Because we think we'll probably push about a week's worth of revenue or so from Q1 to Q2 because customers just won't be there to take delivery, and as you saw, the growth rates have been really exceptional for us in China."
154924,407124595,1088180,"Agilent Technologies, Inc., Q4 2016 Earnings Call, Nov 15, 2016",2016-11-15,"Earnings Calls","Agilent Technologies, Inc.","Analysts","So I'm going to -- I appreciate the New Year's comment. So I'm actually going to follow that up with another question. It's like are you -- have you had any conversations with your customers that -- I mean, obviously, you're not the only ones trying to fi",100,"So I'm going to -- I appreciate the New Year's comment. So I'm actually going to follow that up with another question. It's like are you -- have you had any conversations with your customers that -- I mean, obviously, you're not the only ones trying to figure out what the new world order is in terms of how spending is going to be. Are you worried at all about potential in terms of lower CapEx spending, lower spending beginning of the year as people try to get their arms around what exactly the new administration has in store?"
154924,407124595,1088180,"Agilent Technologies, Inc., Q4 2016 Earnings Call, Nov 15, 2016",2016-11-15,"Earnings Calls","Agilent Technologies, Inc.","Executives","No, actually, we don't have that concern. What we've been more thinking about is where's the thing going long term. So -- but in the next quarter, we don't have any real concerns about that. So -- and that's why we are doing a full year guidance here in N",81,"No, actually, we don't have that concern. What we've been more thinking about is where's the thing going long term. So -- but in the next quarter, we don't have any real concerns about that. So -- and that's why we are doing a full year guidance here in November. And it's really hard to see what's going to happen longer term throughout the year. But in the next quarter or so, we wouldn't expect that to have any significant impact."
154924,407124595,1088180,"Agilent Technologies, Inc., Q4 2016 Earnings Call, Nov 15, 2016",2016-11-15,"Earnings Calls","Agilent Technologies, Inc.","Operator","And our next question comes from the line of Paul Knight from Janney.",13,"And our next question comes from the line of Paul Knight from Janney."
154924,407124595,1088180,"Agilent Technologies, Inc., Q4 2016 Earnings Call, Nov 15, 2016",2016-11-15,"Earnings Calls","Agilent Technologies, Inc.","Analysts","This is actually Bill [ph] on behalf of Paul. Maybe just touching on China again. Could you maybe talk about what your underlying trends have been driving the outsize growth for the company. Is it biopharma? Is it food? Is it environmental? And how does t",53,"This is actually Bill [ph] on behalf of Paul. Maybe just touching on China again. Could you maybe talk about what your underlying trends have been driving the outsize growth for the company. Is it biopharma? Is it food? Is it environmental? And how does that impact as you look to next year?"
154924,407124595,1088180,"Agilent Technologies, Inc., Q4 2016 Earnings Call, Nov 15, 2016",2016-11-15,"Earnings Calls","Agilent Technologies, Inc.","Executives","Yes, thanks for the question. I have to say it really was across the board with one exception, which is the chemical and energy market. So all the other markets were up quite substantially for us. And I think this is consistent with what we had talked abo",248,"Yes, thanks for the question. I have to say it really was across the board with one exception, which is the chemical and energy market. So all the other markets were up quite substantially for us. And I think this is consistent with what we had talked about in prior calls, which is really there's going to be a level of investment in China relative to quality of life issues and in environmental, in food, lined up directly with their 5-year plan that they're in the midst of a major improvement in their overall pharma industry and that there's a lot of money going on to research. So -- and then I think the reason Agilent has been able to do so well here is we've got this combination of we've been working the organizational structure, the -- our channel model in the country. We've had a lot of stability over the last 18 months. So we've got a really strong team there. And that combination of the team, our historical strength in China and the new products we have, it's all coming together in terms of growth. And I guess, I maybe just add one thing and, Mark, perhaps, you can comment here. We often talk about the strength of end markets and the new products going to these end markets, but I think there's something going on relative to your business there and the move to services, I think, is worth a comment on as well."
154924,407124595,1088180,"Agilent Technologies, Inc., Q4 2016 Earnings Call, Nov 15, 2016",2016-11-15,"Earnings Calls","Agilent Technologies, Inc.","Executives","Thanks, Mike, and thanks, Bill [ph]. To add a little color to that is we've seen a fundamental shift in buying behaviors in China, largely shifting from the core areas and around Shanghai, Beijing, to some of the more Tier 2, Tier 3 cities, where services",152,"Thanks, Mike, and thanks, Bill [ph]. To add a little color to that is we've seen a fundamental shift in buying behaviors in China, largely shifting from the core areas and around Shanghai, Beijing, to some of the more Tier 2, Tier 3 cities, where services now is viewed as the commonplace purchasing item in China, and it's certainly driving the growth. But the breadth of services, I think, in China, as well as the consumables business now, is the rest of the story, where they have reached the size and scale that they have the same interest that we'd find in the Western markets around enterprise services and consumables all coming together. So starting, as you've mentioned, Mike, with our extraordinarily strong position to start with, the installed base of China has just allowed us to build the business and truly outgrow our expectations in the second half around this, too."
154924,407124595,1088180,"Agilent Technologies, Inc., Q4 2016 Earnings Call, Nov 15, 2016",2016-11-15,"Earnings Calls","Agilent Technologies, Inc.","Executives","Yes, I mentioned -- I ask Mark to comment on that because as you may recall, we really have changed the portfolio composition of the company, doing much more in the aftermarket. So cath lab instruments are actually less than 50% now of total company's rev",66,"Yes, I mentioned -- I ask Mark to comment on that because as you may recall, we really have changed the portfolio composition of the company, doing much more in the aftermarket. So cath lab instruments are actually less than 50% now of total company's revenue. And historically, China has been driven by new instrument purchases. We're seeing increasing growth also coming from services and consumables."
154924,407124595,1088180,"Agilent Technologies, Inc., Q4 2016 Earnings Call, Nov 15, 2016",2016-11-15,"Earnings Calls","Agilent Technologies, Inc.","Analysts","Great. And then just a follow-up for Didier on the guidance. CapEx up to about $200 million this year. Could you maybe just talk about where the incremental dollars are going and maybe what you think the maintenance CapEx is for Agilent as a whole?",45,"Great. And then just a follow-up for Didier on the guidance. CapEx up to about $200 million this year. Could you maybe just talk about where the incremental dollars are going and maybe what you think the maintenance CapEx is for Agilent as a whole?"
154924,407124595,1088180,"Agilent Technologies, Inc., Q4 2016 Earnings Call, Nov 15, 2016",2016-11-15,"Earnings Calls","Agilent Technologies, Inc.","Executives","Yes, the main reason for the increase, which is about $60 million, from $139 million this year to $200 million next year, is really the significant increase that we're planning in terms of our nucleic acid facilities, RNA-based therapeutics and -- in Colo",148,"Yes, the main reason for the increase, which is about $60 million, from $139 million this year to $200 million next year, is really the significant increase that we're planning in terms of our nucleic acid facilities, RNA-based therapeutics and -- in Colorado. So we had one facility. We're still expanding the capacity of that facility, but we are building and we just started a few weeks ago 20 miles away a second facility that will kind of double the capacity when it will be put in production end of 2018, 2019. So that is the main reason for the increase. And starting in 2018, we should start -- we will see a reduction in the CapEx. This is not the run rate. Our CapEx run rate is still between -- like between $100 million and $120 million per year. So this is way above our run rate."
154924,407124595,1088180,"Agilent Technologies, Inc., Q4 2016 Earnings Call, Nov 15, 2016",2016-11-15,"Earnings Calls","Agilent Technologies, Inc.","Operator","And our next question comes from the line of Jack Meehan from Barclays.",13,"And our next question comes from the line of Jack Meehan from Barclays."
154924,407124595,1088180,"Agilent Technologies, Inc., Q4 2016 Earnings Call, Nov 15, 2016",2016-11-15,"Earnings Calls","Agilent Technologies, Inc.","Analysts","I wanted to follow up on the diagnostics business. Really, I thought it was a nice quarter on a tough comp. I know you talked about the PD-L1. But just any -- I wanted to focus on the Omnis and just whether you think you're picking up steam into 2017 and",60,"I wanted to follow up on the diagnostics business. Really, I thought it was a nice quarter on a tough comp. I know you talked about the PD-L1. But just any -- I wanted to focus on the Omnis and just whether you think you're picking up steam into 2017 and anything worth watching on the reimbursement side with that?"
154924,407124595,1088180,"Agilent Technologies, Inc., Q4 2016 Earnings Call, Nov 15, 2016",2016-11-15,"Earnings Calls","Agilent Technologies, Inc.","Executives","Yes, Jack, thanks for the question. I think I'll pass it over to Jacob, maybe a little bit more color on the quarter results.",24,"Yes, Jack, thanks for the question. I think I'll pass it over to Jacob, maybe a little bit more color on the quarter results."
154924,407124595,1088180,"Agilent Technologies, Inc., Q4 2016 Earnings Call, Nov 15, 2016",2016-11-15,"Earnings Calls","Agilent Technologies, Inc.","Executives","Yes, it's -- we really continue to see overall in our ratings pickup definitely by Omnis that we see the growth is coming back. It's a nice momentum we're seeing and it continues to -- basically, it has continued to increase over -- during '16. So with th",119,"Yes, it's -- we really continue to see overall in our ratings pickup definitely by Omnis that we see the growth is coming back. It's a nice momentum we're seeing and it continues to -- basically, it has continued to increase over -- during '16. So with that momentum, we expect that we will continue to see a good performance into '17 also. From a reimbursement perspective, obviously, there are already some expectation how that will look like into '17 and '18 with the pharma and so on. But now we will have to see what happens under the new administration here whether that will change anything. But so far, we actually don't expect any significant changes into '17."
154924,407124595,1088180,"Agilent Technologies, Inc., Q4 2016 Earnings Call, Nov 15, 2016",2016-11-15,"Earnings Calls","Agilent Technologies, Inc.","Analysts","Great, that's helpful. And then I just wanted to follow up on the margin again. And just from our seat, what we should be watching? And what would push you to the 22% above level for this year? What are some of the actions that you think are going to be c",55,"Great, that's helpful. And then I just wanted to follow up on the margin again. And just from our seat, what we should be watching? And what would push you to the 22% above level for this year? What are some of the actions that you think are going to be critical for doing that?"
154924,407124595,1088180,"Agilent Technologies, Inc., Q4 2016 Earnings Call, Nov 15, 2016",2016-11-15,"Earnings Calls","Agilent Technologies, Inc.","Executives","Yes, I mean, Didier, feel free to augment my response here. But I think, obviously, it's going to be volume, which is about 60% of the margin improvement comes from volume. And the things that we can control, we're on top of. So it's really -- that's the",161,"Yes, I mean, Didier, feel free to augment my response here. But I think, obviously, it's going to be volume, which is about 60% of the margin improvement comes from volume. And the things that we can control, we're on top of. So it's really -- that's the one thing I can't control is what's going to happen in the market. So obviously, there's that 60% tied to margin. And then we've got some pretty big initiatives in the gross margin area, with our water fulfillment team. I think you may have heard me speak previously about some of our work in value engineering, material cost, reductions in logistics. So I think also we keep an eye on our gross margins as we work through the year. Some of the things take a while until actually they start coming through your P&L. But once they're there, they're there for extended period of time. And, Didier, anything else you'd add to that?"
154924,407124595,1088180,"Agilent Technologies, Inc., Q4 2016 Earnings Call, Nov 15, 2016",2016-11-15,"Earnings Calls","Agilent Technologies, Inc.","Executives","No, I mean, just that, I mean, we do have stretch goals. As we mentioned, we are paid internally on achieving 22%. And that means all of us have stretch goals to make -- to achieve that -- to contribute to the 22%. And OSS, under Henrik, the order fulfill",77,"No, I mean, just that, I mean, we do have stretch goals. As we mentioned, we are paid internally on achieving 22%. And that means all of us have stretch goals to make -- to achieve that -- to contribute to the 22%. And OSS, under Henrik, the order fulfillment and supply chain organization, which has delivered greatly in '16 is looking at opportunities to deliver even more in '17, which would help us bridge the gap."
154924,407124595,1088180,"Agilent Technologies, Inc., Q4 2016 Earnings Call, Nov 15, 2016",2016-11-15,"Earnings Calls","Agilent Technologies, Inc.","Executives","Yes. And thanks, Didier. I had one additional thought here is, I think it's important to remind everyone is that some of the things that are going to help in '17 have already been finished in '16. So things such as our simplification of our financial syst",60,"Yes. And thanks, Didier. I had one additional thought here is, I think it's important to remind everyone is that some of the things that are going to help in '17 have already been finished in '16. So things such as our simplification of our financial systems infrastructure. So it's done. And now the savings will show up in '17."
154924,407124595,1088180,"Agilent Technologies, Inc., Q4 2016 Earnings Call, Nov 15, 2016",2016-11-15,"Earnings Calls","Agilent Technologies, Inc.","Operator","And our next question comes from the line of Isaac Ro from Goldman Sachs.",14,"And our next question comes from the line of Isaac Ro from Goldman Sachs."
154924,407124595,1088180,"Agilent Technologies, Inc., Q4 2016 Earnings Call, Nov 15, 2016",2016-11-15,"Earnings Calls","Agilent Technologies, Inc.","Analysts","First question just quickly on the quarter. Curious if you could comment on pacing. You guys have the off-cycle calendar there with October. I'm sure everyone is curious if whether it was on the capital spending side or any particular end market you saw a",65,"First question just quickly on the quarter. Curious if you could comment on pacing. You guys have the off-cycle calendar there with October. I'm sure everyone is curious if whether it was on the capital spending side or any particular end market you saw a meaningful acceleration or deceleration in the month of October to the extent that portends the rest of the calendar year."
154924,407124595,1088180,"Agilent Technologies, Inc., Q4 2016 Earnings Call, Nov 15, 2016",2016-11-15,"Earnings Calls","Agilent Technologies, Inc.","Executives","No, Isaac, I just mentioned that what we saw was really strong pacing throughout the quarter. So it wasn't -- we didn't see something happen all of a sudden in the last 4 or 5 weeks. We had -- we had strength all through 3 quarters of our fiscal year clos",51,"No, Isaac, I just mentioned that what we saw was really strong pacing throughout the quarter. So it wasn't -- we didn't see something happen all of a sudden in the last 4 or 5 weeks. We had -- we had strength all through 3 quarters of our fiscal year close."
154924,407124595,1088180,"Agilent Technologies, Inc., Q4 2016 Earnings Call, Nov 15, 2016",2016-11-15,"Earnings Calls","Agilent Technologies, Inc.","Analysts","Got it. And then maybe a longer-term question, Mike, regarding management incentives. You guys have spent a lot of time over the last couple of years talking about the emphasis on hitting your margin goals and you guys have done that pretty well. So as yo",97,"Got it. And then maybe a longer-term question, Mike, regarding management incentives. You guys have spent a lot of time over the last couple of years talking about the emphasis on hitting your margin goals and you guys have done that pretty well. So as you move pass that 22% number, I was wondering how you think about evolving inside of structure for the management team? And should we assume that the types of incentives you have in place stay in place maybe with slightly different targets? Or could the overall composition evolve a little bit here?"
154924,407124595,1088180,"Agilent Technologies, Inc., Q4 2016 Earnings Call, Nov 15, 2016",2016-11-15,"Earnings Calls","Agilent Technologies, Inc.","Executives","Yes, Isaac, great, great question. And I would point back to what we discussed back at the May AID, where we really said, what this is really all about is generating superior earnings growth, right. So if you think about what we're trying to do here is we",226,"Yes, Isaac, great, great question. And I would point back to what we discussed back at the May AID, where we really said, what this is really all about is generating superior earnings growth, right. So if you think about what we're trying to do here is we're trying to outgrow the market, extend the operation margin to keep driving up our adjusted earnings per share growth. So what we'd like to be able to do is really that should be the focus of the team as we move forward. Operating margin expansion and capital deployment and your growth and market are all ways to get there. So we'd like to really be that have become the cornerstone of our long-term focus. And we want Agilent viewed as a company who grows their earnings faster than revenue. But as I mentioned in the AID is, I really want to also make sure that we don't get so focused on continuing to drive up the operating margin year in and year out that you pass on things that are immediately, say, accretive, maybe they're dilutive on your margins, but with good M&A additions to the business. So I think the way we're going to talk about the company post '17 is very consistent with what we had talked about back in the spring in New York City."
154924,407124595,1088180,"Agilent Technologies, Inc., Q4 2016 Earnings Call, Nov 15, 2016",2016-11-15,"Earnings Calls","Agilent Technologies, Inc.","Operator","And our next question comes from the line of Brandon Couillard from Jefferies.",13,"And our next question comes from the line of Brandon Couillard from Jefferies."
154924,407124595,1088180,"Agilent Technologies, Inc., Q4 2016 Earnings Call, Nov 15, 2016",2016-11-15,"Earnings Calls","Agilent Technologies, Inc.","Analysts","Most of my questions have been addressed. Mike, just curious what you're embedding for the government and academia market globally for next year and any color you can give us sort of regionally would be helpful.",36,"Most of my questions have been addressed. Mike, just curious what you're embedding for the government and academia market globally for next year and any color you can give us sort of regionally would be helpful."
154924,407124595,1088180,"Agilent Technologies, Inc., Q4 2016 Earnings Call, Nov 15, 2016",2016-11-15,"Earnings Calls","Agilent Technologies, Inc.","Executives","Yes, sure, Brandon. As we -- as I look through my notes here, I think we're expecting low single-digit growth. And I think it's important to kind of parse it out by academia and government. So we think that if we go by the major regions, right, China is g",271,"Yes, sure, Brandon. As we -- as I look through my notes here, I think we're expecting low single-digit growth. And I think it's important to kind of parse it out by academia and government. So we think that if we go by the major regions, right, China is going to be strong. And they've actually helped mitigate some of what's been happening in the U.S. and Europe. We're not expecting much in Europe. It's been down. It was down again, but not -- it was basically -- sort of almost feels like the chemical and energy market, which is kind of chugging along at a reduced rate. We're not expecting the governments there to do anything in terms of more stimulus. In fact, one of things we're watching is what are they going to do as a result of Brexit, for those of things. So we expect a strong China, academia and government. We expect a continuation of this current environment in Europe. In the United States, the academia side is not bad. It's what we've seen more has been more on the U.S. government side. The U.S. government -- our U.S. government business is down in 2016 relative to '15. And that's why in my call I mentioned, hey, we need to kind of see where this new administration goes with its budget plans and investment priorities. So right now, we're kind of standing on the sideline just saying it's going to continue to be just like it is, but -- in the United States. But we could see something different in a few months, we just don't know."
154924,407124595,1088180,"Agilent Technologies, Inc., Q4 2016 Earnings Call, Nov 15, 2016",2016-11-15,"Earnings Calls","Agilent Technologies, Inc.","Operator","And our next question comes from the line of Dan Arias from Citigroup.",13,"And our next question comes from the line of Dan Arias from Citigroup."
154924,407124595,1088180,"Agilent Technologies, Inc., Q4 2016 Earnings Call, Nov 15, 2016",2016-11-15,"Earnings Calls","Agilent Technologies, Inc.","Analysts","Mike, just sort of following up on the outlook. Kind of like how are you thinking about the pacing of growth in chemical and energy in '17? Is the assumption that you kind of see some sequential improvement through the year? Or are you basically flat lini",65,"Mike, just sort of following up on the outlook. Kind of like how are you thinking about the pacing of growth in chemical and energy in '17? Is the assumption that you kind of see some sequential improvement through the year? Or are you basically flat lining the business across the quarter just given that we haven't seen much in the way of positive signals?"
154924,407124595,1088180,"Agilent Technologies, Inc., Q4 2016 Earnings Call, Nov 15, 2016",2016-11-15,"Earnings Calls","Agilent Technologies, Inc.","Executives","I think you anticipated my answer. So we basically have a flat line for the year. And it hasn't -- it's been shrinking for the last 7 or 8 quarters 2% or 3%. I think we ended up down about 3% for the full year. And we're basically saying, it's going to be",201,"I think you anticipated my answer. So we basically have a flat line for the year. And it hasn't -- it's been shrinking for the last 7 or 8 quarters 2% or 3%. I think we ended up down about 3% for the full year. And we're basically saying, it's going to be flattish for '17. If there's any good news to that story is the fundamental industries are still out there in terms of gasoline is being produced. We've seen record levels of production in the United States, for example. The plants are running. There's a lot of discussion. There's a lot of reports externally about a turn. Oil prices have been inching up. But our history here is that it's really hard to know exactly when it's going to turn. What I can say is that if you have a profitability productivity message associated with something you can bring to the laboratory, then they might listen to you. And we're hopeful that some of our new product introductions will hit the mark there. But in terms of our overall market assumption and growth assumption for the company, we're assuming flat for '17. No big movements one way or another."
154924,407124595,1088180,"Agilent Technologies, Inc., Q4 2016 Earnings Call, Nov 15, 2016",2016-11-15,"Earnings Calls","Agilent Technologies, Inc.","Analysts","Got it. Okay, great. And then maybe just to go back to the M&A and the margin comments. As we sort of think about the moving parts on the op margin guidance and just what you might look to do this year, how at risk is the current op margin outlook from ad",93,"Got it. Okay, great. And then maybe just to go back to the M&A and the margin comments. As we sort of think about the moving parts on the op margin guidance and just what you might look to do this year, how at risk is the current op margin outlook from additional M&A? I mean, obviously, it's tough to discuss these things in the abstract. But are you open to further dilution if the right asset comes along? Or do you kind of think you hold the line with the current forecasts?"
154924,407124595,1088180,"Agilent Technologies, Inc., Q4 2016 Earnings Call, Nov 15, 2016",2016-11-15,"Earnings Calls","Agilent Technologies, Inc.","Executives","Yes. No, I think what we've said, and I'm really trying to be -- have actions that are consistent with our prior communication. We said we would look at acquisitions that could be short-term dilutive in nature, and we did one the latter part of '16. And w",154,"Yes. No, I think what we've said, and I'm really trying to be -- have actions that are consistent with our prior communication. We said we would look at acquisitions that could be short-term dilutive in nature, and we did one the latter part of '16. And we just love having iLab part of the portfolio. It's going to be -- it's a great addition to the business. But right now, it's not at the corporate average. We'll move it up. So if we saw other opportunities like that, we would pursue them. But I think if you want to look at the type of the deals and the size and other things, just look at what we've done so far to give you kind of a sense of the things that we're looking at going forward. We like accretive deals, and we like ones that can move up -- move the margins up."
154924,407124595,1088180,"Agilent Technologies, Inc., Q4 2016 Earnings Call, Nov 15, 2016",2016-11-15,"Earnings Calls","Agilent Technologies, Inc.","Operator","And our next question comes from the line of Puneet Souda from Leerink Partners.",14,"And our next question comes from the line of Puneet Souda from Leerink Partners."
154924,407124595,1088180,"Agilent Technologies, Inc., Q4 2016 Earnings Call, Nov 15, 2016",2016-11-15,"Earnings Calls","Agilent Technologies, Inc.","Analysts","Just a quick follow-up, if I could, on the pharma. And just wanted to understand, there's clearly a solid contribution here. If you could maybe help us parse out. Is that more coming from sort of a small molecules or macro molecules? Or is this -- are we",86,"Just a quick follow-up, if I could, on the pharma. And just wanted to understand, there's clearly a solid contribution here. If you could maybe help us parse out. Is that more coming from sort of a small molecules or macro molecules? Or is this -- are we thinking about them correctly? Or maybe we should be thinking about in terms of the service contract share that you're gaining and via the CrossLab Group? Help us, if you could parse that out a little bit."
154924,407124595,1088180,"Agilent Technologies, Inc., Q4 2016 Earnings Call, Nov 15, 2016",2016-11-15,"Earnings Calls","Agilent Technologies, Inc.","Executives","Yes, sure. So there's a couple of things going on, which is in terms of the overall fundamental end-market growth rates, we think biopharma and the small molecule side of pharma are both growing quite strongly. The small molecule side is really being driv",196,"Yes, sure. So there's a couple of things going on, which is in terms of the overall fundamental end-market growth rates, we think biopharma and the small molecule side of pharma are both growing quite strongly. The small molecule side is really being driven by a conversion to the new technology, the liquid chromatography in particular. Also, an increasing interest in enterprise service, what we have to offer from ACG. So I think what's been going on here for Agilent, we've had a combination of really strong end-market growth. There's a new market that has and will continue to develop in the services side, and we're doing well there, along with our new instruments in the pharma. When I look at '17, we think that the biopharma side of that market is going to continue to go quite strongly. It's been an area of prioritization for us in terms of new solutions. But we do think that over time, that the small molecule stuff will start to move back towards more of its long-term growth rates. And, Patrick, I think what do we kind of think about our long-term growth rates in the small molecule side?"
154924,407124595,1088180,"Agilent Technologies, Inc., Q4 2016 Earnings Call, Nov 15, 2016",2016-11-15,"Earnings Calls","Agilent Technologies, Inc.","Executives","Well, on the small molecule side, I think we are more in the low- to mid-single-digits range; whereas in biopharma we're more optimistic, and it continues to be double digit. That's our projection right now.",35,"Well, on the small molecule side, I think we are more in the low- to mid-single-digits range; whereas in biopharma we're more optimistic, and it continues to be double digit. That's our projection right now."
154924,407124595,1088180,"Agilent Technologies, Inc., Q4 2016 Earnings Call, Nov 15, 2016",2016-11-15,"Earnings Calls","Agilent Technologies, Inc.","Analysts","All right. Great. Just one more. In terms of the chemical and energy market side, I mean, we get the view into 2017. But as you have conversation with the labs and lab directors, just help us understand how they're thinking about capital equipment in 2017",71,"All right. Great. Just one more. In terms of the chemical and energy market side, I mean, we get the view into 2017. But as you have conversation with the labs and lab directors, just help us understand how they're thinking about capital equipment in 2017 knowing these times and knowing that the progression that's been? Or are they thinking more in 2018 terms in the -- on the capital equipment?"
154924,407124595,1088180,"Agilent Technologies, Inc., Q4 2016 Earnings Call, Nov 15, 2016",2016-11-15,"Earnings Calls","Agilent Technologies, Inc.","Executives","I have to say, I don't think they really know yet as well. What they're doing right now is in they're right in the midst of their capital budgeting process. So what I can tell you is I've had a couple conversations with customers over the last 2 or 3 week",295,"I have to say, I don't think they really know yet as well. What they're doing right now is in they're right in the midst of their capital budgeting process. So what I can tell you is I've had a couple conversations with customers over the last 2 or 3 weeks on this exact topic. And what they described for me is, hey, our end -- these are -- one customer was somebody who provides services into -- and equipment into the energy market. So listen, we're starting to get interest in quotes, but we're not sure whether it's going to hit in '17 or '18. When we had our VIP launch for the Intuvo 9000 GC, a lot our customers were in the chemical and energy space. And it's, ""Listen, we love this productivity message you have here. I think there's a real economic ROI. I'm now right in the midst of my budgeting process inside the company. Maybe I'll be able to get this thing through this year or maybe the following year."" Because there still seems to be the sentiment, particularly with the larger companies that they want to hold on to the equipment as long as they can before they have to replace it. So -- and again, that's why I pointed to the fact that it's not all negative because of the fact that we do have a strong service and consumables offerings into that space. But again, we just don't -- I don't think our customers know yet as well what's going to happen. We do know it's going to happen. History will repeat itself. There will be a replenishment of aged equipment. But again, we're just not confident enough right now to say when that's going to occur."
154924,407124595,1088180,"Agilent Technologies, Inc., Q4 2016 Earnings Call, Nov 15, 2016",2016-11-15,"Earnings Calls","Agilent Technologies, Inc.","Operator","And that concludes our question-and-answer session for today. I would like to turn the conference back over to Alicia Rodriguez for any closing comments.",25,"And that concludes our question-and-answer session for today. I would like to turn the conference back over to Alicia Rodriguez for any closing comments."
154924,407124595,1088180,"Agilent Technologies, Inc., Q4 2016 Earnings Call, Nov 15, 2016",2016-11-15,"Earnings Calls","Agilent Technologies, Inc.","Executives","Thank you, everybody. And on behalf of the management team, I wanted to thank you for joining us on the call. If you have any questions, feel free to give us a call in IR. Appreciate it very much. Bye-bye.",40,"Thank you, everybody. And on behalf of the management team, I wanted to thank you for joining us on the call. If you have any questions, feel free to give us a call in IR. Appreciate it very much. Bye-bye."
154924,407124595,1088180,"Agilent Technologies, Inc., Q4 2016 Earnings Call, Nov 15, 2016",2016-11-15,"Earnings Calls","Agilent Technologies, Inc.","Operator","Ladies and gentlemen, thank you for your participation in today's conference. This does conclude the program, and you may now disconnect. Everyone, have a great day.",26,"Ladies and gentlemen, thank you for your participation in today's conference. This does conclude the program, and you may now disconnect. Everyone, have a great day."
154924,407124595,1100879,"Agilent Technologies, Inc., Q4 2016 Earnings Call, Nov 15, 2016",2016-11-15,"Earnings Calls","Agilent Technologies, Inc.","Operator","Good day, ladies and gentlemen, and welcome to the Agilent Technologies Fourth Quarter 2016 Earnings Conference Call. [Operator Instructions] As a reminder, this conference is being recorded. I would now like to hand the floor over to Alicia Rodriguez,",47,"Good day, ladies and gentlemen, and welcome to the Agilent Technologies Fourth Quarter 2016 Earnings Conference Call. [Operator Instructions] As a reminder, this conference is being recorded. 
I would now like to hand the floor over to Alicia Rodriguez, Vice President of Investor Relations. Please go ahead."
154924,407124595,1100879,"Agilent Technologies, Inc., Q4 2016 Earnings Call, Nov 15, 2016",2016-11-15,"Earnings Calls","Agilent Technologies, Inc.","Executives","Thank you, Karen, and welcome, everyone, to Agilent's Fourth Quarter Conference Call for Fiscal Year 2016. With me are Mike McMullen, Agilent's President and CEO; and Didier Hirsch, Agilent's Senior Vice President and CFO. Joining in the Q&A after Didier'",285,"Thank you, Karen, and welcome, everyone, to Agilent's Fourth Quarter Conference Call for Fiscal Year 2016. With me are Mike McMullen, Agilent's President and CEO; and Didier Hirsch, Agilent's Senior Vice President and CFO. Joining in the Q&A after Didier's comments will be Patrick Kaltenbach, President of Agilent's Life Sciences and Applied Markets Group; Jacob Thaysen, President of Agilent's Diagnostics and Genomics Group; and Mark Doak, President of the Agilent CrossLab Group.
You can find the press release and information to supplement today's discussion on our website at www.investor.agilent.com. While there, please click on the link for financial results under the Financial Information tab. You will find an investor presentation along with revenue breakouts and currency impacts, business segment results and historical financials for Agilent's operations. We will also post a copy of the prepared remarks following this call.
Today's comments by Mike and Didier will refer to non-GAAP financial measures. You will find the most directly comparable GAAP financial metrics and reconciliations on our website. We will refer to core revenue growth, which excludes the impact of currency, the NMR business and acquisitions and divestitures within the past 12 months. Unless otherwise noted, all references to increases or decreases in financial metrics are year-over-year. Guidance is based on exchange rates as of the last day of the reported quarter.
We will also make forward-looking statements about the financial performance of the company. These statements are subject to risks and uncertainties and are only valid as of today. The company assumes no obligation to update them. Please look at the company's recent SEC filings for a more complete picture of our risks and other factors.
And now let me turn the call over to Mike."
154924,407124595,1100879,"Agilent Technologies, Inc., Q4 2016 Earnings Call, Nov 15, 2016",2016-11-15,"Earnings Calls","Agilent Technologies, Inc.","Executives","Thanks, Alicia, and hello, everyone. I'm very pleased to announce that our Agilent team ended 2016 with another strong quarter of excellent results. I will start by looking at our key numbers from the quarter. First, we continued to deliver above-market",1998,"Thanks, Alicia, and hello, everyone. I'm very pleased to announce that our Agilent team ended 2016 with another strong quarter of excellent results. 
I will start by looking at our key numbers from the quarter. First, we continued to deliver above-market growth. Revenues of $1.1 billion exceeded the high end of the guidance by a sizeable $41 million and were up 6.3% on a core basis. We were the first surprised by the strength of our instrument business in pharma, China and Europe, which far exceeded our expectations. 
Second, our adjusted EPS of $0.59 was $0.07 above the high end of our guidance. 
Finally, we continued our track record of improving profitability as we delivered another quarter of operating margin expansion. Adjusted operating margin of 22.5% was up 60 basis points from Q4 of fiscal 2015. 
Turning to our full year results. Core revenue continued to outperform the market, growing 5.9%. We increased operating margins 110 basis points to 20.7% from 2015. These results drove a 14% increase in adjusted earnings per share for the full year. 
We are capping off the second year of our company transformation with stellar performance by the Agilent team. Our fourth quarter and full year results demonstrate our continued ability to win in the market. We are outgrowing the market while expanding margins and fully leveraging our strong balance sheet. 
In the past year, we distributed $150 million in cash dividends, repurchased $434 million of our shares and invested $480 million directly into the business through M&A, strategic transactions and capital expenditures. 
Let me now address what's happening in our end markets and business groups. I'll start with the end markets. Our Q4 trends were similar to what we experienced last quarter with pharma and academia and government being the exceptions. We had expected continued strength in pharma, but our 16% growth on a difficult compare exceeded our expectations. Growth is being driven by strong customer acceptance of our new products and enterprise service offerings. Academia and government's decline of 2% was less than expected. European spending is holding up better than projected, while our U.S. government investments continue to lag 2015 spending levels. 
Clinical and diagnostics grew 8% over last year, led by continued growth in reagents.
Within our applied end markets, food is up 10% with strong demand in China and Americas. China also drove growth in environmental market, up 3%. 
Chemical and energy declined 3% in line with expectations due to continued effect of crude oil prices and macroeconomic uncertainties. We expect this market to remain challenging for the rest of calendar year 2016 and into 2017, with no significant downward or upward movements.
Geographically, Asia, led by China, and Europe were stronger than forecast. Our Asia business, excluding Japan, grew double digit, driven by greater than 25% growth in China. While the overall European market remains challenged, we delivered solid mid-single-digit growth. European pharma and food markets were strong and academia and government funding was stable with Q3. Japan and Americas were flat with growth constrained by continued chemical and energy market weakness and specific to the U.S., slow U.S. government funding. 
Moving on to the business groups. Life Sciences and Applied Markets Group delivered core revenue growth of 5%. Better-than-expected revenues from our analytical lab instruments business was driven by an attractive combination of introducing new products into growing markets. This applied in particular to our new lineup of chromatography and mass spectrometry products targeted at the pharma in applied food, environmental and forensics markets. LSAG's operating margin for the quarter was 22.8%, up 280 basis points from a year ago.
We are building for the future. In August, we introduced the transformational Intuvo 9000 GC system. Building on our recognized GC leadership, the Intuvo system revolutionized the way users perform gas chromatography. Industry experts recognize unique innovation being delivered by Agilent with press coverage at 100% positive. Intuvo is featured this month on the cover LCGC magazine, a major trade publication. 
Customer response is also very positive to this introduction, confirming our undisputed market leadership in gas chromatography. We anticipate a measured uptake in revenue. Limited international shipments are expected in Q1 of fiscal 2017, with volumes expected to increase over subsequent quarters.
Another industry-unique product, the Agilent 8900 Triple Quad ICP-MS system, which we just introduced in Q3, is also being well received in the market. This instrument is rapidly becoming the solution of choice in labs that demand the highest standards of performance. 
Next, the Agilent CrossLab Group continues to deliver strong, sustained growth with core revenue up 8%. Growth is healthy in both services and consumables. ACG's operating margin for the quarter was 22.7%, down 240 basis points from a year ago and in line with expectations.
ACG results were driven by strong pharma, food, clinical and diagnostic markets, where our CrossLab customer value proposition is being well received. Unlike our instrument business, ACG also grew in the chemical and energy markets. Laboratories supporting strong production levels drove demand for consumables. There is also continued demand for services, as customers focus on keeping their older instruments operational.
We are investing for the future in ACG. We just introduced a new range of innovative and differentiated supplies. These new offerings enable the Agilent Intuvo 9000 GC to be the most efficient and cost-effective premium GC to own and operate. We continue to successfully integrate the recently acquired iLab business, which brings differentiated capabilities to core lab managers. 
Last, but certainly not least in terms of impact, the momentum in the Diagnostics and Genomics Group continued, with delivery of 8% core growth. Our laser focus on improving the previously acquired Dako business is paying off. The pathology business continues its steady climb back to market growth rates, with strong -- with strength in reagents and companion diagnostics.
Our nucleic acid solutions business, for which we recently announced a significant production capacity, grew double digits. This growth reflects the increasing demand for oligonucleotides for RNA-based drugs. DDG's operating margin for the quarter was 19.6%, up 40 basis points from a year ago. 
In October, there was some exciting news from Merck for lung cancer patients and for Agilent. Merck's KEYTRUDA is now approved by the FDA for first-line treatment for metastatic non-small-cell lung cancer for patients with high rates of PD-L1 expression. In conjunction, Agilent's pharmDx companion diagnostics PD-L1 test is now approved for expanded use. This is the first time an Agilent's PD-L1 companion diagnostic is approved for first-line testing.
The theme of investing for our future is also evident in DDG. We launched a comprehensive offering of pooled CRISPR libraries for functional genomics. This will help accelerate research into complex diseases and drug discovery. We signed an agreement with the Burning Rock Biotech to develop cancer diagnostics in China based on Agilent SureSelect solutions. And we broke ground and initiated construction on the previously announced $120 million investment in a new factory in Colorado to expand nucleic acid production capacity.
Turning now to operating margin. We remain focused on operating margin improvement. Since the new Agilent leadership team was appointed, we have delivered 7 consecutive quarters of improved operating margin and strong growth. Despite continued challenges in the chemical and energy business, we have improved adjusted operating margin by 280 basis points in the first 2 years of the company's transformation. We have completely absorbed and offset the $40 million of dis-synergy costs due to the spin-off of Keysight.
On the operations front, our Agile Agilent program continues to simplify the company and lower operating costs. This program is designed to keep us nimble, improve our interaction with customers and lower our costs. It is having an impact and will continue to deliver savings in 2017 and beyond. 
In the coming year, we will realize cost savings from the completion of the integration of Dako in early 2017, a simplified enterprise IT systems environment and other cost-savings initiatives.
Turning to our FY '17 market and company outlook. As a reminder, our shareholder value creation model for superior earnings growth is to outgrow the market and expand operating margins with a balanced deployment of our capital. Didier will go through the specifics of our Q1 '17 and full year guidance. I want to share our thinking about end markets and our initial guidance philosophy, given an environment of increased uncertainty. This is a change since our last call and the May 2016 Analyst Investor Day. 
In our end markets, we expect continued strength in pharma, accompanied by continued solid growth in the food, environmental and clinical research and diagnostics markets. Geographically, China and India are expected to grow at significantly higher rates than other countries. There remains considerable uncertainty about European markets. We are forecasting moderate growth in the United States with the U.S. government policies and spending and chemical and energy markets being the wildcards.
Chemical and energy, while entering a period of easier compares and improved oil prices, has not yet returned to growth. We expect a continued subdued academic and government research market in the coming year until uncertainties resulting from Brexit and the U.S. elections play out. We are also keeping a watchful eye on how potential new U.S. government driven trade and currency evaluation discussions could impact our business.
We finished 2016 very strongly, and we are well positioned for future growth with a pipeline of new offerings. In our initial revenue guidance for 2017, however, we want to be on the cautious side. We want to see some more clarity on U.S. and European government actions and have better indicators of when we will return to growth in our industrial end markets. 
Predicting end-market growth in today's uncertain political and economic environment is challenging. However, I can predict quite confidently that we will continue our track record of outgrowing the market whatever market environment we encounter. We continue to expand our customer channel reach and fortify our portfolio, which strengthens us well for the coming year and beyond. 
The transformation of Agilent we discussed at the May Analyst and Investor Day is in full force. The new leadership team, put in place in early 2015, continues to deliver strong operating results each and every quarter. We are building momentum for future growth. 
We have improved our adjusted operating margins by 200 basis points over the past 2 years and our march to improved operating margins will continue in 2017. However, in our initial operating margin and earnings per share guidance for 2017, we want to be on the cautious side. Since our May Analyst and Investor Day meeting, changes in exchange rate, pension expenses and the recent iLab acquisition are having a short-term dilutive impact on our operating margins of 0.5%. The Agilent team, however, is laser-focused on improving another 130 basis points of operating margin. We have an internal action plan aligned with achieving a 22% operating margin goal in fiscal 2017, excluding M&A impact. This is the primary goal for our executive team's compensation. We continue to hold ourselves to a higher level of performance, expectations than reflected in our initial full year earnings guidance.
As you assess our future possibilities, I will leave you with a few thoughts. We are expanding our product portfolio and extending into adjacent markets. We're improving the customer experience by streamlining processes and modernizing systems, making the company more efficient and customer friendly. Our Agile Agilent program has and will continue to deliver incremental improvements in operating margin. The One Agilent team continues to work well together and is determined to win in the market. We believe we are well positioned to sustain our strong operational performance and achieve our long-term goals. The entire Agilent team is energized and committed to deliver future growth. 
Thank you for being on the call today. I will now turn it over to Didier, who will provide initial insights on our financial results and initial guidance for our fiscal Q1 and full year 2017. Didier?"
154924,407124595,1100879,"Agilent Technologies, Inc., Q4 2016 Earnings Call, Nov 15, 2016",2016-11-15,"Earnings Calls","Agilent Technologies, Inc.","Executives","Thank you, Mike, and hello, everyone. As Mike stated, we are very pleased with our Q4 and full year performance, both well over the high end of our guidance. We delivered above-market core revenue growth of 6.3% and 5.9%, respectively; and our operating",577,"Thank you, Mike, and hello, everyone. As Mike stated, we are very pleased with our Q4 and full year performance, both well over the high end of our guidance. 
We delivered above-market core revenue growth of 6.3% and 5.9%, respectively; and our operating margin, adjusted for income from Keysight, was up 60 basis points and 110 basis points, respectively. 
Our full year EPS at $1.98 is 14% higher than the previous year. Please note that we have reduced our pro forma tax rate by 1 percentage points, which had a $0.02 impact on our EPS. Our operating cash flow for the full year, at $793 million, reflects our strong overall performance. 
And turning to capital returns. For the first -- for the year, we returned $584 million to shareholders in the form of dividends and buybacks or 89% of our free cash flow. 
I will now turn to the guidance for fiscal year 2017. As Mike stated, our initial guidance, like last year, assumes that -- what we believe to be appropriate caution. Our fiscal year '17 revenue guidance of $4.35 billion to $4.37 billion corresponds to a core revenue growth of 4% to 4.5%. It is based on October 31 exchange rates and currency had a 0.6 percentage point impact -- negative impact on revenues. We project fiscal year '17 adjusted operating margin of 21% to 21.5% and fiscal year '17 EPS of $2.10 to $2.16, growing 8% at midpoint. 
As you update your models for fiscal year '17, please consider the following 10 points: First, annual salary increases will be effective December 1, 2016. Second, stock-based compensation will be about $59 million. And as we front end the recognition of stock-based compensation, the Q1 expense will be about $23 million. Third, the reduction in bond yields is negatively impacting our annual pension expenses by about $12 million. Fourth, depreciation is projected to be $104 million for the fiscal year. Fifth, the non-GAAP effective tax rate is projected to remain at 19%. Sixth, we plan to return approximately $600 million in capital to shareholders, including $170 million in dividends and $430 million in buybacks, subject to customary conditions. Seventh, we plan to borrow $250 million in the second half to fund a portion of our capital returns. Eighth, net interest expense is forecasted at $71 million and other income at $11 million. Ninth, for purpose of our EPS guidance, we have assumed a diluted share count of 324 million shares, 5 million shares less than the average diluted share count in fiscal year '16. And finally, tenth, we expect operating cash flow of $825 million and capital expenditures of $200 million, about $60 million over fiscal year '16, mostly due to the investment in the second nucleic acid facility.
Now finally, moving to the guidance for our first quarter. First, please note that Lunar New Year falls in Q1 this year versus Q2 last year, meaning about $15 million of revenue shifting from Q1 to Q2. We expect Q1 revenues of $1.04 billion to $1.06 billion and EPS of $0.48 to $0.50. At midpoint, revenue will grow 2.2% on a core basis and EPS will grow 7%. And as customary, Q1 EPS is negatively impacted by the December salary increase, front loading of stock-based compensation and the increase in payroll taxes due to the disbursement of the variable and incentive pay of the previous year. 
With that, I'll turn it over to Alicia for the Q&A."
154924,407124595,1100879,"Agilent Technologies, Inc., Q4 2016 Earnings Call, Nov 15, 2016",2016-11-15,"Earnings Calls","Agilent Technologies, Inc.","Executives","Thank you, Didier. Karen, will you please give the instructions for the Q&A.",13,"Thank you, Didier. Karen, will you please give the instructions for the Q&A."
154924,407124595,1100879,"Agilent Technologies, Inc., Q4 2016 Earnings Call, Nov 15, 2016",2016-11-15,"Earnings Calls","Agilent Technologies, Inc.","Operator","[Operator Instructions] Our first question comes from the line of Steve Beuchaw from Morgan Stanley.",15,"[Operator Instructions] Our first question comes from the line of Steve Beuchaw from Morgan Stanley."
154924,407124595,1100879,"Agilent Technologies, Inc., Q4 2016 Earnings Call, Nov 15, 2016",2016-11-15,"Earnings Calls","Agilent Technologies, Inc.","Analysts","First question for me is I wonder if you could just juxtapose your results against what we've heard from others in the category over the last several weeks. I mean, it sounds like a particularly strong category by number -- quarter by number of metrics. Y",99,"First question for me is I wonder if you could just juxtapose your results against what we've heard from others in the category over the last several weeks. I mean, it sounds like a particularly strong category by number -- quarter by number of metrics. You actually accelerated while we saw a number of others decelerate in terms of organic growth in the quarter. Can you give us, from a high level, what you think are the keys there in terms of positioning? Why it is the quarter was so good for you guys relative to the market?"
154924,407124595,1100879,"Agilent Technologies, Inc., Q4 2016 Earnings Call, Nov 15, 2016",2016-11-15,"Earnings Calls","Agilent Technologies, Inc.","Executives","Yes, thanks, Steve. The headline for me was as we looked throughout the quarter, we were winning more business than we planned. So we're winning a lot of business in our core markets. I think some of the end-market strength that we planned too was actuall",135,"Yes, thanks, Steve. The headline for me was as we looked throughout the quarter, we were winning more business than we planned. So we're winning a lot of business in our core markets. I think some of the end-market strength that we planned too was actually fairly similar to what I've seen other people comment on relative to the strength of China, strength of pharma, continued subdued but kind of a stable academia and government environment. And for us, I think we were just delighted by our performance, in particular, in our analytical instrument business where we seem to be winning more business than we planned and we think that bodes well for the strength of our portfolio and some of the things we've been doing over the last year in our channels as well."
154924,407124595,1100879,"Agilent Technologies, Inc., Q4 2016 Earnings Call, Nov 15, 2016",2016-11-15,"Earnings Calls","Agilent Technologies, Inc.","Analysts","And then so the follow-up, I guess, just to dig a little deeper would be, did you notice anything in terms of instrument trends relative to consumables trends accelerating or decelerating? And what is that telling you about end of year, I should say end o",51,"And then so the follow-up, I guess, just to dig a little deeper would be, did you notice anything in terms of instrument trends relative to consumables trends accelerating or decelerating? And what is that telling you about end of year, I should say end of calendar year budget flush?"
154924,407124595,1100879,"Agilent Technologies, Inc., Q4 2016 Earnings Call, Nov 15, 2016",2016-11-15,"Earnings Calls","Agilent Technologies, Inc.","Executives","Yes, we were talking a bit about this yesterday with the team. And if you look at our performance through the quarter, we got off to a strong start in August and it continued throughout the quarter. And sometimes, it's hard to tell over first month where",93,"Yes, we were talking a bit about this yesterday with the team. And if you look at our performance through the quarter, we got off to a strong start in August and it continued throughout the quarter. And sometimes, it's hard to tell over first month where things will land for the quarter. But I'd say by the end of September, we knew we are winning more business than we planned. And it's really shaping up to be a strong quarter for us and really position us well for us going into 2017."
154924,407124595,1100879,"Agilent Technologies, Inc., Q4 2016 Earnings Call, Nov 15, 2016",2016-11-15,"Earnings Calls","Agilent Technologies, Inc.","Operator","And our next question comes from the line of Tycho Peterson from JPMorgan.",13,"And our next question comes from the line of Tycho Peterson from JPMorgan."
154924,407124595,1100879,"Agilent Technologies, Inc., Q4 2016 Earnings Call, Nov 15, 2016",2016-11-15,"Earnings Calls","Agilent Technologies, Inc.","Analysts","Mike, just hoping for a little bit more color on some of the expectations and guidance in particular around pharma. Are you still assuming that's kind of double-digit growth next year? Or are you factoring in a moderation? And on environmental, you manage",78,"Mike, just hoping for a little bit more color on some of the expectations and guidance in particular around pharma. Are you still assuming that's kind of double-digit growth next year? Or are you factoring in a moderation? And on environmental, you managed to grow that business in contrast to what we saw from one of your peers last week. So maybe talk a little bit about contributions from the GC replacement cycle for next year as well."
154924,407124595,1100879,"Agilent Technologies, Inc., Q4 2016 Earnings Call, Nov 15, 2016",2016-11-15,"Earnings Calls","Agilent Technologies, Inc.","Executives","Yes, sure. Tycho, you broke up a bit on the call. So if I don't get to the specific questions, please come back to me. But I think relative to the expectations for end market kind of thinking for growth rate, we had pharma below the double-digit growth th",107,"Yes, sure. Tycho, you broke up a bit on the call. So if I don't get to the specific questions, please come back to me. But I think relative to the expectations for end market kind of thinking for growth rate, we had pharma below the double-digit growth that have been placed in '16. So as we look at our end markets, we would expect a moderation of growth, not because the spends are going to go away, but you really are going to start to get into tough compares. And, Didier, if I remember correctly, we were in the mid- to high single-digit growth for pharma?"
154924,407124595,1100879,"Agilent Technologies, Inc., Q4 2016 Earnings Call, Nov 15, 2016",2016-11-15,"Earnings Calls","Agilent Technologies, Inc.","Executives","Yes.",1,"Yes."
154924,407124595,1100879,"Agilent Technologies, Inc., Q4 2016 Earnings Call, Nov 15, 2016",2016-11-15,"Earnings Calls","Agilent Technologies, Inc.","Executives","And then I think the story -- I think, Tycho, the question was around environmental.",15,"And then I think the story -- I think, Tycho, the question was around environmental."
154924,407124595,1100879,"Agilent Technologies, Inc., Q4 2016 Earnings Call, Nov 15, 2016",2016-11-15,"Earnings Calls","Agilent Technologies, Inc.","Analysts","Yes, and the GC replacement cycle.",6,"Yes, and the GC replacement cycle."
154924,407124595,1100879,"Agilent Technologies, Inc., Q4 2016 Earnings Call, Nov 15, 2016",2016-11-15,"Earnings Calls","Agilent Technologies, Inc.","Executives","Yes, so in environmental, the story really there is China. And we think that's got many quarters in front of us of growth in China. And we -- as you know, I'm fairly bullish on the prospects of that market. And I think we've got kind of a perfect storm he",198,"Yes, so in environmental, the story really there is China. And we think that's got many quarters in front of us of growth in China. And we -- as you know, I'm fairly bullish on the prospects of that market. And I think we've got kind of a perfect storm here going on where we have strong products going into -- in the growing markets. Relative to the GC replacement cycle, this is really about what's going to happen in the chemical and energy market. And I'll make a few comments here, then, Patrick, you may want to provide your perspective as well. So you may have noticed in my call script, I went kind of out my way to talk about a measured ramp-up of our new Intuvo GC because we think we've got a winner product on our hands. We know there's a lot of interest from customers. But we also recognize the reality of constraints they may have in their capital budgets. I know they're working with their own management teams internally of these companies about what they may get in terms of funding in 2017. What are your thoughts, Patrick, on that as well?"
154924,407124595,1100879,"Agilent Technologies, Inc., Q4 2016 Earnings Call, Nov 15, 2016",2016-11-15,"Earnings Calls","Agilent Technologies, Inc.","Executives","Yes, thanks, Mike. Looking at the GC market, we definitely are positioned very well to capture any growth opportunity there. We have launched the Intuvo, which is a strong message to all our customers that we are standing behind them when it comes to driv",169,"Yes, thanks, Mike. Looking at the GC market, we definitely are positioned very well to capture any growth opportunity there. We have launched the Intuvo, which is a strong message to all our customers that we are standing behind them when it comes to drive for lower cost of measurement, when it comes to lower cost of ownership, when it comes to increased productivity and it positions us clearly as the market leader in gas chromatography. So we are in a lot of discussions with them, not only on Intuvo, but I think what the Intuvo launch did for us, we also -- it also spread a lot of discussion again about other -- of our other part of portfolio to 7890 and other products, which are market-leading products. And again, the discussion with the customers in the suppressed market is all about how can we help them increasing their productivity, driving their cost of analysis down and this is where we are exceptionally well positioned with this portfolio."
154924,407124595,1100879,"Agilent Technologies, Inc., Q4 2016 Earnings Call, Nov 15, 2016",2016-11-15,"Earnings Calls","Agilent Technologies, Inc.","Executives","Yes, maybe just to up an exclamation point on this is that we know that the installed base is at historic levels of aging. We know the equipment is being used. And it's just a matter time for that replacement cycle is going to turn on. But as you saw in m",61,"Yes, maybe just to up an exclamation point on this is that we know that the installed base is at historic levels of aging. We know the equipment is being used. And it's just a matter time for that replacement cycle is going to turn on. But as you saw in my call comments, we're not ready to call that yet."
154924,407124595,1100879,"Agilent Technologies, Inc., Q4 2016 Earnings Call, Nov 15, 2016",2016-11-15,"Earnings Calls","Agilent Technologies, Inc.","Analysts","Okay. And then just one clarification on the operating margin guidance. Half of the cut, you're down about 1% from what you talked about the Analyst Day, half of that is from iLab, pension and FX, is the rest just conservatism, given kind of the macro?",46,"Okay. And then just one clarification on the operating margin guidance. Half of the cut, you're down about 1% from what you talked about the Analyst Day, half of that is from iLab, pension and FX, is the rest just conservatism, given kind of the macro?"
154924,407124595,1100879,"Agilent Technologies, Inc., Q4 2016 Earnings Call, Nov 15, 2016",2016-11-15,"Earnings Calls","Agilent Technologies, Inc.","Executives","Yes, actually, I think where we had was the high end of our guidance is around 21.5%, right, Didier? And...",20,"Yes, actually, I think where we had was the high end of our guidance is around 21.5%, right, Didier? And..."
154924,407124595,1100879,"Agilent Technologies, Inc., Q4 2016 Earnings Call, Nov 15, 2016",2016-11-15,"Earnings Calls","Agilent Technologies, Inc.","Executives","So yes, we -- with the high end is at 21.5%, and we are losing about 50 basis points related to the 3 items that were mentioned: currency, acquisition and pension expenses. And the other thing to note is, as Mike has clearly stated, we are still being mea",58,"So yes, we -- with the high end is at 21.5%, and we are losing about 50 basis points related to the 3 items that were mentioned: currency, acquisition and pension expenses. And the other thing to note is, as Mike has clearly stated, we are still being measured on achieving 22% in terms of our variable compensation."
154924,407124595,1100879,"Agilent Technologies, Inc., Q4 2016 Earnings Call, Nov 15, 2016",2016-11-15,"Earnings Calls","Agilent Technologies, Inc.","Executives","Yes, and the way Didier and I talked about this one was listen, we think we've got a path to 22%. But there's lot of higher risks than there was back at the last call and at the May AID. So we thought it was prudent for us to guide this way. But we're all",66,"Yes, and the way Didier and I talked about this one was listen, we think we've got a path to 22%. But there's lot of higher risks than there was back at the last call and at the May AID. So we thought it was prudent for us to guide this way. But we're all out inside, all our comp is tied to the 22% number."
154924,407124595,1100879,"Agilent Technologies, Inc., Q4 2016 Earnings Call, Nov 15, 2016",2016-11-15,"Earnings Calls","Agilent Technologies, Inc.","Executives","With the 3 elements that were clear headwinds.",8,"With the 3 elements that were clear headwinds."
154924,407124595,1100879,"Agilent Technologies, Inc., Q4 2016 Earnings Call, Nov 15, 2016",2016-11-15,"Earnings Calls","Agilent Technologies, Inc.","Operator","And our next question comes from the line of Ross Muken from Evercore ISI.",14,"And our next question comes from the line of Ross Muken from Evercore ISI."
154924,407124595,1100879,"Agilent Technologies, Inc., Q4 2016 Earnings Call, Nov 15, 2016",2016-11-15,"Earnings Calls","Agilent Technologies, Inc.","Analysts","This is Luke in for Ross. Just hoping you could give a little more color on your margin assumption for next year? What you guys are thinking about pacing the FX headwinds, if any, what's going to be operational, what's pricing, et cetera?",43,"This is Luke in for Ross. Just hoping you could give a little more color on your margin assumption for next year? What you guys are thinking about pacing the FX headwinds, if any, what's going to be operational, what's pricing, et cetera?"
154924,407124595,1100879,"Agilent Technologies, Inc., Q4 2016 Earnings Call, Nov 15, 2016",2016-11-15,"Earnings Calls","Agilent Technologies, Inc.","Executives","I think the question, Didier, was relative to the composition of our operating margin improvements for next year. And perhaps we can start with the mix between volume and OpEx and gross margins.",33,"I think the question, Didier, was relative to the composition of our operating margin improvements for next year. And perhaps we can start with the mix between volume and OpEx and gross margins."
154924,407124595,1100879,"Agilent Technologies, Inc., Q4 2016 Earnings Call, Nov 15, 2016",2016-11-15,"Earnings Calls","Agilent Technologies, Inc.","Executives","Yes, I mean, the -- I mean, I'm not going to give you the full bridge. I mean, when we provided the guidance of 21% to 21.5%, we took into account obviously, the -- all the impacts that I've mentioned. So there is -- it's based on the 4.3% core revenue gr",157,"Yes, I mean, the -- I mean, I'm not going to give you the full bridge. I mean, when we provided the guidance of 21% to 21.5%, we took into account obviously, the -- all the impacts that I've mentioned. So there is -- it's based on the 4.3% core revenue growth. So there is clearly an operating leverage impact. And a lot, a lot of actions that are taking place to offset inflation and other headwinds that probably I have mentioned. The guidance assumes some level of increase improvements in gross margins as well as a reduction in terms of our -- the OpEx as a percentage of revenue. So you have a pretty much on all fronts, some improvements, not as much as we had initially anticipated because of the 3 headwinds that I've mentioned. Some of it related to operating leverage and some of it related to the continuation of our Agile Agilent programs."
154924,407124595,1100879,"Agilent Technologies, Inc., Q4 2016 Earnings Call, Nov 15, 2016",2016-11-15,"Earnings Calls","Agilent Technologies, Inc.","Executives","And maybe just reminding the audience, Didier. When we first started this march almost 2 years ago to go to the 22%, we laid out a path, which is really around 60% was going to be on volume, the other 40% was going to be on OpEx improvements in gross marg",64,"And maybe just reminding the audience, Didier. When we first started this march almost 2 years ago to go to the 22%, we laid out a path, which is really around 60% was going to be on volume, the other 40% was going to be on OpEx improvements in gross margin. And I think we're thinking about the same kind of mix for 2017."
154924,407124595,1100879,"Agilent Technologies, Inc., Q4 2016 Earnings Call, Nov 15, 2016",2016-11-15,"Earnings Calls","Agilent Technologies, Inc.","Executives","That's right, yes. Absolutely.",5,"That's right, yes. Absolutely."
154924,407124595,1100879,"Agilent Technologies, Inc., Q4 2016 Earnings Call, Nov 15, 2016",2016-11-15,"Earnings Calls","Agilent Technologies, Inc.","Analysts","Okay, great. And I guess just one more. You guys did really well on the cash flow in '16. I think $647 million and you're guiding for $625 million. Is there any timing impact on that '17 guide? And then, I guess, on the tax of '17, kind of what are you ba",58,"Okay, great. And I guess just one more. You guys did really well on the cash flow in '16. I think $647 million and you're guiding for $625 million. Is there any timing impact on that '17 guide? And then, I guess, on the tax of '17, kind of what are you baking into that benefit down there?"
154924,407124595,1100879,"Agilent Technologies, Inc., Q4 2016 Earnings Call, Nov 15, 2016",2016-11-15,"Earnings Calls","Agilent Technologies, Inc.","Executives","So I assume when you refer to timing impact, you're referring to special -- I mean between '16 and '17, some cash outlays only that couldâ¦",26,"So I assume when you refer to timing impact, you're referring to special -- I mean between '16 and '17, some cash outlays only that couldâ¦"
154924,407124595,1100879,"Agilent Technologies, Inc., Q4 2016 Earnings Call, Nov 15, 2016",2016-11-15,"Earnings Calls","Agilent Technologies, Inc.","Analysts","Yes, correct.",2,"Yes, correct."
154924,407124595,1100879,"Agilent Technologies, Inc., Q4 2016 Earnings Call, Nov 15, 2016",2016-11-15,"Earnings Calls","Agilent Technologies, Inc.","Executives","Yes, there's a little bit. I mean, let me just highlight 2 potentially. This -- in fiscal year '16, we disbursed $66 million for overall Agilent variable pay and pay for results. Next year, we -- but we've changed our program so that we now do a lot of th",218,"Yes, there's a little bit. I mean, let me just highlight 2 potentially. This -- in fiscal year '16, we disbursed $66 million for overall Agilent variable pay and pay for results. Next year, we -- but we've changed our program so that we now do a lot of the cash outlays on an annual basis instead of semi-annual. So we have the full brunt in '17 of improvements in '16 and the fact that we're going to pay in '17 something that is more than pertaining to '16. So it's going to be $91 million; going from $66 million to $91 million. So an increased capital cash outlay. And then second, we did not fund our U.S. pension plan in '16. So our overall contributions to our worldwide pension plan was $24 million. We intend to fund our U.S. pension plan more in '17 and the contribution to the pension plan will move to $45 million. So an increase from $24 million to $45 million. So that -- those are the 2 things that come to mind in terms of explaining some of the variance between '16 and 17. But even with those 2 headwinds, we are still showing, in our initial guidance, a nice increase of $30 million on a year-over-year basis. And your second question?"
154924,407124595,1100879,"Agilent Technologies, Inc., Q4 2016 Earnings Call, Nov 15, 2016",2016-11-15,"Earnings Calls","Agilent Technologies, Inc.","Executives","Related to tax rates.",4,"Related to tax rates."
154924,407124595,1100879,"Agilent Technologies, Inc., Q4 2016 Earnings Call, Nov 15, 2016",2016-11-15,"Earnings Calls","Agilent Technologies, Inc.","Executives","Yes, on the tax rates, I did mention at the May Analyst Day that we were going to work really hard on the reducing our tax rate by 2 percentage points over the course of the next 2 to 3 years. We are very happy to be able to deliver already 1 percentage p",150,"Yes, on the tax rates, I did mention at the May Analyst Day that we were going to work really hard on the reducing our tax rate by 2 percentage points over the course of the next 2 to 3 years. We are very happy to be able to deliver already 1 percentage point in this fiscal year '16. We still are aiming to reduce our effective tax rate by other 1 percentage points over the course of the next 24 months as committed to or as indicated, I would say, in fiscal year -- in -- at the AID. But it's prudent to assume that the reduction will come in fiscal year '18 and not in fiscal year '17. So in your models, we advise you to put a 1 percentage point's reduction in tax rate from 19% to 18% in fiscal year '18, not in fiscal year '17."
154924,407124595,1100879,"Agilent Technologies, Inc., Q4 2016 Earnings Call, Nov 15, 2016",2016-11-15,"Earnings Calls","Agilent Technologies, Inc.","Analysts","Okay. And does that include the FASB 2016-09 benefit?",9,"Okay. And does that include the FASB 2016-09 benefit?"
154924,407124595,1100879,"Agilent Technologies, Inc., Q4 2016 Earnings Call, Nov 15, 2016",2016-11-15,"Earnings Calls","Agilent Technologies, Inc.","Executives","It includes everything.",3,"It includes everything."
154924,407124595,1100879,"Agilent Technologies, Inc., Q4 2016 Earnings Call, Nov 15, 2016",2016-11-15,"Earnings Calls","Agilent Technologies, Inc.","Operator","And our next question comes from the line of Doug Schenkel from Cowen and Company.",15,"And our next question comes from the line of Doug Schenkel from Cowen and Company."
154924,407124595,1100879,"Agilent Technologies, Inc., Q4 2016 Earnings Call, Nov 15, 2016",2016-11-15,"Earnings Calls","Agilent Technologies, Inc.","Analysts","This is Ryan Blicker on for Doug. Would you be willing to provide what your LC/MS growth was in the quarter? And how that was impacted by the comparison relative to recent quarters and maybe what your annual growth was there?",41,"This is Ryan Blicker on for Doug. Would you be willing to provide what your LC/MS growth was in the quarter? And how that was impacted by the comparison relative to recent quarters and maybe what your annual growth was there?"
154924,407124595,1100879,"Agilent Technologies, Inc., Q4 2016 Earnings Call, Nov 15, 2016",2016-11-15,"Earnings Calls","Agilent Technologies, Inc.","Executives","What I can tell you is that -- back to my earlier statement, is that we're winning more business that planned. So we're quite pleased with how we've been doing with the LC/MS portfolio. And, Patrick, you may just want to remind the audience of some of the",96,"What I can tell you is that -- back to my earlier statement, is that we're winning more business that planned. So we're quite pleased with how we've been doing with the LC/MS portfolio. And, Patrick, you may just want to remind the audience of some of the new stuff that we've come out with. So I guess, I'm not comfortable giving the specific of the growth rate. But just giving you a sense of trend of the business and maybe a few proof points of why we believe it's going as well as it is."
154924,407124595,1100879,"Agilent Technologies, Inc., Q4 2016 Earnings Call, Nov 15, 2016",2016-11-15,"Earnings Calls","Agilent Technologies, Inc.","Executives","Sure, again, we are confident that we are outgrowing the market on many fronts. And we have a very strong LC/MS portfolio. We launched a lot of exciting products at ASMS this year. And I think the reception of the market just underlines our strength. The",119,"Sure, again, we are confident that we are outgrowing the market on many fronts. And we have a very strong LC/MS portfolio. We launched a lot of exciting products at ASMS this year. And I think the reception of the market just underlines our strength. The combination of LC and LC/MS is important, and we think both are winning platforms. We see strong adoption across all the end markets. If there was one market where we have seen some headwind, then it was probably at the pain management market segment. But that is also in line with what you probably have heard with some of our competitors. But overall, we have been very pleased with the result in Q4."
154924,407124595,1100879,"Agilent Technologies, Inc., Q4 2016 Earnings Call, Nov 15, 2016",2016-11-15,"Earnings Calls","Agilent Technologies, Inc.","Analysts","Okay, that's helpful. And then it seems like there could be a repatriation holiday of some sort in 2017. I believe over 90% of your cash is currently trapped internationally. Can you provide any initial thoughts on how you would you prioritize repatriated",53,"Okay, that's helpful. And then it seems like there could be a repatriation holiday of some sort in 2017. I believe over 90% of your cash is currently trapped internationally. Can you provide any initial thoughts on how you would you prioritize repatriated cash, specifically on M&A opportunities and returning capital to shareholders?"
154924,407124595,1100879,"Agilent Technologies, Inc., Q4 2016 Earnings Call, Nov 15, 2016",2016-11-15,"Earnings Calls","Agilent Technologies, Inc.","Executives","Yes, sure, Ryan. So Didier, how about I make a few initial comments and then if you wanted to add anything to it. But, firstly, I think we also need to put a series of caveats on my response because we really don't know what this might look like. What str",291,"Yes, sure, Ryan. So Didier, how about I make a few initial comments and then if you wanted to add anything to it. But, firstly, I think we also need to put a series of caveats on my response because we really don't know what this might look like. What strings might be attached to, how you can use it, whether you can use cash in a certain way. But obviously, we would welcome this type of development, including a move to a more permanent reduction in U.S. corporate tax rates. That being said, I think if you go beyond the theory, I assume with those caveats, I think what you'd expect us to do is handle the return to cash very much along the lines of how we're managing our current use of capital. So we would want to use it for U.S.-based M&A, and we'd like to use that in situation where we've been using debt, such as our share repurchases so we would able to finance our share repurchases. And then we might look at our debt structure. But I think what we want to do is, first of all, obviously, understand what are the restrictions that could be tied to it. Also remind the group that some of the cash does need to remain permanently investment overseas. But we were -- if that particular situation would develop, we would like -- we would bring it back and use the cash very much along the lines how we've been using cash with the exception is I won't need to borrow money like I've done in the past for U.S.-based M&A or stock repurchases. I guess you might be okay with that, Didier. You haven't said anything else. Okay."
154924,407124595,1100879,"Agilent Technologies, Inc., Q4 2016 Earnings Call, Nov 15, 2016",2016-11-15,"Earnings Calls","Agilent Technologies, Inc.","Executives","Absolutely. Absolutely. I was just waiting for his bated breath for the fine lines on the -- any chance, but yes.",21,"Absolutely. Absolutely. I was just waiting for his bated breath for the fine lines on the -- any chance, but yes."
154924,407124595,1100879,"Agilent Technologies, Inc., Q4 2016 Earnings Call, Nov 15, 2016",2016-11-15,"Earnings Calls","Agilent Technologies, Inc.","Operator","And our next question comes from the line of Jonathan Groberg from UBS.",13,"And our next question comes from the line of Jonathan Groberg from UBS."
154924,407124595,1100879,"Agilent Technologies, Inc., Q4 2016 Earnings Call, Nov 15, 2016",2016-11-15,"Earnings Calls","Agilent Technologies, Inc.","Analysts","Mike, so I was just going back and looking, you did 6% growth organically for last year, 6% this year in '16. Just at a high level, you had some pretty tough, tough businesses and some of the industrial business this year and still put up 6%. I guess I'm",105,"Mike, so I was just going back and looking, you did 6% growth organically for last year, 6% this year in '16. Just at a high level, you had some pretty tough, tough businesses and some of the industrial business this year and still put up 6%. I guess I'm just wondering, as you look out to '17, are there some initial thoughts you have around the election from an end-market standpoint, outside of tax, that make you incrementally concerned? Is there -- maybe just high level of kind of what makes you think you're going to get that kind of 150 bps slowdown year-over-year."
154924,407124595,1100879,"Agilent Technologies, Inc., Q4 2016 Earnings Call, Nov 15, 2016",2016-11-15,"Earnings Calls","Agilent Technologies, Inc.","Executives","Yes. So great question, Jon, and thanks for that and obviously, we've spent a lot of time talking about this as a team and I mentioned to Alicia before the call, I think we may be the first company in our space that had to do guidance after the U.S. elect",519,"Yes. So great question, Jon, and thanks for that and obviously, we've spent a lot of time talking about this as a team and I mentioned to Alicia before the call, I think we may be the first company in our space that had to do guidance after the U.S. election. So what I'm going to tell you is the kind of factors we're thinking about. And then also give you maybe some little bit more thinking about why we guided the growth rate we did as a company. But we don't yet have a position on these issues. What we do know is there's a multitude of factors that we need to pay attention to. Regulated markets, what's going to happen to other customers in the food markets, the environmental markets, the drug -- the FDA regulatory markets? So we know there's going to be a customer impact. What's going to happen with U.S. government funding? A lot of our business is driven by U.S. government funding. What's going to happen with trade agreements? There's been a lot of noise about Chinese currency. We just talked about the tax. And will the M&A environment change in terms of -- so all I can say right now, Jonathan, is perhaps, like everybody else on this call, we kind of had a sense of the issues, but we don't know which ways these things are going to go yet, so we're not going to call them. And we're just going to -- and that's one of the reasons why we took what we believe to be a prudent, cautious initial guide to FY '17. If I look at the end markets, I mean, pharma's going to continue to be strong. But we don't believe that it can continue to grow in double digits throughout all of FY '17. So we've tapered down our expectations a bit about pharma. We also think that China has been just a -- just fantastic for us. I think our number for the year was 21% growth for the year; I'm dialing that back a bit to double digit. So what we're doing is really just trying to moderate our view of growth for next year based on what we've seen to be some pretty difficult comparisons in some markets that really have been driving the business. As I mentioned to you, the wildcard is the turn on energy. One of the things that you pointed out, Jonathan, and what I'm really delighted is, we've had 6%, close to 6% growth, 2 years in a row with our #2 market declining for 8 quarters. When that market turns, that obviously will help us in the growth.  So -- but I've learned over the first 2 years in this job, it's really hard to call in terms of major markets. So I'm not going to. And we'll just kind of keep an eye on it, and we'll update you as we go through the year, but that's our thinking about how we're viewing the U.S. election and the thought behind our end-market guidance for next year."
154924,407124595,1100879,"Agilent Technologies, Inc., Q4 2016 Earnings Call, Nov 15, 2016",2016-11-15,"Earnings Calls","Agilent Technologies, Inc.","Analysts","And if I could just -- one more on the diagnostic and clinical market?",14,"And if I could just -- one more on the diagnostic and clinical market?"
154924,407124595,1100879,"Agilent Technologies, Inc., Q4 2016 Earnings Call, Nov 15, 2016",2016-11-15,"Earnings Calls","Agilent Technologies, Inc.","Executives","Yes, Jacob's been dying to answer a question.",8,"Yes, Jacob's been dying to answer a question."
154924,407124595,1100879,"Agilent Technologies, Inc., Q4 2016 Earnings Call, Nov 15, 2016",2016-11-15,"Earnings Calls","Agilent Technologies, Inc.","Analysts","Yes, so obviously, another -- you have 8% growth there. Obviously, you're probably going to say too early to think about how hospitals may react to the potential repeal of the ACA. But how about the PD-L1 testing business, how much of your growth was driv",60,"Yes, so obviously, another -- you have 8% growth there. Obviously, you're probably going to say too early to think about how hospitals may react to the potential repeal of the ACA. But how about the PD-L1 testing business, how much of your growth was driven by that market? And any -- can you size that market for us yet?"
154924,407124595,1100879,"Agilent Technologies, Inc., Q4 2016 Earnings Call, Nov 15, 2016",2016-11-15,"Earnings Calls","Agilent Technologies, Inc.","Executives","Well, it's -- I can start by saying that we have been very pleased with the performance of the PD-L1 over the last 12 months, I think it's 13 months now. And it has growing, if not to our expectation, then above even. And we expect that to continue to gro",248,"Well, it's -- I can start by saying that we have been very pleased with the performance of the PD-L1 over the last 12 months, I think it's 13 months now. And it has growing, if not to our expectation, then above even. And we expect that to continue to grow now based on KEYTRUDA going first line. And obviously, now with our companion diagnostic, we will see a bigger demand for it here in U.S., in Europe and in other regions. The market itself is very difficult to size. As you know, there's both been the companion with 1 drug and then there has been the complementary with another drug, and those have very different sizes at this point of time. I still believe that the overall PD-L1 market might end up in the same size as the HER2 market. But the difference is that HER2 is the only one -- one -- basically, one drug, one class of drug, together with one diagnostics, where the PD-L1 will be up to 5 different drugs, maybe more and 5 different diagnostic, maybe even for a lot of indications also. So this is as close as I can get to right now. The market we place in is -- or the 2 companion diagnostics that we have today continues to grow strongly. I won't say that that's the overall arching driver for the 8%. Basically, all our businesses today have a very nice growth performance, but it's definitely contributing."
154924,407124595,1100879,"Agilent Technologies, Inc., Q4 2016 Earnings Call, Nov 15, 2016",2016-11-15,"Earnings Calls","Agilent Technologies, Inc.","Operator","And our next question comes from line of Derik De Bruin from Bank of America.",15,"And our next question comes from line of Derik De Bruin from Bank of America."
154924,407124595,1100879,"Agilent Technologies, Inc., Q4 2016 Earnings Call, Nov 15, 2016",2016-11-15,"Earnings Calls","Agilent Technologies, Inc.","Analysts","The pace in the quarter was very good. Can you talk a little bit about backlog and, I guess, did you pull -- are you worried that you pulled anything from the first quarter in? I mean, any unusual spending patterns that you thought?",44,"The pace in the quarter was very good. Can you talk a little bit about backlog and, I guess, did you pull -- are you worried that you pulled anything from the first quarter in? I mean, any unusual spending patterns that you thought?"
154924,407124595,1100879,"Agilent Technologies, Inc., Q4 2016 Earnings Call, Nov 15, 2016",2016-11-15,"Earnings Calls","Agilent Technologies, Inc.","Executives","Yes, thanks for the question, Derik. So as I mentioned earlier, we saw strength throughout the quarter. And we were quite delighted with the results. And we're not specifically commenting about orders or backlogs. But I did say in my early comments that w",158,"Yes, thanks for the question, Derik. So as I mentioned earlier, we saw strength throughout the quarter. And we were quite delighted with the results. And we're not specifically commenting about orders or backlogs. But I did say in my early comments that we're well positioned for 2017. I would ask you to think about the Q1, particularly the impact of Chinese Lunar New Year. I told Didier, I said, don't want to talk about it in the Q1 call. So let's make sure that we include it in our guide. So that is the one thing that I would ask you to think about in terms of the next 3 months of the company's performance. Because we think we'll probably push about a week's worth of revenue or so from Q1 to Q2 because customers just won't be there to take delivery, and as you saw, the growth rates have been really exceptional for us in China."
154924,407124595,1100879,"Agilent Technologies, Inc., Q4 2016 Earnings Call, Nov 15, 2016",2016-11-15,"Earnings Calls","Agilent Technologies, Inc.","Analysts","So I'm going to -- I appreciate the New Year's comment. So I'm actually going to follow that up with another question. It's like are you -- have you had any conversations with your customers that -- I mean, obviously, you're not the only ones trying to fi",100,"So I'm going to -- I appreciate the New Year's comment. So I'm actually going to follow that up with another question. It's like are you -- have you had any conversations with your customers that -- I mean, obviously, you're not the only ones trying to figure out what the new world order is in terms of how spending is going to be. Are you worried at all about potential in terms of lower CapEx spending, lower spending beginning of the year as people try to get their arms around what exactly the new administration has in store?"
154924,407124595,1100879,"Agilent Technologies, Inc., Q4 2016 Earnings Call, Nov 15, 2016",2016-11-15,"Earnings Calls","Agilent Technologies, Inc.","Executives","No, actually, we don't have that concern. What we've been more thinking about is where's the thing going long term. So -- but in the next quarter, we don't have any real concerns about that. So -- and that's why we are doing a full year guidance here in N",81,"No, actually, we don't have that concern. What we've been more thinking about is where's the thing going long term. So -- but in the next quarter, we don't have any real concerns about that. So -- and that's why we are doing a full year guidance here in November. And it's really hard to see what's going to happen longer term throughout the year. But in the next quarter or so, we wouldn't expect that to have any significant impact."
154924,407124595,1100879,"Agilent Technologies, Inc., Q4 2016 Earnings Call, Nov 15, 2016",2016-11-15,"Earnings Calls","Agilent Technologies, Inc.","Operator","And our next question comes from the line of Paul Knight from Janney.",13,"And our next question comes from the line of Paul Knight from Janney."
154924,407124595,1100879,"Agilent Technologies, Inc., Q4 2016 Earnings Call, Nov 15, 2016",2016-11-15,"Earnings Calls","Agilent Technologies, Inc.","Analysts","This is actually Bill [ph] on behalf of Paul. Maybe just touching on China again. Could you maybe talk about what your underlying trends have been driving the outsize growth for the company. Is it biopharma? Is it food? Is it environmental? And how does t",53,"This is actually Bill [ph] on behalf of Paul. Maybe just touching on China again. Could you maybe talk about what your underlying trends have been driving the outsize growth for the company. Is it biopharma? Is it food? Is it environmental? And how does that impact as you look to next year?"
154924,407124595,1100879,"Agilent Technologies, Inc., Q4 2016 Earnings Call, Nov 15, 2016",2016-11-15,"Earnings Calls","Agilent Technologies, Inc.","Executives","Yes, thanks for the question. I have to say it really was across the board with one exception, which is the chemical and energy market. So all the other markets were up quite substantially for us. And I think this is consistent with what we had talked abo",248,"Yes, thanks for the question. I have to say it really was across the board with one exception, which is the chemical and energy market. So all the other markets were up quite substantially for us. And I think this is consistent with what we had talked about in prior calls, which is really there's going to be a level of investment in China relative to quality of life issues and in environmental, in food, lined up directly with their 5-year plan that they're in the midst of a major improvement in their overall pharma industry and that there's a lot of money going on to research. So -- and then I think the reason Agilent has been able to do so well here is we've got this combination of we've been working the organizational structure, the -- our channel model in the country. We've had a lot of stability over the last 18 months. So we've got a really strong team there. And that combination of the team, our historical strength in China and the new products we have, it's all coming together in terms of growth. And I guess, I maybe just add one thing and, Mark, perhaps, you can comment here. We often talk about the strength of end markets and the new products going to these end markets, but I think there's something going on relative to your business there and the move to services, I think, is worth a comment on as well."
154924,407124595,1100879,"Agilent Technologies, Inc., Q4 2016 Earnings Call, Nov 15, 2016",2016-11-15,"Earnings Calls","Agilent Technologies, Inc.","Executives","Thanks, Mike, and thanks, Bill [ph]. To add a little color to that is we've seen a fundamental shift in buying behaviors in China, largely shifting from the core areas and around Shanghai, Beijing, to some of the more Tier 2, Tier 3 cities, where services",152,"Thanks, Mike, and thanks, Bill [ph]. To add a little color to that is we've seen a fundamental shift in buying behaviors in China, largely shifting from the core areas and around Shanghai, Beijing, to some of the more Tier 2, Tier 3 cities, where services now is viewed as the commonplace purchasing item in China, and it's certainly driving the growth. But the breadth of services, I think, in China, as well as the consumables business now, is the rest of the story, where they have reached the size and scale that they have the same interest that we'd find in the Western markets around enterprise services and consumables all coming together. So starting, as you've mentioned, Mike, with our extraordinarily strong position to start with, the installed base of China has just allowed us to build the business and truly outgrow our expectations in the second half around this, too."
154924,407124595,1100879,"Agilent Technologies, Inc., Q4 2016 Earnings Call, Nov 15, 2016",2016-11-15,"Earnings Calls","Agilent Technologies, Inc.","Executives","Yes, I mentioned -- I ask Mark to comment on that because as you may recall, we really have changed the portfolio composition of the company, doing much more in the aftermarket. So cath lab instruments are actually less than 50% now of total company's rev",66,"Yes, I mentioned -- I ask Mark to comment on that because as you may recall, we really have changed the portfolio composition of the company, doing much more in the aftermarket. So cath lab instruments are actually less than 50% now of total company's revenue. And historically, China has been driven by new instrument purchases. We're seeing increasing growth also coming from services and consumables."
154924,407124595,1100879,"Agilent Technologies, Inc., Q4 2016 Earnings Call, Nov 15, 2016",2016-11-15,"Earnings Calls","Agilent Technologies, Inc.","Analysts","Great. And then just a follow-up for Didier on the guidance. CapEx up to about $200 million this year. Could you maybe just talk about where the incremental dollars are going and maybe what you think the maintenance CapEx is for Agilent as a whole?",45,"Great. And then just a follow-up for Didier on the guidance. CapEx up to about $200 million this year. Could you maybe just talk about where the incremental dollars are going and maybe what you think the maintenance CapEx is for Agilent as a whole?"
154924,407124595,1100879,"Agilent Technologies, Inc., Q4 2016 Earnings Call, Nov 15, 2016",2016-11-15,"Earnings Calls","Agilent Technologies, Inc.","Executives","Yes, the main reason for the increase, which is about $60 million, from $139 million this year to $200 million next year, is really the significant increase that we're planning in terms of our nucleic acid facilities, RNA-based therapeutics and -- in Colo",148,"Yes, the main reason for the increase, which is about $60 million, from $139 million this year to $200 million next year, is really the significant increase that we're planning in terms of our nucleic acid facilities, RNA-based therapeutics and -- in Colorado. So we had one facility. We're still expanding the capacity of that facility, but we are building and we just started a few weeks ago 20 miles away a second facility that will kind of double the capacity when it will be put in production end of 2018, 2019. So that is the main reason for the increase. And starting in 2018, we should start -- we will see a reduction in the CapEx. This is not the run rate. Our CapEx run rate is still between -- like between $100 million and $120 million per year. So this is way above our run rate."
154924,407124595,1100879,"Agilent Technologies, Inc., Q4 2016 Earnings Call, Nov 15, 2016",2016-11-15,"Earnings Calls","Agilent Technologies, Inc.","Operator","And our next question comes from the line of Jack Meehan from Barclays.",13,"And our next question comes from the line of Jack Meehan from Barclays."
154924,407124595,1100879,"Agilent Technologies, Inc., Q4 2016 Earnings Call, Nov 15, 2016",2016-11-15,"Earnings Calls","Agilent Technologies, Inc.","Analysts","I wanted to follow up on the diagnostics business. Really, I thought it was a nice quarter on a tough comp. I know you talked about the PD-L1. But just any -- I wanted to focus on the Omnis and just whether you think you're picking up steam into 2017 and",60,"I wanted to follow up on the diagnostics business. Really, I thought it was a nice quarter on a tough comp. I know you talked about the PD-L1. But just any -- I wanted to focus on the Omnis and just whether you think you're picking up steam into 2017 and anything worth watching on the reimbursement side with that?"
154924,407124595,1100879,"Agilent Technologies, Inc., Q4 2016 Earnings Call, Nov 15, 2016",2016-11-15,"Earnings Calls","Agilent Technologies, Inc.","Executives","Yes, Jack, thanks for the question. I think I'll pass it over to Jacob, maybe a little bit more color on the quarter results.",24,"Yes, Jack, thanks for the question. I think I'll pass it over to Jacob, maybe a little bit more color on the quarter results."
154924,407124595,1100879,"Agilent Technologies, Inc., Q4 2016 Earnings Call, Nov 15, 2016",2016-11-15,"Earnings Calls","Agilent Technologies, Inc.","Executives","Yes, it's -- we really continue to see overall in our ratings pickup definitely by Omnis that we see the growth is coming back. It's a nice momentum we're seeing and it continues to -- basically, it has continued to increase over -- during '16. So with th",119,"Yes, it's -- we really continue to see overall in our ratings pickup definitely by Omnis that we see the growth is coming back. It's a nice momentum we're seeing and it continues to -- basically, it has continued to increase over -- during '16. So with that momentum, we expect that we will continue to see a good performance into '17 also. From a reimbursement perspective, obviously, there are already some expectation how that will look like into '17 and '18 with the pharma and so on. But now we will have to see what happens under the new administration here whether that will change anything. But so far, we actually don't expect any significant changes into '17."
154924,407124595,1100879,"Agilent Technologies, Inc., Q4 2016 Earnings Call, Nov 15, 2016",2016-11-15,"Earnings Calls","Agilent Technologies, Inc.","Analysts","Great, that's helpful. And then I just wanted to follow up on the margin again. And just from our seat, what we should be watching? And what would push you to the 22% above level for this year? What are some of the actions that you think are going to be c",55,"Great, that's helpful. And then I just wanted to follow up on the margin again. And just from our seat, what we should be watching? And what would push you to the 22% above level for this year? What are some of the actions that you think are going to be critical for doing that?"
154924,407124595,1100879,"Agilent Technologies, Inc., Q4 2016 Earnings Call, Nov 15, 2016",2016-11-15,"Earnings Calls","Agilent Technologies, Inc.","Executives","Yes, I mean, Didier, feel free to augment my response here. But I think, obviously, it's going to be volume, which is about 60% of the margin improvement comes from volume. And the things that we can control, we're on top of. So it's really -- that's the",161,"Yes, I mean, Didier, feel free to augment my response here. But I think, obviously, it's going to be volume, which is about 60% of the margin improvement comes from volume. And the things that we can control, we're on top of. So it's really -- that's the one thing I can't control is what's going to happen in the market. So obviously, there's that 60% tied to margin. And then we've got some pretty big initiatives in the gross margin area, with our water fulfillment team. I think you may have heard me speak previously about some of our work in value engineering, material cost, reductions in logistics. So I think also we keep an eye on our gross margins as we work through the year. Some of the things take a while until actually they start coming through your P&L. But once they're there, they're there for extended period of time. And, Didier, anything else you'd add to that?"
154924,407124595,1100879,"Agilent Technologies, Inc., Q4 2016 Earnings Call, Nov 15, 2016",2016-11-15,"Earnings Calls","Agilent Technologies, Inc.","Executives","No, I mean, just that, I mean, we do have stretch goals. As we mentioned, we are paid internally on achieving 22%. And that means all of us have stretch goals to make -- to achieve that -- to contribute to the 22%. And OSS, under Henrik, the order fulfill",77,"No, I mean, just that, I mean, we do have stretch goals. As we mentioned, we are paid internally on achieving 22%. And that means all of us have stretch goals to make -- to achieve that -- to contribute to the 22%. And OSS, under Henrik, the order fulfillment and supply chain organization, which has delivered greatly in '16 is looking at opportunities to deliver even more in '17, which would help us bridge the gap."
154924,407124595,1100879,"Agilent Technologies, Inc., Q4 2016 Earnings Call, Nov 15, 2016",2016-11-15,"Earnings Calls","Agilent Technologies, Inc.","Executives","Yes. And thanks, Didier. I had one additional thought here is, I think it's important to remind everyone is that some of the things that are going to help in '17 have already been finished in '16. So things such as our simplification of our financial syst",60,"Yes. And thanks, Didier. I had one additional thought here is, I think it's important to remind everyone is that some of the things that are going to help in '17 have already been finished in '16. So things such as our simplification of our financial systems infrastructure. So it's done. And now the savings will show up in '17."
154924,407124595,1100879,"Agilent Technologies, Inc., Q4 2016 Earnings Call, Nov 15, 2016",2016-11-15,"Earnings Calls","Agilent Technologies, Inc.","Operator","And our next question comes from the line of Isaac Ro from Goldman Sachs.",14,"And our next question comes from the line of Isaac Ro from Goldman Sachs."
154924,407124595,1100879,"Agilent Technologies, Inc., Q4 2016 Earnings Call, Nov 15, 2016",2016-11-15,"Earnings Calls","Agilent Technologies, Inc.","Analysts","First question just quickly on the quarter. Curious if you could comment on pacing. You guys have the off-cycle calendar there with October. I'm sure everyone is curious if whether it was on the capital spending side or any particular end market you saw a",65,"First question just quickly on the quarter. Curious if you could comment on pacing. You guys have the off-cycle calendar there with October. I'm sure everyone is curious if whether it was on the capital spending side or any particular end market you saw a meaningful acceleration or deceleration in the month of October to the extent that portends the rest of the calendar year."
154924,407124595,1100879,"Agilent Technologies, Inc., Q4 2016 Earnings Call, Nov 15, 2016",2016-11-15,"Earnings Calls","Agilent Technologies, Inc.","Executives","No, Isaac, I just mentioned that what we saw was really strong pacing throughout the quarter. So it wasn't -- we didn't see something happen all of a sudden in the last 4 or 5 weeks. We had -- we had strength all through 3 quarters of our fiscal year clos",51,"No, Isaac, I just mentioned that what we saw was really strong pacing throughout the quarter. So it wasn't -- we didn't see something happen all of a sudden in the last 4 or 5 weeks. We had -- we had strength all through 3 quarters of our fiscal year close."
154924,407124595,1100879,"Agilent Technologies, Inc., Q4 2016 Earnings Call, Nov 15, 2016",2016-11-15,"Earnings Calls","Agilent Technologies, Inc.","Analysts","Got it. And then maybe a longer-term question, Mike, regarding management incentives. You guys have spent a lot of time over the last couple of years talking about the emphasis on hitting your margin goals and you guys have done that pretty well. So as yo",97,"Got it. And then maybe a longer-term question, Mike, regarding management incentives. You guys have spent a lot of time over the last couple of years talking about the emphasis on hitting your margin goals and you guys have done that pretty well. So as you move pass that 22% number, I was wondering how you think about evolving inside of structure for the management team? And should we assume that the types of incentives you have in place stay in place maybe with slightly different targets? Or could the overall composition evolve a little bit here?"
154924,407124595,1100879,"Agilent Technologies, Inc., Q4 2016 Earnings Call, Nov 15, 2016",2016-11-15,"Earnings Calls","Agilent Technologies, Inc.","Executives","Yes, Isaac, great, great question. And I would point back to what we discussed back at the May AID, where we really said, what this is really all about is generating superior earnings growth, right. So if you think about what we're trying to do here is we",226,"Yes, Isaac, great, great question. And I would point back to what we discussed back at the May AID, where we really said, what this is really all about is generating superior earnings growth, right. So if you think about what we're trying to do here is we're trying to outgrow the market, extend the operation margin to keep driving up our adjusted earnings per share growth. So what we'd like to be able to do is really that should be the focus of the team as we move forward. Operating margin expansion and capital deployment and your growth and market are all ways to get there. So we'd like to really be that have become the cornerstone of our long-term focus. And we want Agilent viewed as a company who grows their earnings faster than revenue. But as I mentioned in the AID is, I really want to also make sure that we don't get so focused on continuing to drive up the operating margin year in and year out that you pass on things that are immediately, say, accretive, maybe they're dilutive on your margins, but with good M&A additions to the business. So I think the way we're going to talk about the company post '17 is very consistent with what we had talked about back in the spring in New York City."
154924,407124595,1100879,"Agilent Technologies, Inc., Q4 2016 Earnings Call, Nov 15, 2016",2016-11-15,"Earnings Calls","Agilent Technologies, Inc.","Operator","And our next question comes from the line of Brandon Couillard from Jefferies.",13,"And our next question comes from the line of Brandon Couillard from Jefferies."
154924,407124595,1100879,"Agilent Technologies, Inc., Q4 2016 Earnings Call, Nov 15, 2016",2016-11-15,"Earnings Calls","Agilent Technologies, Inc.","Analysts","Most of my questions have been addressed. Mike, just curious what you're embedding for the government and academia market globally for next year and any color you can give us sort of regionally would be helpful.",36,"Most of my questions have been addressed. Mike, just curious what you're embedding for the government and academia market globally for next year and any color you can give us sort of regionally would be helpful."
154924,407124595,1100879,"Agilent Technologies, Inc., Q4 2016 Earnings Call, Nov 15, 2016",2016-11-15,"Earnings Calls","Agilent Technologies, Inc.","Executives","Yes, sure, Brandon. As we -- as I look through my notes here, I think we're expecting low single-digit growth. And I think it's important to kind of parse it out by academia and government. So we think that if we go by the major regions, right, China is g",271,"Yes, sure, Brandon. As we -- as I look through my notes here, I think we're expecting low single-digit growth. And I think it's important to kind of parse it out by academia and government. So we think that if we go by the major regions, right, China is going to be strong. And they've actually helped mitigate some of what's been happening in the U.S. and Europe. We're not expecting much in Europe. It's been down. It was down again, but not -- it was basically -- sort of almost feels like the chemical and energy market, which is kind of chugging along at a reduced rate. We're not expecting the governments there to do anything in terms of more stimulus. In fact, one of things we're watching is what are they going to do as a result of Brexit, for those of things. So we expect a strong China, academia and government. We expect a continuation of this current environment in Europe. In the United States, the academia side is not bad. It's what we've seen more has been more on the U.S. government side. The U.S. government -- our U.S. government business is down in 2016 relative to '15. And that's why in my call I mentioned, hey, we need to kind of see where this new administration goes with its budget plans and investment priorities. So right now, we're kind of standing on the sideline just saying it's going to continue to be just like it is, but -- in the United States. But we could see something different in a few months, we just don't know."
154924,407124595,1100879,"Agilent Technologies, Inc., Q4 2016 Earnings Call, Nov 15, 2016",2016-11-15,"Earnings Calls","Agilent Technologies, Inc.","Operator","And our next question comes from the line of Dan Arias from Citigroup.",13,"And our next question comes from the line of Dan Arias from Citigroup."
154924,407124595,1100879,"Agilent Technologies, Inc., Q4 2016 Earnings Call, Nov 15, 2016",2016-11-15,"Earnings Calls","Agilent Technologies, Inc.","Analysts","Mike, just sort of following up on the outlook. Kind of like how are you thinking about the pacing of growth in chemical and energy in '17? Is the assumption that you kind of see some sequential improvement through the year? Or are you basically flat lini",65,"Mike, just sort of following up on the outlook. Kind of like how are you thinking about the pacing of growth in chemical and energy in '17? Is the assumption that you kind of see some sequential improvement through the year? Or are you basically flat lining the business across the quarter just given that we haven't seen much in the way of positive signals?"
154924,407124595,1100879,"Agilent Technologies, Inc., Q4 2016 Earnings Call, Nov 15, 2016",2016-11-15,"Earnings Calls","Agilent Technologies, Inc.","Executives","I think you anticipated my answer. So we basically have a flat line for the year. And it hasn't -- it's been shrinking for the last 7 or 8 quarters 2% or 3%. I think we ended up down about 3% for the full year. And we're basically saying, it's going to be",201,"I think you anticipated my answer. So we basically have a flat line for the year. And it hasn't -- it's been shrinking for the last 7 or 8 quarters 2% or 3%. I think we ended up down about 3% for the full year. And we're basically saying, it's going to be flattish for '17. If there's any good news to that story is the fundamental industries are still out there in terms of gasoline is being produced. We've seen record levels of production in the United States, for example. The plants are running. There's a lot of discussion. There's a lot of reports externally about a turn. Oil prices have been inching up. But our history here is that it's really hard to know exactly when it's going to turn. What I can say is that if you have a profitability productivity message associated with something you can bring to the laboratory, then they might listen to you. And we're hopeful that some of our new product introductions will hit the mark there. But in terms of our overall market assumption and growth assumption for the company, we're assuming flat for '17. No big movements one way or another."
154924,407124595,1100879,"Agilent Technologies, Inc., Q4 2016 Earnings Call, Nov 15, 2016",2016-11-15,"Earnings Calls","Agilent Technologies, Inc.","Analysts","Got it. Okay, great. And then maybe just to go back to the M&A and the margin comments. As we sort of think about the moving parts on the op margin guidance and just what you might look to do this year, how at risk is the current op margin outlook from ad",93,"Got it. Okay, great. And then maybe just to go back to the M&A and the margin comments. As we sort of think about the moving parts on the op margin guidance and just what you might look to do this year, how at risk is the current op margin outlook from additional M&A? I mean, obviously, it's tough to discuss these things in the abstract. But are you open to further dilution if the right asset comes along? Or do you kind of think you hold the line with the current forecasts?"
154924,407124595,1100879,"Agilent Technologies, Inc., Q4 2016 Earnings Call, Nov 15, 2016",2016-11-15,"Earnings Calls","Agilent Technologies, Inc.","Executives","Yes. No, I think what we've said, and I'm really trying to be -- have actions that are consistent with our prior communication. We said we would look at acquisitions that could be short-term dilutive in nature, and we did one the latter part of '16. And w",154,"Yes. No, I think what we've said, and I'm really trying to be -- have actions that are consistent with our prior communication. We said we would look at acquisitions that could be short-term dilutive in nature, and we did one the latter part of '16. And we just love having iLab part of the portfolio. It's going to be -- it's a great addition to the business. But right now, it's not at the corporate average. We'll move it up. So if we saw other opportunities like that, we would pursue them. But I think if you want to look at the type of the deals and the size and other things, just look at what we've done so far to give you kind of a sense of the things that we're looking at going forward. We like accretive deals, and we like ones that can move up -- move the margins up."
154924,407124595,1100879,"Agilent Technologies, Inc., Q4 2016 Earnings Call, Nov 15, 2016",2016-11-15,"Earnings Calls","Agilent Technologies, Inc.","Operator","And our next question comes from the line of Puneet Souda from Leerink Partners.",14,"And our next question comes from the line of Puneet Souda from Leerink Partners."
154924,407124595,1100879,"Agilent Technologies, Inc., Q4 2016 Earnings Call, Nov 15, 2016",2016-11-15,"Earnings Calls","Agilent Technologies, Inc.","Analysts","Just a quick follow-up, if I could, on the pharma. And just wanted to understand, there's clearly a solid contribution here. If you could maybe help us parse out. Is that more coming from sort of a small molecules or macro molecules? Or is this -- are we",86,"Just a quick follow-up, if I could, on the pharma. And just wanted to understand, there's clearly a solid contribution here. If you could maybe help us parse out. Is that more coming from sort of a small molecules or macro molecules? Or is this -- are we thinking about them correctly? Or maybe we should be thinking about in terms of the service contract share that you're gaining and via the CrossLab Group? Help us, if you could parse that out a little bit."
154924,407124595,1100879,"Agilent Technologies, Inc., Q4 2016 Earnings Call, Nov 15, 2016",2016-11-15,"Earnings Calls","Agilent Technologies, Inc.","Executives","Yes, sure. So there's a couple of things going on, which is in terms of the overall fundamental end-market growth rates, we think biopharma and the small molecule side of pharma are both growing quite strongly. The small molecule side is really being driv",196,"Yes, sure. So there's a couple of things going on, which is in terms of the overall fundamental end-market growth rates, we think biopharma and the small molecule side of pharma are both growing quite strongly. The small molecule side is really being driven by a conversion to the new technology, the liquid chromatography in particular. Also, an increasing interest in enterprise service, what we have to offer from ACG. So I think what's been going on here for Agilent, we've had a combination of really strong end-market growth. There's a new market that has and will continue to develop in the services side, and we're doing well there, along with our new instruments in the pharma. When I look at '17, we think that the biopharma side of that market is going to continue to go quite strongly. It's been an area of prioritization for us in terms of new solutions. But we do think that over time, that the small molecule stuff will start to move back towards more of its long-term growth rates. And, Patrick, I think what do we kind of think about our long-term growth rates in the small molecule side?"
154924,407124595,1100879,"Agilent Technologies, Inc., Q4 2016 Earnings Call, Nov 15, 2016",2016-11-15,"Earnings Calls","Agilent Technologies, Inc.","Executives","Well, on the small molecule side, I think we are more in the low- to mid-single-digits range; whereas in biopharma we're more optimistic, and it continues to be double digit. That's our projection right now.",35,"Well, on the small molecule side, I think we are more in the low- to mid-single-digits range; whereas in biopharma we're more optimistic, and it continues to be double digit. That's our projection right now."
154924,407124595,1100879,"Agilent Technologies, Inc., Q4 2016 Earnings Call, Nov 15, 2016",2016-11-15,"Earnings Calls","Agilent Technologies, Inc.","Analysts","All right. Great. Just one more. In terms of the chemical and energy market side, I mean, we get the view into 2017. But as you have conversation with the labs and lab directors, just help us understand how they're thinking about capital equipment in 2017",71,"All right. Great. Just one more. In terms of the chemical and energy market side, I mean, we get the view into 2017. But as you have conversation with the labs and lab directors, just help us understand how they're thinking about capital equipment in 2017 knowing these times and knowing that the progression that's been? Or are they thinking more in 2018 terms in the -- on the capital equipment?"
154924,407124595,1100879,"Agilent Technologies, Inc., Q4 2016 Earnings Call, Nov 15, 2016",2016-11-15,"Earnings Calls","Agilent Technologies, Inc.","Executives","I have to say, I don't think they really know yet as well. What they're doing right now is in they're right in the midst of their capital budgeting process. So what I can tell you is I've had a couple conversations with customers over the last 2 or 3 week",295,"I have to say, I don't think they really know yet as well. What they're doing right now is in they're right in the midst of their capital budgeting process. So what I can tell you is I've had a couple conversations with customers over the last 2 or 3 weeks on this exact topic. And what they described for me is, hey, our end -- these are -- one customer was somebody who provides services into -- and equipment into the energy market. So listen, we're starting to get interest in quotes, but we're not sure whether it's going to hit in '17 or '18. When we had our VIP launch for the Intuvo 9000 GC, a lot our customers were in the chemical and energy space. And it's, ""Listen, we love this productivity message you have here. I think there's a real economic ROI. I'm now right in the midst of my budgeting process inside the company. Maybe I'll be able to get this thing through this year or maybe the following year."" Because there still seems to be the sentiment, particularly with the larger companies that they want to hold on to the equipment as long as they can before they have to replace it. So -- and again, that's why I pointed to the fact that it's not all negative because of the fact that we do have a strong service and consumables offerings into that space. But again, we just don't -- I don't think our customers know yet as well what's going to happen. We do know it's going to happen. History will repeat itself. There will be a replenishment of aged equipment. But again, we're just not confident enough right now to say when that's going to occur."
154924,407124595,1100879,"Agilent Technologies, Inc., Q4 2016 Earnings Call, Nov 15, 2016",2016-11-15,"Earnings Calls","Agilent Technologies, Inc.","Operator","And that concludes our question-and-answer session for today. I would like to turn the conference back over to Alicia Rodriguez for any closing comments.",25,"And that concludes our question-and-answer session for today. I would like to turn the conference back over to Alicia Rodriguez for any closing comments."
154924,407124595,1100879,"Agilent Technologies, Inc., Q4 2016 Earnings Call, Nov 15, 2016",2016-11-15,"Earnings Calls","Agilent Technologies, Inc.","Executives","Thank you, everybody. And on behalf of the management team, I wanted to thank you for joining us on the call. If you have any questions, feel free to give us a call in IR. Appreciate it very much. Bye-bye.",40,"Thank you, everybody. And on behalf of the management team, I wanted to thank you for joining us on the call. If you have any questions, feel free to give us a call in IR. Appreciate it very much. Bye-bye."
154924,407124595,1100879,"Agilent Technologies, Inc., Q4 2016 Earnings Call, Nov 15, 2016",2016-11-15,"Earnings Calls","Agilent Technologies, Inc.","Operator","Ladies and gentlemen, thank you for your participation in today's conference. This does conclude the program, and you may now disconnect. Everyone, have a great day.",26,"Ladies and gentlemen, thank you for your participation in today's conference. This does conclude the program, and you may now disconnect. Everyone, have a great day."
